

2021-2023

Product Catalog

Compound Libraries, Small Molecules, Natural Compounds

About us

Target Molecule Corp. (TargetMol) is a global high-tech enterprise, headquartered in Boston, MA, specializing in chemical and biological research product and service to meet the research needs of global customers. With the help of fast and efficient global supply chain, professional and rigorous procurement process and timely dynamic news of products, you will save more time with less cost and lead in drug discovery and screening.

Our Product Portfolio

Inhibitor


TargetMol supplies over 10,000 compounds used in the study of cell signaling pathways and drug discovery.

Track the latest scientific research and promptly offer the newest and most popular inhibitors.

100-200 new inhibitors per month.

NMR and HPLC validated to ensure high purity.

Above 95% compounds are in stock.



Compound Libraries

TargetMol provides more than 100 types of compound libraries. They are available for cell induction, signaling pathway and HTS. Compound libraries are useful professional tools for drug discovery and new indication research. Customers can customize individual libraries by selecting specific molecules, quantities, concentrations, and format.




Documentation for TargetMol Compound library

Plate layout data is provided with all library shipments and includes:

Excel: .xls(spreadsheet) file that includes all non-structural fields of the SD files.

SD file: Containing each chemical structure along with the following fields: unique TargetMol ID number, plate or box ID value, Column location, the row location, coordinates(column and row locations combined), MW value, amount of compound and additional descriptions. Discovery Studio is the recommended software to open the SD files.

QA and instruction: Containing the compound Libraries instructions.

Package format	96-well plate	96-well deep-well plate	384-well plate
Quantity	≤ 50μL	>50μL	By customer request
Plate type	V shap, PP, 0.36mL	V Bottom,PP, 2D barcoded, SepraSeal Cap, 1.4mL	V Shape,PP, 0.24mL
Size/solvent	10mM DMSO	10mM DMSO	10mM DMSO
Storage	-20° C (shipping or short-term preservation) -80° C (long-term preservation)		
			

Libraries Contents

Focused Bioactive Libraries

Approved Drug Library	8
FDA Approved & Pharmacopeial Drug Library.....	8
Clinical Compound Library	8
Preclinical Compound Library	8
FDA-approved Drug Library.....	8
Drug Repurposing Library	8
Anti-COVID-19 Compound Library.....	8
Anti-COVID-19 compound library (CADD)	8
3CLpro-Targeted compound library (CADD)	8
ACE2-Targeted compound library (CADD).....	8
RBD-Targeted compound library (CADD)	8
nsp16-Targeted compound library (CADD)	8
PLpro-Targeted compound library (CADD)	8
RdRP-Targeted compound library (CADD)	8
X Domain-Targeted compound library (CADD)	8
nsp15-Targeted compound library (CADD)	9
Protease Inhibitor Library	9
AMPK-Targeted Compound Library	9
Epigenetics Compound Library	9
PI3K-AKT-mTOR Compound Library.....	9
MAPK Inhibitor Library.....	9
GPCR Compound Library	9
Nuclear-receptor Inhibitors Library.....	9
GPCR Library Plus	9
Kinase Inhibitor Library.....	9
Inhibitor Library	9
Tyrosine kinase inhibitor library.....	9
Ion Channel Inhibitor Library.....	9
Neuronal Signaling Compound Library	9
Neurotransmitter Receptor Compound Library	9
Adrenergic Receptor Compound Library	9
Serotonin Compound Library	9
Autophagy Compound Library	9

Histamine & Melatonin Library	9
Cytokine Inhibitor Library	9
JAK STAT Compound Library	9
NF-κB Signaling Compound Library.....	9
DNA Damage & Repair Compound Library	10
TGF-beta/Smad Compound Library.....	10
Wnt&Hedgehog&Notch Compound Library	10
Angiogenesis related Compound Library.....	10
Mitochondrial Targeting Compound Library	10
Calcium Antagonists Library	10
Potassium Channel Blockers Library.....	10
Sodium Channel Blockers Library	10
Chemokine inhibitors Library	10
Cell cycle related Compound Library.....	10
HIF-1 Signaling Pathway Compound Library.....	10
Ubiquitination Compound Library	10
Ferroptosis Compound Library.....	10
Apoptosis Compound Library	10
Phosphatase Inhibitor Library	10
Endoplasmic Reticulum Stress Compound Library	10
Transcription factor targeted Library	10
Nucleotide Compound Library	10
Endocrinology-Hormones Library	10
Human Endogenous Metabolite Compound Library	10
Lipid Metabolism Compound Library.....	10
Glycometabolism Compound Library	11
Oxidation-Reduction Compound Library.....	11
Hematopoietic Toxicity Compound Library.....	11
Histone Modification Research Compound Library	11
DNA damage and repair Library Plus	11
Antibiotics Library.....	11
Cardiotoxicity Compound Library	11
Fluorochemical Library	11
Killers Collection	11
Drug-induced Liver Injury (DILI) Compound Library.....	11

Selected Impurities Library	11
CNS-Penetrant Compound Library.....	11
Bioactive Lipid Compound Library	11
Coagulation and anticoagulation Compound Library	11
Neural Regeneration Compound Library	11
Osteogenesis-related Compound Library.....	11
Stem cell Differentiation Compound Library.....	11
Anti-aging Compound Library	11
Chromatin Modification Compound Library	11
Macrocyclic Compounds Library	11
PPI Inhibitors Library.....	11
Covalent Inhibitor Library	11
Target-Focused Phenotypic Screening Library.....	12
Peptide Compound Library.....	12
Glutamine Metabolism Compound Library	12
Beta-lactam Compound Library	12
Gut Microbial Metabolite Library	12
Microtubule-Targeted Compound Library	12
Anti-virus Compound Library.....	12
Anti-infection Compound Library.....	12
Anti-diabetic Compound Library	12
Anti-cancer Compound Library	12
Anti-cancer Approved drug Library	12
Anti-cancer Clinical Compound Library	12
Anti-cancer Metabolism Compound Library.....	12
Promoting Cancer Cell Differentiation Compound Library	12
Anti-cancer Drug library	13
Anti-cancer Active Compound library	13
Small Molecule Immuno-Oncology Compound Library.....	13
Anticancer Library Plus.....	13
Anti-Lung Cancer Compound Library.....	13
Anti-Breast Cancer Compound Library	13
Anti-Pancreatic Cancer Compound Library	13
Neurodegenerative disease-related Compound Library	13
Bioactive Compound Library	13

Bioactive Compound Supplement Library	13
Antifungal Compound Library	13
Anti-Parasite Library	13
Antibacterial Activity Library.....	14
Nervous system disease Library	14
Immunology/Inflammation Compound Library	14
Nonsteroidal Antiinflammatory Compound Library.....	14
Anti-Metabolism Disease Compound Library	14
Anti-Cardiovascular Disease Compound Library	14
Anti-obesity Compound Library	14
Hematonosis Compound Library	14
Cytoskeletal Signaling Pathway Compound Library.....	14
Anti-Alzheimer's Disease Compound Library	14
Anti-Parkinson's Disease Compound Library	14
Anti-fibrosis Compound Library	14

Natural Product Libraries

Selected Plant-sourced Compound Library.....	15
Natural Compound Library for HTS.....	15
Polyphenolic Natural Compound Library	15
Alkaloids natural compound library.....	15
Flavonoids natural compound library.....	15
Terpene natural compound library	15
Saccharides and glycosides Compound Library	15
Food as Medicine Library	15
Microbial Natural Product Library	15
Antitumor Natural Products Library.....	15
Anti-Inflammatory Tradition Chinese Medicine Library.....	15
Selectable Natural Compound Library.....	15
Anti-gastroenteritis Natural Product Library	15
Natural Compound Library in Chinese Pharmacopoeia	15
Rare Natural Compound Library.....	15
Anti-COVID-19 Traditional Chinese Medicine Compound Library.....	16
Traditional Chinese Medicine Monomer Library	16

Fragment Libraries

Drug-fragment Library.....	16
Featured Fragment Library.....	16
High Solubility Fragment Library.....	16


Diversity Sets

Mini Scaffold Library.....	16
Golden Scaffold Library.....	16

Custom Compound Library

You can select compounds, quantities, format (dry/solid or DMSO), plate map, and concentration to meet your specific requirement.

Please contact us at info@targetmol.com to customize your library.



Compound Libraries

Our compound libraries can be classified as Focused Bioactive Libraries, Natural Product Libraries, Fragment Libraries, and Diversity Sets. These libraries have been extensively validated in our in-house biological assays and widely employed by research institutions and pharmaceutical companies in complementary screening strategies. Identifying novel and robust chemical starting points remains one of the biggest challenges in drug discovery today.

Focused Bioactive Libraries

Product Name	Quantity	Description
Approved Drug Library	2356 compounds	A unique collection of 2356 approved drugs for high throughput screening (HTS) and high content screening (HCS).
FDA Approved & Pharmacopeial Drug Library	2978 compounds	2978 compounds from marketed drugs for high throughput screening (HTS) and high content screening (HCS).
Clinical Compound Library	1537 compounds	A unique collection of 1537 compounds in clinical trial phases for high throughput screening (HTS) and high content screening (HCS).
Preclinical Compound Library	450 compounds	A unique collection of 450 preclinical compounds for high throughput screening (HTS) and high content screening (HCS).
FDA-approved Drug Library	1436 compounds	A unique collection of 1436 FDA approved drugs for high throughput screening (HTS) and high content screening (HCS).
Drug Repurposing Library	3272 compounds	A unique collection of 3272 approved and clinical drugs for high throughput screening (HTS) and high content screening (HCS).
Anti-COVID-19 Compound Library	2448 compounds	A unique collection of 2448 compounds with confirmed anti-SARS-CoV-2 activity or potential activity and part of them are broad-spectrum antiviral agents.
Anti-COVID-19 compound library (CADD)	362 compounds	A unique collection of 362 compounds having the potential of anti-SARS-CoV-2 activity, can be used for high throughput screening and high content screening.
3CLpro-Targeted compound library (CADD)	161 compounds	A unique collection of 161 compounds having the potential of anti-SARS-CoV-2 activity, can be used for high throughput screening and high content screening.
ACE2-Targeted compound library (CADD)	462 compounds	A unique collection of 462 compounds having the potential of anti-SARS-CoV-2 activity, can be used for high throughput screening and high content screening.
RBD-Targeted compound library (CADD)	206 compounds	A unique collection of 206 compounds having the potential of anti-SARS-CoV-2 activity, can be used for high throughput screening and high content screening.
nsp16-Targeted compound library (CADD)	281 compounds	A unique collection of 281 compounds having the potential of anti-SARS-CoV-2 activity, can be used for high throughput screening and high content screening.
PLpro-Targeted compound library (CADD)	474 compounds	A unique collection of 474 compounds having the potential of anti-SARS-CoV-2 activity, can be used for high throughput screening and high content screening.
RdRP-Targeted compound library (CADD)	464 compounds	A unique collection of 464 compounds having the potential of anti-SARS-CoV-2 activity, can be used for high throughput screening and high content screening.
X Domain-Targeted compound library (CADD)	463 compounds	A unique collection of 463 compounds having the potential of anti-SARS-CoV-2 activity, can be used for high throughput screening and high content screening.

Product Name	Quantity	Description
nsp15-Targeted compound library (CADD)	470 compounds	A unique collection of 470 compounds having the potential of anti-SARS-CoV-2 activity, can be used for high throughput screening and high content screening.
Protease Inhibitor Library	295 compounds	A unique collection of 295 protease and proteasome inhibitors for research in chemical genomics, and drug screening.
AMPK-Targeted Compound Library	36 compounds	36 well-chosen unique AMPK-targeted small molecules; All compounds are in stock.
Epigenetics Compound Library	932 compounds	Well-chosen 932 compounds related to epigenetic regulation for research in epigenetics, high throughput screening (HTS) and high content screening (HCS) for new drugs.
PI3K-AKT-mTOR Compound Library	319 compounds	A unique collection of 319 compounds targeting PI3K/Akt/mTOR signaling for research in PI3K/Akt/mTOR signaling, and drug discovery in diseases involved with PI3K/Akt/mTOR signaling.
MAPK Inhibitor Library	234 compounds	A unique collection of 234 compounds targeting MAPK signaling for drug discovery in MAPK related diseases.
GPCR Compound Library	1406 compounds	A unique collection of 1406 GPCR-active agents for high throughput screening and high content screening for GPCR drug discovery, and new GPCR target identification and research.
Nuclear-receptor Inhibitors Library	298 compounds	A unique collection of 298 nuclear receptor signaling targeted compounds for high throughput and high content screening.
GPCR Library Plus	403 compounds	Well-chosen 403 GPCR targeting compounds with unique structures.
Kinase Inhibitor Library	2112 compounds	A unique collection of 2112 kinase inhibitors for high throughput screening and high content screening for drug discovery in kinase related diseases.
Inhibitor Library	4784 compounds	A unique collection of 4784 inhibitors for research in cell signaling, high throughput screening (HTS) and high content screening (HCS) for new drugs.
Tyrosine kinase inhibitor library	590 compounds	A unique collection of 590 tyrosine kinase inhibitors for high throughput screening and high content screening for drug discovery in tyrosine kinase related diseases.
Ion Channel Inhibitor Library	705 compounds	A unique collection of 705 compounds targeting ion channels for research in ion channels-related diseases and ion channel drug discovery.
Neuronal Signaling Compound Library	1672 compounds	A unique collection of 1672 compounds targeting CNS signaling for high throughput screening (HTS) and high content screening (HCS) for new drugs.
Neurotransmitter Receptor Compound Library	956 compounds	A unique collection of 956 neurotransmitter receptor compounds, can be used for HTS and HCS screening.
Adrenergic Receptor Compound Library	117 compounds	A unique collection of 117 bioactive compounds specifically targeting adrenergic receptors, effective tool for screening new drugs or new target identification.
Serotonin Compound Library	170 compounds	A unique collection of 170 compounds targeting serotonin receptors for high throughput screening and high content screening.
Autophagy Compound Library	623 compounds	A unique collection of 623 compounds with defined autophagy-inducing or -inhibitory activity for research in autophagy, high throughput screening (HTS) and high content screening (HCS) for new drugs.
Histamine & Melatonin Library	120 compounds	A unique collection of 120 compounds targeting histaminergic receptor and melatonin receptor for high throughput screening (HTS) and high content screening (HCS) for new drugs.
Cytokine Inhibitor Library	182 compounds	A unique collection of 182 compounds targeting cytokine signaling for high throughput screening and high content screening for drug discovery.
JAK STAT Compound Library	145 compounds	A unique collection of 145 JAK/STAT signaling targeted compounds for high throughput and high content screening.
NF-κB Signaling Compound Library	173 compounds	A unique collection of 173 compounds targeting NF-κB signaling for high throughput screening and high content screening.

Product Name	Quantity	Description
DNA Damage & Repair Compound Library	631 compounds	A unique collection of 631 DNA Damage & Repair related compounds for high throughput screening (HTS) and high content screening (HCS).
TGF-beta/Smad Compound Library	116 compounds	A unique collection of 116 TGF-beta/Smad signaling targeted compounds for high throughput and high content screening.
Wnt&Hedgehog&Notch Compound Library	136 compounds	A unique collection of 136 Wnt/Hedgehog/Notch signaling targeted compounds for high throughput and high content screening.
Angiogenesis related Compound Library	455 compounds	A unique collection of 455 proangiogenic and antiangiogenic compounds for new targets identification, research in mechanisms of angiogenesis, and high throughput screening (HTS) and high content screening (HCS).
Mitochondrial Targeting Compound Library	168 compounds	A unique collection of 168 promising or approved mitochondria-targeted compounds including Idebenone, the only approved drug targeting mitochondria, for research in mitochondrial medicine.
Calcium Antagonists Library	75 compounds	A unique collection of 75 calcium channel blockers and agonists for high throughput and high content screening.
Potassium Channel Blockers Library	90 compounds	A unique collection of 90 potassium channel blockers and agonists for high throughput and high content screening.
Sodium Channel Blockers Library	62 compounds	A unique collection of 62 sodium channel blockers and agonists for high throughput and high content screening.
Chemokine inhibitors Library	27 compounds	A unique collection of 27 chemokines or chemokine receptors targeted compounds for high throughput and high content screening.
Cell cycle related Compound Library	228 compounds	A unique collection of 228 cell cycle related compounds for high throughput screening (HTS) and high content screening (HCS).
HIF-1 Signaling Pathway Compound Library	975 compounds	A unique collection of 975 HIF-1 related small chemicals can be used for drug discovery in ischemic disease and cancer and related mechanism studies.
Ubiquitination Compound Library	95 compounds	A unique collection of 95 ubiquitination related small chemicals can be used for high throughput and high content screening.
Ferroptosis Compound Library	320 compounds	A unique collection of 320 ferroptosis signaling pathway related compounds, a powerful tool for new target identification, drug discovery, and mechanism study.
Apoptosis Compound Library	1343 compounds	A unique collection of 1343 apoptosis-related compounds for apoptosis research, research in tumorigenesis, and anti-cancer drug screening.
Phosphatase Inhibitor Library	39 compounds	A collection of 39 phosphatase inhibitors with known activity.
Endoplasmic Reticulum Stress Compound Library	155 compounds	A unique collection of 155 endoplasmic reticulum stress (ER stress) related compounds used for high throughput screening (HTS) and high content screening (HCS); Targets include GRP78, IRE1, ATF6, PERK, etc. Some compounds have been approved by FDA; Rich documentation with chemical structure, target, and bioactivity information.
Transcription factor targeted Library	449 compounds	Well-chosen 449 compounds with unique structures targeting transcription factor.
Nucleotide Compound Library	179 compounds	A unique collection of 179 nucleoside and nucleotide analogues, can be used for research and development of anti-viral, anti-tumor, anti-fungal, and anti-depressive drugs.
Endocrinology-Hormones Library	297 compounds	A unique collection of 297 compounds targeting endocrine system for high throughput screening (HTS) and high content screening (HCS) for new drugs.
Human Endogenous Metabolite Compound Library	910 compounds	A unique collection of 910 endogenous metabolism-related compounds for research in endogenous metabolism-related diseases and drug screening.
Lipid Metabolism Compound Library	376 compounds	A unique collection of 376 compounds targeting lipid metabolism, can be used for high-throughput screening (HTS) and high-content screening (HCS).

Product Name	Quantity	Description
Glycometabolism Compound Library	638 compounds	638 glycometabolism-related compounds, can be used for HTS and HCT; Targets contain GLUTs, Hexokinase(HK), Pyruvate Kinase(PK), phosphofruktokinase(PFK), IDH1/2, LDH, AMPK, etc.; All compounds are in stock.
Oxidation-Reduction Compound Library	453 compounds	453 small molecule compounds with pro-oxidant or anti-oxidant activity for high-throughput and high-content screening.
Hematopoietic Toxicity Compound Library	104 compounds	A unique collection of 104 compounds with defined hematopoietic toxicity for high throughput and high content drug screening.
Histone Modification Research Compound Library	194 compounds	A unique collection of 194 histone modification related compounds for high throughput screening (HTS) and high content screening (HCS).
DNA damage and repair Library Plus	667 compounds	Well-chosen 667 compounds with unique structures targeting DNA damage & repair.
Antibiotics Library	646 compounds	A unique collection of 646 compounds with antibiotic activity for new antibacterial drug screening.
Cardiotoxicity Compound Library	132 compounds	A unique collection of 132 cardiotoxicity inducing compounds for toxicological study.
Fluorochemical Library	586 compounds	A unique collection of 586 fluorochemicals that can be used for high through-put screening (HTS) and high content screening (HCS).
Killers Collection	277 compounds	A unique collection of 277 toxic substances for high throughput screening (HTS) and high content screening (HCS).
Drug-induced Liver Injury (DILI) Compound Library	595 compounds	A unique collection of 595 hepatotoxicity causing compounds, a powerful tool for drug toxicity study, can be used for HTS and HCS screening.
Selected Impurities Library	200 compounds	A unique collection of 200 drug isomers/metabolites for high throughput screening (HTS) and high content screening (HCS).
CNS-Penetrant Compound Library	516 compounds	A unique collection of 516 CNS-Penetrant compounds for high throughput screening (HTS) and high content screening (HCS).
Bioactive Lipid Compound Library	385 compounds	A unique collection of 385 bioactive lipids related compounds for high throughput screening (HTS) and high content screening (HCS).
Coagulation and anticoagulation Compound Library	154 compounds	A unique collection of 154 procoagulation and anticoagulation related compounds for high throughput screening (HTS) and high content screening (HCS).
Neural Regeneration Compound Library	149 compounds	A unique collection of 149 neuroregeneration related compounds for high throughput and high content screening.
Osteogenesis-related Compound Library	80 compounds	A unique collection of 80 osteogenesis related compounds for high throughput and high content screening.
Stem cell Differentiation Compound Library	1014 compounds	A unique collection of 1014 stem cell differentiation signaling targeted compounds for high throughput and high content screening.
Anti-aging Compound Library	3050 compounds	A unique collection of 3050 anti-aging compounds for high throughput screening (HTS) and high content screening (HCS).
Chromatin Modification Compound Library	192 compounds	A unique collection of 192 compounds targeting chromatin remodeling pathway for high throughput screening (HTS) and high content screening (HCS).
Macrocyclic Compounds Library	146 compounds	146 macrocyclic compounds of known activity for high-throughput, high-content screening.
PPI Inhibitors Library	143 compounds	A unique collection of 143 PPI-related compounds for drug screening.
Covalent Inhibitor Library	670 compounds	A unique collection of 670 covalent inhibitors and other molecules with common warheads like chloroacetyl, 2-Chloropropionyl, Acryloyl, sulfonyl fluoride, alkyne, acrylamide, ketocarbonyl, disulfide bond, etc.

Product Name	Quantity	Description
Target-Focused Phenotypic Screening Library	1832 compounds	A unique collection of 1832 annotated bioactive compounds with clear targets, suitable for phenotypic screening.
Peptide Compound Library	235 compounds	235 peptides can be used in peptide drug development and signaling transduction and mechanism study; Contains hormone peptides (analogs), immunoreactive peptides, neuroactive peptides, anti-tumor active peptides, antimicrobial peptides, substrate peptides, etc.
Glutamine Metabolism Compound Library	455 compounds	A unique collection of 455 glutamine metabolism related compounds can be used for high throughput screening (HTS) and high content screening (HCS), and also is an effective tool for research in glutamine metabolism and cancer; Targets include glutaminase (GLS), ASCT2, glutamate dehydrogenase, c-Myc, etc. Some compounds have been approved by the FDA.
Beta-lactam Compound Library	90 compounds	A unique collection of 90 beta-lactam compounds, can be used in HTS and HCS; Effective tool for research in anti-bacterial and anti-infection; All compounds are in stock.
Gut Microbial Metabolite Library	360 compounds	A unique collection of 360 gut microbial metabolites which can be used for HTS and HCS; Includes short chain fatty acids, amino acids, vitamins, saccharides, lipids, etc.; Effective tool for research in gut microbiome metabolism and related drug development.
Microtubule-Targeted Compound Library	58 compounds	A unique collection of 58 microtubule-targeted compounds can be used in HTS and HCS.
Anti-virus Compound Library	651 compounds	A unique collection of 651 anti-virus compounds effective for new anti-virus drugs high throughput screening and high content screening; Target viruses include HBV, HCV, HIV, HSV, Influenza Virus, Reverse Transcriptase, etc. covering more than 140 targets; Structurally diverse and strong bioactivity.
Anti-infection Compound Library	1326 compounds	A unique collection of 1326 anti-infective compounds including anti-bacterial, anti-fungi, anti-Human Cytomegalovirus (HCMV), anti-HIV, anti-SARS, anti-influenza, etc; Effective tool for new anti-infective drugs high throughput screening and high content screening, containing sulfonamides, tetracyclines, aminoglycosides, and macrolide derivatives, etc.
Anti-diabetic Compound Library	468 compounds	A unique collection of 468 diabetes related compounds; Bioactivity and safety confirmed by clinical research and trials; The major targets include SGLT, PPAR, DPP-4, OC receptor, AMPK, etc.
Anti-cancer Compound Library	4596 compounds	A unique collection of 4596 compounds with anti-cancer activity for high throughput screening (HTS) and high content screening (HCS); Bioactivity and safety profiled in (confirmed by) pre-clinical and clinical settings (research and trials).
Anti-cancer Approved drug Library	397 compounds	A unique collection of 397 approved anti-cancer drugs for high throughput screening (HTS) and high content screening (HCS); These FDA, EMA, or CFDA approved anti-cancer drugs have annotated bioactivity, safety, and bioavailability.
Anti-cancer Clinical Compound Library	711 compounds	A unique collection of 711 anti-cancer compounds for high throughput screening (HTS) and high content screening (HCS); Bioactivity confirmed by pre-clinical research and all of them are currently in clinical trial phases, representing the cutting-edge treatments for cancers.
Anti-cancer Metabolism Compound Library	1072 compounds	A unique collection of 1072 cancer cellular metabolism related compounds for cancer research and high throughput screening (HTS) and high content screening (HCS); Covers 16 major targets related to cancer cellular metabolism (glucose, proteins, lipids and nucleic acids) including ACL, CA, FASN, GLUT, GLS, HMG-CoA, MAGL, MCTs, PDH, PDK, PKM, etc.
Promoting Cancer Cell Differentiation Compound Library	251 compounds	A unique collection of 251 cancer cell differentiation inducing compounds for high throughput and high content screening.

Product Name	Quantity	Description
Anti-cancer Drug library	867 compounds	A unique collection of 867 anticancer drugs for high throughput screening (HTS) and high content screening (HCS); Bioactivity and safety profiled in (confirmed by) pre-clinical and clinical settings (research and trials), an effective tool for molecular mechanism of tumorigenesis, and anti-tumor drug repositioning drug discovery.
Anti-cancer Active Compound library	1459 compounds	A unique collection of 1459 compounds with known anti-cancer activity for high throughput screening (HTS) and high content screening (HCS); Effective tool for molecular mechanism of tumorigenesis, and anti-tumor drug screening; Covers various major targets including PI3K, HDAC, mTOR, CDK, Aurora Kinase, JAK, etc.
Small Molecule Immuno-Oncology Compound Library	340 compounds	A unique collection of 340 compounds acting on immune-oncology therapeutic targets can be used for high throughput and high content screening; Targets include PD-1/PD-L1, HER2, STAT3, CTLA4, IDO, STING, CCR, CXCR, TLR, etc.
Anticancer Library Plus	958 compounds	Well-chosen 958 anti-tumor compounds with unique structures; High antitumor activity: 99% of compounds with IC50 below 3 μM; Covers 59 tumor related targets with each compound having clear target; Detailed information: each compound has information about activity testing method, providing reference for your experimental design.
Anti-Lung Cancer Compound Library	704 compounds	A unique collection of 704 compounds with anti-lung cancer therapeutic activity or targeting lung cancer's major signaling pathways, can be used for anti-lung cancer drug discovery and mechanism study; Targets include EGFR, PI3K, FGFR, HER2, ALK, c-Met, etc.; Some compounds have been in market or in clinical trials.
Anti-Breast Cancer Compound Library	1052 compounds	A unique collection of 1052 compounds with anti-breast cancer therapeutic activity or targeting breast cancer's major signaling pathways, can be used for anti-breast cancer drug discovery and mechanism study; Targets include HER-2, VEGF, EGFR, PARP, CDK4/6, HSP, PD-1, SET7/9, BRCA, etc.; Some compounds have been in market or in clinical trials.
Anti-Pancreatic Cancer Compound Library	788 compounds	A unique collection of 788 pancreatic cancer related compounds can be used in HTS and HCS; Some of them have been approved for clinical use or in clinical trial phases.
Neurodegenerative disease-related Compound Library	902 compounds	A unique collection of 902 compounds related to neurodegenerative diseases can be used for HTS or HCS; Targets include AchE, NMDA, CGRP, β-secretase, γ-secretase, Dopamine receptor, Adenosine receptor, 5-HT receptor, etc.; Some of them are FDA-approved.
Bioactive Compound Library	8172 compounds	A collection of 8172 small molecule compounds with validated activity for high throughput screening (HTS), high content screening (HCS), cell induction, and target identification; All compounds have clear targets; An effective tool for discovering new with old drugs, cell induction, and new drug target screening.
Bioactive Compound Supplement Library	990 compounds	It is well-selected from Bioactive compound library Plus (D7800), from which 1-15 compounds with the highest scores (activity value, pharmacological properties, structure-diversity, etc.) were chosen. This library consists of 990 compounds without compromising the number of targets, but with more unique structures than known drugs and more bioactivity information than drug-like compounds.
Antifungal Compound Library	147 compounds	A unique collection of 147 antifungal compounds effective for drug repurposing screening, combination screening and biological investigation. Contains antifungal agents to treat tinea corporis and Candidiasis, and compounds inhibiting the fungal-specific targets. Bioactivity and safety confirmed by clinical research and trials, some of which are FDA approved.
Anti-Parasite Library	358 compounds	358 well-chosen unique anti-parasitic small molecules; High bioactivity: All compounds with IC50 below 0.9 μM; Most are anti-malaria compounds, but includes anti-trypanosomal, anti-schistosomiasis, and anti-cryptosporidial compounds.

Product Name	Quantity	Description
Antibacterial Activity Library	909 compounds	A unique collection of 909 antibacterial bioactive compounds, a powerful tool for antibacterial drug development; Includes various antibiotics and antibacterial bioactive compounds with unique structures; Detailed information about compound structure, target, activity, etc.
Nervous system disease Library	935 compounds	Well-chosen 935 compounds with unique structures targeting nervous system; High bioactivity: All compounds with IC50 below 3.5 μ M; Covers 52 nervous system disease related targets with each compound having clear target.
Immunology/ Inflammation Compound Library	2682 compounds	A unique collection of 2682 anti-inflammation compounds effective for high throughput screening and high content screening. Bioactivity and safety confirmed by clinical research and trials, some of which are FDA approved.
Nonsteroidal Antiinflammatory Compound Library	530 compounds	A unique collection of 530 nonsteroidal anti-inflammatory related compounds can be used for HTS and HCS; Contains common NSAIDs, such as aspirin, indomethacin, ibuprofen, Sulindac, Piroxicam, etc.
Anti-Metabolism Disease Compound Library	1040 compounds	A unique collection of 1040 metabolism diseases related compounds for high throughput screening (HTS) and high content screening (HCS); Bioactivity and safety confirmed by pre-clinical research and clinical trials and most of them are approved for marketing by FDA, EMA, or CFDA.
Anti-Cardiovascular Disease Compound Library	515 compounds	A unique collection of 515 cardiovascular diseases related compounds for high throughput screening (HTS) and high content screening (HCS); Bioactivity and safety confirmed by pre-clinical research and clinical trials and most of them are approved by FDA, EMA, or CFDA; Covers various major targets including membrane transporter, ion channel, etc.; Effect tool for research in cardiovascular disease.
Anti-obesity Compound Library	1176 compounds	A unique collection of 1176 anti-obesity compounds for high throughput and high content screening.
Hematonosis Compound Library	126 compounds	A unique collection of 126 compounds related to hematologic diseases for high throughput screening (HTS) and high content screening (HCS); Effective tool for research in functions of the hematologic system and related diseases, such as hemophilia, leukemia, β -thalassemia.
Cytoskeletal Signaling Pathway Compound Library	343 compounds	A unique collection of 343 cytoskeleton-related compounds, can be used for HTS and HCS; Targets include Microtubule/Tubulin, Kinesin, PKC, MAPK, etc.; Part of them are FDA-approved drugs; Structural diversity with strong bioactivities and cell permeability.
Anti-Alzheimer's Disease Compound Library	623 compounds	A unique collection of 623 compounds with anti-AD activities or acting on main drug targets of AD can be used for HTS and HCS. Targets include tau protein, γ Secretase, 5-HT Receptor, BACE, etc. Some of them are FDA approved. Detailed information about compound structure, target, activity, IC50, etc.
Anti-Parkinson's Disease Compound Library	184 compounds	A unique collection of 184 compounds with anti-PD activities or acting on main drug targets of PD can be used for HTS and HCS. Targets include Dopamine Receptor, COMT, MAO-B, 5-HT Receptor, etc. Some of them are FDA approved. Detailed information about compound structure, target, activity, IC50, etc.
Anti-fibrosis Compound Library	981 compounds	A unique collection of 981 potential anti-fibrosis compounds, can be used in HTS and HCS; Targets include TGF β , TNF α , MMP, EGFR, NADPH-oxidase, etc. Some compounds are in the market (FDA-approved).

Natural Product Libraries

Product Name	Quantity	Description
Selected Plant-sourced Compound Library	1825 compounds	A unique collection of 1825 plant-sourced compounds that derived from 277 plant species for high throughput screening (HTS) and high content screening (HCS).
Natural Compound Library for HTS	2800 compounds	A unique collection of 2800 pure natural products and their derivatives with known biological activity for drug discovery, pharmacological study, stem cell differentiation, fingerprint study and quality research, and can be used for high throughput screening (HTS) and high content screening (HCS); Documentation with clear source: isolated natural products from plant, animal, microorganism, etc.
Polyphenolic Natural Compound Library	411 compounds	A unique collection of 411 natural polyphenolic compounds for high throughput screening (HTS) and high content screening (HCS).
Alkaloids natural compound library	317 compounds	A unique collection of 317 natural alkaloids can be used for high throughput and high content screening.
Flavonoids natural compound library	252 compounds	A unique collection of 252 flavonoids can be used for high throughput and high content screening.
Terpene natural compound library	312 compounds	A unique collection of 312 natural terpenes and terpenoids can be used for high throughput and high content screening.
Saccharides and glycosides Compound Library	348 compounds	A unique collection of 348 saccharides and glycosides compounds can be used for HTS and HCS.
Food as Medicine Library	588 compounds	A unique collection of 588 compounds from food as medicine for high throughput and high content screening.
Microbial Natural Product Library	134 compounds	A unique collection of 134 microbial natural products for high throughput screening (HTS) and high content screening (HCS); Targets include alpha-glucosidase, beta-lactamase, TNF-alpha, HDAC, PKC, HSP90, etc.
Antitumor Natural Products Library	1025 compounds	A unique collection of 1025 natural products with known anti-cancer activity for high throughput screening (HTS) and high content screening (HCS); Known bioactivity for all compounds: detailed biological and pharmacological information, providing the research foundation and theoretical direction for screening.
Anti-Inflammatory Tradition Chinese Medicine Library	319 compounds	A collection of 319 TCM monomers with anti-inflammatory activity or targeting molecular therapeutic targets in inflammation, a powerful tool for drug discovery and mechanism study; Covers various targets such as COX, CCR, STAT, TGFβ, etc. involved in inflammation; Diversity: includes Flavone, Saponins, Terpenes, Alkaloids, etc.
Selectable Natural Compound Library	18788 compounds	A unique collection of 18788 pure natural products with diverse structures and sources covering various plant, animal, and microbe species; Free SDF data available for each compound structure in this library, an effective tool for virtual screening; All products can be resupplied.
Anti-gastroenteritis Natural Product Library	112 compounds	A unique collection of 112 natural products related to gastroenteritis for high throughput screening (HTS) and high content screening (HCS); Effective tool for research in gastric function and gastric diseases, such as gastritis, gastric ulceration, Crohn's disease, ulcerative colitis, appendicitis, etc. Bioactivity and safety profiled in pre-clinical and clinical settings.
Natural Compound Library in Chinese Pharmacopoeia	1339 compounds	A unique collection of 1339 natural products included in Chinese Pharmacopoeia (CP), a powerful tool for drug development and pharmacological study; Diversified structures: including flavonoids, polyphenols, Alkaloids, etc.; Clear source: known active natural products selected from animals, plants, or microorganisms with clear species information.
Rare Natural Compound Library	193 compounds	A unique collection of 193 rare natural products, which can be used for high throughput screening (HTS) and high content screening (HCS); Documentation with clear source: isolated natural products from plant, animal, microorganism, etc.

Product Name	Quantity	Description
Anti-COVID-19 Traditional Chinese Medicine Compound Library	389 compounds	A unique collection of 389 monomers from 60 TCM plants, a powerful tool for anti-COVID-19 drug discovery, can be used for HTS and HCS screening.
Traditional Chinese Medicine Monomer Library	1594 compounds	A unique collection of 1594 compounds (TCM monomers) sourcing from traditional Chinese Medicines, is a powerful tool for drug discovery and research in mechanism; Sources from about 300 Chinese Herbal Medicines, such as Panax natoginseng, Licorice, Angelica, Pericarpium Citri Reticulatae, Coptis chinensis, Panax ginseng, etc.; Diversified structures including Flavonoids, Alkaloids, Terpenes, Glycosides, etc.

Fragment Libraries

Product Name	Quantity	Description
Drug-fragment Library	1180 compounds	Quantity: 1180 drug fragments, a must-have tool for FBDD; Physicochemical properties: 53% of fragments are Ro3 compliant, and all fragments matching with approved drugs or clinical compounds will have the best drug potential; Applicable to various detection methods: suitable for SPR, NMR, and X-ray crystallization screening.
Featured Fragment Library	246 compounds	A unique collection of 246 fragment-like small molecules for FBDD.
High Solubility Fragment Library	2746 compounds	More diversity: structurally diverse, medically active, and unique chemistry (strong IP potential); More opportunity for further scaffold modification; Attractively priced.

Diversity Sets

Product Name	Quantity	Description
Mini Scaffold Library	5033 compounds	Diversity: Selected from 1,600,000 drug-like compounds covering rich chemical scaffolds, 5033 compounds representing 5033 scaffolds; Drug-likeness: filtering out reactive, toxic and otherwise undesirable structural motifs, and removing compounds that demonstrate a broad promiscuous activity (PAINS); Cost effective: Liquid small package is available.
Golden Scaffold Library	10000 compounds	Diversity: Selected from 1,600,000 drug-like compounds, 10000 compounds representing 5000 scaffolds selected from a large drug-like chemical source; Drug-likeness: filtering out reactive, toxic and otherwise undesirable structural motifs, and removing compounds that demonstrate a broad promiscuous activity (PAINS); Cost effective: Liquid small package is available.

Table of Contents

Angiogenesis

ALK.....	24
Bcr-Abl.....	25
BTK.....	27
EGFR.....	27
FAK.....	30
FGFR.....	31
FLT.....	32
HER.....	34
HIF.....	35
JAK.....	36
PDGFR.....	37
Src.....	39
Syk.....	41
VDA.....	41
VEGFR.....	41

Apoptosis

Apoptosis.....	45
ASK.....	47
BCL.....	47
Caspase.....	49
c-RET.....	50
Fas/FasL.....	50
Ferroptosis.....	50
IAP.....	51
Mdm2.....	51
OXPHOS.....	52
p53.....	52
PD-1/PD-L1.....	52
PERK.....	53
RIP kinase.....	53
Survivin.....	53
TNF.....	53

Autophagy

Autophagy.....	56
CXCR.....	59
LRRK2.....	60
lysosomal autophagy.....	60
Mitophagy.....	60

Cell Cycle/Checkpoint

Antifolate.....	61
APC.....	61
Aurora Kinase.....	62
CDK.....	63
cell cycle arrest.....	66
Chk.....	66
c-Myc.....	66
Deubiquitinase.....	67
DHFR.....	67
DNA Alkylator/Crosslinker.....	67
DNA/RNA Synthesis.....	67
DYRK.....	71
Ferroptosis.....	71
Haspin Kinase.....	71
KSP.....	71
LIM Kinase.....	72
Nucleoside Antimetabolite/Analog.....	72
PD-1/PD-L1.....	72
PLK.....	72
Rho.....	73
ROCK.....	73
Serine/threonin kinase.....	74
Wee1.....	74

Chromatin/Epigenetic

Aurora Kinase.....	75
DNA Methyltransferase.....	76

Epigenetic Reader Domain	77
HDAC	79
HIF	81
HIF/HIF Prolyl-Hydroxylase	82
Histone Acetylation	82
Histone Acetyltransferase	82
Histone Demethylase	83
Histone Methyltransferase	83
JAK	85
MicroRNA	87
PAD	87
PARP	87
Pim	88
PKC	88
Sirtuin	90

Cytoskeletal Signaling

Akt	92
Bcr-Abl	94
Dynamin	95
FAK	95
Gap Junction Protein	96
HSP	96
Integrin	97
Kinesin	98
Microtubule Associated	98
Myosin	100
PAK	100
PKC	100
ROCK	102
Wnt/beta-catenin	102

DNA Damage/DNA Repair

Antifolate	104
ATM/ATR	104
Deubiquitinase	105
DHFR	105

DNA	105
DNA Alkylation	106
DNA Alkylator/Crosslinker	106
DNA gyrase	106
DNA/RNA Synthesis	107
DNA-PK	110
HDAC	111
MTH1	113
Nucleoside Antimetabolite/Analog	113
PARP	114
PPAR	115
Sirtuin	117
Telomerase	118
Topoisomerase	118

Endocrinology/Hormones

Androgen Receptor	120
Aromatase	121
Estrogen Receptor/ERR	122
Estrogen/progestogen Receptor	122
Glucocorticoid Receptor	124
GPR	126
LHRH	127
Opioid Receptor	127
Oxytocin Receptor	129
RAAS	129
Reductase	131
Thyroid hormone receptor (THR)	131

GPCR/G Protein

5-HT Receptor	132
Adenosine Receptor	138
Adiponectin Receptor	139
Adrenergic Receptor	139
Annexin A	144
Apelin receptor	144
Bombesin Receptor	144

Bradykinin Receptor144
 cAMP145
 Cannabinoid Receptor145
 CaSR.....146
 cholecystokinin.....146
 CRFR.....146
 CXCR.....146
 Dopamine Receptor.....147
 EBI2/GPR183151
 Endothelin Receptor.....151
 GHSR.....151
 Glucagon Receptor152
 GNRH Receptor152
 GPCR19153
 GPR153
 GRK154
 GTPase.....154
 Guanylate Cyclase154
 Hedgehog/Smoothed155
 Histamine Receptor155
 Leukotriene Receptor158
 LPA Receptor158
 Melanin-concentrating Hormone
 Receptor (MCHR).....159
 Melanocortin Receptor159
 Melatonin Receptor159
 Motilin Receptor.....159
 Neurokinin Receptor159
 Neuropeptide Y Receptor160
 Neurotensin Receptor160
 Opioid Receptor160
 OX Receptor.....162
 Oxytocin Receptor162
 PAFR.....162
 Prostaglandin Receptor.....163
 Protease-activated Receptor164
 Ras164

S1P Receptor165
 SGLT165
 Sigma receptor.....166
 Somatostatin.....166
 TSH Receptor.....166
 Vasopressin Receptor167

Immunology/Inammation

AhR.....168
 Antiviral169
 Arginase.....170
 Aryl Hydrocarbon Receptor170
 CCR.....170
 Cell wall170
 Complement System.....171
 COX.....171
 CXCR.....175
 FLAP176
 gp120/CD4.....176
 Histamine Receptor176
 IL Receptor179
 Immunology & Inflammation related ... 180
 Interleukin Related181
 IRAK.....181
 LTR.....181
 MALT182
 MRP.....182
 MyD88182
 NADPH-oxidase.....182
 NO Synthase.....183
 NOD.....183
 NOD-like Receptor (NLR)183
 NOS.....183
 Nrf2184
 PD-1/PD-L1.....185
 PGE Synthase185
 Prostaglandin Receptor.....185

Reactive Oxygen Species.....186
 ROS186
 STING187
 TLR188

JAK/STAT signaling

EGFR.....189
 HER192
 JAK193
 Pim.....195
 STAT195

MAPK

ERK.....197
 JNK.....199
 MAPK.....199
 MEK.....200
 MLK201
 MNK.....201
 p38 MAPK201
 Raf203
 Ras204
 S6 Kinase205
 TOPK.....205

Membrane transporter/Ion channel

ABC.....206
 Anion exchanger207
 Aquaporin.....207
 ATP Citrate Lyase.....207
 ATPase207
 BCRP208
 Calcium Channel.....208
 CFTR.....211
 CGRP Receptor211
 Chloride channel211

CRM1212
 GABA Receptor212
 HCN Channel.....215
 iGluR215
 Monoamine Transporter215
 Monocarboxylate Transporter215
 Na+/Ca2+ Exchanger215
 Na-K-Cl cotransporter216
 NPC1L1216
 OAT216
 OCT216
 P2X Receptor216
 P-gp.....216
 Potassium Channel.....217
 Proton pump220
 Sodium Channel220
 TRP/TRPV Channel.....222
 VDAC224

Metabolism

Acetyl-CoA Carboxylase.....225
 aconitase226
 Acyltransferase226
 AhR.....226
 Amino Acids and Derivatives.....226
 Aminopeptidase227
 ATP Citrate Lyase.....227
 Carbonic Anhydrase227
 Carboxypeptidase(CPG2)228
 Casein Kinase228
 CETP.....229
 CPT229
 Decarboxylase.....229
 Dehydrogenase229
 DHFR232
 Electron transport232
 Endogenous Metabolite232

Epoxide Hydrolase.....	238	PPAR.....	254
FAAH.....	238	RAR/RXR.....	256
FABP.....	238	Reactive Oxygen Species.....	256
Factor Xa.....	238	Reductase.....	256
Fatty Acid Synthase.....	239	Retinoid Receptor.....	257
FXR.....	239	ROR.....	257
Glucokinase.....	239	Serine/threonin kinase.....	258
Glutathione Peroxidase.....	240	SGK.....	258
GSNOR.....	240	Stearoyl-CoA Desaturase (SCD).....	258
Hexokinase.....	241	Thioredoxin.....	258
HIF/HIF Prolyl-Hydroxylase.....	241	transaminase.....	259
HMG-CoA Reductase.....	241	Transferase.....	259
HSP.....	241	transporter.....	259
Hydroxylase.....	243	UGT.....	260
IDO.....	243	Vitamin.....	260
Indoleamine 2,3-Dioxygenase (IDO).....	243	Xanthine Oxidase.....	261
Isocitrate Dehydrogenase (IDH).....	243		
LDL.....	244	Microbiology/virology	
Lipase.....	244	Antibacterial.....	262
Lipid.....	244	Antibiotic.....	267
Lipoxygenase.....	244	Antifection.....	271
Liver X Receptor.....	245	Antifungal.....	272
MAO.....	245	Anti-infection.....	274
Mitochondrial Metabolism.....	246	CCR.....	274
MPO.....	247	HBV.....	275
N-acetylglucosaminyltransferase.....	247	HCV Protease.....	275
NADPH.....	247	HIV Protease.....	276
NAMPT.....	248	HSV.....	278
Neprilysin.....	248	Influenza Virus.....	278
P450.....	248	Integrase.....	279
PAI-1.....	250	Parasite.....	279
PDE.....	251	Reverse Transcriptase.....	280
PED.....	252	ribosome.....	280
phosphatase.....	253	RSV.....	281
Phospholipase.....	253	SARS-CoV.....	282
Phosphorylase.....	254	Virus Protease.....	282
PKM.....	254		

Neuroscience

5-HT Receptor	283
AChE.....	289
AChR	289
Adenylyl cyclase.....	295
Adrenergic Receptor.....	295
ATP Citrate Lyase.....	300
BACE	300
Beta Amyloid	301
Beta-secretase	302
CaMK.....	302
COX.....	303
Dopamine Receptor.....	307
FAAH.....	311
GABA Receptor	311
Gamma-secretase.....	314
Glur	314
GlyT	316
Histamine Receptor	316
iGluR	319
MAO.....	320
Melanocortin Receptor.....	321
Monoamine Oxidase.....	321
MT receptor	321
Neurokinin Receptor	321
Neuropeptide Y Receptor	322
NMDAR.....	322
NMU2R.....	323
Norepinephrine.....	323
Opioid Receptor	325
OX Receptor.....	326
P2 Receptor	327
P-gp.....	327
Serotonin Transporter.....	328

NF-κB

IRAK.....	329
-----------	-----

IκB/IKK.....	329
NF-κB	330
NOD.....	333
Reactive Oxygen Species.....	333
RIP kinase	333

PI3K/Akt/mTOR signaling

Akt.....	334
AMPK.....	336
ATM/ATR.....	337
DNA-PK	338
GSK-3	338
MELK	340
mTOR	340
PDK	341
PI3K.....	342
PI4K.....	345
PTEN	345
SIK.....	345

Proteases/Proteasome

Acetyl-CoA Carboxylase.....	346
Acyltransferase	346
ATP Citrate Lyase.....	347
Caspase	347
Cysteine Protease	348
DPP-4	349
Gamma-secretase.....	349
Glutaminase.....	350
HCV Protease.....	350
HIV Protease	351
MMP	353
Neprilysin	354
phosphatase	354
Proteasome	354
Serine Protease.....	355
Thrombin.....	356

Tyrosinase356

Stem Cells

Casein Kinase.....358

Gamma-secretase.....359

GSK-3359

Hedgehog/Smoothened360

Hippo pathway.....361

JAK.....361

Porcupine363

ROCK.....363

Smo.....364

STAT364

Stemness kinase365

TACC.....365

TGF-beta/Smad.....365

Wnt/beta-catenin.....366

YAP367

Tyrosine Kinase/Adaptors

ACK.....368

ALK.....369

Bcr-Abl370

BTK.....371

c-Fms372

c-Kit.....372

c-Met/HGFR374

c-RET.....375

CSF-1R376

Discoidin Domain Receptor (DDR)...376

DYRK376

EGFR.....377

Ephrin Receptor380

FAK.....380

FGFR.....380

FLT382

Hck.....384

HER384

IGF-1R384

PDGFR.....385

PKA.....387

PYK2.....388

Src388

Syk389

TAM Receptor390

Tie-2391

Trk receptor391

Tyrosine Kinases391

VEGFR392

Ubiquitination

DUB.....396

E1/E2/E3 Enzyme.....397

p97397

Proteasome397

Reagent Kits

Protease Inhibitor Cocktail399


Phosphatase Inhibitor Cocktail399

Cell Counting Kit-8 (CCK-8)400

SYBR Green qPCR Master Mix.....400

Angiogenesis

Angiogenesis



ALK

ID	Product Name	Target	Condition
T8399	Crizotinib hydrochloride	ALK; c-Met	FDA Approved
T8387	Alectinib hydrochloride	ALK	FDA Approved
T8152	6-Demethoxytangeretin	ALK; MAPK	
T8108	Blu-782	ALK2	Phase 1
T6496	Vactosertib	ALK1; ALK2; ALK3; ALK4; ALK5	Phase 1/2
T6337	RepSox	ALK5; TGFβR1	
T6158	LDN-193189 HCl	ALK2; ALK3	
T5197	BIBF0775	TGFβR1(ALK5); Alk5	
T4975	SM 16	ALK4; ALK5	Preclinical
T4257	Belizatinib	ALK	Phase 1/2

ID	Product Name	Target	Condition
T4071	TPX0005	ALK; Src	Phase 1/2
T4015	HG-14-10-04	ALK	
T3678	Entrectinib	ALK; ROS1; TrkA; TrkB; TrkC	FDA Approved
T3621	Brigatinib	ALK; EGFR (C797S/del19); FLT3; IGF-1R; ROS1	FDA Approved
T3550	Ensartinib	ALK; MET	Phase 3
T3079	GSK1838705A	ALK; IGF-1R; Insulin Receptor; JNK3; RSK1	Preclinical
T3061	Lorlatinib	ALK; ALK (L1196M); ROS1; ROS1; LTK (TYK1)	FDA Approved
T3059	AP26113	ALK; EGFR (C797S/del19); EGFR (del19); EGFR (del19); IGF-1R	
T3041	ALK inhibitor 2	ALK	
T3031	ALK5 Inhibitor IV	ALK4; ALK5; ALK7	
T2655	CEP37440	ALK; FAK	Phase 1
T2641	KRCA0008	ACK; ALK	
T2612	CEP28122	ALK	Preclinical
T2462	SB505124	ALK4; ALK5	Preclinical
T2449	D 4476	ALK5; CK1; CK1 δ	
T2251	TAE684	ALK	Preclinical
T2098	A77-01	ALK5	
T1962	ASP 3026	ALK	Phase 1
T1944	LDN214117	ALK2	
T1943	ML347	ALK1; ALK2; ALK3; ALK6	
T1942	DMH1	ALK2	
T1936	Alectinib	ALK; ALK (F1174L); ALK (R1275Q); INSR; VEGFR2 (KDR)	FDA Approved
T1935	LDN193189	ALK2; ALK3	
T1914	K 02288	ALK1; ALK2; ALK3; ALK4; ALK6	
T1900	LDN212854	ALK1; ALK2; ALK3; ALK4; ALK5	
T1800	GW 788388	ALK5	
T1791L	LDK378 dihydrochloride	ALK	FDA Approved
T1791	LDK378	ALK; IGF-1R; Insulin Receptor; STK22D	FDA Approved
T1763	SB525334	T β R1; ALK5; ALK4	
T1726	SB 431542	ALK5; ALK4; ALK7	Preclinical
T16708	R-268712	ALK5	
T1661	Crizotinib	ALK; c-Met	FDA Approved

Bcr-Abl

ID	Product Name	Target	Condition
T8488	GMB-475	Bcr-Abl1	
T7861	Flumatinib mesylate	PDGFR β ; c-Kit; c-Abl	Phase 3
T7186	CZC-8004	Abl	
T6348	NVP-BHG712	EphB4; c-Raf; c-Src; c-Abl	

ID	Product Name	Target	Condition
T6311	Bafetinib	Abl; Lyn	Phase 1
T6300	Degrasyn	Bcr-Abl	Preclinical
T6230	Imatinib	v-Abl; c-Kit; PDGFR	FDA Approved
T6196	PP1	Bcr-Abl; Kit; EGFR; Fyn; Lck	
T6128	PHA665752	c-Abl; c-Met; RON; FGFR1; Flk1	Preclinical
T6057	URMC099	Aurora A; Aurora B; Aurora C; Abl1; CDK1; CDK2; c-Met; DLK; IGF-1R; Insulin Receptor; LRRK2; MEKK2; MLK1; MLK2; MLK3; ROCK1; ROCK2; SGK; SGK1; Lck; Syk; TrkA; TrkB; VEGFR1/FLT1	
T5177	Asciminib	Abl1	Phase 3
T4618	K 0859	c-ABL-T334; Abl; Abl (T315I)	
T4320	Flumatinib	c-Abl; PDGFR β ; c-Kit;	Phase 3
T3641	BAW2881	c-Abl; B-Raf (V599E); C-Raf-1; hVEGFR2	
T3196	GNF7	M351T; c-Abl; E255V; G250E; T315I	
T3071	GZD 824	Abl (E254K)	Phase 2
T3068	AT9283	Aurora A; Aurora B; Abl1 (T315I); JAK2; JAK3	Phase 1
T3063	PD173955	Bcr-Abl; Src	Preclinical
T2920	Berberamine dihydrochloride	Abl	Approved
T2802	Nocodazole	Abl; Abl (E255K); Abl (T315I); microtubule	
T2640	DCC2036	Abl1; p-Abl1 (native); p-Abl1 (T315I); u-Abl1 (native); FLT3	Phase 1/2
T2609	Masitinib	Abl1; c-Fms; Kit; Hck; PDGFR α ; PDGFR β ; Lyn B; Src	Approved
T2429	GZD824 Dimesylate	Abl; Abl (E255K); Abl (H396P); Abl (M351T); Abl (Q252H)	Phase 2
T2415	PP121	Hck; mTOR; PDGFR; Src; VEGFR; Abl	
T2372	Ponatinib	Abl; c-Kit; FGFR1; PDGFR α ; c-Src; VEGFR2	FDA Approved
T2341	KW2449	Aurora A; Abl; Abl (T315I); Kit; FGFR1; FLT3; FLT3 (D835Y); JAK2; Src	Phase 1/2
T2328	Radotinib	Bcr-Abl1	Approved
T2293	SGX523	Abl; c-Met; p38 α ; B-Raf (V599E); C-Raf	Phase 1
T2147	Nilotinib (monohydrochloride monohydrate)	Bcr-Abl	FDA Approved
T2116	AEE788	c-Abl; c-Fms; EGFR; HER2/ErbB2; FLT1	Phase 1/2
T2094	Danuserib	Aurora A; Aurora B; Aurora C; Abl; RET; FGFR1; TrkA	Phase 2
T2070	CEP32496	Abl1; c-Kit; RET; PDGFR β ; Lck	Phase 1
T1817	GNF2	Bcr-Abl (K562 cell line); Bcr-Abl (SUP-B15 cell line)	
T1803	GNF5	Bcr-Abl	
T1754	ZM 306416	Abl; Src; VEGFR1	
T1621	Imatinib Mesylate	v-Abl; c-Kit; PDGFR	FDA Approved
T1524	Nilotinib	Bcr-Abl	FDA Approved
T1448L	Dasatinib monohydrate	Abl; c-Kit (D816V); c-Kit (wt); EphA2; Src	FDA Approved
T1448	Dasatinib	Abl; c-Kit (D816V); c-Kit (wt); Src	FDA Approved
T0152	Bosutinib	Abl; c-Src	FDA Approved

BTK

ID	Product Name	Target	Condition
TQ0230	BTK IN-1	BTK	
T8636	Ibrutinib deacryloylpiperidine	Btk	
T7584	zanubrutinib	BTK	FDA Approved
T6921	ONO-4059 analogue	BTK	
T6918	Olmutinib	EGFR (cell: H1975); EGFR (cell: HCC827); BTK	Approved
T6217	LFM-A13	BTK	Preclinical
T6078	Saracatinib	c-Src; Lck; BLK; EGFR (L858R); EGFR (L861Q); c-Yes; FGR; Fyn; Lyn	Phase 2
T5407	BMS986195	BTK	Phase 1
T5138	BMS986142	BTK	Phase 2
T4391	Syk Inhibitor II (hydrochloride)	Syk; PKC ϵ ; PKC β II; ZAP-70; Btk; Itk; ZAP70; Btk	
T4387	evobrutinib	BTK	Phase 2
T4337	PCI29732	BTK; Itk	
T4268	CHMFL-BMX-078	Bmx	
T3626	Acalabrutinib	BTK	FDA Approved
T3024	Avitinib	EGFR; JAK3; BTK	Phase 2
T2603	Spebrutinib	BRK; BTK; c-Src; Lyn; Yes	Phase 2
T2472	CGI1746	BTK	
T2302	CNX774	BTK	
T1976	RN486	BTK	
T1835	Ibrutinib	BLK; Bmx; BTK; FGR; CSK	FDA Approved
T14323	ARQ 531	WT-BTK; C481S-BTK	Phase 2
T12542	PRN1008	BTK; BMX; ITK; TEC; RLK; BLK; EGFR; ERBB2; ERBB4	Phase 3
T12317	Orelabrutinib	BTK	
T10629	Btk inhibitor 2	BTK	
T10625	IBT6A	BTK	

EGFR

ID	Product Name	Target	Condition
T9905	Cetuximab (anti-EGFR)	EGFR	Approved
T8872	(Rac)-JBJ-04-125-02	EGFR (L858R/T790M)	
T8758	Poziotinib hydrochloride	EGFR	
T8751	AZD8931 diFuMaric acid	EGFR; ErbB2; ErbB3	
T8679	Epidermal Growth Factor	EGFR	
T8460	Olmutinib	EGFR	
T8431	JCN037	EGFR	
T8189	Dihydroberberine	hERG; HSP90	

ID	Product Name	Target	Condition
T8151	Mobocertinib	EGFR	
T7649	Tyrphostin A1	EGFR	
T7322	Theliatinib	EGFR	
T7198	E-4031	hERG Potassium Channel	
T7175	AST2818 mesylate	EGFR	Phase 3
T6932	PD168393	EGFR; FGFR; Insulin Receptor; PDGFR; PKC	Preclinical
T6918	Olmутinib	EGFR (cell: H1975); EGFR (cell: HCC827); BTK	Approved
T6824	EAI045	EGFR mutants	
T6734	WZ8040	EGFR (T790M)	
T6733	WZ3146	EGFR (E746_A750); EGFR (E746_A750/T790M); EGFR (L858R); EGFR (L858R/T790M)	
T6712	Tyrphostin AG 879	EGFR; HER2-Neu; PDGFR; Trk	
T6427	Butein	EGFR; p60c-src	
T6331	AST-1306 TsOH	EGFR; EGFR (T790M/L858R); HER2/ErbB2; HER2/ErbB2; FLT1	Phase 1
T6328	Desmethyl Erlotinib	EGFR	
T6266	PP2	EGFR; JAK2; Fyn; Lck; ZAP70	
T6238	WZ4002	EGFR (L858R); EGFR (L858R/T790M)	
T6235	Lapatinib Ditosylate	EGFR; HER2/ErbB2	FDA Approved
T6227	Benidipine hydrochloride	EGFR (L861Q); c-Src; c-Yes; Lck; Lyn	Approved
T6196	PP1	Bcr-Abl; Kit; EGFR; Fyn; Lck	
T6153	Icotinib	EGFR	Approved
T6136	Canertinib	EGFR; HER2/ErbB2	Phase 2
T6124	Mubritinib	EGFR; HER2/ErbB2; FGFR; JAK1; PDGFR	Phase 1
T6092	Sapitinib	EGFR; HER2/ErbB2; HER2/ErbB2	Phase 1/2
T6078	Saracatinib	c-Src; Lck; BLK; EGFR (L858R); EGFR (L861Q); c-Yes; FGR; Fyn; Lyn	Phase 2
T6008	CNX2006	EGFR (mutant)	
T5675	HS-10296 hydrochloride	EGFR	Phase 3
T5437	Gefitinib-based PROTAC 3	EGFR	
T5410	PD158780	EGFR; ErbB2; ErbB3; ErbB4	
T5168	EGFR Inhibitor	EGFR; EGFR (L858R); EGFR (L861Q)	
T5155	AG 99	EGFR	
T4694	AG-1557 hydrochloride (189290-58-2(free base))	hERG; EGFR	
T4612	NS309	Potassium Channel; hERG	Preclinical
T4528	Tyrphostin AG 528	EGFR; ErbB2	
T4326	AG 555	EGFR	
T4296	MTX211	EGFR; PI3K	Preclinical
T4249	AZD3759 hydrochloride	EGFR (exon 19De); EGFR (L858R); EGFR (wt)	Phase 2/3
T4205	AG 494	EGFR	
T4014	CP724714	HER2/ErbB2	

ID	Product Name	Target	Condition
T3870	Cyasterone	EGFR	
T3721	Avitinib maleate	EGFR	Phase 2
T3659	AZD3759	EGFR (exon 19Del); EGFR (L858R); EGFR (WT)	Phase 2/3
T3634	Osimertinib mesylate	EGFR (L858R); EGFR (L858R/T790M)	FDA Approved
T3621	Brigatinib	ALK; EGFR (C797S/del19); FLT3; IGF-1R; ROS1	FDA Approved
T3558	EBE-A22	EGFR/ErbB1	
T3554	RG 14620	HER14 colony formation; HER14 DNA synthesis; EGFR	
T3545	RG 13022	EGFR	Preclinical
T3506	Nazartinib	EGFR (mutant)	Phase 3
T3402	Ginsenoside Rg3	EGFR	Approved
T3192	NS1643	HERG	
T3108	CUDC101	EGFR; HDAC; HDAC1; HDAC10; HDAC2; HDAC3; HDAC4; HDAC5; HDAC6; HDAC7; HDAC8; HDAC9; HER2	Phase 1
T3059	AP26113	ALK; EGFR (C797S/del19); EGFR (del19); EGFR (del19); IGF-1R	
T3024	Avitinib	EGFR; JAK3; BTK	Phase 2
T2S0961	Chalcone	EGFR	
T2995	Chrysophanic Acid	EGFR	Approved
T2959	Ginsenoside Rh2	EGFR	
T2894	Norcantharidin	c-Met; EGFR	Preclinical
T2859	Biochanin A	EGFR; FAAH (human); FAAH (mouse); FAAH (rat)	
T2851	Daphnetin	EGFR; PKA; PKC	Approved
T2705	Mutant EGFR inhibitor	EGFR (mutant)	
T2642	PD173074	EGFR; FGFR1; Insulin Receptor; c-Src; VEGFR2	Preclinical
T2501	Canertinib dihydrochloride	EGFR; HER2/ErbB2	Phase 2
T2491	AZ5104	EGFR (L858R); EGFR (L858R/T790M); EGFR (L861Q); EGFR (wildtype); HER2/ErbB2	
T2490	Osimertinib	EGFR (Exon 19 deletion); EGFR (L858R/T790M)	FDA Approved
T2483	Dacomitinib	EGFR; HER2/ErbB2; HER2/ErbB2	FDA Approved
T2479	Tyrphostin 9	EGFR; PDGFR	Preclinical
T2446	KI8751	c-Kit; EGFR; FGFR2; PDGFR α ; VEGFR2	
T2369	Rociletinib	EGFR (L858R/T790M); EGFR (wt)	Approved
T2364	Irbinitinib	EGFR; HER2/ErbB2; p95 HER2	FDA Approved
T2327	Pelitinib	EGFR; HER2/ErbB2; MEK; Raf; Src	Phase 2
T2325	Neratinib	EGFR; HER2	FDA Approved
T2303	Afatinib	EGFR (L858R); EGFR (L858R/T790M); EGFR (wt); HER2; HER4	FDA Approved
T2280	Endoxifen Z-isomer	hERG Potassium Channel; ER; ERR; hERG	Phase 3
T2245	CL387785	EGFR	Preclinical
T21312	Afatinib free base	EGFR	FDA Approved
T2116	AEE788	c-Abl; c-Fms; EGFR; HER2/ErbB2; FLT1	Phase 1/2
T2106	WS6	ErbB3-Binding Protein-1 (EBP2); I κ B kinase	

ID	Product Name	Target	Condition
T2063	AG18	EGFR	Preclinical
T2055	WS3	ErbB3-Binding Protein-1 (EBP1); IκB kinase	
T2047	AG1478	EGFR; HER2; PDGFR	Preclinical
T2041	PD153035	EGFR	Phase 1
T2035	WHI-P258	EGFR; JAK3	
T2034	AG1557	hERG; EGFR	
T2032	WHI-P180	CDK2; EGFR	Preclinical
T1985	WHI-P154	EGFR; JAK3; Src; VEGFR	Preclinical
T19814	CP-380736	EGFR	
T1773	Afatinib Dimaleate	EGFR (L858R); EGFR (L858R/T790M); EGFR (wt); HER2	FDA Approved
T1761	PD153035 hydrochloride	EGFR; EGFR	Preclinical
T1737	Genistein	EGFR	Approved
T1656	Vandetanib	EGFR; VEGFR2; VEGFR3	FDA Approved
T16369	O-Desmethyl gefitinib	EGFR	
T1291	Cisapride	5-HT; Potassium Channel; hERG channel	FDA Approved
T1266	Terfenadine	HT; mAChR; Potassium Channel; hERG	Approved
T1181	Gefitinib	Tyr1173 (NR6W cells); Tyr1173 (NR6wtEGFR cells); Tyr992 (NR6W cells); Tyr992 (NR6wtEGFR cells); Tyr992	FDA Approved
T1144L	Lidocaine Hydrochloride hydrate	EGFR; Sodium Channel	FDA Approved
T11213	Epertinib hydrochloride	EGFR; HER4; HER2	
T11161	EGFR-IN-7	EGFR	
T10419	AV-412	EGFR; EGFR(L858R); EGFR(T790M); EGFR(L858R/T790M); ErbB2	Phase 1
T0801	Tannic acid	CXCR; hERG channel	FDA Approved
T0373L	Erlotinib hydrochloride	EGFR	FDA Approved
T0373	Erlotinib	EGFR	FDA Approved
T0129	Sanguinarine chloride	Egr-1; VEGFR	Approved
T0078L	Lapatinib ditosylate monohydrate	EGFR; HER2/ErbB2	FDA Approved
T0078	Lapatinib	EGFR; HER2/ErbB2	FDA Approved

FAK

ID	Product Name	Target	Condition
T8544	Masitinib mesylate	Kit; PDGFRα; PDGFRβ; Lyn; LCK; FGFR3; FAK	Approved
T7119	Y15	FAK	
T6419	BMS536924	FAK; IGF-1R; Insulin Receptor; MEK; Lck	Preclinical
T6177	PF-562271 besylate	CDK1/CyclinB; CDK2/CyclinE; CDK3/CyclinE; FAK; PYK2	Phase 1
T5480	BI-4464	PTK2/FAK	
T3391	Corosolic acid	FAK	
T3122	(+)-Fangchinoline	FAK	

ID	Product Name	Target	Condition
T2809	(+)-Thalrugosine	FAK	
T2655	CEP37440	ALK; FAK	Phase 1
T2465	PF562271	CDK1/CyclinB; CDK2/CyclinE; CDK3/CyclinE; FAK; PYK2	Phase 1
T2314	PF 431396	FAK; PYK2	
T2281	GSK2256098	FAK	Phase 2
T21768	PF-562271 HCl	FAK; PYK2; CDK2/CDK3/CDK1/CDK7	Phase 1
T2001	PF 573228	FAK	Preclinical
T1996	Defactinib	FAK	Phase 2
T1950	PND1186	FAK	Phase 1
T1918	TAE226	c-Met; FAK; IGF-1R; Insulin Receptor; PYK2	Preclinical
T0263	Chloropyramine hydrochloride	FAK-VEGFR-3; H1 receptor	Approved

FGFR

ID	Product Name	Target	Condition
TQ0228	Derazantinib	FGFR1; FGFR2; FGFR3	Phase 2
TQ0015	PRN1371	FGFR1; FGFR2; FGFR3; FGFR4; CSF-1R	Phase 1
T8544	Masitinib mesylate	Kit; PDGFR α ; PDGFR β ; Lyn; LCK; FGFR3; FAK	Approved
T8541	Lenvatinib mesylate	VEGFR; VEGFR3; VEGFR1; FGFR1; PDGFR α ; PDGFR β ; c-Kit	FDA Approved
T8492	BO-264	FGFR; Apoptosis	
T7738	H3B-6527	FGFR	
T7611	ODM-203	FGFR; VEGFR	Phase 2
T7104	Dovitinib lactate	FGFR3	Phase 2
T6996	SU5402	FGFR1; PDGFR β ; VEGFR2	Preclinical
T6932	PD168393	EGFR; FGFR; Insulin Receptor; PDGFR; PKC	Preclinical
T6930	Pazopanib HCl	FGFR; PDGFR; VEGFR1; VEGFR2; VEGFR3; c-Kit; c-Fms	FDA Approved
T6920	ON123300	CDK; Ark5; RET; Fyn; PDGFR β ; FGFR1	Preclinical
T6836	FIIN2	FGFR1; FGFR2; FGFR3; FGFR4	
T6711	Tyrphostin AG 1296	PDGFR; c-Kit (Swiss 3T3); FGFR (Swiss 3T3)	Preclinical
T6479	Dovitinib Lactate	c-Kit; FGFR1; FGFR3; FLT3; VEGFR3/FLT4	
T6338	PHA680632	Aurora A; Aurora B; Aurora C; FGFR1; PLK1	Preclinical
T6289	Dovitinib	c-Kit; FGFR1; FGFR3; FLT3; VEGFR3/FLT4	Phase 2
T6184	Orantinib	FGFR1; PDGFR β ; Flk1	Phase 1
T6154	SU11274	CDK2; Met; RON; FGFR1; Flk1	Preclinical
T6128	PHA665752	c-Abl; c-Met; RON; FGFR1; Flk1	Preclinical
T6124	Mubritinib	EGFR; HER2/ErbB2; FGFR; JAK1; PDGFR	Phase 1
T6082	SSR128129E	FGFR1	
T6024	CH5183284	FGFR1; FGFR2; FGFR3; FGFR4	Phase 2
T5473	ASP-5878	FGFR1/2/3/4	Phase 1
T5122	Alofanib	FGFR2	Preclinical

ID	Product Name	Target	Condition
T5044	TAS120	FGFR	Phase 1/2
T5001	Nintedanib Ethanesulfonate Salt	VEGFR1/2/3; FGFR1/2/3; PDGFR α / β	FDA Approved
T4318	ACTB1003	FGFR1, VEGFR2, Tie-2	Phase 1
T4235	Roblitinib	FGFR4	Phase 1/2
T4075	Sulfatinib	FGFR1; hERG; KDR	Phase 3
T3726	Erdafitinib	FGFR1; FGFR2; FGFR3; FGFR4	FDA Approved
T3714	SUN 11602	ERK1; ERK2; FGFR	
T3492	PD166866	FGFR1	
T3466	FIIN3	FGFR1; FGFR2; FGFR3; FGFR4	
T3456	BLU554	FGFR1; FGFR2; FGFR3; FGFR4	Phase 1
T3274	S49076	Met; FGFR2; FGFR3; AXL; Mer	Phase 1/2
T2642	PD173074	EGFR; FGFR1; Insulin Receptor; c-Src; VEGFR2	Preclinical
T2608	CHIR98014	bFGFR; GSK-3 α ; GSK-3 β ; p70 S6K; c-Src	
T2576	Brivanib Alaninate	FGFR1; Flk1; VEGFR1; VEGFR2	Phase 3
T2446	KI8751	c-Kit; EGFR; FGFR2; PDGFR α ; VEGFR2	
T2372	Ponatinib	Abl; c-Kit; FGFR1; PDGFR α ; c-Src; VEGFR2	FDA Approved
T2361	LY2874455	FGFR1; FGFR2; FGFR3; FGFR4; VEGFR2	Phase 2
T2347	BLU9931	FGFR1; FGFR2; FGFR3; FGFR4	Preclinical
T2341	KW2449	Aurora A; Abl; Abl (T315I); Kit; FGFR1; FLT3; FLT3 (D835Y); JAK2; Src	Phase 1/2
T22306	DGY-06-116	Src; FGFR1	
T2215	Ferulic Acid	FGFR1	Approved
T2094	Danuserib	Aurora A; Aurora B; Aurora C; Abl; RET; FGFR1; TrkA	Phase 2
T1975	Infigratinib	FGFR1; FGFR2; FGFR3; FGFR3 (K650E); FGFR4	Phase 3
T1948	AZD4547	FGFR1; FGFR2; FGFR3; FGFR4; KDR	Phase 2/3
T1895	SKLB 610	FGFR; PDGFR; VEGFR	
T1886	TAK632	Aurora B; FGFR3; PDGFR β ; B-Raf; C-Raf	Preclinical
T1777	Nintedanib	FLT3; Lck; VEGFR1; VEGFR2; VEGFR3; FGPR1; FGFR2; FGFR3; PDGFR α ; PDGFR β	FDA Approved
T1639	Amlexanox	FGFR1; IL-3; Protein S100-P; IKK ϵ ; TBK1	FDA Approved
T1338	Sucralfate	FGF2; Fibrinogen chain; Pepsin; PGF	FDA Approved
T12401	Pemigatinib	FGFR1; FGFR2; FGFR3; FGFR4	FDA Approved
T0724	Formononetin	FGFR	
T0520	Lenvatinib	FGFR1; PDGFR β ; VEGFR1/FLT1; VEGFR2/KDR; VEGFR3/FLT4	FDA Approved

FLT

ID	Product Name	Target	Condition
TQ0059	Ilorasertib	Aurora A; Aurora B; Aurora C; PDGFR β ; RET; FLT1; VEGFR1; VEGFR2; VEGFR3	Phase 2

ID	Product Name	Target	Condition
T8326	BMS-2	Met; FLT3; VEGFR2	
T8317	5'-Fluorouridirubinoxime	FLT3	
T7673	ATH 686	FLT3	
T7007	UNC2025	FLT3; AXL; Mer; Tyro3	Preclinical
T6982	SGI7079	Met; RET; FLT3; Yes; AXL; Mer	
T6756	AMG 925	FLT3; CDK4; CDK1	Phase 1
T6479	Dovitinib Lactate	c-Kit; FGFR1; FGFR3; FLT3; VEGFR3/FLT4	
T6458	CYC116	Aurora A; Aurora B; CDK2/CyclinE; CDK9/CyclinT; FLT3; p70 S6K; VEGFR2	Phase 1
T6350	CHIR124	Chk1; FLT3; GSK-3; PDGFR; Fyn	Preclinical
T6331	AST-1306 TsOH	EGFR; EGFR (T790M/L858R); HER2/ErbB2; HER2/ErbB2; FLT1	Phase 1
T6289	Dovitinib	c-Kit; FGFR1; FGFR3; FLT3; VEGFR3/FLT4	Phase 2
T6138	TCS 359	FLT3	
T6080	NVP-AEW541	FLT1; FLT3; IGF-1R; Insulin Receptor; Tek	Phase 1
T6020	Pacritinib	FLT3; FLT3 (D835Y); JAK2; JAK2 (V617F); Tyk2; JAK3	Approved
T4428	CCT241736	FLT3; Aurora Kinase	
T4419	UNC2025 2HCl (1429881-91-3(free base))	Mer; Flt3	
T4409	Gilteritinib	FLT3; AXL; c-KIT	FDA Approved
T4261	BPR1J-097 hydrochloride (1327167-19-0(free base))	FLT3	
T4227	SB1317 hydrochloride (1204918-72-8(free base))	CDK2; FLT3; JAK2	Phase 1/2
T4213	NCT503	PHGDH(Cell-free); FLT3; AXL	
T4209	TAK-659 hydrochloride	FLT3; JAK3; Syk; ZAP70; VEGFR2	Phase 2
T4053	AST 487	c-Kit; RET; FLT4; KDR	Preclinical
T3621	Brigatinib	ALK; EGFR (C797S/del19); FLT3; IGF-1R; ROS1	FDA Approved
T3351	CC223	c-Fms; DNA-PK; FLT4; mTOR; PI3K-α	Phase 2
T3166	VX-11e	Aurora A; CDK2; ERK2; FLT3; GSK-3	
T3078	SGI-1776 free base	FLT3; Pim1; Pim2; Pim3	Phase 1
T3072	XL019	FLT3; JAK1; JAK2; JAK3; PDGFRβ	Phase 1
T3065	TG101209	RET; FLT3; JAK2; JAK3	Preclinical
T2677	Crenolanib	PDGFRα; PDGFRβ; FLT3	Approved
T2640	DCC2036	Abl1; p-Abl1 (native); p-Abl1 (T315I); u-Abl1 (native); FLT3	Phase 1/2
T2638	Gandotinib	FLT3; JAK1; JAK2; JAK2; JAK2 (V617F)	Phase 2
T2624	OSI 930	CSF-1R; FLT1; C-Raf; Lck; VEGFR2 (KDR)	Phase 1
T2620	G749	Aurora B; RET; FLT3; FLT3 (D835Y); Mer	Preclinical
T2586	Cabozantinib	c-Kit; c-Met; VEGFR2/KDR; FLT4; Axl; RET; FLT3	FDA Approved
T2516	Amuvatinib	c-Kit (D816H); FLT3 (D835Y); PDGFRα (V561D)	Phase 2
T2514	Linifanib	Kit; CSF-1R; FLT3; VEGFR1/FLT1; VEGFR2/KDR; PDGFRβ	Phase 1

ID	Product Name	Target	Condition
T2500	Cediranib	c-Kit; PDGFRβ; VEGFR1/FLT1; VEGFR2/KDR; VEGFR3/FLT4; Flt4; Flt1	Approved
T2358	ENMD2076	Aurora A; RET; FLT3; Src; VEGFR3/FLT4; Src	Phase 2
T2341	KW2449	Aurora A; Abl; Abl (T315I); Kit; FGFR1; FLT3; FLT3 (D835Y); JAK2; Src	Phase 1/2
T2272	BPR1J097	FLT3	
T2116	AEE788	c-Abl; c-Fms; EGFR; HER2/ErbB2; FLT1	Phase 1/2
T2115	Pexidartinib	Kit; CSF-1R; FLT3	FDA Approved
T2066	Quizartinib	FLT3 (ITD); FLT3 (WT)	Approved
T2051	FLT3-IN-1	FLT3	
T1995	Fedratinib	JAK2; JAK2 (V617F); RET; FLT3	FDA Approved
T1938	FLT3-IN-2	FLT3	
T1836	AZD2932	c-Kit; FLT3; PDGFRβ; VEGFR2	
T1777	Nintedanib	FLT3; Lck; VEGFR1; VEGFR2; VEGFR3; FGPR1; FGFR2; FGFR3; PDGFRα; PDGFRβ	FDA Approved
T1667	Tandutinib	c-Kit; CSF-1R; FLT3; PDGFRβ; Src	Phase 2
T16144	MRX-2843	FLT3; MERTK	Phase 1
T15199	Edicotinib	FLT3; CSF-1R; kit	Phase 2
T0374L	Sunitinib	c-Kit; FLT3; PDGFRβ; VEGFR2	FDA Approved
T0374	Sunitinib Malate	Kit; FLT3; PDGFRβ; VEGFR2	FDA Approved
T0093L	Sorafenib	c-Kit; FLT3; mPDGFRβ; PDGFRβ; B-Raf; B-Raf (V599E); Raf-1; VEGFR2/Flk2	FDA Approved
T0093	Sorafenib tosylate	c-Kit; FLT3; mPDGFRβ; PDGFRβ; B-Raf; B-Raf (V599E); Raf-1; VEGFR2/Flk1	FDA Approved

HER

ID	Product Name	Target	Condition
T7819	TAS0728	HER2	Phase 1/2
T6712	Tyrphostin AG 879	EGFR; HER2-Neu; PDGFR; Trk	
T6341	PF04929113	HER2; HSP90	Phase 2
T5398	BMS 599626 2HCl (873837-23-1(HCl))	HER1; HER2; HER4	Phase 1
T4S0544	Furanodienone	HER2	
T4612	NS309	Potassium Channel; hERG	Preclinical
T4342	PF-04929113 Mesylate	HSP90; HER2	Phase 2
T4075	Sulfatinib	FGFR1; hERG; KDR	Phase 3
T3673	Mollugin	HER2; JAK2	
T3554	RG 14620	HER14 colony formation; HER14 DNA synthesis; EGFR	
T3192	NS1643	hERG	
T3108	CUDC101	EGFR; HDAC; HDAC1; HDAC10; HDAC2; HDAC3; HDAC4; HDAC5; HDAC6; HDAC7; HDAC8; HDAC9; HER2	Phase 1
T2630	Pozotinib	HER1; HER2; HER4	Phase 2

ID	Product Name	Target	Condition
T2364	Irbinitinib	EGFR; HER2/ErbB2; p95 HER2	FDA Approved
T2325	Neratinib	EGFR; HER2	FDA Approved
T2303	Afatinib	EGFR (L858R); EGFR (L858R/T790M); EGFR (wt); HER2; HER4	FDA Approved
T2280	Endoxifen Z-isomer	hERG Potassium Channel; ER; ERR; hERG	Phase 3
T22431	SU5204	VEGFR2; HER2	
T2047	AG1478	EGFR; HER2; PDGFR	Preclinical
T1773	Afatinib Dimaleate	EGFR (L858R); EGFR (L858R/T790M); EGFR (wt); HER2	FDA Approved
T1266	Terfenadine	HT; mAChR; Potassium Channel; hERG	Approved
T11213	Epertinib hydrochloride	EGFR; HER4; HER2	
T0801	Tannic acid	CXCR; hERG channel	FDA Approved

HIF

ID	Product Name	Target	Condition
T7848	PT-2385	HIF-2 α	Phase 2
T7802	M1001	HIF-2 α	
T7692	2,4-DPD	HIF-PH	
T6961	PX-478 2HCl	HIF-1 α	Phase 1
T6929	Pantoprazole sodium	HIF-1 α ; pronton pump	FDA Approved
T5537	IDF-11774	HIF-1 α	
T4S1551	Cinnamaldehyde	HIF- α	
T4S0800	Demethyleberberine	CYP17; HIF; NOS	
T4651	Vadadustat	HIF-PH	Approved
T4381	Lifigiquat	sGC; HIF-1 α	Preclinical
T3494	LW6	HIF-1; MDH2	
T3404	Cucurbitacin B	HIF-1; PTEN; STAT3	
T3197	Daprodustat	HIF-PH	Approved
T3169	KC7F2	HIF-1 α	
T3027	Sodium Aescinate	HIF-1 α	Approved
T2515	Roxadustat	HIF-PH	Approved
T2488	BAY 87-2243	HIF-1 α	Phase 1
T2220	2-Methoxyestradiol	HIF-1 α ; HIF-2 α ; Microtubule depolymerization	Approved
T1939	DMOG	HIF-PH	
T13050	SYP-5	HIF	
T12675L	PT2399	HIF-2 α	
T11589	Hydroxycitric acid tripotassium hydrate	ATP citrate lyase; HIF	
T0447	Carvedilol	Adrenergic Receptor; HIF; E-selectin; NADPH; Vcam; Potassium Channel; VEGFR; LDL oxidation	FDA Approved
T0153	Oltipraz	Reverse Transcriptase; HIF-1 α	Phase 3

JAK

ID	Product Name	Target	Condition
TQ0037	Abrocitinib	JAK1; JAK2	Phase 3
T8742	JAK2 inhibitor G5-7	JAK2	
T8719	SC99	STAT3; JAK2	
T8546	BD750	JAK3; STAT5	
T7503	Upadacitinib	JAK1; JAK2	FDA Approved
T6933	Peficitinib	JAK3; JAK1; Tyk2; JAK2	Approved
T6920	ON123300	CDK; Ark5; RET; Fyn; PDGFRβ; FGFR1	Preclinical
T6916	OICR9429	WDR5	
T6914	Oclacitinib maleate	JAK1; JAK2; TYK2; JAK3; JAK1-dependent	
T6838	FLLL32	JAK2	
T6790	BMS911543	JAK2 ; SET-2; TYK2; JAK3; JAK1	Phase 1/2
T6321	Tofacitinib	JAK1; JAK2; JAK3; ROCK2; Lck	FDA Approved
T6309	AZ 960	JAK2; JAK2	Preclinical
T6266	PP2	EGFR; JAK2; Fyn; Lck; ZAP70	
T6156	S-Ruxolitinib	JAK2; JAK1; Tyk2	FDA Approved
T6145	ZM 39923 HCl	TGM2 , JAK3 , EGFR , JAK1	
T6124	Mubritinib	EGFR; HER2/ErbB2; FGFR; JAK1; PDGFR	Phase 1
T6122	CEP33779	JAK2	
T6020	Pacritinib	FLT3; FLT3 (D835Y); JAK2; JAK2 (V617F); Tyk2; JAK3	Approved
T5492	JAK3-IN-6	JAK3	
T5382	PF-06651600	JAK3	Phase 2/3
T5140	WDR5-0103 hydrochloride[890190-22-4(free base)]	WDR5	
T5091	FM381	JAK3	
T4672	Brevilin A	Antifection; JAK; STAT	
T4657L	WHI-P97 HCl 211555-05-4(free base)	JAK3	
T4657	WHI-P97	JAK3	Preclinical
T4227	SB1317 hydrochloride (1204918-72-8(free base))	CDK2; FLT3; JAK2	Phase 1/2
T4210	SAR20347	JAK1; JAK2; JAK3; TYK2	Preclinical
T4209	TAK-659 hydrochloride	FLT3; JAK3; Syk; ZAP70; VEGFR2	Phase 2
T3998	Itacitinib	JAK1	Phase 3
T3673	Mollugin	HER2; JAK2	
T3620	Solcitinib	JAK1	Phase 1
T3398	Icaritin	JAK2; STAT3	Phase 3
T3201	WDR5-0103	WDR5	
T3080	Pyridone 6	JAK1; JAK2; JAK3; Tyk2	
T3076	GLPG0634 analogue	JAK1; JAK2; JAK3; TYK2	
T3072	XL019	FLT3; JAK1; JAK2; JAK3; PDGFRβ	Phase 1

ID	Product Name	Target	Condition
T3069	AZD1480	JAK2	Phase 1
T3068	AT9283	Aurora A; Aurora B; Abl1 (T315I); JAK2; JAK3	Phase 1
T3065	TG101209	RET; FLT3; JAK2; JAK3	Preclinical
T3043	Ruxolitinib (INCB-18424) phosphate	JAK1; JAK2	FDA Approved
T3042	JAK2 Inhibitor V	JAK2; JAK2 (V617F)	
T3024	Avitinib	EGFR; JAK3; BTK	Phase 2
T2853	Curcumol	JAK	Phase 3
T2709	TAK901	CLK2; JAK3; c-Src; FGR; Yes1	Phase 1
T2638	Gandotinib	FLT3; JAK1; JAK2; JAK2; JAK2 (V617F)	Phase 2
T2636	Decernotinib	JAK1; JAK2; JAK3; Tyk2	Phase 3
T2487	Cerdulatinib	JAK1; JAKs; Syk; Tyk2	Phase 2
T2485	Baricitinib	Chk2; JAK1; JAK2; JAK3; Tyk2	FDA Approved
T2398	Tofacitinib Citrate	JAK1; JAK2; JAK3	FDA Approved
T2360	Baricitinib Phosphate	JAK1; JAK2; JAK3; Tyk2	FDA Approved
T2341	KW2449	Aurora A; Abl; Abl (T315I); Kit; FGFR1; FLT3; FLT3 (D835Y); JAK2; Src	Phase 1/2
T2156	WP1066	JAK2; STAT3	Phase 1/2
T2045	WHI-P131	JAK3; JAK3	Preclinical
T2035	WHI-P258	EGFR; JAK3	
T2012	Oclacitinib	JAKs	
T1995	Fedratinib	JAK2; JAK2 (V617F); RET; FLT3	FDA Approved
T1985	WHI-P154	EGFR; JAK3; Src; VEGFR	Preclinical
T1929	Filgotinib	JAK1; JAK2; JAK3; Tyk2	Approved
T1849	Momelotinib	JAK1; JAK2; JAK3	Phase 3
T1829	Ruxolitinib	JAK1; JAK2; Tyk2	FDA Approved
T17019	TCS 21311	JAK3; JAK2; JAK1; PKC α ; PKC θ ; GSK-3 β	
T14687	BMS-986165	Tyk2 JH2; JAK1 JH2	Phase 3
T14331	Gusacitinib	SYK; JAK	Phase 2
T12427	PF-06700841 (P-Tosylate)	JAK1; JAK2; JAK3	Phase 2

PDGFR

ID	Product Name	Target	Condition
TQ0059	Ilorasertib	Aurora A; Aurora B; Aurora C; PDGFR β ; RET; FLT1; VEGFR1; VEGFR2; VEGFR3	Phase 2
TN1969	N-(p-Coumaroyl) serotonin	PDGFR	
T8544	Masitinib mesylate	Kit; PDGFR α ; PDGFR β ; Lyn; LCK; FGFR3; FAK	Approved
T8541	Lenvatinib mesylate	VEGFR; VEGFR3; VEGFR1; FGFR1; PDGFR α ; PDGFR β ; c-Kit	FDA Approved
T8491	Vorolanib	VEGFR; PDGFR	Phase 2/3
T8482	Ripretinib	Kit; PDGFR	FDA Approved

ID	Product Name	Target	Condition
T8402	Regorafenib Hydrochloride	VEGFR; PDGFR; RET; Raf-1	FDA Approved
T7861	Flumatinib mesylate	PDGFRβ ; c-Kit ; c-Abl	Phase 3
T6996	SU5402	FGFR1; PDGFRβ; VEGFR2	Preclinical
T6932	PD168393	EGFR; FGFR; Insulin Receptor; PDGFR; PKC	Preclinical
T6930	Pazopanib HCl	FGFR; PDGFR; VEGFR1; VEGFR2; VEGFR3; c-Kit; c-Fms	FDA Approved
T6920	ON123300	CDK; Ark5; RET; Fyn; PDGFRβ; FGFR1	Preclinical
T6720	Vatalanib 2HCl	PDGFRβ; VEGFR1/FLT1; VEGFR2/Flk1; VEGFR2/KDR; VEGFR3/FLT4	Phase 1
T6712	Tyrphostin AG 879	EGFR; HER2-Neu; PDGFR; Trk	
T6711	Tyrphostin AG 1296	PDGFR; c-Kit (Swiss 3T3); FGFR (Swiss 3T3)	Preclinical
T6513	Bisindolylmaleimide I	PDGFR; PKCα; PKCβ1; PKCβ2; PKCγ	
T6350	CHIR124	Chk1; FLT3; GSK-3; PDGFR; Fyn	Preclinical
T6230	Imatinib	v-Abl; c-Kit; PDGFR	FDA Approved
T6184	Orantinib	FGFR1; PDGFRβ; Flk1	Phase 1
T6166	Telatinib	c-Kit; PDGFRα; VEGFR2; VEGFR3	Phase 2
T6124	Mubritinib	EGFR; HER2/ErbB2; FGFR; JAK1; PDGFR	Phase 1
T6097	GNF5837	Kit; PDGFRβ; TrkA; TrkB; TrkC	
T6091	CP673451	c-Kit; PDGFRα; PDGFRβ; VEGFR1; VEGFR2	Preclinical
T5466	Tyrosine kinase-IN-1	KDR; Flt-1; FGFR1; PDGFRα; PDGFRα	
T5109	Avapritinib	PDGFRα, c-Kit (D816V)	FDA Approved
T5001	Nintedanib Ethanesulfonate Salt	VEGFR1/2/3; FGFR1/2/3; PDGFRα/β	FDA Approved
T4320	Flumatinib	c-Abl; PDGFRβ; c-Kit;	Phase 3
T3570	NSC 86429	PDGFR; VEGFR	
T3476	J1101	Ephrin Receptor; PDGFR; VEGFR	Phase 1/2
T3463	NVP-ACC789	VEGFR; PDGFR-β	
T3072	XL019	FLT3; JAK1; JAK2; JAK3; PDGFRβ	Phase 1
T2734	Sennoside B	PDGFR	
T2677	Crenolanib	PDGFRα; PDGFRβ; FLT3	Approved
T2609	Masitinib	Abl1; c-Fms; Kit; Hck; PDGFRα; PDGFRβ; Lyn B; Src	Approved
T2516	Amuvatinib	c-Kit (D816H); FLT3 (D835Y); PDGFRα (V561D)	Phase 2
T2514	Linifanib	Kit; CSF-1R; FLT3; VEGFR1/FLT1; VEGFR2/KDR; PDGFRβ	Phase 1
T2500	Cediranib	c-Kit; PDGFRβ; VEGFR1/FLT1; VEGFR2/KDR; VEGFR3/FLT4; Flt4; Flt1	Approved
T2479	Tyrphostin 9	EGFR; PDGFR	Preclinical
T2456	Tivozanib	EphB2; PDGFRα; VEGFR1; VEGFR2; VEGFR3	Approved
T2446	KI8751	c-Kit; EGFR; FGFR2; PDGFRα; VEGFR2	
T2415	PP121	Hck; mTOR; PDGFR; Src; VEGFR; Abl	
T2372	Ponatinib	Abl; c-Kit; FGFR1; PDGFRα; c-Src; VEGFR2	FDA Approved
T2070	CEP32496	Abl1; c-Kit; RET; PDGFRβ; Lck	Phase 1
T2047	AG1478	EGFR; HER2; PDGFR	Preclinical
T1895	SKLB 610	FGFR; PDGFR; VEGFR	

ID	Product Name	Target	Condition
T1886	TAK632	Aurora B; FGFR3; PDGFRβ; B-Raf; C-Raf	Preclinical
T1836	AZD2932	c-Kit; FLT3; PDGFRβ; VEGFR2	
T1792L	Regorafenib monohydrate	murine VEGFR2; murine VEGFR3; PDGFRβ; Kit; RET; RAF-1; B-RAF; B-Raf (V600E)	FDA Approved
T1777	Nintedanib	FLT3; Lck; VEGFR1; VEGFR2; VEGFR3; FGPR1; FGFR2; FGFR3; PDGFRα; PDGFRβ	FDA Approved
T1667	Tandutinib	c-Kit; CSF-1R; FLT3; PDGFRβ; Src	Phase 2
T1621	Imatinib Mesylate	v-Abl; c-Kit; PDGFR	FDA Approved
T15616	JNJ-10198409	PDGFRβ; PDGFRα	
T1452	Axitinib	PDGFRβ; VEGFR1; VEGFR2; VEGFR3; c-kit	FDA Approved
T10157	Regorafenib N-oxide (M2)	VEGFR1; VEGFR2; VEGFR3; PDGFRβ; RET; Kit; Raf-1	
T0520	Lenvatinib	FGFR1; PDGFRβ; VEGFR1/FLT1; VEGFR2/KDR; VEGFR3/FLT4	FDA Approved
T0374L	Sunitinib	c-Kit; FLT3; PDGFRβ; VEGFR2	FDA Approved
T0374	Sunitinib Malate	Kit; FLT3; PDGFRβ; VEGFR2	FDA Approved
T0097L	Pazopanib	c-Kit; PDGFR; VEGFR1; VEGFR2; VEGFR3	FDA Approved
T0093L	Sorafenib	c-Kit; FLT3; mPDGFRβ; PDGFRβ; B-Raf; B-Raf (V599E); Raf-1; VEGFR2/Flk2	FDA Approved
T0093	Sorafenib tosylate	c-Kit; FLT3; mPDGFRβ; PDGFRβ; B-Raf; B-Raf (V599E); Raf-1; VEGFR2/Flk1	FDA Approved
T0080	Trapidil	PDE; PDGFR	Approved

Src

ID	Product Name	Target	Condition
T8544	Masitinib mesylate	Kit; PDGFRα; PDGFRβ; Lyn; LCK; FGFR3; FAK	Approved
T8499	eCF506	Src	
T7371	1-Naphthyl PP1 hydrochloride	Src	
T7345	7-Hydroxy-4-chromone	Src	
T7123	AMG-47a	Lck	
T6997	SU6656	Fyn; Lyn; Src; Yes	
T6982	SGI7079	Met; RET; FLT3; Yes; AXL; Mer	
T6920	ON123300	CDK; Ark5; RET; Fyn; PDGFRβ; FGFR1	Preclinical
T6896	Tolimidone	Lyn kinase	Phase 2
T6886	MCB613	Src	
T6680	Staurosporine	PKC; PKCα; PKCγ; PKCη; c-Fgr	
T6427	Butein	EGFR; p60c-src	
T6419	BMS536924	FAK; IGF-1R; Insulin Receptor; MEK; Lck	Preclinical
T6350	CHIR124	Chk1; FLT3; GSK-3; PDGFR; Fyn	Preclinical
T6348	NVP-BHG712	EphB4; c-Raf; c-Src; c-Abl	
T6345	KX2-391	Src (Hep 3B); Src (Hep G2); Src (HuH7); Src (PLC/PRF/5)	Phase 3
T6321	Tofacitinib	JAK1; JAK2; JAK3; ROCK2; Lck	FDA Approved

ID	Product Name	Target	Condition
T6315	MLN8054	Aurora A; Aurora B; CK2; PKA; Lck	
T6311	Bafetinib	Abl; Lyn	Phase 1
T6266	PP2	EGFR; JAK2; Fyn; Lck; ZAP70	
T6227	Benidipine hydrochloride	EGFR (L861Q); c-Src; c-Yes; Lck; Lyn	Approved
T6196	PP1	Bcr-Abl; Kit; EGFR; Fyn; Lck	
T6078	Saracatinib	c-Src; Lck; BLK; EGFR (L858R); EGFR (L861Q); c-Yes; FGR; Fyn; Lyn	Phase 2
T6077	ZM 447439	Aurora A; Aurora B; MEK1; Lck; Src	Preclinical
T6028	PF477736	c-Fms; Chk1; Chk2; Yes; VEGFR2	Phase 1
T4618	K 0859	c-ABL-T334I; Abl; Abl (T315I)	
T4597	UM164	c-Src; p38α; p38β	
T4301	AD80	RET, RAF, SRC, S6K; RET V804M; RET V804L	
T4133	CCT196969	C-RAF; Src	
T4071	TPX0005	ALK; Src	Phase 1/2
T3935	1-Naphthyl PP1	Src	
T3593	Src Inhibitor 1	Lck; Src	
T3319	Scutellarein	Src	
T3063	PD173955	Bcr-Abl; Src	Preclinical
T2709	TAK901	CLK2; JAK3; c-Src; FGR; Yes1	Phase 1
T2696	PRT062607 hydrochloride	MLK1; FGR; Syk	Phase 1
T2642	PD173074	EGFR; FGFR1; Insulin Receptor; c-Src; VEGFR2	Preclinical
T2624	OSI 930	CSF-1R; FLT1; C-Raf; Lck; VEGFR2 (KDR)	Phase 1
T2609	Masitinib	Abl1; c-Fms; Kit; Hck; PDGFRα; PDGFRβ; Lyn B; Src	Approved
T2608	CHIR98014	bFGFR; GSK-3α; GSK-3β; p70 S6K; c-Src	
T2603	Spebrutinib	BRK; BTK; c-Src; Lyn; Yes	Phase 2
T2582	Apatinib	c-Kit; RET; c-Src; VEGFR2	Approved
T2415	PP121	Hck; mTOR; PDGFR; Src; VEGFR; Abl	
T2372	Ponatinib	Abl; c-Kit; FGFR1; PDGFRα; c-Src; VEGFR2	FDA Approved
T2358	ENMD2076	Aurora A; RET; FLT3; Src; VEGFR3/FLT4; Src	Phase 2
T2341	KW2449	Aurora A; Abl; Abl (T315I); Kit; FGFR1; FLT3; FLT3 (D835Y); JAK2; Src	Phase 1/2
T2327	Pelitinib	EGFR; HER2/ErbB2; MEK; Raf; Src	Phase 2
T22306	DGY-06-116	Src; FGFR1	
T2070	CEP32496	Abl1; c-Kit; RET; PDGFRβ; Lck	Phase 1
T1985	WHI-P154	EGFR; JAK3; Src; VEGFR	Preclinical
T1835	Ibrutinib	BLK; Bmx; BTK; FGR; CSK	FDA Approved
T1812	KX1004	Src-PTK	
T1811	WH-4-023	Lck; Src	
T1777	Nintedanib	FLT3; Lck; VEGFR1; VEGFR2; VEGFR3; FGPR1; FGFR2; FGFR3; PDGFRα; PDGFRβ	FDA Approved
T1754	ZM 306416	Abl; Src; VEGFR1	
T16760	RK-24466	Lck	

ID	Product Name	Target	Condition
T1667	Tandutinib	c-Kit; CSF-1R; FLT3; PDGFR β ; Src	Phase 2
T1448L	Dasatinib monohydrate	Abl; c-Kit (D816V); c-Kit (wt); EphA2; Src	FDA Approved
T1448	Dasatinib	Abl; c-Kit (D816V); c-Kit (wt); Src	FDA Approved
T0152	Bosutinib	Abl; c-Src	FDA Approved

Syk

ID	Product Name	Target	Condition
T7035	ANTHRAQUINONE-2-CARBOXYLIC ACID	IRAK-1; Syk	
T6174	R406	Syk	
T6115	Fostamatinib	Adenosine transporter; A3; Monoamine transporter; Syk	FDA Approved
T6101	Entospletinib	Syk	Approved
T4391	Syk Inhibitor II (hydrochloride)	Syk; PKC ϵ ; PKC β II; ZAP-70; Btk; Itk; ZAP70; Btk	
T4263	BAY 61-3606	Syk	
T4209	TAK-659 hydrochloride	FLT3; JAK3; Syk; ZAP70; VEGFR2	Phase 2
T3185	(E)-Elafibranor	Syk	Phase 2
T2696	PRT062607 hydrochloride	MLK1; FGR; Syk	Phase 1
T2605	R788 Disodium	Syk	FDA Approved
T2487	Cerdulatinib	JAK1; JAKs; Syk; Tyk2	Phase 2
T2467	R406 free base	Syk	
T11824LL	Lanraplenib	SYK	phase 2
T0465	Ellagic acid	Carbonic anhydrase; CK2; Smoothened; PKA; PKC; Syk; ATP-competitive CK2	Phase 2

VDA

ID	Product Name	Target	Condition
T6273	DMXAA	DT-diaphorase	Phase 2
T3112	Verteporfin	VDA	FDA Approved

VEGFR


ID	Product Name	Target	Condition
TQ0059	Ilorasertib	Aurora A; Aurora B; Aurora C; PDGFR β ; RET; FLT1; VEGFR1; VEGFR2; VEGFR3	Phase 2
TQ0021	Ningetinib	c-Met; VEGFR2; AXL	Phase 1/2
TN1126	Sakuranetin	PPAR; NF- κ B; VEGFR	
TJS0339	Coumarin-3-carboxylic acid	VEGFR	

ID	Product Name	Target	Condition
T8541	Lenvatinib mesylate	VEGFR; VEGFR3; VEGFR1; FGFR1; PDGFRα; PDGFRβ; c-Kit	FDA Approved
T8496	MAZ51	VEGFR3	
T8491	Vorolanib	VEGFR; PDGFR	Phase 2/3
T8402	Regorafenib Hydrochloride	VEGFR; PDGFR; RET; Raf-1	FDA Approved
T8326	BMS-2	Met; FLT3; VEGFR2	
T7945	SU14813	VEGFR; Kit	
T7611	ODM-203	FGFR; VEGFR	Phase 2
T7493	AG-13958	VEGFR	
T7203	Oglufanide	VEGFR	Phase 2
T6996	SU5402	FGFR1; PDGFRβ; VEGFR2	Preclinical
T6930	Pazopanib HCl	FGFR; PDGFR; VEGFR1; VEGFR2; VEGFR3; c-Kit; c-Fms	FDA Approved
T6720	Vatalanib 2HCl	PDGFRβ; VEGFR1/FLT1; VEGFR2/Flk1; VEGFR2/KDR; VEGFR3/FLT4	Phase 1
T6517	Golvatinib	c-Met; VEGFR2	Phase 1/2
T6479	Dovitinib Lactate	c-Kit; FGFR1; FGFR3; FLT3; VEGFR3/FLT4	
T6458	CYC116	Aurora A; Aurora B; CDK2/CyclinE; CDK9/CyclinT; FLT3; p70 S6K; VEGFR2	Phase 1
T6351	MGCD-265 analog	Met; RON; VEGFR1; VEGFR2; VEGFR3	Phase 1
T6289	Dovitinib	c-Kit; FGFR1; FGFR3; FLT3; VEGFR3/FLT4	Phase 2
T6199	Ribociclib	CDK4; VEGFR4; VEGFR6	FDA Approved
T6184	Orantinib	FGFR1; PDGFRβ; Flk1	Phase 1
T6166	Telatinib	c-Kit; PDGFRα; VEGFR2; VEGFR3	Phase 2
T6154	SU11274	CDK2; Met; RON; FGFR1; Flk1	Preclinical
T6137	KRN633	VEGFR1; VEGFR2; VEGFR3	Phase 1
T6128	PHA665752	c-Abl; c-Met; RON; FGFR1; Flk1	Preclinical
T6091	CP673451	c-Kit; PDGFRα; PDGFRβ; VEGFR1; VEGFR2	Preclinical
T6028	PF477736	c-Fms; Chk1; Chk2; Yes; VEGFR2	Phase 1
T5S1632	8-O-Acetylshanzhiside methyl ester	TNF-α; NF-Kb; VEGFR; Akt; Caspase	
T5466	Tyrosine kinase-IN-1	KDR; Flt-1; FGFR1; PDGFRα; PDGFRα	
T5349	SCR-1481B1	VEGFR1	
T5171	Treprostinil Sodium	DP1, IP, EP2; VEGFR2; RET	FDA Approved
T5164	Cabozantinib hydrochloride (849217-68-1 (free base))	c-Kit; c-Met; VEGFR2/KDR; FLT4; Axl; RORy; RORα	FDA Approved
T5001	Nintedanib Ethanesulfonate Salt	VEGFR1/2/3; FGFR1/2/3; PDGFRα/β	FDA Approved
T4554	AG 1406	VEGFR2	
T4425	JK-P3	VEGFR2	
T4349	Sitravatinib	DDR2; EPHA3; Axl; Mer; VEGFR3 (FLT4); Mer; VEGFR3 (FLT4)	Phase 2
T4318	ACTB1003	FGFR1, VEGFR2, Tie-2	Phase 1
T4315	Ki20227	CSF-1R, VEGFR2; VEGFR2	Preclinical

ID	Product Name	Target	Condition
T4288	hVEGF-IN-1	VEGF-A	
T4209	TAK-659 hydrochloride	FLT3; JAK3; Syk; ZAP70; VEGFR2	Phase 2
T4075	Sulfatinib	FGFR1; hERG; KDR	Phase 3
T4053	AST 487	c-Kit; RET; FLT4; KDR	Preclinical
T4026	VEGFR2 Kinase Inhibitor I	VEGFR2	
T3980	Su1498	VEGFR2	
T3691	SAR131675	VEGFR3	Preclinical
T3641	BAW2881	c-Abl; B-Raf (V599E); C-Raf-1; hVEGFR2	
T3599	BFH772	VEGFR2	Phase 2
T3570	NSC 86429	PDGFR; VEGFR	
T3566	SU 5205	VEGFR2	
T3560	Desmethylanethol trithione	Akt; VEGFR	
T3476	JI101	Ephrin Receptor; PDGFR; VEGFR	Phase 1/2
T3463	NVP-ACC789	VEGFR; PDGFR-β	
T3113	Foretinib	Met; RON; Tie-2; VEGFR2 (KDR); VEGFR3/FLT4	Phase 1
T2906	Tanshinone IIA	VEGFR2	Phase 4
T2656	Fruquintinib	VEGFR	Approved
T2642	PD173074	EGFR; FGFR1; Insulin Receptor; c-Src; VEGFR2	Preclinical
T2624	OSI 930	CSF-1R; FLT1; C-Raf; Lck; VEGFR2 (KDR)	Phase 1
T2586	Cabozantinib	c-Kit; c-Met; VEGFR2/KDR; FLT4; Axl; RET; FLT3	FDA Approved
T2576	Brivanib Alaninate	FGFR1; Flk1; VEGFR1; VEGFR2	Phase 3
T2514	Linifanib	Kit; CSF-1R; FLT3; VEGFR1/FLT1; VEGFR2/KDR; PDGFRβ	Phase 1
T2500	Cediranib	c-Kit; PDGFRβ; VEGFR1/FLT1; VEGFR2/KDR; VEGFR3/FLT4; Flt4; Flt1	Approved
T2496	(Z)-Semaxinib	VEGFR2/Flk1	Phase 1
T2456	Tivozanib	EphB2; PDGFRα; VEGFR1; VEGFR2; VEGFR3	Approved
T2446	KI8751	c-Kit; EGFR; FGFR2; PDGFRα; VEGFR2	
T2421	SKLB1002	VEGFR2	
T2419	BMS794833	Met; VEGFR2	Preclinical
T2415	PP121	Hck; mTOR; PDGFR; Src; VEGFR; Abl	
T2372	Ponatinib	Abl; c-Kit; FGFR1; PDGFRα; c-Src; VEGFR2	FDA Approved
T2361	LY2874455	FGFR1; FGFR2; FGFR3; FGFR4; VEGFR2	Phase 2
T2358	ENMD2076	Aurora A; RET; FLT3; Src; VEGFR3/FLT4; Src	Phase 2
T2288	Motesanib	VEGFR1; VEGFR2; VEGFR3; c-Kit	Phase 3
T22432	SU5208	VEGFR2	
T22431	SU5204	VEGFR2; HER2	
T2064	Semaxinib	Flk1	Phase 1
T2056L	UNC0064-12 hydrochloride (1430089-64-7 (free base))	VEGFR2	
T2054	Altiratinib	c-Met; Tie-2; VEGFR; TrkA; TrkC	Phase 1
T1985	WHI-P154	EGFR; JAK3; Src; VEGFR	Preclinical

ID	Product Name	Target	Condition
T1948	AZD4547	FGFR1; FGFR2; FGFR3; FGFR4; KDR	Phase 2/3
T1936	Alectinib	ALK; ALK (F1174L); ALK (R1275Q); INSR; VEGFR2 (KDR)	FDA Approved
T1895	SKLB 610	FGFR; PDGFR; VEGFR	
T1837	BX912	CDK2/CyclinE; Chk1; PDK1; PKA; VEGFR2 (KDR)	Preclinical
T1836	AZD2932	c-Kit; FLT3; PDGFR β ; VEGFR2	
T1797	Cabozantinib Malate	Kit; c-Met; AXL; VEGFR2/KDR; VEGFR3/FLT4	FDA Approved
T1792L	Regorafenib monohydrate	murine VEGFR2; murine VEGFR3; PDGFR β ; Kit; RET; RAF-1; B-RAF; B-Raf (V600E)	FDA Approved
T1792	Regorafenib	Kit; RET; Raf-1; VEGFR1; VEGFR2	FDA Approved
T1777	Nintedanib	FLT3; Lck; VEGFR1; VEGFR2; VEGFR3; FGPR1; FGFR2; FGFR3; PDGFR α ; PDGFR β	FDA Approved
T1754	ZM 306416	Abl; Src; VEGFR1	
T1738	Taxifolin	β -adrenergic receptor; TNF- α ; Collagenase Tyrosinase; Beta-nerve growth factor; VEGFR2	
T17219	Vatalanib free base	VEGFR2	
T1656	Vandetanib	EGFR; VEGFR2; VEGFR3	FDA Approved
T1452	Axitinib	PDGFR β ; VEGFR1; VEGFR2; VEGFR3; c-kit	FDA Approved
T11520	GW806742X	MLKL; VEGFR2	
T0520	Lenvatinib	FGFR1; PDGFR β ; VEGFR1/FLT1; VEGFR2/KDR; VEGFR3/FLT4	FDA Approved
T0447	Carvedilol	Adrenergic Receptor; HIF; E-selectin; NADPH; Vcam; Potassium Channel; VEGFR; LDL oxidation	FDA Approved
T0374L	Sunitinib	c-Kit; FLT3; PDGFR β ; VEGFR2	FDA Approved
T0374	Sunitinib Malate	Kit; FLT3; PDGFR β ; VEGFR2	FDA Approved
T0342	Carvedilol phosphate	Adrenergic Receptor; Gap Junction Protein; E-selectin; NADPH dehydrogenase; Natriuretic peptides B; VCAM1; Potassium Channel; VEGFR; LDL oxidation	FDA Approved
T0129	Sanguinarine chloride	Egr-1; VEGFR	Approved
T0097L	Pazopanib	c-Kit; PDGFR; VEGFR1; VEGFR2; VEGFR3	FDA Approved
T0093L	Sorafenib	c-Kit; FLT3; mPDGFR β ; PDGFR β ; B-Raf; B-Raf (V599E); Raf-1; VEGFR2/Flk2	FDA Approved
T0093	Sorafenib tosylate	c-Kit; FLT3; mPDGFR β ; PDGFR β ; B-Raf; B-Raf (V599E); Raf-1; VEGFR2/Flk1	FDA Approved

Apoptosis



Apoptosis

Apoptosis

ID	Product Name	Target	Condition
TN2269	Tetramethylcurcumin	STAT3; Apoptosis	
TN2215	Sodium taurochenodeoxycholate	apoptosis	
TN2069	Picrocrocin	Apoptosis	
TN1684	Ginsenoside F5	Apoptosis	
TN1421	Bacopaside II	Apoptosis	
TN1087	Deoxydophyllotoxin	microtubule; Autophagy; Apoptosis	
T8762	SW-106065	apoptosis	
T8717	Examorelin Aceate (140703-51-1 (free base))	Apoptosis	
T8716	physalin F	Apoptosis	
T8678	Naphthazarin	apoptosis	
T8531	m-3M3FBS	PLC; Apoptosis	

ID	Product Name	Target	Condition
T8492	BO-264	FGFR; Apoptosis	
T8478	SC-43	SHP-1; STAT3; apoptosis	
T8464	RA-9	Apoptosis; deubiquitinating enzymes (DUBs)	
T8297	Gomisin N	Apoptosis inducer	
T7845	BTZO-1	Apoptosis	
T7791	Iberdomide	cereblon	Phase 1
T7337	Kinetin riboside	Apoptosis inducer	
T7174	Urolithin A	apoptosis; autophagy; DNA synthesis	
T6740	Bafilomycin A1	apoptosis; autophagy	
T5S1000	Sophoraflavanone G	Apoptosis inducer	
T5822	5-Benzylidene-3-ethyl rhodanine	Apoptosis	
T5793	Britannin	Apoptosis inducer; autophagy	
T5780	HYPOCRELLIN B	Apoptosis inducer	
T5753	Flavokawain C	Apoptosis protein	
T5514	Epibrassinolide	Apoptosis inducer	
T5132	9-dihydro-13-acetylbaccatin III	Apoptosis inducer	
T4S1540	Myrislignan	NF-κB; Apoptosis	
T4588	Glycochenodeoxycholic Acid	Apoptosis; Endogenous Metabolite	
T4241	Rubiadin	caspase-3; PARP cleavage; Free radical scavengers	
T4004	Concanavalin A	Apoptosis	
T3916	Ginsenoside F2	Apoptosis inducer	
T3908	10-Gingerol	Apoptosis inducer	
T3902	Atractylenolide III	Apoptosis inducer	
T3849	Kinsenoside; (+)-Kinsenoside	Apoptosis	
T3796	Betulinaldehyde	Apoptosis inducer	
T3771	Methyl protodioscin	Apoptosis inducer	
T3759	3,4-Dimethoxycinnamic acid	Apoptosis	
T3752	4-Hydroxybenzyl alcohol	Apoptosis	
T3488	Tectorigenin	Apoptosis inducer	
T3405	6-Gingerol	AMPK; Apoptosis	
T3373	Columbianadin	Apoptosis	
T3008	2-Methoxynaphthoquinone	Apoptosis	
T2S2382	3'-Hydroxypterostilbene	Apoptosis inducer; Autophagy	
T2S1396	3-O-Acetyloleanolic acid	Apoptosis	
T2S1008	Oxysphoridine	Antioxidant; Apoptosis	
T2S0618	β-Elementic Acid	COX-2; Apoptosis inducer	
T2829	Isoalantolactone	Apoptosis	

ID	Product Name	Target	Condition
T2808	Bilobalide	Apoptosis inhibitor	Preclinical
T2799	(20S)-Protopanaxadiol	Apoptosis inducer	
T2733	Sarsasapogenin	Apoptosis inducer	Phase 2
T21876	DC_AC50	Atox1; CCS; Apoptosis	
T20792	W-7 HCl	calmodulin; apoptosis	
T19831	Sodium Oxamate	LDH; CDK; Apoptosis	
T1882	Methylisoidigotin	Apoptosis inducer	Approved
T16974	TAK-243	UBA1; NF-κB; Apoptosis	Phase 1
T16791	Rottlerin	PKCδ; PKCα; PKCγ; PKCβ; PKCη; PKCζ; PKCε; CKII; PKA; CaM kinase II; Apoptosis; Autophagy	
T16684	Puromycin aminonucleoside	apoptosis; dipeptidyl peptidase II; antibiotic	
T16363	NVP-2	CDK9; Apoptosis	
T15433	GSK2795039	NADPH; apoptosis; ROS	
T14298	Rimiducid	Fas; FKBP; Apoptosis	Phase 2
T14177	Alexidine dihydrochloride	PTPMT1; apoptosis	
T13818	Phytohemagglutinin	Apoptosis	
T13647	Dextran sulfate sodium salt (MW 16000-24000)	HIV; Apoptosis	FDA Approved
T13476	β-Elementene	Apoptosis	Phase 3
T12516	Polyinosinic-polycytidylic acid sodium	TLR3; RIG-I; MDA5; apoptosis	
T11826	LCH-7749944	PAK4; apoptosis	
T11820	LAT1-IN-1	LAT1; Apoptosis	

ASK

ID	Product Name	Target	Condition
T5190	GS444217	ASK1	Preclinical
T3350	Selonsertib	ASK1	Phase 3
T3101	NQD1	ASK1; MAP3K5	

BCL

ID	Product Name	Target	Condition
TN1918	Medicarpin	ROS; JNK; Bcl-2	
TN1406	Aromadendrin	Bcl-2; Bcl-xL	
T9113	Myristicin	Antifection; Bcl-2; Caspase; CYP17; GABA Receptor; IL Receptor; NO; PARP	
T6749	A1331852	BCL-XL; Bcl-W; Bcl-2; Mcl-1	
T6748	A1155463	Bcl-xL; Bcl-2	
T6396	AT101 acetate	Mcl-1; Bcl-2; Bcl-xL	Phase 2

ID	Product Name	Target	Condition
T6281	TW37	Mcl-1; Bcl-2; Bcl-xL	
T6275	Obatoclox Mesylate	Bcl-2	Phase 1/2
T6185	Gambogic Acid	Bfl-1; Mcl-1; Bcl-2; Bcl-B; Bcl-w	Preclinical
T6034	UMI77	Mcl-1	
T5739	Paederosidic acid	Bcl-2	
T5679	trans-Ferulic acid	Bax	
T5668	Acetyl-trans-resveratrol	STAT3; Mcl-1	
T5346	S63845	MCL-1	
T5210	BAI1	Bax	
T5108	ML311	Mcl-1	
T5104	BTSA1	Bax	
T4S0181	Hinokiflavone	MMP; bax; bcl-2	
T4089	FX1	BCL-6	
T4088	Thymoquinon	Bcl-2	
T3940	CID5721353	Bcl-6	
T3867	Alpinetin	Bcl-2	
T3864	Erianin	Bcl-2	
T3706	BDA366	Bcl-2	
T3697	3,6'-Disinapoyl sucrose	Bcl-2; CREB	
T2730	Gossypol acetic acid	Bcl-2	Phase 2
T2632	A1210477	Mcl-1	
T2119	ABT199	Bcl-2	FDA Approved
T2101	Navitoclax	Bcl-2; Bcl-w; Bcl-xL	Phase 2
T2099	ABT737	Bcl-2; Bcl-B; Bcl-w; Bcl-xL	Preclinical
T1980	HA14-1	Bcl-2	Preclinical
T1901	TG003	mCLK1; mCLK2; mCLK4	
T17018	TCPOBOP	Bcl-2	
T1493	BH311	Bcl-xL-BH3; p53/MDM2	
T14834	BT2	BDK; Mcl-1	
T14561	BI-3812	Bcl-6	
T14376	AZD4320	BCL-2; BCL-xL	
T1119	Rasagiline	Bcl-2; MAO-A; MAO-B	FDA Approved
T10990	Dehydrocorydaline chloride	p38 MAPK; Bax; Bcl-2; caspase-7; caspase-8; PARP	
T0448	Dexibuprofen	Bcl-2; COX; Cystic fibrosis transmembrane conductance regulator; PPAR γ ; thrombomodulin	Approved
T0186	Docetaxel trihydrate	Bcl-2; Tubulin β -1 chain	FDA Approved

Caspase

ID	Product Name	Target	Condition
TP1466	Z-VAD-FMK	caspase-1	
T9113	Myristicin	Antifection; Bcl-2; Caspase; CYP17; GABA Receptor; IL Receptor; NO; PARP	
T8652	CASP3 Activator 1541	caspase-3	
T8296	4',5,7-Trimethoxyflavone	Caspase-3; PARP	
T8092	Taurohodoxycholeic acid sodium salt hydrate	Caspase	
T7374	2-HBA	NQO1; Caspase	
T7020	Z-VAD(OH)-FMK	Caspase-8	
T7019	Z-IETD-FMK	Caspase-8	
T7016	VR23	Caspase-like proteasomes; Chymotrypsin-like proteasomes; Trypsin-like proteasomes	
T6993	Sodium Tauroursodeoxycholate (TUDC)	Caspase; ERK	
T6826	Emricasan	Caspase	Phase 2
T6191	Tasisulam	Caspase	Preclinical
T6090	Belnacasan	Caspase-1; Caspase-4	Phase 2
T6013	Z-VAD(OMe)-FMK	Pan-caspase	Preclinical
T6005	Z-DEVD-FMK	Caspase-3	
T5S2283	Sesamol	p38 MAPK; Caspase-3	
T5S2083	Puerarin 6''-O-Xyloside	Caspase	
T5S1632	8-O-Acetylshanzhiside methyl ester	TNF- α ; NF-Kb; VEGFR; Akt; Caspase	
T5574	Guggulsterone E&Z	JNK; Akt; Caspase	
T5558	Chelidonic acid	Caspase-1; NF-kB	
T4S2012	Dihydro Sanguinarine	Caspase	
T4S1335	Daphnoretin	Caspase-3	
T3S1227	Aristololactam I	Caspase-3	
T3S0335	Soyasaponin Bb	Caspase-3; NF-Kb	
T3914	Saikosaponin C	Caspase-3	
T3907	Senegenin	Caspase-3	
T3600	Licochalcone A	Caspase-3; UGT1A1	Phase 1
T3519	Polyphyllin B	Caspase-2	
T2A2481	Taurochenodeoxycholic Acid	Caspase; TNF- α	Approved
T2503	PAC1	Procaspase-3	Phase 1
T2122	Ixazomib	20S proteasome; 20S proteasome; caspase-like (β 1)	FDA Approved
T1772	Apoptosis Activator 2	Caspase-3	
T10990	Dehydrocorydaline chloride	p38 MAPK; Bax; Bcl-2; caspase-7; caspase-8; PARP	
T10580	BOC-D-FMK	Caspase	
T0282	Q-VD-OPH	Caspase-1; Caspase-3; Caspase-8; Caspase-9	

c-RET

ID	Product Name	Target	Condition
TQ0277	Pralsetinib	RET	FDA Approved
TQ0059	Ilorasertib	Aurora A; Aurora B; Aurora C; PDGFRβ; RET; FLT1; VEGFR1; VEGFR2; VEGFR3	Phase 2
T8541	Lenvatinib mesylate	VEGFR; VEGFR3; VEGFR1; FGFR1; PDGFRα; PDGFRβ; c-Kit	FDA Approved
T8467	RET V804M-IN-1	RET V804M	
T8402	Regorafenib Hydrochloride	VEGFR; PDGFR; RET; Raf-1	FDA Approved
T8222	Selpercatinib	RET	FDA Approved
T7418	BBT594	RET	
T6982	SGI7079	Met; RET; FLT3; Yes; AXL; Mer	
T6920	ON123300	CDK; Ark5; RET; Fyn; PDGFRβ; FGFR1	Preclinical
T5491	GSK3179106	RET	Phase 1
T5171	Treprostinil Sodium	DP1, IP, EP2; VEGFR2; RET	FDA Approved
T4301	AD80	RET, RAF, SRC, S6K; RET V804M; RET V804L	
T4053	AST 487	c-Kit; RET; FLT4; KDR	Preclinical
T3065	TG101209	RET; FLT3; JAK2; JAK3	Preclinical
T2620	G749	Aurora B; RET; FLT3; FLT3 (D835Y); Mer	Preclinical
T2586	Cabozantinib	c-Kit; c-Met; VEGFR2/KDR; FLT4; Axl; RET; FLT3	FDA Approved
T2358	ENMD2076	Aurora A; RET; FLT3; Src; VEGFR3/FLT4; Src	Phase 2
T2282	RPI1	Met; RET; CTND1; DCDB2; PLCγ	
T2094	Danuseritib	Aurora A; Aurora B; Aurora C; Abl; RET; FGFR1; TrkA	Phase 2
T2070	CEP32496	Abl1; c-Kit; RET; PDGFRβ; Lck	Phase 1
T1995	Fedratinib	JAK2; JAK2 (V617F); RET; FLT3	FDA Approved
T1792L	Regorafenib monohydrate	murine VEGFR2; murine VEGFR3; PDGFRβ; Kit; RET; RAF-1; B-RAF; B-Raf (V600E)	FDA Approved
T1792	Regorafenib	Kit; RET; Raf-1; VEGFR1; VEGFR2	FDA Approved
T10157	Regorafenib N-oxyde (M2)	VEGFR1; VEGFR2; VEGFR3; PDGFRβ; RET; Kit; Raf-1	

Fas/FasL

ID	Product Name	Target	Condition
T4S0290	Chikusetsusaponin IV	Fas/FasL	

Ferroptosis

ID	Product Name	Target	Condition
T8662	UAMC-3203 hydrochloride	Ferroptosis	
T6500	Ferrostatin-1	Ferroptosis	
T5523	Imidazole ketone erastin	Ferroptosis activator	
T5343	UAMC3203	Ferroptosis	

ID	Product Name	Target	Condition
T4066	FIN56	Ferroptosis	
T2858	Baicalein	XO	Approved
T2376	Liproxstatin-1	Ferroptosis	
T19467	NADPH (tetracyclohexanamine)	Ferroptosis	
T1765	Erastin	Ferroptosis	Phase 2
T1637	Deferoxamine Mesylate	Iron; Ferroptosis	FDA Approved
T11631	iFSP1	Ferroptosis	

IAP

ID	Product Name	Target	Condition
TQ0029	ASTX660	clAP; XIAP	Phase 2
T6763	AT406	clAP1-BIR3; clAP2-BIR3; XIAP-BIR3	Phase 3
T6485	Embelin	XIAP; 5-Lipoxygenase; mPGES-1	FDA Approved
T6428	BV6	clAP1; XIAP	
T6299	GDC0152	clAP1-BIR3; clAP2-BIR3; MLXBIR3SG; XIAP-BIR2; XIAP-BIR3	Preclinical
T6007	Birinapant	clAP1; XIAP	Phase 2
T3981	Acacetin	COX-2; XIAP	
T2080	LCL161	clAP	Phase 2
T12932L	SM-164	XIAP; clAP-1; XIAP; clAP-2; clAP	

Mdm2

ID	Product Name	Target	Condition
T6965	RG7112	Mdm2	Phase 1
T6614	Nutlin-3b	Mdm2	Preclinical
T6254	Idasanutlin	Mdm2	Phase 3
T6149	YH239-EE	p53/MDM2	
T6023	Nutlin-3a	p53/MDM2	Preclinical
T4459	PK11007	p53/MDM2	
T3653	MX69	Mdm2	
T3517	RO8994	Mdm2; P53	
T3184	Kevetrin hydrochloride	Mdm2; p53	Phase 2
T2243	Serdemetan	HDM2; Mdm2; p53	Phase 1
T2179	Triptolide	heat shock factor (HSF1)(in ALL cell lines); Mdm2	Approved
T21773	SP 141	Mdm2	
T2158	Nutlin3	p53-MDM2	Preclinical
T1919	Tenovin-1	Mdm2; p53	
T1798	RITA	Mdm2; p53	Preclinical

ID	Product Name	Target	Condition
T16523L	PhiKan 083	p53/MDM2	
T1493	BH311	Bcl-xL-BH3; p53/MDM2	
T11980	MD-224	Mdm2; PROTAC	

OXPHOS

ID	Product Name	Target	Condition
T8532	IM156	oxidative phosphorylation (OXPHOS)	
T8500	VLX600	oxidative phosphorylation (OXPHOS)	
T14497	BAM 15	oxidative phosphorylation (OXPHOS)	

p53

ID	Product Name	Target	Condition
T8480	Tenovin-6 Hydrochloride	SIRT1; SIRT2; SIRT3; HDAC8; p53	
T7703	PK11007	p53	
T6910	NSC59984	p53	
T6909	NSC348884	nucleophosmin	
T6210	Pifithrin- μ	p53	
T5S0331	Isoliquiritin	p53	
T4414	PRIMA-1Met	p53 activator; TrxR1 inhibitor	Phase 3
T4325	COT12	p53 mutants	Phase 1/2
T4126	CBL0137	p53; NF- κ B	Phase 1
T3637	Pifithrin- β hydrobromide	p53	Preclinical
T3517	RO8994	Mdm2; P53	
T3375	Verbascoide	p53; PARP1; PKC	
T3184	Kevetrin hydrochloride	Mdm2; p53	Phase 2
T3000	Magnolol	NF- κ B; p53; PPAR γ ; RXR α	Approved
T2970	Rotenone	NAPDH; p53	
T2947	Indole-3-carbinol	NF- κ B; p53	Preclinical
T2707	Pifithrin- α	p53	
T2464	NSC319726	p53 (R175)	
T2243	Serdemetan	HDM2; Mdm2; p53	Phase 1
T1919	Tenovin-1	Mdm2; p53	
T1798	RITA	Mdm2; p53	Preclinical

PD-1/PD-L1

ID	Product Name	Target	Condition
T8470	BMS-1001	PD-1/PD-L1	

ID	Product Name	Target	Condition
T5697	BMS1166	PD-1/PD-L1	
T4696	BMS202 hydrochloride (1675203-84-5(free base))	PD-1/PD-L1	
T3655	PD-1/PD-L1 inhibitor 1	PD-1/PD-L1	
T3146	PD1-PDL1 inhibitor 2	PD-1/PD-L1	
T10565	BMS-1001 hydrochloride	PD-1/PD-L1	

PERK

ID	Product Name	Target	Condition
T7150	BTdCPU	eIF-2 α	
T6183	ISRIB (trans-isomer)	PERK	
T4304	Azoramide	PERK	
T3045	Salubrinal	eIF-2 α	
T2665	4EGI1	eIF-4E/eIF-4 g	Preclinical
T2654	GSK2656157	PERK	
T2614	GSK2606414	eIF-2AK1 (HRI); eIF-2AK2 (PKR); eIF-2AK3 (PERK)	
T2417	Sal003	eIF-2 α phosphatase	
T1742	4E1rcat	eIF-4E; eIF-4 g	

RIP kinase

ID	Product Name	Target	Condition
T7504	Necrostatin 2 racemate	RIPK1	
T5401	GSK2983559	RIP2	Phase 1

Survivin

ID	Product Name	Target	Condition
T8469	LQZ-7I	Survivin	
T3S1471	Cucurbitacin IIA	Survivin	
T2111	YM155	Survivin	Phase 2


TNF

ID	Product Name	Target	Condition
TQ0181	Resatorvid	TLR4; TNF-R	Phase 3
TN2197	Secoisolariciresinol	TNF- α	Phase 2
TN1936	Mogroside IIIe	TNF- α ; IL Receptor; TLR	
TN1742	Homovanillyl alcohol	TNF- α	

ID	Product Name	Target	Condition
T8845	UTL-5g	TNF- α	
T8692	(Rac)-Benpyrine	TNF- α	
T8440	LASSBio-1135	TRPV1; TNF- α	
T7795	RIPA-56	RIP1	
T7397	GSK547	RIP1	
T7151	GSK2982772	RIP1	Phase 2
T6S2099	Geraniin	Antioxidant; TNF- α	
T6S0653	Linarin	TNF- α inhibitor	
T6852	GSK481	RIP1	
T6815	HS1371	RIP3	
T6591	ML130	NOD1; NOD2; TNF- α	
T6204	QNZ	NF- κ B; TNF- α	
T5S2129	Sciadopitysin	TNF- α	
T5S1632	8-O-Acetylshanzhiside methyl ester	TNF- α ; NF- κ B; VEGFR; Akt; Caspase	
T5S0167	Atractylenolide I	TNF- α ; IL-6	
T5788	XYLOBIOSE	TNF- α ; IL-1 β	
T5785	MALTOTETRAOSE	TNF- α	
T5779	MOSLOFLAVONE	TNF- α ; IL-1 β	
T5660	Menthone	TNF- α ; NF- κ B; IL receptor	
T5054	GSK963 (Racemate)	RIP1	
T4S0998	Trifolirhizin	TNF- α	
T4S0217	HOMOPLANTAGININ	TNF- α /p65	
T4637	R7050	TNF- α	
T4450	GIBH130	IL-1 β ; TNF- α	
T4412	Roquinimex	TNF	Phase 1
T4319	Hispidol	TNF- α	
T4074	GSK872	RIP3K	
T3S1641	Esculentoside H	TNF- α	
T3997	WEHI345	RIPK2	
T3805	Cimifugin beta-D-glucopyranoside	TNF- α	
T3790	Hederacoside D	TNF- α	
T3561	CPI1189	TNF- α	Phase 2
T3537	GSK583	RIP1; RIP3	
T3332	Isosteviol	COX-2; IL-6; NF- κ B; Potassium Channel; TNF- α	Phase 2
T3280	Disodium clodronate tetrahydrate	IL-1 β ; IL-6; TNF- α	Approved
T2S2264	Linalool	TNF- α ; IL-6	
T2S0731	Trilobatin	TNF- α	
T2S0501	Ilexgenin A	IL Receptor; TNF- α	

ID	Product Name	Target	Condition
T2A2481	Taurochenodeoxycholic Acid	Caspase; TNF- α	Approved
T2993	Cordycepin	TNF- α	Phase 1
T2932	Ginsenoside Rh1	IL Receptor; PPAR; TNF Receptor	
T2794	Astilbin	Keap1-Nrf2; NF- κ B; TNF- α	
T2384	Pomalidomide	TNF- α	FDA Approved
T2367	SKF86002	p38 MAPK; TNF- α	
T2205	Theophylline-7-acetic acid	A1; A2; A3; HDAC2; PDE4; PKA; TNF- α	Approved
T2065	Bioymifi	DR5	
T2048	LY364947	CK1 δ ; MLK-7K; TGF β RI; TGF β RII; RIPK2	
T1847	Necrostatin-1	RIP1	
T1813	VGX1027	IL-10; IL-1 β ; TNF- α	Phase 1
T1738	Taxifolin	β -adrenergic receptor; TNF- α ; Collagenase Tyrosinase; Beta-nerve growth factor; VEGFR2	
T1642	Lenalidomide	TNF- α	FDA Approved
T15437	GSK3145095	RIP1	Phase 2
T13951	UCB-9260	TNF	
T1265	Amrinone	PDE; TNF- α	FDA Approved
T0875	Acetylcysteine	ROS; TNF- α	FDA Approved
T0694	Pranlukast	IL-5; CysLTR; NF- κ B; Eosinophil cationic protein; Mucin-2; TNF- α	Approved
T0429	Glucosamine	Chitosanase; MMP-9; NF- κ B; IF γ ; TNF- α	Approved
T0213	Thalidomide	TNF- α	FDA Approved
T0131	Cepharanthine	TNF- α	Approved
T0122	Bengenin	IL-1 β ; IL-6; NF- κ B; NOD; TNF- α	Approved

Autophagy



Autophagy

Autophagy

ID	Product Name	Target	Condition
TN6705	Graveoline	autophagy	
TN2244	Sulfuretin	(HO)-1	
TN1087	Deoxypodophyllotoxin	microtubule; Autophagy; Apoptosis	
T8853	ULK-101	ULK1	
T8850	sbp-7455	ULK1; ULK2	
T8808L	LYN-1604 2HCl 2216753-86-3(HCl)	ULK1	
T8689	CHLOROQUINE	HIV-1; autophagy; TLR; SARS-COV-2	FDA Approved
T8526	Metformin	AMPK; Autophagy	FDA Approved
T8322	BL-918	ULK1	
T8308	NL-1	mitoNEET	
T8200	Ginkgolide K	Autophagy	
T8166	Pennogenin 3-O-beta-chacotrioside	Autophagy	
T8081	LC3-mHTT-IN-AN1	mHTT-LC3 Linker Compound	
T7370	Talarozole	RAMBA; CYP	Phase 1/2
T7311	Oxyphenisatin acetate	Autophagy	
T7174	Urolithin A	apoptosis; autophagy; DNA synthesis	

ID	Product Name	Target	Condition
T6S1917	Gomisin A	Autophagy	Phase 3
T6S1315	Oroxilin A	Autophagy; HIF/HIF Prolyl-Hydroxylase	
T6858	Hydroxyprogesterone caproate	ULK1; ULK2	FDA Approved
T6799	IITZ-01	PI3Ky; Autophagy	
T6740	Bafilomycin A1	apoptosis; autophagy	
T6473	Dioscin	Autophagy	
T6056	Thiamet G	O-GlcNAcase	
T5S2102	Leonurine	Autophagy	
T5S1467	Cucurbitacin E	CDK1/cyclinB1; Autophagy	
T5S1097	Neferine	Autophagy; NF-κB	
T5S0658	Corynoxine	Autophagy	
T5793	Britannin	Apoptosis inducer; autophagy	
T5538	DC661	Autophagy/PPT1	
T5515	Hemin	(HO)-1	Approved
T5403	ULK-101	ULK1	
T5356	MRT68921 HCl	ULK1; ULK2	
T5211	NSC185058	ATG4B; Autophagy	
T5181	CA-5f	Autophagy	
T5162	MRT67307 HCl (1190378-57-4(free base))	IKK ε ; TBK1; ULK1; ULK2; NUAK1	
T5143	Corynoxine hydrochloride(6877-32-3(free base))	Autophagy	
T5080	Spermidine hydrochloride	NMDA receptor; Autophagy	
T5045	GSK4112	Rev-ErbBα	
T4977	Sofalcone	Heme oxygenase-1	Approved
T4519	Alisol A	Autophagy	
T4414	PRIMA-1Met	p53 activator; TrxR1 inhibitor	Phase 3
T4219	Autophinib	rapamycin-induced autophagy; starvation-induced autophagy; VPS34	
T3952	TPEN	Autophagy	
T3735	Tetrahydro Curcumin	Autophagy; CYP2C9; CYP3A4; Endogenous Metabolite	
T3688	SR9011	Rev-ErbBα; Rev-ErbBβ	Preclinical
T3685	SR9009	Rev-ErbBα; Rev-ErbBβ	Preclinical
T3362	Eupatilin	Autophagy; PPAR	Approved
T3155	SMER28	Autophagy	
T3054	Daurisoline	Autophagy	Approved
T2S2382	3'-Hydroxypterostilbene	Apoptosis inducer; Autophagy	
T2997	Rheic Acid	Autophagy	
T2988	(-)-Epigallocatechin Gallate	Autophagy	
T2957	Arctigenin	Autophagy; MMP	Approved
T2950	Schisandrin	Autophagy	

ID	Product Name	Target	Condition
T2941	Glucosamine hydrochloride	Autophagy; HIF/HIF Prolyl-Hydroxylase	Approved
T2888	Pterostilbene	Autophagy	Phase 1
T2822	Ginsenoside Rb1	Autophagy; IRAK; Mitophagy; (Na,K)-ATPase; NF-κB	
T2754	Oxymatrine	Autophagy	Approved
T2731	Usnic Acid	Autophagy	
T2188	Thonzonium Bromide	DHPS	FDA Approved
T2187	2-Aminobenzenesulfonamide	DHPS	Approved
T2128	SBI0206965	ULK1	
T20879	Tacrolimus hydrate	FKBP; Phosphatase; Autophagy; Bacterial; Antibiotic	FDA Approved
T1879	3-Methyladenine	PI3Ky; Vps34	
T16791	Rotterlin	PKCδ; PKCα; PKCγ; PKCβ; PKCη; PKCζ; PKCε; CKII; PKA; CaM kinase III; Apoptosis; Autophagy	
T1666	Fludrocortisone acetate	Autophagy; Mineralocorticoid Receptor	FDA Approved
T1662	5-Aminolevulinic acid hydrochloride	Autophagy	FDA Approved
T1660	Silibinin	Autophagy	Approved
T1554	Iohexol	Autophagy; Mitophagy	FDA Approved
T1537	Rapamycin	mTOR; Autophagy	FDA Approved
T15024	Silmitasertib sodium salt	CK2; Autophagy	Phase 1/2
T12831L	SAR405	Vps34; Vps34; Autophagy	
T1248	Sulfanitran	DHPS	
T12352L	Oxidopamine hydrobromide	neurotransmitter dopamine; Autophagy	
T1035	Hesperidin	Autophagy	Approved
T0987	Gimeracil	DHPS	Approved
T0982	(+)-Emetine dihydrochloride hydrate	Autophagy; Parasite	Approved
T0930	Sulfadiazine	DHPS	FDA Approved
T0913	Sulfamerazine	DHPS	FDA Approved
T0885	Sulfamethoxazole	DHPS; FolC	FDA Approved
T0836	Sulfadoxine	DHPS; DHFR	FDA Approved
T0828	Bromhexine hydrochloride	Autophagy	Approved
T0767	Sulfapyridine	DHPS	FDA Approved
T0757	Omeprazole	Autophagy; Proton pump	FDA Approved
T0754	Sulfamethizole	DHPS	FDA Approved
T0750	Sulfisoxazole	DHPS	FDA Approved
T0749	Succinylsulfathiazole	DHPS; DHPS	Approved
T0747	Sulfathiazole	DHPS; DHPS	FDA Approved
T0722	Ursolic acid	Autophagy	Phase 1
T0618	Indole-3-Glyoxyl Chloride	Lysozyme	
T0607	Dihydroartemisinin	Autophagy; NF-κB	Approved
T0510	Sulfaguanidine	DHPS	Approved

ID	Product Name	Target	Condition
T0415	Guanidine hydrochloride	Arginase; Lysozyme; Ribonuclease pancreatic; Argininosuccinate synthase	FDA Approved
T0251	Gemcitabine	Autophagy; DNA synthesis	FDA Approved
T0194	Chloroquine diphosphate	Autophagy; TLR7; TLR9	FDA Approved
T0123	Sulfanilamide	DHPS	FDA Approved
T0087L	Sulfacetamide sodium	Autophagy	FDA Approved
T0087	Sulfacetamide sodium salt hydrate	DHPS	FDA Approved
T0026	Sulfalen	DHPS	Approved

CXCR

ID	Product Name	Target	Condition
TP1348	FC131 TFA	CXCR4; HIV	
T8497	SX-682	CXCR1; CXCR2	Phase 1
T7681	AZD-5069	CXCR2	Phase 2
T7499	TAK-779	CCR2; CXCR	
T7130	Navarixin	CXCR1; CXCR2	Phase 2
T5849	JMS-17-2	CX3CR1	
T5207	LIT927	CXCL12	
T5193	Danirixin	CXCR2	Phase 2
T4163	Repertaxin	CXCR1; CXCR2	Phase 3
T4033	MSX130	CXCR4	
T4032	MSX127	CXCR4	
T3992	MSX122	CXCR4; CXCL12	Phase 2
T3396	Baohuoside I	CXCR4	Preclinical
T3327	Arteether	CCL4; CCL5; CXCL10; CXCL9	Approved
T3047	SRT3109	CXCR2	
T2477	UNBS5162	CXCL	Phase 1
T1955	SB225002	CXCR2	Preclinical
T1776L	Plerixafor 8HCl (AMD3100 8HCl)	CXCL12; CXCR4	FDA Approved
T1776	Plerixafor	CXCL12; CXCR4	FDA Approved
T1739	WZ811	CXCR4	
T17208	USL311	CXCR4	Phase 1/2
T14665L	Motixafortide TFA(664334-36-5,Free)	CXCR4	Phase 2
T10297L	AMG 487	CXCR3	
T0801	Tannic acid	CXCR; hERG channel	FDA Approved

LRRK2

ID	Product Name	Target	Condition
T7729	PF-06454589	LRRK2	
T7196	HG-10-102-01	LRRK2	
T7155	JH-II-127	LRRK2	
T6176	IKK16	IKK2; IKK; LRRK2; IKK1	
T6057	URMC099	Aurora A; Aurora B; Aurora C; Abl1; CDK1; CDK2; c-Met; DLK; IGF-1R; Insulin Receptor; LRRK2; MEKK2; MLK1; MLK2; MLK3; ROCK1; ROCK2; SGK; SGK1; Lck; Syk; TrkA; TrkB; VEGFR1/FLT1	
T6031	GNE0877	LRRK2	
T5428	BIX 02565	RSK2; LRRK2	
T5139	CZC-25146 hydrochloride	LRRK2 (G2019S), LRRK2 (WT)	
T2246	LRRK2-IN-1	DCLK1; DCLK2; LRRK2 (A2016T); LRRK2 (G2019S); LRRK2 (WT)	
T2240	GSK2578215A	LRRK2 (G2019S); LRRK2 (WT)	
T2050	PF06447475	G2019S LRRK2; LRRK2	
T2022	CZC54252	LRRK2	
T2014	CCG1423	RhoA; LRRK2 wild-type; G2019S LRRK2	
T1945	GNE7915	LRRK2; LRRK2	
T1770	GNE9605	LRRK2; LRRK2	
T16512	PFE-360	LRRK2	
T16115	MLi-2	LRRK2	


lysosomal autophagy

ID	Product Name	Target	Condition
T3437	Lys05	lysosomal autophagy(1205Lu); lysosomal autophagy(c8161); lysosomal autophagy(HT-29); lysosomal autophagy(LN229)	
T1885	Siramesine hydrochloride	lysosome-destabilizing agent; $\sigma 2$	Preclinical

Mitophagy

ID	Product Name	Target	Condition
T2822	Ginsenoside Rb1	Autophagy; IRAK; Mitophagy; (Na,K)-ATPase; NF- κ B	
T1662	5-Aminolevulinic acid hydrochloride	Autophagy	FDA Approved
T1554	lohexol	Autophagy; Mitophagy	FDA Approved
T13809	P62-mediated mitophagy inducer	mitophagy	

Cell Cycle/Checkpoint



Cell Cycle/Checkpoint

Antifolate

ID	Product Name	Target	Condition
T8548	Metoprine	histamine N-methyltransferase; antifolate	
T7730	Aminopterin	Antifolate	
T7593	Levomefolate calcium	Antifolate	FDA Approved

APC

ID	Product Name	Target	Condition
T8561	Apcin	Cdc20	

Aurora Kinase

ID	Product Name	Target	Condition
TQ0059	Iloraseritib	Aurora A; Aurora B; Aurora C; PDGFRβ; RET; FLT1; VEGFR1; VEGFR2; VEGFR3	Phase 2
T8685	SP-146	Aurora B	
T6785	BI847325	Aurora A (Human); Aurora B (Xenopus laevis); Aurora C (Human); MEK1; MEK2	Phase 1
T6532	Hesperadin	Aurora B (human); TBAUK1	
T6458	CYC116	Aurora A; Aurora B; CDK2/CyclinE; CDK9/CyclinT; FLT3; p70 S6K; VEGFR2	Phase 1
T6380	AMG900	Aurora A; Aurora B; Aurora C; p38α; Tyk2	Phase 1
T6338	PHA680632	Aurora A; Aurora B; Aurora C; FGFR1; PLK1	Preclinical
T6315	MLN8054	Aurora A; Aurora B; CK2; PKA; Lck	
T6126	JNJ7706621	CDK2/CyclinE, CDK2/CyclinA, CDK1/CyclinB, Aurora A, Aurora B	Preclinical
T6077	ZM 447439	Aurora A; Aurora B; MEK1; Lck; Src	Preclinical
T6057	URMC099	Aurora A; Aurora B; Aurora C; Abl1; CDK1; CDK2; c-Met; DLK; IGF-1R; Insulin Receptor; LRRK2; MEKK2; MLK1; MLK2; MLK3; ROCK1; ROCK2; SGK; SGK1; Lck; Syk; TrkA; TrkB; VEGFR1/FLT1	
T5524	Aurora Kinase Inhibitor III	Aurora A	
T4428	CCT241736	FLT3; Aurora Kinase	
T3166	VX-11e	Aurora A; CDK2; ERK2; FLT3; GSK-3	
T3109	Pyrazolanthrone	Aurora A; JNK1; JNK2; JNK3; TrkA	Preclinical
T3068	AT9283	Aurora A; Aurora B; Abl1 (T315I); JAK2; JAK3	Phase 1
T2620	G749	Aurora B; RET; FLT3; FLT3 (D835Y); Mer	Preclinical
T2617	SNS-314 Mesylate	Aurora A; Aurora B; Aurora C	Phase 1
T2611	CCT137690	Aurora A; Aurora B; Aurora C	
T2602	1H-Pyrazole-3-acetamide	Aurora B	Phase 2
T2509	Tozasertib	Aurora A; Aurora B; Aurora C	Approved
T2471	MK8745	Aurora A; Aurora B	
T2358	ENMD2076	Aurora A; RET; FLT3; Src; VEGFR3/FLT4; Src	Phase 2
T2341	KW2449	Aurora A; Abl; Abl (T315I); Kit; FGFR1; FLT3; FLT3 (D835Y); JAK2; Src	Phase 1/2
T2241	Alisertib	Aurora A	Phase 1
T21981	Phthalazinone pyrazole	Aurora A	
T2118	SC514	Aurora B; CDK2/CyclinA; IKK2; p38α; PRAK	
T2094	Danusertib	Aurora A; Aurora B; Aurora C; Abl; RET; FGFR1; TrkA	Phase 2
T1886	TAK632	Aurora B; FGFR3; PDGFRβ; B-Raf; C-Raf	Preclinical
T1825	Reversine	A3; Aurora A; Aurora B; Aurora C	

CDK

ID	Product Name	Target	Condition
TQ0266	MSC2530818	CDK8	
T8866	GW779439X	CDK	
T8819	SU-9516	CDK	
T8801	SRI-29329	CLK	
T8796	CAN508	CDK9/cyclinT1	
T8484	JSH-150	CDK9	
T8463	PF-06873600	CDK2	Phase 2
T8430	Senexin B	CDK8; CDK19	
T8378	AS2863619	STAT5; CDK8; CDK19	
T8325	SR-4835	CDK	
T8230	PNU 112455A	CDK	
T7810	LY-3177833	Cdc7	
T7698	BS194	CDKs	
T7444	6-(Dimethylamino)purine	CDK; serine threonine protein kinase	
T7426	Alsterpaullone	CDK	
T7296	THZ2	CDK	
T7167	Purvalanol B	CDK	
T7093	Rafoxanide	CDK3/4	
T6940	PHA767491 HCl	Cdk1; Cdk2; Cdk9; Cdc7; GSK-3β	Phase 1
T6920	ON123300	CDK; Ark5; RET; Fyn; PDGFRβ; FGFR1	Preclinical
T6866	K03861	CDK2(A144C); CDK2(C118L); CDK2(C118L/A144C); CDK2(WT)	
T6756	AMG 925	FLT3; CDK4; CDK1	Phase 1
T6735	XL413 hydrochloride	CK2; Cdc7; Pim1; Cdc7	Phase 1/2
T6563	LDC000067	CDK1; CDK2; CDK4; CDK6; CDK9	
T6458	CYC116	Aurora A; Aurora B; CDK2/CyclinE; CDK9/CyclinT; FLT3; p70 S6k; VEGFR2	Phase 1
T6255	Bromosporine	BRD; CECR2	
T6240	Palbociclib Isethionate	CDK4/CyclinD1; CDK4/CyclinD3; CDK6/CyclinD2	FDA Approved
T6239	Palbociclib hydrochloride	CDK4/CyclinD1; CDK4/CyclinD3; CDK6/CyclinD2	FDA Approved
T6205	AT7519	CDK2/CyclinA; CDK4/CyclinD1; CDK5/p35; CDK9/CyclinT; GSK-3β	Phase 2
T6199	Ribociclib	CDK4; VEGFR4; VEGFR6	FDA Approved
T6177	PF-562271 besylate	CDK1/CyclinB; CDK2/CyclinE; CDK3/CyclinE; FAK; PYK2	Phase 1
T6169	Indirubin	GSK-3β, CDK2/CyclinA, CDK5/p35, CDK1/CyclinB, C-Raf	Approved
T6167	SU9516	CDK1; CDK2; CDK4; p38; PKC	Preclinical
T6162	BS-181 HCl	CDK7	
T6154	SU11274	CDK2; Met; RON; FGFR1; Flk1	Preclinical
T6139L	A-674563 2HCl(552325-73-2(fb-2hcl))	Akt1; CDK2; PKA; ERK2; PKCδ	

ID	Product Name	Target	Condition
T6126	JNJ7706621	CDK2/CyclinE, CDK2/CyclinA , CDK1/CyclinB , Aurora A , Aurora B	Preclinical
T6081	Miliciclib	CDK2/CyclinA; CDK4/CyclinD1; CDK5/p35; CDK7/CyclinH; TrkA	Phase 2
T6057	URMC099	Aurora A; Aurora B; Aurora C; Abl1; CDK1; CDK2; c-Met; DLK; IGF-1R; Insulin Receptor; LRRK2; MEKK2; MLK1; MLK2; MLK3; ROCK1; ROCK2; SGK; SGK1; Lck; Syk; TrkA; TrkB; VEGFR1/FLT1	
T6052	GW 441756	CDK2; C-Raf-1; TrkA	
T6049	SNS032	CDK2/CyclinA; CDK2/CyclinE; CDK7/CyclinH; CDK9/CyclinT; GSK-3 α	Phase 2
T5S1467	Cucurbitacin E	CDK1/cyclinB1; Autophagy	
T5673	Senexin A	CDK8	
T5533	MC180295	CDK9/cyclinT1	
T5405	BI-1347	CDK8	
T5395	BSJ-03-123	CDK6	
T5358	Longdaysin	CK1 α ; CK1 δ ; CDK7; ERK2	
T5200	Indirubin-3'-monoxime	GSK-3 β ; CDK1/CyclinB; CDK2/CyclinE; CDK5/p25	
T4482	CC671	CLK2; TTK	Preclinical
T4417	LDC-4297 HCl (1453834-21-3(free base))	CDK7	
T4321	Indisulam	carbonic anhydrase; CDK	Phase 2
T4293	THZ531	CDK12,CDK13	Preclinical
T4227	SB1317 hydrochloride (1204918-72-8(free base))	CDK2; FLT3; JAK2	Phase 1/2
T3971	CASIN	STAT3; GTPase Cdc42	
T3700	SCH900776 S-isomer	CDK2; Chk1; Chk2	Phase 2
T3664	THZ1	CDK7	Preclinical
T3590	NSC23005	P18INK	
T3589	NSC23005 Sodium	p18INK4C	
T3207	Briciclib	Cyclin D1	Phase 1
T3195	CVT313	CDK1; CDK2; CDK4	Preclinical
T3186	NU2058	CDK1; CDK2; Topo II	Preclinical
T3166	VX-11e	Aurora A; CDK2; ERK2; FLT3; GSK-3	
T3111	LY2835219	CDK4; CDK6	FDA Approved
T2933	Wogonin	CDK	Preclinical
T2709	TAK901	CLK2; JAK3; c-Src; FGR; Yes1	Phase 1
T2695	TBB	CK2; CDK2; GSK-3 β	
T2679	BMS265246	CDK1/CyclinB; CDK2/CyclinE; CDK4/CyclinD	Preclinical
T2615	Flavopiridol hydrochloride	CDK1; CDK2; CDK4; CDK6; CDK7	Phase 2
T2506	AZD5438	CDK1; CDK2; CDK9	Phase 1
T2465	PF562271	CDK1/CyclinB; CDK2/CyclinE; CDK3/CyclinE; FAK; PYK2	Phase 1
T2463	ML141	cdc42	Preclinical

ID	Product Name	Target	Condition
T2440	IC261	CK1; CDK5	
T2381	Abemaciclib	CDK4; CDK6	FDA Approved
T2378	RGB-286638 free base	CDK1/cyclinB1; CDK2/cyclinE; CDK3/cyclinE; CDK4/cyclinD1; CDK9/cyclinT1; p35-CDK5	Phase 1
T2356	Ro 3306	CDK1; ERK; PKA; PKC δ ; SGK	
T2247	KenPaullone	CDK1/CyclinB; CDK2/CyclinA; CDK2/CyclinE; CDK5/p35; GSK-3 β	Preclinical
T2246	LRRK2-IN-1	DCLK1; DCLK2; LRRK2 (A2016T); LRRK2 (G2019S); LRRK2 (WT)	
T2193	2-Chloropyrazine	CDK2	
T2153	1 nM-PP1	CDK7; permeable protein kinase D (PKD)	
T2118	SC514	Aurora B; CDK2/CyclinA; IKK2; p38 α ; PRAK	
T2113	PHA793887	CDK1/CyclinB; CDK2/CyclinA; CDK2/CyclinE; CDK5/p25; CDK7/CyclinH	Phase 1
T2095	Roscovitine	Cdc2/CyclinB; CDK2/CyclinA; CDK2/CyclinE; CDK5/p35	Phase 2
T2059	Purvalanol A	Cdc2/CyclinB; CDK2/CyclinA; CDK2/CyclinE; CDK4/CyclinD1	
T2032	WHI-P180	CDK2; EGFR	Preclinical
T2029	Bohemine	CDK	Preclinical
T2028	NG52	Cdc28p	
T19831	Sodium Oxamate	LDH; CDK; Apoptosis	
T1917	6-BIO	CDK1/CyclinB; CDK2/CyclinA; CDK5/p35; GSK-3; Tyk2	
T1912	Dinaciclib	CDK1; CDK2; CDK5; CDK9	Approved
T1855	ZCL 278	Cdc42 GTPase	
T1837	BX912	CDK2/CyclinE; Chk1; PDK1; PKA; VEGFR2 (KDR)	Preclinical
T1830	BX795	CDK2/CyclinE; Chk1; c-Kit; PDK1	Preclinical
T1785	Palbociclib	CDK4; CDK6	FDA Approved
T1778	AT 7519 hydrochloride salt	CDK2/CyclinA; CDK4/CyclinD1; CDK5/p35; CDK9/CyclinT; GSK-3 β	Phase 2
T17069	THAL-SNS-032	CDK9	
T16363	NVP-2	CDK9; Apoptosis	
T15732	Ribociclib succinate	CDK4; CDK6	FDA Approved
T14919	CDKI-73	CDK9	
T14916	CDK2-IN-4	cdk2/cyclinA; Cdk1/cyclinB	
T14778	BRD6989	CDK8; recombinant CDK8; recombinant CDK19; IL-10	
T13467	(\pm)-BAY-1251152	CDK9	
T13202	Trilaciclib hydrochloride	Cdk4/cyclin D1; cdk6/cyclin D3	Phase 3
T12617L	(R)-CR8	CDK	
T11345L	Lerociclib dihydrochloride	Cdk4/cyclin D1; cdk6/cyclin D3; CDK9/Cyclin T; CDK5/p35; Cdk5/p25; cdk2/cyclin A; CDK2/cyclinE; CDK1/cyclinB1; CDK7/Cyclin H/MAT1	Phase 1/2
T10744L	SEL120-34A HCl	CDK8/CycC; CDK19/CycC; CDK9/cycT	
T10436	AZD4573	CDK9	Phase 1

cell cycle arrest

ID	Product Name	Target	Condition
T4189	4-Oxofenretinide	cell cycle arrest and apoptosis	Preclinical
T3811	Ginsenoside C-K	cell cycle arrest; CYP2C9; CYP2A6	
T3774	Gracillin	cell cycle arrest	
T3386	Kaempferitrin	cell cycle arrest; PFK	

Chk

ID	Product Name	Target	Condition
T7300	GDC-0575	Chk1	Phase 1
T7080	CCT245737	Chk1	Phase 2
T6931	PD0166285	Wee1; Chk1; Myt1	Preclinical
T6350	CHIR124	Chk1; FLT3; GSK-3; PDGFR; Fyn	Preclinical
T6093	AZD7762	Chk1; Chk2	Phase 1
T6084	Rabusertib	Chk1; PDK1	Phase 1
T6028	PF477736	c-Fms; Chk1; Chk2; Yes; VEGFR2	Phase 1
T4327	Prexasertib dihydrochloride	Chk1; Chk2; RSK	Phase 2
T4310	Prexasertib	Chk1, Chk2	Phase 2
T3700	SCH900776 S-isomer	CDK2; Chk1; Chk2	Phase 2
T2485	Baricitinib	Chk2; JAK1; JAK2; JAK3; Tyk2	FDA Approved
T21331	SAR-020106	CHK1	
T2033	BML277	Chk2	
T1837	BX912	CDK2/CyclinE; Chk1; PDK1; PKA; VEGFR2 (KDR)	Preclinical
T1830	BX795	CDK2/CyclinE; Chk1; c-Kit; PDK1	Preclinical

c-Myc

ID	Product Name	Target	Condition
T4367	Mycro-3	c-Myc	
T4252	ML327	MYC	
T3686	10074-G5	c-Myc	
T3048	10058-F4	c-Myc-MAX	
T12133	MYCi975	MYC	
T12132	MYCi361	MYC	
T10352	APTO-253	c-Myc	Phase 1
T0617	Nicotinamide-N-oxide	c-Myc	

Deubiquitinase

ID	Product Name	Target	Condition
T8464	RA-9	Apoptosis; deubiquitinating enzymes (DUBs)	
T7685	USP25/28 inhibitor AZ1	USP25/28	
T11464	GRL0617	deubiquitinase; SARS-CoV P1pro	

DHFR

ID	Product Name	Target	Condition
T6226	Pemetrexed Disodium Hydrate	DHFR; DHFR; GARFT; Thymidylate synthase	FDA Approved
T6120	Pralatrexate	DHFR; Axl(KPL-4 cells); Axl(SUM149 cells)	FDA Approved
T4558	Trioxsalen	DHFR	FDA Approved
T2204	Diaveridine	DHFR	
T1326	Gentamycin sulfate	DNase I; DHFR; 16S ribosome; 30S ribosome	FDA Approved
T1153	Trimethoprim	DHFR; Thymidylate synthase	FDA Approved
T0849	Pyrimethamine	DHFR	FDA Approved
T0836	Sulfadoxine	DHPS; DHFR	FDA Approved
T0748	Sulfameter	DHFR	FDA Approved
T0738	Urea	Arginase-1; Carbonic anhydrase II; DHFR; Sulfoxide reductase catalytic subunit YedY; Wnt/ β -catenin	FDA Approved
T0189L	Pemetrexed disodium	DHFR; GARFT; Thymidylate synthase	FDA Approved
T0189	Pemetrexed acid	DHFR; GARFT; Thymidylate synthase	FDA Approved

DNA Alkylator/Crosslinker

ID	Product Name	Target	Condition
T8554	KCC-07	MBD2 (methyl-CpG-binding domain protein 2)	
T3091	Carmustine	DNA Alkylator	FDA Approved

DNA/RNA Synthesis

ID	Product Name	Target	Condition
TP1430	DTP3 TFA	GADD45 β /MKK7	
TL0005	(-)-3,5-Dicaffeoyl quinic acid	tRNA synthetase of Giardia lamblia	
T8886	NITD-2	RNA Synthesis	
T8800	NSAH	RR	
T8785	HALOFUGINONE LACTATE	prolyl-tRNA synthetase; TGF- β	Phase 2
T8647	BCH001	PAPD5	
T7747	Datelliptium chloride hydrochloride	DNA synthesis	

ID	Product Name	Target	Condition
T7655	Fialuridine	DNA polymerase	
T7525	Didox	ribonucleotide reductase(RR)	
T7174	Urolithin A	apoptosis; autophagy; DNA synthesis	
T7004	Tubercidin	DNA/RNA Synthesis	Approved
T6S0139	Neobavaisoflavone	DNA polymerase	
T6974	Saccharin 1-methylimidazole (SMI)	DNA/RNA Synthesis	
T6908	NSC228155	KIX-KID interaction; EGFR	
T6894	ML264	KLF5	
T6632	Raltitrexed	Thymidylate synthase	Approved
T6603	Nelarabine	DNA synthesis (ALL-SIL cells); DNA synthesis (HSB2 cells); DNA synthesis (JURKAT cells); DNA synthesis (PER-255 cells)	FDA Approved
T6501	Fludarabine Phosphate	DNA polymerase α ; DNA polymerase δ	FDA Approved
T6456	CRT0044876	APE1	
T6446	Clevudine	DNA polymerase; RNA polymerase	Approved
T6369	Adenine sulfate	DNA/RNA Synthesis	FDA Approved
T6244	Cidofovir	DNA/RNA Synthesis	FDA Approved
T6226	Pemetrexed Disodium Hydrate	DHFR; DHFR; GARFT; Thymidylate synthase	FDA Approved
T6225	Adenine hydrochloride	DNA/RNA Synthesis	
T6194	Fidaxomicin	RNA polymerase	FDA Approved
T6116	Bleomycin Sulfate	DNA/RNA Synthesis	FDA Approved
T6069	Gemcitabine HCl	DNA synthesis	FDA Approved
T5942	Docosanoic acid	DNA polymerase beta	
T5413	ML216	BLM helicase	
T4687	Ro 5-3335	CBF β -Runx1	Preclinical
T4656	B02	RAD51	
T4641	LMI 070	DNA/RNA Synthesis	Phase 2
T4569	Lucanthone	APE1	Phase 2
T4517	L189	DNA Ligase I; DNA Ligase III; DNA Ligase IV	
T4470	Pyridostatin TFA	G-quadruplexe	
T4457	Pyridostatin Trihydrochloride(free base 1085412-37-8)	G-quadruplexe	
T4382	Proguanil hydrochloride	dihydrofolate reductase; thymidylate synthase; NADH dehydrogenase	FDA Approved
T4356	Compound 3A	RNA polymerase I	
T4336	IPTG	DNA/RNA Synthesis	
T4311	HAMNO	DNA replication	
T4228	Nolatrexed	Thymidylate synthase	Phase 3
T4226	Amenamevir	helicase-primase	Approved
T4060	Acelarin	DNA synthesis	Phase 3

ID	Product Name	Target	Condition
T4010	Juglone	RNA polymerase	
T3772	Maslinic acid	DNA polymerase B	
T3658	TAS102	DNA/RNA Synthesis	FDA Approved
T3628	Madrasin	DNA/RNA Synthesis	
T3524	Halofuginone hydrobromide	ProRS; prolyl-tRNA synthetase	Phase 2
T3400	Bakuchiol	DNA polymerase I	
T3343	5-methoxyflavone	DNA/RNA Synthesis	
T3157	COH29	RNR(KB cell)	Phase 1
T2942	Psoralen	DNA/RNA Synthesis	Approved
T2708	SL327	AP-1; MEK1; MEK2	
T2628	R12	RAD51	
T2504	Pritelivir	helicase primase; HSV-2	Phase 2
T2410	Nedaplatin	DNA synthesis	Approved
T2276	R11	RAD51	
T2275	YK-4-279	RNA helicase A	
T2219	Puromycin dihydrochloride	DNA synthesis; 60S ribosome	
T2201	6-Mercaptopurine monohydrate	DNA synthesis; PRPP Amidotransferase	FDA Approved
T2100	CX5461	Pol I-driven transcription of rRNA	Phase 2
T20945	2,4-D	DNA synthesis	
T19833	5-Fluoroorotic acid	thymidylate synthase	
T1982	Triapine	RR	Phase 2
T1840	Isoidigotin	DNA polymerase	
T1767	BMH21	RNA polymerase I	
T1724	SCR7 pyrazine	DNA Ligase IV	
T1721	2'-Deoxyuridine	Thymidylate synthase; Upp	
T1703	SN38	Topo I; DNA synthesis	Phase 2
T1679	Thiostrepton	DNA synthesis	Approved
T1665	Daptomycin	DNA synthesis	FDA Approved
T1663	Deoxythymidine triphosphate	DNA/RNA Synthesis	
T1646	Famciclovir	DNA polymerase; HSV	FDA Approved
T1629	Rifapentine	RNA polymerase	FDA Approved
T1617	Enrofloxacin	DNA synthesis	Approved
T1600	Doxifluridine	Thymidine phosphorylase	Approved
T1591	Cyclocytidine hydrochloride	DNA/RNA Synthesis	Approved
T1564	Cisplatin	DNA synthesis	FDA Approved
T15611	JH-RE-06	REV1-REV7	
T1558	Resveratrol	COX-1; COX-2; DNA polymerase α ; IKK β ; LOX; Quinone reductase 2; SIRT1; SIRT2	Approved

ID	Product Name	Target	Condition
T1511	D Daunorubicin hydrochloride	DNA synthesis	FDA Approved
T1506	Vidarabine	DNA polymerase; DNA polymerase; Tyrosine Kinases	FDA Approved
T1501	Rifabutin	RNA polymerase; Endoplasmic; HSP90	FDA Approved
T1488	Procarbazine hydrochloride	DNA/RNA Synthesis	FDA Approved
T1465	Mupirocin	DNA synthesis	FDA Approved
T1454	Aciclovir	DNA synthesis	FDA Approved
T1428	Trifluridine	DNA/RNA Synthesis; Thymidylate synthase	FDA Approved
T1417	Mechlorethamine hydrochloride	DNA/RNA Synthesis	FDA Approved
T1408	Capecitabine	Thymidine phosphorylase	FDA Approved
T1378	Tegafur	DNA synthesis	Approved
T13584	BMVC-8C3O	G-quadruplexe	
T1349	5-Fluorouridine	DNA synthesis; Upp	
T1307	Carmofur	DNA/RNA Synthesis	Approved
T1276	Danofloxacin mesylate	DNA-gyrase	Approved
T1272	Cytarabine	DNA synthesis	FDA Approved
T1233	Oxolinic acid	bacterial DNA gyrase; DNA synthesis; dopamine uptake	Approved
T1178	Temozolomide	DNA replication	FDA Approved
T1154	Rifaximin	DNA/RNA Synthesis	FDA Approved
T1153	Trimethoprim	DHFR; Thymidylate synthase	FDA Approved
T1120	Dacarbazine	DNA polymerase beta	FDA Approved
T1087	Valacyclovir hydrochloride	DNA polymerase	FDA Approved
T1086	Vitamin D2	DNA polymerase; VD3	FDA Approved
T1058	Carboplatin	DNA synthesis	FDA Approved
T1055	Ifosfamide	DNA/RNA Synthesis	FDA Approved
T1038	Fludarabine	STAT1; DNA synthesis	FDA Approved
T0986	Fluorocytosine	DNA synthesis	FDA Approved
T0984	Fluorouracil	Thymidylate synthase	FDA Approved
T0964	Floxuridine	Thymidylate synthase	FDA Approved
T0926	Azelaic acid	DNA polymerase I; ThxR	FDA Approved
T0684	Ribavirin	ADK; IMPDH1; RNA polymerase	FDA Approved
T0681	Rifampicin	14- α Demethylase; DNA/RNA Synthesis	FDA Approved
T0676	Hydroxyurea	ribonucleoside diphosphate reductase	FDA Approved
T0415	Guanidine hydrochloride	Arginase; Lysozyme; Ribonuclease pancreatic; Argininosuccinate synthase	FDA Approved
T0353	Osalmid	RR	Approved
T0297	Clofarabine	RR	FDA Approved
T0251	Gemcitabine	Autophagy; DNA synthesis	FDA Approved
T0189L	Pemetrexed disodium	DHFR; GARFT; Thymidylate synthase	FDA Approved
T0189	Pemetrexed acid	DHFR; GARFT; Thymidylate synthase	FDA Approved

ID	Product Name	Target	Condition
T0164	Oxaliplatin	DNA synthesis	FDA Approved
T0148	Calcium folinate	Thymidylate synthase; VB	FDA Approved

DYRK

ID	Product Name	Target	Condition
TQ0111	LDN-192960	DYRK2; Haspin	
T6257	AZ191	DYRK1A; DYRK1B; DYRK2	
T2811	Harmine hydrochloride	GluR1; DYRK1A; DYRK1B; DYRK2	
T2431	ID8	DYRK	
T11447	GNF4877	GSK3β; DYRK1A	

Ferroptosis

ID	Product Name	Target	Condition
T8662	UAMC-3203 hydrochloride	Ferroptosis	
T6500	Ferrostatin-1	Ferroptosis	
T5523	Imidazole ketone erastin	Ferroptosis activator	
T5343	UAMC3203	Ferroptosis	
T4066	FIN56	Ferroptosis	
T2858	Baicalein	XO	Approved
T2376	Liproxstatin-1	Ferroptosis	
T19467	NADPH (tetracyclohexanamine)	Ferroptosis	
T1765	Erastin	Ferroptosis	Phase 2
T1637	Deferoxamine Mesylate	Iron; Ferroptosis	FDA Approved
T11631	iFSP1	Ferroptosis	

Haspin Kinase

ID	Product Name	Target	Condition
TQ0111	LDN-192960	DYRK2; Haspin	

KSP

ID	Product Name	Target	Condition
T2255	SB743921	KSP; KSP (Colo205 cells); KSP (MV522 cells); KSP (MX1 cells); KSP (SKOV3 cells)	Phase 1/2
T2103	Ispinesib	KSP (HsEg5)	Phase 1

LIM Kinase

ID	Product Name	Target	Condition
T7128	TH 257	LIMK	
T4600	BMS3	LIMK1; LIMK2	
T4598	BMS5	LIMK1; LIMK2	
T3960	T56-LIMKi	LIMK2	

Nucleoside Antimetabolite/Analog

ID	Product Name	Target	Condition
T8354	Triazavirin	Nucleoside Analogue; Influenza virus	
T7621	6-Thioinosine	Nucleoside Antimetabolite/Analog	
T7514	N2-Methylguanosine	Nucleoside	
T7491	6-O-Methyl Guanosine	Nucleoside	
T7351	3-Methylcytidine	Nucleoside	
T7319	7-Methylguanosine	cNIIIB nucleotidase	
T2366	Tipiracil hydrochloride	Nucleoside Antimetabolite/Analog	FDA Approved
T1591L	Cytidine	Nucleoside Analogue	Approved
T0853	Adenosine	Nucleoside	FDA Approved
T0543	7-Methylxanthine	Nucleoside Antimetabolite/Analog	
T0532	Dihydrothymine	Nucleoside Analogue	

PD-1/PD-L1

ID	Product Name	Target	Condition
T8470	BMS-1001	PD-1/PD-L1	
T5697	BMS1166	PD-1/PD-L1	
T4696	BMS202 hydrochloride (1675203-84-5(free base))	PD-1/PD-L1	
T3655	PD-1/PD-L1 inhibitor 1	PD-1/PD-L1	
T3146	PD1-PDL1 inhibitor 2	PD-1/PD-L1	
T10565	BMS-1001 hydrochloride	PD-1/PD-L1	

PLK

ID	Product Name	Target	Condition
T7200	TAK-960	PLK	Phase 1
T6338	PHA680632	Aurora A; Aurora B; Aurora C; FGFR1; PLK1	Preclinical
T6282	GSK461364	PLK1	Phase 1
T6247	NMS-P937	PLK1; PLK2; PLK3	Phase 2
T6173	BI 2536	BRD4; PLK1; PLK2; PLK3	Phase 1

ID	Product Name	Target	Condition
T6070	ON-01910	PLK1	
T6019	Volasertib	PLK1	Approved
T5818	ON-01910	PLK1	Phase 3
T2634	RO 3280	PLK1	
T2438	HMN214	PLK1	Phase 1
T2271	SBE 13 hydrochloride	PLK1; PLK2; PLK3	
T0973	Pyridoxine	PLK	FDA Approved

Rho

ID	Product Name	Target	Condition
TP2327L	Y16 acetate(53-73-6 free base)	Rho GEFs	
T7764	CCG-222740	Rho	
T7391	SAR407899	Rho	Phase 2
T6739	Zoledronic Acid	Rho	FDA Approved
T6483	EHT 1864	Rac1; Rac1b; Rac2; Rac3	Preclinical
T6342	NSC 23766 trihydrochloride	Rac GTPase	
T4306	CCG203971	Rho	
T3553	Y16	Rho GEFs	
T2427	EHop016	Rac1	
T2014	CCG1423	RhoA; LRRK2 wild-type; G2019S LRRK2	
T1237	Azathioprine	HGPRT; Rac1	FDA Approved

ROCK

ID	Product Name	Target	Condition
TQ0319	Ripasudil hydrochloride dihydrate	ROCK1; ROCK2	Approved
T7301	BDP5290	ROCK	
T6867	KD025	ROCK2; ROCK2	Phase 2
T6321	Tofacitinib	JAK1; JAK2; JAK3; ROCK2; Lck	FDA Approved
T4276	Hydroxyfasudil Hydrochloride	ROCK	
T4095	ZINC00881524	ROCK	
T3518	GSK269962A	MSK1; ROCK1; ROCK2; RSK1	
T3513	GSK180736A	GRK1; GRK2; GRK5; PKA; ROCK	
T3060	Fasudil hydrochloride	PKA; PKG; PKC; ROCK2; MLCK	Approved
T2633	GSK429286A	ROCK1; ROCK2	
T2482	AT13148	Akt1; Akt2; Akt3; PKA; ROCK1; ROCK2; p70 S6K; RSK1; SGK3	Phase 1
T2155	Thiazovivin	ROCK	

ID	Product Name	Target	Condition
T2011	RKI1313	ROCK1; ROCK2	
T1898	RKI1447	ROCK1; ROCK2	
T1725	Y-27632 dihydrochloride	ROCK1 (p160ROCK); ROCK2	Preclinical




Serine/threonin kinase

ID	Product Name	Target	Condition
TQ0104	CRT0066101 dihydrochloride	PKD1; PKD2; PKD3	
T7444	6-(Dimethylamino)purine	CDK; serine threonine protein kinase	
T5194	SPHINX31	SRPK1	
T4291	(+)-Isocorydine hydrochloride	eukaryote protein kinases; tyrosine kinase	
T3060	Fasudil hydrochloride	PKA; PKG; PKC; ROCK2; MLCK	Approved
T3050	ML-7 hydrochloride	PKA; PKC; MLCK	
T2458	CID755673	PKD1; PKD2; PKD3	
T2153	1 nM-PP1	CDK7; permeable protein kinase D (PKD)	
T2062	kb NB 142-70	PKD1; PKD2; PKD3	
T1954	SRPIN340	SRPK1	
T1863	CID2011756	PKD	
T1808	kb-NB77-78	PKD1	
T0610	Piceatannol	cAK; PKC; MLCK	Approved

Wee1

ID	Product Name	Target	Condition
T8916	JUN76288	Wee1	
T6931	PD0166285	Wee1; Chk1; Myt1	Preclinical
T2077	Adavosertib	Wee1	Phase 2

Chromatin/Epigenetic

	Epigenetic Writer	Epigenetic Reader	Epigenetic Eraser
<p>Pan inhibitor GSK-525762A Selective inhibitor (+)-JQ-1(BRD4) RVX-208(BRD2) UNC119(L3MBTL3)</p>	<p>Epigenetic Writer</p> 	<p>Epigenetic Reader</p> <p>Alteration of DNA-templated Processes Recruitment</p> 	<p>Epigenetic Eraser</p> <p>Removal of Modification</p> 
<p>Histone Acetylation</p> <p>Histone Acetyltransferase inhibitor C646</p>	<p>Histone Acetyltransferase(HATs) GCN5/IPCAF GNAT Related(e.g., HAT1) Myst Family(e.g. TIP60, HBO1) CBP/p300 Family TAF250 Family Src Family (e.g. Src3, Src1)</p>	<p>Bromodomain Proteins e.g. most HATs BET Family (BRD2, BRD, BDF) Brg-1</p>	<p>Histone Deacetylases (HDACs) Class I: HDAC1-3, HDAC5 Class IIa: HDAC4-5, HDAC7, HDAC9 Class IIb: HDAC6, HDAC10 Class III: Sirt 1-7 Class IV: HDAC11</p>
<p>Histone Methylation</p> <p>Histone Methyltransferase inhibitor GSK503 EP26438 unc0379 EP2005887 BRD4770</p>	<p>Lysine Methyltransferase (KMTs) KMT1A—1F(e.g. G9a, GLP) MLL Family(e.g. NSD1) DOT1/DOT1L KMT3A-KMT3C KMT5A, KMT5B KMT6/EZH2 KMT7/SET7&9 KMT8/RIZ1</p>	<p>Royal Family -Chromo-domain Proteins e.g. HP-1 like -Tudor-domain Proteins, e.g. SMN -PHD Proteins, e.g. CBD, ING2, DNMT3L</p>	<p>Lysine Demethylases (KDMs) LSD1/KDM JHDM/Jumonji</p>
<p>Histone Phosphorylation</p> <p>DNA Methyltransferase inhibitor mylosar Decogen Zebularine Lomeguatib</p>	<p>Serine/Threonine Kinases e.g. MST, AMPK Haspin, VRK, Aurora B PKCo, PKCb, MSK1/2, JNK</p>	<p>14-3-3 Proteins Seven Isoforms: theta, gamma, zeta, eta, epsilon, beta, mu</p>	<p>Protein Phosphatases e.g. Serine/Threonine Phosphatases (PPP2CA, PPP2CB, PPP1CC) Protein Phosphatase 1D Eye-absent Homologues(EYA1-3)</p>
<p>DNA Methylation</p>	<p>DNMT1 DNMT3A DNMT3B</p>	<p>MeCP2 MBD1-4</p>	<p>Not Clear ---only putative targets so far</p>

Aurora Kinase

ID	Product Name	Target	Condition
TQ0059	Ilorasertib	Aurora A; Aurora B; Aurora C; PDGFRβ; RET; FLT1; VEGFR1; VEGFR2; VEGFR3	Phase 2
T8685	SP-146	Aurora B	
T6785	BI847325	Aurora A (Human); Aurora B (Xenopus laevis); Aurora C (Human); MEK1; MEK2	Phase 1
T6532	Hesperadin	Aurora B (human); TbAUK1	
T6458	CYC116	Aurora A; Aurora B; CDK2/CyclinE; CDK9/CyclinT; FLT3; p70 S6K; VEGFR2	Phase 1
T6380	AMG900	Aurora A; Aurora B; Aurora C; p38α; Tyk2	Phase 1
T6338	PHA680632	Aurora A; Aurora B; Aurora C; FGFR1; PLK1	Preclinical
T6315	MLN8054	Aurora A; Aurora B; CK2; PKA; Lck	
T6126	JNJ7706621	CDK2/CyclinE, CDK2/CyclinA, CDK1/CyclinB, Aurora A, Aurora B	Preclinical

ID	Product Name	Target	Condition
T6077	ZM 447439	Aurora A; Aurora B; MEK1; Lck; Src	Preclinical
T6057	URMC099	Aurora A; Aurora B; Aurora C; Abl1; CDK1; CDK2; c-Met; DLK; IGF-1R; Insulin Receptor; LRRK2; MEKK2; MLK1; MLK2; MLK3; ROCK1; ROCK2; SGK; TrkB; VEGFR1/FLT1	
T5524	Aurora Kinase Inhibitor III	Aurora A	
T4428	CCT241736	FLT3; Aurora Kinase	
T3166	VX-11e	Aurora A; CDK2; ERK2; FLT3; GSK-3	
T3109	Pyrazolanthrone	Aurora A; JNK1; JNK2; JNK3; TrkA	Preclinical
T3068	AT9283	Aurora A; Aurora B; Abl1 (T315I); JAK2; JAK3	Phase 1
T2620	G749	Aurora B; RET; FLT3; FLT3 (D835Y); Mer	Preclinical
T2617	SNS-314 Mesylate	Aurora A; Aurora B; Aurora C	Phase 1
T2611	CCT137690	Aurora A; Aurora B; Aurora C	
T2602	1H-Pyrazole-3-acetamide	Aurora B	Phase 2
T2509	Tozasertib	Aurora A; Aurora B; Aurora C	Approved
T2471	MK8745	Aurora A; Aurora B	
T2358	ENMD2076	Aurora A; RET; FLT3; Src; VEGFR3/FLT4; Src	Phase 2
T2341	KW2449	Aurora A; Abl; Abl (T315I); Kit; FGFR1; FLT3; FLT3 (D835Y); JAK2; Src	Phase 1/2
T2241	Alisertib	Aurora A	Phase 1
T21981	Phthalazinone pyrazole	Aurora A	
T2118	SC514	Aurora B; CDK2/CyclinA; IKK2; p38 α ; PRAK	
T2094	Danuseritib	Aurora A; Aurora B; Aurora C; Abl; RET; FGFR1; TrkA	Phase 2
T1886	TAK632	Aurora B; FGFR3; PDGFR β ; B-Raf; C-Raf	Preclinical
T1825	Reversine	A3; Aurora A; Aurora B; Aurora C	

DNA Methyltransferase

ID	Product Name	Target	Condition
T7718	2'-DEOXY-5-FLUOROCYTIDINE	DNA methyltransferase (DNMT)	Phase 1
T7457	5-Methyl-2'-deoxycytidine	Human Endogenous Metabolite; DNA methylation	
T7194	CM-272	DNA methyltransferase (DNMT)	
T5198	Bobcat339 hydrochloride	TET1; TET2	
T3606	Gamma-Oryzanol	DNA methyltransferase (DNMT); DNMT3a	Approved
T3458	EED226	EED; PRC2	
T3089	Thioguanine	DNMT1; USP2	FDA Approved
T2169	Zebularine	Cytidine deaminase	
T2038	RG108	DNA methyltransferase (DNMT)	
T1904	SGI1027	DNMT1; DNMT3A; DNMT3B	
T15080	DC-05	DNMT1; PRMT1	
T1508	Decitabine	DNA methyltransferase (DNMT)	FDA Approved

ID	Product Name	Target	Condition
T1339	5-Azacytidine	DNA methyltransferase (DNMT)	FDA Approved
T0018	Procainamide hydrochloride	AChR; DNA (cytosine-5)-methyltransferase 1; Sodium Channel	FDA Approved

Epigenetic Reader Domain

ID	Product Name	Target	Condition
TQ0253	PLX51107	BET	Phase 1
TQ0083	NI-57	BRPF1; BRPF2; BRPF3	
TL0007	Bisdemethoxycurcumin	p300; Wnt/ β -catenin	
T8778	TTK21	CBP/p300	
T8774	MS7972	CREBBP	
T8658	NEO2734	p300/CBP; BET bromodomain	
T8495	Alobresib	BET	Phase 1/2
T8453	UNC1079	L3MBTL3	
T7863	Hexamethylene bisacetamide	BET	
T7856	nAS-E	CREB	
T7297	KG-501	CREB	
T7264	CBP/EP300-IN-1	CBP/EP300	
T6939	PFI3	SMARCA2; SMARCA4; PB1(5) bromodomains	
T6859	I-BRD9	BRD9	
T6828	ZL0420	BRD4	
T6811	CPI637	BRD4; CBP; EP300	
T6786	BI9564	BRD9	
T6783	BI7273	BRD7; BRD9	
T6668	SGC-CBP30	CREBBP; EP300	
T6389	Anacardic Acid	PCAF(p300/CBP-associated factor); p300 histone acetyltransferase; p300/CBP	Preclinical
T6255	Bromosporine	BRD; CECR2	
T6222	PFI1	BRD2; BRD4	
T6173	BI 2536	BRD4; PLK1; PLK2; PLK3	Phase 1
T6032	Birabresib	BRDs	Phase 2
T6026	CPI203	BRD4	Preclinical
T6021	GSK1324726A	BRD2; BRD3; BRD4	
T5575	Cyclogalegenol	CREB	
T5468	YF-2	CBP; PCAF; GCN5	
T5443	JQ-1 carboxylic acid	BRD4	
T5442	A1874	BRD4; PROTAC	
T5440	Dbet57	BD1-BRD4	
T5436	MZ 1	BRD4	

ID	Product Name	Target	Condition
T5435	ARV-771	BET	
T5434	ARV-825	BRD4	
T5417	INCB057643	BET	Phase 1/2
T5318	CREB inhibitor	CREB	
T5130	dBET6	BET	
T4697	ABBV744	BET bromodomain	Phase 1
T4495	dBET1	BET	
T4365	FL411	BRD4	
T4345	CeMMEC1	BRD4; TAF1	
T4247	I-CBP112 hydrochloride	CBP/p300, Leukemia cell; CBP/p300, Prostate cancer cell	
T4012	UNC 926 hydrochloride	L3MBTL1	
T3986	SF2523	DNA-PK; BRD4; mTOR; PI3K α ; PI3K γ	Preclinical
T3969	I-CBP112	CBP/p300(Leukemia cell)	
T3712	Mivebresib	BET	Phase 1
T3697	3,6'-Disinapoyl sucrose	Bcl-2; CREB	
T3504	AZD5153 6-Hydroxy-2-naphthoic acid	BD1-BRD4; FL-BRD4	Phase 1
T3311	GSK6853	BRPF1; BRPF2; BRPF3	
T3217	PF-CBP1 hydrochloride	CREBBP; p300/CBP	
T2480	Apabetalone	BD2	Phase 3
T2452	C646	p300/CBP	
T2442	CPI203	BRD4	Preclinical
T2436	GSK2801	BAZ2A; BAZ2B	
T2379	UNC1215	L3MBTL3; L3MBTL3; L3MBTL3-D274A	
T2252	UNC669	L3MBTL1; L3MBTL3; L3MBTL4	
T2237	ICG001	Wnt/ β -catenin; CBP	Phase 1
T2127	OF1	BRPF1B; BRPF2	
T2120	I-BET151	BRD2; BRD3; BRD4	
T2110	(+)-JQ-1	BRD4 (1); BRD4 (2)	Preclinical
T2072	BET bromodomain inhibitor	BET bromodomain	
T19935	XD14	BET bromodomain	
T1993	J147	BDNF	Phase 1
T1973	PF4	BRPF1; BRPF2; BRPF3	
T1972	GSK 5959	BRPF1	
T19618	(R)-(-)-JQ1 Enantiomer	BET bromodomain	
T1906	Molibresib	BET proteins	Phase 1/2
T1854	MS436	BRD4 (1); BRD4 (2)	
T17311	(+)-JQ1 PA	BET	
T16154	MS417	BRD4	
T15216	EML 425	p300; CBP	

ID	Product Name	Target	Condition
T1516	Curcumin	p300 histone acetyltransferase; KEAP1-Nrf2	Phase 2
T14073	A-485	CBP/p300; histone acetyltransferase	
T12112	MS402	BRD4-BD1; BRD2-BD1; BRD3-BD1; BRD3-BD2; BRD2-BD2; BRD4-BD2	
T11563	Histone Acetyltransferase Inhibitor II	p300	
T11136	E-7386	CBP	Phase 1
T10717	CBP-IN-1	p300/CBP	Phase 1/2
T0808	Diflunisal	p300	FDA Approved

HDAC

ID	Product Name	Target	Condition
TQ0074	ACY-775	HDAC6	
T8517	PXD-101	HDAC	FDA Approved
T8508	HDAC-IN-3	HDAC	
T8480	Tenovin-6 Hydrochloride	SIRT1; SIRT2; SIRT3; HDAC8; p53	
T8233	BRD3308	HDAC3	
T7691	NSC 3852	HDAC	
T7664	Pyroxamide	HDAC	
T7385	WT-161	HDAC	
T7082	HDAC8-IN-1	HDAC8	
T7064	Valproic Acid	GABA; Sodium Channel; HDACs; HDAC1	FDA Approved
T6980	Scriptaid	HDAC	
T6865	Quisinostat 2HCl	HDAC1; HDAC10; HDAC11; HDAC2; HDAC4	Phase 2
T6695	Tasquinomod	HDAC4	Phase 3
T6639	RG2833	HDAC1; HDAC3	Phase 1
T6481	Droxinostat	HDAC10; HDAC3; HDAC6; HDAC8; HDAC9	
T6474	Divalproex Sodium	HDAC	FDA Approved
T6421	BRD73954	HDAC2; HDAC4; HDAC6; HDAC8	
T6392	AR42	HDAC	Preclinical
T6362	4SC202	HDAC1; HDAC11; HDAC2; HDAC3; HDAC5	Phase 2
T6327	Tubacin	HDAC6	
T6325	PCI34051	HDAC1; HDAC10; HDAC2; HDAC6; HDAC8	Preclinical
T6279	Givinostat hydrochloride monohydrate	HD1-A; HD1-B; HD2	Phase 3
T6270	Trichostatin A	HDAC	Phase 1
T6233	Entinostat	HDAC1; HDAC3	Approved
T6161	Tubastatin A HCl	HDAC1; HDAC2; HDAC3; HDAC6; HDAC8	
T6061	LMK235	HDAC4; HDAC5	
T6055	Quisinostat	HDAC1; HDAC10; HDAC11; HDAC2; HDAC3; HDAC4; HDAC5; HDAC8	Phase 2

ID	Product Name	Target	Condition
T6006	Romidepsin	HDAC1; HDAC2	FDA Approved
T5886	Benzenebutyric acid	HDAC	Approved
T5830	SKLB-23bb	HDAC6	
T5631	SIS17	HDAC11	
T5347	CXD-101	HDAC; HDAC1 ; HDAC3 ; HDAC2	Phase 2
T5332	TH34	HDAC6; HDAC8; HDAC10	
T4481	Tucidinostat	HDAC1; HDAC2; HDAC3; HDAC10	Approved
T4477	4SC-202 tosylate	HDAC1; HDAC2; HDAC3; HDAC5; HDAC9; HDAC10; HDAC11;	Phase 2
T4389	SR4370	HDAC1; HDAC2; HDAC3	
T4370	Resminostat hydrochloride	HDAC1; HDAC3; HDAC6; HDAC8	Phase 2
T3983	TMP 195	HDAC4; HDAC5; HDAC7; HDAC9	
T3937	Methyl L-histidinate dihydrochloride	HDAC	
T3878	Raddeanin A	HDAC	
T3753	Sinapinic Acid	ACE; HDAC	
T3661	Citarinostat	HDAC1; HDAC2; HDAC3; HDAC6; HDAC8	Phase 2
T3516	Minomustine	HDAC1; HDAC2; HDAC3; HDAC6; HDAC8	Phase 1/2
T3509	ACY738	HDAC6	Preclinical
T3358	ITSA1	HDAC	
T3206	PAOA	HDAC	
T3205	UF010	HDAC	
T3204	BML210	HDAC	
T3199	PTACH	HDAC	
T3193	Pimelic diphenylamide 106	HDAC	
T3108	CUDC101	EGFR; HDAC; HDAC1; HDAC10; HDAC2; HDAC3; HDAC4; HDAC5; HDAC6; HDAC7; HDAC8; HDAC9; HER2	Phase 1
T2512	Mocetinostat	HDAC1; HDAC11; HDAC2; HDAC3	Approved
T2489	Rocilinostat	HDAC1; HDAC2; HDAC3; HDAC6; HDAC8	Phase 2
T2383	Panobinostat	HDAC	FDA Approved
T2294	BG45	HDAC1; HDAC2; HDAC3; HDAC6	
T2266	Santacruzamate A	HDAC2; HDAC4; HDAC6	
T2205	Theophylline-7-acetic acid	A1; A2; A3; HDAC2; PDE4; PKA; TNF- α	Approved
T2157	Histone Deacetylase Inhibitor III	HDAC	
T2140	Parthenolide	NF- κ B	Phase 2
T2078	PI3K/HDAC Inhibitor	HDAC1; HDAC10; HDAC11; HDAC2; HDAC3	Phase 2
T2025	Chidamide	HDAC1; HDAC2; HDAC3; HDAC8	Approved
T2023	MC1568	HD1-A (Maize); HD1-B (Maize)	
T1983	CAY10603	HDAC1; HDAC6	Phase 1
T19687	Phenylethyl isothiocyanate	HDAC	
T1966	Tubastatin A	HDAC6	

ID	Product Name	Target	Condition
T1890	Pracinostat	HDAC1; HDAC10; HDAC11; HDAC2; HDAC3; HDAC4; HDAC5; HDAC6; HDAC7; HDAC8; HDAC9	Approved
T1888	CI994	HDAC1; HDAC2; HDAC3	Phase 2
T1857	TMP269	HDAC4; HDAC5; HDAC7; HDAC9	
T1852	Belinostat	HDAC	FDA Approved
T1819	Nexturastat A	HDAC6	
T1762	RGFP 966	HDAC3	
T16962	SW-100	HDAC1; HDAC2; HDAC3; HDAC4; HDAC5; HDAC6; HDAC7; HDAC8; HDAC9; HDAC10; HDAC11	
T1602	Valproic acid sodium salt	GABAR; HDAC2; HDAC9	FDA Approved
T1583	Vorinostat	HDAC; HDAC1; HDAC2; HDAC3; HDAC6; HDAC8	FDA Approved
T1535	Sodium Phenylbutyrate	HDAC	FDA Approved
T13996	1-Naphthohydroxamic acid	HDAC8; HDAC1; HDAC6	
T1083L	Theophylline monohydrate	Adenosine receptor; HDAC2; PDE	FDA Approved
T1083	Theophylline	Adenosine receptor; HDAC2; PDE	FDA Approved
T0431	PCI24781	HDAC1; HDAC10; HDAC2; HDAC3/SMRT; HDAC6	Phase 3

HIF

ID	Product Name	Target	Condition
T7848	PT-2385	HIF-2 α	Phase 2
T7802	M1001	HIF-2 α	
T7692	2,4-DPD	HIF-PH	
T6961	PX-478 2HCl	HIF-1 α	Phase 1
T6929	Pantoprazole sodium	HIF-1 α ; proton pump	FDA Approved
T5537	IDF-11774	HIF-1 α	
T4S1551	Cinnamaldehyde	HIF- α	
T4S0800	Demethyleneberberine	CYP17; HIF; NOS	
T4651	Vadadustat	HIF-PH	Approved
T4381	Lifigiquat	sGC; HIF-1 α	Preclinical
T3494	LW6	HIF-1; MDH2	
T3404	Cucurbitacin B	HIF-1; PTEN; STAT3	
T3197	Daprodustat	HIF-PH	Approved
T3169	KC7F2	HIF-1 α	
T3027	Sodium Aescinate	HIF-1 α	Approved
T2515	Roxadustat	HIF-PH	Approved
T2488	BAY 87-2243	HIF-1 α	Phase 1
T2220	2-Methoxyestradiol	HIF-1 α ; HIF-2 α ; Microtubule depolymerization	Approved
T1939	DMOG	HIF-PH	
T13050	SYP-5	HIF	
T12675L	PT2399	HIF-2 α	

ID	Product Name	Target	Condition
T11589	Hydroxycitric acid tripotassium hydrate	ATP citrate lyase; HIF	
T0447	Carvedilol	Adrenergic Receptor; HIF; E-selectin; NADPH; Vcam; Potassium Channel; VEGFR; LDL oxidation	FDA Approved
T0153	Oltipraz	Reverse Transcriptase; HIF-1 α	Phase 3

HIF/HIF Prolyl-Hydroxylase

ID	Product Name	Target	Condition
T7880	IOX4	PHD2	
T6S1315	Oroxlylin A	Autophagy; HIF/HIF Prolyl-Hydroxylase	
T5392	TP0463518	PHD1; PHD2; PHD3	
T5176	Desidustat	HIF hydroxylase	Phase 2
T4106	MK8617	PHD1; PHD2; PHD3	
T3180	HIF-PHD Inhibitor II	PHD1; PHD2; PHD3	
T2941	Glucosamine hydrochloride	Autophagy; HIF/HIF Prolyl-Hydroxylase	Approved
T2652	Molidustat	PHD1; PHD2; PHD3	Phase 3
T2445	FG2216	PHD2	Phase 2
T1823	IOX 2	PHD2	

Histone Acetylation

ID	Product Name	Target	Condition
T4380	Ac-CoA Synthase Inhibitor1	ACSS2	

Histone Acetyltransferase

ID	Product Name	Target	Condition
T8344	CPTH2	Histone Acetyltransferase inhibitor	
T5468	YF-2	CBP; PCAF; GCN5	
T4679	WM1119	KAT6A	
T4362	MOZ-IN-3	MOZ	
T3499	Remodelin	NAT10	
T14073	A-485	CBP/p300; histone acetyltransferase	
T12345	P300/CBP-IN-3	histone acetyltransferase	
T12098	MOZ-IN-2	MOZ	

Histone Demethylase

ID	Product Name	Target	Condition
T7942	Tranylcypromine (hemisulfate)	MAO; LSD1	FDA Approved
T6922	ORY1001	LSD1/KDM1A	Phase 2
T6847	GSK J1	JMJD3 (KDM6B); UTX (KDM6A)	
T6593	ML324	JMJD2	
T6545	IOX1	2OG oxygenases, including the JmjC demethylases; KDM4A/KDM3A	
T6073	OG-L002	LSD1	
T5825	ORY-1001(trans)	LSD1/KDM1A	Phase 2
T5484	GSK467	JARID1A	
T4527	Seclidemstat	LSD1	Phase 1
T4418	GSK2879552 2HCl (1401966-69-5(free base))	LSD1	Phase 1/2
T4383	GSK-J4 Hydrochloride	JMJD3	
T4214	KDM4D-IN-1	KDM4D	
T4100	AS8351	histone demethylase	Preclinical
T3719	Daminozide	KDM2/7 JmjC	
T3576	KDM5-inhibitor	KDM5	
T3552	CPI455	KDM5A	
T3100	GSK J4	JMJD3	
T2315	GSK-LSD1 dihydrochloride	LSD1	
T2304	SP2509	LSD1	
T1868	JIB04	JMJD2A; JMJD2B; JMJD2D; JMJD2E; JARID1A	
T13748	L-2-Hydroxyglutaric acid disodium	Histone Demethylase; Mitochondrial Metabolism	
T13055	T-3775440 hydrochloride	LSD1	
T1025	Tranylcypromine (2-PCPA) hydrochloride	MAO; LSD1	FDA Approved

Histone Methyltransferase

ID	Product Name	Target	Condition
TQ0232	UNC 0646	G9a; GLP	
TQ0100	AZ505	SMYD2	
TQ0069	MI-503	Menin-MLL	
TQ0058	MI-463	Menin-MLL	
T8881	Dot1L-IN-4	DOT1L	
T8768	MM-102 TFA	MLL1	
T8510	CPI-1205	EZH2	
T8201	Gambogenic acid	EZH2	
T7697	BIX-01294	G9a	

ID	Product Name	Target	Condition
T7403	BAY-598	SMYD2	
T7378	BRD9539	G9a	
T7305	JQEZ5	EZH2	
T7157	XY1	PRMT3	
T7089	SGC2085	Coactivator Associated Arginine Methyltransferase 1 (CARM1)	
T6900	MS023	PRMT1; PRMT3; PRMT4; PRMT6; PRMT8	
T6879	LLY507	SMYD2	
T6857	HLCL-61 hydrochloride	PRMT5	
T6853	GSK591	PRMT5	
T6809	CPI169	EZH1; EZH2 WT; EZH2 Y641N	Preclinical
T6790	BMS911543	JAK2 ; SET-2; TYK2; JAK3; JAK1	Phase 1/2
T6484	E11	EZH2	
T6333	MM102	MLL1	
T6076	EPZ015666	PRMT5	Preclinical
T6059	GSK343	EZH1; EZH2	
T5745	GSK3326595	PRMT5	Phase 1/2
T5605	EZM 2302	Coactivator Associated Arginine Methyltransferase 1 (CARM1)	
T5322	BCI121	SMYD3	
T4583	(R)-PFI-2 hydrochloride	SETD7	
T4393	MS049 2HCl (1502816-23-0(free base))	PRMT4; PRMT6	
T4378	MS049	PRMT4; PRMT6	
T4343	A196	SUV420H1; SUV420H2	
T4166	UNC0642	G9a/GLP	
T4021L	UNC3866 TFA(1872382-47-2 free base)	CBX7-H3	
T4021	UNC3866	CBX7-H3	
T4013	SGC2085 HCl	Coactivator Associated Arginine Methyltransferase 1 (CARM1)	
T3624	A366	G9a/GLP	
T3458	EED226	EED; PRC2	
T3257	UNC0638	G9a/GLP	
T3099	Pinometostat	DOT1L	Phase 1
T3084	SGC707	PRMT3; PRMT3	
T3081	EPZ004777	DOT1L	
T3057	UNC1999	EZH1; EZH2	
T2649	MI2	Menin-MLL	Preclinical
T2435	EPZ011989	EZH2	
T2354	UNC0631	G9a	
T2352	AMI1	PRMT1; yeast Hmt1p	

ID	Product Name	Target	Condition
T2097	C7280948	PRMT1	
T2079	GSK126	EZH2	
T1959	BIX 01294 Trihydrochloride	G9a	
T1923	BRD4770	G9a	
T1905	EPZ005687	EZH2	Preclinical
T1868	JIB04	JMJD2A; JMJD2B; JMJD2D; JMJD2E; JARID1A	
T1841	UNC0379	SETD8	
T1788	EPZ6438	EZH2; EZH2	FDA Approved
T1775	GSK503	EZH2	
T16435	PBIT	JARID1B; JARID1A; JARID1C	
T16072	MI-538	Menin-MLL	
T15080	DC-05	DNMT1; PRMT1	
T12428L	PF-06726304	EZH2 WT; EZH2 Y641N	
T11486	GSK2807 Trifluoroacetate	SMYD3	
T0174	Cyproheptadine hydrochloride	5-HT2; SETD7; SETD9	FDA Approved

JAK

ID	Product Name	Target	Condition
TQ0037	Abrocitinib	JAK1; JAK2	Phase 3
T8742	JAK2 inhibitor G5-7	JAK2	
T8719	SC99	STAT3; JAK2	
T8546	BD750	JAK3; STAT5	
T7503	Upadacitinib	JAK1; JAK2	FDA Approved
T6933	Peficitinib	JAK3; JAK1; Tyk2; JAK2	Approved
T6920	ON123300	CDK; Ark5; RET; Fyn; PDGFRβ; FGFR1	Preclinical
T6916	OICR9429	WDR5	
T6914	Oclacitinib maleate	JAK1; JAK2; TYK2; JAK3; JAK1-dependent	
T6838	FLLL32	JAK2	
T6790	BMS911543	JAK2 ; SET-2; TYK2; JAK3; JAK1	Phase 1/2
T6321	Tofacitinib	JAK1; JAK2; JAK3; ROCK2; Lck	FDA Approved
T6309	AZ 960	JAK2; JAK2	Preclinical
T6266	PP2	EGFR; JAK2; Fyn; Lck; ZAP70	
T6156	S-Ruxolitinib	JAK2; JAK1; Tyk2	FDA Approved
T6145	ZM 39923 HCl	TGM2 , JAK3 , EGFR , JAK1	
T6124	Mubritinib	EGFR; HER2/ErbB2; FGFR; JAK1; PDGFR	Phase 1
T6122	CEP33779	JAK2	
T6020	Pacritinib	FLT3; FLT3 (D835Y); JAK2; JAK2 (V617F); Tyk2; JAK3	Approved
T5492	JAK3-IN-6	JAK3	

ID	Product Name	Target	Condition
T5382	PF-06651600	JAK3	Phase 2/3
T5140	WDR5-0103 hydrochloride[890190-22-4(free base)]	WDR5	
T5091	FM381	JAK3	
T4672	Brevilin A	Antifection; JAK; STAT	
T4657L	WHI-P97 HCl 211555-05-4(free base)	JAK3	
T4657	WHI-P97	JAK3	Preclinical
T4227	SB1317 hydrochloride (1204918-72-8(free base))	CDK2; FLT3; JAK2	Phase 1/2
T4210	SAR20347	JAK1; JAK2; JAK3; TYK2	Preclinical
T4209	TAK-659 hydrochloride	FLT3; JAK3; Syk; ZAP70; VEGFR2	Phase 2
T3998	Itacitinib	JAK1	Phase 3
T3673	Mollugin	HER2; JAK2	
T3620	Solcitinib	JAK1	Phase 1
T3398	Icaritin	JAK2; STAT3	Phase 3
T3201	WDR5-0103	WDR5	
T3080	Pyridone 6	JAK1; JAK2; JAK3; Tyk2	
T3076	GLPG0634 analogue	JAK1; JAK2; JAK3; TYK2	
T3072	XL019	FLT3; JAK1; JAK2; JAK3; PDGFRβ	Phase 1
T3069	AZD1480	JAK2	Phase 1
T3068	AT9283	Aurora A; Aurora B; Abl1 (T315I); JAK2; JAK3	Phase 1
T3065	TG101209	RET; FLT3; JAK2; JAK3	Preclinical
T3043	Ruxolitinib (INCB-18424) phosphate	JAK1; JAK2	FDA Approved
T3042	JAK2 Inhibitor V	JAK2; JAK2 (V617F)	
T3024	Avitinib	EGFR; JAK3; BTK	Phase 2
T2853	Curcumol	JAK	Phase 3
T2709	TAK901	CLK2; JAK3; c-Src; FGR; Yes1	Phase 1
T2638	Gandotinib	FLT3; JAK1; JAK2; JAK2; JAK2 (V617F)	Phase 2
T2636	Decernotinib	JAK1; JAK2; JAK3; Tyk2	Phase 3
T2487	Cerdulatinib	JAK1; JAKs; Syk; Tyk2	Phase 2
T2485	Baricitinib	Chk2; JAK1; JAK2; JAK3; Tyk2	FDA Approved
T2398	Tofacitinib Citrate	JAK1; JAK2; JAK3	FDA Approved
T2360	Baricitinib Phosphate	JAK1; JAK2; JAK3; Tyk2	FDA Approved
T2341	KW2449	Aurora A; Abl; Abl (T315I); Kit; FGFR1; FLT3; FLT3 (D835Y); JAK2; Src	Phase 1/2
T2156	WP1066	JAK2; STAT3	Phase 1/2
T2045	WHI-P131	JAK3; JAK3	Preclinical
T2035	WHI-P258	EGFR; JAK3	
T2012	Oclacitinib	JAKs	
T1995	Fedratinib	JAK2; JAK2 (V617F); RET; FLT3	FDA Approved

ID	Product Name	Target	Condition
T1985	WHI-P154	EGFR; JAK3; Src; VEGFR	Preclinical
T1929	Filgotinib	JAK1; JAK2; JAK3; Tyk2	Approved
T1849	Momelotinib	JAK1; JAK2; JAK3	Phase 3
T1829	Ruxolitinib	JAK1; JAK2; Tyk2	FDA Approved
T17019	TCS 21311	JAK3; JAK2; JAK1; PKCα; PKCθ; GSK-3β	
T14687	BMS-986165	Tyk2 JH2; JAK1 JH2	Phase 3
T14331	Gusacitinib	SYK; JAK	Phase 2
T12427	PF-06700841 (P-Tosylate)	JAK1; JAK2; JAK3	Phase 2

MicroRNA

ID	Product Name	Target	Condition
T11850	LIN28 inhibitor LI71	LIN28	

PAD

ID	Product Name	Target	Condition
TQ0067	GSK484 hydrochloride	PAD4	
T8861	GSK199	PAD4	
T22277L	BMS-P5 free base	peptidylarginine deiminase 4 (PAD4)	

PARP

ID	Product Name	Target	Condition
T9113	Myristicin	Antifection; Bcl-2; Caspase; CYP17; GABA Receptor; IL Receptor; NO; PARP	
T8806	Fluzoparib	PARP	
T8296	4',5,7-Trimethoxyflavone	Caspase-3; PARP	
T7896	BYK204165	PARP	
T7042	1,5-Isoquinolinediol	PARP1	
T6942	Picolinamide	PARP	
T6892	Niraparib tosylate	PARP1; PARP2	FDA Approved
T6780	Benzamide	PARP	
T6578	ME0328	PARP1; PARP3	
T6339	AG14361	PARP1	Preclinical
T6329	INO1001	PARP	Phase 1
T6253	Talazoparib	PARP	FDA Approved
T6224	Iniparib	PARP1	Phase 2
T6197	PJ34	PARP1; PARP2	
T6181	UPF 1069	PARP1; PARP2	

ID	Product Name	Target	Condition
T6127	Rucaparib Phosphate	PARP	FDA Approved
T5860	CK-869	ARP2/3	
T5399	GeA-69	PARP14	
T4471	E7449	PARP1/2; tankyrase1/2	
T4463	Rucaparib	PARP1	FDA Approved
T3649	BGP15	PARP	Phase 2
T3375	Verbasocside	p53; PARP1; PKC	
T3231	Niraparib	TANK-1; PARP1; PARP2; PARP3; V-PARP	FDA Approved
T3015	Olaparib	PARP1; PARP2	FDA Approved
T2591	Veliparib	PARP1; PARP2	Phase 3
T2484	AZD2461	PARP	Phase 1
T22414	RBN012759	PARP14	
T22264	AZ9482	PARP	
T21524	4-amino-1,8-Naphthalimide	PARP	
T2124	PJ34 hydrochloride	PARP	
T2105	Veliparib dihydrochloride	PARP1; PARP2	Phase 3
T16807	Rucaparib Camsylate	PARP1	FDA Approved
T12695	RBN-2397	PARP7	
T10990	Dehydrocorydaline chloride	p38 MAPK; Bax; Bcl-2; caspase-7; caspase-8; PARP	

Pim

ID	Product Name	Target	Condition
TQ0201	Hispidulin	Pim1	
T8114	Quercetagetin	Pim1	
T6735	XL413 hydrochloride	CK2; Cdc7; Pim1; Cdc7	Phase 1/2
T6148	CX-6258 HCl	Pim1; Pim2; Pim3	
T5093	Pim1/AKK1-IN-1	Pim1; MST2	
T4523	TP3654	Pim 1, Pim 3; Pim-2	Phase 1
T4215	SMI-4a	Pim 1; Pim 2	Preclinical
T3989	SMI-16a	Pim1; Pim2	
T3078	SGI-1776 free base	FLT3; Pim1; Pim2; Pim3	Phase 1
T3058	SMI-4a	Pim1	Preclinical
T2300	AZD1208	Pim1; Pim2; Pim3	Phase 1
T2253	TCS PIM-1 1	Pim1	

PKC

ID	Product Name	Target	Condition
TQ0198	Phorbol 12-myristate 13-acetate	SphK; PKC	

ID	Product Name	Target	Condition
TP1053L	Protein Kinase C 19-31 acetate(121545-65-1 free base)	PKC	
TN1299	6,7,4'-Trihydroxyisoflavone	CDK1; CDK2; PKC	
T8764	PKC-iota inhibitor 1	PKC-i	
T8681	HA-1004 dihydrochloride	PKA; PKC; calcium channel	
T8376	PKCβ inhibitor 1	PKCβ	
T7792	Hispidin	PKCβ	
T7659	Bisindolylmaleimide IV	PKC	
T7604	Valrubicin	PKC	FDA Approved
T6932	PD168393	EGFR; FGFR; Insulin Receptor; PDGFR; PKC	Preclinical
T6680	Staurosporine	PKC; PKCα; PKCγ; PKCη; c-Fgr	
T6643	Ro 31-8220 Mesylate	PKCα; PKCβ1; PKCβ2; PKCγ; PKCε	Preclinical
T6605	NH125	CaMKII; eEF-2 kinase; PKA; PKC	
T6588	Mitoxantrone	Topo II; PKC	FDA Approved
T6513	Bisindolylmaleimide I	PDGFR; PKCα; PKCβ1; PKCβ2; PKCγ	
T6313	Go 6983	PKCα; PKCβ; PKCγ; PKCδ; PKCζ	
T6285	GSK690693	Akt1; Akt3; PKCη; PKCθ; PrkX	Phase 1
T6280	Enzastaurin	PKCα; PKCβ; PKCγ; PKCε	Approved
T6278	Sotrastaurin	PKCα; PKCβ1; PKCδ; PKCη; PKCθ	Phase 1/2
T6167	SU9516	CDK1; CDK2; CDK4; p38; PKC	Preclinical
T6139L	A-674563 2HCl(552325-73-2(fb-2hcl))	Akt1; CDK2; PKA; ERK2; PKCδ	
T5S2017	Ingenol	PKC	
T5891	D-ERYTHRO-SPHINGOSINE	PKC; PP2A; Human Endogenous Metabolite	
T5817	PKC-theta inhibitor	PKCθ	
T5796	Plantainoside D	ACE; PKC	
T5771	Hypocrellin A	PKC	
T5600	LXS196	PKC	Phase 1/2
T5239	Cholesterol 3-Sulfate Sodium Salt	PKC	
T4391	Syk Inhibitor II (hydrochloride)	Syk; PKCε; PKCβII; ZAP-70; Btk; Itk; ZAP70; Btk	
T4037	Phorbol	PKC	
T3S1416	Decursin	PKCα	
T3684	CP21R7	GSK-3β; PKCα	
T3419	Chelerythrine chloride	PKC	Preclinical
T3375	Verbascoide	p53; PARP1; PKC	
T3211	Midostaurin	PPK; PKCα; PKCβ1; PKCβ2; PKCγ	FDA Approved
T3060	Fasudil hydrochloride	PKA; PKG; PKC; ROCK2; MLCK	Approved
T3050	ML-7 hydrochloride	PKA; PKC; MLCK	
T2851	Daphnetin	EGFR; PKA; PKC	Approved


ID	Product Name	Target	Condition
T2757	Myricetrin	PKCα; PKCε	
T2441	TAS301	PKC	Preclinical
T2356	Ro 3306	CDK1; ERK; PKA; PKCδ; SGK	
T17019	TCS 21311	JAK3; JAK2; JAK1; PKCα; PKCθ; GSK-3β	
T16791	Rottlerin	PKCδ; PKCα; PKCγ; PKCβ; PKCη; PKCζ; PKCε; CKII; PKA; CaM kinase III; Apoptosis; Autophagy	
T1648	Vitamin E	GST Mu 3; GST omega-1; GSTP; SEC14-like protein; PKC; VE	FDA Approved
T14069	A-3 hydrochloride	CK1; CK2; PKC; PKA	
T11740	Delcasertib	PKCδ	Phase 2
T0979	Dequalinium chloride	PKC	Approved
T0610	Piceatannol	cAK; PKC; MLCK	Approved
T0465	Ellagic acid	Carbonic anhydrase; CK2; Smoothened; PKA; PKC; Syk; ATP-competitive CK2	Phase 2
T0228	Methyl hesperidin	Akt; PKC	Approved
T0033	Miltefosine	PKC; Akt	FDA Approved

Sirtuin

ID	Product Name	Target	Condition
T8480	Tenovin-6 Hydrochloride	SIRT1; SIRT2; SIRT3; HDAC8; p53	
T8346	SRT1460	SIRT1	
T7679	UBCS039	SIRT	
T6984	SirReal2	SIRT2	
T6679	SRT2104	SIRT1	Phase 1
T6678	Splitomicin	SIRT2p	
T6671	Sirtinol	SIRT1; SIRT2	
T6371	AGK2	SIRT2	
T6220	Nicotinamide riboside chloride	SIRT1/3	
T6111	Selisistat	SIRT1	Phase 2
T5725	lithospermic acid B	SIRT	
T5618	AK-1	SIRT2	
T5490	AK-7	SIRT2	
T5124	SRT 1720 dihydrochloride[925434-55-5(free base)]	SIRT1; SIRT2	Preclinical
T5096	SRT 1720	SIRT1	Preclinical
T4328	OSS_128167	SIRT6; SIRT2; SIRT1	
T4108	3-TYP	SIRT1; SIRT2; SIRT3	
T4062	CAY10602	SIRT1	
T4019	Cambinol	SIRT1; SIRT2	

ID	Product Name	Target	Condition
T3953	Salermide	SIRT1; SIRT2	
T3447	Thiomyristoyl	SIRT1; SIRT2	
T2S0300	Hydrocoumarin	SIRT1; SIRT2	
T2879	Fisetin	SIRT	
T2750	Ginkgolide C	AMPK; MMP; Sirtuin	
T2412	SRT1720 hydrochloride	SIRT1	Preclinical
T1887	Inauhzin	SIRT1	
T1873	Tenovin3	SIRT2	
T1818	Tenovin-6	SIRT1; SIRT2; SIRT3	
T16932	SRT 2183	SIRT1	
T1558	Resveratrol	COX-1; COX-2; DNA polymerase α ; IKK β ; LOX; Quinone reductase 2; SIRT1; SIRT2	Approved
T13795	Nicotinamide riboside	SIRT1; SIRT3	
T0934	Nicotinamide	SIRT	FDA Approved

Cytoskeletal Signaling



Akt

ID	Product Name	Target	Condition
TN1034	Sennidin B	Akt; GLUT; PI3K	
TN1033	Sennidin A	Akt; GLUT; PI3K	
T7885	Afuresertib hydrochloride	Akt	Phase 1
T7315	BAY1125976	Akt	Phase 1
T6S0619	Pachymic acid	Akt; ERK	
T6S0525	Farrerol	Akt; p38; ERK	
T6849	Uprosertib	Akt1; Akt2; Akt3	Phase 2
T6817	Deguelin	PI3K; Akt	
T6304	AT7867	Akt1; Akt2; Akt3; PKA; p70 S6K	Preclinical
T6285	GSK690693	Akt1; Akt3; PKC η ; PKC θ ; PrkX	Phase 1
T6252	Ipatasertib	Akt1; Akt2; Akt3	Phase 3
T6251	PF04691502	P-Akt (S473); PI3K α ; PI3K β ; PI3K γ ; PI3K δ	Phase 2
T6139L	A-674563 2HCl(552325-73-2(fb-2hcl))	Akt1; CDK2; PKA; ERK2; PKC δ	
T6065	Triciribine	Akt; HIV-1	Phase 1/2

ID	Product Name	Target	Condition
T5S1632	8-O-Acetylshanzhiside methyl ester	TNF- α ; NF-Kb; VEGFR; Akt; Caspase	
T5S0168	Atractylenolide II	STAT3 inhibitor; p38 activator; ERK inhibitor; Akt inhibitor	
T5736	CYNARIN	Akt; PI3K	
T5574	Guggulsterone E&Z	JNK; Akt; Caspase	
T5508	PF-AKT400	Akt	
T4S1419	Praeruptorin A	p38; Akt	
T4A2399	Cinobufotalin	Akt; IL Receptor; MRP1; P-gp	Phase 1
T4489	AZD26	allosteric Akt	
T4046	BX517	PDK1; cAKT2	Preclinical
T3881	Vaccarin	P-Akt; PERK; CD31	
T3729	Ethyl gallate	Akt; MMP-2; MMP-9; NF- κ B	
T3560	Desmethylanethol trithione	Akt; VEGFR	
T3467	Miransertib	Akt	Phase 1/2
T3399	Psoralidin	Akt; Phosphatidylinositol 3-kinase; ER α ; ER β	
T3346	AKT inhibitor VIII	Akt1; Akt2; Akt3	
T3132	SC66	Akt	
T3001	Honokiol	P-Akt; MEK	Phase 2
T2895	Lupeol	P-Akt	
T2790	Oridonin	Akt1,Akt2; AKT2	
T2789	Scutellarin	Akt; STAT	
T2492	Perifosine	Akt	Phase 2
T2482	AT13148	Akt1; Akt2; Akt3; PKA; ROCK1; ROCK2; p70 S6K; RSK1; SGK3	Phase 1
T2420	PHT427	Akt; PDK1	Preclinical
T2274	SC 79	Akt	
T2176	2,3-Butanedione 2-Monoxime	Akt	
T1961	Vistusertib	P-Akt (S473); mTOR; PI3K α ; pS6 (S235/236)	Phase 1/2
T1952	MK-2206 dihydrochloride	Akt1; Akt2; Akt3	Phase 2
T1920	Capivasertib	Akt1; Akt2; Akt3; PKA; mTOR (p70S6K)	Phase 2
T1911	Afuresertib	Akt1; Akt2; Akt3	Phase 2
T16104	ML-9	AKT	
T13265	Urolithin B	NF- κ B; JNK; ERK; Akt; AMPK; Human Endogenous Metabolite	
T0228	Methyl hesperidin	Akt; PKC	Approved
T0033	Miltefosine	PKC; Akt	FDA Approved

Bcr-Abl

ID	Product Name	Target	Condition
T8488	GMB-475	Bcr-Abl1	
T7861	Flumatinib mesylate	PDGFRβ ; c-Kit ; c-Abl	Phase 3
T7186	CZC-8004	Abl	
T6348	NVP-BHG712	EphB4; c-Raf; c-Src; c-Abl	
T6311	Bafetinib	Abl; Lyn	Phase 1
T6300	Degrasyn	Bcr-Abl	Preclinical
T6230	Imatinib	v-Abl; c-Kit; PDGFR	FDA Approved
T6196	PP1	Bcr-Abl; Kit; EGFR; Fyn; Lck	
T6128	PHA665752	c-Abl; c-Met; RON; FGFR1; Flk1	Preclinical
T6057	URMC099	Aurora A; Aurora B; Aurora C; Abl1; CDK1; CDK2; c-Met; DLK; IGF-1R; Insulin Receptor; LRRK2; MEKK2; MLK1; MLK2; MLK3; ROCK1; ROCK2; SGK; SGK1; Lck; Syk; TrkA; TrkB; VEGFR1/FLT1	
T5177	Asciminib	Abl1	Phase 3
T4618	K 0859	c-ABL-T334; Abl; Abl (T315I)	
T4320	Flumatinib	c-Abl; PDGFRβ; c-Kit;	Phase 3
T3641	BAW2881	c-Abl; B-Raf (V599E); C-Raf-1; hVEGFR2	
T3196	GNF7	M351T; c-Abl; E255V; G250E; T315I	
T3071	GZD 824	Abl (E254K)	Phase 2
T3068	AT9283	Aurora A; Aurora B; Abl1 (T315I); JAK2; JAK3	Phase 1
T3063	PD173955	Bcr-Abl; Src	Preclinical
T2920	Berbamine dihydrochloride	Abl	Approved
T2802	Nocodazole	Abl; Abl (E255K); Abl (T315I); microtubule	
T2640	DCC2036	Abl1; p-Abl1 (native); p-Abl1 (T315I); u-Abl1 (native); FLT3	Phase 1/2
T2609	Masitinib	Abl1; c-Fms; Kit; Hck; PDGFRα; PDGFRβ; Lyn B; Src	Approved
T2429	GZD824 Dimesylate	Abl; Abl (E255K); Abl (H396P); Abl (M351T); Abl (Q252H)	Phase 2
T2415	PP121	Hck; mTOR; PDGFR; Src; VEGFR; Abl	
T2372	Ponatinib	Abl; c-Kit; FGFR1; PDGFRα; c-Src; VEGFR2	FDA Approved
T2341	KW2449	Aurora A; Abl; Abl (T315I); Kit; FGFR1; FLT3; FLT3 (D835Y); JAK2; Src	Phase 1/2
T2328	Radotinib	Bcr-Abl1	Approved
T2293	SGX523	Abl; c-Met; p38α; B-Raf (V599E); C-Raf	Phase 1
T2147	Nilotinib (monohydrochloride monohydrate)	Bcr-Abl	FDA Approved
T2116	AEE788	c-Abl; c-Fms; EGFR; HER2/ErbB2; FLT1	Phase 1/2
T2094	Danuseritib	Aurora A; Aurora B; Aurora C; Abl; RET; FGFR1; TrkA	Phase 2
T2070	CEP32496	Abl1; c-Kit; RET; PDGFRβ; Lck	Phase 1
T1817	GNF2	Bcr-Abl (K562 cell line); Bcr-Abl (SUP-B15 cell line)	
T1803	GNF5	Bcr-Abl	

ID	Product Name	Target	Condition
T1754	ZM 306416	Abl; Src; VEGFR1	
T1621	Imatinib Mesylate	v-Abl; c-Kit; PDGFR	FDA Approved
T1524	Nilotinib	Bcr-Abl	FDA Approved
T1448L	Dasatinib monohydrate	Abl; c-Kit (D816V); c-Kit (wt); EphA2; Src	FDA Approved
T1448	Dasatinib	Abl; c-Kit (D816V); c-Kit (wt); Src	FDA Approved
T0152	Bosutinib	Abl; c-Src	FDA Approved

Dynamin

ID	Product Name	Target	Condition
T6822	Dyngo-4a	Dynl (brain); Dynl (rec); DynII (rec)	
T22445	Trimethyloctadecylammonium bromide	Dynamin	
T1907	Mdivi 1	Dnm1 GTPase	
T1848	Dynasore	Dynamin1/2	

FAK

ID	Product Name	Target	Condition
T8544	Masitinib mesylate	Kit; PDGFR α ; PDGFR β ; Lyn; LCK; FGFR3; FAK	Approved
T7119	Y15	FAK	
T6419	BMS536924	FAK; IGF-1R; Insulin Receptor; MEK; Lck	Preclinical
T6177	PF-562271 besylate	CDK1/CyclinB; CDK2/CyclinE; CDK3/CyclinE; FAK; PYK2	Phase 1
T5480	BI-4464	PTK2/FAK	
T3391	Corosolic acid	FAK	
T3122	(+)-Fangchinoline	FAK	
T2809	(+)-Thalrugosine	FAK	
T2655	CEP37440	ALK; FAK	Phase 1
T2465	PF562271	CDK1/CyclinB; CDK2/CyclinE; CDK3/CyclinE; FAK; PYK2	Phase 1
T2314	PF 431396	FAK; PYK2	
T2281	GSK2256098	FAK	Phase 2
T21768	PF-562271 HCl	FAK; PYK2; CDK2/CDK3/CDK1/CDK7	Phase 1
T2001	PF 573228	FAK	Preclinical
T1996	Defactinib	FAK	Phase 2
T1950	PND1186	FAK	Phase 1
T1918	TAE226	c-Met; FAK; IGF-1R; Insulin Receptor; PYK2	Preclinical
T0263	Chloropyramine hydrochloride	FAK-VEGFR-3; H1 receptor	Approved

Gap Junction Protein

ID	Product Name	Target	Condition
TP1563	Gap19 acetate(1507930-57-5,free)	Cx43	
TP1333	Gap 27	Gap Junction Protein	
T5192	Gap 26	Gap Junction Protein	
T16790L	Rotigaptide TFA	Cx43	
T0992	Carbenoxolone disodium	Gap Junction Protein	Approved
T0342	Carvedilol phosphate	Adrenergic Receptor; Gap Junction Protein; E-selectin; NADPH dehydrogenase; Natriuretic peptides B; VCAM1; Potassium Channel; VEGFR; LDL oxidation	FDA Approved

HSP

ID	Product Name	Target	Condition
T8858	DTHIB	HSF1	
T8829	2',4'-DIHYDROXYCHALCONE	HSP90	
T8668	HM03	HSPA5	
T8189	Dihydroberberine	hERG; HSP90	
T7265	HSP27 inhibitor J2	HSP27	
T7010	VER155008	HSP70; HSC70; GRP78	
T6855	HA15	GRP78; HSPA5; BiP	
T6558	KW2478	HSP90	Phase 1/2
T6343	Geldanamycin	HSP90; HSP90; p185	Preclinical
T6341	PF04929113	HER2; HSP90	Phase 2
T6305	SNX2112	HSP90 α ; HSP90 β	Preclinical
T6297	Alvespimycin hydrochloride	HSP90	Phase 1
T6290	Tanespimycin	HSP90	Phase 2
T6284	Onalespib	HSP90	Phase 2
T6248	XL888	HSP90	Phase 1
T6170	Elesclomol	HSP70	Phase 1
T6118	HSP990	HSP90 α ; HSP90 β	Phase 1
T5826	Eupalinolide A	HSP90	
T5350	JG98	HSP70	
T5152	MKT077	HSP70	Preclinical
T5008	Teprenone	HSP	Approved
T4342	PF-04929113 Mesylate	HSP90; HER2	Phase 2
T4125	HSF1A	HSF1	
T3652	KRIBB11	HSF1	
T3594	ML346	HSP70	
T3527	TRC 051384	HSP70	
T3487	HSP70-IN-1	Kasumi-1; HSP	

ID	Product Name	Target	Condition
T3293	Apoptozole	HSC70; HSP70	
T2444	KNK437	HSP105; HSP40; HSP72	Preclinical
T2309	Ganetespib	HSP90	Phase 2
T2286	BIIB021	HSP90	Phase 1
T2268	VER49009	HSP90β	Preclinical
T2258	VER50589	HSP90β	
T2179	Triptolide	heat shock factor (HSF1)(in ALL cell lines); Mdm2	Approved
T2114	NVP-BEP800	HSP90β	Preclinical
T1989	Luminespib	HSP90α; HSP90β	Phase 2
T16994	TAS-116	HSP90α; HSP90β	Phase 1
T1501	Rifabutin	RNA polymerase; Endoplasmic; HSP90	FDA Approved
T13554	Arimoclolomol maleate	HSP	
T10860	Col003	HSP47	
T0756	Ethoxyquin	HSP90	

Integrin

ID	Product Name	Target	Condition
TQ0250	CWHM-12	αVβ1 integrin; αVβ3 integrin; αVβ6 integrin; αVβ8 integrin	
TP1474	LXW7	αVβ3 integrin	
TP1330	Cyclo(RADfK)	Integrin	
TP1204	iRGD peptide	Integrin	
T8523	ILK-IN-3	Integrin	
T7570	RGD peptide GRGDNP(2TFA)	Integrin	
T6813	Cyclo(RGDyK)	αVβ3 integrin	
T6812L	Cyclo(-RGDfK) TFA	αVβ3 integrin	
T6812	Cyclo (-RGDfK)	αVβ3 integrin	
T5488	OSU-T315	ILK	
T5485	OSU-T315 (1,5-regioisomer)	ILK	
T5310	TR14035	α4β7 integrin; α4β1 integrin	Phase 1
T4613	Arg-Gly-Asp TFA (99896-85-2(free base))	Integrin	
T4435	E7820	integrin α2	Phase 2
T4259	GLPG0187	αVβ1 integrin	Phase 1
T3977	Lifitegrast	LFA-1	FDA Approved
T3881	Vaccarin	P-Akt; PERK; CD31	
T3638	Leukadherin-1	CD11b/CD18	
T3529	Bestatin hydrochloride	Aminopeptidase; CD13	Approved
T2537	Tirofiban hydrochloride monohydrate	GPIIb/IIIa; GPIIb/IIIa; ADP	FDA Approved

ID	Product Name	Target	Condition
T2494	Cilengitide	α V β 3 integrin; α V β 5 integrin	Phase 2
T2254	A205804	E-selectin; ICAM-1	
T21781	A 286982	LFA-1; ICAM-1	
T12783	RWJ 50271	LFA-1/ICAM-1	
T10397	ATN-161 trifluoroacetate salt	Integrin α 5 β 1	Phase 1/2
T0447	Carvedilol	Adrenergic Receptor; HIF; E-selectin; NADPH; Vcam; Potassium Channel; VEGFR; LDL oxidation	FDA Approved
T0342	Carvedilol phosphate	Adrenergic Receptor; Gap Junction Protein; E-selectin; NADPH dehydrogenase; Natriuretic peptides B; VCAM1; Potassium Channel; VEGFR; LDL oxidation	FDA Approved

Kinesin

ID	Product Name	Target	Condition
T8487	Empesertib	Mps1	Phase 1
T4048	Monastrol	Eg5	
T3120	K858	Eg5 ATPase	
T3118	Dimethylenastron	Eg5	
T2689	AZ 3146	Mps1	
T2313	MPI0479605	Mps1	Preclinical
T2039	GSK923295	CENP-E	Phase 1

Microtubule Associated

ID	Product Name	Target	Condition
TN1087	Deoxydophyllotoxin	microtubule; Autophagy; Apoptosis	
T8216	T-1101 tosylate	Hec1	
T7003	TRx0237 mesylate	Tau aggregation	Phase 3
T6897	Monomethyl auristatin E	microtubule	Preclinical
T6888	Methylene Blue	Tau aggregation; guanylate cyclase	FDA Approved
T6864	Ixabepilone	microtubule(tubulin stabilising)	FDA Approved
T6490	Epothilone A	Tubulin	Preclinical
T6372	Albendazole Oxide	Tubulin polymerization	FDA Approved
T6272	Fosbretabulin Disodium	Tubulin	Approved
T6213	Vinorelbine Tartrate	Tubulin	FDA Approved
T6212	Combretastatin A4	Tubulin β	Phase 1/2
T6209	CW069	HSET	
T6180	INH6	MB231; MB468	
T6075	Epothilone B	Tubulin	Phase 1
T6071	Parbendazole	microtubule	
T5699	SSE15206	microtubule	

ID	Product Name	Target	Condition
T5170	KHS101 hydrochloride	TACC3	
T4677	MMAD	Microtubule/Tubulin	
T4451	Estramustine phosphate sodium	Microtubule/Tubulin	FDA Approved
T4232	VCMAAE	Microtubule/Tubulin	
T4077	PE859	A β ; tau; A β	
T4029	BTB1	mitotic kinesin Kif18A	
T2937	4'-Demethylepipodophyllotoxin	microtubule	
T2802	Nocodazole	Abl; Abl (E255K); Abl (T315I); microtubule	
T2773	Vindoline	Microtubule	
T2543	Cabazitaxel	microtubule	FDA Approved
T2511	Plinabulin	Tubulin	Phase 3
T2502	INH1	Hec1	
T2220	2-Methoxyestradiol	HIF-1 α ; HIF-2 α ; Microtubule depolymerization	Approved
T2217	Cephalomannine	Microtubule/Tubulin	Approved
T2090	Lexibulin	microtubule	Phase 2
T2060	LR510444	Microtubule disruptor	
T1992	Mertansine	tubulin	
T1910	Ansamitocin P-3	microtubule	
T1820	CK636	Arp2/3 complex (Bovine); Arp2/3 complex (Fission yeast); Human Arp2/3 complex	
T1758	ABT751	microtubule	Phase 2
T1753	D64131	Tubulin polymerization	
T16031	McMMAF	tubulin polymerization; Drug-Linker Conjugates for ADC	
T15576	Indibulin	Tubulin	
T1382	Griseofulvin	Tubulin chain	FDA Approved
T13298	Verubulin hydrochloride	microtubule	Phase 1/2
T13224	Tubulin inhibitor 6	tubulin polymerization	
T1270	Vincristine sulfate	microtubule	FDA Approved
T11917	Lys-SMCC-DM1	tubulin	
T1155	Mebendazole	Tubulin α -1A chain; Tubulin β -4B chain	FDA Approved
T1152	Albendazole	microtubule	FDA Approved
T1121	Podophyllotoxin	microtubule; Topo II	FDA Approved
T1034	Docetaxel	microtubule	FDA Approved
T0968	Paclitaxel	microtubule	FDA Approved
T0938	Thiabendazole	Tubulin β	FDA Approved
T0838	Triclabendazole	Tubulin	FDA Approved
T0714	Oxfendazole	Glucose uptake inhibitor; Tubulin chain	FDA Approved
T0651	N-Phenylbenzylamine	Tubulin polymerization	
T0320	Colchicine	microtubule	FDA Approved
T0190	Vinorelbine	Tubulin β chain	FDA Approved

ID	Product Name	Target	Condition
T0186	Docetaxel trihydrate	Bcl-2; Tubulin β -1 chain	FDA Approved
T0009	Flubendazole	microtubule	Approved
T0006	Methylene Blue trihydrate	Tau aggregation	FDA Approved

Myosin

ID	Product Name	Target	Condition
T7144	BTS	Ca ²⁺ -stimulated myosin S1 ATPase	
T7134	MYK-461	bovine cardiac; human cardiac	Phase 3

PAK

ID	Product Name	Target	Condition
T6840	FRAX486	PAK1; PAK2 ; PAK3 ; PAK4	
T6839	FRAX1036	PAK1; PAK2; PAK4	
T6014	FRAX597	PAK1; PAK2; PAK2; PAK3	
T4354	KPT9274	NAMPT; PAK4	Phase 1
T4230	PF-3758309 hydrochloride	PAK4; PAK1; PAK6; PAK5; PAK3	Phase 1
T11826	LCH-7749944	PAK4; apoptosis	

PKC

ID	Product Name	Target	Condition
TQ0198	Phorbol 12-myristate 13-acetate	SphK; PKC	
TP1053L	Protein Kinase C 19-31 acetate(121545-65-1 free base)	PKC	
TN1299	6,7,4'-Trihydroxyisoflavone	CDK1; CDK2; PKC	
T8764	PKC-iota inhibitor 1	PKC-i	
T8681	HA-1004 dihydrochloride	PKA; PKC; calcium channel	
T8376	PKC β inhibitor 1	PKC β	
T7792	Hispidin	PKC β	
T7659	Bisindolymaleimide IV	PKC	
T7604	Valubicin	PKC	FDA Approved
T6932	PD168393	EGFR; FGFR; Insulin Receptor; PDGFR; PKC	Preclinical
T6680	Staurosporine	PKC; PKC α ; PKC γ ; PKC η ; c-Fgr	
T6643	Ro 31-8220 Mesylate	PKC α ; PKC β 1; PKC β 2; PKC γ ; PKC ϵ	Preclinical
T6605	NH125	CaMKII; eEF-2 kinase; PKA; PKC	
T6588	Mitoxantrone	Topo II; PKC	FDA Approved
T6513	Bisindolymaleimide I	PDGFR; PKC α ; PKC β 1; PKC β 2; PKC γ	
T6313	Go 6983	PKC α ; PKC β ; PKC γ ; PKC δ ; PKC ζ	

ID	Product Name	Target	Condition
T6285	GSK690693	Akt1; Akt3; PKC η ; PKC θ ; PrkX	Phase 1
T6280	Enzastaurin	PKC α ; PKC β ; PKC γ ; PKC ϵ	Approved
T6278	Sotrastaurin	PKC α ; PKC β 1; PKC δ ; PKC η ; PKC θ	Phase 1/2
T6167	SU9516	CDK1; CDK2; CDK4; p38; PKC	Preclinical
T6139L	A-674563 2HCl((552325-73-2(fb-2hcl))	Akt1; CDK2; PKA; ERK2; PKC δ	
T5S2017	Ingenol	PKC	
T5891	D-ERYTHRO-SPHINGOSINE	PKC; PP2A; Human Endogenous Metabolite	
T5817	PKC-theta inhibitor	PKC θ	
T5796	Plantainoside D	ACE; PKC	
T5771	Hypocrellin A	PKC	
T5600	LXS196	PKC	Phase 1/2
T5239	Cholesterol 3-Sulfate Sodium Salt	PKC	
T4391	Syk Inhibitor II (hydrochloride)	Syk; PKC ϵ ; PKC β II; ZAP-70; Btk; Itk; ZAP70; Btk	
T4037	Phorbol	PKC	
T3S1416	Decursin	PKC α	
T3684	CP21R7	GSK-3 β ; PKC α	
T3419	Chelerythrine chloride	PKC	Preclinical
T3375	Verbasoside	p53; PARP1; PKC	
T3211	Midostaurin	PPK; PKC α ; PKC β 1; PKC β 2; PKC γ	FDA Approved
T3060	Fasudil hydrochloride	PKA; PKG; PKC; ROCK2; MLCK	Approved
T3050	ML-7 hydrochloride	PKA; PKC; MLCK	
T2851	Daphnetin	EGFR; PKA; PKC	Approved
T2757	Myricetrin	PKC α ; PKC ϵ	
T2441	TAS301	PKC	Preclinical
T2356	Ro 3306	CDK1; ERK; PKA; PKC δ ; SGK	
T17019	TCS 21311	JAK3; JAK2; JAK1; PKC α ; PKC θ ; GSK-3 β	
T16791	Rottlerin	PKC δ ; PKC α ; PKC γ ; PKC β ; PKC η ; PKC ζ ; PKC ϵ ; CKII; PKA; CaM kinase III; Apoptosis; Autophagy	
T1648	Vitamin E	GST Mu 3; GST omega-1; GSTP; SEC14-like protein; PKC; VE	FDA Approved
T14069	A-3 hydrochloride	CK1; CK2; PKC; PKA	
T11740	Delcasertib	PKC δ	Phase 2
T0979	Dequalinium chloride	PKC	Approved
T0610	Piceatannol	cAK; PKC; MLCK	Approved
T0465	Ellagic acid	Carbonic anhydrase; CK2; Smoothened; PKA; PKC; Syk; ATP-competitive CK2	Phase 2
T0228	Methyl hesperidin	Akt; PKC	Approved
T0033	Miltefosine	PKC; Akt	FDA Approved

ROCK


ID	Product Name	Target	Condition
TQ0319	Ripasudil hydrochloride dihydrate	ROCK1; ROCK2	Approved
T7301	BDP5290	ROCK	
T6867	KD025	ROCK2; ROCK2	Phase 2
T6321	Tofacitinib	JAK1; JAK2; JAK3; ROCK2; Lck	FDA Approved
T4276	Hydroxyfasudil Hydrochloride	ROCK	
T4095	ZINC00881524	ROCK	
T3518	GSK269962A	MSK1; ROCK1; ROCK2; RSK1	
T3513	GSK180736A	GRK1; GRK2; GRK5; PKA; ROCK	
T3060	Fasudil hydrochloride	PKA; PKG; PKC; ROCK2; MLCK	Approved
T2633	GSK429286A	ROCK1; ROCK2	
T2482	AT13148	Akt1; Akt2; Akt3; PKA; ROCK1; ROCK2; p70 S6K; RSK1; SGK3	Phase 1
T2155	Thiazovivin	ROCK	
T2011	RKI1313	ROCK1; ROCK2	
T1898	RKI1447	ROCK1; ROCK2	
T1725	Y-27632 dihydrochloride	ROCK1 (p160ROCK); ROCK2	Preclinical

Wnt/beta-catenin

ID	Product Name	Target	Condition
TQ0215	Salinomycin sodium salt	Wnt/ β -catenin	
TP1263	Fz7-21	human FZD7 CRD; mouse FZD7 CRD	
TL0008	Gigantol	β -catenin; α -glucosidase	
TL0007	Bisdemethoxycurcumin	p300; Wnt/ β -catenin	
T8820	BML-284 HCL	Wnt	
T8710	MSAB	Wnt/ β -catenin	
T8400	Pamidronic acid	β -catenin; Wnt	Phase 4
T8005	Cardiogenol C hydrochloride	Wnt	
T7830	Windorphen	Wnt	
T7399	LF3	Wnt/ β -catenin	
T7333	Pyrvinium pamoate	Wnt	FDA Approved
T7204	PNU 74654	Wnt/ β -catenin	
T6989	SKL2001	Wnt/ β -catenin	
T6868	KYA1797K	Wnt/ β -catenin	
T6842	G007-LK	TNKS1; TNKS2	
T6768	AZ6102	TNKS1; TNKS2	
T5S0754	Isoquercitrin	Wnt/ β -catenin	

ID	Product Name	Target	Condition
T5729	L-quebrachitol	Wnt	
T5642	BC2059	Wnt/ β -catenin	Phase 1
T5636	Adavivint (SM04690)	Wnt	Phase 3
T4S1943	Kirenol	Wnt/ β -catenin	
T4486	iCRT 14	Wnt	
T4468	WAY 316606	sFRP-1	
T4302	iCRT3	Wnt,Wnt/ β -catenin	
T4245	IWP 4	Wnt	
T4043	ETC159	β -catenin	Phase 1
T4011	NCB0846	TNFK	Preclinical
T3S0153	Xanthatin	Wnt/ β -catenin	
T3635	IQ1	Wnt	
T3168	MN64	Tankyrase; TNKS1; TNKS2	
T3144	Wnt agonist 1	Wnt	
T3062	WIKI4	TNKS2	
T2818	Methyl Vanillate	Wnt	
T2702	IWP2	Wnt	
T2651	IWR-1-endo	Wnt	
T2413	FH535	PPAR γ ; PPAR δ ; Wnt/ β -catenin	
T22775	exo-IWR-1	wnt	
T2237	ICG001	Wnt/ β -catenin; CBP	Phase 1
T2052	KY02111	Wnt	
T2003	Isx 9	Wnt/ β -catenin	
T1971	WAY262611	Wnt/ β -catenin	
T1878	XAV939	TNKS1; TNKS2	
T1807	JW55	TNKS1; TNKS2; auto-PARsylation of TNKS2; auto-PARsylation of TNKS1	
T17142	Toxoflavin	TCF4/ β -catenin	
T14907	CCT251545	Wnt	
T0738	Urea	Arginase-1; Carbonic anhydrase II; DHFR; Sulfoxide reductase catalytic subunit YedY; Wnt/ β -catenin	FDA Approved

DNA Damage/DNA Repair



DNA Damage/DNA Repair

Antifolate

ID	Product Name	Target	Condition
T8548	Metoprine	histamine N-methyltransferase; antifolate	
T7730	Aminopterin	Antifolate	
T7593	Levomefolate calcium	Antifolate	FDA Approved

ATM/ATR

ID	Product Name	Target	Condition
T8660	AZ-32	ATM	
T7318	BAY-1895344	ATR	
T6770	AZD0156	ATM	Phase 1
T6283	Wortmannin	PI3K , DNA-PK , ATM , MLCK , ATR	Preclinical
T6261	CP466722	ATM	Preclinical
T6100	Torin 2	ATM; ATR; DNA-PK; mTOR	
T5175	azd1390	ATM	Phase 1
T4443	AZ32	ATM; ATM (in cell)	Preclinical

ID	Product Name	Target	Condition
T4251	GJ103 sodium salt	ATM	
T3338	AZD6738	ATR	Phase 2
T3134	Mirin	MRN	
T3032	VE821	ATR	Preclinical
T2925	Schizandrin B	ATR	
T2685	KU55933	ATM; ATR; DNA-PK; mTOR; PI3K	Preclinical
T2669	Berzosertib	ATM; ATR	Phase 2
T2616	PIK93	ATM; C2β; DNA-PK; hsVps34; mTORC1; p110α; p110β; p110γ; p110δ; PI3KIIIβ	
T2474	KU60019	ATM	
T2433	NU7026	ATM; ATR; DNA-PK; PI3K	
T2235	Dactolisib	ATR; mTOR (p70S6K); p110α; p110γ; p110δ	Phase 2
T2084	ETP46464	ATM; ATR; DNA-PK; mTOR; PI3Kα	
T1958	AZ20	ATR; mTOR	
T1821	CGK 733	ATM; ATR	

Deubiquitinase

ID	Product Name	Target	Condition
T8464	RA-9	Apoptosis; deubiquitinating enzymes (DUBs)	
T7685	USP25/28 inhibitor AZ1	USP25/28	
T11464	GRL0617	deubiquitinase; SARS-CoV Plpro	

DHFR

ID	Product Name	Target	Condition
T6226	Pemetrexed Disodium Hydrate	DHFR; DHFR; GARFT; Thymidylate synthase	FDA Approved
T6120	Pralatrexate	DHFR; Axl(KPL-4 cells); Axl(SUM149 cells)	FDA Approved
T4558	Trioxsalen	DHFR	FDA Approved
T2204	Diaveridine	DHFR	
T1326	Gentamycin sulfate	DNase I; DHFR; 16S ribosome; 30S ribosome	FDA Approved
T1153	Trimethoprim	DHFR; Thymidylate synthase	FDA Approved
T0849	Pyrimethamine	DHFR	FDA Approved
T0836	Sulfadoxine	DHPS; DHFR	FDA Approved
T0748	Sulfameter	DHFR	FDA Approved
T0738	Urea	Arginase-1; Carbonic anhydrase II; DHFR; Sulfoxide reductase catalytic subunit YedY; Wnt/β-catenin	FDA Approved
T0189L	Pemetrexed disodium	DHFR; GARFT; Thymidylate synthase	FDA Approved
T0189	Pemetrexed acid	DHFR; GARFT; Thymidylate synthase	FDA Approved

DNA

ID	Product Name	Target	Condition
T7031	Aristolochic acid B	DNA mutation	
T4575	Chromium picolinate	p38; DNA mutation	Approved
T3103	L67	DNA ligases	
T0438	Proflavine Hemisulfate	DNA mutation; Lfrf; QacR; Thrombin	Approved

DNA Alkylation

ID	Product Name	Target	Condition
T7539	O6-Benzylguanine	O6-alkylguanine-DNA-alkyltransferas	
T7221	Satraplatin	DNA Alkylating	Phase 1/2
T6798	Tretazicar	DNA alkylator	Phase 2
T6057	URMC099	Aurora A; Aurora B; Aurora C; Ab1; CDK1; CDK2; c-Met; DLK; IGF-1R; Insulin Receptor; LRRK2; MEKK2; MLK1; MLK2; MLK3; ROCK1; ROCK2; SGK; SGK1; Lck; Syk; TrkA; TrkB; VEGFR1/FLT1	
T5846	Methylnitroinosoguanidine	DNA alkylator	
T4368	Miriplatin	DNA Alkylator/Crosslinker	Approved
T4350	Palifosfamide	DNA alkylator	Phase 3
T4024	Norharmane	DNA	
T3707	GNE3511	DLK; MAP3K12	
T2495	Lomeguatrib	O6-alkylguanine-DNA-alkyltransferas	Phase 2
T1601	Lomustine	DNA Alkylating; Stathmin-4	FDA Approved
T1548	8-Methoxy psoralen	DNA	FDA Approved
T1507	Streptozocin	DNA alkylator	FDA Approved
T1343L	Crystal Violet	DNA	FDA Approved
T1250	Triethylenethiophosphoramidate	DNA Alkylation	FDA Approved
T1241	Altretamine	DNA Alkylating	FDA Approved
T0975	Chloroambucil	DNA Alkylation	FDA Approved
T0951	Hydroxychloroquine sulfate	DNA; TLR9	FDA Approved
T0942	Quinacrine dihydrochloride	DNA; Histamine N-methyltransferase; PLA2; PLCLP	Phase 2
T0923	Busulfan	DNA Alkylation	FDA Approved
T0707	Cyclophosphamide monohydrate	DNA; MRP1	FDA Approved
T0377	Clofazimine	DNA; CzcO-like	FDA Approved

DNA Alkylator/Crosslinker

ID	Product Name	Target	Condition
T8554	KCC-07	MBD2 (methyl-CpG-binding domain protein 2)	
T3091	Carmustine	DNA Alkylator	FDA Approved

DNA gyrase

ID	Product Name	Target	Condition
TQ0063	Zoliflodacin	Topoisomerase; DNA gyrase	Phase 3
T8747	Levofloxacin hydrochloride	DNA gyrase; Topo II; Topo IV	FDA Approved
T7786	Tryptanthrin	DNA gyrase	
T2353	BRD7716	DNA gyrase	
T1492	Gemifloxacin mesylate	DNA gyrase; Topo II	FDA Approved
T1451	Levofloxacin Hemihydrate	DNA gyrase; Topo II; Topo IV	FDA Approved
T13231	Trovafloxacin	DNA gyrase; Topoisomerase; bacterial	FDA Approved
T1306	Norfloxacin	DNA gyrase; Topo II	FDA Approved
T1294	Fleroxacin	DNA gyrase; Topo II; Topo IV	Approved
T1095	Sparfloxacin	DNA gyrase; Topo II; Topo IV	FDA Approved
T0974	Novobiocin Sodium	ABCG2; DNA gyrase; Bile salt export pump; Topo I	FDA Approved
T0717	Enoxacin Sesquihydrate	DNA gyrase; Topo II; Topo IV	FDA Approved
T0250	Ciprofloxacin hydrochloride	DNA gyrase; Topo II; Topo IV	FDA Approved
T0116	Balofloxacin	DNA gyrase	Approved

DNA/RNA Synthesis

ID	Product Name	Target	Condition
TP1430	DTP3 TFA	GADD45β/MKK7	
TL0005	(-)-3,5-Dicaffeoyl quinic acid	tRNA synthetase of Giardia lamblia	
T8886	NITD-2	RNA Synthesis	
T8800	NSAH	RR	
T8785	HALOFLUGINONE LACTATE	prolyl-tRNA synthetase; TGF-β	Phase 2
T8647	BCH001	PAPD5	
T7747	Datelliptium chloride hydrochloride	DNA synthesis	
T7655	Fialuridine	DNA polymerase	
T7525	Didox	ribonucleotide reductase(RR)	
T7174	Urolithin A	apoptosis; autophagy; DNA synthesis	
T7004	Tubercidin	DNA/RNA Synthesis	Approved
T6S0139	Neobavaisoflavone	DNA polymerase	
T6974	Saccharin 1-methylimidazole (SMI)	DNA/RNA Synthesis	
T6908	NSC228155	KIX-KID interaction; EGFR	
T6894	ML264	KLF5	
T6632	Raltitrexed	Thymidylate synthase	Approved
T6603	Nelarabine	DNA synthesis (ALL-SIL cells); DNA synthesis (HSB2 cells); DNA synthesis (JURKAT cells); DNA synthesis (PER-255 cells)	FDA Approved
T6501	Fludarabine Phosphate	DNA polymerase α; DNA polymerase δ	FDA Approved
T6456	CRT0044876	APE1	

ID	Product Name	Target	Condition
T6446	Clevudine	DNA polymerase; RNA polymerase	Approved
T6369	Adenine sulfate	DNA/RNA Synthesis	FDA Approved
T6244	Cidofovir	DNA/RNA Synthesis	FDA Approved
T6226	Pemetrexed Disodium Hydrate	DHFR; DHFR; GARFT; Thymidylate synthase	FDA Approved
T6225	Adenine hydrochloride	DNA/RNA Synthesis	
T6194	Fidaxomicin	RNA polymerase	FDA Approved
T6116	Bleomycin Sulfate	DNA/RNA Synthesis	FDA Approved
T6069	Gemcitabine HCl	DNA synthesis	FDA Approved
T5942	Docosanoic acid	DNA polymerase beta	
T5413	ML216	BLM helicase	
T4687	Ro 5-3335	CBFβ-Runx1	Preclinical
T4656	B02	RAD51	
T4641	LMI 070	DNA/RNA Synthesis	Phase 2
T4569	Lucanthone	APE1	Phase 2
T4517	L189	DNA Ligase I; DNA Ligase III; DNA Ligase IV	
T4470	Pyridostatin TFA	G-quadruplexe	
T4457	Pyridostatin Trihydrochloride(free base 1085412-37-8)	G-quadruplexe	
T4382	Proguanil hydrochloride	dihydrofolate reductase; thymidylate synthase; NADH dehydrogenase	FDA Approved
T4356	Compound 3A	RNA polymerase I	
T4336	IPTG	DNA/RNA Synthesis	
T4311	HAMNO	DNA replication	
T4228	Nolatrexed	Thymidylate synthase	Phase 3
T4226	Amenamevir	helicase-primase	Approved
T4060	Acelarin	DNA synthesis	Phase 3
T4010	Juglone	RNA polymerase	
T3772	Maslinic acid	DNA polymerase B	
T3658	TAS102	DNA/RNA Synthesis	FDA Approved
T3628	Madrasin	DNA/RNA Synthesis	
T3524	Halofuginone hydrobromide	ProRS; prolyl-tRNA synthetase	Phase 2
T3400	Bakuchiol	DNA polymerase I	
T3343	5-methoxyflavone	DNA/RNA Synthesis	
T3157	COH29	RNR(KB cell)	Phase 1
T2942	Psoralen	DNA/RNA Synthesis	Approved
T2708	SL327	AP-1; MEK1; MEK2	
T2628	R12	RAD51	
T2504	Pritelivir	helicase primase; HSV-2	Phase 2
T2410	Nedaplatin	DNA synthesis	Approved
T2276	R11	RAD51	

ID	Product Name	Target	Condition
T2275	YK-4-279	RNA helicase A	
T2219	Puromycin dihydrochloride	DNA synthesis; 60S ribosome	
T2201	6-Mercaptopurine monohydrate	DNA synthesis; PRPP Amidotransferase	FDA Approved
T2100	CX5461	Pol I-driven transcription of rRNA	Phase 2
T20945	2,4-D	DNA synthesis	
T19833	5-Fluoroorotic acid	thymidylate synthase	
T1982	Triapine	RR	Phase 2
T1840	Isoindigotin	DNA polymerase	
T1767	BMH21	RNA polymerase I	
T1724	SCR7 pyrazine	DNA Ligase IV	
T1721	2'-Deoxyuridine	Thymidylate synthase; Upp	
T1703	SN38	Topo I; DNA synthesis	Phase 2
T1679	Thiostrepton	DNA synthesis	Approved
T1665	Daptomycin	DNA synthesis	FDA Approved
T1663	Deoxythymidine triphosphate	DNA/RNA Synthesis	
T1646	Famciclovir	DNA polymerase; HSV	FDA Approved
T1629	Rifapentine	RNA polymerase	FDA Approved
T1617	Enrofloxacin	DNA synthesis	Approved
T1600	Doxifluridine	Thymidine phosphorylase	Approved
T1591	Cyclocytidine hydrochloride	DNA/RNA Synthesis	Approved
T1564	Cisplatin	DNA synthesis	FDA Approved
T15611	JH-RE-06	REV1-REV7	
T1558	Resveratrol	COX-1; COX-2; DNA polymerase α ; IKK β ; LOX; Quinone reductase 2; SIRT1; SIRT2	Approved
T1511	Daunorubicin hydrochloride	DNA synthesis	FDA Approved
T1506	Vidarabine	DNA polymerase; DNA polymerase; Tyrosine Kinases	FDA Approved
T1501	Rifabutin	RNA polymerase; Endoplasmic; HSP90	FDA Approved
T1488	Procarbazine hydrochloride	DNA/RNA Synthesis	FDA Approved
T1465	Mupirocin	DNA synthesis	FDA Approved
T1454	Aciclovir	DNA synthesis	FDA Approved
T1428	Trifluridine	DNA/RNA Synthesis; Thymidylate synthase	FDA Approved
T1417	Mechlorethamine hydrochloride	DNA/RNA Synthesis	FDA Approved
T1408	Capecitabine	Thymidine phosphorylase	FDA Approved
T1378	Tegafur	DNA synthesis	Approved
T13584	BMVC-8C30	G-quadruplexe	
T1349	5-Fluorouridine	DNA synthesis; Upp	
T1307	Carmofur	DNA/RNA Synthesis	Approved
T1276	Danofloxacin mesylate	DNA-gyrase	Approved

ID	Product Name	Target	Condition
T1272	Cytarabine	DNA synthesis	FDA Approved
T1233	Oxolinic acid	bacterial DNA gyrase; DNA synthesis; dopamine uptake	Approved
T1178	Temozolomide	DNA replication	FDA Approved
T1154	Rifaximin	DNA/RNA Synthesis	FDA Approved
T1153	Trimethoprim	DHFR; Thymidylate synthase	FDA Approved
T1120	Dacarbazine	DNA polymerase beta	FDA Approved
T1087	Valacyclovir hydrochloride	DNA polymerase	FDA Approved
T1086	Vitamin D2	DNA polymerase; VD3	FDA Approved
T1058	Carboplatin	DNA synthesis	FDA Approved
T1055	Ifosfamide	DNA/RNA Synthesis	FDA Approved
T1038	Fludarabine	STAT1; DNA synthesis	FDA Approved
T0986	Fluorocytosine	DNA synthesis	FDA Approved
T0984	Fluorouracil	Thymidylate synthase	FDA Approved
T0964	Floxuridine	Thymidylate synthase	FDA Approved
T0926	Azelaic acid	DNA polymerase I; ThxR	FDA Approved
T0684	Ribavirin	ADK; IMPDH1; RNA polymerase	FDA Approved
T0681	Rifampicin	14- α Demethylase; DNA/RNA Synthesis	FDA Approved
T0676	Hydroxyurea	ribonucleoside diphosphate reductase	FDA Approved
T0415	Guanidine hydrochloride	Arginase; Lysozyme; Ribonuclease pancreatic; Argininosuccinate synthase	FDA Approved
T0353	Osalmid	RR	Approved
T0297	Clofarabine	RR	FDA Approved
T0251	Gemcitabine	Autophagy; DNA synthesis	FDA Approved
T0189L	Pemetrexed disodium	DHFR; GARFT; Thymidylate synthase	FDA Approved
T0189	Pemetrexed acid	DHFR; GARFT; Thymidylate synthase	FDA Approved
T0164	Oxaliplatin	DNA synthesis	FDA Approved
T0148	Calcium folinate	Thymidylate synthase; VB	FDA Approved

DNA-PK

ID	Product Name	Target	Condition
TQ0031	Nedisertib	DNA-PK	Phase 1/2
T7122	AZD-7648	DNA-PK	Phase 2
T7014	Voxtalisib	DNA-PK; PI3K α ; PI3K β ; PI3K γ ; PI3K δ	Phase 1/2
T6883	LY3023414	DNA-PK; mTOR kinase; class I PI3K isoforms	Phase 2
T6319	OSI027	DNA-PK; mTOR; mTORC1; mTORC2; PI3K γ	Phase 1
T6283	Wortmannin	PI3K , DNA-PK , ATM , MLCK , ATR	Preclinical
T6276	NU7441	DNA-PK	
T6143	PI103	DNA-PK; p110 α ; p110 β ; p110 γ ; p110 δ ; mTOR	Preclinical
T6100	Torin 2	ATM; ATR; DNA-PK; mTOR	
T6087	AZD6482	DNA-PK; PI3K α ; PI3K β ; PI3K γ ; PI3K δ	Phase 1

ID	Product Name	Target	Condition
T6045	Torin 1	DNA-PK; mTOR; mTORC1; mTORC2; p110γ	
T5166	Leniolisib	PI3Kδ; DNA-PK	Phase 2/3
T4339	YU238259	HDR	
T3986	SF2523	DNA-PK; BRD4; mTOR; PI3Kα; PI3Kγ	Preclinical
T3586	Compound 401	DNA-PK	
T3541	CC115	DNA-PK; mTOR; PI3Kα	Phase 1
T3351	CC223	c-Fms; DNA-PK; FLT4; mTOR; PI3K-α	Phase 2
T2685	KU55933	ATM; ATR; DNA-PK; mTOR; PI3K	Preclinical
T2667	PIK75	DNA-PK; p110α; p110β; p110γ; p110δ	
T2616	PIK93	ATM; C2β; DNA-PK; hsVps34; mTORC1; p110α; p110β; p110γ; p110δ; PI3KIIIβ	
T2461	PIK90	PI3Kα; PI3Kβ; PI3Kγ; PI3Kδ; DNA-PK	
T2433	NU7026	ATM; ATR; DNA-PK; PI3K	
T2377	XL147 analogue	DNA-PK; PI3Kα; PI3Kβ; PI3Kγ; PI3Kδ	Phase 1/2
T2287	PIK-75 hydrochloride	DNA-PK; p110α; p110β; p110γ; p110δ	
T2084	ETP46464	ATM; ATR; DNA-PK; mTOR; PI3Kα	
T2083	PI3065	DNA-PK; mTOR; p110α; p110β; p110δ	
T2008	LY294002	p110α; p110β; p110δ; DNA-PK	Preclinical
T1826	Voxtalib Analogue	DNA-PK; PI3Kα; PI3Kβ; PI3Kγ; PI3Kδ	Phase 1/2
T15789	LTURM34	DNA-PK; PI3Kβ; PI4Kδ	

HDAC

ID	Product Name	Target	Condition
TQ0074	ACY-775	HDAC6	
T8517	PXD-101	HDAC	FDA Approved
T8508	HDAC-IN-3	HDAC	
T8480	Tenovin-6 Hydrochloride	SIRT1; SIRT2; SIRT3; HDAC8; p53	
T8233	BRD3308	HDAC3	
T7691	NSC 3852	HDAC	
T7664	Pyroxamide	HDAC	
T7385	WT-161	HDAC	
T7082	HDAC8-IN-1	HDAC8	
T7064	Valproic Acid	GABA; Sodium Channel; HDACs; HDAC1	FDA Approved
T6980	Scriptaid	HDAC	
T6865	Quisinostat 2HCl	HDAC1; HDAC10; HDAC11; HDAC2; HDAC4	Phase 2
T6695	Tasquinimod	HDAC4	Phase 3
T6639	RG2833	HDAC1; HDAC3	Phase 1
T6481	Droxinostat	HDAC10; HDAC3; HDAC6; HDAC8; HDAC9	
T6474	Divalproex Sodium	HDAC	FDA Approved
T6421	BRD73954	HDAC2; HDAC4; HDAC6; HDAC8	

ID	Product Name	Target	Condition
T6392	AR42	HDAC	Preclinical
T6362	4SC202	HDAC1; HDAC11; HDAC2; HDAC3; HDAC5	Phase 2
T6327	Tubacin	HDAC6	
T6325	PCI34051	HDAC1; HDAC10; HDAC2; HDAC6; HDAC8	Preclinical
T6279	Givinostat hydrochloride monohydrate	HD1-A; HD1-B; HD2	Phase 3
T6270	Trichostatin A	HDAC	Phase 1
T6233	Entinostat	HDAC1; HDAC3	Approved
T6161	Tubastatin A HCl	HDAC1; HDAC2; HDAC3; HDAC6; HDAC8	
T6061	LMK235	HDAC4; HDAC5	
T6055	Quisinostat	HDAC1; HDAC10; HDAC11; HDAC2; HDAC3; HDAC4; HDAC5; HDAC8	Phase 2
T6006	Romidepsin	HDAC1; HDAC2	FDA Approved
T5886	Benzenebutyric acid	HDAC	Approved
T5830	SKLB-23bb	HDAC6	
T5631	SIS17	HDAC11	
T5347	CXD-101	HDAC; HDAC1; HDAC3; HDAC2	Phase 2
T5332	TH34	HDAC6; HDAC8; HDAC10	
T4481	Tucidinostat	HDAC1; HDAC2; HDAC3; HDAC10	Approved
T4477	4SC-202 tosylate	HDAC1; HDAC2; HDAC3; HDAC5; HDAC9; HDAC10; HDAC11;	Phase 2
T4389	SR4370	HDAC1; HDAC2; HDAC3	
T4370	Resminostat hydrochloride	HDAC1; HDAC3; HDAC6; HDAC8	Phase 2
T3983	TMP 195	HDAC4; HDAC5; HDAC7; HDAC9	
T3937	Methyl L-histidinate dihydrochloride	HDAC	
T3878	Raddeanin A	HDAC	
T3753	Sinapinic Acid	ACE; HDAC	
T3661	Citarinostat	HDAC1; HDAC2; HDAC3; HDAC6; HDAC8	Phase 2
T3516	Minomustine	HDAC1; HDAC2; HDAC3; HDAC6; HDAC8	Phase 1/2
T3509	ACY738	HDAC6	Preclinical
T3358	ITSA1	HDAC	
T3206	PAOA	HDAC	
T3205	UF010	HDAC	
T3204	BML210	HDAC	
T3199	PTACH	HDAC	
T3193	Pimelic diphenylamide 106	HDAC	
T3108	CUDC101	EGFR; HDAC; HDAC1; HDAC10; HDAC2; HDAC3; HDAC4; HDAC5; HDAC6; HDAC7; HDAC8; HDAC9; HER2	Phase 1
T2512	Mocetinostat	HDAC1; HDAC11; HDAC2; HDAC3	Approved
T2489	Rocilinostat	HDAC1; HDAC2; HDAC3; HDAC6; HDAC8	Phase 2
T2383	Panobinostat	HDAC	FDA Approved
T2294	BG45	HDAC1; HDAC2; HDAC3; HDAC6	

ID	Product Name	Target	Condition
T2266	Santacruzamate A	HDAC2; HDAC4; HDAC6	
T2205	Theophylline-7-acetic acid	A1; A2; A3; HDAC2; PDE4; PKA; TNF- α	Approved
T2157	Histone Deacetylase Inhibitor III	HDAC	
T2140	Parthenolide	NF- κ B	Phase 2
T2078	PI3K/HDAC Inhibitor	HDAC1; HDAC10; HDAC11; HDAC2; HDAC3	Phase 2
T2025	Chidamide	HDAC1; HDAC2; HDAC3; HDAC8	Approved
T2023	MC1568	HD1-A (Maize); HD1-B (Maize)	
T1983	CAY10603	HDAC1; HDAC6	Phase 1
T19687	Phenylethyl isothiocyanate	HDAC	
T1966	Tubastatin A	HDAC6	
T1890	Pracinostat	HDAC1; HDAC10; HDAC11; HDAC2; HDAC3; HDAC4; HDAC5; HDAC6; HDAC7; HDAC8; HDAC9	Approved
T1888	CI994	HDAC1; HDAC2; HDAC3	Phase 2
T1857	TMP269	HDAC4; HDAC5; HDAC7; HDAC9	
T1852	Belinostat	HDAC	FDA Approved
T1819	Nexturastat A	HDAC6	
T1762	RGFP 966	HDAC3	
T16962	SW-100	HDAC1; HDAC2; HDAC3; HDAC4; HDAC5; HDAC6; HDAC7; HDAC8; HDAC9; HDAC10; HDAC11	
T1602	Valproic acid sodium salt	GABAR; HDAC2; HDAC9	FDA Approved
T1583	Vorinostat	HDAC; HDAC1; HDAC2; HDAC3; HDAC6; HDAC8	FDA Approved
T1535	Sodium Phenylbutyrate	HDAC	FDA Approved
T13996	1-Naphthohydroxamic acid	HDAC8; HDAC1; HDAC6	
T1083L	Theophylline monohydrate	Adenosine receptor; HDAC2; PDE	FDA Approved
T1083	Theophylline	Adenosine receptor; HDAC2; PDE	FDA Approved
T0431	PCI24781	HDAC1; HDAC10; HDAC2; HDAC3/SMRT; HDAC6	Phase 3

MTH1

ID	Product Name	Target	Condition
T6357	(S)-crizotinib	MTH1	FDA Approved
T2069L	TH287 hydrochloride	MTH1	
T2069	TH287 hydrochloride	MTH1	
T2037	TH588	MTH1	

Nucleoside Antimetabolite/Analog

ID	Product Name	Target	Condition
T8354	Triazavirin	Nucleoside Analogue; Influenza virus	
T7621	6-Thioinosine	Nucleoside Antimetabolite/Analog	
T7514	N2-Methylguanosine	Nucleoside	

ID	Product Name	Target	Condition
T7491	6-O-Methyl Guanosine	Nucleoside	
T7351	3-Methylcytidine	Nucleoside	
T7319	7-Methylguanosine	cNIIIB nucleotidase	
T2366	Tipiracil hydrochloride	Nucleoside Antimetabolite/Analog	FDA Approved
T1591L	Cytidine	Nucleoside Analogue	Approved
T0853	Adenosine	Nucleoside	FDA Approved
T0543	7-Methylxanthine	Nucleoside Antimetabolite/Analog	
T0532	Dihydrothymine	Nucleoside Analogue	

PARP

ID	Product Name	Target	Condition
T9113	Myristicin	Antifection; Bcl-2; Caspase; CYP17; GABA Receptor; IL Receptor; NO; PARP	
T8806	Fluzoparib	PARP	
T8296	4',5,7-Trimethoxyflavone	Caspase-3; PARP	
T7896	BYK204165	PARP	
T7042	1,5-Isoquinolinediol	PARP1	
T6942	Picolinamide	PARP	
T6892	Niraparib tosylate	PARP1; PARP2	FDA Approved
T6780	Benzamide	PARP	
T6578	ME0328	PARP1; PARP3	
T6339	AG14361	PARP1	Preclinical
T6329	INO1001	PARP	Phase 1
T6253	Talazoparib	PARP	FDA Approved
T6224	Iniparib	PARP1	Phase 2
T6197	PJ34	PARP1; PARP2	
T6181	UPF 1069	PARP1; PARP2	
T6127	Rucaparib Phosphate	PARP	FDA Approved
T5860	CK-869	ARP2/3	
T5399	GeA-69	PARP14	
T4471	E7449	PARP1/2; tankyrase1/2	
T4463	Rucaparib	PARP1	FDA Approved
T3649	BGP15	PARP	Phase 2
T3375	Verbasoside	p53; PARP1; PKC	
T3231	Niraparib	TANK-1; PARP1; PARP2; PARP3; V-PARP	FDA Approved
T3015	Olaparib	PARP1; PARP2	FDA Approved
T2591	Veliparib	PARP1; PARP2	Phase 3
T2484	AZD2461	PARP	Phase 1
T22414	RBN012759	PARP14	
T22264	AZ9482	PARP	

ID	Product Name	Target	Condition
T21524	4-amino-1,8-Naphthalimide	PARP	
T2124	PJ34 hydrochloride	PARP	
T2105	Veliparib dihydrochloride	PARP1; PARP2	Phase 3
T16807	Rucaparib Camsylate	PARP1	FDA Approved
T12695	RBN-2397	PARP7	
T10990	Dehydrocorydaline chloride	p38 MAPK; Bax; Bcl-2; caspase-7; caspase-8; PARP	

PPAR

ID	Product Name	Target	Condition
TWS0787	Oroxin A	PPAR γ agonist; α -glucosidase	
TQ0156	GW1929	PPAR γ	Preclinical
TN1126	Sakuranetin	PPAR; NF- κ B; VEGFR	
T8780	INT-131	PPAR γ	Phase 2
T8486	GW 6471	PPAR α	
T8184	Fucosterol	PPAR α	
T7821	DG172 (dihydrochloride)	PPAR	
T7443	4'-Methoxychalcone	PPAR γ	
T7395	Lanifibranor	PPAR	Phase 2
T7159	L-165041	PPAR	
T6926	Palmidrol	PPAR α	Preclinical
T6842	G007-LK	TNKS1; TNKS2	
T6768	AZ6102	TNKS1; TNKS2	
T6689	T0070907	PPAR α ; PPAR γ ; PPAR δ	
T6646	Rosiglitazone HCl	PPAR	FDA Approved
T6524	GW0742	PPAR δ ; PPAR α ; PPAR γ	Preclinical
T6151	GW501516	PPAR δ	Phase 2
T5891	D-ERYTHRO-SPHINGOSINE	PKC; PP2A; Human Endogenous Metabolite	
T5764	Alliin	PPAR γ ; NF- κ B	
T5532	BMS-687453	PPAR α	
T4S2128	Bilobetin	PPAR α	
T4628	MBX 8025	PPAR α /PPAR δ	Phase 3
T4449	LB100	PP2A	Phase 1
T4408	Elafibranor	PPAR- α ; PPAR- δ	Phase 3
T4353	SR18292	PGC-1 α	
T3954	Adelmidrol	COX; NF- κ B; PPAR	Phase 2
T3941	Choline Fenofibrate	P450; PPAR	FDA Approved
T3710	XMD16-5	TNK2; TNK2	
T3709	XMD8-87	TNK2; TNK2	
T3362	Eupatilin	Autophagy; PPAR	Approved
T3254	PHYTOL	PPAR	

ID	Product Name	Target	Condition
T3170	Troglitazone	PPAR γ	FDA Approved
T3138	Astaxanthin	PPAR γ	
T3090	Abietic Acid	MMP-1; PPAR α ; PPAR γ ; 5-lipoxygenase	
T3062	WIKI4	TNKS2	
T3056	Bavachinin	PPAR	
T3000	Magnolol	NF- κ B; p53; PPAR γ ; RXR α	Approved
T2985	Gypenoside XLIX	PPAR α	
T2932	Ginsenoside Rh1	IL Receptor; PPAR; TNF Receptor	
T2674	GSK0660	PPAR β ; PPAR δ	
T2413	FH535	PPAR γ ; PPAR δ ; Wnt/ β -catenin	
T2396	Ramatroban	CRT θ 2; TXA2R	Approved
T2269	Pirinixic Acid	PPAR α	Approved
T2260	GW 9662	PPAR α ; PPAR γ ; PPAR δ	
T1941	GSK3787	PPAR δ	Preclinical
T1807	JW55	TNKS1; TNKS2; auto-PARsylation of TNKS2; auto-PARsylation of TNKS1	
T1674	Nateglinide	Potassium Channel; PPAR γ	FDA Approved
T1622	Rosiglitazone maleate	PPAR γ	FDA Approved
T16074	Mifobate	PPAR γ	
T1603	Glipizide	ABCC; PPAR γ	FDA Approved
T16022	Arhalofenate	PPAR γ	Phase 2/3
T15453	GW7647	PPAR α ; PPAR γ ; PPAR δ	
T1415	Gemfibrozil	PPAR α ; CYP2C9; IA2	FDA Approved
T1402	Fenofibric acid	MMP; PPAR α ; COX-2	FDA Approved
T1298	Clofibrate	PPAR α	FDA Approved
T1264	Ciprofibrate	PPAR	Approved
T1238	Daidzein	PPAR	Approved
T12296	Oleylethanolamide	Human Endogenous Metabolite; PPAR α	
T1149	Fenofibrate	CYP2B6; CYP2C; CYP2C19; PPAR α	FDA Approved
T1088	Repaglinide	Potassium Channel; PPAR γ	FDA Approved
T0841	Bezafibrate	PPAR α	Approved
T0705	Triflusal	PDE; TXA2R	Approved
T0646	Mesalamine	COX; ALOX5; MPO; NF- κ B; PPAR γ	FDA Approved
T0448	Dexibuprofen	Bcl-2; COX; Cystic fibrosis transmembrane conductance regulator; PPAR γ ; thrombomodulin	Approved
T0334	Rosiglitazone	PPAR	FDA Approved
T0214L	Pioglitazone hydrochloride	human PPAR γ ; mouse PPAR γ	FDA Approved
T0214	Pioglitazone	PPAR	FDA Approved
T0212	Seratrodast	COX; TXA2R	Approved
T0061	Clofibrlic acid	PPAR	FDA Approved

Sirtuin

ID	Product Name	Target	Condition
T8480	Tenovin-6 Hydrochloride	SIRT1; SIRT2; SIRT3; HDAC8; p53	
T8346	SRT1460	SIRT1	
T7679	UBCS039	SIRT	
T6984	SirReal2	SIRT2	
T6679	SRT2104	SIRT1	Phase 1
T6678	Splitomicin	SIRT2p	
T6671	Sirtinol	SIRT1; SIRT2	
T6371	AGK2	SIRT2	
T6220	Nicotinamide riboside chloride	SIRT1/3	
T6111	Selisistat	SIRT1	Phase 2
T5725	lithospermic acid B	SIRT	
T5618	AK-1	SIRT2	
T5490	AK-7	SIRT2	
T5124	SRT 1720 dihydrochloride[925434-55-5(free base)]	SIRT1; SIRT2	Preclinical
T5096	SRT 1720	SIRT1	Preclinical
T4328	OSS_128167	SIRT6; SIRT2; SIRT1	
T4108	3-TYP	SIRT1; SIRT2; SIRT3	
T4062	CAY10602	SIRT1	
T4019	Cambinol	SIRT1; SIRT2	
T3953	Salermide	SIRT1; SIRT2	
T3447	Thiomyristoyl	SIRT1; SIRT2	
T2S0300	Hydrocoumarin	SIRT1; SIRT2	
T2879	Fisetin	SIRT	
T2750	Ginkgolide C	AMPK; MMP; Sirtuin	
T2412	SRT1720 hydrochloride	SIRT1	Preclinical
T1887	Inauhzin	SIRT1	
T1873	Tenovin3	SIRT2	
T1818	Tenovin-6	SIRT1; SIRT2; SIRT3	
T16932	SRT 2183	SIRT1	
T1558	Resveratrol	COX-1; COX-2; DNA polymerase α ; IKK β ; LOX; Quinone reductase 2; SIRT1; SIRT2	Approved
T13795	Nicotinamide riboside	SIRT1; SIRT3	
T0934	Nicotinamide	SIRT	FDA Approved

Telomerase


ID	Product Name	Target	Condition
T7447	Adefovir	Telomerase reverse transcriptase	
T7409	360A	Telomerase	
T3333	Cycloastragenol	Telomerase	
T3182	L-778123 hydrochloride	Farnesyl transferase (FTase); FPTase	Phase 2
T2902	Costunolide	FPTase; Telomerase (MCF-7); Telomerase (MDA-MB-231)	
T2380	BIBR 1532	Telomerase	
T1416	Zidovudine	Reverse Transcriptase; Telomerase reverse transcriptase	FDA Approved
T10760	Ceramides Mixture	Telomerase	

Topoisomerase

ID	Product Name	Target	Condition
TQ0088	Exatecan Mesylate	Topo I	Phase 3
TQ0063	Zoliflodacin	Topoisomerase; DNA gyrase	Phase 3
TN2105	Proscillaridin A	topoisomerase I; topoisomerase II	
T8747	Levofloxacin hydrochloride	DNA gyrase; Topo II; Topo IV	FDA Approved
T7551	Belotecan hydrochloride	Topo I	Approved
T7309	TAS-103 (dihydrochloride)	topo I/II	
T7187	Genz-644282	Topoisomerase	Phase 1
T7048	1,4-Naphthoquinone	MAO; DNA topoisomerase; acetyltransferase	
T6628	Pirarubicin	Topo II	Approved
T6588	Mitoxantrone	Topo II; PKC	FDA Approved
T6567	Levofloxacin	Topo II; Topo IV	FDA Approved
T6467	Dexrazoxane HCl	Topoisomerase	FDA Approved
T6336	Amonafide	Topo II	Phase 2
T6228	Irinotecan	Topo I	FDA Approved
T5S1952	9-Methoxycamptothecin	Topoisomerase	
T5853	Rubitecan	topoisomerase I	Phase 1
T5820	Amsacrine hydrochloride	Topoisomerase	Approved
T5394	Prulifloxacin	Topo II; Topo IV	Approved
T4952	10-Hydroxycamptothecin	Topo I	Approved
T4614	Ellipticine hydrochloride	Topo II	
T4047	Bisantrone	Topoisomerase	Phase 3
T3S1957	9-Aminocamptothecin	Topo I	Phase 2
T3481	Bimolane	Topo II	
T3339	Sophoridine	Topo I	Approved
T3186	NU2058	CDK1; CDK2; Topo II	Preclinical
T3181	SW044248	Topo I	

ID	Product Name	Target	Condition
T3117	Marbofloxacin	Topo II; Topo IV	FDA Approved
T2830	Betulinic acid	Aminopeptidase N; HIV-1; Eukaryotic topoisomerase I	Phase 1
T2764	10-Hydroxycamptothecin	Topo I	Approved
T2394	Pixantrone dimaleate	Topoisomerase	Approved
T2160	Suramin Sodium Salt	Topo II	Phase 2
T1703	SN38	Topo I; DNA synthesis	Phase 2
T1640	Ciprofloxacin	Topo II; Topo IV	FDA Approved
T1625	Lomefloxacin hydrochloride	Topo II	FDA Approved
T1620	Pazufloxacin Mesylate	Topo II	Approved
T1523	Teniposide	Topo II	FDA Approved
T1521	Hydroxy Camptothecine	Topo I	Approved
T1492	Gemifloxacin mesylate	DNA gyrase; Topo II	FDA Approved
T1451	Levofloxacin Hemihydrate	DNA gyrase; Topo II; Topo IV	FDA Approved
T1444	Lomefloxacin	Topo II; Topo IV	FDA Approved
T13231	Trovafoxacin	DNA gyrase; Topoisomerase; bacterial	FDA Approved
T1306	Norfloxacin	DNA gyrase; Topo II	FDA Approved
T1294	Fleroxacin	DNA gyrase; Topo II; Topo IV	Approved
T1293	Gatifloxacin	Topo IV	FDA Approved
T1174	Topotecan hydrochloride	Topo I (DU-145 Luc cells); Topo I (MCF-7 Luc cells)	FDA Approved
T1123	(S)-(+)-Camptothecin	Topo I	Approved
T1121	Podophyllotoxin	microtubule; Topo II	FDA Approved
T1095	Sparfloxacin	DNA gyrase; Topo II; Topo IV	FDA Approved
T1060	Flumequine	Topo II	
T1020	Doxorubicin hydrochloride	Topo II	FDA Approved
T0974	Novobiocin Sodium	ABCG2; DNA gyrase; Bile salt export pump; Topo I	FDA Approved
T0909L	Nalidixic acid sodium salt	Topo II	FDA Approved
T0909	Nalidixic acid	Topo II	FDA Approved
T0902	Ofloxacin	Topo	FDA Approved
T0717L	Enoxacin	Topo II; Topo IV	FDA Approved
T0717	Enoxacin Sesquihydrate	DNA gyrase; Topo II; Topo IV	FDA Approved
T0486L	Irinotecan Hydrochloride	Topo I	FDA Approved
T0486	Irinotecan hydrochloride trihydrate	Topo I	FDA Approved
T0425L	Pefloxacin Mesylate Dihydrate	Topo II	Approved
T0425	Pefloxacin Mesylate	Topo IV	Approved
T0331	Moxifloxacin hydrochloride	Topo II; Topo IV	FDA Approved
T0274	Cinoxacin	Topo II	FDA Approved
T0250	Ciprofloxacin hydrochloride	DNA gyrase; Topo II; Topo IV	FDA Approved
T0132	Etoposide	Topo II	FDA Approved
T0125	Epirubicin hydrochloride	Topo	FDA Approved

Endocrinology/Hormones



Endocrinology/Hormones

Androgen Receptor

ID	Product Name	Target	Condition
TQ0214	Dimethylcurcumin	Androgen Receptor	Phase 2
TQ0209	Ailanthone	Androgen Receptor	
TCS1372	Atratic acid	Androgen Receptor; PTP1B	
T8709	Nandrolone phenpropionate	androgen receptor	FDA Approved
T8592	CTK8A3536	Androgen receptor	
T8217	Enzalutamide carboxylic acid	Androgen Receptor	FDA Approved
T7690	2-hydroxy Flutamide	Androgen Receptor	Phase 2
T7440	4,4'-DDE	Androgen Receptor	
T7358	YK11	Androgen Receptor	
T6915	Darolutamide	Androgen Receptor	FDA Approved
T6889	MI136	Androgen Receptor	

ID	Product Name	Target	Condition
T6829	EPI001	Androgen Receptor	Preclinical
T6509	Galeterone	Androgen Receptor; CYP17	Phase 2
T6002	Enzalutamide	Androgen Receptor	FDA Approved
T4358	Testolone	Androgen Receptor	Phase 1
T4357	LGD3303	Androgen Receptor	Preclinical
T3618	GSK2881078	Androgen Receptor	Phase 2
T3393	Triptophenolide	Androgen Receptor	
T3357	17 alpha-propionate	Androgen Receptor	FDA Approved
T3137	Parenabol	Androgen Receptor	
T2991	3,3'-Diindolylmethane	Androgen Receptor	
T2408	Ostarine	Androgen Receptor	Phase 2
T2339	Apalutamide	Androgen Receptor; GABAR	FDA Approved
T2236	RU58841	Androgen Receptor	Phase 1
T2207	Adrenosterone	Androgen Receptor	Approved
T2195	Epiandrosterone	Androgen Receptor; PR	
T2108	Andarine	Androgen Receptor	Phase 1
T19450	N-desmethyl Enzalutamide	Androgen receptor	
T1596	Chlormadinone acetate	Androgen Receptor	Approved
T1541	Drospirenone	Androgen Receptor; COX-2; PR; Mineralocorticoid Receptor	FDA Approved
T1480	Danazol	Androgen Receptor; ER; ER; GNRHR	FDA Approved
T13273	UT-34	androgen receptor	
T1167	Cyproterone acetate	Androgen Receptor	Approved
T0856L	Dehydroepiandrosterone	Androgen Receptor	FDA Approved
T0856	Dehydroepiandrosterone acetate	Androgen Receptor	FDA Approved
T0489	Flutamide	Androgen Receptor	FDA Approved
T0476	Abbolactone	Androgen Receptor	FDA Approved
T0380	Bicalutamide	Androgen Receptor	FDA Approved
T0272	Nilutamide	Androgen Receptor	FDA Approved
T0135	Estradiol valerate	Androgen Receptor	FDA Approved

Aromatase

ID	Product Name	Target	Condition
T7556	Fadrozole hydrochloride	Aromatase	
T7197	Fadrozole	Aromatase	Approved
T6917	Oleuropein	Aromatase; ROS	
T3390	Obacunone	p38 MAPK; Aromatase	
T202744	alpha-Naphthoflavone	Aromatase	
T21311	Testolactone	aromatase	FDA Approved

ID	Product Name	Target	Condition
T1692	3,4-Dimethoxyhydrocinnamic acid	Aromatase	
T1590	Letrozole	Aromatase	FDA Approved
T1587	Exemestane	Aromatase (human); Aromatase (rat)	FDA Approved
T1103	Aminoglutethimide	Aromatase	FDA Approved
T1099	Formestane	Aromatase	Approved
T0393	Anastrozole	Aromatase	FDA Approved

Estrogen Receptor/ERR

ID	Product Name	Target	Condition
TN1148	Isosporalenoside	Estrogen Receptor/ERR; Estrogen/progestogen Receptor	

Estrogen/progestogen Receptor

ID	Product Name	Target	Condition
TN1148	Isosporalenoside	Estrogen Receptor/ERR; Estrogen/progestogen Receptor	
T7974	Lynestrenol	progesterone receptor	Approved
T7904	SR 19881	ERR γ	
T7709	(E/Z)-GSK5182	ERR γ ; ROS	
T7644	DPN	ER β	
T7223	Gestrinone	ER	Approved
T6906	Tamoxifen	ER	FDA Approved
T6819	Desogestrel	ER; PR	FDA Approved
T6743	4-Hydroxytamoxifen	ER	Phase 3
T6713	Ulipristal	PR	FDA Approved
T6683	STF62247	ER	Preclinical
T6620	Ospemifene	ER	FDA Approved
T6533	Hexestrol	ER α ; ER β	
T6491	Equol	ER β	
T5835	PROTAC ER α ligand 2	ERR α	
T5633	H3B-5942	ER α	
T5531	GSK-4716	ERR β / γ	
T5174	Nestoron	PR	FDA Approved
T5118	GDC0810	ER α	Phase 1
T5040	Medroxyprogesterone	Estrogen/progestogen Receptor	FDA Approved
T4549	Tibolone	ER	Approved
T4505	Ferrous Bisglycinate	ER; PR	FDA Approved
T4420	(Z)-4-hydroxy Tamoxifen	ER	Phase 3
T4388	PHTPP	ER β	

ID	Product Name	Target	Condition
T4281	(E/Z)-Endoxifen	ER	
T4000	(±)-Equol	ER α ; ER β	
T3975	AZD9496	ER α ; ER α ; ER α	Phase 1
T3958	WAY 200070	ERR α ; ERR β	Preclinical
T3846	Bavachin	ER α ; ER β	
T3806	kaempferide	ER	
T3717	β -thujaplicin	ER α	
T3645	Endoxifen E-isomer hydrochloride	ERR	
T3399	Psoralidin	Akt; Phosphatidylinositol 3-kinase; ER α ; ER β	
T3378	17 α -Estradiol	ER α ; ER β	Approved
T3325	Liquiritigenin	ER β	
T2973	Astragaloside IV	ERS	
T2810	(20S)-Protopanaxatriol	ER; Glucocorticoid Receptor; LXR	
T2598	Thymopentin	ER	Approved
T2597	Norgestrel	ER	FDA Approved
T2577	Dienogest	ER	FDA Approved
T2569	Chlorotrianisene	ER	FDA Approved
T2567	Etonogestrel	ER	FDA Approved
T2559	Allylestrenol	ER	Approved
T2544	Bazedoxifene acetate	ER α ; ER β	FDA Approved
T2527	Ulipristal acetate	PR	FDA Approved
T2280	Endoxifen Z-isomer	hERG Potassium Channel; ER; ERR; hERG	Phase 3
T2250	DY131	ERR β ; ERR γ	
T2231	17-Beta-Estradiol-3,17-Dipropionate	ER	FDA Approved
T2195	Epiandrosterone	Androgen Receptor; PR	
T2177	Kaempferol	ER	
T2146	Fulvestrant	ER	FDA Approved
T1688	5Beta-Pregnane-3Alpha,20alpha-Diol	ER	
T1659	Melatonin	CAM; ER; melatonin receptor; MPO; ROR β	Approved
T1579	Mestranol	ER	FDA Approved
T1571	Estriol	ER; MRP1	Approved
T1549	Raloxifene hydrochloride	ER; AO; SERM	FDA Approved
T1541	Drospirenone	Androgen Receptor; COX-2; PR; Mineralocorticoid Receptor	FDA Approved
T1536	Promestriene	ER	Approved
T1514	Norethindrone	ER	FDA Approved
T1490	Gestodene	ER	Approved
T1480	Danazol	Androgen Receptor; ER; ER; GNRHR	FDA Approved
T1464	Toremifene citrate	ER	FDA Approved

ID	Product Name	Target	Condition
T1438	Butoconazole nitrate	ER	FDA Approved
T1429	Hydroxyprogesterone	ER	FDA Approved
T1424	Ethinyl estradiol	ER	FDA Approved
T1377	Methylidienedione	ER	
T1284	Megestrol acetate	ER; Glucocorticoid Receptor	FDA Approved
T12832	SAR439859	ER α	
T1263	Levonorgestrel	ER; SRD5A1	FDA Approved
T1261	Medroxyprogesterone Acetate	ER; PR	FDA Approved
T1216	Diethylstilbestrol	ER	FDA Approved
T1193	Clomifene citrate	ER	FDA Approved
T1102	Mifepristone	PR; Glucocorticoid Receptor	FDA Approved
T1048	Estradiol	ER	FDA Approved
T1009	Aquacrine	ER	FDA Approved
T0996	Ethinodiol diacetate	ER	FDA Approved
T0870	Altrenogest	ER	FDA Approved
T0835	Tamoxifen Z-isomer citrate	ER	FDA Approved
T0709	Pimaricin	ER	FDA Approved
T0593	XCT790	ERR α	
T0478	Progesterone	ER; κ -opioid receptor	FDA Approved
T0384	Estradiol benzoate	mER α ; hER α	FDA Approved
T0345	Estropipate	ER	FDA Approved
T0301	Ethisterone	ER	Approved
T0188	Fluticasone propionate	ER; Mineralocorticoid Receptor; Glucocorticoid Receptor; Cytosolic PLA2	FDA Approved
T0168	Depofemin	ER	FDA Approved
T0139	Toremifene	ER	FDA Approved
T0040	Quinestrol	ER	FDA Approved
T0035	Dienestrol	ER	FDA Approved

Glucocorticoid Receptor

ID	Product Name	Target	Condition
TQ0225	AZD7594	Glucocorticoid Receptor	Phase 2
T8777	Beclomethasone	glucocorticoid receptor	FDA Approved
T8396	Prednisone acetate	Glucocorticoid Receptor	FDA Approved
T6580	Meprednisone	Glucocorticoid Receptor	FDA Approved
T6503	Fluorometholone Acetate	Glucocorticoid Receptor	FDA Approved
T6502	Flucicnionide	Glucocorticoid Receptor	FDA Approved
T6022	LY404039	Recombinant human mGlu2; Recombinant human mGlu3; Rat neurons expressing native mGlu2/3	
T3962	TPI1	recombinant SHP-1	

ID	Product Name	Target	Condition
T3316	Fluoromethalone	Glucocorticoid Receptor	FDA Approved
T3096	Potassium canrenoate	Mineralocorticoid Receptor	Approved
T2884	Cortisone	Glucocorticoid Receptor	FDA Approved
T2810	(20S)-Protopanaxatriol	ER; Glucocorticoid Receptor; LXR	
T2748	Cortodoxone	Glucocorticoid Receptor	
T2548	Diflorasone	Glucocorticoid Receptor	FDA Approved
T2526	Ciclesonide	Glucocorticoid Receptor	FDA Approved
T21395	Finerenone	Mineralocorticoid Receptor	
T1749	AL082D06	Glucocorticoid Receptor	
T16727	Relacorilant	Glucocorticoid receptor	Phase 2
T1666	Fludrocortisone acetate	Autophagy; Mineralocorticoid Receptor	FDA Approved
T1652	Betamethasone	Glucocorticoid Receptor	FDA Approved
T1614	Hydrocortisone	Glucocorticoid Receptor	FDA Approved
T1573	Flunisolide	Glucocorticoid Receptor	FDA Approved
T1561	Clobetasol propionate	Glucocorticoid Receptor	FDA Approved
T1560	Prednisolone	Glucocorticoid Receptor	FDA Approved
T1559	Betamethasone dipropionate	Glucocorticoid Receptor	FDA Approved
T15451	GW-870086	glucocorticoid receptor	
T1541	Drospirenone	Androgen Receptor; COX-2; PR; Mineralocorticoid Receptor	FDA Approved
T15389L	Glucagon hydrochloride	glucocorticoid receptor	FDA Approved
T1531	Mometasone furoate	Glucocorticoid Receptor	FDA Approved
T1284	Megestrol acetate	ER; Glucocorticoid Receptor	FDA Approved
T1243	Hydrocortisone acetate	Annexin A1; Glucocorticoid Receptor	FDA Approved
T1171	Methylprednisolone	Glucocorticoid Receptor	FDA Approved
T1168	Desonide	Glucocorticoid Receptor	FDA Approved
T1163	Betamethasone 17-valerate	Glucocorticoid Receptor	FDA Approved
T1127	Beclomethasone dipropionate	Glucocorticoid Receptor	FDA Approved
T1124	Flumethasone	Glucocorticoid Receptor	FDA Approved
T1102	Mifepristone	PR; Glucocorticoid Receptor	FDA Approved
T1076	Dexamethasone	Glucocorticoid Receptor; IL receptor	FDA Approved
T1018	Prednisone	Glucocorticoid Receptor; MRP1	FDA Approved
T0977	Medrysone	Glucocorticoid Receptor; Corticosteroid-binding globulin	FDA Approved
T0948L	Corticosterone	Glucocorticoid Receptor	Phase 2
T0947	Dexamethason acetate	Annexin A1; Glucocorticoid Receptor; IL receptor; iNOS	FDA Approved
T0820	Triamcinolone acetonide	Glucocorticoid Receptor	FDA Approved
T0798	Triamcinolone	COX; Glucocorticoid Receptor	FDA Approved
T0485	Deflazacort	Glucocorticoid Receptor	FDA Approved
T0367	Fluocinolone acetonide	Glucocorticoid Receptor	FDA Approved

ID	Product Name	Target	Condition
T0354	Canrenone	Mineralocorticoid Receptor	Approved
T0343	Nimodipine	AhR; Calcium Channel; Mineralocorticoid Receptor	FDA Approved
T0337	Prednisolone-21-acetate	Glucocorticoid Receptor	FDA Approved
T0270	Hydrocortisone butyrate	Annexin A1; Glucocorticoid Receptor	FDA Approved
T0261	Amcinonide	Annexin A1; Glucocorticoid Receptor	FDA Approved
T0208	Prednisolone phosphate sodium	Glucocorticoid Receptor	FDA Approved
T0188	Fluticasone propionate	ER; Mineralocorticoid Receptor; Glucocorticoid Receptor; Cytosolic PLA2	FDA Approved
T0181	Loteprednol etabonate	Glucocorticoid Receptor	FDA Approved
T0107	Halcinonide	Glucocorticoid Receptor	FDA Approved
T0094	Budesonide	Glucocorticoid Receptor	FDA Approved
T0083	Eplerenone	Mineralocorticoid Receptor	FDA Approved
T0034	Cortisone acetate	Glucocorticoid Receptor	FDA Approved

GPR

ID	Product Name	Target	Condition
TQ0108	MK-6892	GPR109A	
TP1666L	Kisspeptin-10, rat acetate(478507-53-8 free base)	GPR54	Phase 3
TP1345	Kisspeptin-10, human (TFA) (374675-21-5, FREE)	GPR54	
TN2268	Tetrahydromagnolol	Cannabinoid Receptor; GPR; GABA	
T8901	YUM70	GRP78	
T8353	Pamoic acid	GPR35	
T8329	AR 231453	GPR119	
T7713	Benzylnicotinate	GPR109	
T7482	3-chloro-5-hydroxybenzoic Acid	GPR81	
T7359	CAY10471 Racemate	CRTh2 (DP2) receptor	
T7261	Grp94 Inhibitor-1	Grp94	
T7127	DC260126	GPR40	
T7010	VER155008	HSP70; HSC70; GRP78	
T6855	HA15	GRP78; HSPA5; BiP	
T6399	AZD1981	CRTh2 (DP2) receptor	Phase 2
T5828	MS21570	GPR171	
T5036	cangrelor tetrasodium	GPR17	FDA Approved
T4689	Palosuran hydrochloride 540769-28-6(free base)	Urotensin Receptor (GPR14)	Phase 2
T4626	TC-O 9311	hGPR139	
T4566	Lodoxamide	Histamine Receptor	FDA Approved
T4312	GPR120 receptor agonist	GPR120	

ID	Product Name	Target	Condition
T3965	Fevipirant	CRTh2	Phase 3
T3520	Setipirant	CRTh2	Phase 2
T3433	TUG891	GPR120	
T3176	APD597	GPR119	Phase 1
T3171	GSK137647A	GPR120	
T3119	JNJ63533054	hGPR139	
T2701	GSK1292263	GPR119	Phase 2
T2664	Timapirant	DP2	Phase 3
T2528	Latanoprost	prostanoid selective FP receptor; retinoid X receptor α	FDA Approved
T2396	Ramatroban	CRTh2; TXA2R	Approved
T2351	TAK875	GPR40(FFA1)	Phase 3
T2088	APD 668	GPR119	Phase 1
T2036	GTPL5846	GPR84	
T1915	AM251	CB1; GPR55	
T1793	MBX2982	GPR119	Phase 1
T1781	GW 9508	GPR120; GPR40(FFA1)	
T1237	Azathioprine	HGPRT; Rac1	FDA Approved
T11560	hGPR91 antagonist 1	HGPR91	

LHRH

ID	Product Name	Target	Condition
T3538	Sufugolix	human LHRH; monkey LHRH	Phase 1

Opioid Receptor

ID	Product Name	Target	Condition
TWS0414	Cannabidiol	GPR55 antagonist; CB1 antagonist; CB2 inverse agonist; VR1	FDA Approved
TQ0267	Endomorphin-1	μ -opioid receptor	
TP2050L	CTAP(TFA)	δ -opioid receptor	
TP2036L	DPDPE TFA	δ -opioid receptor	
TP1905	DADLE	δ -opioid receptor	
TP1832	Gluten Exorphin C	δ -opioid receptor; μ -opioid receptor	
TP1813L	Dynorphin A 1-10 acetate(79994-24-4 free base)	κ -opioid receptor	
TP1793L	Nociceptin (1-13) amide TFA	Opioid receptor-like1 (ORL1)	
TP1367	[D-Ala2]leucine-enkephalin	Opioid Receptor	
TP1254	[Met5]-Enkephalin, amide TFA	δ and ζ opioid receptor	
TP1179L	Porcine dynorphin A(1-13) acetate(72957-38-1 free base)	κ -opioid receptor	
TP1071	Nociceptin	Opioid Receptor	

ID	Product Name	Target	Condition
T8571	ML-184	GPR55	
T8557	N-terminally acetylated Leu-enkephalin	Opioid Receptor	
T8455	Spinorphin	enkephalin degrading enzymes	
T7665	[Leu5]-Enkephalin TFA(58822-25-6(free bas))	δ-opioid receptor; Human Endogenous Metabolite	
T7639	Deltorphin 2(TFA)	δ-opioid receptor	
T7637	Deltorphin I(TFA)	δ-opioid receptor	
T7613	β-Casomorphin, human(TFA)	Opioid Receptor	
T7576L	β-Casomorphin, bovine TFA(72122-62-4(free base))	Opioid Receptor	
T7567L	Adrenorphin 3TFA(88377-68-8(free base))	μ-opioid receptor	
T7218	Endomorphin 2	μ-opioid receptor	
T7211	Tyr-Gly-Gly-Phe-Met-OH	Opioid Receptor	
T6553	JTC801	Opioid receptor-like1 (ORL1)	Phase 2
T6221	Nalmefene hydrochloride	Opioid Receptor	FDA Approved
T6175	ADL5859 HCl	δ-opioid receptor; κ-opioid receptor; μ-opioid receptor	Phase 2
T5167	Cebranopadol	Opioid Receptor; NOP	Phase 2
T5158	N-Desmethylclozapine	5-HT2C; D4; δ-opioid receptor	Phase 2
T4691	Asimadoline hydrochloride	κ-opioid receptor	Phase 2
T4478	CID 16020046	GPR55	
T4411	DAMGO TFA (78123-71-4(Free base))	μ-opioid receptor	
T4407	SR17018	μ-opioid receptor	
T4386	PZM21	μ opioid receptor	
T4351	DAMGO	μ-opioid receptor	
T4236	AR-M 1000390 hydrochloride	δ-opioid receptor	Preclinical
T3417	Amentoflavone	COX; COX-2; κ-opioid receptor; CYP2C9; CYP3A4; PLA2	
T2870	(+)-Matrine	κ-opioid receptor	
T2388	Nalfurafine hydrochloride	κ-opioid receptor	Approved
T21422	Methylnaltrexone bromide	μ-opioid receptor	FDA Approved
T2071	MCOPPB trihydrochloride	Opioid Receptor	
T20435L	Leuphasyll TFA	δ-opioid receptor	
T1407	L-Menthol	Opioid Receptor; κ-opioid receptor	FDA Approved
T13414	ZT 52656A hydrochloride	kappa opioid receptor	
T1242	Alvimopan	μ-opioid receptor	FDA Approved
T0981	Noscapine hydrochloride	Opioid alkaloid	Approved
T0963	Naltrexone hydrochloride	Opioid Receptor	FDA Approved
T0929	Docusate sodium	Opioid Receptor	Approved
T0918	Trimebutine	Opioid Receptor	Approved

ID	Product Name	Target	Condition
T0783	Mianserin hydrochloride	5-HT; HT; Sert (Sodium-dependent); Adrenergic Receptor; DA transporter; Dopamine; Noradrenaline transporter (Sodium-dependent)κ-opioid receptor	Approved
T0478	Progesterone	ER; κ-opioid receptor	FDA Approved
T0209	Loperamide hydrochloride	δ-opioid receptor; κ-opioid receptor; κ-opioid receptor; μ-opioid receptor	FDA Approved
T0201	Meptazinol hydrochloride	Opioid Receptor	Approved
T0137	Mirtazapine	5-HT; HT; Sert (Sodium-dependent); Adrenergic Receptor; DA transporter; Dopamine; κ-opioid receptor	FDA Approved
T0102	Naloxone hydrochloride	Opioid Receptor	FDA Approved

Oxytocin Receptor

ID	Product Name	Target	Condition
T7601	Carbetocin	Oxytocin Receptor	Approved
T5148	Atosiban acetate	Oxytocin Receptor	Approved
T5145	Oxytocin acetate	Oxytocin Receptor	FDA Approved
T11857	LIT-001	oxytocin receptor	

RAAS

ID	Product Name	Target	Condition
TP1828	N-Acetyl-Ser-Asp-Lys-Pro	ACE	
TP1622	DX600 TFA	ACE2	
TP1187	CNP (1-22), human	Angiotensin Receptor	
TP1016L	Aviptadil Acetate	ACE	
T8560	Angiotensin II acetate	angiotensin AT1 receptor	FDA Approved
T8270	Deserpidine	ACE	Approved
T7808	Alacepril	Angiotensin Receptor	Approved
T7797	Tasosartan	AT2 receptor	
T7743	ANGIOTENSIN IV TFA(12676-15-2(free base))	angiotensin AT1 receptor	
T7668	VTP-27999 TFA	Renin	
T7616L	A 779 3TFA(159432-28-7(free base))	Angiotensin Receptor	
T7577	Angiotensin III, human, mouse(3TFA)	angiotensin II receptor	
T7510	Leucylarginylproline	ACE	
T7354	H-Val-Pro-Pro-OH	ACE	
T7339	Angiotensin 1-7	ACE	
T7040	Angiotensin II human	AT receptor	FDA Approved
T6716	Valsartan	angiotensin II receptor	FDA Approved
T6698	Temocapril HCl	ACE	Approved

ID	Product Name	Target	Condition
T6595	Moexipril HCl	ACE	FDA Approved
T6542	Imidapril HCl	ACE	Approved
T6486	Enalapril Maleate	ACE	FDA Approved
T6340	Enalaprilat Dihydrate	ACE	FDA Approved
T6219	Azilsartan Medoxomil	AT1 receptor	FDA Approved
T6133	Remodelin hydrobromide	acetyl-transferase NAT10	
T6067	PD123319	AT2 receptor	
T5964	Olmesartan	angiotensin II receptor	FDA Approved
T5796	Plantainoside D	ACE; PKC	
T5701	OPHIOPOGONIN D	angiotensin II receptor	
T5355	Sparsentan	angiotensin II receptor; Endothelin A receptor	Phase 3
T5030	Zofenopril (calcium)	ACE	Approved
T4431	EMA401	angiotensin II receptor	Phase 2
T3851	Vicenin -2	ACE	
T3753	Sinapinic Acid	ACE; HDAC	
T3461	Losartan Carboxylic Acid	AT1 receptor	Preclinical
T3281	Delapril Hydrochloride	ACE	Approved
T2531	Eprosartan Mesylate	AT1 receptor	FDA Approved
T2400	Candesartan Cilexetil	angiotensin II receptor	FDA Approved
T2322	Fimasartan	AGTR1	Approved
T2321	Protodioscin	Androgen Receptor	
T2318	LCZ696	RAAS	FDA Approved
T2270	Trans-Tranilast	Angiotensin Receptor	Approved
T21418	Lisinopril	ACE	FDA Approved
T1940	BTB06584	ATPase; Acetohydroxyacid synthase	
T1645	Ramipril	ACE	FDA Approved
T1615	Irbesartan	AT1 receptor	FDA Approved
T1570	Telmisartan	angiotensin II type 1 receptor	FDA Approved
T1520	Aliskiren hemifumarate	Renin	FDA Approved
T1518	Olmesartan Medoxomil	angiotensin II receptor	FDA Approved
T1489	Fosinopril sodium	ACE	FDA Approved
T1484L	Perindopril erbumine	MRP1; ACE	FDA Approved
T1462	Captopril	ACE	FDA Approved
T1461	Candesartan	AT1 receptor	FDA Approved
T13865	Resorcinolnaphthalein	ACE2	
T1057	Azilsartan	AT1 receptor	FDA Approved
T0805	Quinapril hydrochloride	ACE	FDA Approved
T0706	Lisinopril dihydrate	MRP1; ACE	FDA Approved
T0215L	Losartan	AT1 receptor	FDA Approved
T0215	Losartan potassium	AT1 receptor	FDA Approved
T0180	Benazepril hydrochloride	ACE	FDA Approved


Reductase

ID	Product Name	Target	Condition
TN2601	12-O-Methylcarnosic acid	5- α reductase	
T6S2384	Poliumoside	Aldose reductase	
T6S0840	Engeletin	Aldose reductase	
T6102	2'-acetylacteoside	Aldose reductase; Antioxidant	
T5813	BYAKANGELICIN	Aldose reductase	
T5195	Alrestatin	Aldose reductase	Phase 2
T5015	Gonadorelin Acetate	5- α reductase	FDA Approved
T4918	DL-Glyceraldehyde	Aldose reductase	
T3915	Ginsenoside Ro	5- α reductase	
T3665	Tectoridin	Aldose reductase	
T2013	Ponalrestat	Aldose reductase	Preclinical
T1499	Dutasteride	5- α reductase	FDA Approved
T1458	Epalrestat	Aldose reductase	Approved
T0725	Isoliquiritigenin	Aldose reductase	Approved
T0488	Finasteride	5- α reductase	FDA Approved

Thyroid hormone receptor (THR)

ID	Product Name	Target	Condition
T7578	reverse T3	Thyroid hormone	
T5360	Eprotirome	THR	Phase 3
T5313	Sobetirome	TR β	Phase 1/2
T4461	3,5-Diiodo-L-thyronine	THR	
T3595	MGL3196	THR- β	Phase 2
T22355	Levothyroxine sodium	Thyroid Hormone	FDA Approved
T1669	Liothyronine sodium	TR α ; TR β	FDA Approved
T1653	O-(4-Hydroxy-3-iodophenyl)-3,5-diiodo-L-tyrosine	TR α ; TR β	FDA Approved
T1604	Tiratricol	Thyroid hormone	Approved
T15699	L-Thyroxine sodium salt pentahydrate	Thyroid Hormone	FDA Approved
T1310	Deracil	Thyroid peripheral conversion	Approved
T1309	Propylthiouracil	Thyroid peripheral conversion	FDA Approved
T13072	Taltirelin acetate	THR	Approved
T0952	Carbimazole	Thyroid peroxidase	Approved
T0864	L-Thyroxine	Thyroid hormone	FDA Approved
T0840	Methimazole	Thyroid peripheral conversion	FDA Approved

GPCR/G Protein



5-HT Receptor

ID	Product Name	Target	Condition
TQ0084	Lumateperone Tosylate	5-HT2A antagonist; SERT	FDA Approved
TN1740	Homoeriodictyol	GLUT; 5-HT Receptor; Sodium Channel	
TN1032	Geissoschizine methyl ether	5-HT1A	
TJS0341	7-Amino-4-(trifluoromethyl) coumarin	HTR1E	
T8757	R-Lorcaserin hydrochloride hemihydrate	5-HT2C	
T8737	GR 125743	5-HT1B/1D	
T8720	PRX-07034	5-HT6	
T8702	SKF-83566	D1; D5; 5-HT2	
T8666	Naratriptan	5-HT1	FDA Approved
T8593	RU 24969	5-HT	
T8475	3-AQC	5-HT3	

ID	Product Name	Target	Condition
T8445	PU-02	5-HT3	
T8441	Lerisetron	5-HT3	
T8438	4i	5-HT3	
T8413	Lasmiditan succinate	5-HT	FDA Approved
T8398	Lasmiditan hydrochloride	5-HT	FDA Approved
T8357	SB-200646	5-HT2B; 5-HT2C	
T8140	Tianeptine	5-HT	Approved
T8136	Perospirone hydrochloride	5-HT	Approved
T8128	Mosapride	5-HT	Approved
T7694	6-fluoro-DL-Tryptophan	5-HT	
T7521	Azaphen	serotonin reuptake	
T7519	RS 127445	5-HT2B	
T7412	Tandospirone citrate	5-HT	Approved
T7350	Nelotanserin	5-HT	Phase 2
T7281	F-15599	5-HT1A	
T7277	SB 242084 dihydrochloride hydrate	5-HT2C	
T7135	Phenylbiguanide	5-HT3	
T7103	idalopirdine	5-HT6	
T6S0654	Isocorynoxetine	5-HT	
T6973	RS127445	5-HT2B; 5-HT2B	Preclinical
T6959	PRX-08066 Maleic acid	5-HT2B	
T6958	Prucalopride Succinate	5-HT4A ; 5-HT4B	FDA Approved
T6946	Pimavanserin tartrate	5-HT2A	FDA Approved
T6814	Cyproheptadine HCl	HT	FDA Approved
T6728	VUF 10166	5-HT3A; 5-HT3AB	
T6616	Ondansetron HCl	5-HT3	FDA Approved
T6615	Ondansetron	5-HT3 receptor; 5-HT	FDA Approved
T6602	Naratriptan hydrochloride	5-HT1	FDA Approved
T6600	Naftopidil DiHCl	5-HT1A; α 1-adrenergic receptor	Approved
T6597	Mosapride Citrate	5-HT4	Approved
T6493	Escitalopram Oxalate	SSRI; 5-HT	FDA Approved
T6488	Epinastine HCl	HT	FDA Approved
T6461	Dapoxetine HCl	5-HT	Approved
T6426	Buclicline HCl	HT; Cholinergic	
T6423	BRL-15572 dihydrochloride	5-HT1A; 5-HT1D; 5-HT2A; 5-HT2B; 5-HT7	
T6241	Quetiapine Fumarate	HT; Adrenergic Receptor; Dopamine	FDA Approved
T6232	Vilazodone HCl	5-HT1A; SSRI	FDA Approved
T6188	Desvenlafaxine succinate hydrate	5-HT; Norepinephrine (NE)	FDA Approved
T5S1389	Escin IB	5-HT Receptor; NO	

ID	Product Name	Target	Condition
T5858	Sertindole	D2; 5-HT	Approved
T5389	Volinanserin	5-HT2	Phase 3
T5387	LP-211	5-HT7; D2 receptor; 5-HT1A receptor	
T5380	Ansofaxine hydrochloride	serotonin reuptake; dopamine reuptake; norepinephrine reuptake	
T5336	Zacopride hydrochloride	5-HT3 antagonist; 5-HT4 agonist; IK1/Kir2.1 agonist	
T5271	5-Methoxytryptamine	5-HT	
T5179	AVN492	5-HT6; 5-HT6R	
T5158	N-Desmethylclozapine	5-HT2C; D4; δ -opioid receptor	Phase 2
T4S1659	Xanthotoxol	5-HT Receptor	
T4978	Sarpogrelate hydrochloride	5-HT2; 5-HT2A	Approved
T4577	Cariprazine	D3; D2; 5-HT1A	FDA Approved
T4576	Perospirone	5-HT2A; D2; 5-HT1A	Approved
T4568	Dolasetron	5-HT3	FDA Approved
T4562	Ramosetron	5-HT3	Approved
T4560	Alprenolol	β -adrenergic receptor; 5-HT	Approved
T4494	CLOZAPINE N-OXIDE	5-HT	
T4305	8-OH-Dpat	5-HT1A,5-HT7	
T4297	Flibanserin	5-HT1A; 5-HT2A; D4 receptor	FDA Approved
T4266	LY 334370	5-HT1F	
T4008	Metergoline	5-HT1; 5-HT2; 5-HT2; 5-HT2; 5-HT7	Approved
T3S0478	Scopolamine	muscarinic receptor; 5-HT3	FDA Approved
T3704	Lasmiditan	5-HT1F	FDA Approved
T3648	YL0919	5-HT; 5-HT1A	
T3526	Dasotraline hydrochloride	5-HT; Dopamine; Norepinephrine (NE)	Phase 3
T3497	Ocaperidona	D2; 5-HT2	Phase 2
T3431	Pardoprunox hydrochloride	5-HT1A; D2; D3	Phase 3
T3369	Nuciferine	5-HT2A; 5-HT2B; 5-HT2C; 5-HT7; D5 receptor	
T3275	Nefazodone hydrochloride	5-HT	FDA Approved
T3269	Metadoxine	5-HT2B	Approved
T3179	Eptapirone	5-HT1A	Phase 1
T3085	Piperacetazine	5-HT; Dopamine	FDA Approved
T3046	BMY 7378 dihydrochloride	5-HT1A; 5-HT1C; α 1D-adrenoceptor; α 2C-adrenoceptor; D2	Preclinical
T2S0007	Sodium ferulic	5-HT Receptor	Approved
T2874	Tetrahydroberberine THB	5-HT; Dopamine	
T2815	Puerarin	5-HT	Approved
T2714	Rotundine	5-HT1A; D1; D2; D3	
T2688	LY310762	5-HT1D	
T2631	WAY-100635 Maleate	5-HT	Preclinical
T2599	Pirenperone	5-HT2	

ID	Product Name	Target	Condition
T2589	Dalasetron Mesylate Hydrate	5-HT3	FDA Approved
T2565	Hesperetin	HT; TGFβ	Approved
T2542	Prucalopride	5-HT4A; 5-HT4B	FDA Approved
T2525	Alosetron hydrochloride	5-HT3	FDA Approved
T2459	BRL54443	5-HT1A; 5-HT1B; 5-HT1D; 5-HT1E; 5-HT1F	
T2428	TG6-10-1	5-HT2B	
T2402	Tianeptine sodium	5-HT	Approved
T2395L	Vortioxetine HBr	5-HT1A; 5-HT1B; 5-HT3A; 5-HT7; SERT	FDA Approved
T2395	Vortioxetine	5-HT1A; 5-HT1B; 5-HT3A; 5-HT7; SERT	FDA Approved
T2344	LY344864	5-HT1F	Preclinical
T2317	Almotriptan Malate	5-HT1B/1D	FDA Approved
T2306	Brexpirazole	5-HT1A; 5-HT2A; α1B-adrenergic receptor; α2C receptors; D2L	FDA Approved
T2289	RU 24969 hemisuccinate	5-HT1A; 5-HT1B	Preclinical
T2278	Piboserod	5-HT4	Phase 2
T22379L	NLX-204 hydrochloride (2170405-10-2 free base)	5-HT1A	
T22359	MDL 100009	5-HT2A	
T2226	Pergolide mesylate salt	5-HT receptor; Adrenergic receptor; Dopamine receptor	FDA Approved
T22236	Alprenolol hydrochloride	5-HT1A	
T2209	Serotonin hydrochloride	5-HT; COMT	Approved
T2190	Methiothepin mesylate	5-HT; Dopamine	
T21337	Lurasidone	5-HT7; 5-HT1A; D2	FDA Approved
T2132	Buspiron hydrochloride	5-HT; Dopamine	FDA Approved
T21231	Almotriptan	5-HT1B/1D	FDA Approved
T21013	Clomipramine	5-HT	FDA Approved
T2092	Amitifadine hydrochloride	5-HT; Dopamine; Norepinephrine (NE)	Phase 2/3
T2076	Pimavanserin	5-HT2A	FDA Approved
T1951	Asenapine Maleate	5-HT2A; 5-HT2B; 5-HT2C; 5-HT6; 5-HT7	FDA Approved
T1774	SB 742457	5-HT6	Phase 3
T1735	Lurasidone hydrochloride	5-HT1A; 5-HT2A; 5-HT7; D2; Norepinephrine α2C	FDA Approved
T1644	Dopamine hydrochloride	5-HT; DA transporter; Dopamine	FDA Approved
T16421	p-MPPI hydrochloride	5-HT1A	
T1636	Paroxetine hydrochloride	5-HT; AChR; GRK2	FDA Approved
T1619	Trazodone hydrochloride	5-HT; Sert (Sodium-dependent); Adrenergic Receptor; H1 receptor	FDA Approved
T1580	Desvenlafaxine	5-HT; Norepinephrine (NE)	FDA Approved
T1567	Olanzapine	5-HT; HT; mAChR; Adrenergic Receptor; Dopamine	FDA Approved
T1566	Aripiprazole	5-HT1A	FDA Approved
T1551	Tegaserod maleate	5-HT; Sert (Sodium-dependent)	FDA Approved

ID	Product Name	Target	Condition
T1540	Doxepin hydrochloride	5-HT; HT; Sert (Sodium-dependent); mAChR; Adrenergic Receptor; Dopamine; Noradrenaline transporter (Sodium-dependent)	FDA Approved
T1528	Azasetron hydrochloride	5-HT3	Approved
T1512	Rizatriptan benzoate	5-HT	FDA Approved
T1509	Cyclobenzaprine hydrochloride	5-HT	FDA Approved
T1483	Citalopram HBr	5-HT	FDA Approved
T1478	Ondansetron hydrochloride	5-HT3	FDA Approved
T1471	Duloxetine hydrochloride	Sert (Sodium-dependent); DA transporter; Noradrenaline transporter (Sodium-dependent)	FDA Approved
T1445	Agomelatine	5-HT	Approved
T1442	Pizotifen	5-HT	Approved
T1412	Loxapine succinate salt	5-HT2 (bovine); 5-HT2 (bovine); 5-HT2 (human); D2; D4	FDA Approved
T1384	Chlorpromazine hydrochloride	5-HT2A; D2	FDA Approved
T1327	Nortriptyline hydrochloride	5-HT; Sert (Sodium-dependent); mAChR; Adrenergic Receptor; Dopamine; H1 receptor; Noradrenaline transporter (Sodium-dependent)	FDA Approved
T1317	Cinchonidine	SERT	Approved
T1291	Cisapride	5-HT; Potassium Channel; hERG channel	FDA Approved
T12899L	SEP-363856 hydrochloride	5-HT1A Receptor; 5-HT1B Receptor; 5-HT1D Receptor; 5-HT2A Receptor; 5-HT2C Receptor; 5-HT7 Receptor; TAAR1	
T1279	Vilazodone	5-HT; Sert (Sodium-dependent)	FDA Approved
T12773	RS102895 hydrochloride	CCR2; CCR1; Human α 1a receptor; Human α 1d receptor; 5-HT1A	
T1266	Terfenadine	HT; mAChR; Potassium Channel; hERG	Approved
T1180	Blonanserin	5-HT2; D2	Approved
T1173	Tropisetron hydrochloride	5-HT	Approved
T1170	Olopatadine hydrochloride	HT	FDA Approved
T1156	Palonosetron hydrochloride	5-HT	FDA Approved
T1092	Zolmitriptan	5-HT	FDA Approved
T1090	Perphenazine	CAM; Dopamine; 5-HT2A receptor; Histamine H1 receptor; Alpha-1A adrenergic receptor	FDA Approved
T1081	Nafronyl oxalate	5-HT	Approved
T1077	Fluvoxamine maleate	5-HT	FDA Approved
T1069	Metoclopramide hydrochloride	5-HT; mAChR; Dopamine	FDA Approved
T1066	Ketanserin	5-HT2A; 5-HT2C (Human); 5-HT2C (Rat)	Approved
T1045	Trimipramine maleate	5-HT; Sert (Sodium-dependent); Adrenergic Receptor; DA transporter; Dopamine; H1 receptor; Noradrenaline transporter (Sodium-dependent)	FDA Approved
T1042	Granisetron hydrochloride	5-HT	FDA Approved
T0991	Desipramine hydrochloride	5-HT; Adrenergic Receptor	FDA Approved
T0965	Histamine	HT	FDA Approved

ID	Product Name	Target	Condition
T0869	Atomoxetine hydrochloride	5-HT; DA transporter; Norepinephrine (NE) transporter	FDA Approved
T0811	Amisulpride	5-HT; Dopamine	FDA Approved
T0802	Procaine hydrochloride	5-HT3; nAChR; NMDA receptor; Sodium channel	FDA Approved
T0785	Dexchlorpheniramine Maleate	Sert (Sodium-dependent); DA transporter; H1 receptor; Noradrenaline transporter (Sodium-dependent)	FDA Approved
T0783	Mianserin hydrochloride	5-HT; HT; Sert (Sodium-dependent); Adrenergic Receptor; DA transporter; Dopamine; Noradrenaline transporter (Sodium-dependent)κ-opioid receptor	Approved
T0766	Promazine hydrochloride	5-HT; mAChR; Adrenergic Receptor; Dopamine	FDA Approved
T0723	Cloperastine hydrochloride	HT	Approved
T0716	Molindone hydrochloride	5-HT; mAChR; Dopamine	FDA Approved
T0680	Lamotrigine	5-HT (human platelets); 5-HT (rat brain synaptosomes)	FDA Approved
T0678	Amitriptyline hydrochloride	5-HT; 5-HT2; 5-HT4; Norepinephrine receptor; σ1	FDA Approved
T0663	2-Bromo-6-methoxynaphthalene	Sert (Sodium-dependent)	
T0647	Tryptamine	5-HT; AADH; hTRPA1	
T0525	Flopropione	5-HT1A	Approved
T0482	Sertraline hydrochloride	5-HT	FDA Approved
T0472	Venlafaxine hydrochloride	5-HT	FDA Approved
T0450L	Fluoxetine hydrochloride	5-HT; Sert (Sodium-dependent)	FDA Approved
T0450	Fluoxetine	Sert (Sodium-dependent); MRP1	FDA Approved
T0445	Promethazine	5-HT; mAChR; Adrenergic Receptor; CAM; D2; H1 receptor	FDA Approved
T0428	Alverine citrate	5-HT	Approved
T0370	Pheniramine maleate	HT	Approved
T0365	Thioridazine hydrochloride	5-HT; Adrenergic Receptor; Dopamine; Potassium Channel	FDA Approved
T0351	Risperidal	5-HT2A; α2C-adrenergic receptor; D2; D2L; D3	FDA Approved
T0333	Aniracetam	5-HT; Dopamine; AMPA; GluR	Approved
T0318	Ataractan	5-HT	
T0302	Triflupromazine hydrochloride	5-HT; mAChR; Dopamine	FDA Approved
T0255	Clomipramine hydrochloride	5-HT; Sert (Sodium-dependent); GSTP; Noradrenaline transporter (Sodium-dependent); dopamine transporter (DAT)	FDA Approved
T0236	Azatadine Maleate	HT; Cholinergic	FDA Approved
T0225	Pizotifen Malate	5-HT	Approved
T0217	Levodropropizine	HT	Approved
T0216	Eletriptan HBr	5-HT1B; 5-HT1D	FDA Approved
T0205	Brompheniramine hydrogen maleate	HT	FDA Approved
T0204	Protriptyline hydrochloride	Sert (Sodium-dependent)	FDA Approved
T0203	Sumatriptan succinate	5-HT	FDA Approved
T0174	Cyproheptadine hydrochloride	5-HT2; SETD7; SETD9	FDA Approved

ID	Product Name	Target	Condition
T0172	Maprotiline hydrochloride	5-HT; mAChR; Adrenergic Receptor; H1 receptor; Noradrenaline transporter (Sodium-dependent)	FDA Approved
T0165	Urapidil	5-HT; α 1-adrenergic receptor	Approved
T0137	Mirtazapine	5-HT; HT; Sert (Sodium-dependent); Adrenergic Receptor; DA transporter; Dopamine; κ -opioid receptor	FDA Approved
T0113	Mebhydrolin napadisylate	HT; mAChR	Approved
T0088	Urapidil hydrochloride	5-HT; α -adrenergic receptor	Approved
T0081	Lafutidine	HT	Approved
T0076	Paliperidone	5-HT; β -adrenergic receptor; Dopamine; H1 receptor	FDA Approved
T0074L	Chlorprothixene hydrochloride	5-HT; mAChR; Dopamine; H1 receptor	FDA Approved
T0074	Chlorprothixene	5-HT6; 5-HT7; D2; D3; H1 receptor	FDA Approved
T0031L2	Ziprasidone	5-HT transporter; 5-HT1A; 5-HT1B; 5-HT1D; 5-HT2A; 5-HT2C; 5-HT6; 5-HT7; α 1A-adrenergic receptor; α 2A-adrenergic receptor; D1; D2; D3; H1 receptor; norepinephrine transporter (NET)	FDA Approved
T0031L	Ziprasidone hydrochloride	5-HT transporter; 5-HT1A; 5-HT1B; 5-HT1D; 5-HT2A; 5-HT2C; 5-HT6; 5-HT7; α 1A-adrenergic receptor; α 2A-adrenergic receptor; D1; D2; D3; H1 receptor; norepinephrine transporter (NET)	FDA Approved
T0031	Ziprasidone hydrochloride monohydrate	5-HT transporter; 5-HT1A; 5-HT1B; 5-HT1D; 5-HT2A; 5-HT2C; 5-HT6; 5-HT7; α 1A-adrenergic receptor; α 2A-adrenergic receptor; D1; D2; D3; H1 receptor; norepinephrine transporter (NET)	FDA Approved
T0025	Haloperidol	5-HT; Dopamine	FDA Approved

Adenosine Receptor

ID	Product Name	Target	Condition
T8613	1-Ethyl-6-aminouracil	A2B adenosine receptor	
T8598	CHEMBL241987	A3	
T8512	BAY-545	A2B adenosine receptor	
T8312	Derenofylline	A1	Phase 2
T7683	Adenosine amine congener	A1	
T7509	PD 117519	A2	
T7320	Tozadenant	adenosine A2A	Phase 3
T7188	Piclidienoson	A3	Phase 3
T7183	CPI-444	A2A	Phase 1/2
T7021	ZM241385	A2A	Preclinical
T6979	SCH58261	A2A (bovine); A2A (rat); A2A (rat)	Phase 2
T6884	2-Cl-IB-MECA	A3	Phase 2
T6552	Istradefylline	A2A	FDA Approved
T6441	CGS 21680 HCl	A2	Preclinical
T6115	Fostamatinib	Adenosine transporter; A3; Monoamine transporter; Syk	FDA Approved

ID	Product Name	Target	Condition
T4290	Preladenant	A2A	Phase 1/2
T4265	AZD4635	A2A	Phase 2
T2671	Regadenoson	A2A	FDA Approved
T2373	Vipadenant	A1; A2A; A3	Preclinical
T23336	SCH 442416	A2A	
T2205	Theophylline-7-acetic acid	A1; A2; A3; HDAC2; PDE4; PKA; TNF- α	Approved
T1825	Reversine	A3; Aurora A; Aurora B; Aurora C	
T14078	AB928	A2aR/A2bR	Phase 1/2
T0070	Pentoxifylline	A2; PDE	FDA Approved

Adiponectin Receptor

ID	Product Name	Target	Condition
T6519	Gramine	Adiponectin Receptor; Adrenergic Receptor	
T2257	AdipoRon	AdipoR1; AdipoR2	

Adrenergic Receptor

ID	Product Name	Target	Condition
T8810	Terbutaline	β 2-adrenergic receptor	FDA Approved
T8738	LUN42518 HCl 47142-51-8 (free base)	α -adrenergic receptor	
T8696	Propranolol hydrochloride	β 1-adrenergic receptor; β 2-adrenergic receptor	FDA Approved
T8663	nifenalol.HCl	β -adrenergic receptor	
T8595	Practolol	β -adrenoceptor	
T8580	Bupranolol	β 2-adrenergic receptor	
T8358	Fenoterol	β 2-adrenergic receptor	Approved
T8348	Phentolamine	α 1-adrenergic receptor; α 2-adrenergic receptor	FDA Approved
T8149	Dobutamine (hydrochloride)	Adrenergic Receptor	FDA Approved
T8143	Bevantolol hydrochloride	β 1-adrenoceptor	Approved
T7164	Levalbuterol tartrate	β 2-adrenergic receptor	Approved
T7160	Lofexidine	α 2 receptor	FDA Approved
T7079	Batefenterol	β 2-adrenoceptor	Phase 2
T7046	Xylazine	α 2 adrenergic receptor	
T7044	Norepinephrine	MMP-2; MMP-9; α 2A adrenoceptor; α 1 adrenoceptor; β 1 adrenoceptor	FDA Approved
T6872	L755507	β 3-adrenergic receptor	Preclinical
T6765	Atipamezole hydrochloride	α 2-adrenoceptor antagonist	Approved
T6703	Tetrahydrozoline HCl	α -adrenergic receptor	FDA Approved
T6701	Terazosin hydrochloride dihydrate	α 1-adrenoceptor	FDA Approved

ID	Product Name	Target	Condition
T6688	Synephrine HCl	α -adrenergic receptor	
T6662	Scopine	α 1-adrenergic receptor	
T6653	Salmeterol Xinafoate	β 2-adrenergic receptor; WT β 2AR	FDA Approved
T6652	Salbutamol Sulfate	β 2-adrenergic receptor	FDA Approved
T6600	Naftopidil DiHCl	5-HT1A; α 1-adrenergic receptor	Approved
T6579	Medetomidine HCl	α 2-adrenoceptor	Approved
T6565	Levobetaxolol HCl	β 1-adrenergic receptor , β 2-adrenergic receptor	FDA Approved
T6522	Guanabenz Acetate	α 2A-adrenergic receptor; α 2B-adrenergic receptor; α 2C-adrenergic receptor	FDA Approved
T6519	Gramine	Adiponectin Receptor; Adrenergic Receptor	
T6505	Formoterol Hemifumarate	β 2-adrenergic receptor	FDA Approved
T6466	Dexmedetomidine HCl	α 2-adrenoceptor	FDA Approved
T6422	Brimonidine Tartrate	α 2A-adrenergic receptor	FDA Approved
T6408	Betaxolol	beta1 adrenergic receptor	FDA Approved
T6241	Quetiapine Fumarate	HT; Adrenergic Receptor; Dopamine	FDA Approved
T5S2178	Fargesin	β 1-adrenergic receptor	
T5471	GUANABENZ	α 2 adrenergic receptor	Approved
T5327	Amezinium (methylsulfate)	α -adrenergic receptor; β 1-adrenergic receptor	Approved
T5159	BI 1744 hydrochloride	β 2-adrenoceptor	FDA Approved
T5134	Vilanterol trifenate	β 2-adrenoceptor; β 1-adrenoceptor; β 3-adrenoceptor	FDA Approved
T5105	1-(2-Pyridyl)piperazine	α 2-adrenoceptor	
T5035	Methoxyphenamine Hydrochloride	β -adrenergic receptor	Approved
T5028	Landiolol hydrochloride	β 1-adrenergic receptor	Approved
T4S0998	Trifolirhizin	TNF- α	
T4983	Isoetharine mesylate salt	β -adrenergic receptor; PXR	FDA Approved
T4963	Higenamine	α 1-adrenergic receptor	
T4560	Alprenolol	β -adrenergic receptor; 5-HT	Approved
T4548	Procaterol hydrochloride	β 2-adrenergic receptor	Approved
T4526	Piperoxan hydrochloride	α 2 receptor	
T4429	Rauwolscine hydrochloride	α 2 adrenergic receptor	Approved
T3996	Dapiprazole Hydrochloride	α 1-adrenergic receptor	FDA Approved
T3457	Olodaterol	β 2-adrenoceptor	FDA Approved
T3284	Carazolol	β -adrenergic receptor	Approved
T3278	Piribedil	α 2-adrenergic; D2; D3	Approved
T3277	Tulobuterol hydrochloride	β 2-adrenergic receptor	Approved
T3232	Higenamine Hydrochloride	β 2-adrenergic receptor	Approved
T3165	Metoprolol Succinate	β 1-adrenergic receptor	FDA Approved
T3046	BMY 7378 dihydrochloride	5-HT1A; 5-HT1C; α 1D-adrenoceptor; α 2C-adrenoceptor; D2	Preclinical
T3033	Deoxycorticosterone acetate	Adrenergic Receptor	FDA Approved

ID	Product Name	Target	Condition
T2889	Isoferulic acid	Adrenergic Receptor	Approved
T2580	Formoterol	β 2-adrenergic receptor	FDA Approved
T2547	Droxidopa	Adrenergic Receptor	FDA Approved
T2546	Pimozide	D2; Potassium Channel; α 1-adrenoceptor	FDA Approved
T2535	Ivabradine hydrochloride	Adrenergic Receptor	FDA Approved
T2524	Dexmedetomidine	α 2 receptor	FDA Approved
T23283	RX 821002 hydrochloride	α 2-adrenoceptor	
T2320	Indacaterol	β -adrenoceptor; β 1-adrenoceptor; β 2-adrenoceptor	FDA Approved
T2306	Brexpiprazole	5-HT1A; 5-HT2A; α 1B-adrenergic receptor; α 2C receptors; D2L	FDA Approved
T2226	Pergolide mesylate salt	5-HT receptor; Adrenergic receptor; Dopamine receptor	FDA Approved
T2150	Guanfacine hydrochloride	α 2A-adrenoceptor; α 2B-adrenoceptors	FDA Approved
T2142	Yohimbine hydrochloride	α 2 adrenergic receptor	Approved
T21066	Norepinephrine bitartrate salt	Adrenergic Receptor	FDA Approved
T1738	Taxifolin	β -adrenergic receptor; TNF- α ; Collagenase Tyrosinase; Beta-nerve growth factor; VEGFR2	
T1696	2-(1-Piperazinyl)pyrimidine	α -adrenergic receptor	
T1680	Tolazoline hydrochloride	α -adrenergic receptor	FDA Approved
T1671	Mirabegron	β 3-adrenoceptor	FDA Approved
T1632	Amitraz	α -adrenergic receptor	Approved
T1619	Trazodone hydrochloride	5-HT; Sert (Sodium-dependent); Adrenergic Receptor; H1 receptor	FDA Approved
T1584	Terbutaline Sulfate	β 2-adrenergic receptor	FDA Approved
T1577	Midodrine hydrochloride	α 1-adrenergic receptor	FDA Approved
T1567	Olanzapine	5-HT; HT; mAChR; Adrenergic Receptor; Dopamine	FDA Approved
T1540	Doxepin hydrochloride	5-HT; HT; Sert (Sodium-dependent); mAChR; Adrenergic Receptor; Dopamine; Noradrenaline transporter (Sodium-dependent)	FDA Approved
T1539	lloperidone	α -adrenergic receptor; Dopamine	FDA Approved
T1504	Silodosin	β -adrenergic receptor	FDA Approved
T1503	Esmolol hydrochloride	β -adrenergic receptor	FDA Approved
T1500	Xylazine hydrochloride	α 2 adrenergic receptor	FDA Approved
T1496	Amiodarone hydrochloride	β -adrenergic receptor; Potassium Channel; ATP-sensitive potassium channel	FDA Approved
T1459	Cisatracurium besylate	AChR; Adrenergic Receptor	FDA Approved
T1446	Bambuterol hydrochloride	AChR; β -adrenergic receptor	Approved
T1433	Ritodrine hydrochloride	β -adrenergic receptor	FDA Approved
T1415	Gemfibrozil	PPAR α ; CYP2C9; 1A2	FDA Approved
T1327	Nortriptyline hydrochloride	5-HT; Sert (Sodium-dependent); mAChR; Adrenergic Receptor; Dopamine; H1 receptor; Noradrenaline transporter (Sodium-dependent)	FDA Approved
T13016	SR59230A	β 3-adrenoceptor	
T1287	Synephrine	Adrenergic Receptor	Approved

ID	Product Name	Target	Condition
T1282	Carteolol hydrochloride	β -adrenergic receptor	FDA Approved
T1275	Phentolamine mesilate	α -adrenergic receptor; α -adrenoceptor	FDA Approved
T12643	(R)-Terazosin	α 1a-adrenoceptor; α 1b-adrenoceptor ; α 1d-adrenoceptor	FDA Approved
T1247	Clonidine hydrochloride	α 2 adrenergic receptor	FDA Approved
T1239	Indacaterol maleate	β 1-adrenoceptor; β 2-adrenoceptor	FDA Approved
T1215	Nicardipine hydrochloride	mAChR; Adrenergic Receptor; Calcium Channel	FDA Approved
T1203	Nadolol	β -adrenergic receptor	FDA Approved
T1158	Phenoxybenzamine hydrochloride	α -adrenergic receptor; CAM	FDA Approved
T1139	Salbutamol	β -adrenergic receptor	FDA Approved
T1132	Nicergoline	Adrenergic Receptor	Approved
T11318	Dopexamine hydrochloride	β 2-adrenergic receptor	Phase 4
T10952	Dabuzalgron	α 1A-adrenergic receptor	
T1090	Perphenazine	CAM; Dopamine; 5-HT2A receptor; Histamine H1 receptor; Alpha-1A adrenergic receptor	FDA Approved
T1073	Dronedaron hydrochloride	Adrenergic Receptor; Calcium Channel; Potassium Channel; Sodium Channel	FDA Approved
T1071L2	DL-Adrenalin	α -adrenergic receptor	Approved
T1071L	DL-Adrenaline Hydrochloride	Adrenergic Receptor	FDA Approved
T1064	Noradrenaline bitartrate monohydrate	β 1-adrenergic receptor; β 1-selective adrenergic receptor	FDA Approved
T1056	Isoprenaline hydrochloride	Adrenergic Receptor; cAMP PDE; PI3K	FDA Approved
T1050	Prazosin hydrochloride	ABCG; Adrenergic Receptor; MRP1; Potassium Channel	FDA Approved
T1045	Trimipramine maleate	5-HT; Sert (Sodium-dependent); Adrenergic Receptor; DA transporter; Dopamine; H1 receptor; Noradrenaline transporter (Sodium-dependent)	FDA Approved
T1012	Acebutolol hydrochloride	β -adrenergic receptor	FDA Approved
T0993	Methoxamine hydrochloride	Adrenergic Receptor	FDA Approved
T0991	Desipramine hydrochloride	5-HT; Adrenergic Receptor	FDA Approved
T0970	Anisodamine	Adrenergic Receptor	Approved
T0948	Adrenalone hydrochloride	α 1-adrenergic receptor	Approved
T0871	Noradrenaline bitartrate	Adrenergic Receptor	FDA Approved
T0852	Carbazochrome sodium sulfonate	Adrenergic Receptor	Approved
T0812	Propranolol hydrochloride	β -adrenergic receptor	FDA Approved
T0783	Mianserin hydrochloride	5-HT; HT; Sert (Sodium-dependent); Adrenergic Receptor; DA transporter; Dopamine; Noradrenaline transporter (Sodium-dependent) κ -opioid receptor	Approved
T0766	Promazine hydrochloride	5-HT; mAChR; Adrenergic Receptor; Dopamine	FDA Approved
T0696	Naftopidil	α 1A-adrenergic receptor; α 1B-adrenergic receptor; α 1D-adrenergic receptor	Approved
T0487	Metoprolol tartrate	β -adrenergic receptor	FDA Approved

ID	Product Name	Target	Condition
T0483	Sotalol hydrochloride	β -adrenergic receptor; Potassium Channel	FDA Approved
T0475	Timolol Maleate	β 1-adrenergic receptor; β 2-adrenergic receptor	FDA Approved
T0455	Clozapine	M1 mAChR; α 2-adrenoceptor; D2	FDA Approved
T0453	Phenylephrine hydrochloride	α 1-adrenergic receptor	FDA Approved
T0447	Carvedilol	Adrenergic Receptor; HIF; E-selectin; NADPH; Vcam; Potassium Channel; VEGFR; LDL oxidation	FDA Approved
T0446	Naphazoline hydrochloride	Adrenergic Receptor	FDA Approved
T0445L	Promethazine hydrochloride	α -adrenergic receptor; H1 receptor	FDA Approved
T0445	Promethazine	5-HT; mAChR; Adrenergic Receptor; CAM; D2; H1 receptor	FDA Approved
T0397	Tetryzoline	α -adrenergic receptor	Approved
T0394	Moxisylyte hydrochloride	Adrenergic Receptor	Approved
T0365	Thioridazine hydrochloride	5-HT; Adrenergic Receptor; Dopamine; Potassium Channel	FDA Approved
T0351	Risperidal	5-HT2A; α 2C-adrenergic receptor; D2; D2L; D3	FDA Approved
T0348	Labetalol hydrochloride	α 1-adrenergic receptor	FDA Approved
T0342	Carvedilol phosphate	Adrenergic Receptor; Gap Junction Protein; E-selectin; NADPH dehydrogenase; Natriuretic peptides B; VCAM1; Potassium Channel; VEGFR; LDL oxidation	FDA Approved
T0324	Isoxsuprine hydrochloride	β -adrenergic receptor	Approved
T0317	Buflomedil hydrochloride	α -adrenergic receptor	Approved
T0290	Tizanidine hydrochloride	α 2 adrenergic receptor	FDA Approved
T0279	Metaraminol bitartrate	α -adrenergic receptor	FDA Approved
T0248	Clorprenaline hydrochloride	β -adrenergic receptor	Approved
T0226	Betaxolol hydrochloride	β 1-adrenergic receptor	FDA Approved
T0210	Tamsulosin hydrochloride	α 1A-adrenergic receptor; α 1B-adrenergic receptor; α 1D-adrenergic receptor	FDA Approved
T0197	Terazosin hydrochloride	α -adrenergic receptor	FDA Approved
T0173	Nylidrin hydrochloride	β -adrenergic receptor	Approved
T0172	Maprotiline hydrochloride	5-HT; mAChR; Adrenergic Receptor; H1 receptor; Noradrenaline transporter (Sodium-dependent)	FDA Approved
T0165	Urapidil	5-HT; α 1-adrenergic receptor	Approved
T0154	Nebivolol hydrochloride	β 1-adrenoceptor	FDA Approved
T0143	(\pm)-Bisoprolol hemifumarate	β 1-adrenergic receptor	FDA Approved
T0137	Mirtazapine	5-HT; HT; Sert (Sodium-dependent); Adrenergic Receptor; DA transporter; Dopamine; κ -opioid receptor	FDA Approved
T0115	Idazoxan hydrochloride	Adrenergic Receptor	Preclinical
T0103	Dipivefrin hydrochloride	AChR; Adrenergic Receptor	FDA Approved
T0101	Doxazosin mesylate	α 1-adrenergic receptor	FDA Approved
T0091	Alfuzosin hydrochloride	α -adrenergic receptor	FDA Approved
T0088	Urapidil hydrochloride	5-HT; α -adrenergic receptor	Approved

ID	Product Name	Target	Condition
T0076	Paliperidone	5-HT; β -adrenergic receptor; Dopamine; H1 receptor	FDA Approved
T0042	Xylometazoline hydrochloride	α 1A-adrenergic receptor; α 1B-adrenergic receptor; α 1D-adrenergic receptor; α 2A-adrenergic receptor; α 2B-adrenergic receptor	Approved
T0031L2	Ziprasidone	5-HT transporter; 5-HT1A; 5-HT1B; 5-HT1D; 5-HT2A; 5-HT2C; 5-HT6; 5-HT7; α 1A-adrenergic receptor; α 2A-adrenergic receptor; D1; D2; D3; H1 receptor; norepinephrine transporter (NET)	FDA Approved
T0031L	Ziprasidone hydrochloride	5-HT transporter; 5-HT1A; 5-HT1B; 5-HT1D; 5-HT2A; 5-HT2C; 5-HT6; 5-HT7; α 1A-adrenergic receptor; α 2A-adrenergic receptor; D1; D2; D3; H1 receptor; norepinephrine transporter (NET)	FDA Approved
T0031	Ziprasidone hydrochloride monohydrate	5-HT transporter; 5-HT1A; 5-HT1B; 5-HT1D; 5-HT2A; 5-HT2C; 5-HT6; 5-HT7; α 1A-adrenergic receptor; α 2A-adrenergic receptor; D1; D2; D3; H1 receptor; norepinephrine transporter (NET)	FDA Approved
T0007	Atenolol	β 1-adrenergic receptor; β 2-adrenergic receptor	FDA Approved

Annexin A

ID	Product Name	Target	Condition
T1243	Hydrocortisone acetate	Annexin A1; Glucocorticoid Receptor	FDA Approved
T0947	Dexamethason acetate	Annexin A1; Glucocorticoid Receptor; IL receptor; iNOS	FDA Approved
T0270	Hydrocortisone butyrate	Annexin A1; Glucocorticoid Receptor	FDA Approved
T0261	Amcinonide	Annexin A1; Glucocorticoid Receptor	FDA Approved
T0221	Thiopropine	Annexin A5	

Apelin receptor

ID	Product Name	Target	Condition
T4390	ML221	APJ	

Bombesin Receptor

ID	Product Name	Target	Condition
T4540	ML 18	BRS-3	

Bradykinin Receptor

ID	Product Name	Target	Condition
TP1933	R715 TFA(185052-09-9 free base)	bradykinin B1	
TP1277	Bradykinin	Bradykinin Receptor; Endogenous Metabolite	Phase 4
TP1181	Bradykinin (2-9)	Bradykinin Receptor	

ID	Product Name	Target	Condition
T8809	[Des-Arg9]-Bradykinin TFA	Bradykinin Receptor	
T5048	SSR240612	B1 Receptor	Phase 2
T22344	Icatibant Acetate	bradykinin B2	FDA Approved
T21610	Bradykinin (acetate)	Bradykinin Receptor	Phase 4

cAMP

ID	Product Name	Target	Condition
TN1334	7-O-Methylrosmanol	cAMP	
T6536	HJC0350	EPAC2	
T2244	ESI09	EPAC1; EPAC2	
T15247	ESI-05	EPAC2	
T0830	Bithionol	sAC	

Cannabinoid Receptor

ID	Product Name	Target	Condition
TWS0414	Cannabidiol	GPR55 antagonist; CB1 antagonist; CB2 inverse agonist; VR1	FDA Approved
TN2268	Tetrahyromagnolol	Cannabinoid Receptor; GPR; GABA	
T9114	β -Caryophyllene	CB2	
T8511	TM38837	CB1	
T7705	GW 405833	CB2	
T7375	A-836339	CB	
T7316	LY2828360	CB	Phase 2
T6527	GW842166X	CB2	Phase 1
T6417	BML190	CB2	
T5996	CB1-IN-1	CB1	
T4654	SLV319	CB1	Phase 2
T4458	WIN 55,212-2 Mesylate	CB1R; CB2R	Preclinical
T4453	JD5037	CB1R	Preclinical
T3S0738	yangonin	NF- κ B; CB1	
T3699	Bay 59-3074	CB1; CB2	
T3530	Otenabant	CB1	Phase 3
T2635	Org 27569	CB1	
T2264	AM281	CB	Preclinical
T1915	AM251	CB1; GPR55	
T1796	Otenabant hydrochloride	hCB1; hCB2; rCB1	Phase 3
T1519L	Rimonabant	ACAT; hCB1; hCB2	Approved
T1519	Rimonabant hydrochloride	CB1	Approved

CaSR

ID	Product Name	Target	Condition
TP1236	Etelcalcetide hydrochloride	CaSR	FDA Approved
T8403	Cinacalcet	CaSR	FDA Approved
T4967	NPS-2143 HCL	CaSR	Preclinical
T2406	Cinacalcet hydrochloride	CaSR	FDA Approved
T15261	Evocalcet	CaSR	Approved

cholecystokinin

ID	Product Name	Target	Condition
T6940	PHA767491 HCl	Cdk1; Cdk2; Cdk9; Cdc7; GSK-3 β	Phase 1
T6735	XL413 hydrochloride	CK2; Cdc7; Pim1; Cdc7	Phase 1/2
T2312	Loxiglumide	CCK	
T1052	Proglumide	CCK	Approved

CRFR

ID	Product Name	Target	Condition
T7361	Verucerfont	CRF	Phase 2

CXCR

ID	Product Name	Target	Condition
TP1348	FC131 TFA	CXCR4; HIV	
T8497	SX-682	CXCR1; CXCR2	Phase 1
T7681	AZD-5069	CXCR2	Phase 2
T7499	TAK-779	CCR2; CXCR	
T7130	Navarixin	CXCR1; CXCR2	Phase 2
T5849	JMS-17-2	CX3CR1	
T5207	LIT927	CXCL12	
T5193	Danirixin	CXCR2	Phase 2
T4163	Repertaxin	CXCR1; CXCR2	Phase 3
T4033	MSX130	CXCR4	
T4032	MSX127	CXCR4	
T3992	MSX122	CXCR4; CXCL12	Phase 2
T3396	Baohuoside I	CXCR4	Preclinical
T3327	Arteether	CCL4; CCL5; CXCL10; CXCL9	Approved
T3047	SRT3109	CXCR2	
T2477	UNBS5162	CXCL	Phase 1

ID	Product Name	Target	Condition
T1955	SB225002	CXCR2	Preclinical
T1776L	Plerixafor 8HCl (AMD3100 8HCl)	CXCL12; CXCR4	FDA Approved
T1776	Plerixafor	CXCL12; CXCR4	FDA Approved
T1739	WZ811	CXCR4	
T17208	USL311	CXCR4	Phase 1/2
T14665L	Motixafortide TFA(664334-36-5,Free)	CXCR4	Phase 2
T10297L	AMG 487	CXCR3	
T0801	Tannic acid	CXCR; hERG channel	FDA Approved

Dopamine Receptor

ID	Product Name	Target	Condition
TP1085L	Neuromedin N acetate(92169-45-4 free base)	D2	
TN2252	Syrosingopine	dopamine	
T8702	SKF-83566	D1; D5; 5-HT2	
T8633	9-FLUORENOL	dopamine reuptake	
T8423	ML417	D3	
T8389	Trifluoperazine	D2	FDA Approved
T8385	Metoclopramide hydrochloride hydrate	D2	FDA Approved
T8382	Cariprazine HCl	D2; D3	FDA Approved
T7943	Fluphenazine decanoate	D2	FDA Approved
T7834	ABT-724	D4	
T7728	ACEPROMAZINE MALEATE	Dopamine	
T7654	L-DOPA methyl ester (hydrochloride)	D1	
T7635	Raclopride	Dopamine	
T7632	Veralipride	D2	
T7583	solriamfetol	norepinephrine transporter (NET); dopamine transporter	FDA Approved
T7569	Clebopride malate	Dopamine	Approved
T7553	(+)-PD 128907 hydrochloride	Dopamine	
T7352	Pridopidine	Dopamine	Phase 3
T7308	Nomifensine	dopamine reuptake	
T7180	Sultopride hydrochloride	Dopamine	
T7153	Vanoxerine dihydrochloride	dopamine uptake	Phase 3
T7070	Nomifensine (maleate)	dopamine uptake	
T6988	SKF38393 HCl	D1; D5 receptor	Preclinical
T6951	Pramipexole 2HCl Monohydrate	D2S; D2L; D3; D4	FDA Approved

ID	Product Name	Target	Condition
T6835	Fenoldopam mesylate	dopamine-1 receptor	FDA Approved
T6648	Rotundine	D1 receptor, 5-HT1A, D2 receptor, D3 receptor	Approved
T6647	Rotigotine	D2; D3	FDA Approved
T6241	Quetiapine Fumarate	HT; Adrenergic Receptor; Dopamine	FDA Approved
T5954	Alpha-Methyl dopa Sesquihydrate	DOPA decarboxylase	
T5858	Sertindole	D2; 5-HT	Approved
T5842	Bromocriptine mesylate	D2	FDA Approved
T5397	A-381393	D4	
T5387	LP-211	5-HT7; D2 receptor; 5-HT1A receptor	
T5380	Ansofaxine hydrochloride	serotonin reuptake; dopamine reuptake; norepinephrine reuptake	
T5158	N-Desmethylclozapine	5-HT2C; D4; δ -opioid receptor	Phase 2
T5135	Fupentixol Dihydrochloride	D1, D2	Approved
T5047	PD-168077 maleate	D4	
T5009	Trimethobenzamide hydrochloride	D2	FDA Approved
T4616	5-Chloro-2-methoxyprocainamide	dopamine D2	FDA Approved
T4577	Cariprazine	D3; D2; 5-HT1A	FDA Approved
T4576	Perospirone	5-HT2A; D2; 5-HT1A	Approved
T4369	SCH 23390 hydrochloride	D1; D5	
T4297	Flibanserin	5-HT1A; 5-HT2A; D4 receptor	FDA Approved
T4274	Melitracen hydrochloride	D1; D2	Approved
T4262	BisfluoroModafinil	dopaminergic	
T4117	Zuclopenthixol	D1; D2	Approved
T4081	MPTP-hydrochloride	Dopamine	
T3526	Dasotraline hydrochloride	5-HT; Dopamine; Norepinephrine (NE)	Phase 3
T3497	Ocapерidona	D2; 5-HT2	Phase 2
T3431	Pardoprunox hydrochloride	5-HT1A; D2; D3	Phase 3
T3369	Nuciferine	5-HT2A; 5-HT2B; 5-HT2C; 5-HT7; D5 receptor	
T3278	Piribedil	α 2-adrenergic; D2; D3	Approved
T3187	Fluoroclebopride	D2	
T3085	Piperacetazine	5-HT; Dopamine	FDA Approved
T3046	BMY 7378 dihydrochloride	5-HT1A; 5-HT1C; α 1D-adrenoceptor; α 2C-adrenoceptor; D2	Preclinical
T2874	Tetrahydroberberine THB	5-HT; Dopamine	
T2714	Rotundine	5-HT1A; D1; D2; D3	
T2592	Ropinirole hydrochloride	D2	FDA Approved
T2574	Alizapride hydrochloride	Dopamine	Approved
T2564	Flupenthixol dihydrochloride	Dopamine	Approved
T2546	Pimozide	D2; Potassium Channel; α 1-adrenoceptor	FDA Approved

ID	Product Name	Target	Condition
T2306	Brexpiprazole	5-HT1A; 5-HT2A; α 1B-adrenergic receptor; α 2C receptors; D2L	FDA Approved
T22292	Chlorpromazine	Dopamine	FDA Approved
T2226	Pergolide mesylate salt	5-HT receptor; Adrenergic receptor; Dopamine receptor	FDA Approved
T2190	Methiothepin mesylate	5-HT; Dopamine	
T21337	Lurasidone	5-HT7; 5-HT1A; D2	FDA Approved
T2132	Buspiron hydrochloride	5-HT; Dopamine	FDA Approved
T2092	Amitifadine hydrochloride	5-HT; Dopamine; Norepinephrine (NE)	Phase 2/3
T1871	GBR12935	Dopamine	
T1735	Lurasidone hydrochloride	5-HT1A; 5-HT2A; 5-HT7; D2; Norepinephrine α 2C	FDA Approved
T1644	Dopamine hydrochloride	5-HT; DA transporter; Dopamine	FDA Approved
T16392	ONC206	Dopamine	
T1567	Olanzapine	5-HT; HT; mAChR; Adrenergic Receptor; Dopamine	FDA Approved
T1540	Doxepin hydrochloride	5-HT; HT; Sert (Sodium-dependent); mAChR; Adrenergic Receptor; Dopamine; Noradrenaline transporter (Sodium-dependent)	FDA Approved
T1539	lloperidone	α -adrenergic receptor; Dopamine	FDA Approved
T1517	Benserazide hydrochloride	DOPA decarboxylase; Dopamine	Approved
T1476	Pramipexole	D2L; D2L; D3; D4	FDA Approved
T1471	Duloxetine hydrochloride	Sert (Sodium-dependent); DA transporter; Noradrenaline transporter (Sodium-dependent)	FDA Approved
T1412	Loxapine succinate salt	5-HT2 (bovine); 5-HT2 (bovine); 5-HT2 (human); D2; D4	FDA Approved
T1406	Amantadine hydrochloride	Dopamine	FDA Approved
T1384	Chlorpromazine hydrochloride	5-HT2A; D2	FDA Approved
T1336	Benztrapine mesylate	DAT	FDA Approved
T1327	Nortriptyline hydrochloride	5-HT; Sert (Sodium-dependent); mAChR; Adrenergic Receptor; Dopamine; H1 receptor; Noradrenaline transporter (Sodium-dependent)	FDA Approved
T1322	Bendazol	Dopamine	FDA Approved
T1292	Tiapride hydrochloride	D2; D3	Approved
T12352L	Oxidopamine hydrobromide	neurotransmitter dopamine; Autophagy	
T12352	Oxidopamine hydrochloride	dopamine	
T1233	Oxolinic acid	bacterial DNA gyrase; DNA synthesis; dopamine uptake	Approved
T1222	Trifluoperazine dihydrochloride	D2	FDA Approved
T1211	Levosulpiride	Dopamine	Approved
T1201	Sulpiride	Dopamine	Approved
T1180	Blonanserin	5-HT2; D2	Approved
T1175	Bromopride	Dopamine	Approved
T1105	Penfluridol	Dopamine	Approved
T1090	Perphenazine	CAM; Dopamine; 5-HT2A receptor; Histamine H1 receptor; Alpha-1A adrenergic receptor	FDA Approved

ID	Product Name	Target	Condition
T1069	Metoclopramide hydrochloride	5-HT; mAChR; Dopamine	FDA Approved
T1045	Trimipramine maleate	5-HT; Sert (Sodium-dependent); Adrenergic Receptor; DA transporter; Dopamine; H1 receptor; Noradrenaline transporter (Sodium-dependent)	FDA Approved
T0990	Droperidol	D2	FDA Approved
T0869	Atomoxetine hydrochloride	5-HT; DA transporter; Norepinephrine (NE) transporter	FDA Approved
T0848	Levodopa	Dopamine	FDA Approved
T0811	Amisulpride	5-HT; Dopamine	FDA Approved
T0785	Dexchlorpheniramine Maleate	Sert (Sodium-dependent); DA transporter; H1 receptor; Noradrenaline transporter (Sodium-dependent)	FDA Approved
T0783	Mianserin hydrochloride	5-HT; HT; Sert (Sodium-dependent); Adrenergic Receptor; DA transporter; Dopamine; Noradrenaline transporter (Sodium-dependent); κ -opioid receptor	Approved
T0776	Phenothiazine	Dopamine	FDA Approved
T0766	Promazine hydrochloride	5-HT; mAChR; Adrenergic Receptor; Dopamine	FDA Approved
T0719	Tetrabenazine	D2; Synaptic vesicular amine transporter	FDA Approved
T0716	Molindone hydrochloride	5-HT; mAChR; Dopamine	FDA Approved
T0505	L-(-)- α -Methyldopa	DOPA decarboxylase	FDA Approved
T0469	Octopamine hydrochloride	Dopamine	Approved
T0455	Clozapine	M1 mAChR; α 2-adrenoceptor; D2	FDA Approved
T0445	Promethazine	5-HT; mAChR; Adrenergic Receptor; CAM; D2; H1 receptor	FDA Approved
T0385	Prochlorperazine Maleate	D2	FDA Approved
T0365	Thioridazine hydrochloride	5-HT; Adrenergic Receptor; Dopamine; Potassium Channel	FDA Approved
T0351	Risperidal	5-HT _{2A} ; α 2C-adrenergic receptor; D2; D _{2L} ; D ₃	FDA Approved
T0333	Aniracetam	5-HT; Dopamine; AMPA; GluR	Approved
T0322	Fipexide	Dopamine	Approved
T0302	Triflupromazine hydrochloride	5-HT; mAChR; Dopamine	FDA Approved
T0287	Hexamethonium Bromide	mAChR; Dopamine	Approved
T0280	Spiperone	Dopamine	Approved
T0255	Clomipramine hydrochloride	5-HT; Sert (Sodium-dependent); GSTP; Noradrenaline transporter (Sodium-dependent); dopamine transporter (DAT)	FDA Approved
T0137	Mirtazapine	5-HT; HT; Sert (Sodium-dependent); Adrenergic Receptor; DA transporter; Dopamine; κ -opioid receptor	FDA Approved
T0136	Citicoline	Dopamine	Approved
T0082	Domperidone	D2; D3	Approved
T0076	Paliperidone	5-HT; β -adrenergic receptor; Dopamine; H1 receptor	FDA Approved
T0074L	Chlorprothixene hydrochloride	5-HT; mAChR; Dopamine; H1 receptor	FDA Approved
T0074	Chlorprothixene	5-HT ₆ ; 5-HT ₇ ; D ₂ ; D ₃ ; H1 receptor	FDA Approved
T0068	Fluphenazine hydrochloride	Dopamine	FDA Approved

ID	Product Name	Target	Condition
T0031L2	Ziprasidone	5-HT transporter; 5-HT1A; 5-HT1B; 5-HT1D; 5-HT2A; 5-HT2C; 5-HT6; 5-HT7; α 1A-adrenergic receptor; α 2A-adrenergic receptor; D1; D2; D3; H1 receptor; norepinephrine transporter (NET)	FDA Approved
T0031L	Ziprasidone hydrochloride	5-HT transporter; 5-HT1A; 5-HT1B; 5-HT1D; 5-HT2A; 5-HT2C; 5-HT6; 5-HT7; α 1A-adrenergic receptor; α 2A-adrenergic receptor; D1; D2; D3; H1 receptor; norepinephrine transporter (NET)	FDA Approved
T0031	Ziprasidone hydrochloride monohydrate	5-HT transporter; 5-HT1A; 5-HT1B; 5-HT1D; 5-HT2A; 5-HT2C; 5-HT6; 5-HT7; α 1A-adrenergic receptor; α 2A-adrenergic receptor; D1; D2; D3; H1 receptor; norepinephrine transporter (NET)	FDA Approved
T0025	Haloperidol	5-HT; Dopamine	FDA Approved

EBI2/GPR183

ID	Product Name	Target	Condition
T8234	ML401	GPR183	
T7156	NIBR189	GPR183	
T14063	7 α ,25-Dihydroxycholesterol	Human Endogenous Metabolite; GPR183	

Endothelin Receptor

ID	Product Name	Target	Condition
T7817	Aprocitenan	ET-A ; ET-B	Phase 3
T6792	BQ123	Endothelin A receptor	Phase 1
T6672	Sitaxentan sodium	ET-A	Phase 2
T6265	Bosentan Hydrate	ET-A , ET-B	FDA Approved
T6264	Bosentan	ET-A; ET-B	FDA Approved
T5458	Darusentan	Endothelin A receptor	Phase 3
T5355	Sparsentan	angiotensin II receptor; Endothelin A receptor	Phase 3
T3474	RO 46-8443	ET-B	
T3194	Ro 46-2005	ET-A; ET-B	Preclinical
T2561	Macitentan	ET-A; ET-B	FDA Approved
T1655	Ambrisentan	ET-A	FDA Approved

GHSR

ID	Product Name	Target	Condition
TQ0022	Capromorelin Tartrate	hGHS-R1a	Phase 1
TP2328L	CJC-1295 acetate(863288-34-0 free base)	GHRH	
T7398	ONC212	GPR132	
T7325	GHRP-6 acetate	GHS-R	

ID	Product Name	Target	Condition
T7225	AnaMorelin hydrochloride	ghrelin receptor	Phase 2
T7112	Ibutamoren Mesylate	GHSR	Phase 2
T5025L	Pralmorelin acetate 158861-67-7(free base)	GHS-R	
T4648	TC-G-1008	rat GPR39; human GPR39	
T10319	Anamorelin	ghrelin receptor	Approved

Glucagon Receptor

ID	Product Name	Target	Condition
TP1796	Albiglutide TFA	GLP-1	Phase 4
TP1469	Lixisenatide acetate	GLP-1	FDA Approved
TP1419L	HAEGTFT acetate(926018-95-3 free base)	Glucagon Receptor	
T8876	PF-06882961 Tris	GLP-1	Phase 1
T8748	Exendin-4 acetate	GLP-1	Phase 4
T7364	NNC-0640	human glucagon receptor	
T6876	Liraglutide	GLP-1	FDA Approved
T3984	GLP-1(7-36)	GLP-1	Phase 1
T3967	Exendin-4	glucagon-like peptide-1 receptor	FDA Approved
T3896	Shanzhiside methyl ester	GLP-1	
T3422	GRA-Ex-25	human glucagon receptor; rat glucagon receptor	
T19850	Semaglutide	GLP-1	FDA Approved
T12431	PF-06882961	GLP-1	Phase 2

GNRH Receptor

ID	Product Name	Target	Condition
TP2323L	Deslorelin acetate	GnRHR	Phase 2
TP1307	Buserelin Acetate	GNRHR	Approved
T5520	Cetrorelix	GNRHR	Approved
T5031	Elagolix sodium	GNRHR	FDA Approved
T5021	Leuprolide Acetate	GNRHR	FDA Approved
T5018	Leuprorelin	GNRHR	FDA Approved
T4102	Goserelin acetate	GNRHR	FDA Approved
T3630	Relugolix	GNRHR	Approved
T21410	Triptorelin Acetate	GNRHR	FDA Approved
T21309	Nafarelin acetate	GNRHR	FDA Approved
T1494	Alarelin	GNRHR	Approved
T1480	Danazol	Androgen Receptor; ER; ER; GNRHR	FDA Approved

GPCR19

ID	Product Name	Target	Condition
TQ0252	BAR502	GPBAR1; FXR	
T8818	TC-G 1005	hTGR5	
T8752	BAR 501 impurity	GPBAR1	
T7428	SBI-115	TGR5	
T5077	Sodium Desoxycholate	TGR5	FDA Approved
T4352	SB756050	TGR5	Phase 2
T4083	BAR 501	GPBAR1	
T2968	Hyodeoxycholic acid	FXR; TGR5 (GPCR19)	Approved
T2965	Deoxycholic acid	Endogenous Metabolite; GPCR19	FDA Approved
T1824	TGR5 Receptor Agonist	TGR5	

GPR

ID	Product Name	Target	Condition
TQ0108	MK-6892	GPR109A	
TP1666L	Kisspeptin-10, rat acetate(478507-53-8 free base)	GPR54	Phase 3
TP1345	Kisspeptin-10, human (TFA) (374675-21-5,FREE)	GPR54	
TN2268	Tetrahydromagnolol	Cannabinoid Receptor; GPR; GABA	
T8901	YUM70	GRP78	
T8353	Pamoic acid	GPR35	
T8329	AR 231453	GPR119	
T7713	Benzyl nicotinate	GPR109	
T7482	3-chloro-5-hydroxybenzoic Acid	GPR81	
T7359	CAY10471 Racemate	CRTh2 (DP2) receptor	
T7261	Grp94 Inhibitor-1	Grp94	
T7127	DC260126	GPR40	
T7010	VER155008	HSP70; HSC70; GRP78	
T6855	HA15	GRP78; HSPA5; BiP	
T6399	AZD1981	CRTh2 (DP2) receptor	Phase 2
T5828	MS21570	GPR171	
T5036	cangrelor tetrasodium	GPR17	FDA Approved
T4689	Palosuran hydrochloride 540769-28-6(free base)	Urotensin Receptor (GPR14)	Phase 2
T4626	TC-O 9311	hGPR139	
T4566	Lodoxamide	Histamine Receptor	FDA Approved
T4312	GPR120 receptor agonist	GPR120	
T3965	Fevipirant	CRTh2	Phase 3

ID	Product Name	Target	Condition
T3520	Setipiprant	CRTh2	Phase 2
T3433	TUG891	GPR120	
T3176	APD597	GPR119	Phase 1
T3171	GSK137647A	GPR120	
T3119	JNJ63533054	hGPR139	
T2701	GSK1292263	GPR119	Phase 2
T2664	Timapiprant	DP2	Phase 3
T2528	Latanoprost	prostanoid selective FP receptor; retinoid X receptor α	FDA Approved
T2396	Ramatroban	CRTh2; TXA2R	Approved
T2351	TAK875	GPR40(FFA1)	Phase 3
T2088	APD 668	GPR119	Phase 1
T2036	GTPL5846	GPR84	
T1915	AM251	CB1; GPR55	
T1793	MBX2982	GPR119	Phase 1
T1781	GW 9508	GPR120; GPR40(FFA1)	
T1237	Azathioprine	HGPRT; Rac1	FDA Approved
T11560	hGPR91 antagonist 1	HGPR91	

GRK

ID	Product Name	Target	Condition
T3513	GSK180736A	GRK1; GRK2; GRK5; PKA; ROCK	
T3498	CCG215022	GRK1; GRK2; GRK5; PKA	
T1636	Paroxetine hydrochloride	5-HT; AChR; GRK2	FDA Approved

GTPase

ID	Product Name	Target	Condition
T6634	RBC8	GTPases RalA; GTPases RalB	
T6434	CCG 50014	RGS16; RGS19; RGS4; RGS8	
T4022	QS 11	ARFGAP1	

Guanylate Cyclase

ID	Product Name	Target	Condition
T7201	Nelociguat	Guanylate Cyclase	Phase 2
T17226	Vericiguat	guanylate cyclase	FDA Approved
T11852	Linaclotide	Guanylate cyclase	FDA Approved

Hedgehog/Smoothened

ID	Product Name	Target	Condition
T6891	MK4101	Smoothened	Phase 1
T6514	Glasdegib	Smoothened	FDA Approved
T4211	SAG hydrochloride (912545-86-9(free base))	Hedgehog/Smoothened	
T3588	JK184	Hedgehog	
T3460	HhAntag	Gli	Preclinical
T3363	Jervine	Hedgehog; Smoothened	
T3156	Ciliobrevin A	Hedgehog	
T3070	GANT61	GLI1	
T2825	Cyclopamine	Smoothened	Preclinical
T2666	Taladegib	Smoothened	Phase 1/2
T2590	Vismodegib	Hedgehog; ABCG2	FDA Approved
T2450	SANT1	Smoothened	
T2299	BMS833923	Smoothened	Phase 2
T1926	NVP-LDE225	Smoothened; Smoothened	FDA Approved
T1810	Purmorphamine	Smoothened	
T1543	Naftifine hydrochloride	Smoothened	FDA Approved
T14188	ALLO-2	Smoothened	
T1094	Tolnaftate	Smoothened	Approved
T0465	Ellagic acid	Carbonic anhydrase; CK2; Smoothened; PKA; PKC; Syk; ATP-competitive CK2	Phase 2

Histamine Receptor

ID	Product Name	Target	Condition
TN1154	6-Methoxyluteolin	Calcium Channel; Histamine Receptor	
TN1008	Psoralenoxide	H1 receptor	
T8822	JNJ-5207852 dihydrochloride	H3 receptor	
T8599	Betazole hydrochloride	H2 receptor	FDA Approved
T8548	Metoprine	histamine N-methyltransferase; antifolate	
T8514	LML-134	H3 receptor	Phase 2
T8439	Clobenpropit dihydrobromide	H3 receptor	
T7564	Chlorphenoxamine	Histamine Receptor	
T7524	Metiamide	H2 receptor	
T7413	JNJ-5207852	H3 receptor	
T7176	Pitolisant hydrochloride	H3 receptor	FDA Approved
T7085	Mebhydroline	H1 receptor	Approved
T6535	Histamine Phosphate	Histamine H1 receptor , Histamine H2 receptor	FDA Approved
T6534	Histamine 2HCl	H1 receptor; H2 receptor	Approved

ID	Product Name	Target	Condition
T6405	Bepotastine Besilate	H1 receptor	FDA Approved
T6242	Rupatadine Fumarate	H1 receptor; PAFR	Approved
T6164	Ciproxifan	H3 receptor	Preclinical
T5829	H4 Receptor antagonist 1	H4 receptor	
T5495	Decloxizine dihydrochloride	H1 receptor	Approved
T4566	Lodoxamide	Histamine Receptor	FDA Approved
T4563	Thonzylamine	H1 receptor	Approved
T4551	Acrivastine	H1 receptor	FDA Approved
T4507	Chlorphenesin	Histamine release	FDA Approved
T4499	Mequitazine	H1 receptor	Approved
T4250	Bilastine	H1 receptor; H1 receptor(in guinea-pig cerebellum)	Approved
T4195	Betahistine	H1 receptor	Approved
T4099	S38093	Human H3 receptor; Mouse H3 receptor; Rat H3 receptor	Phase 2
T3979	Emedastine	H1 receptor	FDA Approved
T3963	VUF10460	H4 receptor	
T3723	Dioxopromethazine hydrochloride	H1 receptor	
T3610	Ranitidin	H2 receptor	FDA Approved
T3429	Protopine	H1 receptor; platelet aggregation	
T2848	Osthole	H1 receptor	Preclinical
T2533	Alcaftadine	H1 receptor; H2 receptor; H4 receptor	FDA Approved
T2520	Desloratadine	H1 receptor	FDA Approved
T2335	Ebastine	H1 receptor	Approved
T22713	Decloxizine	H1 receptor	Approved
T2232	JNJ7777120	H4 receptor	Preclinical
T2222	Carbinoxamine Maleate Salt	H1 receptor	FDA Approved
T2200	Hydroxyzine dihydrochloride	H1 receptor	FDA Approved
T20884	Hydroxyzine free base	H1 receptor	Approved
T20712	Conessine	H3 receptor	
T2004	Ciproxifan maleate	H3 receptor	Preclinical
T1822L	Clemizole hydrochloride	NS4BH1 histamine receptor	Approved
T1822	Clemizole	NS4BH1 histamine receptor	Phase 2
T1627	Famotidine	H2 receptor	FDA Approved
T1619	Trazodone hydrochloride	5-HT ₂ ; Sert (Sodium-dependent); Adrenergic Receptor; H1 receptor	FDA Approved
T1575	Nizatidine	AChE; H2 receptor	FDA Approved
T1553	Chlorpheniramine maleate	H1 receptor	FDA Approved
T1470L	Fexofenadine hydrochloride	H1 receptor	FDA Approved
T1470	Fexofenadine hydrochloride	Histamine H1 receptor	FDA Approved

ID	Product Name	Target	Condition
T1469	Levocetirizine	H1 receptor	FDA Approved
T1425	Pemrolast potassium	H1 receptor	FDA Approved
T1393	Sodium butanoate	H1 receptor	Phase 3
T1327	Nortriptyline hydrochloride	5-HT; Sert (Sodium-dependent); mAChR; Adrenergic Receptor; Dopamine; H1 receptor; Noradrenaline transporter (Sodium-dependent)	FDA Approved
T1308	Orphenadrine hydrochloride	H1 receptor; NMDA receptor; Noradrenaline transporter (Sodium-dependent); Sodium Channel	FDA Approved
T1278	Astemizole	H1 receptor; Potassium Channel	
T1269	Tripeleminamine hydrochloride	H1 receptor	FDA Approved
T1232	Pyrimilamine maleate	H1 receptor	FDA Approved
T1182	Propionyl-L-carnitine hydrochloride	H1 receptor	Approved
T1115	Doxylamine succinate	H1 receptor	FDA Approved
T1110	Meclizine dihydrochloride	H1 receptor	FDA Approved
T1097	Loratadine	B(0)AT2	FDA Approved
T1090	Perphenazine	CAM; Dopamine; 5-HT2A receptor; Histamine H1 receptor; Alpha-1A adrenergic receptor	FDA Approved
T1045	Trimipramine maleate	5-HT; Sert (Sodium-dependent); Adrenergic Receptor; DA transporter; Dopamine; H1 receptor; Noradrenaline transporter (Sodium-dependent)	FDA Approved
T1030	Triprolidine hydrochloride	H1 receptor	FDA Approved
T0994	Ketotifen fumarate	H1 receptor; PDE	FDA Approved
T0942	Quinacrine dihydrochloride	DNA; Histamine N-methyltransferase; PLA2; PLCLP	Phase 2
T0903	Stugeron	Calcium Channel; H1 receptor	Approved
T0865	Ranitidine Hydrochloride	H2 receptor	FDA Approved
T0797	Cimetidine	H2 receptor	FDA Approved
T0785	Dexchlorpheniramine Maleate	Sert (Sodium-dependent); DA transporter; H1 receptor; Noradrenaline transporter (Sodium-dependent)	FDA Approved
T0468	Xylocaine	H1 receptor	FDA Approved
T0445L	Promethazine hydrochloride	α -adrenergic receptor; H1 receptor	FDA Approved
T0445	Promethazine	5-HT; mAChR; Adrenergic Receptor; CAM; D2; H1 receptor	FDA Approved
T0381	Amodiaquine hydrochloride	histamine N-methyl transferase	FDA Approved
T0330	Diphenhydramine hydrochloride	H1 receptor	FDA Approved
T0298	Dimenhydrinate	H1 receptor	FDA Approved
T0263	Chloropyramine hydrochloride	FAK-VEGFR-3; H1 receptor	Approved
T0246L	Bethahistine mesylate	H1 receptor; H3 receptor	Approved
T0246	Bethahistine dihydrochloride	H3 receptor	Approved
T0211L	Azelastine hydrochloride	H1 receptor	FDA Approved

ID	Product Name	Target	Condition
T0172	Maprotiline hydrochloride	5-HT; mAChR; Adrenergic Receptor; H1 receptor; Noradrenaline transporter (Sodium-dependent)	FDA Approved
T0157	Roxatidine Acetate hydrochloride	H2 receptor	Approved
T0147	Clemastine fumarate	H1 receptor	FDA Approved
T0118	Mizolastine	H1 receptor	Approved
T0092	Antazoline hydrochloride	H1 receptor	FDA Approved
T0089	Cetirizine dihydrochloride	H1 receptor	FDA Approved
T0076	Paliperidone	5-HT; β -adrenergic receptor; Dopamine; H1 receptor	FDA Approved
T0074L	Chlorprothixene hydrochloride	5-HT; mAChR; Dopamine; H1 receptor	FDA Approved
T0074	Chlorprothixene	5-HT ₆ ; 5-HT ₇ ; D ₂ ; D ₃ ; H1 receptor	FDA Approved
T0059	Diphenylpyraline hydrochloride	H1 receptor	FDA Approved
T0053	Hydroxyzine Pamoate	H1 receptor	FDA Approved
T0031L2	Ziprasidone	5-HT transporter; 5-HT _{1A} ; 5-HT _{1B} ; 5-HT _{1D} ; 5-HT _{2A} ; 5-HT _{2C} ; 5-HT ₆ ; 5-HT ₇ ; α 1A-adrenergic receptor; α 2A-adrenergic receptor; D ₁ ; D ₂ ; D ₃ ; H1 receptor; norepinephrine transporter (NET)	FDA Approved
T0031L	Ziprasidone hydrochloride	5-HT transporter; 5-HT _{1A} ; 5-HT _{1B} ; 5-HT _{1D} ; 5-HT _{2A} ; 5-HT _{2C} ; 5-HT ₆ ; 5-HT ₇ ; α 1A-adrenergic receptor; α 2A-adrenergic receptor; D ₁ ; D ₂ ; D ₃ ; H1 receptor; norepinephrine transporter (NET)	FDA Approved
T0031	Ziprasidone hydrochloride monohydrate	5-HT transporter; 5-HT _{1A} ; 5-HT _{1B} ; 5-HT _{1D} ; 5-HT _{2A} ; 5-HT _{2C} ; 5-HT ₆ ; 5-HT ₇ ; α 1A-adrenergic receptor; α 2A-adrenergic receptor; D ₁ ; D ₂ ; D ₃ ; H1 receptor; norepinephrine transporter (NET)	FDA Approved

Leukotriene Receptor

ID	Product Name	Target	Condition
T22946	LY 255283	BLT2	

LPA Receptor

ID	Product Name	Target	Condition
T7689	Tetradecyl Phosphonate	LPA1/2/3	
T7393	ONO-7300243	LPA1	
T6108	Ki16425	LPA1; LPA2; LPA3	Preclinical
T4278	AM966	LPA1	Preclinical
T4016	BMS986020	LPA1	Phase 2
T21654	1-Oleoyl lysophosphatidic acid sodium salt	LPA1; LPA2	
T2000	AM095	LPA1	Preclinical
T10293	AM095 free acid	LPA1	

Melanin-concentrating Hormone Receptor (MCHR)

ID	Product Name	Target	Condition
TP1996	MCH (human, mouse, rat)	MCH1-R	
T8004	SNAP 94847 hydrochloride	MCH1-R	

Melanocortin Receptor

ID	Product Name	Target	Condition
TP1898	HS 024	melanocortin-4 receptor (MC4R)	
TP1889	MCL 0020	melanocortin-4 receptor (MC4R)	
TP1324	Melanotan (MT)-II	melanocortin receptors	
TP1101	Nonapeptide-1 acetate salt	α-MSH	
T8485	THIQ	melanocortin-4 receptor (MC4R)	
T7608	Bremelanotide Acetate	Melanocortin Receptor	FDA Approved
T5464	JNJ-10229570	MC1R; MC5R	

Melatonin Receptor

ID	Product Name	Target	Condition
T3495	Tasimelteon	Melatonin Receptor; MT2 receptor; MT1 receptor	FDA Approved
T1659	Melatonin	CAM; ER; melatonin receptor; MPO; RORβ	Approved

Motilin Receptor

ID	Product Name	Target	Condition
TP1425	Motilin (26-47), human, porcine	Motilin Receptor	

Neurokinin Receptor

ID	Product Name	Target	Condition
TP1883	[Lys5,MeLeu9,Nle10]-NKA(4-10)	NK2	
TP1572	GR-73632	NK-1	
TP1385	Neurokinin A(4-10) TFA(97559-35-8 free base)	NK2	
TP1087	Substance P	Human Endogenous Metabolite; NK1	
TP1008	Neurokinin A	NK2	
T8789	N-Acetyl-L-tryptophan	Human Endogenous Metabolite; NK1	
T8235	L-732138	NK-1	
T7828	Bhsar-sp	NK-1	

ID	Product Name	Target	Condition
T7633	Senktide	NK3	
T7549	Talnetant	NK3	Phase 2
T7209	Maropitant	NK1	
T6905	Netupitant	NK1	FDA Approved
T3724	Rolapitant hydrochloride	NK1	FDA Approved
T1790	Fosaprepitant dimeglumine	NK1	FDA Approved
T1743	Aprepitant	NK1	FDA Approved

Neuropeptide Y Receptor

ID	Product Name	Target	Condition
TQ0286	MK-0557	neuropeptide Y (NPY) Y5 receptor	Phase 2
T8559	GALNON TFA(475115-35-6(free base))	galanin receptor	
T5587	CGP71683 hydrochloride	Y5 receptor	
T17222	Velneperit	neuropeptide Y (NPY) Y5 receptor	Phase 2

Neurotensin Receptor

ID	Product Name	Target	Condition
TP1310	Neurotensin	Neurotensin Receptor	
T16860	SBI-553	NTR1	

Opioid Receptor

ID	Product Name	Target	Condition
TWS0414	Cannabidiol	GPR55 antagonist; CB1 antagonist; CB2 inverse agonist; VR1	FDA Approved
TQ0267	Endomorphin-1	μ-opioid receptor	
TP2050L	CTAP(TFA)	δ-opioid receptor	
TP2036L	DPDPE TFA	δ-opioid receptor	
TP1905	DADLE	δ-opioid receptor	
TP1832	Gluten Exorphin C	δ-opioid receptor; μ-opioid receptor	
TP1813L	Dynorphin A 1-10 acetate(79994-24-4 free base)	κ-opioid receptor	
TP1793L	Nociceptin (1-13) amide TFA	Opioid receptor-like1 (ORL1)	
TP1367	[D-Ala2]leucine-enkephalin	Opioid Receptor	
TP1254	[Met5]-Enkephalin, amide TFA	δ and ζ opioid receptor	
TP1179L	Porcine dynorphin A(1-13) acetate(72957-38-1 free base)	κ-opioid receptor	
TP1071	Nociceptin	Opioid Receptor	

ID	Product Name	Target	Condition
T8571	ML-184	GPR55	
T8557	N-terminally acetylated Leu-enkephalin	Opioid Receptor	
T8455	Spinorphin	enkephalin degrading enzymes	
T7665	[Leu5]-Enkephalin TFA(58822-25-6(free bas))	δ-opioid receptor; Human Endogenous Metabolite	
T7639	Deltorphin 2(TFA)	δ-opioid receptor	
T7637	Deltorphin I(TFA)	δ-opioid receptor	
T7613	β-Casomorphin, human(TFA)	Opioid Receptor	
T7576L	β-Casomorphin, bovine TFA(72122-62-4(free base))	Opioid Receptor	
T7567L	Adrenorphin 3TFA(88377-68-8(free base))	μ-opioid receptor	
T7218	Endomorphin 2	μ-opioid receptor	
T7211	Tyr-Gly-Gly-Phe-Met-OH	Opioid Receptor	
T6553	JTC801	Opioid receptor-like1 (ORL1)	Phase 2
T6221	Nalmefene hydrochloride	Opioid Receptor	FDA Approved
T6175	ADL5859 HCl	δ-opioid receptor; κ-opioid receptor; μ-opioid receptor	Phase 2
T5167	Cebranopadol	Opioid Receptor; NOP	Phase 2
T5158	N-Desmethylozapine	5-HT2C; D4; δ-opioid receptor	Phase 2
T4691	Asimadoline hydrochloride	κ-opioid receptor	Phase 2
T4478	CID 16020046	GPR55	
T4411	DAMGO TFA (78123-71-4(Free base))	μ-opioid receptor	
T4407	SR17018	μ-opioid receptor	
T4386	PZM21	μ opioid receptor	
T4351	DAMGO	μ-opioid receptor	
T4236	AR-M 1000390 hydrochloride	δ-opioid receptor	Preclinical
T3417	Amentoflavone	COX; COX-2; κ-opioid receptor; CYP2C9; CYP3A4; PLA2	
T2870	(+)-Matrine	κ-opioid receptor	
T2388	Nalfurafine hydrochloride	κ-opioid receptor	Approved
T21422	Methylnaltrexone bromide	μ-opioid receptor	FDA Approved
T2071	MCOPPB trihydrochloride	Opioid Receptor	
T20435L	Leuphasyl TFA	δ-opioid receptor	
T1407	L-Menthol	Opioid Receptor; κ-opioid receptor	FDA Approved
T13414	ZT 52656A hydrochloride	kappa opioid receptor	
T1242	Alvimopan	μ-opioid receptor	FDA Approved
T0981	Noscapine hydrochloride	Opioid alkaloid	Approved
T0963	Naltrexone hydrochloride	Opioid Receptor	FDA Approved
T0929	Docusate sodium	Opioid Receptor	Approved
T0918	Trimebutine	Opioid Receptor	Approved

ID	Product Name	Target	Condition
T0783	Mianserin hydrochloride	5-HT ₂ ; HT ₂ ; Sert (Sodium-dependent); Adrenergic Receptor; DA transporter; Dopamine; Noradrenaline transporter (Sodium-dependent); κ -opioid receptor	Approved
T0478	Progesterone	ER; κ -opioid receptor	FDA Approved
T0209	Loperamide hydrochloride	δ -opioid receptor; κ -opioid receptor; μ -opioid receptor;	FDA Approved
T0201	Meptazinol hydrochloride	Opioid Receptor	Approved
T0137	Mirtazapine	5-HT ₂ ; HT ₂ ; Sert (Sodium-dependent); Adrenergic Receptor; DA transporter; Dopamine; κ -opioid receptor	FDA Approved
T0102	Naloxone hydrochloride	Opioid Receptor	FDA Approved

OX Receptor

ID	Product Name	Target	Condition
T6140	SB334867	OX1	Preclinical
T5500	DORA-22	OX Receptor	
T4965	TCS-OX2-29	OX2	
T3722	MK1064	OX2	
T3347	PF3274167	OXTR	Phase 1
T3177	Orexin 2 Receptor Agonist	O2XR	
T2710	TCS 1102	OX1; OX2	
T2613	Almorexant	OX1; OX2	Phase 3
T1913	MK3697	OX2	Phase 2
T11186	EMPA	OX2 Receptor	

Oxytocin Receptor

ID	Product Name	Target	Condition
T7601	Carbetocin	Oxytocin Receptor	Approved
T5148	Atosiban acetate	Oxytocin Receptor	Approved
T5145	Oxytocin acetate	Oxytocin Receptor	FDA Approved
T11857	LIT-001	oxytocin receptor	

PAFR

ID	Product Name	Target	Condition
T6242	Rupatadine Fumarate	H1 receptor; PAFR	Approved
T2751	Ginkgolide B	PAFR	Preclinical

Prostaglandin Receptor

ID	Product Name	Target	Condition
TQ0203	Taflopust	PGF2 α	FDA Approved
TQ0025	E7046	EP4	Phase 1
TN1006	Tirucalol	PGE; NO Synthase; NOS	
T7968	Dazoxiben	Thromboxane (TX) synthase	
T7652	AM211	prostaglandin D2 receptor	
T7053	p-Hydroxy-cinnamic acid	Thromboxane A2 synthetase; PGE2	
T6485	Embelin	XIAP; 5-Lipoxygenase; mPGES-1	FDA Approved
T5847	Cloprostenol sodium	PGF2 α receptor	
T5841	Travoprost	Prostaglandin Receptor	FDA Approved
T5774	7-demethylsuberosin	PGE2	
T5758	sphondin	COX-2; PGE2	
T5482	TG4-155	EP2	
T5386	Asapiprant	DP1 receptor	Phase 3
T5171	Treprostinil Sodium	DP1, IP, EP2; VEGFR2; RET	FDA Approved
T5014	Prostaglandin E2 (PGE2)	EP2 Receptor; Human Endogenous Metabolite	FDA Approved
T4981	Anisotropine Methylbromide	Cholinergic; DP1; IP; EP2	FDA Approved
T4635	Ralinepag	Prostacyclin receptor; rat IP	Phase 3
T4546	Dinoprost Tromethamine	PEG	FDA Approved
T3S2007	MRE269	prostaglandin I2 receptor	
T3903	Angoroside C	PGE2	
T3889	Platycodin D	PGE2	
T3306	PF04418948	PGE2	Phase 1
T3276	Benorilate	PGF	Approved
T3174	Taprenepag	PGE2	Phase 2
T2868	Evodiamine	PGE	Preclinical
T2786	Oxysophocarpine	PGE2	
T2538	Bimatoprost	PGF2; PGE2	FDA Approved
T1978	GW 627368X	EP4	
T1626	Alprostadi	PGE	FDA Approved
T15259	Evatanepag	PGE2	
T14865	Carboprost tromethamine	prostaglandin F2 α	FDA Approved
T0795	Rutin	AKR	Approved
T0159	Pranoprofen	PGE2	Approved
T0002	Ethamsylate	Prostaglandin Receptor	Approved

Protease-activated Receptor

ID	Product Name	Target	Condition
TP1925L	tcY-NH2 TFA(327177-34-4 free base)	PAR-4	
TP1904L	FSLLRy-NH2 TFA(245329-02-6 free base)	PAR2	
TP1378	2-Furoyl-LIGRLO-amide TFA(729589-58-6 free base)	PAR2	
TP1046L	PAR-2 Activating Peptide acetate(171436-38-7 free base)	PAR-2	
T7740	Protease-Activated Receptor-4 diTFA(245443-52-1(free base))	PAR-4	
T7674	Thrombin Receptor Activator for Peptide	PAR-1	
T7625	TRAP-6(2TFA)	PAR-1	
T7573L	TFLLR-NH2 2TFA(197794-83-5(free base))	PAR1	
T7513	Protease-Activated Receptor-2, amide	PAR2	
T7137	I-191	PAR-2	
T7013	Vorapaxar	PAR-1	FDA Approved
T3098	Vorapaxar sulfate	PAR-1	FDA Approved
T1893	ML 161	PAR-1	

Ras

ID	Product Name	Target	Condition
T8870	1-(4-methansulfinylphenyl) ethanone	Ras	
T8843	APS6-45	MAPK; Ras	
T8756	KRAS inhibitor-9	KRAS	
T8684	AMG-510	KRAS G12C	Phase 3
T8375	ML-210	Gpx4; Ras	
T8369	MRTX849	KRAS G12C	Phase 1/2
T8006	Oncrasin 1	K-Ras	
T7609	ARS-1620	KRAS G12C	
T7558	CID-1067700	Rab7	
T7326	6H05 TFA	KRAS G12C	
T7131	Antineoplaston A10	Ras	Phase 2
T6302	Lonafarnib	K-ras-4B; H-ras; N-ras	Approved
T6163	Salirasib	PPMTase	Phase 1/2
T5469	K-Ras-IN-1	K-Ras	
T5379	Antineoplaston A10	Ras	

ID	Product Name	Target	Condition
T4619	ML098	Rab7	
T22258	AMG-510 racemate	KRAS G12C	
T22249	1588-A4	KRAS G12C	
T16143	MRTX-1257	KRAS G12C	
T12979	BI-3406	KRAS-SOS1; MAPK	

S1P Receptor

ID	Product Name	Target	Condition
TQ0198	Phorbol 12-myristate 13-acetate	SphK; PKC	
T8840	PF-543	SphK1	
T8461	SKI V	SphK; PI3K	
T7939	Fingolimod	S1P	FDA Approved
T7360	GSK2018682	S1P	
T6923	Ozanimod	S1P1; S1P5	FDA Approved
T6750	ABC294640	SphK2	Phase 2
T6673	SKI II	SphK1	
T6403	Siponimod	S1P1; S1P2; S1P3; S1P4; S1P5	FDA Approved
T4658	MHP	SphK	
T4031	S1p-receptor-agonist-1	S1P	
T3961	CYM 5541	S1P3	
T3258	Ponesimod	S1P1	Phase 3
T2539	Fingolimod hydrochloride	S1P; Trpm7	FDA Approved
T22703	CYM 5520	S1P2	
T2026	CYM5442	SphK	
T17183	TY-52156	S1P3	
T15032	CYM50308	S1P4; S1P5	
T10305	Amiselimod hydrochloride	S1P1	Phase 1

SGLT

ID	Product Name	Target	Condition
T7217	EGT1442	SGLT2	Phase 3
T5016	Tofogliflozin hydrate	SGLT2; ROS	Approved
T4999	Ertugliflozin	SGLT2	FDA Approved
T4460	Dapagliflozin ((2S)-1,2-propanediol, hydrate)	SGLT2	FDA Approved
T3547	Sotagliflozin	SGLT1; SGLT2	Approved
T2924	Phloretin	SGLT1; SGLT2	
T2922	Phlorizin	hSGLT1; hSGLT2	Preclinical

ID	Product Name	Target	Condition
T2389	Dapagliflozin	hSGLT2	FDA Approved
T2385	Ipragliflozin	SGLT2	Approved
T1782	Canagliflozin	hSGLT2; mSGLT2; rSGLT2	FDA Approved
T1766	Empagliflozin	SGLT1; SGLT2; SGLT4; SGLT5; SGLT6	FDA Approved
T16083	Mizagliflozin	hSGLT1; hSGLT2	
T15656	KGA-2727	SGLT1	

Sigma receptor

ID	Product Name	Target	Condition
T8834	EST64454	σ 1	
T7952	Noscapine	σ -receptor	Approved
T7488	BD1063	σ 1	
T5969	Ditolyguanidine	σ 1/ σ 2	
T5027	Dimemorfan phosphate	σ 1	Approved
T4596	4-IBP	σ 1; σ 2	
T4229	S1RA hydrochloride	σ 2	Phase 2
T4111	Anavex 2-73	σ 1	Phase 2/3
T3597	Cutamesine dihydrochloride	σ 1	Phase 1
T3198L	PRE-084 hydrochloride	σ 1	
T3198	PRE-084 hydrochloride	σ 1	
T1885	Siramesine hydrochloride	lysosome-stabilizing agent; σ 2	Preclinical
T1740	BD1047.2HBr	σ 1	Preclinical
T15393	Glycerol phenylbutyrate	σ 2	FDA Approved
T0678	Amitriptyline hydrochloride	5-HT; 5-HT2; 5-HT4; Norepinephrine receptor; σ 1	FDA Approved

Somatostatin

ID	Product Name	Target	Condition
T4119	Octreotide Acetate	Somatostatin Receptor	FDA Approved
T1080	2-Aminoethanethiol	Cystine; NPYR2; Somatostatin Receptor	FDA Approved


TSH Receptor

ID	Product Name	Target	Condition
T5383	D3- β Arr	thyrotropin receptor (TSHR)	
T12073	ML-109	thyrotropin receptor (TSHR)	

Vasopressin Receptor

ID	Product Name	Target	Condition
T7303	Lixivaptan	Vasopressin Receptor	Phase 2
T6453	Conivaptan hydrochloride	vasopressin receptor 1a; vasopressin receptor 2	FDA Approved
T6288	Mozavaptan	Vasopressin receptor 1; Vasopressin receptor 2	Approved
T5144	Desmopressin acetate	Vasopressin receptor 1; vasopressin receptor 1a; Vasopressin receptor 2	FDA Approved
T5019	Desmopressin	Vasopressin receptor 1; vasopressin receptor 1a; Vasopressin receptor 2	FDA Approved
T4355	OPC 21268	Vasopressin receptor 1	Phase 2
T4141	RO 5028442	hV1a receptor; mV1a receptor	Phase 3
T2568	Felypressin	vasopressin receptor 1a	Approved
T2326	Tolvaptan	vasopressin receptor 1a; vasopressin receptor 2	FDA Approved
T13920L	Terlipressin Acetate	vasopressin V1	

Immunology/Inflammation



AhR

ID	Product Name	Target	Condition
T9112	(-)-Perillaldehyde	AhR; ROS; NRF2/HO1	
T7202	ITE	AhR	
T5622	AHR antagonist 1	AhR	
T5541	PDM 11	AhR	
T5281	3-Methylindole	AhR	
T4938	Indoxyl sulfate potassium salt	AhR	
T4928	L-Kynurenine	Human Endogenous Metabolite; AhR	
T4644	Benvitimod	AhR	Phase 3
T4608	PDM2	AhR	
T4607	CAY10465	AhR	
T2448	CH 223191	AhR	
T1960	YL109	AhR	

ID	Product Name	Target	Condition
T1831	StemRegenin 1	AhR	
T1159	Leflunomide	AhR; DHODH; Protein-tyrosine kinase 2	FDA Approved
T1046	Mexiletine hydrochloride	AhR; Voltage-gated sodium channel	FDA Approved
T0343	Nimodipine	AhR; Calcium Channel; Mineralocorticoid Receptor	FDA Approved

Antiviral

ID	Product Name	Target	Condition
TWS2045	Bruceine D	Antiviral	
T8904	Riamilovir	Antiviral	
T8625	5-Fluorocytidine	antiviral	
T8187	Tetrahydroepiberberine	Antifungal; PI-3 virus	
T7994	3-Methoxyflavone	Antiviral	
T7035	ANTHRAQUINONE-2-CARBOXYLIC ACID	IRAK-1; Syk	
T6S1529	1,5-Dicaffeoylquinic acid	Antiviral; Antioxidant	
T6S0923	Hypericin	antibacterial; antiviral; tyrosine kinases	Phase 3
T6354	(+)-Usniacin	Antibacterial; Antiviral	
T5S0092	Epigoitrin	Antiviral	
T5354	CA-4948	IRAK-4	Phase 1
T5110	IRAK inhibitor 6	IRAK-4	
T5094	IRAK inhibitor 1	IRAK-4; JNK-1	
T4683	3'-Deoxy-3'-fluorothymidine	Antiviral	
T4593	ISOPIMPINELLIN	Antiviral	
T4547	Grazoprevir	NS3/4a protease; gt1a; gt1b	FDA Approved
T4536	Pleconaril	Antiviral	Phase 2
T4492	pocapavir	Antiviral	Phase 2
T4374	Edoxudine	Antiviral	Approved
T4140	IRAK4-IN-1	IRAK-4	
T3S0872	Paederoside	Antiviral	
T3905	Isomangiferin	Antiviral; Free radical scavengers	
T3444	Merimepodib	Antiviral; IMPDH	Phase 2
T3366	Cephalotaxine	Antiviral	
T2945	Germacrone	Antiviral; CYP2B6; CYP3A4	
T2885	Esculin	Antibacterial; Antiviral	
T2457	IRAK-1/4 Inhibitor	IRAK-1; IRAK-4	
T2279	Tizoxanide	Antiviral	FDA Approved
T1750	Pirodavir	Rhinovirus	Phase 2
T0304	Methylthiouracil	antithyroid	Approved
T0090	Moroxydine hydrochloride	DNA viruses; RNA viruses	Approved

Arginase

ID	Product Name	Target	Condition
T0738	Urea	Arginase-1; Carbonic anhydrase II; DHFR; Sulfoxide reductase catalytic subunit YedY; Wnt/ β -catenin	FDA Approved
T0415	Guanidine hydrochloride	Arginase; Lysozyme; Ribonuclease pancreatic; Argininosuccinate synthase	FDA Approved

Aryl Hydrocarbon Receptor

ID	Product Name	Target	Condition
T15410	GNF351	aryl hydrocarbon receptor	

CCR

ID	Product Name	Target	Condition
TQ0297	Cenicriviroc	CCR2; CCR5; HIV-1; HIV-2	Phase 3
TQ0283	RS102895	CCR1	
T7624	DAPTA(TFA)	CCR5	Phase 2
T7499	TAK-779	CCR2; CXCR	
T6413	Bindarit	MCP-1/CCL2; MCP-2/CCL8; MCP-3/CCL7	Phase 2
T6016	Maraviroc	MIP-1 α ; MIP-1 β ; RANTES	FDA Approved
T5384	RS 504393	CCR2	
T4674	SB 297006	CCR3	
T4584	BMS813160	CCR2; CCR5	Phase 2
T4300	AZD2098	CCR4	Preclinical
T3435	Vicriviroc maleate	CCR5	Phase 2
T3430	PF4136309	CCR2	Phase 1
T3360	ZK 756326	CCR8	
T3327	Arteether	CCL4; CCL5; CXCL10; CXCL9	Approved
T3188	NSC5844	CCR1	
T2375	BX471	human CCR1	Preclinical
T12773	RS102895 hydrochloride	CCR2; CCR1; Human α 1a receptor; Human α 1d receptor; 5-HT1A	
T11699	J-113863	CCR1; CCR3	

Cell wall

ID	Product Name	Target	Condition
T21518	Colistin Methanesulfonate (sodium salt)	cell wall	FDA Approved
T1245	Colistin sulfate	cell wall	FDA Approved
T1147	Chlorhexidine hydrochloride	HNMT; CAT; cell wall	FDA Approved

ID	Product Name	Target	Condition
T1143	Carbenicillin disodium	cell wall	FDA Approved
T0832	Vancomycin hydrochloride	cell wall	FDA Approved

Complement System

ID	Product Name	Target	Condition
TP1304	Compstatin	Complement System	
T8223	Avacopan	complement 5a receptor (C5aR)	Phase 2
T7776	ADH-503	CD11b	
T7497L	C3a 70-77 2TFA(63555-63-5(free base))	Complement system	

COX

ID	Product Name	Target	Condition
TQ0180	Chebulagic acid	COX; LOX	
TN2139	Regaloside B	iNOS; COX-2	
TN1723	Hamaudol	COX-1; COX-2	
TN1377	alpha-Spinasterol	COX-1; COX-2; TRPV1	
TN1273	4',7-Dihydroxyflavone	COX; NOD1	
TN1100	Nepodin	COX; AMPK; GLUT	
TN1040	Skullcapflavone II	TGFβ; COX	
T8505	Sc 236	COX-2	
T8356	FPL 62064	COX; 5-LOX	
T8236	RHC 80267	COX; phosphatidylcholine; DAGL	
T7838	Losartan Carboxaldehyde	COX-2	
T7670	Mavacoxib	COX-2	
T7662	6-methoxy Naphthalene Acetic Acid	COX	
T7596	Firocoxib	COX-2	
T7207	FK 3311	COX-2	
T7113	6-paradol	COX-2	
T7081	CCCP	TBK1; IFN-β	
T6S1652	Benzoylpaeoniflorin	COX-1; COX-2	
T6S0722	Isoorientin	Antioxidant; COX-2	
T6S0077	Byakangelicol	COX-2	
T6970	RK33	DDX3	
T6893	MK886	COX-1; COX-2	Preclinical
T6737	Zaltoprofen	COX-1; COX-2	Approved
T6687	Suprofen	COX-1; COX-2	FDA Approved
T6574	Lumiracoxib	COX-1; COX-2	Approved

ID	Product Name	Target	Condition
T6540	Ibuprofen Lysine	COX	FDA Approved
T6465	Dexamethasone Sodium Phosphate	COX-2; IL receptor	FDA Approved
T6424	Bromfenac Sodium	COX1 , COX-2	FDA Approved
T6387	Ampiroxicam	COX	Approved
T5807	Stylopine hydrochloride	Inos; COX-2	
T5759	marmesin	5-Lipoxygenase; COX-2	
T5758	sphondin	COX-2; PGE2	
T5727	CAFESTOL	ERK; COX-2; NF-κB	
T5688	Micheliolide	Inos; COX-2	
T5681	ETHYL CAFFEATE	iNOS,COX-2; PGE2	
T5460	Mofezolac	COX	Approved
T5430	8-SHOGAOL	COX-2	
T5032	Iguratimod	COX-2; MIF	Approved
T5010	Propyphenazone (4-Isopropylantipyrine)	COX-2	Approved
T4S2126	Ginkgetin	STAT3; COX-2	
T4A2456	Gamabufotalin	COX-2	
T4643	TFAP	COX-1	
T4503	Talniflumate	hCLCA1/mCLCA3; COX; Cl-/HCO3- exchanger; GCNT3	Approved
T4313	Tinoridine hydrochloride	COX	Approved
T4101	SC560	COX-1; COX-2	
T4092	AG 126	COX-2; ERK1,2	
T3S1553	Cinnamic aldehyde	COX-2	
T3981	Acacetin	COX-2; XIAP	
T3954	Adelmidrol	COX; NF-κB; PPAR	Phase 2
T3884	Neoandrographolide	COX-2; iNOS	
T3883	Roburic acid	COX-1; COX-2	
T3868	Agnuside	COX-2; P-gp (P-glycoprotein)	
T3747	syringaldehyde	COX-2	
T3744	Veratric acid	COX	
T3500	Flurbiprofen Axetil	COX-1; COX-2	FDA Approved
T3417	Amentoflavone	COX; COX-2; κ-opioid receptor; CYP2C9; CYP3A4; PLA2	
T3342	Xanthohumol	COX	Phase 1
T3332	Isosteviol	COX-2; IL-6; NF-κB; Potassium Channel; TNF-α	Phase 2
T3214	NS398	COX-2	Preclinical
T2S0618	β-Elementic Acid	COX-2; Apoptosis inducer	
T2972	Rutaecarpine	COX-2	
T2878	Ginsenoside Rd	Calcium Channel; COX; P450; NF-κB	
T2856	Epicatchin	COX	Phase 2
T2826	Asarylaldehyde	COX-2	

ID	Product Name	Target	Condition
T2778	(+)-Catechin Hydrate	Antioxidant; COX-1	
T2732	(-)-Epicatechin gallate	COX	Phase 2
T2553	Etofenamate	COX	Approved
T2550	Tolmetin	COX-1; COX-2	FDA Approved
T2403	Bromfenac sodium	COX-2	FDA Approved
T23333	SC 58125	COX-2	
T2230	Paeoniflorin	COX	Phase 3
T2225	4-Hydroxyantipyrine	COX-1; COX-2	Approved
T1867	ATB 346	COX-2	Phase 2
T1780	Parecoxib	COX-2	Approved
T1720	Amenac Sodium Monohydrate	COX-1; COX-2	Approved
T1586	Tenoxicam	COX	Approved
T1582L	Naproxen sodium	COX-1; COX-2	FDA Approved
T1582	Naproxen	COX	FDA Approved
T1574	Etoricoxib	COX	Approved
T15645	Pamicogrel	COX	
T1558	Resveratrol	COX-1; COX-2; DNA polymerase α ; IKK β ; LOX; Quinone reductase 2; SIRT1; SIRT2	Approved
T1555	Diclofenac sodium	COX-1; COX-2	FDA Approved
T1544	Olsalazine disodium	COX; IF γ	FDA Approved
T1541	Drospirenone	Androgen Receptor; COX-2; PR; Mineralocorticoid Receptor	FDA Approved
T1468	Lornoxicam	COX-1; COX-2	Approved
T1467	Acemetacin	COX	Approved
T1432	Phenylbutazone	COX	FDA Approved
T1427	Fosfosal	COX	Approved
T1423	Hydroxytoluic acid	COX	
T1421	Aceclofenac	COX	Approved
T1420	Diethylcarbazine citrate	COX-1; ALOX5	FDA Approved
T1402	Fenofibric acid	MMP; PPAR α ; COX-2	FDA Approved
T1401	Meclofenoxate hydrochloride	COX; ALOX5	Approved
T1394	Ibuprofen	COX-1; COX-2	FDA Approved
T1376	2-Amino-5-methyl-3-thiophenecarbonitrile	COX	
T1325	Carprofen	COX-2	FDA Approved
T1301	Guaiacol	COX; NF- κ B	Approved
T1296	Aminopar	COX-2; ALOX5; MPO; NF- κ B	FDA Approved
T1280	Nepafenac	COX-1; COX-2	FDA Approved
T1258	Nabumetone	COX-1; COX-2; MPO	FDA Approved
T1212	Ketorolac tromethamine salt	COX-1; COX-2	FDA Approved

ID	Product Name	Target	Condition
T1209	Flunixin meglumin	COX-1; COX-2	Approved
T1191L	Dipyron	COX-1	Approved
T1191	Analgin	COX-1	Approved
T1185	Rofecoxib	COX-2	FDA Approved
T1133	Nimesulide	COX-2	Approved
T11005	Desmethyl Celecoxib	COX-2	
T1002	Etodolac	COX; RXR-alpha	FDA Approved
T0980	Nifenazone	COX	Approved
T0961	Trometamol	COX	FDA Approved
T0907	Sulfasalazine	COX-1; COX-2; NF-κB	FDA Approved
T0890	Mefenamic acid	COX-1; COX-2	FDA Approved
T0888	4-Biphenylacetic acid	COX	Approved
T0867	Bufexamac	IFN-α	Approved
T0858	Flufenamic acid	COX	Approved
T0855	(R)-Naproxen	COX	FDA Approved
T0839L	(S)-(+)-Ketoprofen	COX-1; COX-2	FDA Approved
T0839	Ketoprofen	COX-1; COX-2; MRAP4	FDA Approved
T0826	Meloxicam	COX	FDA Approved
T0825	Ebselen	COX	Phase 2
T0824	Nonoxynol	COX	FDA Approved
T0822	Cianidanol	COX-1; COX-2	Approved
T0798	Triamcinolone	COX; Glucocorticoid Receptor	FDA Approved
T0784	Tolfenamic Acid	COX-2	Approved
T0778	Phenacetin	COX-1	Approved
T0758	Piroxicam	COX	FDA Approved
T0734	Antipyrine	COX	Approved
T0726	Benzydamine hydrochloride	COX	Approved
T0708	Oxaprozin	COX	FDA Approved
T0693	Niflumic acid	COX; Monocarboxylate transporter; Chloride channel protein CIC-Ka; PLA2; UGT	Approved
T0649	Salicylic acid	COX	Approved
T0646	Mesalamine	COX; ALOX5; MPO; NF-κB; PPARγ	FDA Approved
T0498	Sasapyrine	COX-1; COX-2	Approved
T0484	Deracoxib	COX-2	FDA Approved
T0477	Zileuton	COX-1; 5-Lipoxygenase	FDA Approved
T0466	Celecoxib	COX-2	FDA Approved
T0463	Loxoprofen	COX	Approved
T0459	Sulindac	COX	FDA Approved
T0458	Indometacin	COX-1; COX-1; COX-2; PDE2; PLA2	FDA Approved
T0456	Cinchophen	COX	Approved

ID	Product Name	Target	Condition
T0451	Minoxidil	COX-1; Potassium Channel	FDA Approved
T0448	Dexibuprofen	Bcl-2; COX; Cystic fibrosis transmembrane conductance regulator; PPARγ; thrombomodulin	Approved
T0443	Salicoside	COX	Approved
T0441	Pasiniazid	COX; NADPH	Approved
T0436	Aceexamid Acid	Amino Acids and Derivatives; COX	Approved
T0435	Sulfinpyrazone	COX; cMOAT	FDA Approved
T0432	Diclofenac diethylamine	COX; huMan COX-2(in CHO cells); human COX-1(in CHO cells); ovine COX-2; ovine COX-1	FDA Approved
T0424	Bismuth subsalicylat	COX-1; COX-2	FDA Approved
T0335	Sodium salicylate	COX-1; COX-3; NF-κB	Approved
T0321	Indoprofen	COX	
T0291	Flurbiprofen	COX; MRP	FDA Approved
T0285	Isoxicam	COX	
T0260	Meclofenamate Sodium	COX-1; COX-2	FDA Approved
T0219	Valdecoxib	COX-2	FDA Approved
T0212	Seratrodist	COX; TXA2R	Approved
T0196	Diclofenac	COX	FDA Approved
T0184	Fenoprofen calcium dihydrate	COX-1; COX-2	FDA Approved
T0065	Acetaminophen	COX-1; COX-2	FDA Approved
T0058	2-Ethoxybenzamide	COX	Approved
T0057	Famprofazone	COX-1; COX-2	Approved
T0055	Glafenine	COX	Approved
T0050	4-Aminoantipyrine	COX	Approved
T0005	Aspirin	COX-1; COX-2	FDA Approved
T0004	Salicylamide	COX-1; COX-2	Approved

CXCR

ID	Product Name	Target	Condition
TP1348	FC131 TFA	CXCR4; HIV	
T8497	SX-682	CXCR1; CXCR2	Phase 1
T7681	AZD-5069	CXCR2	Phase 2
T7499	TAK-779	CCR2; CXCR	
T7130	Navarixin	CXCR1; CXCR2	Phase 2
T5849	JMS-17-2	CX3CR1	
T5207	LIT927	CXCL12	
T5193	Danirixin	CXCR2	Phase 2
T4163	Repertaxin	CXCR1; CXCR2	Phase 3
T4033	MSX130	CXCR4	
T4032	MSX127	CXCR4	

ID	Product Name	Target	Condition
T3992	MSX122	CXCR4; CXCL12	Phase 2
T3396	Baohuoside I	CXCR4	Preclinical
T3327	Arteether	CCL4; CCL5; CXCL10; CXCL9	Approved
T3047	SRT3109	CXCR2	
T2477	UNBS5162	CXCL	Phase 1
T1955	SB225002	CXCR2	Preclinical
T1776L	Plerixafor 8HCl (AMD3100 8HCl)	CXCL12; CXCR4	FDA Approved
T1776	Plerixafor	CXCL12; CXCR4	FDA Approved
T1739	WZ811	CXCR4	
T17208	USL311	CXCR4	Phase 1/2
T14665L	Motixafortide TFA(664334-36-5,Free)	CXCR4	Phase 2
T10297L	AMG 487	CXCR3	
T0801	Tannic acid	CXCR; hERG channel	FDA Approved

FLAP

ID	Product Name	Target	Condition
T8844	Diflapolin	sHE; FLAP	

gp120/CD4

ID	Product Name	Target	Condition
T6256	YYA021	Gp120; HIV	

Histamine Receptor

ID	Product Name	Target	Condition
TN1154	6-Methoxyloleolin	Calcium Channel; Histamine Receptor	
TN1008	Psoralenoside	H1 receptor	
T8822	JNJ-5207852 dihydrochloride	H3 receptor	
T8599	Betazole hydrochloride	H2 receptor	FDA Approved
T8548	Metoprine	histamine N-methyltransferase; antifolate	
T8514	LML-134	H3 receptor	Phase 2
T8439	Clobenpropit dihydrobromide	H3 receptor	
T7564	Chlorphenoxamine	Histamine Receptor	
T7524	Metiamide	H2 receptor	
T7413	JNJ-5207852	H3 receptor	
T7176	Pitolisant hydrochloride	H3 receptor	FDA Approved

ID	Product Name	Target	Condition
T7085	Mebhydroline	H1 receptor	Approved
T6535	Histamine Phosphate	Histamine H1 receptor , Histamine H2 receptor	FDA Approved
T6534	Histamine 2HCl	H1 receptor; H2 receptor	Approved
T6405	Bepotastine Besilate	H1 receptor	FDA Approved
T6242	Rupatadine Fumarate	H1 receptor; PAFR	Approved
T6164	Ciproxifan	H3 receptor	Preclinical
T5829	H4 Receptor antagonist 1	H4 receptor	
T5495	Decloxizine dihydrochloride	H1 receptor	Approved
T4566	Lodoxamide	Histamine Receptor	FDA Approved
T4563	Thonzylamine	H1 receptor	Approved
T4551	Acrivastine	H1 receptor	FDA Approved
T4507	Chlorphenesin	Histamine release	FDA Approved
T4499	Mequitazine	H1 receptor	Approved
T4250	Bilastine	H1 receptor; H1 receptor(in guinea-pig cerebellum)	Approved
T4195	Bethahistine	H1 receptor	Approved
T4099	S38093	Human H3 receptor; Mouse H3 receptor; Rat H3 receptor	Phase 2
T3979	Emedastine	H1 receptor	FDA Approved
T3963	VUF10460	H4 receptor	
T3723	Dioxopromethazine hydrochloride	H1 receptor	
T3610	Ranitidin	H2 receptor	FDA Approved
T3429	Protopine	H1 receptor; platelet aggregation	
T2848	Osthole	H1 receptor	Preclinical
T2533	Alcaftadine	H1 receptor; H2 receptor; H4 receptor	FDA Approved
T2520	Desloratadine	H1 receptor	FDA Approved
T2335	Ebastine	H1 receptor	Approved
T22713	Decloxizine	H1 receptor	Approved
T2232	JNJ7777120	H4 receptor	Preclinical
T2222	Carbinoxamine Maleate Salt	H1 receptor	FDA Approved
T2200	Hydroxyzine dihydrochloride	H1 receptor	FDA Approved
T20884	Hydroxyzine free base	H1 receptor	Approved
T20712	Conessine	H3 receptor	
T2004	Ciproxifan maleate	H3 receptor	Preclinical
T1822L	Clemizole hydrochloride	NS4BH1 histamine receptor	Approved
T1822	Clemizole	NS4BH1 histamine receptor	Phase 2
T1627	Famotidine	H2 receptor	FDA Approved
T1619	Trazodone hydrochloride	5-HT; Sert (Sodium-dependent); Adrenergic Receptor; H1 receptor	FDA Approved
T1575	Nizatidine	AChE; H2 receptor	FDA Approved
T1553	Chlorpheniramine maleate	H1 receptor	FDA Approved

ID	Product Name	Target	Condition
T1470L	Fexofenadine hydrochloride	H1 receptor	FDA Approved
T1470	Fexofenadine hydrochloride	Histamine H1 receptor	FDA Approved
T1469	Levocetirizine	H1 receptor	FDA Approved
T1425	Pemrolast potassium	H1 receptor	FDA Approved
T1393	Sodium butanoate	H1 receptor	Phase 3
T1327	Nortriptyline hydrochloride	5-HT; Sert (Sodium-dependent); mAChR; Adrenergic Receptor; Dopamine; H1 receptor; Noradrenaline transporter (Sodium-dependent)	FDA Approved
T1308	Orphenadrine hydrochloride	H1 receptor; NMDA receptor; Noradrenaline transporter (Sodium-dependent); Sodium Channel	FDA Approved
T1278	Astemizole	H1 receptor; Potassium Channel	
T1269	Tripelennamine hydrochloride	H1 receptor	FDA Approved
T1232	Pyrimamine maleate	H1 receptor	FDA Approved
T1182	Propionyl-L-carnitine hydrochloride	H1 receptor	Approved
T1115	Doxylamine succinate	H1 receptor	FDA Approved
T1110	Meclizine dihydrochloride	H1 receptor	FDA Approved
T1097	Loratadine	B(0)AT2	FDA Approved
T1090	Perphenazine	CAM; Dopamine; 5-HT2A receptor; Histamine H1 receptor; Alpha-1A adrenergic receptor	FDA Approved
T1045	Trimipramine maleate	5-HT; Sert (Sodium-dependent); Adrenergic Receptor; DA transporter; Dopamine; H1 receptor; Noradrenaline transporter (Sodium-dependent)	FDA Approved
T1030	Tripolidine hydrochloride	H1 receptor	FDA Approved
T0994	Ketotifen fumarate	H1 receptor; PDE	FDA Approved
T0942	Quinacrine dihydrochloride	DNA; Histamine N-methyltransferase; PLA2; PLCLP	Phase 2
T0903	Stugeron	Calcium Channel; H1 receptor	Approved
T0865	Ranitidine Hydrochloride	H2 receptor	FDA Approved
T0797	Cimetidine	H2 receptor	FDA Approved
T0785	Dexchlorpheniramine Maleate	Sert (Sodium-dependent); DA transporter; H1 receptor; Noradrenaline transporter (Sodium-dependent)	FDA Approved
T0468	Xylocaine	H1 receptor	FDA Approved
T0445L	Promethazine hydrochloride	α -adrenergic receptor; H1 receptor	FDA Approved
T0445	Promethazine	5-HT; mAChR; Adrenergic Receptor; CAM; D2; H1 receptor	FDA Approved
T0381	Amodiaquine hydrochloride	histamine N-methyl transferase	FDA Approved
T0330	Diphenhydramine hydrochloride	H1 receptor	FDA Approved
T0298	Dimenhydrinate	H1 receptor	FDA Approved
T0263	Chloropyramine hydrochloride	FAK-VEGFR-3; H1 receptor	Approved
T0246L	Betahistine mesylate	H1 receptor; H3 receptor	Approved

ID	Product Name	Target	Condition
T0246	Bethahistine dihydrochloride	H3 receptor	Approved
T0211L	Azelastine hydrochloride	H1 receptor	FDA Approved
T0172	Maprotiline hydrochloride	5-HT; mAChR; Adrenergic Receptor; H1 receptor; Noradrenaline transporter (Sodium-dependent)	FDA Approved
T0157	Roxatidine Acetate hydrochloride	H2 receptor	Approved
T0147	Clemastine fumarate	H1 receptor	FDA Approved
T0118	Mizolastine	H1 receptor	Approved
T0092	Antazoline hydrochloride	H1 receptor	FDA Approved
T0089	Cetirizine dihydrochloride	H1 receptor	FDA Approved
T0076	Paliperidone	5-HT; β -adrenergic receptor; Dopamine; H1 receptor	FDA Approved
T0074L	Chlorprothixene hydrochloride	5-HT; mAChR; Dopamine; H1 receptor	FDA Approved
T0074	Chlorprothixene	5-HT6; 5-HT7; D2; D3; H1 receptor	FDA Approved
T0059	Diphenylpyraline hydrochloride	H1 receptor	FDA Approved
T0053	Hydroxyzine Pamoate	H1 receptor	FDA Approved
T0031L2	Ziprasidone	5-HT transporter; 5-HT1A; 5-HT1B; 5-HT1D; 5-HT2A; 5-HT2C; 5-HT6; 5-HT7; α 1A-adrenergic receptor; α 2A-adrenergic receptor; D1; D2; D3; H1 receptor; norepinephrine transporter (NET)	FDA Approved
T0031L	Ziprasidone hydrochloride	5-HT transporter; 5-HT1A; 5-HT1B; 5-HT1D; 5-HT2A; 5-HT2C; 5-HT6; 5-HT7; α 1A-adrenergic receptor; α 2A-adrenergic receptor; D1; D2; D3; H1 receptor; norepinephrine transporter (NET)	FDA Approved
T0031	Ziprasidone hydrochloride monohydrate	5-HT transporter; 5-HT1A; 5-HT1B; 5-HT1D; 5-HT2A; 5-HT2C; 5-HT6; 5-HT7; α 1A-adrenergic receptor; α 2A-adrenergic receptor; D1; D2; D3; H1 receptor; norepinephrine transporter (NET)	FDA Approved

IL Receptor

ID	Product Name	Target	Condition
TN1936	Mogroside IIIe	TNF- α ; IL Receptor; TLR	
TN1035	Irisolidone	VRAC; IL Receptor; NF-Kb	
TN1012	Febrifugine	Antifection; IL Receptor	
T9113	Myristicin	Antifection; Bcl-2; Caspase; CYP17; GABA Receptor; IL Receptor; NO; PARP	
T8867	RO2959 Hydrochloride	CRAC channel; IL-2	
T8828	CP 424174	IL-1 β	
T8280	Desacetyl asperulosidic acid	IL-2	
T6465	Dexamethasone Sodium Phosphate	COX-2; IL receptor	FDA Approved
T5S0167	Atractylenolide I	TNF- α ; IL-6	
T5788	XYLOBIOSE	TNF- α ; IL-1 β	

ID	Product Name	Target	Condition
T5779	MOSLOFLAVONE	TNF- α ; IL-1 β	
T5680	ALOIN	MMP; IL Receptor	
T5660	Menthone	TNF- α ; NF- κ B; IL receptor	
T4S0795	Berberrubine	IL-8	
T4A2399	Cinobufotalin	Akt; IL Receptor; MRP1; P-gp	Phase 1
T4450	GIBH130	IL-1 β ; TNF- α	
T4279	Esonarimod	IL-1	Phase 3
T3S0364	L-Arginine	IL-2	FDA Approved
T3910	Anemoside B4	IL-10	
T3830	20R-Ginsenoside Rg2	IL-1 α	
T3614	Isoprinosine	IL-2	Approved
T3533	Apilimod mesylate	IL-12; IL-23	Phase 1
T3416	Aucubin	IL-1 β ; NF- κ B	
T3332	Isosteviol	COX-2; IL-6; NF- κ B; Potassium Channel; TNF- α	Phase 2
T3280	Disodium clodronate tetrahydrate	IL-1 β ; IL-6; TNF- α	Approved
T3133	YM90709	IL-5	
T2S0501	Ilexgenin A	IL Receptor; TNF- α	
T2932	Ginsenoside Rh1	IL Receptor; PPAR; TNF Receptor	
T2018	Apilimod	IL-12; IL-23; PIKfyve	Phase 1
T1846	Y320	ATGL; IL-17 production	
T1813	VGX1027	IL-10; IL-1 β ; TNF- α	Phase 1
T1639	Amlexanox	FGFR1; IL-3; Protein S100-P; IKK ϵ ; TBK1	FDA Approved
T14778	BRD6989	CDK8; recombinant CDK8; recombinant CDK19; IL-10	
T1347	2-Benzothiazolamine	IL-8	
T1273	Diacerein	IL-1 β	Approved
T1246	Bornyl acetate	IL receptor	
T1076	Dexamethasone	Glucocorticoid Receptor; IL receptor	FDA Approved
T0947	Dexamethason acetate	Annexin A1; Glucocorticoid Receptor; IL receptor; iNOS	FDA Approved
T0694	Pranlukast	IL-5; CysLTR; NF- κ B; Eosinophil cationic protein; Mucin-2; TNF- α	Approved
T0122	Bengenin	IL-1 β ; IL-6; NF- κ B; NOD; TNF- α	Approved
T0117	Suplatast tosilate	Th2 cytokine	Approved
Fr14115	Terpineol	Antifection; IL Receptor	

Immunology & Inflammation related

ID	Product Name	Target	Condition
TP2324	Thymulin	Immunology & Inflammation related	
TN1697	Glucosyringic acid	Immunology & Inflammation related	
TN1256	3-O-Acetyl-16 alpha-hydroxytrametenolic acid	Immunology & Inflammation related	

ID	Product Name	Target	Condition
TN1015	Meranzin	Immunology & Inflammation related	
T8846	beta-Escin	Immunology & Inflammation related	
T8145	Benzyl cinnamate	Immunology & Inflammation related	
T7522	GI 254023X	MMP-9; ADAM10	
T4S1849	Tubeimoside III	Immunology & Inflammation related	
T4122	TAPI-1 trifluoroacetate (171235-71-5(free base))	ADAM17/TACE	
T3834	8-Epideoxyloganic acid	Immunology & Inflammation related; ROS	
T13410	ZLDI-8	ADAM-17	

Interleukin Related

ID	Product Name	Target	Condition
T6207	SC144	gp130	
T5641	RP-54745	interleukin-1	
T5359	RCGD423	gp130	

IRAK

ID	Product Name	Target	Condition
T2822	Ginsenoside Rb1	Autophagy; IRAK; Mitophagy; (Na,K)-ATPase; NF-κB	

LTR

ID	Product Name	Target	Condition
T8727	TH1020	TLR5; Bacterial	
T7841	MK 571	CysLTR1	
T4192	hns-PLA Inhibitor	LTA(4)H-h; hnsPLA2	
T4114	Diffractic Acid	LTB4	
T3738	3-(4-Hydroxyphenyl)-1-propanol	LTR	
T3715	Acebilustat	LTB4	Phase 2
T3148	Propanoic acid	CysLTR1	Phase 2
T1677L	Montelukast sodium	CysLTR1	FDA Approved
T1677	Montelukast	ALOX5; CysLTR1	FDA Approved
T1257	Ubenimex	LTA(4)H-h; APN	Approved
T0694	Pranlukast	IL-5; CysLTR; NF-κB; Eosinophil cationic protein; Mucin-2; TNF-α	Approved

MALT

ID	Product Name	Target	Condition
T2350	MI 2 (MALT1 inhibitor)	MALT1	Preclinical

MRP

ID	Product Name	Target	Condition
T8596	Ceefourin 1	MRP4	
T1571	Estriol	ER; MRP1	Approved
T1484L	Perindopril erbumine	MRP1; ACE	FDA Approved
T1434	Clarithromycin	MRP1; 50S ribosome	FDA Approved
T1130	Gramicidin	MRP1	FDA Approved
T1050	Prazosin hydrochloride	ABCG; Adrenergic Receptor; MRP1; Potassium Channel	FDA Approved
T1018	Prednisone	Glucocorticoid Receptor; MRP1	FDA Approved
T0924	Benzocaine	MRP1; LCE 1; Sodium Channel	Approved
T0866	Propafenone	MRP1; Potassium Channel; Sodium Channel	FDA Approved
T0839	Ketoprofen	COX-1; COX-2; MRAP4	FDA Approved
T0791	Reserpine	MRP1; SVAT; Bile salt export pump	FDA Approved
T0760	Cholesterol	MRP1; ROR α	
T0707	Cyclophosphamide monohydrate	DNA; MRP1	FDA Approved
T0706	Lisinopril dihydrate	MRP1; ACE	FDA Approved
T0450	Fluoxetine	Sert (Sodium-dependent); MRP1	FDA Approved
T0291	Flurbiprofen	COX; MRP	FDA Approved

MyD88

ID	Product Name	Target	Condition
T13063	T6167923	MyD88	

NADPH-oxidase

ID	Product Name	Target	Condition
T8408	GKT136901	NOX1	
T8107	GLX351322	NOX4	
T6099	GKT137831	NOX1; NOX4	Phase 2
T10353	APX-115 free base	Nox1; Nox2; Nox4	
T0679	Ketoconazole	12-hydroxylase; 17-hydroxylase; Steroid 21-hydroxylase; Testosterone 6 beta-hydroxylase; Cyclosporine oxidase; CYP24A1; CYP3A4	FDA Approved

NO Synthase

ID	Product Name	Target	Condition
TN2286	Tsugaric acid A	NO Synthase	
TN2003	Obtucarbamate A	NO Synthase	
TN1546	Dactylorhin A	NO Synthase	
TN1006	Tirucalol	PGE; NO Synthase; NOS	
T7992	4-Hydroxyflavanone	nitric oxide	
T12808	S-Nitroso-N-acetyl-DL-penicillamine	NO Synthase	Phase 4

NOD

ID	Product Name	Target	Condition
TQ0165	Arglabin	NLRP3	
TN1273	4',7-Dihydroxyflavone	COX; NOD1	
T7682	Asymmetric dimethylarginine	NO synthesis; Human Endogenous Metabolite	
T7597	6-Biopterin	NO synthesis	
T6S1367	Procyanidin B2	NLRP3	
T6887	MCC950 sodium	NLRP3	
T6591	ML130	NOD1; NOD2; TNF- α	
T5838	L-Canavanine sulfate	NO synthesis	
T4217	INF39	NLRP3	
T4164	CY09	NLRP3	
T3587	NOD-IN-1	NOD1; NOD2	
T3230	NLRP3 Inflammasome Inhibitor I	NLRP3	
T3092	Nigericin sodium salt	NLRP3	
T2845	Imperatorin	BChE; NO synthesis; TRPV1	Approved
T15052	Dapansutrile	NLRP3	Phase 2
T0122	Bengenin	IL-1 β ; IL-6; NF- κ B; NOD; TNF- α	Approved
T0109	Molsidomine	NOD	Approved

NOD-like Receptor (NLR)

ID	Product Name	Target	Condition
T0772	Troxerutin	NOD-like Receptor (NLR)	Approved

NOS

ID	Product Name	Target	Condition
TN2139	Regaloside B	iNOS; COX-2	

ID	Product Name	Target	Condition
TN1006	Tirucalol	PGE; NO Synthase; NOS	
T8213	Isolinderalactone	STAT3; iNOS	
T7543	S-(2-aminoethyl) Isothiourea (dihydrobromide)	NOS	
T7474	7-Nitroindazole	NOS	
T7191	Diphenyleneiodonium chloride	NOS	
T6570	L-NAME hydrochloride	eNOS; iNOS; nNOS	Phase 2
T5S0281	Tubuloside A	NOS	
T5807	Stylopine hydrochloride	Inos; COX-2	
T5688	Micheliolide	Inos; COX-2	
T5681	ETHYL CAFFEATE	iNOS, COX-2; PGE2	
T5676	(Z)-SU4312	MAO-B; NOS	
T4S0800	Demethyleneberberine	CYP17; HIF; NOS	
T4953	Neotuberostemonine	NOS	
T3884	Neoandrographolide	COX-2; iNOS	
T3491	1400W dihydrochloride	eNOS; iNOS; nNOS	
T3408	eleutheroside-b	NOS	Preclinical
T2876	Flavone	NOS	
T19916	TRIM	nNOS	
T0947	Dexamethason acetate	Annexin A1; Glucocorticoid Receptor; IL receptor; iNOS	FDA Approved
T0358	Aminoguanidine hydrochloride	iNOS	FDA Approved
T0344	Miconazole	14- α Demethylase; eNOS; iNOS; Potassium Channel	FDA Approved

Nrf2

ID	Product Name	Target	Condition
TQ0211	Brusatol	Nrf2	
TN6711	toralactone	Nrf2	
TN1548	Daidzin 6''-O-malonate	ROS; Nrf2	
T9112	(-)-Perillaldehyde	AhR; ROS; NRF2/HO1	
T8704	4-hydroxyphenyl acetate	NRF2	
T6919	Omaveloxolone	Nrf2	Phase 2
T5S1805	5,7-Dihydroxychromone	Nrf2	
T5364	TBHQ	Nrf2	
T4360	ML385	Nrf2	
T3012	Mangiferin	Nrf2; p50; p65	
T2915	Bardoxolone	Nrf2	Phase 1
T1593	Ezetimibe	NPC1L1; Nrf2; Sterol O-acyltransferase	FDA Approved
T12253	Nrf2-IN-1	Nrf2	

PD-1/PD-L1

ID	Product Name	Target	Condition
T8470	BMS-1001	PD-1/PD-L1	
T5697	BMS1166	PD-1/PD-L1	
T4696	BMS202 hydrochloride (1675203-84-5(free base))	PD-1/PD-L1	
T3655	PD-1/PD-L1 inhibitor 1	PD-1/PD-L1	
T3146	PD1-PDL1 inhibitor 2	PD-1/PD-L1	
T10565	BMS-1001 hydrochloride	PD-1/PD-L1	

PGE Synthase

ID	Product Name	Target	Condition
T4S0227	Sinensetin	hPGDS	
T2681	hPGDS-IN-1	hPGDS	
T1804	HPGDS-inhibitor-1	hPGDS	
T15757	Limaprost	PGE Synthase	Approved

Prostaglandin Receptor

ID	Product Name	Target	Condition
TQ0203	Tafuprost	PGF2 α	FDA Approved
TQ0025	E7046	EP4	Phase 1
TN1006	Tirucallol	PGE; NO Synthase; NOS	
T7968	Dazoxiben	Thromboxane (TX) synthase	
T7652	AM211	prostaglandin D2 receptor	
T7053	p-Hydroxy-cinnamic acid	Thromboxane A2 synthetase; PGE2	
T6485	Embelin	XIAP; 5-Lipoxygenase; mPGES-1	FDA Approved
T5847	Cloprostenol sodium	PGF2 α receptor	
T5841	Travoprost	Prostaglandin Receptor	FDA Approved
T5774	7-demethylsuberosin	PGE2	
T5758	sphondin	COX-2; PGE2	
T5482	TG4-155	EP2	
T5386	Asapiprant	DP1 receptor	Phase 3
T5171	Treprostinil Sodium	DP1, IP, EP2; VEGFR2; RET	FDA Approved
T5014	Prostaglandin E2 (PGE2)	EP2 Receptor; Human Endogenous Metabolite	FDA Approved
T4981	Anisotropine Methylbromide	Cholinergic; DP1; IP; EP2	FDA Approved
T4635	Ralinepag	Prostacyclin receptor; rat IP	Phase 3
T4546	Dinoprost Tromethamine	PEG	FDA Approved
T3S2007	MRE269	prostaglandin I2 receptor	

ID	Product Name	Target	Condition
T3903	Angoroside C	PGE2	
T3889	Platycodin D	PGE2	
T3306	PF04418948	PGE2	Phase 1
T3276	Benorilate	PGF	Approved
T3174	Taprenepag	PGE2	Phase 2
T2868	Evodiamine	PGE	Preclinical
T2786	Oxysophocarpine	PGE2	
T2538	Bimatoprost	PGF2; PGE2	FDA Approved
T1978	GW 627368X	EP4	
T1626	Alprostadil	PGE	FDA Approved
T15259	Evatanepag	PGE2	
T14865	Carboprost tromethamine	prostaglandin F2 α	FDA Approved
T0795	Rutin	AKR	Approved
T0159	Pranoprofen	PGE2	Approved
T0002	Ethamsylate	Prostaglandin Receptor	Approved

Reactive Oxygen Species

ID	Product Name	Target	Condition
T8320	J-14	sulfiredoxin	
T7098	BAPTA	Ca ²⁺ chelator	

ROS

ID	Product Name	Target	Condition
TN1918	Medicarpin	ROS; JNK; Bcl-2	
TN1721	Gypenoside L	ROS; Calcium Channel	
TN1548	Daidzin 6''-O-malonate	ROS; Nrf2	
TN1146	8-Prenylnaringenin	ROS	
T9112	(-)-Perillaldehyde	AhR; ROS; NRF2/HO1	
T8347	Rifamycin S	Bacterial; ROS	Phase 3
T8255	(\pm)-Catechin hydrate	ROS	
T7709	(E/Z)-GSK5182	ERR γ ; ROS	
T6947	Piperlongumine	ROS	
T6917	Oleuropein	Aromatase; ROS	
T6699	Tempol	ROS	Phase 1
T5518	N-acetylcysteine amide	ROS	Phase 1
T5426	DMNQ	ROS	
T5016	Tofogliflozin hydrate	SGLT2; ROS	Approved
T4957	Carnosic acid	ROS	

ID	Product Name	Target	Condition
T4309	CIL56	ROS	
T3834	8-Epideoxyloganic acid	Immunology & Inflammation related; ROS	
T3678	Entrectinib	ALK; ROS1; TrkA; TrkB; TrkC	FDA Approved
T3621	Brigatinib	ALK; EGFR (C797S/del19); FLT3; IGF-1R; ROS1	FDA Approved
T3415	Secoisolariciresinol diglucoside	ROS	Preclinical
T3374	Dihydrotanshinone I	ROS	
T3061	Lorlatinib	ALK; ALK (L1196M); ROS1; ROS1; LTK (TYK1)	FDA Approved
T2858	Baicalein	XO	Approved
T2841	Plumbagin	ROS	
T2397	Topiroxostat	XO	Approved
T22318	DS-6051b	ROS1; TrkA; TrkB; TrkC	
T1694	Oxypurinol	XO	Phase 1
T1630	Tiopronin	ROS	FDA Approved
T15433	GSK2795039	NADPH; apoptosis; ROS	
T1363	4-Methoxy-2-oxo-1,2-dihydro-pyridine-3-carbonitrile	XO	
T10668	Camalexin	ROS	
T0877	Gallic acid	ROS	Approved
T0875	Acetylcysteine	ROS; TNF- α	FDA Approved
T0773	Febuxostat	XO	FDA Approved
T0692	Allopurinol	XO	FDA Approved
T0437	Inosine	XO	FDA Approved


STING

ID	Product Name	Target	Condition
T8798	MSA-2	STING	
T8655	SR-717	STING	
T8328	STING agonist-1	STING	
T7329	C-178	mSTING	
T5674	H-151	STING	
T5516	diABZI STING agonist-1 trihydrochloride	STING	
T5317	Cridanimod	mSTING	Phase 2
T5154	C176	STING	

TLR

ID	Product Name	Target	Condition
TQ0205	Procyanidin B1	TLR4/MD-2	
TQ0181	Resatorvid	TLR4; TNF-R	Phase 3
TP1938L	RS09 2TFA 1449566-36-2(free base)	TLR4	
TP1067	Pam3CSK4 TFA	TLR2/1	
TN2008	Okanin	TLR4; NF-κB	
TN1936	Mogroside IIIe	TNF-α; IL Receptor; TLR	
T8689	CHLOROQUINE	HIV-1; autophagy; TLR; SARS-COV-2	FDA Approved
T8503	TLR4-IN-C34	TLR4	
T8316	1V209	TLR7	
T7860	SM 324405	TLR7	
T7672	MD2-TLR4-IN-1	MD2-TLR4	
T7347	CU-CPT-8m	TLR8	
T7317	CU-CPT-9a	TLR8	
T7302	CU-CPT9b	TLR8	
T6964	Resiquimod	TLR7; TLR8	Phase 2
T6898	Motolimod	TLR8	Phase 2
T6846	Vesatolimod	TLR7	Phase 2
T5561	TLR7/8 agonist 1 dihydrochloride	TLR7; TLR8	
T4258	TLR7-agonist-1	TLR7	
T4231	MD2-IN-1	Myeloid differentiation protein 2 (MD2)	
T4206	E6446	TLR7; TLR9	
T4080	Leonurine hydrochloride	TLR	
T4068	E6446 dihydrochloride	TLR	
T3502	C29	TLR2/1; TLR2/6	Preclinical
T2911	Stevioside	TLR2	
T23171	Poly(I:C)	TLR3	
T15777	Loxoribine	TLR7	
T15020	CU-CPT22	TLR2/1	
T15017	CU-T12-9	TLR2; TLR1	
T12516	Polyinosinic-polycytidylic acid sodium	TLR3; RIG-I; MDA5; apoptosis	
T10899	CU-CPT17e	TLR3; TLR8; TLR9	
T0951	Hydroxychloroquine sulfate	DNA; TLR9	FDA Approved
T0194	Chloroquine diphosphate	Autophagy; TLR7; TLR9	FDA Approved
T0134	Imiquimod	TLR7; TLR8	FDA Approved

JAK/STAT signaling



EGFR

ID	Product Name	Target	Condition
T9905	Cetuximab (anti-EGFR)	EGFR	Approved
T8872	(Rac)-JBJ-04-125-02	EGFR (L858R/T790M)	
T8758	Poziotinib hydrochloride	EGFR	
T8751	AZD8931 diFuMaric acid	EGFR; ErbB2; ErbB3	
T8679	Epidermal Growth Factor	EGFR	
T8460	Olmutinib	EGFR	
T8431	JCN037	EGFR	

ID	Product Name	Target	Condition
T8189	Dihydroberberine	hERG; HSP90	
T8151	Mobocertinib	EGFR	
T7649	Tyrphostin A1	EGFR	
T7322	Theliatinib	EGFR	
T7198	E-4031	hERG Potassium Channel	
T7175	AST2818 mesylate	EGFR	Phase 3
T6932	PD168393	EGFR; FGFR; Insulin Receptor; PDGFR; PKC	Preclinical
T6918	Olmotinib	EGFR (cell: H1975); EGFR (cell: HCC827); BTK	Approved
T6824	EAI045	EGFR mutants	
T6734	WZ8040	EGFR (T790M)	
T6733	WZ3146	EGFR (E746_A750); EGFR (E746_A750/T790M); EGFR (L858R); EGFR (L858R/T790M)	
T6712	Tyrphostin AG 879	EGFR; HER2-Neu; PDGFR; Trk	
T6427	Butein	EGFR; p60c-src	
T6331	AST-1306 TsOH	EGFR; EGFR (T790M/L858R); HER2/ErbB2; HER2/ErbB2; FLT1	Phase 1
T6328	Desmethyl Erlotinib	EGFR	
T6266	PP2	EGFR; JAK2; Fyn; Lck; ZAP70	
T6238	WZ4002	EGFR (L858R); EGFR (L858R/T790M)	
T6235	Lapatinib Ditosylate	EGFR; HER2/ErbB2	FDA Approved
T6227	Benidipine hydrochloride	EGFR (L861Q); c-Src; c-Yes; Lck; Lyn	Approved
T6196	PP1	Bcr-Abl; Kit; EGFR; Fyn; Lck	
T6153	Icotinib	EGFR	Approved
T6136	Canertinib	EGFR; HER2/ErbB2	Phase 2
T6124	Mubritinib	EGFR; HER2/ErbB2; FGFR; JAK1; PDGFR	Phase 1
T6092	Sapitinib	EGFR; HER2/ErbB2; HER2/ErbB2	Phase 1/2
T6078	Saracatinib	c-Src; Lck; BLK; EGFR (L858R); EGFR (L861Q); c-Yes; FGR; Fyn; Lyn	Phase 2
T6008	CNX2006	EGFR (mutant)	
T5675	HS-10296 hydrochloride	EGFR	Phase 3
T5437	Gefitinib-based PROTAC 3	EGFR	
T5410	PD158780	EGFR; ErbB2; ErbB3; ErbB4	
T5168	EGFR Inhibitor	EGFR; EGFR (L858R); EGFR (L861Q)	
T5155	AG 99	EGFR	
T4694	AG-1557 hydrochloride (189290-58-2(free base))	hERG; EGFR	
T4612	NS309	Potassium Channel; hERG	Preclinical
T4528	Tyrphostin AG 528	EGFR; ErbB2	
T4326	AG 555	EGFR	
T4296	MTX211	EGFR; PI3K	Preclinical
T4249	AZD3759 hydrochloride	EGFR (exon 19De); EGFR (L858R); EGFR (wt)	Phase 2/3
T4205	AG 494	EGFR	

ID	Product Name	Target	Condition
T4014	CP724714	HER2/ErbB2	
T3870	Cyasterone	EGFR	
T3721	Avitinib maleate	EGFR	Phase 2
T3659	AZD3759	EGFR (exon 19Del); EGFR (L858R); EGFR (WT)	Phase 2/3
T3634	Osimertinib mesylate	EGFR (L858R); EGFR (L858R/T790M)	FDA Approved
T3621	Brigatinib	ALK; EGFR (C797S/del19); FLT3; IGF-1R; ROS1	FDA Approved
T3558	EBE-A22	EGFR/ErbB1	
T3554	RG 14620	HER14 colony formation; HER14 DNA synthesis; EGFR	
T3545	RG 13022	EGFR	Preclinical
T3506	Nazartinib	EGFR (mutant)	Phase 3
T3402	Ginsenoside Rg3	EGFR	Approved
T3192	NS1643	HERG	
T3108	CUDC101	EGFR; HDAC; HDAC1; HDAC10; HDAC2; HDAC3; HDAC4; HDAC5; HDAC6; HDAC7; HDAC8; HDAC9; HER2	Phase 1
T3059	AP26113	ALK; EGFR (C797S/del19); EGFR (del19); EGFR (del19); IGF-1R	
T3024	Avitinib	EGFR; JAK3; BTK	Phase 2
T2S0961	Chalcone	EGFR	
T2995	Chrysophanic Acid	EGFR	Approved
T2959	Ginsenoside Rh2	EGFR	
T2894	Norcantharidin	c-Met; EGFR	Preclinical
T2859	Biochanin A	EGFR; FAAH (human); FAAH (mouse); FAAH (rat)	
T2851	Daphnetin	EGFR; PKA; PKC	Approved
T2705	Mutant EGFR inhibitor	EGFR (mutant)	
T2642	PD173074	EGFR; FGFR1; Insulin Receptor; c-Src; VEGFR2	Preclinical
T2501	Canertinib dihydrochloride	EGFR; HER2/ErbB2	Phase 2
T2491	AZ5104	EGFR (L858R); EGFR (L858R/T790M); EGFR (L861Q); EGFR (wildtype); HER2/ErbB2	
T2490	Osimertinib	EGFR (Exon 19 deletion); EGFR (L858R/T790M)	FDA Approved
T2483	Dacomitinib	EGFR; HER2/ErbB2; HER2/ErbB2	FDA Approved
T2479	Tyrphostin 9	EGFR; PDGFR	Preclinical
T2446	KI8751	c-Kit; EGFR; FGFR2; PDGFR α ; VEGFR2	
T2369	Rociletinib	EGFR (L858R/T790M); EGFR (wt)	Approved
T2364	Irbinitinib	EGFR; HER2/ErbB2; p95 HER2	FDA Approved
T2327	Pelitinib	EGFR; HER2/ErbB2; MEK; Raf; Src	Phase 2
T2325	Neratinib	EGFR; HER2	FDA Approved
T2303	Afatinib	EGFR (L858R); EGFR (L858R/T790M); EGFR (wt); HER2; HER4	FDA Approved
T2280	Endoxifen Z-isomer	hERG Potassium Channel; ER; ERR; hERG	Phase 3
T2245	CL387785	EGFR	Preclinical
T21312	Afatinib free base	EGFR	FDA Approved
T2116	AEE788	c-Abl; c-Fms; EGFR; HER2/ErbB2; FLT1	Phase 1/2

ID	Product Name	Target	Condition
T2106	WS6	ErbB3-Binding Protein-1 (EBP2); IκB kinase	
T2063	AG18	EGFR	Preclinical
T2055	WS3	ErbB3-Binding Protein-1 (EBP1); IκB kinase	
T2047	AG1478	EGFR; HER2; PDGFR	Preclinical
T2041	PD153035	EGFR	Phase 1
T2035	WHI-P258	EGFR; JAK3	
T2034	AG1557	hERG; EGFR	
T2032	WHI-P180	CDK2; EGFR	Preclinical
T1985	WHI-P154	EGFR; JAK3; Src; VEGFR	Preclinical
T19814	CP-380736	EGFR	
T1773	Afatinib Dimaleate	EGFR (L858R); EGFR (L858R/T790M); EGFR (wt); HER2	FDA Approved
T1761	PD153035 hydrochloride	EGFR; EGFR	Preclinical
T1737	Genistein	EGFR	Approved
T1656	Vandetanib	EGFR; VEGFR2; VEGFR3	FDA Approved
T16369	O-Desmethyl gefitinib	EGFR	
T1291	Cisapride	5-HT; Potassium Channel; hERG channel	FDA Approved
T1266	Terfenadine	HT; mAChR; Potassium Channel; hERG	Approved
T1181	Gefitinib	Tyr1173 (NR6W cells); Tyr1173 (NR6wtEGFR cells); Tyr992 (NR6W cells); Tyr992 (NR6wtEGFR cells); Tyr992	FDA Approved
T1144L	Lidocaine Hydrochloride hydrate	EGFR; Sodium Channel	FDA Approved
T11213	Epertinib hydrochloride	EGFR; HER4; HER2	
T11161	EGFR-IN-7	EGFR	
T10419	AV-412	EGFR; EGFR(L858R); EGFR(T790M); EGFR(L858R/T790M); ErbB2	Phase 1
T0801	Tannic acid	CXCR; hERG channel	FDA Approved
T0373L	Erlotinib hydrochloride	EGFR	FDA Approved
T0373	Erlotinib	EGFR	FDA Approved
T0129	Sanguinarine chloride	Egr-1; VEGFR	Approved
T0078L	Lapatinib ditosylate monohydrate	EGFR; HER2/ErbB2	FDA Approved
T0078	Lapatinib	EGFR; HER2/ErbB2	FDA Approved

HER

ID	Product Name	Target	Condition
T7819	TAS0728	HER2	Phase 1/2
T6712	Tyrphostin AG 879	EGFR; HER2-Neu; PDGFR; Trk	
T6341	PF04929113	HER2; HSP90	Phase 2
T5398	BMS 599626 2HCl (873837-23-1(HCl))	HER1; HER2; HER4	Phase 1
T4S0544	Furanodienone	HER2	

ID	Product Name	Target	Condition
T4612	NS309	Potassium Channel; hERG	Preclinical
T4342	PF-04929113 Mesylate	HSP90; HER2	Phase 2
T4075	Sulfatinib	FGFR1; hERG; KDR	Phase 3
T3673	Mollugin	HER2; JAK2	
T3554	RG 14620	HER14 colony formation; HER14 DNA synthesis; EGFR	
T3192	NS1643	hERG	
T3108	CUDC101	EGFR; HDAC; HDAC1; HDAC10; HDAC2; HDAC3; HDAC4; HDAC5; HDAC6; HDAC7; HDAC8; HDAC9; HER2	Phase 1
T2630	Pozotinib	HER1; HER2; HER4	Phase 2
T2364	Irbinitinib	EGFR; HER2/ErbB2; p95 HER2	FDA Approved
T2325	Neratinib	EGFR; HER2	FDA Approved
T2303	Afatinib	EGFR (L858R); EGFR (L858R/T790M); EGFR (wt); HER2; HER4	FDA Approved
T2280	Endoxifen Z-isomer	hERG Potassium Channel; ER; ERR; hERG	Phase 3
T22431	SU5204	VEGFR2; HER2	
T2047	AG1478	EGFR; HER2; PDGFR	Preclinical
T1773	Afatinib Dimaleate	EGFR (L858R); EGFR (L858R/T790M); EGFR (wt); HER2	FDA Approved
T1266	Terfenadine	HT; mAChR; Potassium Channel; hERG	Approved
T11213	Epertinib hydrochloride	EGFR; HER4; HER2	
T0801	Tannic acid	CXCR; hERG channel	FDA Approved

JAK

ID	Product Name	Target	Condition
TQ0037	Abrocitinib	JAK1; JAK2	Phase 3
T8742	JAK2 inhibitor G5-7	JAK2	
T8719	SC99	STAT3; JAK2	
T8546	BD750	JAK3; STAT5	
T7503	Upadacitinib	JAK1; JAK2	FDA Approved
T6933	Peficitinib	JAK3; JAK1; Tyk2; JAK2	Approved
T6920	ON123300	CDK; Ark5; RET; Fyn; PDGFRβ; FGFR1	Preclinical
T6916	OICR9429	WDR5	
T6914	Oclacitinib maleate	JAK1; JAK2; TYK2; JAK3; JAK1-dependent	
T6838	FLLL32	JAK2	
T6790	BMS911543	JAK2 ; SET-2; TYK2; JAK3; JAK1	Phase 1/2
T6321	Tofacitinib	JAK1; JAK2; JAK3; ROCK2; Lck	FDA Approved
T6309	AZ 960	JAK2; JAK2	Preclinical
T6266	PP2	EGFR; JAK2; Fyn; Lck; ZAP70	
T6156	S-Ruxolitinib	JAK2; JAK1; Tyk2	FDA Approved
T6145	ZM 39923 HCl	TGM2 , JAK3 , EGFR , JAK1	
T6124	Mubritinib	EGFR; HER2/ErbB2; FGFR; JAK1; PDGFR	Phase 1

ID	Product Name	Target	Condition
T6122	CEP33779	JAK2	
T6020	Pacritinib	FLT3; FLT3 (D835Y); JAK2; JAK2 (V617F); Tyk2; JAK3	Approved
T5492	JAK3-IN-6	JAK3	
T5382	PF-06651600	JAK3	Phase 2/3
T5140	WDR5-0103 hydrochloride[890190-22-4(free base)]	WDR5	
T5091	FM381	JAK3	
T4672	Brevilin A	Antifetion; JAK; STAT	
T4657L	WHI-P97 HCl 211555-05-4(free base)	JAK3	
T4657	WHI-P97	JAK3	Preclinical
T4227	SB1317 hydrochloride (1204918-72-8(free base))	CDK2; FLT3; JAK2	Phase 1/2
T4210	SAR20347	JAK1; JAK2; JAK3; TYK2	Preclinical
T4209	TAK-659 hydrochloride	FLT3; JAK3; Syk; ZAP70; VEGFR2	Phase 2
T3998	Itacitinib	JAK1	Phase 3
T3673	Mollugin	HER2; JAK2	
T3620	Solcitinib	JAK1	Phase 1
T3398	Icaritin	JAK2; STAT3	Phase 3
T3201	WDR5-0103	WDR5	
T3080	Pyridone 6	JAK1; JAK2; JAK3; Tyk2	
T3076	GLPG0634 analogue	JAK1; JAK2; JAK3; TYK2	
T3072	XL019	FLT3; JAK1; JAK2; JAK3; PDGFRβ	Phase 1
T3069	AZD1480	JAK2	Phase 1
T3068	AT9283	Aurora A; Aurora B; Abl1 (T315I); JAK2; JAK3	Phase 1
T3065	TG101209	RET; FLT3; JAK2; JAK3	Preclinical
T3043	Ruxolitinib (INCB-18424) phosphate	JAK1; JAK2	FDA Approved
T3042	JAK2 Inhibitor V	JAK2; JAK2 (V617F)	
T3024	Avitinib	EGFR; JAK3; BTK	Phase 2
T2853	Curcumol	JAK	Phase 3
T2709	TAK901	CLK2; JAK3; c-Src; FGR; Yes1	Phase 1
T2638	Gandotinib	FLT3; JAK1; JAK2; JAK2; JAK2 (V617F)	Phase 2
T2636	Decernotinib	JAK1; JAK2; JAK3; Tyk2	Phase 3
T2487	Cerdulatinib	JAK1; JAKs; Syk; Tyk2	Phase 2
T2485	Baricitinib	Chk2; JAK1; JAK2; JAK3; Tyk2	FDA Approved
T2398	Tofacitinib Citrate	JAK1; JAK2; JAK3	FDA Approved
T2360	Baricitinib Phosphate	JAK1; JAK2; JAK3; Tyk2	FDA Approved
T2341	KW2449	Aurora A; Abl; Abl (T315I); Kit; FGFR1; FLT3; FLT3 (D835Y); JAK2; Src	Phase 1/2
T2156	WP1066	JAK2; STAT3	Phase 1/2
T2045	WHI-P131	JAK3; JAK3	Preclinical

ID	Product Name	Target	Condition
T2035	WHI-P258	EGFR; JAK3	
T2012	Oclacitinib	JAKs	
T1995	Fedratinib	JAK2; JAK2 (V617F); RET; FLT3	FDA Approved
T1985	WHI-P154	EGFR; JAK3; Src; VEGFR	Preclinical
T1929	Filgotinib	JAK1; JAK2; JAK3; Tyk2	Approved
T1849	Momelotinib	JAK1; JAK2; JAK3	Phase 3
T1829	Ruxolitinib	JAK1; JAK2; Tyk2	FDA Approved
T17019	TCS 21311	JAK3; JAK2; JAK1; PKC α ; PKC θ ; GSK-3 β	
T14687	BMS-986165	Tyk2 JH2; JAK1 JH2	Phase 3
T14331	Gusacitinib	SYK; JAK	Phase 2
T12427	PF-06700841 (P-Tosylate)	JAK1; JAK2; JAK3	Phase 2

Pim


ID	Product Name	Target	Condition
TQ0201	Hispidulin	Pim1	
T8114	Quercetagenin	Pim1	
T6735	XL413 hydrochloride	CK2; Cdc7; Pim1; Cdc7	Phase 1/2
T6148	CX-6258 HCl	Pim1; Pim2; Pim3	
T5093	Pim1/AKK1-IN-1	Pim1; MST2	
T4523	TP3654	Pim 1, Pim 3; Pim-2	Phase 1
T4215	SMI-4a	Pim 1; Pim 2	Preclinical
T3989	SMI-16a	Pim1; Pim2	
T3078	SGI-1776 free base	FLT3; Pim1; Pim2; Pim3	Phase 1
T3058	SMI-4a	Pim1	Preclinical
T2300	AZD1208	Pim1; Pim2; Pim3	Phase 1
T2253	TCS PIM-1 1	Pim1	

STAT

ID	Product Name	Target	Condition
TP1856	Colivelin	STAT3; Amyloid- β	
TP1433	CMD178 TFA	STAT5	
TN2346	Mogrol	ERK1; ERK2; STAT3	
TN2269	Tetramethylcurcumin	STAT3; Apoptosis	
T8719	SC99	STAT3; JAK2	
T8597	ML116	STAT3	
T8546	BD750	JAK3; STAT5	
T8478	SC-43	SHP-1; STAT3; apoptosis	
T8476	RSVA 405	STAT3; AMPK	

ID	Product Name	Target	Condition
T8378	AS2863619	STAT5; CDK8; CDK19	
T8213	Isolinderalactone	STAT3; iNOS	
T6S1373	Vitexicarpin	STAT3	
T6S0141	Corylin	STAT3	
T6669	SH-4-54	STAT3; STAT5	
T6537	HO3867	STAT3	
T6308	Stattic	STAT3	
T5S1607	Morusin	STAT3; NF-Kb	
T5S0168	Attractylenolide II	STAT3 inhibitor; p38 activator; ERK inhibitor; Akt inhibitor	
T5668	Acetyl-trans-resveratrol	STAT3; Mcl-1	
T4S2126	Ginkgetin	STAT3; COX-2	
T4S0145	Corylifol A	UGT1A1; hCE2; STAT3	
T4672	Brevilin A	Antifection; JAK; STAT	
T4650	C188-9	STAT3	Phase 1
T4615	Balsalazide disodium salt dihydrate	STAT	FDA Approved
T4476	AS1517499	STAT6	Preclinical
T4234	HJC0152 hydrochloride	STAT3	
T4216	STAT5 Inhibitor	STAT5β	
T4034	Solamargine	p38 MAPK; STAT3	
T3S1775	Tectochrysin	STAT3	
T3971	CASIN	STAT3; GTPase Cdc42	
T3913	Saikosaponin D	NF-κB; STAT3	
T3708	BP-1-102	STAT3	
T3404	Cucurbitacin B	HIF-1; PTEN; STAT3	
T3398	Icaritin	JAK2; STAT3	Phase 3
T3380	Homoharringtonine	STAT3	FDA Approved
T3218	Napabucasin	STAT3	Phase 3
T2896	Helenine	STAT	
T2867	Diosgenin	STAT3	
T2814	Cryptotanshinone	STAT3	
T2789	Scutellarin	Akt; STAT	
T2505	S31201	STAT3	
T2168	2-NP	STAT1	
T2156	WP1066	JAK2; STAT3	Phase 1/2
T21267	HODHBt	STAT5	
T1563	Nifuroxazide	STAT1; STAT3; STAT5	Approved
T13009	STAT3-IN-1	STAT3	
T1038	Fludarabine	STAT1; DNA synthesis	FDA Approved
T0711	Niclosamide	STAT3	FDA Approved
T0433	Artesunate	STAT	Approved

MAPK



MAPK

ERK

ID	Product Name	Target	Condition
TQ0005	KO-947	ERK1; ERK2	Phase 1
TN2346	Mogrol	ERK1; ERK2; STAT3	
TN2165	Rubrofusarin-6-O-beta-D-gentiobioside	TGFβ; NF-κB; ERK	
TMS2181	trans-Zeatin	ERK; MEK	
T8472	ASTX029	ERK1/2	
T7005	Ulixertinib	ERK2	Phase 2
T6S1572	Saquinone	ERK; p38	
T6S0655	Corynoxine	ERK1,2	
T6S0619	Pachymic acid	Akt; ERK	
T6S0525	Farrerol	Akt; p38; ERK	
T6S0117	Avicularin	ERK	

ID	Product Name	Target	Condition
T6993	Sodium Tauroursodeoxycholate (TUDC)	Caspase; ERK	
T6948	Pluripotin	ERK1; RasGAP	Phase 1/2
T6818	DEL22379	ERK	
T6511	Ravoxertinib	ERK1; ERK2	Phase 1
T6324	BIX02188	ERK5; MEK1; MEK2; MEK5; TGFβR1	
T6218	Selumetinib	MEK1; ERK1; ERK2	FDA Approved
T6183	ISRIB (trans-isomer)	PERK	
T6139L	A-674563 2HCl(552325-73-2(fb-2hcl))	Akt1; CDK2; PKA; ERK2; PKCδ	
T6083	AZD8330	ERK phosphorylation; MEK1/2	Phase 1
T6066	SCH772984	ERK1; ERK2	Preclinical
T5S2361	Epiberberine	ERK1/2; MEK1; AChE; BChE; BACE1	
T5S0168	Attractylenolide II	STAT3 inhibitor; p38 activator; ERK inhibitor; Akt inhibitor	
T5S0045	Isofraxidin	p38; ERK	
T5727	CAFESTOL	ERK; COX-2; NF-κB	
T5535	ERK5-IN-2	ERK5	
T5358	Longdaysin	CKIα; CKIδ; CDK7; ERK2	
T5184	ERK5-IN-1	ERK5	
T4S2326	Cornuside	JNK1/2; ERK1/2	
T4S2063	Tetrahydrocoptisine	NF-κB; ERK; p38 MAPK	
T4S0878	Prunetin	NF-κB; ERK	
T4518	Licochalcone D	ERK phosphorylation	
T4092	AG 126	COX-2; ERK1,2	
T4091	LY3214996	ERK1; ERK2	Phase 1
T3S2344	Dimethylacrylshikonin	ERK	
T3881	Vaccarin	P-Akt; PERK; CD31	
T3876	Loureirin B	ERK; JNK; PAI-1; Potassium Channel; PAI-1	
T3857	magnolin	ERK1; ERK2	
T3714	SUN 11602	ERK1; ERK2; FGFR	
T3668	Galangin	ERK; NF-κB	
T3166	VX-11e	Aurora A; CDK2; ERK2; FLT3; GSK-3	
T2P2806	Hederacolchiside A1	MEK; ERK	
T2961	Notoginsenoside R1	ERK1; ERK2	
T2654	GSK2656157	PERK	
T2416	BIX02189	ERK5; MEK1; MEK2; MEK5; TGFβR1	
T2356	Ro 3306	CDK1; ERK; PKA; PKCδ; SGK	
T21295	BIX 02189	ERK; MEK	
T2027	ISRIB	PERK	
T1956	FR180204	ERK1; ERK2	

ID	Product Name	Target	Condition
T1933	NVP 231	CERK	
T1842	XMD17109	ERK5	
T13265	Urolithin B	NF-κB; JNK; ERK; Akt; AMPK; Human Endogenous Metabolite	

JNK

ID	Product Name	Target	Condition
TP1430	DTP3 TFA	GADD45β/MKK7	
TN1918	Medicarpin	ROS; JNK; Bcl-2	
T8477	IQ3	JNK3; JNK1; JNK2	
T7677	JNK Inhibitor VIII	JNK1:2 nM (Ki); JNK1:45 nM (IC50); JNK2:4 nM (Ki); JNK2:160 nM (IC50); JNK3:52 nM (Ki)	
T6784	BI-78D3	JNK	
T6758	Anisomycin	JNK	Approved
T5833	CC-401 Hydrochloride	JNK	Phase 1
T5574	Guggulsterone E&Z	JNK; Akt; Caspase	
T5094	IRAK inhibitor 1	IRAK-4; JNK-1	
T4S2326	Cornuside	JNK1/2; ERK1/2	
T4S1962	beta-Asarone	NF-κB; JNK	
T3S0737	Flavokawain A	p38	
T3876	Loureirin B	ERK; JNK; PAI-1; Potassium Channel; PAI-1	
T3627	IQ-1S	JNK1; JNK2; JNK3; NF-κB	
T3598	JNK-IN-7	JNK1; JNK2; JNK3	Phase 2
T3200	DB07268	JNK1	
T3109	Pyrazolanthrone	Aurora A; JNK1; JNK2; JNK3; TrkA	Preclinical
T3079	GSK1838705A	ALK; IGF-1R; Insulin Receptor; JNK3; RSK1	Preclinical
T2872	Ginsenoside Re	Amyloid-β; JNK; NF-κB	Phase 1
T2675	AS 602801	JNK1; JNK2; JNK3	Phase 2
T2668	JNK-IN-8	Kit (V559D); Kit (V559D,T670I); JNK1; JNK2; JNK3	
T2343	AS601245	hJNK1; hJNK2; hJNK3	Phase 1
T2234	SC202671	JNK2; JNK3	
T14895	Tanzisertib	JNK3; JNK2; JNK1	Phase 2
T13265	Urolithin B	NF-κB; JNK; ERK; Akt; AMPK; Human Endogenous Metabolite	

MAPK

ID	Product Name	Target	Condition
TN1445	Bisabolangelone	MAPK	
T8843	APS6-45	MAPK; Ras	
T8152	6-Demethoxytangeretin	ALK; MAPK	

ID	Product Name	Target	Condition
T7283	sodium lauroyl- α -hydroxyethyl sulfonate	MAPKs; NF- κ B	
T6760	APS-2-79	KSR2	
T5S1895	Norisoboldine	MAPK	
T5643	NG25	MAP4K2/TAK1	
T5483	DMX-5084	MAP4K4/MINK1/MAP4K6	
T4221	PF6260933	MAP4K4 for Cell; MAP4K4 for Kinase	
T3836	Eudesmin	MAPK	
T3707	GNE3511	DLK; MAP3K12	
T3672	Nomilin	MAPK	
T3410	Momordin Ic	MAPK; PI3K	
T3101	NQD11	ASK1; MAP3K5	
T2382	Vemurafenib	ACK1; MAP4K5 (KHS1); B-Raf; B-Raf (V600E); C-Raf; SRMS; FGR	FDA Approved
T12979	BI-3406	KRAS-SOS1; MAPK	

MEK

ID	Product Name	Target	Condition
TMS2181	trans-Zeatin	ERK; MEK	
T7742	GW 284543 hydrochloride	MEK5	
T6971	RO5126766	MEK1; B-Raf; B-Raf (V600E); C-Raf	Phase 1
T6843	GDC0623	MEK1	Phase 1
T6785	BI847325	Aurora A (Human); Aurora B (Xenopus laevis); Aurora C (Human); MEK1; MEK2	Phase 1
T6636	Refametinib	MEK1; MEK2	Phase 2
T6419	BMS536924	FAK; IGF-1R; Insulin Receptor; MEK; Lck	Preclinical
T6324	BIX02188	ERK5; MEK1; MEK2; MEK5; TGF β R1	
T6223	U0126-EtOH	MEK1; MEK2	Preclinical
T6218	Selumetinib	MEK1; ERK1; ERK2	FDA Approved
T6189	PD0325901	MEK	Phase 2
T6152	PD318088	MEK1; MEK2	
T6131	Pimasertib	MEK1/2 (MM cell line)	Phase 2
T6083	AZD8330	ERK phosphorylation; MEK1/2	Phase 1
T6077	ZM 447439	Aurora A; Aurora B; MEK1; Lck; Src	Preclinical
T6066	SCH772984	ERK1; ERK2	Preclinical
T6057	URMC099	Aurora A; Aurora B; Aurora C; Abl1; CDK1; CDK2; c-Met; DLK; IGF-1R; Insulin Receptor; LRRK2; MEKK2; MLK1; MLK2; MLK3; ROCK1; ROCK2; SGK; SGK1; Lck; Syk; TrkA; TrkB; VEGFR1/FLT1	
T5S2361	Epiberberine	ERK1/2; MEK1; AChE; BChE; BACE1	
T5857	Trametinib DMSO solvate	MEK1/2	FDA Approved
T5412	RO4987655	MEK1; MEK2	Phase 1

ID	Product Name	Target	Condition
T3623	Cobimetinib	MEK1	FDA Approved
T3001	Honokiol	P-Akt; MEK	Phase 2
T2P2806	Hederacolchiside A1	MEK; ERK	
T2836	Isorhamnetin	MEK; PI3K	
T2708	SL327	AP-1; MEK1; MEK2	
T2623	PD 98059	MEK1	
T2508	Binimetinib	MEK	FDA Approved
T2443	CI1040	MEK1; MEK2	Phase 2
T2416	BIX02189	ERK5; MEK1; MEK2; MEK5; TGFβR1	
T2327	Pelitinib	EGFR; HER2/ErbB2; MEK; Raf; Src	Phase 2
T21295	BIX 02189	ERK; MEK	
T2125	Trametinib	MEK1; MEK2	FDA Approved

MLK

ID	Product Name	Target	Condition
T7129	Necrosulfonamide	necrosis(MLKL)	
T6904	Necrosulfonamid	necrosis(MLKL)	
T6057	URMC099	Aurora A; Aurora B; Aurora C; Abl1; CDK1; CDK2; c-Met; DLK; IGF-1R; Insulin Receptor; LRRK2; MEK2; MLK1; MLK2; MLK3; ROCK1; ROCK2; SGK; SGK1; Lck; Syk; TrkA; TrkB; VEGFR1/FLT1	
T2696	PRT062607 hydrochloride	MLK1; FGR; Syk	Phase 1
T2048	LY364947	CK1δ; MLK-7K; TGFβRI; TGFβRII; RIPK2	
T11520	GW806742X	MLKL; VEGFR2	

MNK

ID	Product Name	Target	Condition
T6440	CGP 57380	MNK2; MNK1	
T4424	SLV2436	MNK1; MNK2	Preclinical
T3468	eFT508	MNK1; MNK2	Phase 2
T15250	ETC-206	MNK1; MNK2	

p38 MAPK

ID	Product Name	Target	Condition
T7667	R1487	p38α	
T7661	SD 169	p38	
T7367	Acumapimod	p38	
T7276	SD 0006	p38 MAPK	
T7030	anemarsaponin B	p38	

ID	Product Name	Target	Condition
T6S1572	Sauchinone	ERK; p38	
T6S0525	Farrerol	Akt; p38; ERK	
T6976	SB239063	p38 α ; p38 β	Preclinical
T6934	Pexmetinib	p38 MAPK; Tie-2	Phase 1
T6927	Pamapimod	p38 α ; p38 β	Preclinical
T6789	BMS582949	p38 MAPK	Phase 2
T6380	AMG900	Aurora A; Aurora B; Aurora C; p38 α ; Tyk2	Phase 1
T6277	Doramapimod	p38 α	Phase 2
T6167	SU9516	CDK1; CDK2; CDK4; p38; PKC	Preclinical
T6130	Skepinone-L	p38 α	
T6089	Neflamapimod	p38 α ; p38 β	Phase 2
T6047	Ralimetinib Mesylate	p38 α	Phase 2
T5S2283	Sesamol	p38 MAPK; Caspase-3	
T5S0168	Attractylenolide II	STAT3 inhibitor; p38 activator; ERK inhibitor; Akt inhibitor	
T5S0045	Isofraxidin	p38; ERK	
T5814	Aurantiamide	NF- κ B; p38	
T5494	MW-150	p38 α	
T5393	CK1-IN-1	CK1; p38 σ MAPK	
T5172	AZ304	B-Raf (V600E); B-Raf (WT); p38; CSF1R	Preclinical
T4S2063	Tetrahydrocoptisine	NF- κ B; ERK; p38 MAPK	
T4S1419	Praeruptorin A	p38; Akt	
T4S0398	Rosin	p38	
T4646	TA02	p38 MAPK	
T4645	TA01	CK1 ϵ ; CK1 δ ; p38 MAPK	
T4597	UM164	c-Src; p38 α ; p38 β	
T4575	Chromium picolinate	p38; DNA mutation	Approved
T4078	SB242235	p38 MAPK	Phase 1
T4034	Solamargine	p38 MAPK; STAT3	
T3S0737	Flavokawain A	p38	
T3462	BMS-582949 HCl	p38 α	Phase 2
T3390	Obacunone	p38 MAPK; Aromatase	
T3025	Asiaticoside	p38 MAPK; TGF β 1	
T2827	Asiatic acid	p38 MAPK	Approved
T2513	VX702	p38 α	Phase 1
T2432	PD 169316	p38	
T2367	SKF86002	p38 MAPK; TNF- α	
T2301	SB202190	p38 α ; p38 β	
T2293	SGX523	Abl; c-Met; p38 α ; B-Raf (V599E); C-Raf	Phase 1
T2277	Losmapimod	p38 α ; p38 β	Phase 3
T2118	SC514	Aurora B; CDK2/CyclinA; IKK2; p38 α ; PRAK	

ID	Product Name	Target	Condition
T1974	PH797804	p38 α ; p38 β	Phase 2
T1922	Pseudolaric Acid B	p38	Preclinical
T1764	SB203580	p38 MAPK	Preclinical
T10990	Dehydrocorydaline chloride	p38 MAPK; Bax; Bcl-2; caspase-7; caspase-8; PARP	

Raf

ID	Product Name	Target	Condition
TQ0048	BI-882370	B-Raf; C-Raf; B-Raf (V600E)	Preclinical
T8823	Locostatin	Raf-1	
T8746L	I-49 free base	SOS1	
T8745	Compound 23	B-Raf (V600E)	
T8721L	I-37 free base(2359690-13-2(free base))	SOS1	
T8654	Plx-4032	B-Raf	FDA Approved
T8474	Dabrafenib Mesylate	Raf	FDA Approved
T8402	Regorafenib Hydrochloride	VEGFR; PDGFR; RET; Raf-1	FDA Approved
T7414	ARS-853	K-Ras(G12C)	
T6971	RO5126766	MEK1; B-Raf; B-Raf (V600E); C-Raf	Phase 1
T6948	Pluripotin	ERK1; RasGAP	Phase 1/2
T6895	MLN2480	Raf	Phase 2
T6882	LY3009120	B-Raf (WT); B-Raf (V600E); C-Raf	Phase 1
T6556	K-Ras(G12C) inhibitor 9	K-Ras(G12C)	
T6555	K-Ras(G12C) inhibitor 12	K-Ras(G12C)	
T6525	GW5074	C-Raf	
T6487	Encorafenib	B-Raf (V600E)	FDA Approved
T6348	NVP-BHG712	EphB4; c-Raf; c-Src; c-Abl	
T6320	GDC0879	B-Raf	
T6302	Lonafarnib	K-ras-4B; H-ras; N-ras	Approved
T6169	Indirubin	GSK-3 β , CDK2/CyclinA , CDK5/p35 , CDK1/CyclinB , C-Raf	Approved
T6052	GW 441756	CDK2; C-Raf-1; TrkA	
T5634	Belvarafenib	Raf	Phase 1
T5418	BAY-293	SOS1	
T5172	AZ304	B-Raf (V600E); B-Raf (WT); p38; CSF1R	Preclinical
T4301	AD80	RET, RAF, SRC, S6K; RET V804M; RET V804L	
T4194	CID25014542	Raf	
T4167	B-Raf inhibitor 1 dihydrochloride	B-Raf	
T4133	CCT196969	C-RAF; Src	
T3725	K-Ras(G12C) Inhibitor 6	K-Ras	
T3711	RAF709	B-Raf; C-Raf	

ID	Product Name	Target	Condition
T3641	BAW2881	c-Abl; B-Raf (V599E); C-Raf-1; hVEGFR2	
T3579	PLX8394	BRAFV600E	Phase 1/2
T2624	OSI 930	CSF-1R; FLT1; C-Raf; Lck; VEGFR2 (KDR)	Phase 1
T2473	PLX4720	B-Raf; B-Raf (V600E); C-Raf-1 (Y340D/Y341D)	Preclinical
T2382	Vemurafenib	ACK1; MAP4K5 (KHS1); B-Raf; B-Raf (V600E); C-Raf; SRMS; FGR	FDA Approved
T2327	Pelitinib	EGFR; HER2/ErbB2; MEK; Raf; Src	Phase 2
T2295	SB590885	B-Raf	Preclinical
T2293	SGX523	Abl; c-Met; p38α; B-Raf (V599E); C-Raf	Phase 1
T1953	L779450	Raf	
T1903	Dabrafenib	B-Raf; B-Raf (V600E); C-Raf	FDA Approved
T1892	Kobe2602	Ras-Raf	
T1886	TAK632	Aurora B; FGFR3; PDGFRβ; B-Raf; C-Raf	Preclinical
T1876	Kobe0065	Ras-Raf	
T1851	ZM 336372	C-Raf	
T1845	B-Raf IN 1	B-Raf; C-Raf	
T1792L	Regorafenib monohydrate	murine VEGFR2; murine VEGFR3; PDGFRβ; Kit; RET; RAF-1; B-RAF; B-Raf (V600E)	FDA Approved
T1792	Regorafenib	Kit; RET; Raf-1; VEGFR1; VEGFR2	FDA Approved
T11898	LXH254	C-Raf; B-Raf	Phase 2
T10157	Regorafenib N-oxide (M2)	VEGFR1; VEGFR2; VEGFR3; PDGFRβ; RET; Kit; Raf-1	
T0093L	Sorafenib	c-Kit; FLT3; mPDGFRβ; PDGFRβ; B-Raf; B-Raf (V599E); Raf-1; VEGFR2/Flk2	FDA Approved
T0093	Sorafenib tosylate	c-Kit; FLT3; mPDGFRβ; PDGFRβ; B-Raf; B-Raf (V599E); Raf-1; VEGFR2/Flk1	FDA Approved

Ras

ID	Product Name	Target	Condition
T8870	1-(4-methansulfinylphenyl) ethanone	Ras	
T8843	APS6-45	MAPK; Ras	
T8756	KRAS inhibitor-9	KRAS	
T8684	AMG-510	KRAS G12C	Phase 3
T8375	ML-210	Gpx4; Ras	
T8369	MRTX849	KRAS G12C	Phase 1/2
T8006	Oncrasin 1	K-Ras	
T7609	ARS-1620	KRAS G12C	
T7558	CID-1067700	Rab7	
T7326	6H05 TFA	KRAS G12C	
T7131	Antineoplaston A10	Ras	Phase 2
T6302	Lonafarnib	K-ras-4B; H-ras; N-ras	Approved

ID	Product Name	Target	Condition
T6163	Salirasib	PPMTase	Phase 1/2
T5469	K-Ras-IN-1	K-Ras	
T5379	Antineoplaston A10	Ras	
T4619	ML098	Rab7	
T22258	AMG-510 racemate	KRAS G12C	
T22249	1588-A4	KRAS G12C	
T16143	MRTX-1257	KRAS G12C	
T12979	BI-3406	KRAS-SOS1; MAPK	


S6 Kinase

ID	Product Name	Target	Condition
TN1712	Gossypin	RSK2	
T6S1302	Carnosol	RSK2	
T6878	LJI308	RSK1; RSK2; RSK3	
T6877	LJH685	RSK1; RSK2; RSK3	
T6458	CYC116	Aurora A; Aurora B; CDK2/CyclinE; CDK9/CyclinT; FLT3; p70 S6K; VEGFR2	Phase 1
T6304	AT7867	Akt1; Akt2; Akt3; PKA; p70 S6K	Preclinical
T6250	H 89 2HCl	PKA; S6K1	
T6171	BI-D1870	RSK1; RSK2; RSK3; RSK4	
T5428	BIX 02565	RSK2; LRRK2	
T4488	GSK25	RSK1; mTOR (p70S6K)	
T4327	Prexasertib dihydrochloride	Chk1; Chk2; RSK	Phase 2
T4301	AD80	RET, RAF, SRC, S6K; RET V804M; RET V804L	
T3518	GSK269962A	MSK1; ROCK1; ROCK2; RSK1	
T3079	GSK1838705A	ALK; IGF-1R; Insulin Receptor; JNK3; RSK1	Preclinical
T2608	CHIR98014	bFGFR; GSK-3 α ; GSK-3 β ; p70 S6K; c-Src	
T2482	AT13148	Akt1; Akt2; Akt3; PKA; ROCK1; ROCK2; p70 S6K; RSK1; SGK3	Phase 1
T2265	PI3K-IN-2	pPKB; pS6; PI3K α ; PI3K β ; mTOR; PI3K γ ; PI3K δ	Phase 2
T22422	S6K-18	S6K1	
T2002	PF4708671	p70 S6K	
T1961	Vistusertib	P-Akt (S473); mTOR; PI3K α ; pS6 (S235/236)	Phase 1/2
T1746	LY2584702 tosylate	p70 S6K	Phase 1

TOPK

ID	Product Name	Target	Condition
T4135	OTS964	TOPK	Preclinical
T4134	OTS514 hydrochloride(1338540-63-8(free base))	TOPK	Preclinical

Membrane transporter/Ion channel



ABC

ID	Product Name	Target	Condition
T8165	Erythrodiol	ABCA1	
T2590	Vismodegib	Hedgehog; ABCG2	FDA Approved
T18975	DIDS sodium salt	ABCA1; VDAC1	
T1603	Glipizide	ABCC; PPAR γ	FDA Approved
T1050	Prazosin hydrochloride	ABCG; Adrenergic Receptor; MRP1; Potassium Channel	FDA Approved
T0974	Novobiocin Sodium	ABCG2; DNA gyrase; Bile salt export pump; Topo I	FDA Approved
T0490	Chlorpropamide	ABCC8	FDA Approved
T0254	Probucol	ABCA1; CES1	FDA Approved
T0128	Vigabatrin	ABAT; GABA	FDA Approved
T0055L	Glafenine Hydrochloride	ABCG2	Approved

Anion exchanger

ID	Product Name	Target	Condition
T4503	Talinflumate	hCLCA1/mCLCA3; COX; Cl-/HCO3- exchanger; GCNT3	Approved

Aquaporin

ID	Product Name	Target	Condition
T5102	TGN020	AQP4	

ATP Citrate Lyase

ID	Product Name	Target	Condition
T7424	NDI-091143	ACLY	
T3625	ETC1002	ACL	FDA Approved
T11589	Hydroxycitric acid tripotassium hydrate	ATP citrate lyase; HIF	

ATPase

ID	Product Name	Target	Condition
TQ0184	Chebulinic acid	bacterial DNA gyrase; Smad3; H+/K+-ATPase	
TN2239	Strictosamide	Sodium Channel; ATPase; Potassium Channel	
TN1103	Diphyllin	HIV-1; Vesicular stomatitis virus (VSV); Vacuolar type H+-ATPase	
T8183	Deslanoside	Na+/K+-ATPase	Approved
T7540	BHQ	Ca2+-ATPase	
T7411	Rbin-1	ATPase	
T7144	BTS	Ca2+-stimulated myosin S1 ATPase	
T6S1049	Wilforine	(Na,K)-ATPase	
T6834	FCCP	ATPase	
T6587	Mitiglinide Calcium	ATP-sensitive K+ channels	Approved
T6323	Oligomycin A	ATP synthase	
T6062	Brefeldin A	ATPase (HCT 116)	Preclinical
T6038	(-)-Blebbistatin	non-muscle myosin II ATPases	
T4861	trans-Aconitic acid	Human Endogenous Metabolite; ATP-citrate synthase(rat)	
T3S0870	Paederosidic acid methyl ester	ATPase; NO; Potassium Channel	
T3480	Sudoterb free base	ATP	Phase 2
T3432	Cinobufagin	Na+/K+-ATPase	
T2822	Ginsenoside Rb1	Autophagy; IRAK; Mitophagy; (Na,K)-ATPase; NF-kB	
T2686L	Esomeprazole Sodium	H+/K+-ATPase	FDA Approved
T2686	Esomeprazole Magnesium	H+/K+-ATPase	FDA Approved
T2621	Rostafuroxin	Na+/K+-ATPase	Phase 2
T2537	Tirofiban hydrochloride monohydrate	GPLIb/IIIa; GPLIb/IIIa; ADP	FDA Approved
T2405	Revaprazan hydrochloride	H+/K+-ATPase	Approved

ID	Product Name	Target	Condition
T2404	Vonoprazan fumarate	H ⁺ /K ⁺ -ATPase	Approved
T22280	BRITE338733	ATPase	
T2089	Eniporide	Na ⁺ /K ⁺ -ATPase	Phase 2
T2006	Omecamtiv mecarbil	ATPase	Phase 3
T1940	BTB06584	ATPase; Acetohydroxyacid synthase	
T1719	Bufalin	Na ⁺ /K ⁺ -ATPase	
T17030	Tegoprazan	H ⁺ /K ⁺ -ATPase	Phase 3
T1670	Lanatoside C	Na ⁺ /K ⁺ -ATPase	Approved
T15373	Gboxin	F0F1 ATP synthase	
T14965	Cilibrevin D	ATPase	
T1496	Amiodarone hydrochloride	β-adrenergic receptor; Potassium Channel; ATP-sensitive potassium channel	FDA Approved
T1482	Ciclopirox	Na ⁺ /K ⁺ -ATPase	FDA Approved
T1318	Ouabain octahydrate	Na ⁺ /K ⁺ -ATPase	Approved
T1137	Clorsulon	Antibiotic; ATP	FDA Approved
T1114	Ciclopirox ethanolamine	ATPase; iron	FDA Approved
T0859	Fenbufen	ATP synthesis	Approved
T0465	Ellagic acid	Carbonic anhydrase; CK2; Smoothened; PKA; PKC; Syk; ATP-competitive CK2	Phase 2
T0295	Digitoxin	organic anion transporter; Na ⁺ /K ⁺ -ATPase	FDA Approved
T0126	Diazoxide	Na ⁺ /K ⁺ -ATPase; Potassium Channel	FDA Approved
T0114	Trichlormethiazide	Na ⁺ /K ⁺ -ATPase; Carbonic anhydrase	FDA Approved

BCRP

ID	Product Name	Target	Condition
T4595	YHO13177	BCRP	Preclinical
T3581	KS176	BKCa-channel; BCRP(Pheo A)	

Calcium Channel

ID	Product Name	Target	Condition
TN2703	2',3'-Dihydroxy-4'-methoxyacetophenone	Calcium Channel	
TN1721	Gypenoside L	ROS; Calcium Channel	
TN1154	6-Methoxyluteolin	Calcium Channel; Histamine Receptor	
TCS0102	Pulegone	L-type calcium channel	
T8867	RO2959 Hydrochloride	CRAC channel; IL-2	
T8815	Azumolene	Calcium Channel	
T8681	HA-1004 dihydrochloride	PKA; PKC; calcium channel	
T8674	SR33805	Calcium Channel	

ID	Product Name	Target	Condition
T8448	ZSET-1446	Calcium Channel	Phase 2
T8401	Efonidipine hydrochloride monoethanolate	Calcium Channel	Approved
T7603	Pinaverium bromide	Calcium Channel	Approved
T7550	Barnidipine	Calcium Channel	
T7373	CDN1163	Calcium Channel	
T7338	DHBP dibromide	Calcium Channel	
T7334	NP118809	Calcium Channel	
T7216	Mirogabalin	$\alpha 2\delta$ calcium channels	Approved
T7056	Dronedarone	Potassium Channel; Sodium channel; Calcium channel	FDA Approved
T6S1500	Ginsenoside-Rf	N-type Ca ²⁺ channel	
T6S0659	Rhynchophylline	Calcium Channel	
T6874	Lercanidipine hydrochloride	Calcium Channel	Approved
T6777	Bay K 8644	L-type calcium channel	
T6633	Ranolazine	Calcium Channel	FDA Approved
T6577	Manidipine	Calcium Channel	Approved
T6571	Lomerizine hydrochloride	L-type calcium channel; T-type calcium channel	Approved
T6507	Gabapentin HCl	GABAR; $\alpha 2\delta$ subunit of calcium channel	FDA Approved
T6395	Astragaloside A	Calcium Channel	
T5856	Barnidipine	Calcium Channel	Approved
T5632	MK-8998	T-type calcium channel	Phase 2
T5391	Bepidil hydrochloride	Calcium Channel	FDA Approved
T5376	Aranidipine	Calcium Channel	Approved
T5120	alpha-L-Rhamnose	Calcium Channel	
T4693	2-APB	TRPV1; TRPV2; TRPV3; TRPC6; TRPM8; IP3 receptor	
T4669	Fantofarone	Calcium Channel	
T4284	(S)-Amlodipine Besylate (103129-82-4(free base))	Calcium channel	FDA Approved
T4054	Dantrolene sodium hemiheptahydrate	Calcium Channel	FDA Approved
T3S1916	Heteroclitin D	L-type calcium channel	
T3904	Gomisin J	AMPK; Calcium Channel	
T3703	ABT639	Calcium Channel	Phase 2
T3543	NS 638	K ⁺ -stimulated intracellular Ca ²⁺ -elevation	Preclinical
T3508	SEA0400	NCX	Preclinical
T3377	phenylalanine	$\alpha 2\delta$ calcium channels	FDA Approved
T2996	Tetrandrine	Calcium Channel	Approved
T2878	Ginsenoside Rd	Calcium Channel; COX; P450; NF- κ B	
T2782L	Catharanthine Tartrate(2468-21-5(free base))	L-type calcium channel	
T2604	1-Ethyl-2-benzimidazolinone	Calcium Channel	

ID	Product Name	Target	Condition
T2519	Lercanidipine	Calcium Channel	Approved
T2323	Efonidipine	Calcium Channel	Approved
T21454	Nicardipine	calcium channel	FDA Approved
T19765	MDK-4025	Calcium Channel	
T1641	Strontium ranelate	Calcium Channel	Approved
T16339	Norverapamil hydrochloride	Calcium channel blocker; P-gp (P-glycoprotein)	
T1545	(S)-Amlodipine	Calcium Channel	Approved
T15423	GSK-7975A	CRAC channel	
T1474	Otilonium bromide	mAChR; Calcium Channel	Approved
T1439	Lacidipine	Calcium Channel	Approved
T1435	Praziquantel	Calcium Channel	FDA Approved
T1422	Nilvadipine	Calcium Channel	Approved
T1385	Amlodipine	Calcium Channel	FDA Approved
T1234	5,5-Dimethylloxazolidine-2,4-dione	Calcium Channel	FDA Approved
T1215	Nicardipine hydrochloride	mAChR; Adrenergic Receptor; Calcium Channel	FDA Approved
T12032	Mibefradil dihydrochloride	T-type calcium channel; L-type calcium channel	Phase 1
T1197	Trimebutine maleate	Calcium Channel	Approved
T1146	Nifedipine	Calcium Channel; CAM; Potassium Channel	FDA Approved
T11102	DS16570511	mitochondrial calcium uniporter	
T1073	Dronedaron hydrochloride	Adrenergic Receptor; Calcium Channel; Potassium Channel; Sodium Channel	FDA Approved
T1010	Verapamil hydrochloride	Calcium Channel	FDA Approved
T0999	Clevidipine butyrate	AChR; Calcium Channel	FDA Approved
T0957	Isradipine	Calcium Channel	FDA Approved
T0903	Stugeron	Calcium Channel; H1 receptor	Approved
T0806	Flunarizine dihydrochloride	Calcium Channel	Approved
T0728	Ethosuximide	Calcium Channel	FDA Approved
T0702	Gabapentin	GABAR; calcium channel	FDA Approved
T0388	Cilnidipine	Dual L-and N-type calcium channel	Approved
T0368	Cinpezate maleate	Calcium Channel	Approved
T0343	Nimodipine	AhR; Calcium Channel; Mineralocorticoid Receptor	FDA Approved
T0327	Fendiline hydrochloride	Calcium Channel	Approved
T0283	Trimethadione	Calcium Channel	FDA Approved
T0267	Zonisamide	Calcium Channel; Carbonic anhydrase; Sodium Channel	FDA Approved
T0231	Amlodipine Besylate	Calcium Channel	FDA Approved
T0207	Ranolazine dihydrochloride	Calcium Channel; Sodium Channel	FDA Approved
T0193	Manidipine dihydrochloride	Calcium Channel	Approved
T0192	Levetiracetam	Calcium Channel; Synaptic vesicle glycoprotein 2A	FDA Approved
T0163	Nisoldipine	L-type Cav1.2	FDA Approved

ID	Product Name	Target	Condition
T0145	Felodipine	L-type calcium channel	FDA Approved
T0121	Azelinidipine	Calcium Channel	Approved
T0119	Nitrendipine	Calcium Channel	Approved
T0112	Diltiazem hydrochloride	Calcium Channel	FDA Approved
T0077	Dantrolene sodium salt	Calcium Channel; Ryanodine receptor 1	FDA Approved

CFTR

ID	Product Name	Target	Condition
T7083	GLPG1837	CFTR	Phase 2
T5312	FDL169	CFTR	Phase 1/2
T3135	KM11060	CFTR	
T2595	Lumacaftor	F508del-CFTR	FDA Approved
T2588	Ivacaftor	F508del-CFTR; G551D-CFTR	FDA Approved
T2486	IOWH032	CFTR	Phase 2
T2451	GlyH101	CFTR	
T2355	CFTRinh172	CFTR	
T2263	VX661	VFTR	FDA Approved
T1874	PPQ102	CFTR	
T1805	Ataluren	CFTR	Approved
T14935	Elexacaftor	CFTR	FDA Approved
T0429	Glucosamine	Chitosanase; MMP-9; NF-κB; IFγ; TNF-α	Approved

CGRP Receptor

ID	Product Name	Target	Condition
TP1040L	Calcitonin (salmon) Acetate(47931-85-1(free base))	calcitonin receptor; amylin	FDA Approved
T4610	BMS927711	CGRP	FDA Approved

Chloride channel

ID	Product Name	Target	Condition
TN1035	Irisolidone	VRAC; IL Receptor; NF-Kb	
T8039	Brucine sulfate heptahydrate	glycine receptor	
T7638	NPPB	Chloride channel	
T5225	Hypotaurine	Glycine receptor	
T4811	D-Alanine	Glycine receptor	
T4503	Talinflumate	hCLCA1/mCLCA3; COX; Cl-/HCO3- exchanger; GCNT3	Approved

ID	Product Name	Target	Condition
T4330	CaCCinh-A01	TMEM16A; CaCC	
T2498	Adjudin	Chloride Channel; Mitochondrial Metabolism	
T16346	NS1652	chloride channel	
T13059	T16Ainh-A01	TMEM16A Chloride channel	
T1125	(+)-Shikonin	TMEM16A chloride channel; PKM2; NF- κ B; TNF- α	
T10979	DCPIB	VRAC; TRESK; TASK-1; TASK-3	
T0954	Anestan	Glycine receptor; GABAR; NMDA receptor; Potassium Channel	FDA Approved
T0275	Meticrane	Chloride Channel; Sodium Channel	Approved
T0052L	Strychnine Sulfate	nAChR; Glycine receptor	
T0051	Urethane	α 4 β 2 nAChR; glycine receptors; GABAR; AMPA; NMDA receptor	Approved
T0019	Betaine hydrochloride	Glycine betaine-binding periplasmic protein; Circadian clock protein KaiB	FDA Approved

CRM1

ID	Product Name	Target	Condition
T6123	Verdinexor	CRM1	Phase 1
T6074	KPT276	CRM1	
T1844	KPT330	CRM1; XPO1	Phase 3

GABA Receptor

ID	Product Name	Target	Condition
TN2268	Tetrahydromagnolol	Cannabinoid Receptor; GPR; GABA	
TMS0418	Dihydroergotoxine mesylate	GABAR	FDA Approved
T9113	Myristicin	Antifection; Bcl-2; Caspase; CYP17; GABA Receptor; IL Receptor; NO; PARP	
T8887	2' MeO6MF	GABAA	
T8664	SSD114 hydrochloride	GABA	
T8639	Phenibut (hydrochloride)	GABAB	
T8630	Baclofen hydrochloride	GABA	FDA Approved
T8572	CL 218872	GABAA	
T8568	Suritazole	GABAA	
T8193	Thujone	GABAA; AChR	
T8162	Cannabidivarin	GABAA	Phase 2
T8040	Cholesterol myristate	nicotinic acetylcholine receptor; GABAA receptor; inward-rectifier potassium ion channel	
T8036	6-Methylflavone	α 1 β 2 γ 2L GABAA receptor; α 1 β 2 GABAA receptor	
T7803	Gaboxadol (hydrochloride)	GABA	

ID	Product Name	Target	Condition
T7794	Zuranolone	GABAA	Phase 3
T7793	6-(4-Methoxyphenyl)-3-pyridazinamine	GABAA	
T7721	Ganaxolone	GABAA	Phase 2
T7699	AZD-7325	GABA	Phase 2
T7622	Gabazine	GABAA	
T7595	L-DAB HBR	GABA; Human Endogenous Metabolite	
T7557	Guvacine hydrochloride	GABA	
T7165	Basmisanil	GABAA α 5	Phase 2
T7136	AZD6280	GABAA	Phase 1
T7064	Valproic Acid	GABA; Sodium Channel; HDACs; HDAC1	FDA Approved
T7000	Tiagabine hydrochloride	GABA uptake	FDA Approved
T6507	Gabapentin HCl	GABAR; α 2 δ subunit of calcium channel	FDA Approved
T6355	(R)-baclofen	GABAR	FDA Approved
T5880	Aminoxyacetic acid hemihydrochloride	GABA; MAS	
T5734	(+)-BORNEOL	GABA	
T5375	Loreclezole	GABAA	
T5330	Fluralaner	GABA	
T4993	Afloqualone	GABAR	FDA Approved
T4688	Pipequaline hydrochloride	GABAA	
T4682	Allopregnanolone	GABA	FDA Approved
T4522	SSD114 hydrochloride	GABAB	
T4440	Saclofen	GABAB	
T4363	CGP 52432	GABAB	
T4176	rac-BHFF	GABAB	
T3S2259	Methyl eugenol	GABAA	
T3S2100	Securinine	GABAA	
T3927	Phellopterin	GABA	
T3741	(-)-borneol	GABA	
T3644	U93631	GABA	
T3403	Glabridin	T1 tyrosinase; T3 tyrosinase; α 1 β 2y2 (GABAA receptor); α 1 β 3y2 (GABAA receptor); α 1 β 2 (GABAA receptor); α 1 β 1y2 (GABAA receptor)	
T3318	Wogonoside	GABA	
T2998	Dihydromyricetin	GABAR; mTOR	Phase 2
T2990	Phenibut	GABAR	
T2983	3,4,5-Trimethoxycinnamic acid	GABAR	
T2940	6-Hydroxyflavone	GABAR	
T2850	(+)-Bicuculline	GABAR	Approved
T2775	Baicalin	GABAR	Approved

ID	Product Name	Target	Condition
T2749	Ginkgolide A	GABAR	
T2339	Apalutamide	Androgen Receptor; GABAR	FDA Approved
T2196	Fipronil	GABA; GluCl channels	Approved
T2067	NS 11394	GABAA	
T19624	Fasoracetam	GABA	
T1860	AWD 131-138	GABAR	Phase 1
T1673	Acamprosate calcium	GABAR	FDA Approved
T1602	Valproic acid sodium salt	GABAR; HDAC2; HDAC9	FDA Approved
T15212	Emamectin Benzoate	GABA Receptor	
T1413	Pentetrazol	GABAR	Phase 2
T1396	Bemegrid	GABAR	Approved
T13690	Etifoxine hydrochloride	GABA	
T1300	Propofol	GABAR; Sodium Channel	FDA Approved
T1240	Flumazenil	GABAR	FDA Approved
T11822	LAU159	$\alpha 1\beta 3$ GABA	
T11349	GABAA receptor agent 1	GABAA	
T11307	Fluxametamide	GABA	
T1128	Oxiracetam	GABAR	Approved
T11277	FG 7142	GABAA receptor	
T1089	Etomidate	GABAR	FDA Approved
T1065	Baclofen	GABAR	FDA Approved
T0958	Penicillin G sodium salt	PBPs; GABAR	FDA Approved
T0954	Anestan	Glycine receptor; GABAR; NMDA receptor; Potassium Channel	FDA Approved
T0710	L-Cycloserine	GABA	FDA Approved
T0702	Gabapentin	GABAR; calcium channel	FDA Approved
T0675	Topiramate	Carbonic anhydrase; GABAR; mGluR5	FDA Approved
T0627	beta-Alanine	GABAR	
T0508	4-Aminobutyric acid	GABA	Approved
T0349	Riluzole	NMDA receptor; Sodium Channel; GABA	FDA Approved
T0169	Nefiracetam	GABAR	Phase 2
T0128	Vigabatrin	ABAT; GABA	FDA Approved
T0051	Urethane	$\alpha 4\beta 2$ nAChR; glycine receptors; GABAR; AMPA; NMDA receptor	Approved
T0048	Nikethamide	GABAR	Approved
T0024	Primidone	nAChR; GABAR; GluR2; Sodium Channel	FDA Approved

HCN Channel

ID	Product Name	Target	Condition
T7516	ZD7288	HCN	

iGluR

ID	Product Name	Target	Condition
T8458	CNQX disodium	AMPA	
T7599	Sunifiram	iGluR	
T7580	CX546	AMPA	
T202728	glycine	Endogenous Metabolite; iGluR; MT2 receptor; MT1 receptor	FDA Approved

Monoamine Transporter

ID	Product Name	Target	Condition
T7651	Rose Bengal	vesicular monoamine transporter (VMAT)	Approved
T7563	NBI-98782	VMAT2	
T7147	Valbenazine	VMAT2	FDA Approved
T6115	Fostamatinib	Adenosine transporter; A3; Monoamine transporter; Syk	FDA Approved
T4590	L-KAWAIN	Monoamine transporter	Approved
T3534	TETRABENAZINE	VMAT-2	FDA Approved

Monocarboxylate Transporter

ID	Product Name	Target	Condition
T7460	α -Cyano-4-hydroxycinnamic acid(α -CHCA)	MCT	
T5845	7-(Diethylamino)coumarin-3-carboxylic acid	MCT1	
T5208	BAY8002	MCT1	
T3210	AZD3965	MCT1	Phase 1
T1768	7ACC2	lactate transport	
T0693	Niflumic acid	COX; Monocarboxylate transporter; Chloride channel protein ClC-Ka; PLA2; UGT	Approved
T0689	D-Phenylalanine	Monocarboxylate transporter	Approved

Na⁺/Ca²⁺ Exchanger

ID	Product Name	Target	Condition
T6144	KB-R7943	Na ⁺ /Ca ²⁺ Exchanger	

Na-K-Cl cotransporter

ID	Product Name	Target	Condition
T1410	Torsemide	Na-K-Cl cotransporter	FDA Approved

ID	Product Name	Target	Condition
T0837	Furosemide	Na-K-Cl cotransporter	FDA Approved
T0108	Bumetanide	Na-K-Cl cotransporter	FDA Approved

NPC1L1

ID	Product Name	Target	Condition
T7798	FGH-10019	SREBPs	
T6832	Fatostatin	SREBPs	
T4317	PF 429242	SREBP1; SREBP	Preclinical
T1593	Ezetimibe	NPC1L1; Nrf2; Sterol O-acyltransferase	FDA Approved

OAT

ID	Product Name	Target	Condition
T6875	Lesinurad	OAT1; OAT3	FDA Approved
T3994	Verinurad	URAT1	Phase 2

OCT

ID	Product Name	Target	Condition
T2439	O4I1	OCT3; OCT4	
T2437	O4I2	OCT3; OCT4	
T2040	OAC1	Oct4	
T2019	OAC2	Oct4	

P2X Receptor

ID	Product Name	Target	Condition
T1352	Adenosine 5'-triphosphate disodium salt	P2X Receptor	Phase 3

P-gp

ID	Product Name	Target	Condition
T8426	Encequidar	P-gp (P-glycoprotein)	Phase 1
T6287	Tariquidar	P-gp (P-glycoprotein)	Phase 2
T6018	Zosuquidar 3HCl	P-gp (P-glycoprotein)	Approved
T4A2399	Cinobufotalin	Akt; IL Receptor; MRP1; P-gp	Phase 1
T3868	Agnuside	COX-2; P-gp (P-glycoprotein)	

ID	Product Name	Target	Condition
T3392	Sinapine thiocyanate	P-gp (P-glycoprotein)	
T3002	Piperine	P-gp (P-glycoprotein); CYP3A4	Approved
T2S2018	7-beta-Hydroxylathyrol	P-gp (P-glycoprotein)	
T2S0410	Euphorbia factor L1	ABCB1	
T2893	Muscone	MMP-9; P-gp (P-glycoprotein)	
T2657	Elacridar	P-gp (P-glycoprotein)	Phase 1
T16339	Norverapamil hydrochloride	Calcium channel blocker; P-gp (P-glycoprotein)	
T0012	Cinchonine	P-gp (P-glycoprotein)	Phase 1

Potassium Channel

ID	Product Name	Target	Condition
TN2239	Strictosamide	Sodium Channel; ATPase; Potassium Channel	
T8700	TKIM	TREK-1	
T8446	QO-40	KCNQ2/Q3 potassium channel	
T8361	Tetraethylammonium bromide	Potassium Channel	
T8182	Guan-fu base A	CYP2D6; HERG channel	
T8040	Cholesterol myristate	nicotinic acetylcholine receptor; GABAA receptor; inward-rectifier potassium ion channel	
T7899	VU0810464	GIRK	
T7775	A2764 dihydrochloride	mTRESK channel	
T7653	JNJ 303	IKs	
T7612	ICA 110381	KCNQ2/Q3 potassium channel	
T7512	BMS-191011	Potassium Channel	
T7505	Azimilide Dihydrochloride	Potassium Channel	Phase 3
T7198	E-4031	hERG Potassium Channel	
T7195	GSK369796 Dihydrochloride	potassium ion channel	Phase 1
T7056	Dronedrone	Potassium Channel; Sodium channel; Calcium channel	FDA Approved
T6978	Almitrine dimesylate	Potassium Channel	Approved
T6631	Quinine HCl Dihydrate	Potassium channel	FDA Approved
T6504	Flupirtine maleate	NMDA receptor; Potassium Channel	Approved
T6476	Dofetilide	Potassium Channel	FDA Approved
T5585	AM-92016 hydrochloride	rectifier potassium current	
T5444	CLP-290	KCC2	
T5336	Zacopride hydrochloride	5-HT3 antagonist; 5-HT4 agonist; IK1/Kir2.1 agonist	
T5183	AUT1	Kv3.1b channels; Kv3.2a channels	
T5180	SKA31	KCa3.1 channel	
T4612	NS309	Potassium Channel; hERG	Preclinical
T4316	ML365	TASK-1	

ID	Product Name	Target	Condition
T4224	ML335	TREK-1; TREK-2	
T4030	ML213	Kv7.2 (KCNQ2) channels; Kv7.4 (KCNQ4) channels	
T3S0870	Paederosidic acid methyl ester	ATPase; NO; Potassium Channel	
T3959	ICA069673	KCNQ2/Q3 potassium channel	
T3876	Loureirin B	ERK; JNK; PAI-1; Potassium Channel; PAI-1	
T3581	KS176	BKCa-channel; BCRP(Pheo A)	
T3557	GAL021	BKCa-channel	Phase 1
T3528	Senicapoc	Gardos channel	Phase 2
T3332	Isosteviol	COX-2; IL-6; NF-κB; Potassium Channel; TNF-α	Phase 2
T3303	ML277	KCNQ1	
T3102	NS 1619	Potassium Channel	Preclinical
T2546	Pimozide	D2; Potassium Channel; α1-adrenoceptor	FDA Approved
T21487	Retigabine dihydrochloride	KCNQ3/5; KCNQ2/Q3; KCQN4	
T1752	NS6180	KCa3.1 channel	
T17262	XE 991 dihydrochloride	Kv7.1 channel; Kv7.2 channel; Kv7.2 + Kv7.3 channel; M-current	
T1674	Nateglinide	Potassium Channel; PPARγ	FDA Approved
T1650	Chlorzoxazone	Potassium Channel	FDA Approved
T1634	Glyburide	Bile salt export pump; Potassium Channel	FDA Approved
T16110	ML418	Kir7.1	
T15758	Linopirdine	TRPV1; M-type K+ current	
T15555	IK1 inhibitor PA-6	KIR2.x currents	
T15545	ICA-27243	KCNQ2/Q3 potassium channel	
T1530	Mitiglinide calcium	Potassium Channel	Approved
T1527	Gliclazide	Potassium Channel	Approved
T1498	Indapamide	Potassium Channel	FDA Approved
T1496	Amiodarone hydrochloride	β-adrenergic receptor; Potassium Channel; ATP-sensitive potassium channel	FDA Approved
T1453	Phenformin hydrochloride	AMPK; Potassium Channel	
T1449	Hydrochlorothiazide	Carbonic anhydrase; Potassium Channel	FDA Approved
T1334	Hydroquinidine	Potassium Channel; Sodium Channel	Approved
T1333	Tolazamide	Potassium Channel	FDA Approved
T13320L	VU591	Kir1.1; ROMK	
T13320	VU591 hydrochloride	Kir1.1	
T13316	VU0134992 hydrochloride	Kir4.1	
T1320	Disopyramide	mAChR; Potassium Channel; Sodium Channel	FDA Approved
T1291	Cisapride	5-HT; Potassium Channel; hERG channel	FDA Approved
T1278	Astemizole	H1 receptor; Potassium Channel	
T1266	Terfenadine	HT; mAChR; Potassium Channel; hERG	Approved
T1260	Sodium cromoglycate	Protein S100-P; Potassium Channel	FDA Approved
T12478	Pinacidil monohydrate	Potassium Channel	FDA Approved

ID	Product Name	Target	Condition
T1204	Bendroflumethiazide	Carbonic anhydrase; Potassium Channel	FDA Approved
T1146	Nifedipine	Calcium Channel; CAM; Potassium Channel	FDA Approved
T1138	Taurocholic acid sodium salt hydrate	Gastrotropin; Bile salt-activated lipase	FDA Approved
T10979	DCPIB	VRAC; TRESK; TASK-1; TASK-3	
T1088	Repaglinide	Potassium Channel; PPAR γ	FDA Approved
T1073	Dronedaron hydrochloride	Adrenergic Receptor; Calcium Channel; Potassium Channel; Sodium Channel	FDA Approved
T1054	Tolbutamide	Potassium Channel	FDA Approved
T1050	Prazosin hydrochloride	ABCG; Adrenergic Receptor; MRP1; Potassium Channel	FDA Approved
T0974	Novobiocin Sodium	ABCG2; DNA gyrase; Bile salt export pump; Topo I	FDA Approved
T0954	Anestan	Glycine receptor; GABAR; NMDA receptor; Potassium Channel	FDA Approved
T0916	Butyl 4-aminobenzoate	Potassium Channel inhibitor	Approved
T0866	Propafenone	MRP1; Potassium Channel; Sodium Channel	FDA Approved
T0847	Chenodeoxycholic acid	Bile acid receptor	FDA Approved
T0816	Acetohexamide	NADPH; Potassium Channel	FDA Approved
T0791	Reserpine	MRP1; SVAT; Bile salt export pump	FDA Approved
T0700	Ursodeoxycholic acid	Bile salt export pump	FDA Approved
T0690	Quinine	Fe(II)-protoporphyrin IX; Platelet glycoprotein IX; Potassium Channel	FDA Approved
T0483	Sotalol hydrochloride	β -adrenergic receptor; Potassium Channel	FDA Approved
T0451	Minoxidil	COX-1; Potassium Channel	FDA Approved
T0447	Carvedilol	Adrenergic Receptor; HIF; E-selectin; NADPH; Vcam; Potassium Channel; VEGFR; LDL oxidation	FDA Approved
T0386	Ropivacaine hydrochloride	Sodium Channel; K2P (two-pore domain potassium channel) TREK-1	FDA Approved
T0371	Gliquidone	Potassium Channel	Approved
T0365	Thioridazine hydrochloride	5-HT; Adrenergic Receptor; Dopamine; Potassium Channel	FDA Approved
T0344	Miconazole	14- α Demethylase; eNOS; iNOS; Potassium Channel	FDA Approved
T0342	Carvedilol phosphate	Adrenergic Receptor; Gap Junction Protein; E-selectin; NADPH dehydrogenase; Natriuretic peptides B; VCAM1; Potassium Channel; VEGFR; LDL oxidation	FDA Approved
T0266	Quinidine hydrochloride	Potassium Channel; Sodium Channel	FDA Approved
T0161	Pantoprazole Sodium Hydrate	Potassium-transporting ATPase; Proton pump	FDA Approved
T0150	Hydroxyhexamide	ATP-sensitive potassium (KATP) channels	FDA Approved
T0127	Glimepiride	SUR1; SUR2A; SUR2B	FDA Approved
T0126	Diazoxide	Na ⁺ /K ⁺ -ATPase; Potassium Channel	FDA Approved
T0075	Nicorandil	Potassium Channel	Approved
T0038	Doxapram hydrochloride monohydrate	TASK-1; TASK-1/TASK-3 heterodimeric; TASK-3	FDA Approved

Proton pump

ID	Product Name	Target	Condition
T8388	Vonoprazan	potassium-competitive acid	Approved
T8386	Esomeprazole Magnesium trihydrate	Proton pump	FDA Approved
T6928	Pantoprazole	Proton pump	FDA Approved
T6700	Tenatoprazole	Proton pump	Phase 1
T2687	Omeprazole sulfide	Proton pump	FDA Approved
T1756	Ilaprazole sodium	Proton pump	Approved
T1734	Rabeprazole Related Compound E	Proton pump	FDA Approved
T1651	Rebeprazole sodium	Proton pump	FDA Approved
T1021	R-(+)-Lansoprazole	Proton pump	FDA Approved
T0757	Omeprazole	Autophagy; Proton pump	FDA Approved
T0674	Lansoprazole	Proton pump	FDA Approved
T0502	Zinc pyrithione	Proton pump	FDA Approved
T0161	Pantoprazole Sodium Hydrate	Potassium-transporting ATPase; Proton pump	FDA Approved

Sodium Channel

ID	Product Name	Target	Condition
TQ0157	EIPA	TRPP3 channel; Na ⁺ /H ⁺ -exchanger (NHE)	
TN2239	Strictosamide	Sodium Channel; ATPase; Potassium Channel	
TN1740	Homoeriodictyol	GLUT; 5-HT Receptor; Sodium Channel	
T8711	PF-05186462	Nav1.7 channel	
T8444	N-Me-aminopyrimidinone9	Sodium Channel	
T8299	Dimethyl lithospermate B	Sodium Channel	
T7811	Pilsicainide HCl	Sodium Channel	Approved
T7547	Ralfinamide mesylate	Sodium Channel	
T7349	Ralfinamide	Na-channel	Phase 3
T7336	ICA-121431	Nav1.7 channel	
T7219	Flecainide (acetate)	Nav1.5 channel	FDA Approved
T7182	Metaflumizone	Sodium Channel	
T7066	Fosphenytoin sodium	Sodium Channel	Approved
T7064	Valproic Acid	GABA; Sodium Channel; HDACs; HDAC1	FDA Approved
T7056	Dronedarone	Potassium Channel; Sodium channel; Calcium channel	FDA Approved
T6955	Propafenone HCl	Sodium Channel	FDA Approved
T6953	Prilocaine	Sodium Channel	FDA Approved
T6782L	Benzocaine xHCl(94-09-7 (free base))	Na ⁺ channel	Approved
T6566	Levobupivacaine HCl	Sodium Channel	FDA Approved

ID	Product Name	Target	Condition
T6541	Ibutilide Fumarate	Sodium Channel	FDA Approved
T6234	Ambroxol hydrochloride	Sodium Channel	Approved
T5333	Rimeporide hydrochloride	NHE-1	
T5324	BI 01383298	SLC13A5	
T5319	Rimeporide	NHE-1	Phase 1
T4699	Hexamethylene amiloride	NHE exchangers; TRPA1; ASIC3; P2X7	
T4550	Ajmaline	sodium channel	Approved
T4539	Nicainoprol	Sodium Channel	
T4490	PF01247324	Na(V1.8) channel	
T3364	Veratramine	Sodium Channel	
T3285	Eslicarbazepine Acetate	Beta-secretase; Sodium Channel	FDA Approved
T2806	Lappaconitine	Sodium Channel	Approved
T2523	Rufinamide	Sodium Channel	FDA Approved
T2391	Camostat mesilate	epithelial sodium channel (ENaC)	Approved
T2342	CNV1014802	Sodium Channel	Phase 3
T2192	Indazole	Sodium Channel	
T2135	Aconitine	Sodium Channel	Approved
T2131	Articaine HCl	Sodium Channel	FDA Approved
T2049	GS967	late INa ,isolated hearts; late INa ,ventricular myocytes	Phase 1
T2024	A803467	Na(V1.8) channel	Preclinical
T19644	Benzonatate	sodium channel	FDA Approved
T1787	Levobupivacaine	Sodium Channel	FDA Approved
T1389	Dyclonine hydrochloride	Sodium Channel	FDA Approved
T1386	Phenazopyridine hydrochloride	Sodium Channel	FDA Approved
T1334	Hydroquinidine	Potassium Channel; Sodium Channel	Approved
T1332	Permethrin	Sodium Channel	FDA Approved
T1320	Disopyramide	mAChR; Potassium Channel; Sodium Channel	FDA Approved
T1308	Orphenadrine hydrochloride	H1 receptor; NMDA receptor; Noradrenaline transporter (Sodium-dependent); Sodium Channel	FDA Approved
T1300	Propofol	GABAR; Sodium Channel	FDA Approved
T1198	Tetracaine hydrochloride	Sodium Channel	FDA Approved
T1144L	Lidocaine Hydrochloride hydrate	EGFR; Sodium Channel	FDA Approved
T1144	Lidocaine hydrochloride	Sodium Channel	FDA Approved
T1073	Dronedaron hydrochloride	Adrenergic Receptor; Calcium Channel; Potassium Channel; Sodium Channel	FDA Approved
T1046	Mexiletine hydrochloride	AhR; Voltage-gated sodium channel	FDA Approved
T0946	Mepivacaine hydrochloride	Sodium Channel	FDA Approved
T0943	Carbamazepine	Sodium Channel	FDA Approved
T0939	Phenytoin	Sodium Channel	FDA Approved
T0924	Benzocaine	MRP1; LCE 1; Sodium Channel	Approved

ID	Product Name	Target	Condition
T0866	Propafenone	MRP1; Potassium Channel; Sodium Channel	FDA Approved
T0843	Ademine	ENaC; ENaCoS583	FDA Approved
T0802	Procaine hydrochloride	5-HT3; nAChR; NMDA receptor; Sodium channel	FDA Approved
T0796	Propitocaine hydrochloride	Sodium Channel	FDA Approved
T0792	(-)-Sparteine sulfate pentahydrate	Sodium Channel	Approved
T0511	Tolperisone hydrochloride	Sodium Channel	Approved
T0470	Nefopam hydrochloride	Sodium Channel	Approved
T0460	Pramoxine hydrochloride	Sodium Channel	FDA Approved
T0440	Oxcarbazepine	Sodium Channel	FDA Approved
T0386L	Ropivacaine	Sodium Channel	FDA Approved
T0386	Ropivacaine hydrochloride	Sodium Channel; K2P (two-pore domain potassium channel) TREK-1	FDA Approved
T0378	Oxybuprocaine hydrochloride	Sodium Channel	Approved
T0364L	Dibucaine hydrochloride	AChR; Sodium Channel	FDA Approved
T0364	Dibucaine	AChR; CAM; Sodium Channel	FDA Approved
T0349	Riluzole	NMDA receptor; Sodium Channel; GABA	FDA Approved
T0275	Metricrane	Chloride Channel; Sodium Channel	Approved
T0267	Zonisamide	Calcium Channel; Carbonic anhydrase; Sodium Channel	FDA Approved
T0266	Quinidine hydrochloride	Potassium Channel; Sodium Channel	FDA Approved
T0249	Acecaïnide	Sodium Channel	Approved
T0222	Proparacaine hydrochloride	Voltage-gated sodium channel	FDA Approved
T0207	Ranolazine dihydrochloride	Calcium Channel; Sodium Channel	FDA Approved
T0175L	Amiloride hydrochloride dihydrate	Amiloride-sensitive sodium channel	FDA Approved
T0167	Vinpocetine	NF-κB; PDE; Sodium Channel	Approved
T0044	Oxethazaine	Sodium Channel	Approved
T0030	Bupivacaine hydrochloride	Sodium Channel	FDA Approved
T0029	Procaine	Sodium Channel	FDA Approved
T0024	Primidone	nAChR; GABAR; GluR2; Sodium Channel	FDA Approved
T0018	Procainamide hydrochloride	AChR; DNA (cytosine-5)-methyltransferase 1; Sodium Channel	FDA Approved
T0008	Phenytoin sodium	Sodium Channel	FDA Approved

TRP/TRPV Channel

ID	Product Name	Target	Condition
TQ0157	EIPA	TRPP3 channel; Na ⁺ /H ⁺ -exchanger (NHE)	
TN1377	alpha-Spinasterol	COX-1; COX-2; TRPV1	
T8607	M-084 hydrochloride	TRPC4; TRPC5	


ID	Product Name	Target	Condition
T8565	N4-benzyl-N2-methylquinazoline-2,4-diamine hydrochloride	TRPC4	
T8528	AC1903	TRPC5	
T8449	TC-I2000	TRPM8	
T8442	M8-B Hydrochloride	TRPM8	
T8440	LASSBio-1135	TRPV1; TNF- α	
T8425	Linoleoyl Ethanolamide	TRPV1	
T8410	ASP7663	TRPA1	
T8307	Hydroxy- α -sanshool	TRPA1; TRPV1	
T7572	RN-1734	hTRPV4	
T7526	JNJ-17203212	TRPV1	
T7430	AM-0902	TRPA1	
T7416	WS-12	TRPM8	
T7205	A 967079	TRPA1	
T7189	AMG9810	TRPV1	
T7177	Capsazepine	TRPA1	
T7102	BCTC	TRPV1/8	
T6977	SB366791	TRPV1	
T6848	GSK1016790A	hTRPV4; mTRPV4	
T6660	SB705498	hTRPV1; hTRPV1	Phase 1
T6617	Optovin	TRPA1	
T6530	HCO30031	TRPA1	
T6379	AMG517	TRPV1	Phase 1
T5962	N-Ethyl-p-menthane-3-carboxamide	TRPM8	
T5786	TETRAHYDROPIPERINE	Htrpv1; CYP450	
T5698	TRPM8 antagonist 2	TRPM8	
T5640	GSK2193874	TRPV4	
T5479	AMG-333	TRPM8	Phase 1
T4699	Hexamethylene amiloride	NHE exchangers; TRPA1; ASIC3; P2X7	
T4693	2-APB	TRPV1; TRPV2; TRPV3; TRPC6; TRPM8; IP3 receptor	
T4680	HCO67047	hTRPV4/mTRPV4	
T4385	PF4840154	rTRPA1; hTRPA1	
T4028	ML329	TRPM-1	
T3865	beta-Eudesmol	nAChR; TRPA1; TRPV3; TRPM8	
T3727	Methyl syringate	hTRPA1	
T2994	Cardamonin	hTRPA1 cation channel	
T2952	Camphor	TRP	Approved
T2845	Imperatorin	BChE; NO synthesis; TRPV1	Approved
T2807	Caffeic Acid	5-Lipoxygenase; Endogenous Metabolite; hTRPA1	Approved

ID	Product Name	Target	Condition
T2711	TCS 5861528	TRPA1	
T2298	ML204	TRPC4; TRPC5	
T2170	SKF-96365 hydrochloride	TRP	Preclinical
T2007	RQ00203078	TRPM8	
T1814	ICILIN	TRPM8	
T16688	Pyr6	TRPC3	
T16686	Pyr10	TRPC3	
T15758	Linopirdine	TRPV1; M-type K+ current	
T13214L	TRPV4 agonist-1 free base	TRPV4	
T1321	Nonivamide	TRPV1	
T11394	GFB-8438	TRPC5	
T1109	Zucapsaicin	hTRPV1	FDA Approved
T1062	Capsaicin	hTRPV1(in HEK293 cell)	FDA Approved
T10537	BI-749327	mouse TRPC6; human TRPC6; guinea pig TRPC6	
T0882	D-Camphor	TRPV3	Approved
T0647	Tryptamine	5-HT; AADH; hTRPA1	
T0457	Probenecid	TRPV2	FDA Approved
T0399	Methyl salicylate	TRPV1	FDA Approved

VDAC

ID	Product Name	Target	Condition
T8215	VBIT-12	VDAC1	
T18975	DIDS sodium salt	ABCA1; VDAC1	
T13287	VBIT-4	VDAC1	

Metabolism



Acetyl-CoA Carboxylase

ID	Product Name	Target	Condition
TQ0243	ND-646	ACC	
T7184	ND-630	ACC	Phase 2
T7163	PF 05175157	ACC	Phase 2
T3988	TOFA	ACC1	
T3622	CP-640186 hydrochloride	ACC1; ACC2	
T3510	Olumacostat Glasaretil	ACC	Phase 3
T1889	CP 640186	ACC	

Metabolism

aconitase

ID	Product Name	Target	Condition
T5564	Tricarballic acid	aconitase	

Acyltransferase

ID	Product Name	Target	Condition
T2753	Avasimibe	ACAT; CYP1A2; CYP2C19; CYP2C9	Phase 3
T1519L	Rimonabant	ACAT; hCB1; hCB2	Approved
T12225L	Nevanimibe hydrochloride	ACAT-1	Phase 2
T11733	K-604 dihydrochloride	ACAT-1; ACAT-2	
T10035	10,12-Tricosadiynoic acid	acyl-CoA oxidase-1	

AhR

ID	Product Name	Target	Condition
T9112	(-)-Perillaldehyde	AhR; ROS; NRF2/HO1	
T7202	ITE	AhR	
T5622	AHR antagonist 1	AhR	
T5541	PDM 11	AhR	
T5281	3-Methylindole	AhR	
T4938	Indoxyl sulfate potassium salt	AhR	
T4928	L-Kynurenine	Human Endogenous Metabolite; AhR	
T4644	Benvitimod	AhR	Phase 3
T4608	PDM2	AhR	
T4607	CAY10465	AhR	
T2448	CH 223191	AhR	
T1960	YL109	AhR	
T1831	StemRegenin 1	AhR	
T1159	Leflunomide	AhR; DHODH; Protein-tyrosine kinase 2	FDA Approved
T1046	Mexiletine hydrochloride	AhR; Voltage-gated sodium channel	FDA Approved
T0343	Nimodipine	AhR; Calcium Channel; Mineralocorticoid Receptor	FDA Approved

Amino Acids and Derivatives

ID	Product Name	Target	Condition
T5372	L-(+)-Selenomethionine	Amino Acids and Derivatives	FDA Approved
T3695	Pepstatin	aspartic protease	Preclinical
T1324	Phosphoserine	Amino Acids and Derivatives; NMDA receptor	
T0436	Acexamic Acid	Amino Acids and Derivatives; COX	Approved

Aminopeptidase

ID	Product Name	Target	Condition
TQ0047	DG051	LTA4H	Phase 2
T6301	Tosedostat	M1-aminopeptidase	Approved
T5652	L(+)-Leucinol	Aminopeptidase	
T3529	Bestatin hydrochloride	Aminopeptidase; CD13	Approved
T2830	Betulinic acid	Aminopeptidase N; HIV-1; Eukaryotic topoisomerase I	Phase 1

ATP Citrate Lyase

ID	Product Name	Target	Condition
T7424	NDI-091143	ACLY	
T3625	ETC1002	ACL	FDA Approved
T11589	Hydroxycitric acid tripotassium hydrate	ATP citrate lyase; HIF	

Carbonic Anhydrase

ID	Product Name	Target	Condition
TN6707	Methyl 2,4-dihydroxybenzoate	Carbonic anhydrase II	
T8827	EMAC10101d	hCAII	
T6S0221	Eriocitrin	Carbonic Anhydrase VA isozyme	
T6781	Benzenesulfonamide	carbonic anhydrases	
T6469	Dichlorphenamide	carbonic anhydrase	FDA Approved
T5012	Ethoxzolamide	Carbonic anhydrase	FDA Approved
T4S2354	Dimethylfraxetin	Carbonic Anhydrase	
T4321	Indisulam	carbonic anhydrase; CDK	Phase 2
T2616	PIK93	ATM; C2β; DNA-PK; hsVps34; mTORC1; p110α; p110β; p110γ; p110δ; PI3KIIIβ	
T2530	Levosimendan	Cardiac troponin C	Approved
T2134	Dorzolamide hydrochloride	Carbonic anhydrase I; Carbonic anhydrase II; Carbonic anhydrase IV	FDA Approved
T2017	U104	Carbonic anhydrase I; Carbonic anhydrase II; Carbonic anhydrase IX; CAXII	
T1999	Taselisib	PI3Kα; PI3Kβ; PI3Kγ; PI3Kδ; C2β	Phase 1
T1449	Hydrochlorothiazide	Carbonic anhydrase; Potassium Channel	FDA Approved
T1409	Methocarbamol	CA1	FDA Approved
T1204	Bendroflumethiazide	Carbonic anhydrase; Potassium Channel	FDA Approved
T1026	Mafenide hydrochloride	Carbonic anhydrase VI	FDA Approved
T0813	Acetazolamide	Carbonic anhydrase	FDA Approved
T0782	Benzthiazide	Carbonic anhydrase	FDA Approved

ID	Product Name	Target	Condition
T0738	Urea	Arginase-1; Carbonic anhydrase II; DHFR; Sulfoxide reductase catalytic subunit YedY; Wnt/ β -catenin	FDA Approved
T0677	Chlorothiazide	Carbonic anhydrase	FDA Approved
T0675	Topiramate	Carbonic anhydrase; GABAR; mGluR5	FDA Approved
T0515	Tioxolone	Carbonic anhydrase I	Approved
T0465	Ellagic acid	Carbonic anhydrase; CK2; Smoothened; PKA; PKC; Syk; ATP-competitive CK2	Phase 2
T0267	Zonisamide	Calcium Channel; Carbonic anhydrase; Sodium Channel	FDA Approved
T0142	Brinzolamide	Carbonic anhydrase II	FDA Approved
T0114	Trichlormethiazide	Na ⁺ /K ⁺ -ATPase; Carbonic anhydrase	FDA Approved
T0106	Methazolamide	bCAIV; hCAI; hCAII	FDA Approved

Carboxypeptidase(CPG2)

ID	Product Name	Target	Condition
T6801	CeMMEC13	TAF1	
T4345	CeMMEC1	BRD4; TAF1	
T3440	2-PMPA	GCPII	Preclinical

Casein Kinase

ID	Product Name	Target	Condition
T7390	DMAT	CK2	
T6735	XL413 hydrochloride	CK2; Cdc7; Pim1; Cdc7	Phase 1/2
T6315	MLN8054	Aurora A; Aurora B; CK2; PKA; Lck	
T6208	AS252424	Casein Kinase 2 , PI3Ky , PI3K α	
T5393	CK1-IN-1	CK1; p38 σ MAPK	
T5358	Longdaysin	CKI α ; CK1 δ ; CDK7; ERK2	
T5056	PF4800567	CK1 ϵ	
T4645	TA01	CK1 ϵ ; CK1 δ ; p38 MAPK	
T3972	SR3029	CK1 δ	
T3073	PF670462	CK1 ϵ	
T2869	Emodin	CK2	Preclinical
T2695	TBB	CK2; CDK2; GSK-3 β	
T2449	D 4476	ALK5; CK1; CK1 δ	
T2440	IC261	CK1; CDK5	
T2259	Silmitasertib	CK2	Phase 1/2
T2048	LY364947	CK1 δ ; MLK-7K; TGF β RI; TGF β RII; RIPK2	
T1828	TTP 22	CK2	
T15024	Silmitasertib sodium salt	CK2; Autophagy	Phase 1/2

ID	Product Name	Target	Condition
T14069	A-3 hydrochloride	CK1; CK2; PKC; PKA	
T0465	Ellagic acid	Carbonic anhydrase; CK2; Smoothened; PKA; PKC; Syk; ATP-competitive CK2	Phase 2

CETP

ID	Product Name	Target	Condition
T6267	Lomitapide	MTP	FDA Approved
T6262	Evacetrapib	CETP	Phase 1
T6048	Dalcetrapib	rhCETP	Phase 3
T2499	Torcetrapib	CETP	Phase 2
T1928	Anacetrapib	Mutant CETP (C13S); rhCETP	Phase 3

CPT

ID	Product Name	Target	Condition
T4535	(R)-Etomoxir sodium salt	CPT-1	Phase 2

Decarboxylase

ID	Product Name	Target	Condition
T7454	4-Bromo-3-hydroxybenzoic acid	histidine decarboxylase	
T6795	Carbidopa	aromatic-L-amino-acid decarboxylase	FDA Approved
T2593	Eflornithine hydrochloride Monohydrate	Decarboxylase	FDA Approved
T2148	Carbidopa Hydrate	aromatic-L-amino-acid decarboxylase	FDA Approved

Dehydrogenase

ID	Product Name	Target	Condition
TN1829	Kakkalide	LDH	
TJS1382	Taraxerone	ALDH	
T8767	PfDHODH-IN-2	PfDHODH	
T8640	G6PDi-1	G6PD	
T8332	Bipenquinatate	DHODH	
T8003	Methotrexate disodium	hDHFR(dihydrofolate reductase)	Phase 3
T7835	CM 10	ALDH1	
T7741	DS-1001b	IDH1	
T7400	RRX-001	G6PD	Phase 3

ID	Product Name	Target	Condition
T6903	NCT501	ALDH1A1	
T6518	Gossypol	dehydrogenase	Phase 1
T6384	Ammonium Glycyrrhizinate	11-beta-hydroxysteroid dehydrogenase	Approved
T6293	Mycophenolate Mofetil	IMPDH	FDA Approved
T6157	CPI613	α -ketoglutarate dehydrogenase; PDH	Phase 3
T5S2195	Sibiricose A5	Dehydrogenase	
T5705	Glomeratose A	lactate dehydrogenase	
T5702	Tenuifoliside B	Dehydrogenase	
T5427	GSK1940029	SCD	Phase 1
T4515	A939572	mSCD1/hSCD1	
T4295	(R)-GNE-140	LDH	
T4213	NCT503	PHGDH(Cell-free); FLT3; AXL	
T4173	R162	glutamate dehydrogenase 1 (GDH1)	
T3617	Ivosidenib	IDH1	FDA Approved
T3542	BVT14225	11 β -HSD1	
T3494	LW6	HIF-1; MDH2	
T3444	Merimepodib	Antiviral; IMPDH	Phase 2
T3175	AZ33	LDHA	
T3044	Teriflunomide	Dihydroorotate Dehydrogenase	FDA Approved
T3019	Rheochrysidin	6-phosphogluconate dehydrogenase	
T3009	3-Nitropropanoic acid	Dehydrogenase	
T2S2211	Tenuifoliside C	lactate dehydrogenase	
T2970	Rotenone	NAPDH; p53	
T2901	Daidzin	ALDH- I ; ALDH- II	Approved
T2741	Glycyrrhizin	Dehydrogenase; MAO	Approved
T2662	Alda-1	ALDH2	
T2650	MK8245	SCD1 (human); SCD1 (mouse); SCD1 (rat)	Phase 1
T2601	Vidofludimus	Human DHODH	Phase 2
T2447	AZD7545	PDHK1; PDHK2	Preclinical
T23533	WIN 18446	ALDH1a2	
T2346	Enasidenib	IDH2	FDA Approved
T22253	AG-120 (racemic)	IDH1	FDA Approved
T2121	SW033291	15-PGDH; 15-PGDH	
T2104	AGI5198	R132C-IDH1; R132H-IDH1	
T2057	BVT 2733	11 β -HSD1	
T2043	IDH1-IN-1	mutant IDH1 R132H	
T19831	Sodium Oxamate	LDH; CDK; Apoptosis	
T1979	AVN944	IMPDH	Phase 1
T1869	PluriSln 1	SCD	
T1809	AGI6780	IDH2 R140Q mutant	

ID	Product Name	Target	Condition
T1717	Mangostin	IDH1-R132H	
T16384	Olutasidenib	R132C-IDH1; R132H-IDH1	Phase 1/2
T1608	Exherin trifluoroacetate	N-cadherin	Phase 1
T16068	MF-438	SCD	
T15435	GSK2837808A	LDHA; LDHB	
T15022	CVT-10216	ALDH2	
T1491	Atovaquone	DHODH; Cytochrome b	FDA Approved
T14884	CBR-5884	PHGDH; serine synthesis	
T14878	CAY10566	SCD1	
T1485	Methotrexate	hDHFR	FDA Approved
T1473	Trilostane	3 β -hydroxysteroid dehydrogenase	FDA Approved
T14501	BAY-2402234	DHODH	Phase 1
T1374	2-Picolinyl hydrazide	CAT; NADPH	
T1335	Mycophenolic acid	DH; UGT	FDA Approved
T11829	LDH-IN-1	LDHA; LDHB	
T1165	Ethinamide	CAT; NADPH	FDA Approved
T1159	Leflunomide	AhR; DHODH; Protein-tyrosine kinase 2	FDA Approved
T11020	DHODH-IN-11	DHODH	
T10384	ASLAN003	DHODH	Phase 2
T10140	4-Diethylaminobenzaldehyde	ALDH	
T0972	Isoniazid	CAT; NADPH	FDA Approved
T0897	Furacilin	Malate dehydrogenase; Pyruvate dehydrogenase; Glutathione reductase	FDA Approved
T0746	Orotic acid	DHOase	Approved
T0732	Benzyl alcohol	ALDH	FDA Approved
T0684	Ribavirin	ADK; IMPDH1; RNA polymerase	FDA Approved
T0647	Tryptamine	5-HT; AADH; hTRPA1	
T0522	Diammonium Glycyrrhizinate	11-beta-hydroxysteroid dehydrogenase	Approved
T0494	Tetramisole hydrochloride	SDH	Approved
T0414	D-Mannitol	MDH	FDA Approved
T0361	Isovaleramide	Alcohol DHO	Phase 2
T0293	Metryrapone	Camphor 5-monooxygenase; 11 β -HSD1	FDA Approved
T0256	Lithium citrate tribasic tetrahydrate	IMPDH; mGluR3; GSK-3 β	FDA Approved
T0054	Disulfiram	ALDH1; DBH	FDA Approved
T0036	Enoxolone	Dehydrogenase	Approved
T0010	Mercaptopurine	IMPDH; HPRT	FDA Approved

DHFR

ID	Product Name	Target	Condition
T6226	Pemetrexed Disodium Hydrate	DHFR; DHFR; GARFT; Thymidylate synthase	FDA Approved
T6120	Pralatrexate	DHFR; Axl(KPL-4 cells); Axl(SUM149 cells)	FDA Approved
T4558	Trioxsalen	DHFR	FDA Approved
T2204	Diaveridine	DHFR	
T1326	Gentamycin sulfate	DNase I; DHFR; 16S ribosome; 30S ribosome	FDA Approved
T1153	Trimethoprim	DHFR; Thymidylate synthase	FDA Approved
T0849	Pyrimethamine	DHFR	FDA Approved
T0836	Sulfadoxine	DHPS; DHFR	FDA Approved
T0748	Sulfameter	DHFR	FDA Approved
T0738	Urea	Arginase-1; Carbonic anhydrase II; DHFR; Sulfoxide reductase catalytic subunit YedY; Wnt/ β -catenin	FDA Approved
T0189L	Pemetrexed disodium	DHFR; GARFT; Thymidylate synthase	FDA Approved
T0189	Pemetrexed acid	DHFR; GARFT; Thymidylate synthase	FDA Approved

Electron transport

ID	Product Name	Target	Condition
T4382	Proguanil hydrochloride	dihydrofolate reductase; thymidylate synthase; NADH dehydrogenase	FDA Approved

Endogenous Metabolite

ID	Product Name	Target	Condition
TQ0285	Spaglumic acid	Human Endogenous Metabolite	
TQ0265	Indolelactic acid	Endogenous Metabolite	
TP1442	Neuromedin B	Endogenous Metabolite	
TP1277	Bradykinin	Bradykinin Receptor; Endogenous Metabolite	Phase 4
TP1266	γ -Glu-Phe TFA(7432-24-8 free base)	Endogenous Metabolite	
TP1087	Substance P	Human Endogenous Metabolite; NK1	
TN2349	Taurodeoxycholate sodium salt	Human Endogenous Metabolite	
TJO2691	L-(-)-Fucose	Endogenous Metabolite	Phase 2
T8811	Tuftsins 3TFA	Human Endogenous Metabolite	
T8790	1-Methylhistamine dihydrochloride	Human Endogenous Metabolite	
T8789	N-Acetyl-L-tryptophan	Human Endogenous Metabolite; NK1	
T8783	4-Methylbiphenyl	Human Endogenous Metabolite	
T8547	DCBA	Drug Metabolite	
T8392	L(+)-Asparagine monohydrate	Human Endogenous Metabolite	Approved

ID	Product Name	Target	Condition
T8274	3-Methyl-L-histidine	Human Endogenous Metabolite	
T8271	10Z-Nonadecenoic acid	Human Endogenous Metabolite	
T8264	3-Methyl-2-oxovaleric acid	Human Endogenous Metabolite	
T8227	5'-Methylthioadenosine	Human Endogenous Metabolite	
T8150	1-Methyl-6-oxo-1,6-dihydropyridine-3-carboxamide	Human Endogenous Metabolite	
T8105	Indole-3-carboxaldehyde	Human Endogenous Metabolite	
T8094	16-Dehydroprogesterone	Human Endogenous Metabolite	
T8075	1,3-Dimethyluric acid	Human Endogenous Metabolite	
T8053	Ac-Arg-OH	Human Endogenous Metabolite	
T8043	5 α -Cholestane	Human Endogenous Metabolite	
T8037	H-Phe-Phe-OH	Human Endogenous Metabolite	
T8026	(S)-(-)-Limonene	Human Endogenous Metabolite	
T7868	Farnesol	Human Endogenous Metabolite	
T7773	DPPC	Human Endogenous Metabolite	
T7682	Asymmetric dimethylarginine	NO synthesis; Human Endogenous Metabolite	
T7665	[Leu5]-Enkephalin TFA(58822-25-6(free bas))	δ -opioid receptor; Human Endogenous Metabolite	
T7647	Eicosadienoic acid	Human Endogenous Metabolite	
T7646	Alloepipregnanolone	Human Endogenous Metabolite	
T7641	5-Hydroxytryptophol	Human Endogenous Metabolite	
T7634	3-Hydroxymandelic Acid	Human Endogenous Metabolite	
T7628	3 β -Hydroxy-5-cholenoic acid	Human Endogenous Metabolite	
T7606	Guanosine 5'-diphosphate disodium salt	Human Endogenous Metabolite	
T7595	L-DAB HBR	GABA; Human Endogenous Metabolite	
T7571	1-Methyladenosine	Endogenous Metabolite	
T7565	3-Hydroxycapric acid	Human Endogenous Metabolite	
T7520	Deoxycytidine triphosphate	Human Endogenous Metabolite	
T7511	Cyclo(his-pro)	Human Endogenous Metabolite ; NF- κ B	
T7508	N-Acetylputrescine hydrochloride	Human Endogenous Metabolite	
T7458	5-Phenylvaleric Acid	Human Endogenous Metabolite	
T7457	5-Methyl-2'-deoxycytidine	Human Endogenous Metabolite; DNA methylation	
T7408	all-trans-4-Oxoretinoic acid	Human Endogenous Metabolite	
T7357	(S)-b-aminoisobutyric acid	Human Endogenous Metabolite	
T7344	SDMA	Human Endogenous Metabolite	
T7335	L-2,3-Diaminopropionic acid	Human Endogenous Metabolite	
T7331	Ursocholic acid	Human Endogenous Metabolite	
T7210	Guanosine 5'-diphosphate	Human Endogenous Metabolite	

ID	Product Name	Target	Condition
T7154	trans-trans-Muconic acid	Human Endogenous Metabolite	
T7095	Hexacosanoic acid	Human Endogenous Metabolite	
T7094	Levomefolic Acid	Human Endogenous Metabolite	FDA Approved
T6S0232	Eriodictyol	Endogenous Metabolite; Keap1-Nrf2	
T6523	Guanosine	Endogenous Metabolite	
T6060	(±) Anabesine	Human Endogenous Metabolite	
T6000	D-DELTA-TOCOPHEROL	Human Endogenous Metabolite	
T5986	3-Hydroxypicolinic acid	Human Endogenous Metabolite	
T5984	Indole-3-carboxylic acid	Human Endogenous Metabolite	
T5982	3-Methoxybenzoic acid	Human Endogenous Metabolite	
T5980	2-Ketoglutaric acid	Human Endogenous Metabolite	
T5968	DL-Homocysteinethiolactone hydrochloride	Human Endogenous Metabolite	
T5915	D-chiro-Inositol	Human Endogenous Metabolite	
T5912	5-Methylcytidine	Human Endogenous Metabolite	
T5891	D-ERYTHRO-SPHINGOSINE	PKC; PP2A; Human Endogenous Metabolite	
T5890	2,4-Dihydroxybenzoic acid	Human Endogenous Metabolite	
T5875	4-Methoxycinnamic acid	Human Endogenous Metabolite	
T5874	2-Methoxybenzoic acid	Human Endogenous Metabolite	
T5873	2,6-Dihydroxybenzoic acid	Human Endogenous Metabolite	
T5646	Cinnamic acid	Endogenous Metabolite	
T5589	H-Gly-Pro-OH	Human Endogenous Metabolite	
T5583	D-(+)-Turanoose	Human Endogenous Metabolite	
T5573	Coenzyme Q9	Human Endogenous Metabolite	
T5569	3-Amino-4-methylpentanoic acid	Human Endogenous Metabolite	
T5568	H-Tyr(3-I)-OH	Human Endogenous Metabolite	
T5557	Propylparaben	Human Endogenous Metabolite	Approved
T5556	5a-Pregnane-3,20-dione	Human Endogenous Metabolite	
T5089	5-Aminovaleric acid	Endogenous Metabolite	
T5014	Prostaglandin E2 (PGE2)	EP2 Receptor; Human Endogenous Metabolite	FDA Approved
T4S2157	Campesterol	Human Endogenous Metabolite	
T4973	1,7-DIMETHYLXANTHINE	Human Endogenous Metabolite	
T4972	2'-Deoxycytidine-5'-diphosphate trisodium	Human Endogenous Metabolite	
T4971	5'-DEOXYADENOSINE	Human Endogenous Metabolite	
T4970	LANOSTEROL	Human Endogenous Metabolite	
T4969	Guanosine 5'-triphosphate trisodium salt	Human Endogenous Metabolite	
T4947	3-Hydroxybutyric acid	Human Endogenous Metabolite	
T4945	DL-Normetanephine hydrochloride	Human Endogenous Metabolite	

ID	Product Name	Target	Condition
T4944	Nervonic acid	Human Endogenous Metabolite	
T4934	1-Methyl-L-histidine	Human Endogenous Metabolite	
T4933	Na-Acetyl-L-asparagine	Human Endogenous Metabolite	
T4928	L-Kynurenine	Human Endogenous Metabolite; AhR	
T4927	4-Guanidinobutyric acid	Human Endogenous Metabolite	
T4923	7-Dehydrocholesterol	Human Endogenous Metabolite	
T4921	Oxoadipic acid	Human Endogenous Metabolite	
T4919	3-Ureidopropionic acid	Human Endogenous Metabolite	
T4917	(L)-Dehydroascorbic acid	Human Endogenous Metabolite	Preclinical
T4907	3,4-Dihydroxyphenylacetic acid	Human Endogenous Metabolite	
T4899	L-Histidinol dihydrochloride	Human Endogenous Metabolite	
T4895	Cadaverine dihydrochloride	Human Endogenous Metabolite	
T4894	L-(-)-Arabitol	Human Endogenous Metabolite	
T4893	Spermidine	Human Endogenous Metabolite	
T4892	3-(2-Hydroxyphenyl) propionic acid	Human Endogenous Metabolite	
T4890	3-Nitro-L-tyrosine	Human Endogenous Metabolite	
T4887	DL-3-AMINOISOBUTYRIC ACID	Human Endogenous Metabolite	
T4886	Dihydrouracil	Human Endogenous Metabolite	
T4883	Creatine	Endogenous Metabolite	Approved
T4877	L-Homocystine	Human Endogenous Metabolite	
T4874	Thiamine pyrophosphate	Human Endogenous Metabolite	Approved
T4873	2-Amino-1-phenylethanol	Human Endogenous Metabolite	
T4872	Palmitoleic acid	Human Endogenous Metabolite	
T4870	Petroselinic acid	Human Endogenous Metabolite	
T4867	Erucic acid	Human Endogenous Metabolite	
T4863	DL-Homocysteine	Human Endogenous Metabolite	
T4862	Oxaloacetic acid	Human Endogenous Metabolite	
T4861	trans-Aconitic acid	Human Endogenous Metabolite; ATP-citrate synthase(rat)	
T4858	4-Hydroxyphenylpyruvic acid	Human Endogenous Metabolite	
T4856	Na-Acetyl-L-lysine	Human Endogenous Metabolite	
T4855	Tricosanoic acid	Human Endogenous Metabolite	
T4852	Glycerol trimyristate	Human Endogenous Metabolite	
T4850	2-Picolinic acid	Endogenous Metabolite	Phase 2
T4848	DL-Mandelic acid	Endogenous Metabolite	
T4845	L-Lactic acid	Endogenous Metabolite	
T4844	L-Methionine	Endogenous Metabolite	FDA Approved
T4839	N-Acetyl-L-alanine	Endogenous Metabolite	

ID	Product Name	Target	Condition
T4838	L-(-)-Malic acid	Endogenous Metabolite	
T4837	Itaconic acid	Endogenous Metabolite	
T4834	Indole-3-acetamide	Endogenous Metabolite	
T4832	Cytosine	Endogenous Metabolite	
T4825	D(+)-Xylose	Endogenous Metabolite	FDA Approved
T4813	L-Citrulline	Endogenous Metabolite	Phase 3
T4812	D-Mannose	Endogenous Metabolite	Phase 4
T4794	Glutaric acid	Endogenous Metabolite	
T4780	Quinaldic acid	Endogenous Metabolite	
T4776	Glycerol	Endogenous Metabolite	Approved
T4768	Diethyl oxalpropionate	Endogenous Metabolite	
T4767	Formamide	Endogenous Metabolite	
T4766	3-Methylglutaric acid	Endogenous Metabolite	
T4765	L-Norleucine	Endogenous Metabolite	Phase 2
T4762	L-Pipecolic acid	Endogenous Metabolite	
T4758	2'-Deoxycytidine monohydrate	Endogenous Metabolite	
T4757	L-Homoserine	Endogenous Metabolite	
T4749	Squalene	Endogenous Metabolite	Approved
T4740	Elaidic acid	Human Endogenous Metabolite	
T4729	Phosphonoacetic acid	Human Endogenous Metabolite	
T4728	4-ACETAMIDOBUTYRIC ACID	Human Endogenous Metabolite	
T4725	N-Acetyl-D-mannosamine	Endogenous Metabolite	
T4723	D-(-)-Tagatose	Endogenous Metabolite	Approved
T4716	Pyrrrole-2-carboxylic acid	Endogenous Metabolite	
T4713	Phosphocholine chloride calcium salt tet	Endogenous Metabolite	
T4707	3-Hydroxyanthranilic acid	Endogenous Metabolite	
T4702	(3-Carboxypropyl) trimethylammonium chlor	Endogenous Metabolite	
T4685	INOSINIC ACID	Endogenous Metabolite	
T4588	Glycochenodeoxycholic Acid	Apoptosis; Endogenous Metabolite	
T4525	Citraconic acid	Endogenous Metabolite	
T4514	N-Acetyl-D-Glucosamine	Human Endogenous Metabolite	Approved
T4120	N,N-Dimethylglycine	Endogenous Metabolite	
T3763	Fumaric acid	Endogenous Metabolite	Approved
T3735	Tetrahydro Curcumin	Autophagy; CYP2C9; CYP3A4; Endogenous Metabolite	
T3007	Spermine	Endogenous Metabolite	Preclinical
T202774	L-Asparagine	Endogenous Metabolite	Approved
T202730	serine	Endogenous Metabolite	FDA Approved
T202728	glycine	Endogenous Metabolite; iGluR; MT2 receptor; MT1 receptor	FDA Approved

ID	Product Name	Target	Condition
T202721	cysteine	Endogenous Metabolite	FDA Approved
T202683	proline	Endogenous Metabolite	FDA Approved
T2A2497	glutamic acid	Endogenous Metabolite	Approved
T2A2476	L-Hydroxyprolin	Endogenous Metabolite	Approved
T2971	Phytic acid	Endogenous Metabolite; Xanthine Oxidase	Preclinical
T2965	Deoxycholic acid	Endogenous Metabolite; GPCR19	FDA Approved
T2963	Cholic Acid	Endogenous Metabolite	FDA Approved
T2934	Bilirubin	Endogenous Metabolite	
T2908	Palmitic acid	Endogenous Metabolite	
T2807	Caffeic Acid	5-Lipoxygenase; Endogenous Metabolite; hTRPA1	Approved
T2796	Coenzyme Q10	Endogenous Metabolite	Approved
T2719	Succinic acid	Endogenous Metabolite	Approved
T21629	Loxapine	5-HT2 (bovine); 5-HT2 (bovine); 5-HT2 (human); D2; D4	FDA Approved
T20446	Creosol	Human Endogenous Metabolite	
T20257	Methyl 4-anisate	Endogenous Metabolite	
T19418	Methionine sulfoxide	Human Endogenous Metabolite	Approved
T19350	H-Val-Ala-OH	Human Endogenous Metabolite	
T19344	Glycogen	Human Endogenous Metabolite	
T19180	Adrenic Acid	Human Endogenous Metabolite	
T19160	7,8-Dihydro-L-biopterin	Human Endogenous Metabolite	
T1723	ADP	Endogenous Metabolite	Preclinical
T1705	4-Amino-5-imidazolecarboxamide	Endogenous Metabolite	
T16674	Pseudouridine	Human Endogenous Metabolite	
T16338	Norgestimate metabolite Norelgestromin	Drug Metabolite	
T14128	Adenosylcobalamin	Human Endogenous Metabolite	Approved
T14063	7 α ,25-Dihydroxycholesterol	Human Endogenous Metabolite; GPR183	
T13265	Urolithin B	NF- κ B; JNK; ERK; Akt; AMPK; Human Endogenous Metabolite	
T1311	4-aminobenzoic acid	Endogenous Metabolite	
T12296	Oleoylethanolamide	Human Endogenous Metabolite; PPAR α	
T10857	Coenzyme A	Human Endogenous Metabolite	Phase 3
T0925	Allantoin	Endogenous Metabolite; Imidazoline Receptor	Approved
T0887	D(+)-Glucose	Endogenous Metabolite	FDA Approved
T0591	Alpha-D-galactose	Endogenous Metabolite	Phase 1
T0583	Erythritol	Endogenous Metabolite	Phase 1
T0529	Dulcitol	Endogenous Metabolite	
T0496	Creatinine	Endogenous Metabolite	
Fr16745	4-Hydroxyphenylacetoneitrile	Human Endogenous Metabolite	
Fr14438	p-Toluic Acid	Human Endogenous Metabolite	
Fr13756	Isonicotinic acid	Human Endogenous Metabolite	

Epoxide Hydrolase

ID	Product Name	Target	Condition
T14315	AR-9281	s-EH	

FAAH

ID	Product Name	Target	Condition
T8646	URB937	FAAH	
T7688	4-Nonylphenylboronic acid	FAAH	
T6714	URB597	FAAH	Phase 1
T6043	PF3845	FAAH	
T4323	PF04457845	hFAAH; rFAAH	Phase 2
T3354	BIA10-2474	FAAH	Phase 1
T3215	JNJ42165279	hFAAH; rFAAH	Phase 2
T2859	Biochanin A	EGFR; FAAH (human); FAAH (mouse); FAAH (rat)	
T2684	JNJ1661010	FAAH (human); FAAH (rat)	Preclinical
T2338	JZL195	FAAH; MAGL	
T15268	FAAH-IN-2	FAAH	

FABP

ID	Product Name	Target	Condition
T4534	BMS309403	FABP4; FABP3; FABP5	

Factor Xa

ID	Product Name	Target	Condition
T4980	Betrixaban maleate	Factor Xa	FDA Approved
T4690	Betrixaban hydrochloride(330942-05-7(free base))	Factor Xa	FDA Approved
T4076	Fondaparinux sodium	Factor Xa	FDA Approved
T2368L	Edoxaban	Factor Xa; Thrombin	FDA Approved
T2368	Edoxaban Tosylate Monohydrate	Factor Xa; Factor Xa; Thrombin	FDA Approved
T20454	4-Chlorophenylurea	factor Xa	
T1736	Apixaban	Factor Xa (human); Factor Xa (rabbit)	FDA Approved
T1184	Rivaroxaban	Factor Xa; Thrombin	FDA Approved
T0775	Coumarin	Factor Xa; VK	Approved
T0642	2-Methoxyphenothiazine	Factor Xa	

Fatty Acid Synthase

ID	Product Name	Target	Condition
TJS0387	Deoxyrhapontin	FAS	
T7947	FT113	FAS	
T4380	Ac-CoA Synthase Inhibitor1	ACSS2	
T2468	A 769662	AMPK; FAS	
T15271	FASN-IN-2	FASN	
T14298	Rimiducid	Fas; FKBP; Apoptosis	Phase 2
T1426	Pyrazinamide	FAS	FDA Approved
T11557	FASN-IN-3	FASN	
T0988	Trimetazidine dihydrochloride	mitochondrial long-chain 3-ketoacyl thiolase	Approved
T0846	L(-)-Carnitine	FAS	FDA Approved
T0686	Orlistat	FAS; triacylglycerol lipase	FDA Approved

FXR

ID	Product Name	Target	Condition
TQ0252	BAR502	GPBAR1; FXR	
T8895	Altenusin	FXR	
T8471	Vonafexor	FXR	
T7886	Nidufexor	FXR	Phase 2
T7436	Cilofexor	FXR	Phase 3
T6690	T0901317	FXR; LXR	Preclinical
T6344	Sevelamer HCl	FXR	FDA Approved
T6053	Turofexorate Isopropyl	FXR	Phase 1
T5264	Androsterone	FXR	
T4379	Tropifexor	FXR	Phase 2
T2968	Hyodeoxycholic acid	FXR; TGR5 (GPCR19)	Approved
T2233	GW 4064	FXR	
T2202	Lithocholic acid	FXR; PXR; VD	FDA Approved
T2015	Fexaramine	FXR	
T1789	Obeticholic Acid	FXR	FDA Approved
T13092	Tauro-Obeticholic acid	FXR	
T11428	Glyco-Obeticholic acid	FXR	

Glucokinase

ID	Product Name	Target	Condition
TWS0787	Oroxin A	PPAR γ agonist; α -glucosidase	
TL0008	Gigantol	β -catenin; α -glucosidase	

ID	Product Name	Target	Condition
T8319	Butyl isobutyl phthalate	α -glucosidase	
T8202	Kaempferol 3-gentiobioside	α -glucosidase	
T6S2122	Ginkgolic acid C13:0	α -glucosidase	
T6S1371	Isovitexin	α -glucosidase	
T6S0535	Pinoresinol diglucoside	α -glucosidase	
T6723	Voglibose	α -glucosidase	Approved
T5690	4',7-DIMETHOXY-5-HYDROXYFLAVONE	α -glucosidase	
T5489	Tryptophan, N-indol-3-ylacetyl- (6CI)	β -D-galactosidase; β -D-glucosidase	
T4280	LTI291	β -glucosidase	Phase 2
T4049	Genz-123346 free base	GL1 synthase	
T3S2072	n-Butylideneephthalide	α -glucosidase	
T3S1612	kuwanon G	α -glucosidase; PTP1B; AChE; BChE	
T3871	Sitogluside	α -glucosidase	
T3386	Kaempferitrin	cell cycle arrest; PFK	
T3312	AM2394	glucokinase	
T3260	3PO	PFKFB3	Preclinical
T3235	Rebaudioside A	α -glucosidase	Phase 1
T3105	PFK158	PFKFB3	Phase 1
T3104	LY2608204	glucokinase	Phase 1
T2455	PFK015	PFKFB3	
T21344	Duvoglustat hydrochloride	α -glucosidase	
T13130	Terphenyllin	α -glucosidase	
T12056	MK-0941 free base	Glucokinase	
T11741	KAN0438757	PFKFB3	
T0714	Oxfendazole	Glucose uptake inhibitor; Tubulin chain	FDA Approved
T0247	Acarbose	α -glucosidase	FDA Approved

Glutathione Peroxidase

ID	Product Name	Target	Condition
T5463	AZD 3241	myeloperoxidase	Phase 3

GSNOR

ID	Product Name	Target	Condition
T6901	N6022	S-nitrosogluthathione reductase (GSNOR); S-nitrosogluthathione reductase (GSNOR)	Phase 1

Hexokinase

ID	Product Name	Target	Condition
T5882	3-Bromopyruvic acid	hexokinase II	FDA Approved

HIF/HIF Prolyl-Hydroxylase

ID	Product Name	Target	Condition
T7880	IOX4	PHD2	
T6S1315	Oroxilin A	Autophagy; HIF/HIF Prolyl-Hydroxylase	
T5392	TP0463518	PHD1; PHD2; PHD3	
T5176	Desidustat	HIF hydroxylase	Phase 2
T4106	MK8617	PHD1; PHD2; PHD3	
T3180	HIF-PHD Inhibitor II	PHD1; PHD2; PHD3	
T2941	Glucosamine hydrochloride	Autophagy; HIF/HIF Prolyl-Hydroxylase	Approved
T2652	Molidustat	PHD1; PHD2; PHD3	Phase 3
T2445	FG2216	PHD2	Phase 2
T1823	IOX 2	PHD2	

HMG-CoA Reductase

ID	Product Name	Target	Condition
T6994	SR12813	HMG-CoA reductase	Preclinical
T6450	Clinofibrate	HMGCR	Approved
T4717	25-Hydroxycholesterol	HMG-CoA Reductase	
T3698	alpha-Asarone	HMGCR; CYP2D6; CYP3A4	
T3116	Atorvastatin Calcium	HMG-CoA reductase	FDA Approved
T20765	Atorvastatin	HMG-CoA reductase	FDA Approved
T1676	Rosuvastatin	HMG-CoA reductase	FDA Approved
T1664	Meglutol	HMG-CoA reductase	
T1510	Rosuvastatin calcium	HMG-CoA reductase	FDA Approved
T1487	Fluvastatin sodium salt	HMG-CoA reductase	FDA Approved
T1207	Lovastatin	HMG-CoA reductase	FDA Approved
T0687	Simvastatin	HMG-CoA reductase	FDA Approved
T0683	Mevastatin	HMG-CoA reductase; CES1	
T0672	Pravastatin sodium	HMG-CoA reductase	FDA Approved

HSP

ID	Product Name	Target	Condition
T8858	DTHIB	HSF1	
T8829	2',4'-DIHYDROXYCHALCONE	HSP90	

ID	Product Name	Target	Condition
T8668	HM03	HSPA5	
T8189	Dihydroberberine	hERG; HSP90	
T7265	HSP27 inhibitor J2	HSP27	
T7010	VER155008	HSP70 ; HSC70 ; GRP78	
T6855	HA15	GRP78; HSPA5; BiP	
T6558	KW2478	HSP90	Phase 1/2
T6343	Geldanamycin	HSP90; HSP90; p185	Preclinical
T6341	PF04929113	HER2; HSP90	Phase 2
T6305	SNX2112	HSP90 α ; HSP90 β	Preclinical
T6297	Alvespimycin hydrochloride	HSP90	Phase 1
T6290	Tanespimycin	HSP90	Phase 2
T6284	Onalespib	HSP90	Phase 2
T6248	XL888	HSP90	Phase 1
T6170	Elesclomol	HSP70	Phase 1
T6118	HSP990	HSP90 α ; HSP90 β	Phase 1
T5826	Eupalinolide A	HSP90	
T5350	JG98	HSP70	
T5152	MKT077	HSP70	Preclinical
T5008	Teprenone	HSP	Approved
T4342	PF-04929113 Mesylate	HSP90; HER2	Phase 2
T4125	HSF1A	HSF1	
T3652	KRIBB11	HSF1	
T3594	ML346	HSP70	
T3527	TRC 051384	HSP70	
T3487	HSP70-IN-1	Kasumi-1; HSP	
T3293	Apoptozole	HSC70; HSP70	
T2444	KNK437	HSP105; HSP40; HSP72	Preclinical
T2309	Ganetespib	HSP90	Phase 2
T2286	BIIB021	HSP90	Phase 1
T2268	VER49009	HSP90 β	Preclinical
T2258	VER50589	HSP90 β	
T2179	Triptolide	heat shock factor (HSF1)(in ALL cell lines); Mdm2	Approved
T2114	NVP-BEP800	HSP90 β	Preclinical
T1989	Luminespib	HSP90 α ; HSP90 β	Phase 2
T16994	TAS-116	HSP90 α ; HSP90 β	Phase 1
T1501	Rifabutin	RNA polymerase; Endoplasmic; HSP90	FDA Approved
T13554	Arimoclolom maleate	HSP	
T10860	Col003	HSP47	
T0756	Ethoxyquin	HSP90	

Hydroxylase

ID	Product Name	Target	Condition
T7117	Sapropterin Hydrochloride	phenylalanine hydroxylas	FDA Approved
T6604	Nepicastat HCl	Dopamine β -hydroxylase; Dopamine β -hydroxylase	Phase 2
T6044	Telotristat Etiprate	Tryptophan hydroxylase	FDA Approved
T6004	Tetrahydropapaverine hydrochloride	Tryptophan hydroxylase	
T4277	Osilodrostat	11 β -hydroxylase,aldosterone synthase	Approved
T3268	Mildronate	Dopamine β -hydroxylase	Approved
T1896	Ro 61-8048	KMO; KMO	Preclinical
T11897	Telotristat ethyl	tryptophan hydroxylase	Approved
T0679	Ketoconazole	12-hydroxylase; 17-hydroxylase; Steroid 21-hydroxylase; Testosterone 6 beta-hydroxylase; Cyclosporine oxidase; CYP24A1; CYP3A4	FDA Approved

IDO

ID	Product Name	Target	Condition
T6543	Indoximod	IDO	Phase 2/3
T6407	Beta-Lapachone	IDO1	Phase 2
T5S0056	Coptisine chloride	IDO	
T5S0053	Coptisine	IDO	
T4532	Linrodostat	IDO1	Phase 3
T4307	PF06840003	IDO1	Phase 1
T4142	DO-IN-2	IDO	
T3548	Epacadostat	IDO1	Phase 3
T2647	INCB024360 analogue	IDO1	
T20513	IDO1-IN-1	IDO1	
T1806	NLG919	IDO	Phase 1
T11901	IDO1-IN-5	IDO1	

Indoleamine 2,3-Dioxygenase (IDO)

ID	Product Name	Target	Condition
TQ0071	Navoximod	IDO	Phase 1
T7181	IDO-IN-1	IDO	

Isocitrate Dehydrogenase (IDH)

ID	Product Name	Target	Condition
T7307	Vorasidenib	mutant isocitrate dehydrogenase(mIDH)	Phase 1

LDL

ID	Product Name	Target	Condition
T4179	Probucol disuccinate	LDL	
T0447	Carvedilol	Adrenergic Receptor; HIF; E-selectin; NADPH; Vcam; Potassium Channel; VEGFR; LDL oxidation	FDA Approved
T0342	Carvedilol phosphate	Adrenergic Receptor; Gap Junction Protein; E-selectin; NADPH dehydrogenase; Natriuretic peptides B; VCAM1; Potassium Channel; VEGFR; LDL oxidation	FDA Approved
T0022	Taurine	LDL; VLDL	FDA Approved

Lipase

ID	Product Name	Target	Condition
T6554	JZL184	MAGL	
T5815	Cravatt Reagent	MAGL	
T5353	ABX-1431	MAGL	Phase 2
T4052	KML29	MAGL	
T3591	URB602	rat brain MGL	
T2966	Beta-Sitosterol	PPL	Approved
T2338	JZL195	FAAH; MAGL	
T2249	XEN445	endothelial lipase	
T1875	Atglistatin	ATGL	
T1846	Y320	ATGL; IL-17 production	

Lipid

ID	Product Name	Target	Condition
T4317	PF 429242	SREBP1; SREBP	Preclinical
T3666	Atractylodin	lipase	
T3283	Cetilistat	Lipase	Approved
T3121	Betulin	SREBP(K562 cell)	Approved
T0857	Fenipentol	CES1	FDA Approved
T0683	Mevastatin	HMG-CoA reductase; CES1	
T0516	Sodium dehydrocholate	lipolysis	Approved
T0254	Probucol	ABCA1; CES1	FDA Approved

Lipoxygenase

ID	Product Name	Target	Condition
TQ0180	Chebulagic acid	COX; LOX	
TN1097	Beta-boswelllic acid	5-Lipoxygenase	

ID	Product Name	Target	Condition
TJS0315	7,8-Dihydroxy-4-methylcoumarin	5-Lipoxygenase	
T8356	FPL 62064	COX; 5-LOX	
T8002	3-Hydroxycoumarin	LOX	
T6S1699	6-Shogaol	LOX	
T6576	Malotilate	5-Lipoxygenase	Approved
T6485	Embelin	XIAP; 5-Lipoxygenase; mPGES-1	FDA Approved
T5759	marmesin	5-Lipoxygenase; COX-2	
T5714	5-DEMETHYLNObILETIN	LOX	
T4347	ML355	12-Lipoxygenase	
T3879	Silychristin	5-Lipoxygenase	
T3090	Abietic Acid	MMP-1; PPAR α ; PPAR γ ; 5-lipoxygenase	
T2807	Caffeic Acid	5-Lipoxygenase; Endogenous Metabolite; hTRPA1	Approved
T2798	Esculetin	Lipoxygenase	Preclinical
T21902	ML351	15 LOX	
T1677	Montelukast	ALOX5; CysLTR1	FDA Approved
T1558	Resveratrol	COX-1; COX-2; DNA polymerase α ; IKK β ; LOX; Quinone reductase 2; SIRT1; SIRT2	Approved
T1420	Diethylcarbamazine citrate	COX-1; ALOX5	FDA Approved
T1401	Meclofenoxate hydrochloride	COX; ALOX5	Approved
T1296	Aminopar	COX-2; ALOX5; MPO; NF- κ B	FDA Approved
T0646	Mesalamine	COX; ALOX5; MPO; NF- κ B; PPAR γ	FDA Approved
T0477	Zileuton	COX-1; 5-Lipoxygenase	FDA Approved

Liver X Receptor

ID	Product Name	Target	Condition
T6690	T0901317	FXR; LXR	Preclinical
T2810	(20S)-Protopanaxatriol	ER; Glucocorticoid Receptor; LXR	

MAO

ID	Product Name	Target	Condition
TN1120	Osthenol	hMAO-A	
TMS1743	Salvigenin	hMAO-A	
T8907	Minaprine dihydrochloride	MAO-A	Approved
T8849	PF-9601N	hMAO-B	
T8589	Amiflamine	MAO-A	
T7942	Tranilcypropromine (hemisulfate)	MAO; LSD1	FDA Approved
T7048	1,4-Naphthoquinone	MAO; DNA topoisomerase; acetyltransferase	

ID	Product Name	Target	Condition
T6962	Rasagiline Mesylate	MAO-A; MAO-B	FDA Approved
T6862	Isatin	MAO	
T6651	Safinamide mesylate	MAO	FDA Approved
T5887	3,4-Dihydro-7-hydroxy-2(1H)-quinolinone	MAO-A	
T5678	N-(2-Aminoethyl)-5-chlor-2-pyridincarbox	MAO-B	
T5676	(Z)-SU4312	MAO-B; NOS	
T5648	Purpurin	MAO-A	
T5323	MD 69276	MAO-A	Approved
T5053	Eprobemide	MAO-A	
T5050	Selegiline hydrochloride	MAO-B	FDA Approved
T3933	Jatrorrhizine	MAO-A; MAO-B	
T3596	TB5	hMAO-B	
T3095	Tyramine	MAOs	
T2900	Paeonol	MAO-A; MAO-B	Approved
T2765	Rosmarinic acid	MAO-A; MAO-B; COMT; IKK β	Phase 4
T2741	Glycyrrhizin	Dehydrogenase; MAO	Approved
T1747	Torezolid	MAO-A; MAO-B	FDA Approved
T1711	Harmine	MAO	
T1613	Hydralazine hydrochloride	MAO	FDA Approved
T1578	Pargyline hydrochloride	MAO	FDA Approved
T1549	Raloxifene hydrochloride	ER; AO; SERM	FDA Approved
T1455	Nialamide	AOA; AOB; COMT	
T1119	Rasagiline	Bcl-2; MAO-A; MAO-B	FDA Approved
T1025	Tranylcypromine (2-PCPA) hydrochloride	MAO; LSD1	FDA Approved
T0966	Senoside A	MAO	Approved
T0821	Iproniazid Phosphate	MAO	
T0751	Furazolidone	MAO	FDA Approved
T0418	Allylthiourea	MAO	
T0391	Linezolid	AOA; AOB	FDA Approved
T0369	Ethaverine hydrochloride	MAO	Approved
T0300	Pargyline	MAO	FDA Approved
T0235	Modaline sulfate	MAO	Approved
T0084	Moclobemide	MAO-A (5-HT)	Approved

Mitochondrial Metabolism

ID	Product Name	Target	Condition
T8433	HQNO	mitochondrial NDH-2	
T8366	Mitochonic acid 5	Mitochondrial Metabolism	

ID	Product Name	Target	Condition
T8308	NL-1	mitoNEET	
T7629	Olesoxime	Mitochondrial Metabolism	Phase 3
T7486	Imeglimin hydrochloride	mitochondrial phospholipid	Phase 3
T5337	IACS10759	complex I of oxidative phosphorylation	
T2A2532	histidine	Mitochondrial Metabolism	FDA Approved
T2498	Adjudin	Chloride Channel; Mitochondrial Metabolism	
T13748	L-2-Hydroxyglutaric acid disodium	Histone Demethylase; Mitochondrial Metabolism	
T10706	CCI-006	Mitochondria	

MPO

ID	Product Name	Target	Condition
T5340	MPO-IN-28	Myeloperoxidase; MPO	
T1659	Melatonin	CAM; ER; melatonin receptor; MPO; ROR β	Approved
T1296	Aminopar	COX-2; ALOX5; MPO; NF- κ B	FDA Approved
T1258	Nabumetone	COX-1; COX-2; MPO	FDA Approved
T0646	Mesalamine	COX; ALOX5; MPO; NF- κ B; PPAR γ	FDA Approved
T0133	Cefdinir	PBPs; MPO	FDA Approved

N-acetylglucosaminyltransferase

ID	Product Name	Target	Condition
T4503	Talniflumate	hCLCA1/mCLCA3; COX; Cl-/HCO ₃ - exchanger; GCNT3	Approved

NADPH

ID	Product Name	Target	Condition
T7406	AKR1C3-IN-1	AKR1C3	
T7374	2-HBA	NQO1; Caspase	
T7149	S29434	Quinone reductase 2(QR2)	
T6391	Acetovanillone	NADPH oxidase	Phase 1
T4529	ASP9521	AKR1C3	Phase 1/2
T4359	VAS2870	NADPH oxidase (NOX)	Preclinical
T1609	NAD+	NADPH; NADPH	
T1558	Resveratrol	COX-1; COX-2; DNA polymerase α ; IKK β ; LOX; Quinone reductase 2; SIRT1; SIRT2	Approved
T15433	GSK2795039	NADPH; apoptosis; ROS	
T14151	AKR1C1-IN-1	AKR1C1; AKR1C2; AKR1C3; AKR1C4	
T1314	Triclosan	NADPH	FDA Approved

ID	Product Name	Target	Condition
T1079	Metronidazole	14- α Demethylase; Fe hydrogenase 1; NADPH nitroreductase	FDA Approved
T0816	Acetohexamide	NADPH; Potassium Channel	FDA Approved
T0809	Dicumarol	NQO1; PDK1	FDA Approved
T0447	Carvedilol	Adrenergic Receptor; HIF; E-selectin; NADPH; Vcam; Potassium Channel; VEGFR; LDL oxidation	FDA Approved
T0441	Pasiniamid	COX; NADPH	Approved
T0342	Carvedilol phosphate	Adrenergic Receptor; Gap Junction Protein; E-selectin; NADPH dehydrogenase; Natriuretic peptides B; VCAM1; Potassium Channel; VEGFR; LDL oxidation	FDA Approved

NAMPT

ID	Product Name	Target	Condition
T6682	STF118804	NAMPT	
T4376	Nampt-IN-1	NAMPT; CSF-1R	
T4354	KPT9274	NAMPT; PAK4	Phase 1
T4335	GNE617	NAMPT	
T1998	CHS 828	NAMPT; NAMPT	Phase 2
T12854	SBI-797812	NAMPT	

Nepriylsin

ID	Product Name	Target	Condition
TQ0106	Sacubitrilat	Nepriylsin	
T19626	LHW090-A7	neutral endopeptidase (NEP)	

P450

ID	Product Name	Target	Condition
TQ0296L	N-Nornuciferine hydrochloride	CYP2D6	
TN1078	Seneciophylline	P450	
TN1023	Miltirone	CYP	
T9113	Myristicin	Antifection; Bcl-2; Caspase; CYP17; GABA Receptor; IL Receptor; NO; PARP	
T8729	DMU2105	CYP1B1	
T8728	DMU2139	CYP1B1	
T8182	Guan-fu base A	CYP2D6; HERG channel	
T8125	Quinidine sulfate	CYP450	FDA Approved
T7618	Pyributicarb	CYP3A4	
T7472	7-Hydroxyflavone	CYP1A2	

ID	Product Name	Target	Condition
T7427	1-Ethynyl-naphthalene	CYP450 1B1	
T7410	Furafylline	CYP450	
T7370	Talarozole	RAMBA; CYP	Phase 1/2
T7088	Difubenzuron	CYP1A1	
T6S1894	Linderane	CYP2C9	
T6S0630	Hypaconitine	CYP17	
T6509	Galeterone	Androgen Receptor; CYP17	Phase 2
T6246	Cobicistat	CYP3A	FDA Approved
T6216	Abiraterone	CYP17	FDA Approved
T6215	Abiraterone Acetate	CYP17	FDA Approved
T6050	TAK-700	17,20-lyase (Human) , 17,20-lyase (Rat)	Phase 3
T6030	XL388	mTOR; mTORC1; mTORC2; CYP2C9; PI3K α	Preclinical
T5S2360	Corydaline	CYP2C; CYP2C9	
T5S0669	Bergamotine	CYP1A1	
T5953	1-Aminobenzotriazole	CYP450	
T5786	TETRAHYDROPIPERINE	Htrpv1; CYP450	
T5715	FLAVOKAVAIN A(P)	CYP450	
T5594	Cedrol	CYP3A4; CYP2B6	
T4S0800	Demethyleneberberine	CYP17; HIF; NOS	
T4567	Sulfaphenazole	CYP2C9	FDA Approved
T4498	Stiripentol	CYP3A4; CYP2C19	FDA Approved
T4188	SDZ285-428	CYP24A1	
T3941	Choline Fenofibrate	P450; PPAR	FDA Approved
T3886	Rosavin	CYP3A4	
T3811	Ginsenoside C-K	cell cycle arrest; CYP2C9; CYP2A6	
T3797	Isosilybin	CYP3A4	
T3776	Rhapontigenin	CYP1A1	
T3736	Olivetol	I κ B; CYP1A1; CYP2C19	
T3735	Tetrahydro Curcumin	Autophagy; CYP2C9; CYP3A4; Endogenous Metabolite	
T3698	alpha-Asarone	HMGCR; CYP2D6; CYP3A4	
T3669	Curcumenol	CYP450	
T3585	TMS	CYP450 1B1	Preclinical
T3417	Amentoflavone	COX; COX-2; κ -opioid receptor; CYP2C9; CYP3A4; PLA2	
T3411	Curdione	CYP3A4	
T3401	Ginsenoside F1	CYP3A4	
T3355	Naloxegol oxalate	CYP3A	FDA Approved
T3002	Piperine	P-gp (P-glycoprotein); CYP3A4	Approved
T2S1434	Bergaptol	CYP3A4	
T2S0663	Humantenmine	CYP450	
T2949	Alizarin	CYP1A1; CYP1A2; CYP1B1	

ID	Product Name	Target	Condition
T2946	Tanshinone IIA sulfonate sodium	CaMK; CYP3A4	Approved
T2945	Germacrone	Antiviral; CYP2B6; CYP3A4	
T2944	Sodium Danshensu	CYP450	
T2878	Ginsenoside Rd	Calcium Channel; COX; P450; NF-κB	
T2838	Naringenin	CYP1A2	Phase 1
T2770	Gentiopticrin	CYP2A6; CYP2E1	
T2761	Naringin dihydrochalcone	CYP	
T2753	Avasimibe	ACAT; CYP1A2; CYP2C19; CYP2C9	Phase 3
T2532	Tauroursodeoxycholic Acid	CYP3A	FDA Approved
T2175	Apigenin	CYP2C9	Approved
T2143	Bergapten	CYP	Phase 3
T1704	Diosmetin	CYP1A1; TrkB	
T1597	Proadifen hydrochloride	CYP	Approved
T1443	Memantine hydrochloride	AMPA; NMDA receptor; Kainate receptor; CYP2B6; CYP2D6	FDA Approved
T1415	Gemfibrozil	PPARα; CYP2C9; 1A2	FDA Approved
T1274	Benzbromarone	CYP2C9	Approved
T1187	Bifonazole	CYP51	Approved
T1149	Fenofibrate	CYP2B6; CYP2C; CYP2C19; PPARα	FDA Approved
T1011	Itraconazole	CYP3A4	FDA Approved
T0920	Ambroxol	CYP3A	Approved
T0679	Ketoconazole	12-hydroxylase; 17-hydroxylase; Steroid 21-hydroxylase; Testosterone 6 beta-hydroxylase; Cyclosporine oxidase; CYP24A1; CYP3A4	FDA Approved
T0660	Beta-Tetralone	CYP2A	
T0603	Phthalic Acid Monoethyl Ester	CYP17	
T0595	Naringin	CYP450	Approved
T0179	Ticagrelor	Midazolam 4-hydroxylation; P2Y12; CYP2C9	FDA Approved

PAI-1

ID	Product Name	Target	Condition
T4S0592	Toddalolactone	PAI-1	
T4255	TM5275 sodium	PAI-1	
T4254	TM5441	PAI-1	
T3876	Loureirin B	ERK; JNK; PAI-1; Potassium Channel; PAI-1	
T2030	Tiplaxtinin	PAI-1	Phase 1

PDE

ID	Product Name	Target	Condition
T8787	Drotaverine hydrochloride	PDE4	Approved
T8659	K-Ras-PDEδ-IN-1	PDE	
T8515	BI-409306	PDE9A	Phase 2
T8506	THPP-1	PDE10A	
T8462	Enoximone	PDE3	Approved
T8454	SEP-0372814	PDE10	
T8405	Vardenafil hydrochloride	PDE5	FDA Approved
T7954	YM976	PDE4	
T7642	Cilostamide	PDE	
T7346	Lodenafil	PDE	
T6S2115	Ginkgolide J	PDE	
T6983	Sildenafil Mesylate	Phosphodiesterase 5	FDA Approved
T6649	S-(+)-Rolipram	PDE4	Preclinical
T6644	Rolipram	PDE4B; PDE4D	Phase 2
T6548	Irsogladine	M1 muscarinic	Approved
T6445	Cilomilast	HPDE4; LPDE4	Phase 3
T6390	Anagrelide HCl	PDE	FDA Approved
T6147	Nortadafafil	PDE5	
T6042	PF-2545920	PDE10A	Phase 2
T5956	VP3.15 dihydrobromide	GSK-3; PDE7	
T5940	Proxiphylline	adenosine A1/A2a receptor; PDE	Approved
T5496	ML-030	PDE4	
T5474	D 159687	PDE4D	
T5411	SEP-0372814	PDE10	
T5106	BRL 50481	PDE7	
T5101	BW-A78U	PDE4	
T5033	Olprinone	PDE3	Approved
T4695	CP671305	PDE	
T4462	Roflumilast N-oxide	PDE4	FDA Approved
T4285	Crisaborole	PDE4	FDA Approved
T4097	Vardenafil hydrochloride trihydrate	PDE1; PDE5	FDA Approved
T4041	GLPG1690	autotaxin	Phase 3
T3987	Lotamilast	PDE4	Phase 2
T3631	PF8380	Autotaxin	
T3465	Vesnarinone	PDE	Approved
T3224	DprE1-IN-1	DprE1; PDE6	
T2923	Apremilast	PDE4	FDA Approved
T2855	Icariin	PDE5	Phase 3
T2334	Avanafil	PDE5	FDA Approved

ID	Product Name	Target	Condition
T2205	Theophylline-7-acetic acid	A1; A2; A3; HDAC2; PDE4; PKA; TNF- α	Approved
T21965	MBCQ	PDE5	
T2137	Ibutilast	PDE	Approved
T1745	TAK063	PDE10A	Phase 2
T17199	Udenafil	PDE5	Approved
T1713	IBMX	PDE3; PDE4; PDE5	
T1708	Pimobendan	PDE3	Approved
T1681	Aminophylline	PDE	FDA Approved
T1618	Dypyridamole	PDE; PDE	FDA Approved
T16079	Mirodenafil	PDE5	
T1398	Tadalafil	PDE5	FDA Approved
T1265	Amrinone	PDE; TNF- α	FDA Approved
T12103	MR-L2	PDE4	
T1112	2-(Hydroxymethyl)pyridine	PDE	
T1096	Milrinone	PDE2; PDE3	FDA Approved
T1083L	Theophylline monohydrate	Adenosine receptor; HDAC2; PDE	FDA Approved
T1083	Theophylline	Adenosine receptor; HDAC2; PDE	FDA Approved
T1056	Isoprenaline hydrochloride	Adrenergic Receptor; cAMP PDE; PI3K	FDA Approved
T1027	Luteolin	PDE1; PDE2; PDE3; PDE4; PDE5	Phase 1
T1024	Roflumilast	PDE4A1; PDE4A4; PDE4B1; PDE4B2; PDE4C1	FDA Approved
T0994	Ketotifen fumarate	H1 receptor; PDE	FDA Approved
T0892	Diprophylline	PDE	FDA Approved
T0705	Triflusal	PDE; TXA2R	Approved
T0625	Theobromine	Adenosine receptor; PDE	FDA Approved
T0480	Doxofylline	PDE	Approved
T0467	Sildenafil citrate	PDE5; PDE6	FDA Approved
T0462	Cilostazol	PDE3	FDA Approved
T0458	Indometacin	COX-1; COX-1; COX-2; PDE2; PLA2	FDA Approved
T0383	Fenspiride hydrochloride	PDE3; PDE4	Approved
T0264	Zomepirac Sodium	PDE2	
T0167	Vinpocetine	NF- κ B; PDE; Sodium Channel	Approved
T0160	Anagrelide	PDE	FDA Approved
T0080	Trapidil	PDE; PDGFR	Approved
T0070	Pentoxifylline	A2; PDE	FDA Approved

PED

ID	Product Name	Target	Condition
T4097	Vardenafil hydrochloride trihydrate	PDE1; PDE5	FDA Approved
T2646	HA130	ATX (autotaxin)	

ID	Product Name	Target	Condition
T22086	HA-155	ATX (autotaxin)	
T10410	ATX inhibitor 1	ATX	

phosphatase

ID	Product Name	Target	Condition
TCS1372	Atraric acid	Androgen Receptor; PTP1B	
T8519	Raphin1 acetate	phosphatase PPP1R15B (R15B)	
T8478	SC-43	SHP-1; STAT3; apoptosis	
T6459	Cyclosporine	calcineurin phosphatase	FDA Approved
T4671	CDC25 Phosphatase Inhibitor I	CDC25A; CDC25B2; CDC25B3; CDC25C; CDC25C-cat	
T4308	F1063-0967	DUSP26	
T4256	PTP1B-IN-2	PTP1B	
T20879	Tacrolimus hydrate	FKBP; Phosphatase; Autophagy; BacteriaL; Antibiotic	FDA Approved
T16350	NSC-87877	SHP-2; SHP-1; DUSP26	
T13176	TNO155	SHP-2	Phase 1/2
T10486	BCI	phosphatase	

Phospholipase

ID	Product Name	Target	Condition
TP1299L	Melittin TFA(20449-79-0(free base))	PLA2	
T8531	m-3M3FBS	PLC; Apoptosis	
T7280	CAY10594	PLD2	
T6529	Halobetasol Propionate	PLA2	FDA Approved
T6243	U73122	PLC	Preclinical
T6109	Darapladib	Lp-PLA2	Phase 3
T5454	ACA	PLA2	
T4S0590	Columbin	PLA2	
T4192	hns-PLA Inhibitor	LTA(4)H-h; hnsPLA2	
T3640	GW 4869	neutral sphingomyelinase	
T3616	Carbazochrome	myosin light-chain kinase; PLA2	Approved
T3580	FIPI	PLD1; PLD2	
T3439	ML348	LYPLA1	
T3417	Amentoflavone	COX; COX-2; κ-opioid receptor; CYP2C9; CYP3A4; PLA2	
T2938	Polydatin	PLA2	
T2907	Tanshinone I	PLA2	Approved
T2282	RPI1	Met; RET; CTND1; DCDB2; PLCy	
T21969	ML-095 hydrochloride	PLAP	

ID	Product Name	Target	Condition
T2044	Varespladib	hnsPLA2	Phase 3
T0944	Levamisole hydrochloride	nAChR; PLAP	FDA Approved
T0942	Quinacrine dihydrochloride	DNA; Histamine N-methyltransferase; PLA2; PLCLP	Phase 2
T0693	Niflumic acid	COX; Monocarboxylate transporter; Chloride channel protein ClC-Ka; PLA2; UGT	Approved
T0458	Indometacin	COX-1; COX-1; COX-2; PDE2; PLA2	FDA Approved
T0188	Fluticasone propionate	ER; Mineralocorticoid Receptor; Glucocorticoid Receptor; Cytosolic PLA2	FDA Approved

Phosphorylase

ID	Product Name	Target	Condition
T8103	H-HoArg-OH	alkaline phosphatase	

PKM

ID	Product Name	Target	Condition
T8363	DL-Serine	pyruvate kinase	
T7214	ML265	PKM2	
T6816	DASA58	PKM2	
T4223	Mitapivat	PKM2	Phase 3
T4170	PKM2 inhibitor	PKM1; PKM2	
T1125	(+)-Shikonin	TMEM16A chloride channel; PKM2; NF-κB; TNF-α	

PPAR

ID	Product Name	Target	Condition
TWS0787	Oroxin A	PPAR γ agonist; α -glucosidase	
TQ0156	GW1929	PPAR γ	Preclinical
TN1126	Sakuranetin	PPAR; NF-κB; VEGFR	
T8780	INT-131	PPAR γ	Phase 2
T8486	GW 6471	PPAR α	
T8184	Fucosterol	PPAR α	
T7821	DG172 (dihydrochloride)	PPAR	
T7443	4 ¹ -Methoxychalcone	PPAR γ	
T7395	Lanifibranor	PPAR	Phase 2
T7159	L-165041	PPAR	
T6926	Palmidrol	PPAR α	Preclinical
T6842	G007-LK	TNKS1; TNKS2	
T6768	AZ6102	TNKS1; TNKS2	
T6689	T0070907	PPAR α ; PPAR γ ; PPAR δ	

ID	Product Name	Target	Condition
T6646	Rosiglitazone HCl	PPAR	FDA Approved
T6524	GW0742	PPAR δ ; PPAR α ; PPAR γ	Preclinical
T6151	GW501516	PPAR δ	Phase 2
T5891	D-ERYTHRO-SPHINGOSINE	PKC; PP2A; Human Endogenous Metabolite	
T5764	Alliin	PPAR γ ; NF- κ B	
T5532	BMS-687453	PPAR α	
T4S2128	Bilobetin	PPAR α	
T4628	MBX 8025	PPAR α /PPAR δ	Phase 3
T4449	LB100	PP2A	Phase 1
T4408	Elafibranor	PPAR- α ; PPAR- δ	Phase 3
T4353	SR18292	PGC-1 α	
T3954	Adelmidrol	COX; NF- κ B; PPAR	Phase 2
T3941	Choline Fenofibrate	P450; PPAR	FDA Approved
T3710	XMD16-5	TNK2; TNK2	
T3709	XMD8-87	TNK2; TNK2	
T3362	Eupatilin	Autophagy; PPAR	Approved
T3254	PHYTOL	PPAR	
T3170	Troglitazone	PPAR γ	FDA Approved
T3138	Astaxanthin	PPAR γ	
T3090	Abietic Acid	MMP-1; PPAR α ; PPAR γ ; 5-lipoxygenase	
T3062	WIKI4	TNKS2	
T3056	Bavachinin	PPAR	
T3000	Magnolol	NF- κ B; p53; PPAR γ ; RXR α	Approved
T2985	Gypenoside XLIX	PPAR α	
T2932	Ginsenoside Rh1	IL Receptor; PPAR; TNF Receptor	
T2674	GSK0660	PPAR β ; PPAR δ	
T2413	FH535	PPAR γ ; PPAR δ ; Wnt/ β -catenin	
T2396	Ramatroban	CRTh2; TXA2R	Approved
T2269	Pirinixic Acid	PPAR α	Approved
T2260	GW 9662	PPAR α ; PPAR γ ; PPAR δ	
T1941	GSK3787	PPAR δ	Preclinical
T1807	JW55	TNKS1; TNKS2; auto-PARsylation of TNKS2; auto-PARsylation of TNKS1	
T1674	Nateglinide	Potassium Channel; PPAR γ	FDA Approved
T1622	Rosiglitazone maleate	PPAR γ	FDA Approved
T16074	Mifobate	PPAR γ	
T1603	Glipizide	ABCC; PPAR γ	FDA Approved
T16022	Arhalofenate	PPAR γ	Phase 2/3
T15453	GW7647	PPAR α ; PPAR γ ; PPAR δ	
T1415	Gemfibrozil	PPAR α ; CYP2C9; 1A2	FDA Approved
T1402	Fenofibric acid	MMP; PPAR α ; COX-2	FDA Approved

ID	Product Name	Target	Condition
T1298	Clofibrate	PPAR α	FDA Approved
T1264	Ciprofibrate	PPAR	Approved
T1238	Daidzein	PPAR	Approved
T12296	Oleoylethanolamide	Human Endogenous Metabolite; PPAR α	
T1149	Fenofibrate	CYP2B6; CYP2C; CYP2C19; PPAR α	FDA Approved
T1088	Repaglinide	Potassium Channel; PPAR γ	FDA Approved
T0841	Bezafibrate	PPAR α	Approved
T0705	Triflusal	PDE; TXA2R	Approved
T0646	Mesalamine	COX; ALOX5; MPO; NF- κ B; PPAR γ	FDA Approved
T0448	Dexibuprofen	Bcl-2; COX; Cystic fibrosis transmembrane conductance regulator; PPAR γ ; thrombomodulin	Approved
T0334	Rosiglitazone	PPAR	FDA Approved
T0214L	Pioglitazone hydrochloride	human PPAR γ ; mouse PPAR γ	FDA Approved
T0214	Pioglitazone	PPAR	FDA Approved
T0212	Seratrodoast	COX; TXA2R	Approved
T0061	Clofibrlic acid	PPAR	FDA Approved

RAR/RXR

ID	Product Name	Target	Condition
T2528	Latanoprost	prostanoid selective FP receptor; retinoid X receptor α	FDA Approved

Reactive Oxygen Species

ID	Product Name	Target	Condition
T8320	J-14	sulfiredoxin	
T7098	BAPTA	Ca ²⁺ chelator	

Reductase

ID	Product Name	Target	Condition
TN2601	12-O-Methylcarnosic acid	5- α reductase	
T6S2384	Poliumoside	Aldose reductase	
T6S0840	Engeletin	Aldose reductase	
T6102	2'-acetylacteoside	Aldose reductase; Antioxidant	
T5813	BYAKANGELICIN	Aldose reductase	
T5195	Alrestatin	Aldose reductase	Phase 2
T5015	Gonadorelin Acetate	5- α reductase	FDA Approved
T4918	DL-Glyceraldehyde	Aldose reductase	
T3915	Ginsenoside Ro	5- α reductase	

ID	Product Name	Target	Condition
T3665	Tectoridin	Aldose reductase	
T2013	Ponalrestat	Aldose reductase	Preclinical
T1499	Dutasteride	5- α reductase	FDA Approved
T1458	Epalrestat	Aldose reductase	Approved
T0725	Isoliquiritigenin	Aldose reductase	Approved
T0488	Finasteride	5- α reductase	FDA Approved

Retinoid Receptor

ID	Product Name	Target	Condition
TQ0097	AGN 193109	RAR α ; RAR β ; RAR γ	
T6696	Tazarotene	RAR	FDA Approved
T6694	Tamibarotene	RAR α ; RAR β	Approved
T6410	Bexarotene	RXR	FDA Approved
T5854	AM580	RAR α	
T5843	R-flurbiprofen	RXR α	Phase 2
T5341	WYC209	RAR	
T4538	palovarotene	RAR γ	Approved
T4371	CD437	RAR γ	Preclinical
T3955	AR7	RAR α	
T3000	Magnolol	NF- κ B; p53; PPAR γ ; RXR α	Approved
T1872	Fenretinide	RAR/RAX	Phase 2
T1611	Isotretinoin	RAR	FDA Approved
T1330	Acitretin	RAR; RXR	FDA Approved
T1288	TTNPB	RAR α ; RAR β ; RAR γ ; RAR γ	
T11844	LG-100064	RXR α ; RXR β ; RXR γ	
T1093	Adapalene	RAR; RXR	FDA Approved
T1051	Tretinoin	RAR	FDA Approved
T1002	Etodolac	COX; RXR-alpha	FDA Approved

ROR

ID	Product Name	Target	Condition
T7388	GSK805	ROR γ t	
T5164	Cabozantinib hydrochloride (849217-68-1(free base))	c-Kit; c-Met; VEGFR2/KDR; FLT4; Axl; ROR γ ; ROR α	FDA Approved
T5163	SR1001	ROR α ; ROR γ	Preclinical
T5160	SR3335	ROR α	
T4670	SR0987	ROR γ t	
T4594	SR 1078	ROR α ; ROR γ	
T4050	GSK2981278	ROR γ	Phase 2

ID	Product Name	Target	Condition
T1659	Melatonin	CAM; ER; melatonin receptor; MPO; ROR β	Approved
T0760	Cholesterol	MRP1; ROR α	

Serine/threonin kinase

ID	Product Name	Target	Condition
TQ0104	CRT0066101 dihydrochloride	PKD1; PKD2; PKD3	
T7444	6-(Dimethylamino)purine	CDK; serine threonine protein kinase	
T5194	SPHINX31	SRPK1	
T4291	(+)-Isocorydine hydrochloride	eukaryote protein kinases; tyrosine kinase	
T3060	Fasudil hydrochloride	PKA; PKG; PKC; ROCK2; MLCK	Approved
T3050	ML-7 hydrochloride	PKA; PKC; MLCK	
T2458	CID755673	PKD1; PKD2; PKD3	
T2153	1 nM-PP1	CDK7; permeable protein kinase D (PKD)	
T2062	kb NB 142-70	PKD1; PKD2; PKD3	
T1954	SRPIN340	SRPK1	
T1863	CID2011756	PKD	
T1808	kb-NB77-78	PKD1	
T0610	Piceatannol	cAK; PKC; MLCK	Approved

SGK

ID	Product Name	Target	Condition
T6635	EMD638683	SGK1	
T2622	GSK650394	SGK1; SGK2	
T2482	AT13148	Akt1; Akt2; Akt3; PKA; ROCK1; ROCK2; p70 S6K; RSK1; SGK3	Phase 1
T2356	Ro 3306	CDK1; ERK; PKA; PKC δ ; SGK	

Stearoyl-CoA Desaturase (SCD)

ID	Product Name	Target	Condition
T6412	CVT-12012	human HEPG2; rat microsomal	

Thioredoxin

ID	Product Name	Target	Condition
T2283	PX12	TRX (HT-29 cells); TRX (MCF-7)	Phase 1

transaminase

ID	Product Name	Target	Condition
T2S1814	p-Hydroxybenzaldehyde	GABA transaminase	

Transferase

ID	Product Name	Target	Condition
T8489	Minodronic acid monohydrate	Farnesyl diphosphate synthase	Approved
T7439	3-Methoxybenzamide	poly(ADP-ribose) synthetase	
T6844	GGTI 298	GGTase I	Preclinical
T6708	Tolcapone	COMT	FDA Approved
T6373	Alendronate sodium hydrate	Farnesyl diphosphate synthase	FDA Approved
T6271	Tipifarnib	Farnesyl transferase (FTase)	Phase 3
T4681	T863	DGAT1	
T4473	Ibiglustat	glucosylceramide synthase	Phase 2/3
T3663	Eliglustat	glucosylceramide synthase	FDA Approved
T3182	L-778123 hydrochloride	Farnesyl transferase (FTase); FPTase	Phase 2
T2765	Rosmarinic acid	MAO-A; MAO-B; COMT; IKK β	Phase 4
T2700	FTI 277 hydrochloride	Farnesyl transferase (FTase); GGTase I	Preclinical
T2644	FK866	NMPRTase	Phase 2
T2216	Entacapone	COMT	FDA Approved
T2209	Serotonin hydrochloride	5-HT; COMT	Approved
T16398	Opicapone	COMT	FDA Approved
T1455	Nialamide	AOA; AOB; COMT	
T0379	Risedronic Acid	Hydroxylapatite; Farnesyl pyrophosphate synthase	FDA Approved

transporter

ID	Product Name	Target	Condition
TN1740	Homoeriodictyol	GLUT; 5-HT Receptor; Sodium Channel	
TN1100	Nepodin	COX; AMPK; GLUT	
TN1034	Sennidin B	Akt; GLUT; PI3K	
TN1033	Sennidin A	Akt; GLUT; PI3K	
T8616	Fasentin	GLUT1; GLUT4	
T7018	WZB117	GLUT1	
T6797	CB839	GLUT	Phase 2
T6791	BPTES	Glutaminase GLS1 (KGA)	
T4138	UCPH101	EAAT1	
T3782	Jujuboside A	GLU	

ID	Product Name	Target	Condition
T3713	BAY876	GLUT1; GLUT2; GLUT3; GLUT4	Preclinical
T2363	STF31	GLUT1	Preclinical

UGT

ID	Product Name	Target	Condition
T4S0145	Corylifol A	UGT1A1; hCCE2; STAT3	
T3824	Jaceosidin	UGT	Approved
T3600	Licochalcone A	Caspase-3; UGT1A1	Phase 1
T3418	Demethylzeylasteral	UGT1A6; UGT2B7	Preclinical
T1565	Deferidone	iron; UGT1-6	FDA Approved
T1335	Mycophenolic acid	DH; UGT	FDA Approved
T0693	Niflumic acid	COX; Monocarboxylate transporter; Chloride channel protein ClC-Ka; PLA2; UGT	Approved

Vitamin


ID	Product Name	Target	Condition
TQ0200	Paricalcitol	vitamin D receptor	FDA Approved
T8293	(+)- γ -Tocopherol	VE	
T7636	Phenprocoumon	vitamin K	FDA Approved
T6430	Calcifediol	Vitamin	FDA Approved
T6316	Calcitriol	vitamin D receptor	FDA Approved
T4107	4-Pyridoxic Acid	VB6	
T3551	Calcium pantothenate	Vitamin	Approved
T3136	Methylcobalamin	Vitamin	Approved
T2570	Menadiol Diacetate	VK4	Approved
T2336	Menatetrenone	VK2 analog	Approved
T2202	Lithocholic acid	FXR; PXR; VD	FDA Approved
T2185	Sodium L-ascorbyl-2-phosphate	VC	
T1648	Vitamin E	GST Mu 3; GST omega-1; GSTP; SEC14-like protein; PKC; VE	FDA Approved
T1633	Beta-Carotene	VA	FDA Approved
T14856	Calcipotriol	Vitamin D receptor	FDA Approved
T1437	Dexpanthenol	VB5	FDA Approved
T1390	Panthenol	VB5	FDA Approved
T1331	Flavin mononucleotide	VB2	FDA Approved
T1183	Retinol	Retinol-binding protein	FDA Approved
T1135	Vitamin D3	vitamin D receptor; H305F/H397Y mutant vitamin D receptor	FDA Approved
T1116	D-Biotin	VB7	FDA Approved

ID	Product Name	Target	Condition
T1086	Vitamin D2	DNA polymerase; VD3	FDA Approved
T1040	Vitamin B12	VB12	FDA Approved
T1016	Vitamin E Acetate	VE	FDA Approved
T0978	D-Pantethine	VB5	Approved
T0973L	Pyridoxine hydrochloride	VB6	FDA Approved
T0937	Riboflavin	VB2	FDA Approved
T0928	L(+)-Ascorbic acid	VC	FDA Approved
T0894	Thiamine hydrochloride	VB1	FDA Approved
T0879	Nicotinic acid	VB3	FDA Approved
T0815L	Warfarin sodium	VKOR complex subunit 1	FDA Approved
T0775	Coumarin	Factor Xa; VK	Approved
T0752	L-Ascorbyl 6-palmitate	VC	
T0685	Retinyl acetate	VA	Approved
T0514	Phenylindione	VKOR complex subunit 1	FDA Approved
T0449	Menadione	Thrombin; VK	FDA Approved
T0421	Inositol	VB	Approved
T0360	chllophenadione	VK	Approved
T0148	Calcium folinate	Thymidylate synthase; VB	FDA Approved
T0062	Folic acid	VB9	FDA Approved

Xanthine Oxidase

ID	Product Name	Target	Condition
T8567	amflutizole	Xanthine oxidase	
T2971	Phytic acid	Endogenous Metabolite; Xanthine Oxidase	Preclinical

Microbiology/virology



Antibacterial

ID	Product Name	Target	Condition
TQ0184	Chebulinic acid	bacterial DNA gyrase; Smad3; H+/K+-ATPase	
TQ0152	Dalfopristin	Antibiotic; Bacterial	FDA Approved
TP1444	Magainin 2	Antibiotic; Bacterial; Fungal	
TP1412	RNAIII-inhibiting peptide TFA	Bacterial	
TP1329	Nisin	Antibiotic; Bacterial	
TP1319	Indolicidin	Bacterial	
TP1309	Gastric mucin	Antibiotic; Bacterial	
TMO2685	10-Hydroxydecanoic Acid	Antibacterial	
TCS0862	4-Methoxybenzoic acid	antibacterial	
T8835	Tosufloxacin hydrochloride	bacterial DNA gyrase	Approved
T8727	TH1020	TLR5; Bacterial	
T8694	ML406	Bacterial; Antibiotic	
T8648	6-AZATHYMINE	Bacterial	
T8620	piperacillin	bacterial	FDA Approved
T8588	Buramate	antibacterial	
T8520	Tetrazole	Bacterial	
T8504	Dianemycin	Bacterial	

ID	Product Name	Target	Condition
T8404	Kasugamycin hydrochloride hydrate	Bacterial	
T8384	Gatifloxacin hydrochloride	Bacterial	FDA Approved
T8365	Methenamine Hippurate	Bacterial	FDA Approved
T8360	(-)- β -Pinene	Bacterial	
T8352	Phanquinone	Bacterial	
T8347	Rifamycin S	Bacterial; ROS	Phase 3
T8323	LoCDE-IN-1	Bacterial	
T8229	5,7,3',4'-Tetramethoxyflavone	Antifungal; Antibacterial	
T8185	Viroallosecurinine	Bacterial	
T8167	medicagenic acid	Antibacterial	
T8142	Difloxacin hydrochloride	Bacterial	
T8138	Phenazine methosulfate	Bacterial	
T8134	Cefathiamidine	Bacterial	Approved
T8130	Ciprofloxacin hydrochloride hydrate	Bacterial	FDA Approved
T8066	Sulbenicillin Sodium	Bacterial	
T8020	Benzoyleneurea	Bacterial	
T7902	Ozenoxacin	Bacterial	FDA Approved
T7883	Proanthocyanidins	Bacterial	
T7804	Garenoxacin mesylate hydrate	Bacterial	Approved
T7777	M 4284	Bacterial; FimH	
T7735	5-Nitro-1,10-phenanthroline	Bacterial	
T7669	RPW-24	Bacterial	
T7650	Resazurin sodium salt	Bacterial	
T7574	Meptyldinocap	Bacterial	
T7560	Pivmecillinam hydrochloride	Bacterial	Approved
T7546	Bethoxazin	Bacterial	
T7420	Valifenalate	Bacterial	
T7419	Sutezolid	Antibacterial	Phase 2
T7387	Ceftaroline fosamil	Bacterial; Antibiotic	FDA Approved
T7342	BM212	Antibacterial	
T7148	JOSAMYCIN	Bacterial	Approved
T7121	Sulfachloropyrazine sodium	bacterial; Parasite	
T7096	Tildipirosin	Bacterial	
T7043	Cefotetan	Antibacterial	FDA Approved
T6S2315	Polyphyllin VI	antibacterial	
T6S2025	8-O-Acetylharpagide	antibacterial	
T6S2024	Harpagide	antibacterial	

ID	Product Name	Target	Condition
T6S1684	8-Gingerol	Antioxidant; antibacterial	
T6S1538	Neochlorogenic acid	antibacterial	
T6S0923	Hypericin	antibacterial; antiviral; tyrosine kinases	Phase 3
T6S0270	Ononin	antibacterial	
T6987	3-Chloro-L-alanine	Bacterial	
T6601	Nanchangmycin	Antibacterial	
T6549	Isepamicin sulfate	Antibacterial	Approved
T6492	Davercin	Antibacterial	Approved
T6437	Cefoperazone	Antibacterial	FDA Approved
T6411	Biapenem	Antibacterial	Approved
T6401	Azithromycin	protein synthesis	FDA Approved
T6386	Ampicillin sodium	β -Lactamase	FDA Approved
T6354	(+)-Usniacin	Antibacterial; Antiviral	
T6268	Ceftiofur hydrochloride	Antibacterial	Approved
T6179	Latamoxef sodium	Antibacterial	Approved
T5S1959	Asarinin	antibacterial	
T5S0814	Berberine hydrogen sulphate	Antibacterial	Approved
T5844	Tolclofos-methyl	Bacterial	
T5816	Qstatin	SmcR	
T5787	Macranthoside B	Antibacterial	
T5547	4-Hydroxy-2,5-dimethyl-3(2H)furanone	Antibacterial	
T5331	KKL-35	trans-translation	
T5274	D-3-Phenyllactic acid	Antibacterial	
T5189	Omadacycline	ribosome 30s subunit	FDA Approved
T5070	5,7-Dihydroxy-4-phenylcoumarin	Antibacterial	
T5041	Faropenem sodium	Bacterial	Approved
T5038	Cephapirin Sodium	Antibacterial	FDA Approved
T5037	Midecamycin	Antibacterial	Approved
T5024	Cefotiam Hexetil Hydrochloride	PBPs	FDA Approved
T5022	Ceforanide	PBPs	FDA Approved
T5006	Flucloxacillin sodium	Bacterial	Approved
T5003	Rifamycin sodium salt	Antibacterial	FDA Approved
T4S1452	Artemisinic acid	Antibacterial	
T4S0867	Pogostone	Antibacterial	
T4S0797	Berberine	Antibacterial	Approved
T4995	Cefpirome sulfate	Bacterial	FDA Approved
T4992	Cefamandole nafate	Bacterial	FDA Approved
T4990	Cefcapene Pivoxil Hydrochloride	Antibacterial	Approved

ID	Product Name	Target	Condition
T4913	Maleic acid	Glutamate Decarboxylase	
T4531	GSK2200150A	Bacterial	
T4504	Triclocarban	Bacterial	Approved
T4501	Ceftizoxime	Antibacterial	FDA Approved
T4445	Tolfenpyrad	Antibacterial	
T4405	Ceftibuten dihydrate	Bacterial; Antibiotic	FDA Approved
T4273	Furagin	Antibacterial	
T4272	4-Hydroxyquinoline	Antibacterial	
T4270	Cefquinome sulfate	Bacterial	
T4267	Tulathromycin A	Antibacterial	
T4208	Targocil	Antibacterial	
T4201	Avibactam sodium	CTX-M-15; KPC-2 β -lactamases; P99 β -lactamases; TEM-1 β -lactamases	FDA Approved
T4165	Delpazolid	Antibacterial	Phase 2
T4084	Antibiotic-202	Antibacterial	
T4063	Delafloxacin	Bacterial	FDA Approved
T4020	Cadazolid	Antibacterial	Phase 3
T3S1858	Lutein	Antibacterial	
T3S0970	Thermopsine	Antibacterial	
T3S0717	Thymol	Antibacterial	Approved
T3S0137	Bavachalcone	Bacterial	
T3642	TBA354	Antibacterial	Phase 1
T3629	Gamithromycin	Antibacterial	
T3052	Sancycline	Antibacterial	
T2S1792	Lycobetaine	Antibacterial	Preclinical
T2S0493	Isoeugenol	Antibacterial	
T2989	4-Hydroxybenzoic acid	Antibacterial	
T2885	Esculin	Antibacterial; Antiviral	
T2740	Cinnamic acid	Antibacterial	
T20879	Tacrolimus hydrate	FKBP; Phosphatase; Autophagy; Bacterial; Antibiotic	FDA Approved
T20550	Thiobarbituric acid	Antibacterial	
T1832	Walrycin B	bacterial WalR response regulator	
T1715	Chitosan	Antibacterial	Approved
T16748	Ridinilazole	Antibacterial	Phase 3
T1654	Pentamidine isethionate	Antibacterial	FDA Approved
T1616	Cefotiam hydrochloride	PBPs	FDA Approved
T15824	Lysergol	Bacterial	
T1526	Nifuratel	Antibacterial	Approved
T1505	Imipenem monohydrate	PBPs; β -Lactamase	FDA Approved
T15033	Cyproconazole	Bacterial	
T1495	Cefaclor monohydrate	PBPs	FDA Approved

ID	Product Name	Target	Condition
T1419	Azithromycin dihydrate	23S rRNA; 50S ribosome	FDA Approved
T14081	AAI101	Bacterial	Phase 2
T1405	Cefditoren pivoxil	PBPs	FDA Approved
T13869L	Ribocil	bacterial	
T13670L	Ligustilide A	bacterial	
T1326	Gentamycin sulfate	DNase I; DHFR; 16S ribosome; 30S ribosome	FDA Approved
T13231	Trovaflaxacin	DNA gyrase; Topoisomerase; bacterial	FDA Approved
T13229	Tunicamycin	Bacterial; antiFungal; Influenza virus; Antibiotic	
T1313	Nitrofurantoin	Antibacterial	FDA Approved
T1305	Ceftazidime	PBPs; Peptidoglycan synthase	FDA Approved
T13038	Sultamicillin	β -Lactamase	
T1297	Eugenol	Antibacterial; Parasite	Approved
T1283	Clinafloxacin	Antibacterial	Preclinical
T12374	PA β N dihydrochloride	Bacterial; efflux pump	
T1233	Oxolinic acid	bacterial DNA gyrase; DNA synthesis; dopamine uptake	Approved
T1228	Cefonicid sodium	PBPs	FDA Approved
T12248	Nourseothricin sulfate	Bacterial	
T1218	Cefoperazone sodium	PBPs	FDA Approved
T1190	Cefmenoxime hydrochloride	PBPs; FtsI	FDA Approved
T1142	Clindamycin phosphate	23S rRNA; 50S ribosome	FDA Approved
T1134	Clofoctol	Antibacterial	Approved
T1122	Cephalothin sodium	PBPs	FDA Approved
T1118	Cefprozil hydrate	PBPs	FDA Approved
T1104	Paromomycin Sulfate	16S rRNA	FDA Approved
T1100	Polymyxin B sulfate	Antibacterial	FDA Approved
T1084	Apramycin sulfate	16S rRNA	FDA Approved
T1078	Sulfadimethoxine	Antibacterial	Approved
T1070	Cefmetazole sodium	Antibacterial	FDA Approved
T1063	Ticarcillin disodium	Antibacterial	FDA Approved
T1036	Netilmicin sulfate	Antibacterial	FDA Approved
T1033	Monensin sodium salt	Antibacterial	Approved
T1032	Erythromycin	23S rRNA; 50S ribosome	FDA Approved
T1029	Aztreonam	PBPs; β -Lactamase	FDA Approved
T1005L	Amoxicillin trihydrate	PBPs	FDA Approved
T1001	Dicloxacillin sodium monohydrate	Antibacterial	FDA Approved
T0958	Penicillin G sodium salt	PBPs; GABAR	FDA Approved
T0953	Cefazolin sodium salt	PBPs; Peptidoglycan synthase; PON	FDA Approved
T0932	Cefixime	PBPs	FDA Approved
T0931	Resorcine	Antibacterial	Approved

ID	Product Name	Target	Condition
T0921	Sulfabenzamide	Antibacterial	FDA Approved
T0911	Cefotaxime sodium	PBPs	FDA Approved
T0880	Bronopol	Antibacterial	Approved
T0868	Cefepime Dihydrochloride Monohydrate	PBPs; FtsI	FDA Approved
T0827	Cefsulodine sodium	Antibacterial	Approved
T0814L	Ampicillin	PBPs	FDA Approved
T0770	Carbadox	Bacterial	FDA Approved
T0699	Sulfamonomethoxine	Antibacterial	Approved
T0409	Phthalylsulfacetamide	Antibacterial	Approved
T0366	Cefadroxil	PBPs	FDA Approved
T0292	Orbifloxacin	Antibacterial	FDA Approved
T0288	Procodazole	Antibacterial	
T0199	Cephadrine	PBPs	FDA Approved
T0198	Sodium ceftiofur	Antibacterial	FDA Approved
T0144	Ftaxilide	Antibacterial	Approved
T0138	Cefpiramide acid	PBPs	FDA Approved
T0133	Cefdinir	PBPs; MPO	FDA Approved
T0049	Azlocillin sodium	PBPs	FDA Approved

Antibiotic

ID	Product Name	Target	Condition
TQ0152	Dalfopristin	Antibiotic; Bacterial	FDA Approved
TP1444	Magainin 2	Antibiotic; Bacterial; Fungal	
TP1329	Nisin	Antibiotic; Bacterial	
TP1309	Gastric mucin	Antibiotic; Bacterial	
T8694	ML406	Bacterial; Antibiotic	
T8641	Vancomycin	antibiotic	FDA Approved
T8298	Vasicine hydrochloride	tuberculosis	
T8118	Bekanamycin	Antibiotic	Approved
T7387	Ceftaroline fosamil	Bacterial; Antibiotic	FDA Approved
T7120	Cefetamet pivoxil hydrochloride	Antibiotic	Approved
T6686	Sulconazole Nitrate	Antibiotic	FDA Approved
T6685	Sulbactam sodium	β -Lactamase	FDA Approved
T6665	Sertaconazole nitrate	Antibiotic	FDA Approved
T6512	Geneticin sulfate	Antibiotic	
T6499	Fenticonazole Nitrate	Antibiotic	Approved
T6448	Clindamycin HCl	Antibiotic	FDA Approved
T6406	Besifloxacin HCl	Antibiotic	FDA Approved

ID	Product Name	Target	Condition
T6377	Aloperine	Antibiotic	
T6231	Tebipenem Pivoxil	Antibiotic	Approved
T6096	Pretomanid	tuberculosis	FDA Approved
T5997	TBAJ-587	tuberculosis	
T5570	Cephalotin acid	β -Lactamase	FDA Approved
T5400	Q203	tuberculosis	Phase 2
T5394	Prulifloxacin	Topo II; Topo IV	Approved
T5315	TCA1	tuberculosis	
T4998	Cefpodoxime proxetil	Antibiotic	FDA Approved
T4991	Ertapenem sodium	Antibiotic	FDA Approved
T4982	Benznidazole	antiprotozoal	FDA Approved
T4753	4-Imidazoleacetic acid hydrochloride	tuberculosis	
T4553	Procaine penicillin G	Antibiotic	Approved
T4405	Ceftibuten dihydrate	Bacterial; Antibiotic	FDA Approved
T4269	Buparvaquone	Antibiotic	
T4248	T.cruzi Inhibitor (1350920-22-7(free base))	Trypanosoma cruzi	
T4218	Broxaldine	antiprotozoal	
T3728	Methylparaben	Antibiotic	
T3607	Kitasamycin	Antibiotic	Approved
T3288	Sulfisomidine	Antibiotic	Approved
T3287	Octenidine Dihydrochloride	Antibiotic	Approved
T3279	Silver sulfadiazine	Antibiotic	FDA Approved
T3272	Metamizole magnesium	Antibiotic	Approved
T3267	Potassium guaiacolsulfonate	Antibiotic	Approved
T3265	Azathramycin	Antibiotic	FDA Approved
T3263	Cefminox Sodium	Antibiotic	Approved
T3139	Sultamicillin Tosylate	Antibiotic	Approved
T3131	Phosphomycin calcium salt	Antibiotic	Approved
T3115	Nicarbazin	Antibiotic	Approved
T3114	Povidone-iodine	Antibiotic	FDA Approved
T2865	Oleanolic Acid	Antibiotic	Approved
T2863	p-Coumaric acid	Antibiotic	
T2585	Bedaquiline	Tubercle bacillus	FDA Approved
T2549	Robenidine hydrochloride	Antibiotic	FDA Approved
T2331	Solithromycin	Antibiotic	Phase 3
T22314	Doripenem	antibiotic	FDA Approved
T2211	Dihydrostreptomycin sulfate	Antibiotic	Approved
T2184L	Sulfamethazine sodium salt	Antibiotic	FDA Approved

ID	Product Name	Target	Condition
T2184	Sulfachloropyridazine	Antibiotic	Approved
T21358	Dalbavancin HCl	antibiotic	FDA Approved
T21023	Bedaquiline fumarate	Antibiotic	FDA Approved
T2096	Neomycin Sulphate B	Antibiotic	FDA Approved
T20879	Tacrolimus hydrate	FKBP; Phosphatase; Autophagy; BacteriaL; Antibiotic	FDA Approved
T1733	Ciprofloxacin EP Impurity A	Antibiotic	
T16684	Puromycin aminonucleoside	apoptosis; dipeptidyl peptidase II; antibiotic	
T1647	Ronidazole	Antibiotic	Approved
T1631	Sulbactam	β -Lactamase	FDA Approved
T1556	Ornidazole	Antibiotic	Approved
T1550	Thiamphenicol	Antibiotic	Approved
T1505	Imipenem monohydrate	PBPs; β -Lactamase	FDA Approved
T1466	Nadifloxacin	Antibiotic	Approved
T1440	Ethacridine lactate monohydrate	Antibiotic	Approved
T1430	Betamipron	Antibiotic	Approved
T1403	Climbazole	Antibiotic	Approved
T1365	Thioisonicotinamide	Tubercle bacillus	Approved
T1323	Artemether	Antibiotic	FDA Approved
T13229	Tunicamycin	Bacterial; antiFungal; Influenza virus; Antibiotic	
T1312	nafillin sodium	β -Lactamase	FDA Approved
T1305	Ceftazidime	PBPs; Peptidoglycan synthase	FDA Approved
T1262	Tazobactam acid	β -Lactamase	FDA Approved
T1227	Cepazine	Antibiotic	Approved
T1226	Bacitracin	Antibiotic	FDA Approved
T1224	Cefuroxime sodium	Antibiotic	FDA Approved
T1214	Ribostamycin sulfate	Antibiotic	Approved
T1213	Piperacillin sodium salt	β -Lactamase	FDA Approved
T1172	Diclazuril	Antibiotic	Approved
T1161	Protionamide	Antibiotic	Approved
T1137	Clorsulon	Antibiotic; ATP	FDA Approved
T1126	Penicillin V potassium salt	Antibiotic	FDA Approved
T1108	Nithiamide	Antibiotic	Approved
T1107	Sarafloxacin hydrochloride	Antibiotic	Approved
T1101	Minocycline hydrochloride	Antibiotic	FDA Approved
T1067	Amphotericin B	Antibiotic	FDA Approved
T1061	Toltrazuril	Antibiotic	Approved
T1044	Clopidol	Antibiotic	FDA Approved
T1037	Doripenem Hydrate	Antibiotic	FDA Approved
T1031	Cloxacillin sodium monohydrate	Antibiotic	FDA Approved

ID	Product Name	Target	Condition
T1029	Aztreonam	PBPs; β -Lactamase	FDA Approved
T1023	Cefoxitin sodium	Antibiotic	FDA Approved
T1003	Tylosin	Antibiotic	FDA Approved
T0967	Teicoplanin	Antibiotic	Approved
T0955	Oxyclozanide	Antibiotic	
T0953	Cefazolin sodium salt	PBPs; Peptidoglycan synthase; PON	FDA Approved
T0927	Butylparaben	Antibiotic	Approved
T0917	Sulfaquinolaxaline sodium	Antibiotic	FDA Approved
T0908	Chloquinan	Antibiotic	Approved
T0901	Chlorobutanol	Antibiotic	Approved
T0900	Cetylpyridinium chloride monohydrate	Antibiotic	Approved
T0899	Dehydroacetic acid	Antibiotic	
T0898	Chloroxylenol	Antibiotic	Approved
T0896	Furaltadone hydrochloride	Antibiotic	Approved
T0893	Tinidazole	Antibiotic	FDA Approved
T0891	4,4'-Diaminodiphenylsulfone	Antibiotic	FDA Approved
T0876	Clioquinol	Antibiotic	FDA Approved
T0874	Dimetridazole	Antibiotic	Approved
T0873	Dinitolmide	Antibiotic	Approved
T0861	Tylosin tartrate	Antibiotic	Approved
T0850	Primaquine diphosphate	Antibiotic	FDA Approved
T0844	Sulfamethoxy-pyridazine	Antibiotic	Approved
T0819	Spiramycin	Antibiotic	Approved
T0814	Ampicillin Trihydrate	β -Lactamase	FDA Approved
T0777	Tilmicosin	Antibiotic	FDA Approved
T0744	Zinc undecylenate	Antibiotic	Approved
T0741	Sulfamethazine	Antibiotic	FDA Approved
T0721	Piroctone olamine	Antibiotic	
T0701	Broxyquinoline	Antibiotic	Approved
T0666	4-Chlorosalicylic acid	Antibiotic; diphenolase; monophenolase	
T0513	Iodoquinol	Antibiotic	Approved
T0512	Phthalylsulfathiazole	Antibiotic	Approved
T0509	Dermofongin	Antibiotic	Approved
T0500	Capitrol	Antibiotic	FDA Approved
T0497	Cetrimonium bromide	Antibiotic	Approved
T0495	Aminothiazole	Antibiotic	Approved
T0461	Berberine hydrochloride	Antibiotic	Approved
T0454L	Florfenicol	Antibiotic	FDA Approved
T0430	Imidazolidinyl urea	Antibiotic	
T0396	Pipemidic acid	Antibiotic	Approved

ID	Product Name	Target	Condition
T0390	Alkomide	Antibiotic	Approved
T0258	Carsalame	Antibiotic	
T0224	Meropenem	β -Lactamase; D-alanyl-D-alanine carboxypeptidase DacB	FDA Approved
T0195	Secnidazole	Antibiotic	FDA Approved
T0187	Amorolfine hydrochloride	Antibiotic	Approved
T0037	Halazone	Antibiotic	Approved

Antifection

ID	Product Name	Target	Condition
TN2085	Piperlonguminine	Antifection	
TN1928	Methyl rosmarinat	Tyrosinase; Antifection; MMP	
TN1839	Kumatakenin	Antifection	
TN1772	Isoastilbin	Antifection; Tyrosinase	
TN1113	Vincetoxicoside B	Antifection	
TN1108	Kaempferol 3-O-beta-sophoroside	Antifection	
TN1084	Desmethybellidifolin	Antifection	
TN1012	Febrifugine	Antifection; IL Receptor	
TL0015	Pyromeconic acid	Antifection	
TCS1772	Dehydroabietic acid	EBV	
T9113	Myristicin	Antifection; Bcl-2; Caspase; CYP17; GABA Receptor; IL Receptor; NO; PARP	
T8247	(+)-Aromadendrene	Antifection	
T8133	SulfadiMethoxine sodium	Antifection	
T8121	Octacosanoic acid	Antifection	
T8019	Sorbic acid	Antifection	
T7999	7-Hydroxyflavanone	Antifection	
T7869	Nicoform	Antifection	
T7733	Cefotaxime	Antifection	Approved
T5778	5,7-DIMETHOXYFLAVONE	Antifection	
T5776	pimpinellin	Antifection	
T5746	Dictamnine	Antifection	
T5691	paulownin	Antifection	
T5544	2-Furoic acid	Antifection	
T5188	GC376 sodium	3CLpro	
T4672	Brevilin A	Antifection; JAK; STAT	
T4202	Delamanid	Antifection	Approved
T3S1534	Secoxyloganin	Antifection	
T3S1088	Isoforsythiaside	Antifection	
T3S0631	Fuziline	Antifection	

ID	Product Name	Target	Condition
T3897	Isoschaftoside	Antifection	
T2213	Terconazole	14- α Demethylase	FDA Approved
T1643	Penciclovir	EBV; HCMV; HSV-1; HSV-2; VZV	FDA Approved
T1388	Fluconazole	14- α Demethylase	FDA Approved
T1290	Oxiconazole nitrate	14- α Demethylase; LSS	FDA Approved
T1190	Cefmenoxime hydrochloride	PBPs; Fts1	FDA Approved
T1147	Chlorhexidine hydrochloride	HNMT; CAT; cell wall	FDA Approved
T1079	Metronidazole	14- α Demethylase; Fe hydrogenase 1; NADPH nitroreductase	FDA Approved
T1000L	Chlorhexidine Acetate	HNMT; CAT	FDA Approved
T1000	Chlorhexidine	HNMT; CAT	FDA Approved
T0884	n-Docosanol	GP340; GP350	FDA Approved
T0868	Cefepime Dihydrochloride Monohydrate	PBPs; Fts1	FDA Approved
T0863	Dendrid	Feline herpesvirus type-1(FHV-1)	FDA Approved
T0688	Ganciclovir	FHV-1	FDA Approved
T0681	Rifampicin	14- α Demethylase; DNA/RNA Synthesis	FDA Approved
T0506	Clotrimazole	14- α Demethylase	FDA Approved
T0444L	Econazole nitrate	14- α Demethylase	FDA Approved
T0444	Econazole	14- α Demethylase	FDA Approved
T0344	Miconazole	14- α Demethylase; eNOS; iNOS; Potassium Channel	FDA Approved
T0146	Vagistat	14- α Demethylase	FDA Approved
T0120	Voriconazole	14- α Demethylase	FDA Approved
Fr14298	2'-Hydroxy-4'-methylacetophenone	Antifection	
Fr14115	Terpineol	Antifection; IL Receptor	

Antifungal

ID	Product Name	Target	Condition
TQ0115	NB-598	Squalene epoxidase	Preclinical
TL0010	CONIFERYL ALCOHOL	Antifungal	
TL0003	ALPHA-PINENE	Antifungal	
T8722	iKIX1	Antifungal	
T8536	Filastatin	antifungal	
T8490	Butoconazole	Antifungal	FDA Approved
T8229	5,7,3',4'-Tetramethoxyflavone	Antifungal; Antibacterial	
T8187	Tetrahydroepiberberine	Antifungal; PI-3 virus	
T8129	Potassium acetate	Antifungal	FDA Approved
T7993	8-Acetyl-7-Hydroxycoumarin	Antifungal	

ID	Product Name	Target	Condition
T7824	Eberconazole Nitrate	Antifungal	
T7765	E 1210	Antifungal	
T7726	Triadimefon	Antifungal	
T7620	2,4,6-Tribromophenyl caproate	Antifungal	
T7592	Trifloxystrobin	Antifungal	
T7152	Ravuconazole	Antifungal	Phase 2
T7110	Thifluzamide	Antifungal	
T7029	Pseudolaric Acid C	Antifungal	
T6944	Thiophanate-Methyl	Antifungal	
T6702	Terbinafine	squalene epoxidase	FDA Approved
T6550	Isoconazole nitrate	Antifungal	Approved
T6211	Posaconazole	Antifungal	FDA Approved
T5S2357	Acetylcorynoline	Antifungal	
T5966	Hexaconazole	Antifungal	
T5881	Fluazinam	Antifungal	
T5872	Folpet	Antifungal	
T5800	Allosecurinin	Antifungal	
T5744	Nsc267697	Antifungal	
T5328	Fosfluconazole	Antifungal	FDA Approved
T4S1439	6'-O-beta-D-Glucosylgentiopicroside	Antifungal	
T4985	Neticonazole Hydrochloride	Antifungal	Approved
T3S1960	Kakuol	Antifungal	
T3349	Tavaborole	Antifungal	FDA Approved
T3329	4',7-Dimethoxyisoflavone	Antifungal	
T3124	Carbendazim	Antifungal	Approved
T2S1865	Octyl gallate	Antioxidant; Antifungal	
T2S0491	Isoeugenyl acetate	Antifungal	
T2975	o-Veratraldehyde	Antifungal	
T2762	Kasugamycin hydrochloride	Antifungal	Approved
T2411	Luliconazole	Antifungal	FDA Approved
T2333	Efinaconazole	Antifungal	FDA Approved
T23133	Pentamidine	antifungal	FDA Approved
T2305	Isavuconazole	Antifungal	FDA Approved
T2199	Myclobutanil	Antifungal	Approved
T21136	Fluxapyroxad	antifungal	
T1799	Cancidas	1,3-beta-D-glucan synthesis	FDA Approved
T1794	Micafungin sodium	1,3-beta-D-glucan synthesis	FDA Approved
T1678	Nystatin	Antifungal	FDA Approved
T16010	Mancozeb	Antifungal	

ID	Product Name	Target	Condition
T1497	Liranaftate	squalene epoxidase	Approved
T1411	Terbinafine hydrochloride	squalene epoxidase	FDA Approved
T13229	Tunicamycin	Bacterial; antiFungal; Influenza virus; Antibiotic	
T1217	Butenafine hydrochloride	Squalene epoxidase	FDA Approved
T1113	Imazalil	Antifungal	Approved
T0834	Ethylparaben	Antifungal	Approved
T0810	Ethambutol dihydrochloride	Antifungal	FDA Approved
T0730	Triacetin	Antifungal	FDA Approved
T0344L	Miconazole nitrate	Antifungal	FDA Approved

Anti-infection

ID	Product Name	Target	Condition
T8627	4-Acetamidobenzenesulfonamide	Anti-infection	
T5602	Benzylpenicillin potassium	Anti-infection	Approved

CCR

ID	Product Name	Target	Condition
TQ0297	Cenicriviroc	CCR2; CCR5; HIV-1; HIV-2	Phase 3
TQ0283	RS102895	CCR1	
T7624	DAPTA(TFA)	CCR5	Phase 2
T7499	TAK-779	CCR2; CXCR	
T6413	Bindarit	MCP-1/CCL2; MCP-2/CCL8; MCP-3/CCL7	Phase 2
T6016	Maraviroc	MIP-1 α ; MIP-1 β ; RANTES	FDA Approved
T5384	RS 504393	CCR2	
T4674	SB 297006	CCR3	
T4584	BMS813160	CCR2; CCR5	Phase 2
T4300	AZD2098	CCR4	Preclinical
T3435	Vicriviroc maleate	CCR5	Phase 2
T3430	PF4136309	CCR2	Phase 1
T3360	ZK 756326	CCR8	
T3327	Arteether	CCL4; CCL5; CXCL10; CXCL9	Approved
T3188	NSC5844	CCR1	
T2375	BX471	human CCR1	Preclinical
T12773	RS102895 hydrochloride	CCR2; CCR1; Human α 1a receptor; Human α 1d receptor; 5-HT1A	
T11699	J-113863	CCR1; CCR3	

HBV

ID	Product Name	Target	Condition
TQ0248	Alisol F	HBV	
T5832	Besifovir	HBV	Approved
T4475	JNJ-632	HBV	
T4121	Bicyclol	HBV	Approved
T3978	GSK2330672	hASBT	Phase 2
T3449	Bay 41-4109 racemate	HBV	
T1599L	Ibandronate sodium	HAP; FPS	FDA Approved
T1337	Pamidronate disodium salt	HAP; FPPS	FDA Approved
T1041	Risedronate Sodium	HAP; FPS	FDA Approved
T0308	Etidronate	HAP; PTPase S; V-type proton ATPase catalytic subunit	FDA Approved
T0085L	Entecavir	HBV(HepG2 cell)	FDA Approved
T0085	Entecavir hydrate	HBV(HepG2 cell)	FDA Approved

HCV Protease

ID	Product Name	Target	Condition
T7215	NM107	HCV	
T7158	Ombitasvir	HCV NS5A	FDA Approved
T6729	Lomibuvir	HCV NS5B 1a; HCV NS5B 1b	Phase 2
T6676	Sofosbuvir	HCV	FDA Approved
T6229	Daclatasvir	HCV NS5A	FDA Approved
T6190	Telaprevir	HCV NS3-4A serine protease	FDA Approved
T6025	Danoprevir	HCV NS3/4A protease	Approved
T5938	4-Phenoxybenzylamine	HCV NS3/4A	
T5396	Letermovir	HCMV	FDA Approved
T5127	ABT530	HCV NS5A	FDA Approved
T5126	Glecaprevir	HCV NS3/4A protease	FDA Approved
T4988	Boceprevir	HCV NS3 protease	FDA Approved
T4686	Simeprevir	HCV NS3/4A protease; HCV	FDA Approved
T4547	Grazoprevir	NS3/4a protease; gt1a; gt1b	FDA Approved
T4544	Elbasvir	HCV NS5A	FDA Approved
T4474	Asunaprevir	HCV NS3/4A protease	Approved
T4203	Ledipasvir acetone	HCV	FDA Approved
T4197	HZ1157	HCV NS3/4A protease	Preclinical
T3489	Dasabuvir	NS5B polymerase	FDA Approved
T3334	Velpatasvir	HCV NS5A	FDA Approved
T3226	Paritaprevir	HCV NS3/4A	FDA Approved
T2774	Lycorine chloride	HCV	
T2162	Maribavir	HCMV	Phase 3

ID	Product Name	Target	Condition
T2117	PSI6206	HCV replicon	Preclinical
T19862	Voxilaprevir	HCV	FDA Approved
T1786	Daclatasvir dihydrochloride	HCV NS5A	FDA Approved
T17029	Tegobuvir	HCV NS5B polymerase	Phase 2
T1643	Penciclovir	EBV; HCMV; HSV-1; HSV-2; VZV	FDA Approved
T16088	MK-0608	HCV replicon	
T15573	Inarigivir soproxil	HCV	Phase 2
T14667	BLT-1	HCV; SR-BI	
T0392	Artemisinin	HCV; Parasite	Approved
T0013	Mecarbinat	HCV	Approved

HIV Protease

ID	Product Name	Target	Condition
TQ0297	Cenicriviroc	CCR2; CCR5; HIV-1; HIV-2	Phase 3
TP1809	TAT	HIV-1	
TP1348	FC131 TFA	CXCR4; HIV	
TN1727	Helichrysetin	HIV	
TN1103	Diphyllin	HIV-1; Vesicular stomatitis virus (VSV); Vacuolar type H ⁺ -ATPase	
TL0006	Chicoric Acid	HIV-I integrase	
T8689	CHLOROQUINE	HIV-1; autophagy; TLR; SARS-COV-2	FDA Approved
T8311	ABX-464	HIV	Phase 2
T7903	Saquinavir	HIV Protease	FDA Approved
T7789	DRB	HIV	
T7779	Nelfinavir	HIV-1	FDA Approved
T7700	Lersivirine(UK 453061)	HIV	Phase 2
T7455	4-Chloro-2-(trifluoroacetyl) aniline hydrochloride	HIV-1 RT	
T7382	NBD-557	HIV	
T7282	Tenofovir alafenamide fumarate	HIV-1	FDA Approved
T7212	Delavirdine (mesylate)	HIV-1	FDA Approved
T7111	Tenofovir Disoproxil	HIV	FDA Approved
T6653	Salmeterol Xinafoate	β2-adrenergic receptor; WT β2AR	FDA Approved
T6420	BMS707035	HIV-I integrase	Preclinical
T6388	Amprenavir	HIV protease	FDA Approved
T6367	Abacavir sulfate	HIV-1 reverse-transcriptase	FDA Approved
T6256	YYA021	Gp120; HIV	
T6198	Dolutegravir	HIV integrase	FDA Approved
T6098	Cabotegravir	HIV integrase	Phase 3

ID	Product Name	Target	Condition
T6065	Triciribine	Akt; HIV-1	Phase 1/2
T6001	Nelfinavir Mesylate	HIV protease	FDA Approved
T5965	Ditiocarb sodium	HIV	
T5863	Indinavir sulfate	HIV Protease	FDA Approved
T5782	Bevirimat	HIV-1	Phase 2
T4S1999	Valepotriate	HIV	
T4S1718	Punicalin	HIV-1	
T4S1383	Escin IA; Aescin IA	HIV-1 protease	
T4S0295	Apigenin 7-glucoside	HIV	
T4962	Ginsenoside Z-R1	HIV	
T4665	BMS626529	HIV	
T4537	SodiumCholate	HIV	
T4493	Bictegravir	HIV-I integrase	FDA Approved
T4182	lavendustin B	Tyrosine Kinase inhibitor; HIV-1 integrase	
T3732	Sebacic acid	HIV	
T3683	lithospermic acid	HIV	
T3632	Doravirine	HIV-1	FDA Approved
T3335	Darunavir Ethanolate	WT HIV-1 protease	FDA Approved
T3321	Oleanonic Acid	HIV	
T3172	Troviridine	HIV RT	
T2S0223	Isosinensetin	Antioxidant; HIV-1	
T2830	Betulinic acid	Aminopeptidase N; HIV-1; Eukaryotic topoisomerase I	Phase 1
T2728	Limonin	HIV Protease	Approved
T2409L	Tenofovir Disoproxil Fumarate	HIV reverse transcriptase	FDA Approved
T2393	Efavirenz	HIV-1 RT	FDA Approved
T2332	Elvitegravir	HIV-1 IIIIB; HIV-2 EHO; HIV-2 ROD	FDA Approved
T2329	Dolutegravir sodium	HIV integrase	FDA Approved
T2324	Darunavir	HIV Protease	FDA Approved
T2239	Raltegravir potassium	HIV; Integrase (IN)	FDA Approved
T1883	Des(benzylpyridyl) Atazanavi	HIV-1 protease	
T1815	Dapivirine	HIV reverse transcriptase	Phase 3
T16764	RN-18	HIV-1	
T1623	Lopinavir	HIV protease	FDA Approved
T1595	Nevirapine	HIV-1 reverse transcriptase	FDA Approved
T15436	GSK2838232	HIV	
T1525	Ritonavir	HIV Protease	FDA Approved
T13647	Dextran sulfate sodium salt (MW 16000-24000)	HIV; Apoptosis	FDA Approved
T1267	Abacavir	HIV-1 reverse-transcriptase	FDA Approved
T11451	GPI-1046	HIV	

ID	Product Name	Target	Condition
T10570	Fostemsavir Tris	HIV-1	FDA Approved
T10111	3-Deazaadenosine hydrochloride	HIV-1, A012 isolate; HIV-1, A018 isolate; S-adenosylhomocysteine hydrolase	
T0110	Zalcitabine	HIV	FDA Approved
T0100L	Atazanavir	HIV Protease	FDA Approved
T0100	Atazanavir sulfate	HIV protease	FDA Approved

HSV

ID	Product Name	Target	Condition
T7983	Isoborneol	HSV-1	
T7972	Gallic aldehyde	HSV-1	
T5542	Tiglic acid	HSV	
T4S0999	Isoxanthohumol	HSV-1; HSV-2; BVDV	
T2843	Aloe-emodin	HSV-1; HSV-2	Approved
T2616	PIK93	ATM; C2β; DNA-PK; hsVps34; mTORC1; p110α; p110β; p110γ; p110δ; PI3KIIIβ	
T2504	Pritelivir	helicase primase; HSV-2	Phase 2
T1646	Famciclovir	DNA polymerase; HSV	FDA Approved
T1643	Penciclovir	EBV; HCMV; HSV-1; HSV-2; VZV	FDA Approved
T13041	Surfactin	HSV-1	
T0718	Brivudine	HSV-1; VZV	Approved

Influenza Virus

ID	Product Name	Target	Condition
TN1103	Diphyllin	HIV-1; Vesicular stomatitis virus (VSV); Vacuolar type H ⁺ -ATPase	
T8793	CBS1117	influenza A virus	
T8502	N-(1-benzyl-4-piperidyl) adamantane-1-carboxamide	Ebola virus	
T8501	3-Phenyl-N-[1-(phenylmethyl)-4-piperidinyl]-tricyclo[3.3.1.1 ^{3,7}]decane-1-carboxamide	Ebola virus	
T8498	EiDD1931	anti-VEEV	
T8354	Triazavirin	Nucleoside Analogue; Influenza virus	
T7785	T-1105	Influenza virus	
T7602	Theaflavin	Influenza A virus	
T7330	Nucleozin	Influenza virus	
T5186	Oseltamivir acid	influenza viral neuraminidase	FDA Approved
T4S1114	Dryocrassin ABBA	Influenza virus	
T4377	Pimodivir	Influenza A polymerases	Phase 3
T4027	KIN1148	Influenza Virus	

ID	Product Name	Target	Condition
T2529	Zanamivir	Influenza A; Influenza B	FDA Approved
T2522	Peramivir Trihydrate	influenza viral neuraminidase	FDA Approved
T15707	Laninamivir	influenza neuraminidase (NA)	Approved
T1486	Osetamivir phosphate	Influenza A and B	FDA Approved
T14495	Baloxavir	Influenza virus	Approved
T13229	Tunicamycin	Bacterial; antiFungal; Influenza virus; Antibiotic	
T12818	S119-8	Influenza B	
T0104	Arbidol hydrochloride	Influenza A virus	Approved

Integrase

ID	Product Name	Target	Condition
T2239L	Raltegravir	Integrase (S217Q PFV); Integrase (WT PFV)	FDA Approved
T2239	Raltegravir potassium	HIV; Integrase (IN)	FDA Approved

Parasite

ID	Product Name	Target	Condition
T8146	Imidocarb dipropionate	Parasite	
T7938	Quinidine	Parasite	FDA Approved
T7901	Emodepside	Parasite	Phase 1
T7744	Piperaquine tetraphosphate tetrahydrate	Parasite	Approved
T7605	Avermectin B1a	Parasite	
T7321	MBP146-78	cGMP	
T7146	Piperazine adipate	Parasite	
T7121	Sulfachloropyrazine sodium	bacterial; Parasite	
T5916	Fmoc-N-Me-Phe-OH	Malaria Parasite	
T5836	Eprinomectin	Parasite	
T5572	2-Benzoxazolinone	L. donovani	
T5477	ELQ-300	Parasite	
T5420	Cycloguanil hydrochloride	Parasite	
T5419	DDD107498	eEF2	Phase 1
T5404	DDD107498 succinate	eEF2	Phase 1
T5325	Nifurtimox	Parasite	FDA Approved
T5052	Ponazuril	Parasite	
T3202	Fluensulfone	Parasite	
T16531	Picaridin	Parasite	
T1383	Biscomate	Parasite	
T1297	Eugenol	Antibacterial; Parasite	Approved

ID	Product Name	Target	Condition
T0982	(+)-Emetine dihydrochloride hydrate	Autophagy; Parasite	Approved
T0471	Decoquinatate	Parasite	FDA Approved
T0395	Pyrantel tartrate	Parasite	FDA Approved
T0392	Artemisinin	HCV; Parasite	Approved
T0376	Crotamiton	Parasite	FDA Approved
T0356	Nitromide	Parasite	
T0286	Bephenium Hydroxynaphthoate	Parasite	Approved
T0066	Dichlorophen	Parasite	FDA Approved

Reverse Transcriptase

ID	Product Name	Target	Condition
T6214	Emtricitabine	Reverse Transcriptase	FDA Approved
T3730	Methyl gallate	Reverse Transcriptase	
T3273	Bifendatatum	Reverse Transcriptase	Approved
T2578	Didanosine	Reverse Transcriptase	FDA Approved
T2551	Etravirine	Reverse Transcriptase	FDA Approved
T2409L	Tenofovir Disoproxil Fumarate	HIV reverse transcriptase	FDA Approved
T2409	Tenofovir alafenamide	Reverse Transcriptase	FDA Approved
T2330	Rilpivirine	Reverse Transcriptase	FDA Approved
T1675	Adefovir dipivoxil	Protein P; Reverse Transcriptase; Reverse Transcriptase	FDA Approved
T1649	Tenofovir	Reverse Transcriptase	FDA Approved
T1513	Telbivudine	Protein P; Reverse Transcriptase; Reverse Transcriptase	FDA Approved
T1416	Zidovudine	Reverse Transcriptase; Telomerase reverse transcriptase	FDA Approved
T1404	Stavudine	Reverse Transcriptase	FDA Approved
T0753	Salicylanilide	Reverse Transcriptase	Approved
T0682	Lamivudine	Reverse Transcriptase	FDA Approved
T0220	Foscarnet sodium	Reverse Transcriptase; Reverse Transcriptase	FDA Approved
T0153	Oltipraz	Reverse Transcriptase; HIF-1 α	Phase 3

ribosome

ID	Product Name	Target	Condition
T6638	Retapamulin	ribosome	FDA Approved
T4222	KKL10	ribosome rescue	
T3125	Amikacin Sulfate Salt	30S ribosome	FDA Approved
T2219	Puromycin dihydrochloride	DNA synthesis; 60S ribosome	
T1687L	Doxycycline hyclate	16S ribosome; 30S ribosome	FDA Approved

ID	Product Name	Target	Condition
T1569	Tigecycline	30S ribosome	FDA Approved
T1557	Acetylspiramycin	50S ribosome	Approved
T1441	Capastat sulfate	70S ribosome	FDA Approved
T1434	Clarithromycin	MRP1; 50S ribosome	FDA Approved
T1419	Azithromycin dihydrate	23S rRNA; 50S ribosome	FDA Approved
T1400	Demeclocycline hydrochloride	30S ribosome	FDA Approved
T1326	Gentamycin sulfate	DNase I; DHFR; 16S ribosome; 30S ribosome	FDA Approved
T1304	Chlortetracycline hydrochloride	30S ribosome	FDA Approved
T1277	Lincomycin hydrochloride	50S ribosome	FDA Approved
T1255	Tobramycin	30S ribosome	FDA Approved
T1235	Lincomycin hydrochloride monohydrate	50S ribosome	FDA Approved
T1205	Chloramphenicol	50S ribosome	FDA Approved
T1151	Roxithromycin	50S ribosome	Approved
T1142	Clindamycin phosphate	23S rRNA; 50S ribosome	FDA Approved
T1032	Erythromycin	23S rRNA; 50S ribosome	FDA Approved
T1022	Hygromycin B	70S ribosome	Approved
T1013	Amikacin	30S ribosome	FDA Approved
T0971	Dirithromycin	50S ribosome; 70S ribosome	FDA Approved
T0950	Neomycin sulfate	30S ribosome	FDA Approved
T0912L	Tetracycline	Major prion protein; 16S ribosome; 30S ribosome	FDA Approved
T0912	Tetracycline hydrochloride	30S ribosome	FDA Approved
T0895	Oxytetracycline	16S ribosome; 30S ribosome	FDA Approved
T0793	Kanamycin sulfate	16S ribosome; 30S ribosome	FDA Approved
T0788	Spectinomycin dihydrochloride	30S ribosome	FDA Approved
T0518	Methacycline hydrochloride	16S ribosome; 30S ribosome	FDA Approved
T0474	Erythromycin ethylsuccinate	50S ribosome	FDA Approved
T0060	Streptomycin sulfate	30S ribosome	FDA Approved

RSV

ID	Product Name	Target	Condition
TQ0085	Presatovir	RSV	Phase 2
T7353	RSV604	RSV	Phase 1


SARS-CoV

ID	Product Name	Target	Condition
T8689	CHLOROQUINE	HIV-1; autophagy; TLR; SARS-COV-2	FDA Approved
T8688	CPD77	SARS-CoV-2	
T8419	XP-59	SARS-CoV	
T8371	ML188	SARS-CoV	
T8309	EIDD-2801	SARS-CoV	
T7766	Remdesivir	SARS-CoV	FDA Approved
T3S0136	O-Methylbroussoualcone B	Plpro	
T12502	PLpro inhibitor	papain-like protease (PLpro)	
T11464	GRL0617	deubiquitinase; SARS-CoV Plpro	

Virus Protease

ID	Product Name	Target	Condition
T7366	NGI-1	oligosaccharyltransferase	

Neuroscience



5-HT Receptor

ID	Product Name	Target	Condition
TQ0084	Lumateperone Tosylate	5-HT2A antagonist; SER7	FDA Approved
TN1740	Homoeriodictyol	GLUT; 5-HT Receptor; Sodium Channel	
TN1032	Geissoschizine methyl ether	5-HT1A	
TJS0341	7-Amino-4-(trifluoromethyl) coumarin	HTR1E	
T8757	R-Lorcaserin hydrochloride hemihydrate	5-HT2C	
T8737	GR 125743	5-HT1B/1D	
T8720	PRX-07034	5-HT6	
T8702	SKF-83566	D1; D5; 5-HT2	
T8666	Naratriptan	5-HT1	FDA Approved
T8593	RU 24969	5-HT	
T8475	3-AQC	5-HT3	
T8445	PU-02	5-HT3	
T8441	Lerisetron	5-HT3	
T8438	4i	5-HT3	
T8413	Lasmiditan succinate	5-HT	FDA Approved
T8398	Lasmiditan hydrochloride	5-HT	FDA Approved
T8357	SB-200646	5-HT2B; 5-HT2C	
T8140	Tianeptine	5-HT	Approved
T8136	Perospirone hydrochloride	5-HT	Approved
T8128	Mosapride	5-HT	Approved
T7694	6-fluoro-DL-Tryptophan	5-HT	

ID	Product Name	Target	Condition
T7521	Azaphen	serotonin reuptake	
T7519	RS 127445	5-HT2B	
T7412	Tandospirone citrate	5-HT	Approved
T7350	Nelotanserin	5-HT	Phase 2
T7281	F-15599	5-HT1A	
T7277	SB 242084 dihydrochloride hydrate	5-HT2C	
T7135	Phenylbiguanide	5-HT3	
T7103	idalopirdine	5-HT6	
T6S0654	Isocorynoxine	5-HT	
T6973	RS127445	5-HT2B; 5-HT2B	Preclinical
T6959	PRX-08066 Maleic acid	5-HT2B	
T6958	Prucalopride Succinate	5-HT4A ; 5-HT4B	FDA Approved
T6946	Pimavanserin tartrate	5-HT2A	FDA Approved
T6814	Cyproheptadine HCl	HT	FDA Approved
T6728	VUF 10166	5-HT3A; 5-HT3AB	
T6616	Ondansetron HCl	5-HT3	FDA Approved
T6615	Ondansetron	5-HT3 receptor; 5-HT	FDA Approved
T6602	Naratriptan hydrochloride	5-HT1	FDA Approved
T6600	Naftopidil DiHCl	5-HT1A; α 1-adrenergic receptor	Approved
T6597	Mosapride Citrate	5-HT4	Approved
T6493	Escitalopram Oxalate	SSRI; 5-HT	FDA Approved
T6488	Epinastine HCl	HT	FDA Approved
T6461	Dapoxetine HCl	5-HT	Approved
T6426	Buclicline HCl	HT; Cholinergic	
T6423	BRL-15572 dihydrochloride	5-HT1A; 5-HT1D; 5-HT2A; 5-HT2B; 5-HT7	
T6241	Quetiapine Fumarate	HT; Adrenergic Receptor; Dopamine	FDA Approved
T6232	Vilazodone HCl	5-HT1A; SSRI	FDA Approved
T6188	Desvenlafaxine succinate hydrate	5-HT; Norepinephrine (NE)	FDA Approved
T5S1389	Escin IB	5-HT Receptor; NO	
T5858	Sertindole	D2; 5-HT	Approved
T5389	Volinanserin	5-HT2	Phase 3
T5387	LP-211	5-HT7; D2 receptor; 5-HT1A receptor	
T5380	Ansofaxine hydrochloride	serotonin reuptake; dopamine reuptake; norepinephrine reuptake	
T5336	Zacopride hydrochloride	5-HT3 antagonist; 5-HT4 agonist; IK1/Kir2.1 agonist	
T5271	5-Methoxytryptamine	5-HT	
T5179	AVN492	5-HT6; 5-HT6R	
T5158	N-Desmethylclozapine	5-HT2C; D4; δ -opioid receptor	Phase 2
T4S1659	Xanthotoxol	5-HT Receptor	
T4978	Sarpogrelate hydrochloride	5-HT2; 5-HT2A	Approved

ID	Product Name	Target	Condition
T4577	Cariprazine	D3; D2; 5-HT1A	FDA Approved
T4576	Perospirone	5-HT2A; D2; 5-HT1A	Approved
T4568	Dolasetron	5-HT3	FDA Approved
T4562	Ramosetron	5-HT3	Approved
T4560	Alprenolol	β -adrenergic receptor; 5-HT	Approved
T4494	CLOZAPINE N-OXIDE	5-HT	
T4305	8-OH-Dpat	5-HT1A,5-HT7	
T4297	Flibanserin	5-HT1A; 5-HT2A; D4 receptor	FDA Approved
T4266	LY 334370	5-HT1F	
T4008	Metergoline	5-HT1; 5-HT2; 5-HT2; 5-HT2; 5-HT7	Approved
T3S0478	Scopolamine	muscarinic receptor; 5-HT3	FDA Approved
T3704	Lasmiditan	5-HT1F	FDA Approved
T3648	YL0919	5-HT; 5-HT1A	
T3526	Dasotraline hydrochloride	5-HT; Dopamine; Norepinephrine (NE)	Phase 3
T3497	Ocaperidona	D2; 5-HT2	Phase 2
T3431	Pardoprunox hydrochloride	5-HT1A; D2; D3	Phase 3
T3369	Nuciferine	5-HT2A; 5-HT2B; 5-HT2C; 5-HT7; D5 receptor	
T3275	Nefazodone hydrochloride	5-HT	FDA Approved
T3269	Metadoxine	5-HT2B	Approved
T3179	Eptapirone	5-HT1A	Phase 1
T3085	Piperacetazine	5-HT; Dopamine	FDA Approved
T3046	BMY 7378 dihydrochloride	5-HT1A; 5-HT1C; α 1D-adrenoceptor; α 2C-adrenoceptor; D2	Preclinical
T2S0007	Sodium ferulic	5-HT Receptor	Approved
T2874	Tetrahydroberberine THB	5-HT; Dopamine	
T2815	Puerarin	5-HT	Approved
T2714	Rotundine	5-HT1A; D1; D2; D3	
T2688	LY310762	5-HT1D	
T2631	WAY-100635 Maleate	5-HT	Preclinical
T2599	Pirenperone	5-HT2	
T2589	Dalasetron Mesylate Hydrate	5-HT3	FDA Approved
T2565	Hesperetin	HT; TGF β	Approved
T2542	Prucalopride	5-HT4A; 5-HT4B	FDA Approved
T2525	Alosetron hydrochloride	5-HT3	FDA Approved
T2459	BRL54443	5-HT1A; 5-HT1B; 5-HT1D; 5-HT1E; 5-HT1F	
T2428	TG6-10-1	5-HT2B	
T2402	Tianeptine sodium	5-HT	Approved
T2395L	Vortioxetine HBr	5-HT1A; 5-HT1B; 5-HT3A; 5-HT7; SERT	FDA Approved
T2395	Vortioxetine	5-HT1A; 5-HT1B; 5-HT3A; 5-HT7; SERT	FDA Approved
T2344	LY344864	5-HT1F	Preclinical

ID	Product Name	Target	Condition
T2317	Almotriptan Malate	5-HT1B/1D	FDA Approved
T2306	Brexpiprazole	5-HT1A; 5-HT2A; α 1B-adrenergic receptor; α 2C receptors; D2L	FDA Approved
T2289	RU 24969 hemisuccinate	5-HT1A; 5-HT1B	Preclinical
T2278	Piboserod	5-HT4	Phase 2
T22379L	NLX-204 hydrochloride (2170405-10-2 free base)	5-HT1A	
T22359	MDL 100009	5-HT2A	
T2226	Pergolide mesylate salt	5-HT receptor; Adrenergic receptor; Dopamine receptor	FDA Approved
T22236	Alprenolol hydrochloride	5-HT1A	
T2209	Serotonin hydrochloride	5-HT; COMT	Approved
T2190	Methiothepin mesylate	5-HT; Dopamine	
T21337	Lurasidone	5-HT7; 5-HT1A; D2	FDA Approved
T2132	Bupirone hydrochloride	5-HT; Dopamine	FDA Approved
T21231	Almotriptan	5-HT1B/1D	FDA Approved
T21013	Clomipramine	5-HT	FDA Approved
T2092	Amitifadine hydrochloride	5-HT; Dopamine; Norepinephrine (NE)	Phase 2/3
T2076	Pimavanserin	5-HT2A	FDA Approved
T1951	Asenapine Maleate	5-HT2A; 5-HT2B; 5-HT2C; 5-HT6; 5-HT7	FDA Approved
T1774	SB 742457	5-HT6	Phase 3
T1735	Lurasidone hydrochloride	5-HT1A; 5-HT2A; 5-HT7; D2; Norepinephrine α 2C	FDA Approved
T1644	Dopamine hydrochloride	5-HT; DA transporter; Dopamine	FDA Approved
T16421	p-MPPI hydrochloride	5-HT1A	
T1636	Paroxetine hydrochloride	5-HT; AChR; GRK2	FDA Approved
T1619	Trazodone hydrochloride	5-HT; Sert (Sodium-dependent); Adrenergic Receptor; H1 receptor	FDA Approved
T1580	Desvenlafaxine	5-HT; Norepinephrine (NE)	FDA Approved
T1567	Olanzapine	5-HT; HT; mAChR; Adrenergic Receptor; Dopamine	FDA Approved
T1566	Aripiprazole	5-HT1A	FDA Approved
T1551	Tegaserod maleate	5-HT; Sert (Sodium-dependent)	FDA Approved
T1540	Doxepin hydrochloride	5-HT; HT; Sert (Sodium-dependent); mAChR; Adrenergic Receptor; Dopamine; Noradrenaline transporter (Sodium-dependent)	FDA Approved
T1528	Azasetron hydrochloride	5-HT3	Approved
T1512	Rizatriptan benzoate	5-HT	FDA Approved
T1509	Cyclobenzaprine hydrochloride	5-HT	FDA Approved
T1483	Citalopram HBr	5-HT	FDA Approved
T1478	Ondansetron hydrochloride	5-HT3	FDA Approved
T1471	Duloxetine hydrochloride	Sert (Sodium-dependent); DA transporter; Noradrenaline transporter (Sodium-dependent)	FDA Approved
T1445	Agomelatine	5-HT	Approved
T1442	Pizotifen	5-HT	Approved

ID	Product Name	Target	Condition
T1412	Loxapine succinate salt	5-HT2 (bovine); 5-HT2 (bovine); 5-HT2 (human); D2; D4	FDA Approved
T1384	Chlorpromazine hydrochloride	5-HT2A; D2	FDA Approved
T1327	Nortriptyline hydrochloride	5-HT; Sert (Sodium-dependent); mAChR; Adrenergic Receptor; Dopamine; H1 receptor; Noradrenaline transporter (Sodium-dependent)	FDA Approved
T1317	Cinchonidine	SERT	Approved
T1291	Cisapride	5-HT; Potassium Channel; hERG channel	FDA Approved
T12899L	SEP-363856 hydrochloride	5-HT1A Receptor; 5-HT1B Receptor; 5-HT1D Receptor; 5-HT2A Receptor; 5-HT2C Receptor; 5-HT7 Receptor; TAAR1	
T1279	Vilazodone	5-HT; Sert (Sodium-dependent)	FDA Approved
T12773	RS102895 hydrochloride	CCR2; CCR1; Human α 1a receptor; Human α 1d receptor; 5-HT1A	
T1266	Terfenadine	HT; mAChR; Potassium Channel; hERG	Approved
T1180	Blonanserin	5-HT2; D2	Approved
T1173	Tropisetron hydrochloride	5-HT	Approved
T1170	Olopatadine hydrochloride	HT	FDA Approved
T1156	Palonosetron hydrochloride	5-HT	FDA Approved
T1092	Zolmitriptan	5-HT	FDA Approved
T1090	Perphenazine	CAM; Dopamine; 5-HT2A receptor; Histamine H1 receptor; Alpha-1A adrenergic receptor	FDA Approved
T1081	Nafronyl oxalate	5-HT	Approved
T1077	Fluvoxamine maleate	5-HT	FDA Approved
T1069	Metoclopramide hydrochloride	5-HT; mAChR; Dopamine	FDA Approved
T1066	Ketanserin	5-HT2A; 5-HT2C (Human); 5-HT2C (Rat)	Approved
T1045	Trimipramine maleate	5-HT; Sert (Sodium-dependent); Adrenergic Receptor; DA transporter; Dopamine; H1 receptor; Noradrenaline transporter (Sodium-dependent)	FDA Approved
T1042	Granisetron hydrochloride	5-HT	FDA Approved
T0991	Desipramine hydrochloride	5-HT; Adrenergic Receptor	FDA Approved
T0965	Histamine	HT	FDA Approved
T0869	Atomoxetine hydrochloride	5-HT; DA transporter; Norepinephrine (NE) transporter	FDA Approved
T0811	Amisulpride	5-HT; Dopamine	FDA Approved
T0802	Procaine hydrochloride	5-HT3; nAChR; NMDA receptor; Sodium channel	FDA Approved
T0785	Dexchlorpheniramine Maleate	Sert (Sodium-dependent); DA transporter; H1 receptor; Noradrenaline transporter (Sodium-dependent)	FDA Approved
T0783	Mianserin hydrochloride	5-HT; HT; Sert (Sodium-dependent); Adrenergic Receptor; DA transporter; Dopamine; Noradrenaline transporter (Sodium-dependent); κ -opioid receptor	Approved
T0766	Promazine hydrochloride	5-HT; mAChR; Adrenergic Receptor; Dopamine	FDA Approved
T0723	Cloperastine hydrochloride	HT	Approved
T0716	Molindone hydrochloride	5-HT; mAChR; Dopamine	FDA Approved
T0680	Lamotrigine	5-HT (human platelets); 5-HT (rat brain synaptosomes)	FDA Approved

ID	Product Name	Target	Condition
T0678	Amitriptyline hydrochloride	5-HT; 5-HT2; 5-HT4; Norepinephrine receptor; α 1	FDA Approved
T0663	2-Bromo-6-methoxynaphthalene	Sert (Sodium-dependent)	
T0647	Tryptamine	5-HT; AADH; hTRPA1	
T0525	Flopropione	5-HT1A	Approved
T0482	Sertraline hydrochloride	5-HT	FDA Approved
T0472	Venlafaxine hydrochloride	5-HT	FDA Approved
T0450L	Fluoxetine hydrochloride	5-HT; Sert (Sodium-dependent)	FDA Approved
T0450	Fluoxetine	Sert (Sodium-dependent); MRP1	FDA Approved
T0445	Promethazine	5-HT; mAChR; Adrenergic Receptor; CAM; D2; H1 receptor	FDA Approved
T0428	Alverine citrate	5-HT	Approved
T0370	Pheniramine maleate	HT	Approved
T0365	Thioridazine hydrochloride	5-HT; Adrenergic Receptor; Dopamine; Potassium Channel	FDA Approved
T0351	Risperidal	5-HT2A; α 2C-adrenergic receptor; D2; D2L; D3	FDA Approved
T0333	Aniracetam	5-HT; Dopamine; AMPA; GluR	Approved
T0318	Ataractan	5-HT	
T0302	Triflupromazine hydrochloride	5-HT; mAChR; Dopamine	FDA Approved
T0255	Clomipramine hydrochloride	5-HT; Sert (Sodium-dependent); GSTP; Noradrenaline transporter (Sodium-dependent); dopamine transporter (DAT)	FDA Approved
T0236	Azatadine Maleate	HT; Cholinergic	FDA Approved
T0225	Pizotifen Malate	5-HT	Approved
T0217	Levodropropizine	HT	Approved
T0216	Eletriptan HBr	5-HT1B; 5-HT1D	FDA Approved
T0205	Brompheniramine hydrogen maleate	HT	FDA Approved
T0204	Protriptyline hydrochloride	Sert (Sodium-dependent)	FDA Approved
T0203	Sumatriptan succinate	5-HT	FDA Approved
T0174	Cyproheptadine hydrochloride	5-HT2; SETD7; SETD9	FDA Approved
T0172	Maprotiline hydrochloride	5-HT; mAChR; Adrenergic Receptor; H1 receptor; Noradrenaline transporter (Sodium-dependent)	FDA Approved
T0165	Urapidil	5-HT; α 1-adrenergic receptor	Approved
T0137	Mirtazapine	5-HT; HT; Sert (Sodium-dependent); Adrenergic Receptor; DA transporter; Dopamine; κ -opioid receptor	FDA Approved
T0113	Mebhydrolin napadisylate	HT; mAChR	Approved
T0088	Urapidil hydrochloride	5-HT; α -adrenergic receptor	Approved
T0081	Lafutidine	HT	Approved
T0076	Paliperidone	5-HT; β -adrenergic receptor; Dopamine; H1 receptor	FDA Approved
T0074L	Chlorprothixene hydrochloride	5-HT; mAChR; Dopamine; H1 receptor	FDA Approved
T0074	Chlorprothixene	5-HT6; 5-HT7; D2; D3; H1 receptor	FDA Approved

ID	Product Name	Target	Condition
T0031L2	Ziprasidone	5-HT transporter; 5-HT1A; 5-HT1B; 5-HT1D; 5-HT2A; 5-HT2C; 5-HT6; 5-HT7; α 1A-adrenergic receptor; α 2A-adrenergic receptor; D1; D2; D3; H1 receptor; norepinephrine transporter (NET)	FDA Approved
T0031L	Ziprasidone hydrochloride	5-HT transporter; 5-HT1A; 5-HT1B; 5-HT1D; 5-HT2A; 5-HT2C; 5-HT6; 5-HT7; α 1A-adrenergic receptor; α 2A-adrenergic receptor; D1; D2; D3; H1 receptor; norepinephrine transporter (NET)	FDA Approved
T0031	Ziprasidone hydrochloride monohydrate	5-HT transporter; 5-HT1A; 5-HT1B; 5-HT1D; 5-HT2A; 5-HT2C; 5-HT6; 5-HT7; α 1A-adrenergic receptor; α 2A-adrenergic receptor; D1; D2; D3; H1 receptor; norepinephrine transporter (NET)	FDA Approved
T0025	Haloperidol	5-HT; Dopamine	FDA Approved

AChE

ID	Product Name	Target	Condition
T7213	Demecarium bromide	cholinesterase	FDA Approved
T13446	(R)-Rivastigmine D6 tartrate	cholinesterase	

AChR

ID	Product Name	Target	Condition
TN1899	Lycoramine	AChE	
TN1736	Hibifolin	Adenosine deaminase	
TN1305	6-Ethoxydihydrosanguinarine	HuAChE	
TN1091	Dehydronuciferine	AChE	
TN1030	N-p-trans-Coumaroyltyramine	AChE	
T8868	4BP-TQS	α 7 nAChRs	
T8770	Harmalol	AChR	
T8725	A 582941 HCl (848591-90-2(free base))	α 7 nAChR	
T8585	TA-03	AChE	
T8552	PSEM 89S TFA	nAChR	
T8383	Cyclopentolate Hydrochloride	M5 mAChR	FDA Approved
T8318	BNC210	α 7 nAChR	Phase 2
T8224	VU0119498	mAChR	
T8219	VU0238441	M5 mAChR	
T8193	Thujone	GABAA; AChR	
T8007	VU0238429	M5 mAChR	
T7955	EB-3D	choline kinase alpha 1 (ChoK α 1)	
T7895	Syn-Ake acetate	Muscarinic AChR	
T7884	NS 1738	nAChR	

ID	Product Name	Target	Condition
T7853	Pachycarpine	AChR	
T7813	CZEN-002	Adenylyl cyclase	
T7780	AVex-73	muscarinic receptor	
T7736	2-Chloroadenosine	Adenosine receptor	
T7695	PNU-282987 S enantiomer free base	α7 nAChR	
T7640	Aldicarb sulfone	AChE	
T7591	Coluracetam	Cholinergic Uptake	
T7561	Benzetimide hydrochloride	AChR	
T7555	Piperidolate hydrochloride	muscarinic receptor	Approved
T7500	Isoxazole	AChR	
T7465	4-Methylbenzylidene camphor	AChE	
T7422	CCMI	nAChR	
T7405	Piperidolate	mAChR	
T7392	Revefenacin	mAChR	FDA Approved
T7340	NECA	Adenosine receptor	
T7193	Encenicline	nAChR	
T7124	Dinotefuran	nAChR; Antiparasitic	
T7114	Galanthaminone	AChE	
T7052	Gnetol	BChE; Tyrosinase	
T7041	Donepezil	AChE	FDA Approved
T7002	Trihexyphenidyl hydrochloride	AChR	FDA Approved
T6S2356	(+)-Corynoline	AChE	
T6950	PNU120596	α7 nAChR	Preclinical
T6745	5-Iodotubercidin	adenosine kinase	
T6744	Methylbenzactyzine Bromide	mAChR	Approved
T6707	Tiotropium Bromide hydrate	AChR	FDA Approved
T6684	Succinylcholine Chloride Dihydrate	nicotinic AChR	FDA Approved
T6618	Orphenadrine Citrate	AChR	FDA Approved
T6607	Nitenpyram	nAChR	
T6575	LY2119620	M2 mAChR; M4 mAChR	
T6548	Irsogladine	M1 muscarinic	Approved
T6547	Ipratropium Bromide	M3 mAChR	FDA Approved
T6478	Donepezil HCl	bAChE; hAChE	FDA Approved
T6426	Buclizine HCl	HT; Cholinergic	
T6397	Atracurium besylate	nAChR	FDA Approved
T6115	Fostamatinib	Adenosine transporter; A3; Monoamine transporter; Syk	FDA Approved
T5S2361	Epiberberine	ERK1/2; MEK1; AChE; BChE; BACE1	

ID	Product Name	Target	Condition
T5S1025	Picfeltaarinen IA	AChE	
T5S0802	Palmitine	AChE; BChE	Approved
T5940	Proxiphylline	adenosine A1/A2a receptor; PDE	Approved
T5855	Edrophonium chloride	AChE	FDA Approved
T5805	Norarecoline hydrochloride	muscarinic receptor	
T5721	Dehydroevodiamine hydrochloride	AChE	
T5655	mAChR-IN-1 hydrochloride	mAChR	
T5081	Adenine hydrochloride hydrate	Adenosine receptor	
T5051	Isopropamide Iodide	muscarinic receptor	FDA Approved
T4S1725	Galanthamine	AChE	Approved
T4S1619	Hyoscyamine sulfate hydrate	muscarinic receptor	
T4S0111	Hupehenine	muscarinic receptor	
T4997	Umeclidinium bromide	M1 mAChR; M2 mAChR; M3 mAChR; M4 mAChR; M5 mAChR	FDA Approved
T4986	Imidafenacin	mAChR	Approved
T4981	Anisotropine Methylbromide	Cholinergic; DP1; IP; EP2	FDA Approved
T4668	ABT-702 dihydrochloride	Adenosine kinase	
T4466	Pitofenone hydrochloride	AChE	
T4439	Choline glycerophosphate	AChE	Approved
T4246	Varenicline	$\alpha 4\beta 2$ nAChR	FDA Approved
T4006	Pentostatin	Adenosine receptor	FDA Approved
T3S1612	kuwanon G	α -glucosidase; PTP1B; AChE; BChE	
T3S0478	Scopolamine	muscarinic receptor; 5-HT3	FDA Approved
T3993	BQCA	M1 mAChR	
T3872	Nodakenin	AChE	
T3865	beta-Eudesmol	nAChR; TRPA1; TRPV3; TRPM8	
T3819	Acetylursolic acid	AChE	
T3791	Atractyloside A	adenine nucleotide translocase	
T3720	Tebanicline hydrochloride	nAChR	Phase 2
T3619	VU 0357017 hydrochloride	M1 mAChR	
T3324	Lycorine	AChR	
T3196	GNF7	M351T; c-Abl; E255V; G250E; T315I	
T3126	Bethanechol chloride	muscarinic receptor	FDA Approved
T3026	(-)-Huperzine A	AChE (G4 form)	Approved
T2984	Scopoletin	mAChR	Approved
T2939	Forskolin	Adenylyl cyclase (AC)	Preclinical
T2846	Isoimperatorin	AChE	
T2845	Imperatorin	BChE; NO synthesis; TRPV1	Approved
T2759	Loganin	NF- κ B; AChE; BChE; BACE1	Approved

ID	Product Name	Target	Condition
T2725	Scopolamine HBr	mAChR	FDA Approved
T2663	GTS 21 dihydrochloride	α 4 β 2 nAChR	Phase 2
T2571	Benactyzine hydrochloride	mAChR	Approved
T2558	Cladribine	Adenosine deaminase (MM1.S cells); Adenosine deaminase (RPMI8226 cells); Adenosine deaminase (U266 cells)	FDA Approved
T2555	Acridinium bromide	M1 mAChR; M2 mAChR; M3 mAChR; M4 mAChR; M5 mAChR	FDA Approved
T2422	PNU 282987	α 7 nAChR	Preclinical
T2390	Cevimeline hydrochloride hemihydrate	mAChR	FDA Approved
T2387	Glycopyrrolate	mAChR M1	FDA Approved
T2337	BMS303141	ACL	
T2319	Acotiamide hydrochloride	AChE	Approved
T2285	EVP-6124 hydrochloride	α 7 nAChR	Phase 3
T2198	Arecoline HBr	mAChR	Approved
T2191	Tacrine hydrochloride hydrate	AChR	FDA Approved
T2183	Scopolamine butylbromide	mAChR	Approved
T2182	Scopolamine HBr trihydrate	mAChR	FDA Approved
T2181	Scopolamine N-oxide HBr	mAChR; Sucrase-isomaltase	Approved
T2172	SQ 22536	adenylate cyclase	
T2141	Mecamylamine hydrochloride	nAChR	FDA Approved
T19084	1-Naphthyl acetate	AChE	
T1760	TBPP	M1 mAChR	
T1682	Methacholine Chloride	mAChR	FDA Approved
T1668	Vinblastine sulfate	nAChR	FDA Approved
T1657	Varenicline Tartrate	mAChR	FDA Approved
T1636	Paroxetine hydrochloride	5-HT; AChR; GRK2	FDA Approved
T1628	Rivastigmine tartrate	AChR	FDA Approved
T1624	Neostigmine bromide	AChE	FDA Approved
T1612	Hodostin	AChR	FDA Approved
T1594	Vecuronium bromide	nAChR	FDA Approved
T1575	Nizatidine	AChE; H2 receptor	FDA Approved
T1567	Olanzapine	5-HT; HT; mAChR; Adrenergic Receptor; Dopamine	FDA Approved
T1552	Itopride hydrochloride	AChE	Approved
T1542	Pirenzepine dihydrochloride	mAChR	Approved
T1540	Doxepin hydrochloride	5-HT; HT; Sert (Sodium-dependent); mAChR; Adrenergic Receptor; Dopamine; Noradrenaline transporter (Sodium-dependent)	FDA Approved
T1534	Darifenacin HBr	M3 mAChR	FDA Approved
T1475	Fesoterodine fumarate	mAChR	FDA Approved

ID	Product Name	Target	Condition
T1474	Otilonium bromide	mAChR; Calcium Channel	Approved
T1472	Tropspium chloride	mAChR	FDA Approved
T1460	Dicyclomine hydrochloride	mAChR	FDA Approved
T1459	Cisatracurium besylate	AChR; Adrenergic Receptor	FDA Approved
T1446	Bambuterol hydrochloride	AChR; β -adrenergic receptor	Approved
T14140	Agaric acid	adenine nucleotide translocase	
T14094	Acetamiprid	nAChR	
T1341	Nortropine	mAChR	
T1328	DL-trihexyphenidyl hydrochloride	mAChR	FDA Approved
T1327	Nortriptyline hydrochloride	5-HT; Sert (Sodium-dependent); mAChR; Adrenergic Receptor; Dopamine; H1 receptor; Noradrenaline transporter (Sodium-dependent)	FDA Approved
T1320	Disopyramide	mAChR; Potassium Channel; Sodium Channel	FDA Approved
T13066	TAK-071	M1 mAChR	Phase 2
T1281	Tropicamide	M4 mAChR	FDA Approved
T1266	Terfenadine	HT; mAChR; Potassium Channel; hERG	Approved
T1231	Pilocarpine nitrate	mAChR	FDA Approved
T1229	Erdosteine	Adenosine deaminase	Approved
T1221	Acetylcholine chloride	AChR	FDA Approved
T1215	Nicardipine hydrochloride	mAChR; Adrenergic Receptor; Calcium Channel	FDA Approved
T1202	(-)-Cotinine	Nicotinic Receptor	Phase 2
T1199	Mitotan	Adrenodoxin	FDA Approved
T1179	Tiotropium bromide	mAChR	FDA Approved
T1111	Pralidoxime Chloride	AchE	FDA Approved
T1083L	Theophylline monohydrate	Adenosine receptor; HDAC2; PDE	FDA Approved
T1083	Theophylline	Adenosine receptor; HDAC2; PDE	FDA Approved
T1072	Loxeen	mAChR	Approved
T1069	Metoclopramide hydrochloride	5-HT; mAChR; Dopamine	FDA Approved
T1049L	Oxybutynin	mAChR	FDA Approved
T1049	Oxybutynin hydrochloride	mAChR	FDA Approved
T1039	Choline chloride	mAChR	FDA Approved
T1006	Propantheline bromide	mAChR	FDA Approved
T0999	Clevipidine butyrate	AChR; Calcium Channel	FDA Approved
T0997	Temephos	AChR	
T0962	L-Hyoscyamine	AChR	Approved
T0944	Levamisole hydrochloride	nAChR; PLAP	FDA Approved
T0862	Diphenidol hydrochloride	mAChR	FDA Approved
T0851	Pregnenolone	mAChR	Approved
T0818	Decamethonium bromide	AChE; nAChR	FDA Approved

ID	Product Name	Target	Condition
T0804	(+)-Pilocarpine hydrochloride	mAChR	FDA Approved
T0802	Procaine hydrochloride	5-HT ₃ ; nAChR; NMDA receptor; Sodium channel	FDA Approved
T0794	Mepenzolate Bromide	mAChR	FDA Approved
T0790	Carbaryl	AChR	
T0786	Clidinium bromide	mAChR	FDA Approved
T0780	Mestinon	AChE	FDA Approved
T0766	Promazine hydrochloride	5-HT; mAChR; Adrenergic Receptor; Dopamine	FDA Approved
T0765	4-Methylpyrazole	ADH; CAT	FDA Approved
T0731	N,N-Diethyl-m-toluamide	AChE	
T0720	Gallamine triethiodide	AChR	FDA Approved
T0716	Molindone hydrochloride	5-HT; mAChR; Dopamine	FDA Approved
T0713	Drofenine hydrochloride	AChE	Approved
T0703	Flavoxate hydrochloride	mAChR	FDA Approved
T0684	Ribavirin	ADK; IMPDH1; RNA polymerase	FDA Approved
T0665	2,6-Dihydroxypurine	Adenosine receptor	
T0625	Theobromine	Adenosine receptor; PDE	FDA Approved
T0594	Diphepanil mesylate	AChR	FDA Approved
T0479	Cytisine	nAChR	Phase 3
T0464	Carbetapentane citrate	AChR	Approved
T0455	Clozapine	M1 mAChR; α 2-adrenoceptor; D2	FDA Approved
T0445	Promethazine	5-HT; mAChR; Adrenergic Receptor; CAM; D2; H1 receptor	FDA Approved
T0427	Homatropine Methylbromide	mAChR (SHR-E); mAChR (WKY-E)	FDA Approved
T0401	Benzethonium chloride	α 4 β 2 nAChRs; α 7 nAChRs	Approved
T0375L2	Atropine sulfate	mAChR	FDA Approved
T0375L	Atropine sulfate monohydrate	mAChR	FDA Approved
T0375	Atropine	mAChR	FDA Approved
T0364L	Dibucaine hydrochloride	AChR; Sodium Channel	FDA Approved
T0364	Dibucaine	AChR; CAM; Sodium Channel	FDA Approved
T0302	Triflupromazine hydrochloride	5-HT; mAChR; Dopamine	FDA Approved
T0296	Pempidine	Nicotinic Receptor; ganglion	Approved
T0287	Hexamethonium Bromide	mAChR; Dopamine	Approved
T0269	Dichlorisone Acetate	AChE	
T0268	Lobeline hydrochloride	nAChR; Nicotinic Receptor	Approved
T0253	Methscopolamine	mAChR	FDA Approved
T0236	Azatadine Maleate	HT; Cholinergic	FDA Approved
T0229	Rivastigmine	AChE	FDA Approved
T0177	Homatropine Bromide	mAChR (SHR-E); mAChR (WKY-E)	FDA Approved

ID	Product Name	Target	Condition
T0172	Maprotiline hydrochloride	5-HT; mAChR; Adrenergic Receptor; H1 receptor; Noradrenaline transporter (Sodium-dependent)	FDA Approved
T0166	Pancuronium bromide	AChR; mAChR	FDA Approved
T0156	Rocuronium bromide	mAChR	FDA Approved
T0130	Physostigmine Salicylate	AChR	Approved
T0113	Mebhydrolin napadisylate	HT; mAChR	Approved
T0111	Solifenacin succinate	mAChR	FDA Approved
T0103	Dipivefrin hydrochloride	AChR; Adrenergic Receptor	FDA Approved
T0099	Tolterodine tartrate	mAChR	FDA Approved
T0098	Ipratropium bromide monohydrate	mAChR	FDA Approved
T0086	Galanthamine HBr	AChE	FDA Approved
T0074L	Chlorprothixene hydrochloride	5-HT; mAChR; Dopamine; H1 receptor	FDA Approved
T0072	Adiphenine hydrochloride	Nicotinic Receptor	Approved
T0064	Adenine	Adenine phosphoribosyltransferase	FDA Approved
T0052L	Strychnine Sulfate	nAChR; Glycine receptor	
T0051	Urethane	$\alpha 4\beta 2$ nAChR; glycine receptors; GABAR; AMPA; NMDA receptor	Approved
T0024	Primidone	nAChR; GABAR; GluR2; Sodium Channel	FDA Approved
T0018	Procainamide hydrochloride	AChR; DNA (cytosine-5)-methyltransferase 1; Sodium Channel	FDA Approved
PDK0015	4-Hydroxycoumarin	AChR	
Fr16605	Lupinine	AChE; BChE	
Fr14127	2,3-Dihydrobenzofuran	AChE; Human Endogenous Metabolite	

Adenylyl cyclase

ID	Product Name	Target	Condition
T10066	2',5'-Dideoxyadenosine	Adenylyl cyclase (AC)	

Adrenergic Receptor

ID	Product Name	Target	Condition
T8810	Terbutaline	$\beta 2$ -adrenergic receptor	FDA Approved
T8738	LUN42518 HCl 47142-51-8 (free base)	α -adrenergic receptor	
T8696	Propranolol hydrochloride	$\beta 1$ -adrenergic receptor; $\beta 2$ -adrenergic receptor	FDA Approved
T8663	nifenalol.HCl	β -adrenergic receptor	
T8595	Practolol	β -adrenoceptor	
T8580	Bupranolol	$\beta 2$ -adrenergic receptor	
T8358	Fenoterol	$\beta 2$ -adrenergic receptor	Approved

ID	Product Name	Target	Condition
T8348	Phentolamine	α 1-adrenergic receptor; α 2-adrenergic receptor	FDA Approved
T8149	Dobutamine (hydrochloride)	Adrenergic Receptor	FDA Approved
T8143	Bevantolol hydrochloride	β 1-adrenoceptor	Approved
T7164	Levalbuterol tartrate	β 2-adrenergic receptor	Approved
T7160	Lofexidine	α 2 receptor	FDA Approved
T7079	Batefenterol	β 2-adrenoceptor	Phase 2
T7046	Xylazine	α 2 adrenergic receptor	
T7044	Norepinephrine	MMP-2; MMP-9; α 2A adrenoceptor; α 1 adrenoceptor; β 1 adrenoceptor	FDA Approved
T6872	L755507	β 3-adrenergic receptor	Preclinical
T6765	Atipamezole hydrochloride	α 2-adrenoceptor antagonist	Approved
T6703	Tetrahydrozoline HCl	α -adrenergic receptor	FDA Approved
T6701	Terazosin hydrochloride dihydrate	α 1-adrenoceptor	FDA Approved
T6688	Synephrine HCl	α -adrenergic receptor	
T6662	Scopine	α 1-adrenergic receptor	
T6653	Salmeterol Xinafoate	β 2-adrenergic receptor; WT β 2AR	FDA Approved
T6652	Salbutamol Sulfate	β 2-adrenergic receptor	FDA Approved
T6600	Naftopidil DiHCl	5-HT1A; α 1-adrenergic receptor	Approved
T6579	Medetomidine HCl	α 2-adrenoceptor	Approved
T6565	Levobetaxolol HCl	β 1-adrenergic receptor , β 2-adrenergic receptor	FDA Approved
T6522	Guanabenz Acetate	α 2A-adrenergic receptor; α 2B-adrenergic receptor; α 2C-adrenergic receptor	FDA Approved
T6519	Gramine	Adiponectin Receptor; Adrenergic Receptor	
T6505	Formoterol Hemifumarate	β 2-adrenergic receptor	FDA Approved
T6466	Dexmedetomidine HCl	α 2-adrenoceptor	FDA Approved
T6422	Brimonidine Tartrate	α 2A-adrenergic receptor	FDA Approved
T6408	Betaxolol	beta1 adrenergic receptor	FDA Approved
T6241	Quetiapine Fumarate	HT; Adrenergic Receptor; Dopamine	FDA Approved
T5S2178	Fargesin	β 1-adrenergic receptor	
T5471	GUANABENZ	α 2 adrenergic receptor	Approved
T5327	Amezinium (methylsulfate)	α -adrenergic receptor; β 1-adrenergic receptor	Approved
T5159	BI 1744 hydrochloride	β 2-adrenoceptor	FDA Approved
T5134	Vilanterol trifenate	β 2-adrenoceptor; β 1-adrenoceptor; β 3-adrenoceptor	FDA Approved
T5105	1-(2-Pyridyl)piperazine	α 2-adrenoceptor	
T5035	Methoxyphenamine Hydrochloride	β -adrenergic receptor	Approved
T5028	Landiolol hydrochloride	β 1-adrenergic receptor	Approved
T4S0998	Trifolirhizin	TNF- α	
T4983	Isoetharine mesylate salt	β -adrenergic receptor; PXR	FDA Approved
T4963	Higenamine	α 1-adrenergic receptor	

ID	Product Name	Target	Condition
T4560	Alprenolol	β -adrenergic receptor; 5-HT	Approved
T4548	Procaterol hydrochloride	β 2-adrenergic receptor	Approved
T4526	Piperoxan hydrochloride	α 2 receptor	
T4429	Rauwolscine hydrochloride	α 2 adrenergic receptor	Approved
T3996	Dapiprazole Hydrochloride	α 1-adrenergic receptor	FDA Approved
T3457	Olodaterol	β 2-adrenoceptor	FDA Approved
T3284	Carazolol	β -adrenergic receptor	Approved
T3278	Piribedil	α 2-adrenergic; D2; D3	Approved
T3277	Tulobuterol hydrochloride	β 2-adrenergic receptor	Approved
T3232	Higenamine Hydrochloride	β 2-adrenergic receptor	Approved
T3165	Metoprolol Succinate	β 1-adrenergic receptor	FDA Approved
T3046	BMY 7378 dihydrochloride	5-HT1A; 5-HT1C; α 1D-adrenoceptor; α 2C-adrenoceptor; D2	Preclinical
T3033	Deoxycorticosterone acetate	Adrenergic Receptor	FDA Approved
T2889	Isoferulic acid	Adrenergic Receptor	Approved
T2580	Formoterol	β 2-adrenergic receptor	FDA Approved
T2547	Droxidopa	Adrenergic Receptor	FDA Approved
T2546	Pimozide	D2; Potassium Channel; α 1-adrenoceptor	FDA Approved
T2535	Ivabradine hydrochloride	Adrenergic Receptor	FDA Approved
T2524	Dexmedetomidine	α 2 receptor	FDA Approved
T23283	RX 821002 hydrochloride	α 2-adrenoceptor	
T2320	Indacaterol	β -adrenoceptor; β 1-adrenoceptor; β 2-adrenoceptor	FDA Approved
T2306	Brexpiprazole	5-HT1A; 5-HT2A; α 1B-adrenergic receptor; α 2C receptors; D2L	FDA Approved
T2226	Pergolide mesylate salt	5-HT receptor; Adrenergic receptor; Dopamine receptor	FDA Approved
T2150	Guanfacine hydrochloride	α 2A-adrenoceptor; α 2B-adrenoceptors	FDA Approved
T2142	Yohimbine hydrochloride	α 2 adrenergic receptor	Approved
T21066	Norepinephrine bitartrate salt	Adrenergic Receptor	FDA Approved
T1738	Taxifolin	β -adrenergic receptor; TNF- α ; Collagenase Tyrosinase; Beta-nerve growth factor; VEGFR2	
T1696	2-(1-Piperazinyl)pyrimidine	α -adrenergic receptor	
T1680	Tolazoline hydrochloride	α -adrenergic receptor	FDA Approved
T1671	Mirabegron	β 3-adrenoceptor	FDA Approved
T1632	Amitraz	α -adrenergic receptor	Approved
T1619	Trazodone hydrochloride	5-HT; Sert (Sodium-dependent); Adrenergic Receptor; H1 receptor	FDA Approved
T1584	Terbutaline Sulfate	β 2-adrenergic receptor	FDA Approved
T1577	Midodrine hydrochloride	α 1-adrenergic receptor	FDA Approved
T1567	Olanzapine	5-HT; HT; mAChR; Adrenergic Receptor; Dopamine	FDA Approved
T1540	Doxepin hydrochloride	5-HT; HT; Sert (Sodium-dependent); mAChR; Adrenergic Receptor; Dopamine; Noradrenaline transporter (Sodium-dependent)	FDA Approved

ID	Product Name	Target	Condition
T1539	lloperidone	α -adrenergic receptor; Dopamine	FDA Approved
T1504	Sildenafil	β -adrenergic receptor	FDA Approved
T1503	Esmolol hydrochloride	β -adrenergic receptor	FDA Approved
T1500	Xylazine hydrochloride	α 2 adrenergic receptor	FDA Approved
T1496	Amiodarone hydrochloride	β -adrenergic receptor; Potassium Channel; ATP-sensitive potassium channel	FDA Approved
T1459	Cisatracurium besylate	AChR; Adrenergic Receptor	FDA Approved
T1446	Bambuterol hydrochloride	AChR; β -adrenergic receptor	Approved
T1433	Ritodrine hydrochloride	β -adrenergic receptor	FDA Approved
T1415	Gemfibrozil	PPAR α ; CYP2C9; 1A2	FDA Approved
T1327	Nortriptyline hydrochloride	5-HT; Sert (Sodium-dependent); mAChR; Adrenergic Receptor; Dopamine; H1 receptor; Noradrenaline transporter (Sodium-dependent)	FDA Approved
T13016	SR59230A	β 3-adrenoceptor	
T1287	Synephrine	Adrenergic Receptor	Approved
T1282	Carteolol hydrochloride	β -adrenergic receptor	FDA Approved
T1275	Phentolamine mesilate	α -adrenergic receptor; α -adrenoceptor	FDA Approved
T12643	(R)-Terazosin	α 1a-adrenoceptor; α 1b-adrenoceptor; α 1d-adrenoceptor	FDA Approved
T1247	Clonidine hydrochloride	α 2 adrenergic receptor	FDA Approved
T1239	Indacaterol maleate	β 1-adrenoceptor; β 2-adrenoceptor	FDA Approved
T1215	Nicardipine hydrochloride	mAChR; Adrenergic Receptor; Calcium Channel	FDA Approved
T1203	Nadolol	β -adrenergic receptor	FDA Approved
T1158	Phenoxybenzamine hydrochloride	α -adrenergic receptor; CAM	FDA Approved
T1139	Salbutamol	β -adrenergic receptor	FDA Approved
T1132	Nicergoline	Adrenergic Receptor	Approved
T11318	Dopexamine hydrochloride	β 2-adrenergic receptor	Phase 4
T10952	Dabuzalgron	α 1A-adrenergic receptor	
T1090	Perphenazine	CAM; Dopamine; 5-HT2A receptor; Histamine H1 receptor; Alpha-1A adrenergic receptor	FDA Approved
T1073	Dronedrone hydrochloride	Adrenergic Receptor; Calcium Channel; Potassium Channel; Sodium Channel	FDA Approved
T1071L2	DL-Adrenalin	α -adrenergic receptor	Approved
T1071L	DL-Adrenaline Hydrochloride	Adrenergic Receptor	FDA Approved
T1064	Noradrenaline bitartrate monohydrate	β 1-adrenergic receptor; β 1-selective adrenergic receptor	FDA Approved
T1056	Isoprenaline hydrochloride	Adrenergic Receptor; cAMP PDE; PI3K	FDA Approved
T1050	Prazosin hydrochloride	ABCG; Adrenergic Receptor; MRP1; Potassium Channel	FDA Approved
T1045	Trimipramine maleate	5-HT; Sert (Sodium-dependent); Adrenergic Receptor; DA transporter; Dopamine; H1 receptor; Noradrenaline transporter (Sodium-dependent)	FDA Approved
T1012	Acebutolol hydrochloride	β -adrenergic receptor	FDA Approved
T0993	Methoxamine hydrochloride	Adrenergic Receptor	FDA Approved

ID	Product Name	Target	Condition
T0991	Desipramine hydrochloride	5-HT; Adrenergic Receptor	FDA Approved
T0970	Anisodamine	Adrenergic Receptor	Approved
T0948	Adrenalone hydrochloride	α 1-adrenergic receptor	Approved
T0871	Noradrenaline bitartrate	Adrenergic Receptor	FDA Approved
T0852	Carbazochrome sodium sulfonate	Adrenergic Receptor	Approved
T0812	Propranolol hydrochloride	β -adrenergic receptor	FDA Approved
T0783	Mianserin hydrochloride	5-HT; HT; Sert (Sodium-dependent); Adrenergic Receptor; DA transporter; Dopamine; Noradrenaline transporter (Sodium-dependent) κ -opioid receptor	Approved
T0766	Promazine hydrochloride	5-HT; mAChR; Adrenergic Receptor; Dopamine	FDA Approved
T0696	Naftopidil	α 1A-adrenergic receptor; α 1B-adrenergic receptor; α 1D-adrenergic receptor	Approved
T0487	Metoprolol tartrate	β -adrenergic receptor	FDA Approved
T0483	Sotalol hydrochloride	β -adrenergic receptor; Potassium Channel	FDA Approved
T0475	Timolol Maleate	β 1-adrenergic receptor; β 2-adrenergic receptor	FDA Approved
T0455	Clozapine	M1 mAChR; α 2-adrenoceptor; D2	FDA Approved
T0453	Phenylephrine hydrochloride	α 1-adrenergic receptor	FDA Approved
T0447	Carvedilol	Adrenergic Receptor; HIF; E-selectin; NADPH; Vcam; Potassium Channel; VEGFR; LDL oxidation	FDA Approved
T0446	Naphazoline hydrochloride	Adrenergic Receptor	FDA Approved
T0445L	Promethazine hydrochloride	α -adrenergic receptor; H1 receptor	FDA Approved
T0445	Promethazine	5-HT; mAChR; Adrenergic Receptor; CAM; D2; H1 receptor	FDA Approved
T0397	Tetryzoline	α -adrenergic receptor	Approved
T0394	Moxisylyte hydrochloride	Adrenergic Receptor	Approved
T0365	Thioridazine hydrochloride	5-HT; Adrenergic Receptor; Dopamine; Potassium Channel	FDA Approved
T0351	Risperidal	5-HT2A; α 2C-adrenergic receptor; D2; D2L; D3	FDA Approved
T0348	Labetalol hydrochloride	α 1-adrenergic receptor	FDA Approved
T0342	Carvedilol phosphate	Adrenergic Receptor; Gap Junction Protein; E-selectin; NADPH dehydrogenase; Natriuretic peptides B; VCAM1; Potassium Channel; VEGFR; LDL oxidation	FDA Approved
T0324	Isoxsuprine hydrochloride	β -adrenergic receptor	Approved
T0317	Buflomedil hydrochloride	α -adrenergic receptor	Approved
T0290	Tizanidine hydrochloride	α 2 adrenergic receptor	FDA Approved
T0279	Metaraminol bitartrate	α -adrenergic receptor	FDA Approved
T0248	Clorprenaline hydrochloride	β -adrenergic receptor	Approved
T0226	Betaxolol hydrochloride	β 1-adrenergic receptor	FDA Approved
T0210	Tamsulosin hydrochloride	α 1A-adrenergic receptor; α 1B-adrenergic receptor; α 1D-adrenergic receptor	FDA Approved
T0197	Terazosin hydrochloride	α -adrenergic receptor	FDA Approved
T0173	Nylidrin hydrochloride	β -adrenergic receptor	Approved

ID	Product Name	Target	Condition
T0172	Maprotiline hydrochloride	5-HT; mAChR; Adrenergic Receptor; H1 receptor; Noradrenaline transporter (Sodium-dependent)	FDA Approved
T0165	Urapidil	5-HT; α 1-adrenergic receptor	Approved
T0154	Nebivolol hydrochloride	β 1-adrenoceptor	FDA Approved
T0143	(\pm)-Bisoprolol hemifumarate	β 1-adrenergic receptor	FDA Approved
T0137	Mirtazapine	5-HT; HT; Sert (Sodium-dependent); Adrenergic Receptor; DA transporter; Dopamine; κ -opioid receptor	FDA Approved
T0115	Idazoxan hydrochloride	Adrenergic Receptor	Preclinical
T0103	Dipivefrin hydrochloride	AChR; Adrenergic Receptor	FDA Approved
T0101	Doxazosin mesylate	α 1-adrenergic receptor	FDA Approved
T0091	Alfuzosin hydrochloride	α -adrenergic receptor	FDA Approved
T0088	Urapidil hydrochloride	5-HT; α -adrenergic receptor	Approved
T0076	Paliperidone	5-HT; β -adrenergic receptor; Dopamine; H1 receptor	FDA Approved
T0042	Xylometazoline hydrochloride	α 1A-adrenergic receptor; α 1B-adrenergic receptor; α 1D-adrenergic receptor; α 2A-adrenergic receptor; α 2B-adrenergic receptor	Approved
T0031L2	Ziprasidone	5-HT transporter; 5-HT1A; 5-HT1B; 5-HT1D; 5-HT2A; 5-HT2C; 5-HT6; 5-HT7; α 1A-adrenergic receptor; α 2A-adrenergic receptor; D1; D2; D3; H1 receptor; norepinephrine transporter (NET)	FDA Approved
T0031L	Ziprasidone hydrochloride	5-HT transporter; 5-HT1A; 5-HT1B; 5-HT1D; 5-HT2A; 5-HT2C; 5-HT6; 5-HT7; α 1A-adrenergic receptor; α 2A-adrenergic receptor; D1; D2; D3; H1 receptor; norepinephrine transporter (NET)	FDA Approved
T0031	Ziprasidone hydrochloride monohydrate	5-HT transporter; 5-HT1A; 5-HT1B; 5-HT1D; 5-HT2A; 5-HT2C; 5-HT6; 5-HT7; α 1A-adrenergic receptor; α 2A-adrenergic receptor; D1; D2; D3; H1 receptor; norepinephrine transporter (NET)	FDA Approved
T0007	Atenolol	β 1-adrenergic receptor; β 2-adrenergic receptor	FDA Approved

ATP Citrate Lyase

ID	Product Name	Target	Condition
T7424	NDI-091143	ACLY	
T3625	ETC1002	ACL	FDA Approved
T11589	Hydroxycitric acid tripotassium hydrate	ATP citrate lyase; HIF	

BACE

ID	Product Name	Target	Condition
T8179	Aloeresin D	BACE1	
T7011	Verubecestat	BACE1; BACE2	Phase 3
T6772	AZD3839	BACE	Phase 1
T6058	LY2886721	BACE	Phase 1/2

ID	Product Name	Target	Condition
T552361	Epiberberine	ERK1/2; MEK1; AChE; BChE; BACE1	
T4398	LX2343	BACE1; PI3K	
T4115	Auraptene	BACE1	
T3394	Timosaponin BII	BACE1; Aβ; β-CTF	
T2759	Loganin	NF-κB; AChE; BChE; BACE1	Approved
T2639	LY2811376	BACE1; Aβ	Phase 1

Beta Amyloid

ID	Product Name	Target	Condition
TP1856	Colivelin	STAT3; Amyloid-β	
TP1786L	Amyloid β-Protein 10-20 acetate(152286-31-2 free base)	Amyloid-β	
TMS1461	Otophyllolide B	Beta Amyloid	
T8012	Scyllo-Inositol	amyloid-β	Phase 2
T7905	PBD-150	glutaminy cyclase (hQC) Y115E-Y117E	
T7680	GSNKGAIIGLM(131602-53-4(free base))	amyloid-β	
T7562	β-Amyloid 31-35(TFA)	amyloid-β	
T7527	Frentizole	amyloid-β	
T7490	ARN2966	amyloid-β	
T6495	EUK 134	Aβ	Preclinical
T6274	RO4929097	Aβ40; γ secretase; Notch	Phase 2
T6202	DAPT	γ secretase(Aβ); Aβ	Preclinical
T5810	TABERSONINE HYDROCHLORIDE	Aβ	
T4422	Edonergic maleate	amyloid-β peptides	Phase 2
T4077	PE859	Aβ; tau; Aβ	
T3394	Timosaponin BII	BACE1; Aβ; β-CTF	
T2872	Ginsenoside Re	Amyloid-β; JNK; NF-κB	Phase 1
T2777	Ginsenoside Rg1	Amyloid-β; NF-κB	
T2639	LY2811376	BACE1; Aβ	Phase 1
T2625	MK0752	Aβ	Phase 1
T2262	CHF5074	Beta Amyloid; γ secretase	Phase 2
T2212	Geniposide	Amyloid-β	Approved
T19892	BSBM7	Aβ	
T19011L	Hoechst 34580 xHCl(23555-00-2(free base))	Amyloid-β	
T14284	Amyloid beta-peptide(25-35)	Amyloid-β	
T0883	Homotaurine	Aβ; GABA	Phase 3

Beta-secretase

ID	Product Name	Target	Condition
T3285	Eslicarbazepine Acetate	Beta-secretase; Sodium Channel	FDA Approved
T3161	BACE-IN-1	Beta-secretase	

CaMK

ID	Product Name	Target	Condition
TP2310	Autocamtide-2-related inhibitory peptide	CaMKII	
TP1403L	Syntide 2 acetate(108334-68-5 free base)	CaMKII	
TP1217L	Autocamtide 2 TFA(129198-88-5 free base)	CaMKII	
TP1216	CaM kinase II inhibitor TFA salt	CaMKII	
T8543	KN-92 hydrochloride	CaMKII	
T6605	NH125	CaMKII; eEF-2 kinase; PKA; PKC	
T4530	KN-92 phosphate	CaMK	
T3S0807	Berbamine	CAMKII γ	Approved
T3777	Praeruptorin A	CAM	
T3650	STO-609 acetate	CaM-KK α ; CaM-KK β	
T3546	STO609	CaM-KK α ; CaM-KK β	
T2946	Tanshinone IIA sulfonate sodium	CaMK; CYP3A4	Approved
T2697	KN93	CaMK	
T2694	KN62	CaMK V ; CaMKII	
T2606	KN-93 Phosphate	CaMKII	
T2159	CaMKP Inhibitor	CaMKP	
T20792	W-7 HCl	calmodulin; apoptosis	
T16791	Rottlerin	PKC δ ; PKC α ; PKC γ ; PKC β ; PKC η ; PKC ζ ; PKC ϵ ; CKII; PKA; CaM kinase III; Apoptosis; Autophagy	
T1659	Melatonin	CAM; ER; melatonin receptor; MPO; ROR β	Approved
T1158	Phenoxybenzamine hydrochloride	α -adrenergic receptor; CAM	FDA Approved
T1146	Nifedipine	Calcium Channel; CAM; Potassium Channel	FDA Approved
T1090	Perphenazine	CAM; Dopamine; 5-HT _{2A} receptor; Histamine H1 receptor; Alpha-1A adrenergic receptor	FDA Approved
T0445	Promethazine	5-HT; mAChR; Adrenergic Receptor; CAM; D2; H1 receptor	FDA Approved
T0364	Dibucaine	AChR; CAM; Sodium Channel	FDA Approved

COX

ID	Product Name	Target	Condition
TQ0180	Chebularic acid	COX; LOX	
TN2139	Regaloside B	iNOS; COX-2	
TN1723	Hamaudol	COX-1; COX-2	
TN1377	alpha-Spinasterol	COX-1; COX-2; TRPV1	
TN1273	4',7-Dihydroxyflavone	COX; NOD1	
TN1100	Nepodin	COX; AMPK; GLUT	
TN1040	Skullcapflavone II	TGFβ; COX	
T8505	Sc 236	COX-2	
T8356	FPL 62064	COX; 5-LOX	
T8236	RHC 80267	COX; phosphatidylcholine; DAGL	
T7838	Losartan Carboxaldehyde	COX-2	
T7670	Mavacoxib	COX-2	
T7662	6-methoxy Naphthalene Acetic Acid	COX	
T7596	Firocoxib	COX-2	
T7207	FK 3311	COX-2	
T7113	6-paradol	COX-2	
T7081	CCCP	TBK1; IFN-β	
T6S1652	Benzoylpaeoniflorin	COX-1; COX-2	
T6S0722	Isorientin	Antioxidant; COX-2	
T6S0077	Byakangelicol	COX-2	
T6970	RK33	DDX3	
T6893	MK886	COX-1; COX-2	Preclinical
T6737	Zaltoprofen	COX-1; COX-2	Approved
T6687	Suprofen	COX-1; COX-2	FDA Approved
T6574	Lumiracoxib	COX-1; COX-2	Approved
T6540	Ibuprofen Lysine	COX	FDA Approved
T6465	Dexamethasone Sodium Phosphate	COX-2; IL receptor	FDA Approved
T6424	Bromfenac Sodium	COX1 , COX-2	FDA Approved
T6387	Ampiroxicam	COX	Approved
T5807	Stylopine hydrochloride	Inos; COX-2	
T5759	marmesin	5-Lipoxygenase; COX-2	
T5758	sphondin	COX-2; PGE2	
T5727	CAFESTOL	ERK; COX-2; NF-κB	
T5688	Micheliolide	Inos; COX-2	
T5681	ETHYL CAFFEATE	iNOS, COX-2; PGE2	
T5460	Mofezolac	COX	Approved
T5430	8-SHOAOL	COX-2	
T5032	Iguratimod	COX-2; MIF	Approved

ID	Product Name	Target	Condition
T5010	Propyphenazone (4-Isopropylantipyrine)	COX-2	Approved
T4S2126	Ginkgetin	STAT3; COX-2	
T4A2456	Gamabufotalin	COX-2	
T4643	TFAP	COX-1	
T4503	Talinflumate	hCLCA1/mCLCA3; COX; Cl-/HCO3- exchanger; GCNT3	Approved
T4313	Tinoridine hydrochloride	COX	Approved
T4101	SC560	COX-1; COX-2	
T4092	AG 126	COX-2; ERK1,2	
T3S1553	Cinnamic aldehyde	COX-2	
T3981	Acacetin	COX-2; XIAP	
T3954	Adelmidrol	COX; NF-κB; PPAR	Phase 2
T3884	Neoandrographolide	COX-2; iNOS	
T3883	Roburic acid	COX-1; COX-2	
T3868	Agnuside	COX-2; P-gp (P-glycoprotein)	
T3747	syringaldehyde	COX-2	
T3744	Veratric acid	COX	
T3500	Flurbiprofen Axetil	COX-1; COX-2	FDA Approved
T3417	Amentoflavone	COX; COX-2; κ-opioid receptor; CYP2C9; CYP3A4; PLA2	
T3342	Xanthohumol	COX	Phase 1
T3332	Isosteviol	COX-2; IL-6; NF-κB; Potassium Channel; TNF-α	Phase 2
T3214	NS398	COX-2	Preclinical
T2S0618	β-Elementic Acid	COX-2; Apoptosis inducer	
T2972	Rutaecarpine	COX-2	
T2878	Ginsenoside Rd	Calcium Channel; COX; P450; NF-κB	
T2856	Epicatechin	COX	Phase 2
T2826	Asarylaldehyde	COX-2	
T2778	(+)-Catechin Hydrate	Antioxidant; COX-1	
T2732	(-)-Epicatechin gallate	COX	Phase 2
T2553	Etofenamate	COX	Approved
T2550	Tolmetin	COX-1; COX-2	FDA Approved
T2403	Bromfenac sodium	COX-2	FDA Approved
T23333	SC 58125	COX-2	
T2230	Paeoniflorin	COX	Phase 3
T2225	4-Hydroxyantipyrine	COX-1; COX-2	Approved
T1867	ATB 346	COX-2	Phase 2
T1780	Parecoxib	COX-2	Approved
T1720	Amfenac Sodium Monohydrate	COX-1; COX-2	Approved
T1586	Tenoxicam	COX	Approved
T1582L	Naproxen sodium	COX-1; COX-2	FDA Approved

ID	Product Name	Target	Condition
T1582	Naproxen	COX	FDA Approved
T1574	Etoricoxib	COX	Approved
T15645	Pamcicogrel	COX	
T1558	Resveratrol	COX-1; COX-2; DNA polymerase α ; IKK β ; LOX; Quinone reductase 2; SIRT1; SIRT2	Approved
T1555	Diclofenac sodium	COX-1; COX-2	FDA Approved
T1544	Olsalazine disodium	COX; IF γ	FDA Approved
T1541	Drospirenone	Androgen Receptor; COX-2; PR; Mineralocorticoid Receptor	FDA Approved
T1468	Lornoxicam	COX-1; COX-2	Approved
T1467	Acemetacin	COX	Approved
T1432	Phenylbutazone	COX	FDA Approved
T1427	Fosfosal	COX	Approved
T1423	Hydroxytoluic acid	COX	
T1421	Aceclofenac	COX	Approved
T1420	Diethylcarbamazine citrate	COX-1; ALOX5	FDA Approved
T1402	Fenofibric acid	MMP; PPAR α ; COX-2	FDA Approved
T1401	Meclofenoxate hydrochloride	COX; ALOX5	Approved
T1394	Ibuprofen	COX-1; COX-2	FDA Approved
T1376	2-Amino-5-methyl-3-thiophenecarbonitrile	COX	
T1325	Carprofen	COX-2	FDA Approved
T1301	Guaiacol	COX; NF- κ B	Approved
T1296	Aminopar	COX-2; ALOX5; MPO; NF- κ B	FDA Approved
T1280	Nepafenac	COX-1; COX-2	FDA Approved
T1258	Nabumetone	COX-1; COX-2; MPO	FDA Approved
T1212	Ketorolac tromethamine salt	COX-1; COX-2	FDA Approved
T1209	Flunixin meglumin	COX-1; COX-2	Approved
T1191L	Dipyron	COX-1	Approved
T1191	Analgin	COX-1	Approved
T1185	Rofecoxib	COX-2	FDA Approved
T1133	Nimesulide	COX-2	Approved
T11005	Desmethyl Celecoxib	COX-2	
T1002	Etodolac	COX; RXR-alpha	FDA Approved
T0980	Nifenazone	COX	Approved
T0961	Trometamol	COX	FDA Approved
T0907	Sulfasalazine	COX-1; COX-2; NF- κ B	FDA Approved
T0890	Mefenamic acid	COX-1; COX-2	FDA Approved
T0888	4-Biphenylacetic acid	COX	Approved
T0867	Bufexamac	IFN- α	Approved

ID	Product Name	Target	Condition
T0858	Flufenamic acid	COX	Approved
T0855	(R)-Naproxen	COX	FDA Approved
T0839L	(S)-(+)-Ketoprofen	COX-1; COX-2	FDA Approved
T0839	Ketoprofen	COX-1; COX-2; MRAP4	FDA Approved
T0826	Meloxicam	COX	FDA Approved
T0825	Ebselen	COX	Phase 2
T0824	Nonoxynol	COX	FDA Approved
T0822	Cianidanol	COX-1; COX-2	Approved
T0798	Triamcinolone	COX; Glucocorticoid Receptor	FDA Approved
T0784	Tolfenamic Acid	COX-2	Approved
T0778	Phenacetin	COX-1	Approved
T0758	Piroxicam	COX	FDA Approved
T0734	Antipyrine	COX	Approved
T0726	Benzydamine hydrochloride	COX	Approved
T0708	Oxaprozin	COX	FDA Approved
T0693	Niflumic acid	COX; Monocarboxylate transporter; Chloride channel protein ClC-Ka; PLA2; UGT	Approved
T0649	Salicylic acid	COX	Approved
T0646	Mesalamine	COX; ALOX5; MPO; NF-κB; PPARγ	FDA Approved
T0498	Sasapyrine	COX-1; COX-2	Approved
T0484	Deracoxib	COX-2	FDA Approved
T0477	Zileuton	COX-1; 5-Lipoxygenase	FDA Approved
T0466	Celecoxib	COX-2	FDA Approved
T0463	Loxoprofen	COX	Approved
T0459	Sulindac	COX	FDA Approved
T0458	Indometacin	COX-1; COX-1; COX-2; PDE2; PLA2	FDA Approved
T0456	Cinchophen	COX	Approved
T0451	Minoxidil	COX-1; Potassium Channel	FDA Approved
T0448	Dexibuprofen	Bcl-2; COX; Cystic fibrosis transmembrane conductance regulator; PPARγ; thrombomodulin	Approved
T0443	Salicoside	COX	Approved
T0441	Pasiniazid	COX; NADPH	Approved
T0436	Aceexamid Acid	Amino Acids and Derivatives; COX	Approved
T0435	Sulfipyrazone	COX; cMOAT	FDA Approved
T0432	Diclofenac diethylamine	COX; huMan COX-2(in CHO cells); human COX-1(in CHO cells); ovine COX-2; ovine COX-1	FDA Approved
T0424	Bismuth subsalicylat	COX-1; COX-2	FDA Approved
T0335	Sodium salicylate	COX-1; COX-3; NF-κB	Approved
T0321	Indoprofen	COX	
T0291	Flurbiprofen	COX; MRP	FDA Approved
T0285	Isoxicam	COX	

ID	Product Name	Target	Condition
T0260	Meclofenamate Sodium	COX-1; COX-2	FDA Approved
T0219	Valdecoxib	COX-2	FDA Approved
T0212	Seratrodoast	COX; TXA2R	Approved
T0196	Diclofenac	COX	FDA Approved
T0184	Fenoprofen calcium dihydrate	COX-1; COX-2	FDA Approved
T0065	Acetaminophen	COX-1; COX-2	FDA Approved
T0058	2-Ethoxybenzamide	COX	Approved
T0057	Famprofazone	COX-1; COX-2	Approved
T0055	Glafenine	COX	Approved
T0050	4-Aminoantipyrene	COX	Approved
T0005	Aspirin	COX-1; COX-2	FDA Approved
T0004	Salicylamide	COX-1; COX-2	Approved

Dopamine Receptor

ID	Product Name	Target	Condition
TP1085+ E9290:H9421L	Neuromedin N acetate(92169-45-4 free base)	D2	
TN2252	Syrosingopine	dopamine	
T8702	SKF-83566	D1; D5; 5-HT2	
T8633	9-FLUORENOL	dopamine reuptake	
T8423	ML417	D3	
T8389	Trifluoperazine	D2	FDA Approved
T8385	Metoclopramide hydrochloride hydrate	D2	FDA Approved
T8382	Cariprazine HCl	D2; D3	FDA Approved
T7943	Fluphenazine decanoate	D2	FDA Approved
T7834	ABT-724	D4	
T7728	ACEPROMAZINE MALEATE	Dopamine	
T7654	L-DOPA methyl ester (hydrochloride)	D1	
T7635	Raclopride	Dopamine	
T7632	Verapride	D2	
T7583	solriamfetol	norepinephrine transporter (NET); dopamine transporter	FDA Approved
T7569	Clebopride malate	Dopamine	Approved
T7553	(+)-PD 128907 hydrochloride	Dopamine	
T7352	Pridopidine	Dopamine	Phase 3
T7308	Nomifensine	dopamine reuptake	
T7180	Sultopride hydrochloride	Dopamine	
T7153	Vanoxerine dihydrochloride	dopamine uptake	Phase 3

ID	Product Name	Target	Condition
T7070	Nomifensine (maleate)	dopamine uptake	
T6988	SKF38393 HCl	D1; D5 receptor	Preclinical
T6951	Pramipexole 2HCl Monohydrate	D2S; D2L; D3; D4	FDA Approved
T6835	Fenoldopam mesylate	dopamine-1 receptor	FDA Approved
T6648	Rotundine	D1 receptor, 5-HT1A, D2 receptor, D3 receptor	Approved
T6647	Rotigotine	D2; D3	FDA Approved
T6241	Quetiapine Fumarate	HT; Adrenergic Receptor; Dopamine	FDA Approved
T5954	Alpha-Methyl dopa Sesquihydrate	DOPA decarboxylase	
T5858	Sertindole	D2; 5-HT	Approved
T5842	Bromocriptine mesylate	D2	FDA Approved
T5397	A-381393	D4	
T5387	LP-211	5-HT7; D2 receptor; 5-HT1A receptor	
T5380	Ansofaxine hydrochloride	serotonin reuptake; dopamine reuptake; norepinephrine reuptake	
T5158	N-Desmethylclozapine	5-HT2C; D4; δ -opioid receptor	Phase 2
T5135	Fupentixol Dihydrochloride	D1, D2	Approved
T5047	PD-168077 maleate	D4	
T5009	Trimethobenzamide hydrochloride	D2	FDA Approved
T4616	5-Chloro-2-methoxyprocainamide	dopamine D2	FDA Approved
T4577	Cariprazine	D3; D2; 5-HT1A	FDA Approved
T4576	Perospirone	5-HT2A; D2; 5-HT1A	Approved
T4369	SCH 23390 hydrochloride	D1; D5	
T4297	Flibanserin	5-HT1A; 5-HT2A; D4 receptor	FDA Approved
T4274	Melitracen hydrochloride	D1; D2	Approved
T4262	BisfluoroModafinil	dopaminergic	
T4117	Zuclopentixol	D1; D2	Approved
T4081	MPTP-hydrochloride	Dopamine	
T3526	Dasotraline hydrochloride	5-HT; Dopamine; Norepinephrine (NE)	Phase 3
T3497	Ocaperidona	D2; 5-HT2	Phase 2
T3431	Pardopruxox hydrochloride	5-HT1A; D2; D3	Phase 3
T3369	Nuciferine	5-HT2A; 5-HT2B; 5-HT2C; 5-HT7; D5 receptor	
T3278	Piribedil	α 2-adrenergic; D2; D3	Approved
T3187	Fluorocleopride	D2	
T3085	Piperacetazine	5-HT; Dopamine	FDA Approved
T3046	BMY 7378 dihydrochloride	5-HT1A; 5-HT1C; α 1D-adrenoceptor; α 2C-adrenoceptor; D2	Preclinical
T2874	Tetrahydroberberine THB	5-HT; Dopamine	
T2714	Rotundine	5-HT1A; D1; D2; D3	
T2592	Ropinirole hydrochloride	D2	FDA Approved

ID	Product Name	Target	Condition
T2574	Alizapride hydrochloride	Dopamine	Approved
T2564	Flupenthixol dihydrochloride	Dopamine	Approved
T2546	Pimozide	D2; Potassium Channel; α 1-adrenoceptor	FDA Approved
T2306	Brexpirazole	5-HT1A; 5-HT2A; α 1B-adrenergic receptor; α 2C receptors; D2L	FDA Approved
T22292	Chlorpromazine	Dopamine	FDA Approved
T2226	Pergolide mesylate salt	5-HT receptor; Adrenergic receptor; Dopamine receptor	FDA Approved
T2190	Methiothepin mesylate	5-HT; Dopamine	
T21337	Lurasidone	5-HT7; 5-HT1A; D2	FDA Approved
T2132	Bupirone hydrochloride	5-HT; Dopamine	FDA Approved
T2092	Amitifadine hydrochloride	5-HT; Dopamine; Norepinephrine (NE)	Phase 2/3
T1871	GBR12935	Dopamine	
T1735	Lurasidone hydrochloride	5-HT1A; 5-HT2A; 5-HT7; D2; Norepinephrine α 2C	FDA Approved
T1644	Dopamine hydrochloride	5-HT; DA transporter; Dopamine	FDA Approved
T16392	ONC206	Dopamine	
T1567	Olanzapine	5-HT; HT; mAChR; Adrenergic Receptor; Dopamine	FDA Approved
T1540	Doxepin hydrochloride	5-HT; HT; Sert (Sodium-dependent); mAChR; Adrenergic Receptor; Dopamine; Noradrenaline transporter (Sodium-dependent)	FDA Approved
T1539	lloperidone	α -adrenergic receptor; Dopamine	FDA Approved
T1517	Benserazide hydrochloride	DOPA decarboxylase; Dopamine	Approved
T1476	Pramipexole	D2L; D2L; D3; D4	FDA Approved
T1471	Duloxetine hydrochloride	Sert (Sodium-dependent); DA transporter; Noradrenaline transporter (Sodium-dependent)	FDA Approved
T1412	Loxapine succinate salt	5-HT2 (bovine); 5-HT2 (bovine); 5-HT2 (human); D2; D4	FDA Approved
T1406	Amantadine hydrochloride	Dopamine	FDA Approved
T1384	Chlorpromazine hydrochloride	5-HT2A; D2	FDA Approved
T1336	Benzotropine mesylate	DAT	FDA Approved
T1327	Nortriptyline hydrochloride	5-HT; Sert (Sodium-dependent); mAChR; Adrenergic Receptor; Dopamine; H1 receptor; Noradrenaline transporter (Sodium-dependent)	FDA Approved
T1322	Bendazol	Dopamine	FDA Approved
T1292	Tiapride hydrochloride	D2; D3	Approved
T12352L	Oxidopamine hydrobromide	neurotransmitter dopamine; Autophagy	
T12352	Oxidopamine hydrochloride	dopamine	
T1233	Oxolinic acid	bacterial DNA gyrase; DNA synthesis; dopamine uptake	Approved
T1222	Trifluoperazine dihydrochloride	D2	FDA Approved
T1211	Levosulpiride	Dopamine	Approved
T1201	Sulpiride	Dopamine	Approved
T1180	Blonanserin	5-HT2; D2	Approved

ID	Product Name	Target	Condition
T1175	Bromopride	Dopamine	Approved
T1105	Penfluridol	Dopamine	Approved
T1090	Perphenazine	CAM; Dopamine; 5-HT _{2A} receptor; Histamine H1 receptor; Alpha-1A adrenergic receptor	FDA Approved
T1069	Metoclopramide hydrochloride	5-HT; mAChR; Dopamine	FDA Approved
T1045	Trimipramine maleate	5-HT; Sert (Sodium-dependent); Adrenergic Receptor; DA transporter; Dopamine; H1 receptor; Noradrenaline transporter (Sodium-dependent)	FDA Approved
T0990	Droperidol	D2	FDA Approved
T0869	Atomoxetine hydrochloride	5-HT; DA transporter; Norepinephrine (NE) transporter	FDA Approved
T0848	Levodopa	Dopamine	FDA Approved
T0811	Amisulpride	5-HT; Dopamine	FDA Approved
T0785	Dexchlorpheniramine Maleate	Sert (Sodium-dependent); DA transporter; H1 receptor; Noradrenaline transporter (Sodium-dependent)	FDA Approved
T0783	Mianserin hydrochloride	5-HT; HT; Sert (Sodium-dependent); Adrenergic Receptor; DA transporter; Dopamine; Noradrenaline transporter (Sodium-dependent) κ -opioid receptor	Approved
T0776	Phenothiazine	Dopamine	FDA Approved
T0766	Promazine hydrochloride	5-HT; mAChR; Adrenergic Receptor; Dopamine	FDA Approved
T0719	Tetrabenazine	D2; Synaptic vesicular amine transporter	FDA Approved
T0716	Molindone hydrochloride	5-HT; mAChR; Dopamine	FDA Approved
T0505	L-(-)- α -Methyldopa	DOPA decarboxylase	FDA Approved
T0469	Octopamine hydrochloride	Dopamine	Approved
T0455	Clozapine	M1 mAChR; α 2-adrenoceptor; D2	FDA Approved
T0445	Promethazine	5-HT; mAChR; Adrenergic Receptor; CAM; D2; H1 receptor	FDA Approved
T0385	Prochlorperazine Maleate	D2	FDA Approved
T0365	Thioridazine hydrochloride	5-HT; Adrenergic Receptor; Dopamine; Potassium Channel	FDA Approved
T0351	Risperidal	5-HT _{2A} ; α 2C-adrenergic receptor; D2; D2L; D3	FDA Approved
T0333	Aniracetam	5-HT; Dopamine; AMPA; GluR	Approved
T0322	Fipexide	Dopamine	Approved
T0302	Triflupromazine hydrochloride	5-HT; mAChR; Dopamine	FDA Approved
T0287	Hexamethonium Bromide	mAChR; Dopamine	Approved
T0280	Siperone	Dopamine	Approved
T0255	Clomipramine hydrochloride	5-HT; Sert (Sodium-dependent); GSP; Noradrenaline transporter (Sodium-dependent); dopamine transporter (DAT)	FDA Approved
T0137	Mirtazapine	5-HT; HT; Sert (Sodium-dependent); Adrenergic Receptor; DA transporter; Dopamine; κ -opioid receptor	FDA Approved
T0136	Citicoline	Dopamine	Approved
T0082	Domperidone	D2; D3	Approved
T0076	Paliperidone	5-HT; β -adrenergic receptor; Dopamine; H1 receptor	FDA Approved

ID	Product Name	Target	Condition
T0074L	Chlorprothixene hydrochloride	5-HT; mAChR; Dopamine; H1 receptor	FDA Approved
T0074	Chlorprothixene	5-HT6; 5-HT7; D2; D3; H1 receptor	FDA Approved
T0068	Fluphenazine hydrochloride	Dopamine	FDA Approved
T0031L2	Ziprasidone	5-HT transporter; 5-HT1A; 5-HT1B; 5-HT1D; 5-HT2A; 5-HT2C; 5-HT6; 5-HT7; α1A-adrenergic receptor; α2A-adrenergic receptor; D1; D2; D3; H1 receptor; norepinephrine transporter (NET)	FDA Approved
T0031L	Ziprasidone hydrochloride	5-HT transporter; 5-HT1A; 5-HT1B; 5-HT1D; 5-HT2A; 5-HT2C; 5-HT6; 5-HT7; α1A-adrenergic receptor; α2A-adrenergic receptor; D1; D2; D3; H1 receptor; norepinephrine transporter (NET)	FDA Approved
T0031	Ziprasidone hydrochloride monohydrate	5-HT transporter; 5-HT1A; 5-HT1B; 5-HT1D; 5-HT2A; 5-HT2C; 5-HT6; 5-HT7; α1A-adrenergic receptor; α2A-adrenergic receptor; D1; D2; D3; H1 receptor; norepinephrine transporter (NET)	FDA Approved
T0025	Haloperidol	5-HT; Dopamine	FDA Approved

FAAH

ID	Product Name	Target	Condition
T8646	URB937	FAAH	
T7688	4-Nonylphenylboronic acid	FAAH	
T6714	URB597	FAAH	Phase 1
T6043	PF3845	FAAH	
T4323	PF04457845	hFAAH; rFAAH	Phase 2
T3354	BIA10-2474	FAAH	Phase 1
T3215	JNJ42165279	hFAAH; rFAAH	Phase 2
T2859	Biochanin A	EGFR; FAAH (human); FAAH (mouse); FAAH (rat)	
T2684	JNJ1661010	FAAH (human); FAAH (rat)	Preclinical
T2338	JZL195	FAAH; MAGL	
T15268	FAAH-IN-2	FAAH	

GABA Receptor

ID	Product Name	Target	Condition
TN2268	Tetrahydromagnolol	Cannabinoid Receptor; GPR; GABA	
TMS0418	Dihydroergotoxine mesylate	GABAR	FDA Approved
T9113	Myristicin	Antifection; Bcl-2; Caspase; CYP17; GABA Receptor; IL Receptor; NO; PARP	
T8887	2' MeO6MF	GABAA	
T8664	SSD114 hydrochloride	GABA	
T8639	Phenibut (hydrochloride)	GABAB	

ID	Product Name	Target	Condition
T8630	Baclofen hydrochloride	GABA	FDA Approved
T8572	CL 218872	GABAA	
T8568	Suritozole	GABAA	
T8193	Thujone	GABAA; AChR	
T8162	Cannabidiavin	GABAA	Phase 2
T8040	Cholesterol myristate	nicotinic acetylcholine receptor; GABAA receptor; inward-rectifier potassium ion channel	
T8036	6-Methylflavone	$\alpha 1\beta 2\gamma 2$ L GABAA receptor; $\alpha 1\beta 2$ GABAA receptor	
T7803	Gaboxadol (hydrochloride)	GABA	
T7794	Zuranolone	GABAA	Phase 3
T7793	6-(4-Methoxyphenyl)-3-pyridazinamine	GABAA	
T7721	Ganaxolone	GABAA	Phase 2
T7699	AZD-7325	GABA	Phase 2
T7622	Gabazine	GABAA	
T7595	L-DAB HBR	GABA; Human Endogenous Metabolite	
T7557	Guvacine hydrochloride	GABA	
T7165	Basmisanil	GABAA $\alpha 5$	Phase 2
T7136	AZD6280	GABAA	Phase 1
T7064	Valproic Acid	GABA; Sodium Channel; HDACs; HDAC1	FDA Approved
T7000	Tiagabine hydrochloride	GABA uptake	FDA Approved
T6507	Gabapentin HCl	GABAR; $\alpha 2\delta$ subunit of calcium channel	FDA Approved
T6355	(R)-baclofen	GABAR	FDA Approved
T5880	Aminoxyacetic acid hemihydrochloride	GABA; MAS	
T5734	(+)-BORNEOL	GABA	
T5375	Loreclezole	GABAA	
T5330	Fluralaner	GABA	
T4993	Afloqualone	GABAR	FDA Approved
T4688	Pipecqualine hydrochloride	GABAA	
T4682	Allopregnanolone	GABA	FDA Approved
T4522	SSD114 hydrochloride	GABAB	
T4440	Saclofen	GABAB	
T4363	CGP 52432	GABAB	
T4176	rac-BHFF	GABAB	
T3S2259	Methyl eugenol	GABAA	
T3S2100	Securinine	GABAA	
T3927	Phellopterin	GABA	
T3741	(-)-borneol	GABA	
T3644	U93631	GABA	
T3403	Glabridin	T1 tyrosinase; T3 tyrosinase; $\alpha 1\beta 2\gamma 2$ (GABAA receptor); $\alpha 1\beta 3\gamma 2$ (GABAA receptor); $\alpha 1\beta 2$ (GABAA receptor); $\alpha 1\beta 1\gamma 2$ (GABAA receptor)	

ID	Product Name	Target	Condition
T3318	Wogonoside	GABA	
T2998	Dihydromyricetin	GABAR; mTOR	Phase 2
T2990	Phenibut	GABAR	
T2983	3,4,5-Trimethoxycinnamic acid	GABAR	
T2940	6-Hydroxyflavone	GABAR	
T2850	(+)-Bicuculline	GABAR	Approved
T2775	Baicalin	GABAR	Approved
T2749	Ginkgolide A	GABAR	
T2339	Apalutamide	Androgen Receptor; GABAR	FDA Approved
T2196	Fipronil	GABA; GluCl channels	Approved
T2067	NS 11394	GABAA	
T19624	Fasoracetam	GABA	
T1860	AWD 131-138	GABAR	Phase 1
T1673	Acamprosate calcium	GABAR	FDA Approved
T1602	Valproic acid sodium salt	GABAR; HDAC2; HDAC9	FDA Approved
T15212	Emamectin Benzoate	GABA Receptor	
T1413	Pentetrazol	GABAR	Phase 2
T1396	Bemegrid	GABAR	Approved
T13690	Etifoxine hydrochloride	GABA	
T1300	Propofol	GABAR; Sodium Channel	FDA Approved
T1240	Flumazenil	GABAR	FDA Approved
T11822	LAU159	$\alpha 1\beta 3$ GABA	
T11349	GABAA receptor agent 1	GABAA	
T11307	Fluxametamide	GABA	
T1128	Oxiracetam	GABAR	Approved
T11277	FG 7142	GABAA receptor	
T1089	Etomidate	GABAR	FDA Approved
T1065	Baclofen	GABAR	FDA Approved
T0958	Penicillin G sodium salt	PBPs; GABAR	FDA Approved
T0954	Anestan	Glycine receptor; GABAR; NMDA receptor; Potassium Channel	FDA Approved
T0883	Homotaurine	A β ; GABA	Phase 3
T0710	L-Cycloserine	GABA	FDA Approved
T0702	Gabapentin	GABAR; calcium channel	FDA Approved
T0675	Topiramate	Carbonic anhydrase; GABAR; mGluR5	FDA Approved
T0627	beta-Alanine	GABAR	
T0508	4-Aminobutyric acid	GABA	Approved
T0349	Riluzole	NMDA receptor; Sodium Channel; GABA	FDA Approved
T0169	Nefiracetam	GABAR	Phase 2
T0128	Vigabatrin	ABAT; GABA	FDA Approved

ID	Product Name	Target	Condition
T0051	Urethane	α 4 β 2 nAChR; glycine receptors; GABAR; AMPA; NMDA receptor	Approved
T0048	Nikethamide	GABAR	Approved
T0024	Primidone	nAChR; GABAR; GluR2; Sodium Channel	FDA Approved

Gamma-secretase

ID	Product Name	Target	Condition
TP1540	Jagged-1 188-204	Notch	
T6870	L-685,458	γ secretase	
T6861	IMR1	Notch	
T6274	RO4929097	$A\beta$ 40; γ secretase; Notch	Phase 2
T6249	Avagacestat	γ secretase($A\beta$ 42) , γ secretase($A\beta$ 40)	Phase 1
T6202	DAPT	γ secretase($A\beta$); $A\beta$	Preclinical
T6135	Dibenzazepine	γ secretase (APPL); γ secretase(Notch)	
T6125	Semagacestat	Notch; γ secretase($A\beta$ 38); γ secretase($A\beta$ 40); γ secretase($A\beta$ 42)	Phase 3
T6063	LY411575	Notch S3 cleavage; γ secretase (cell-based); γ secretase (membrane-based)	
T4364	Aftin4	γ secretase($A\beta$ 42)	
T4077	PE859	$A\beta$; tau; $A\beta$	
T3633	Crenigacestat	Notch-1	Phase 1/2
T3540	IMR-1A	Notch	
T3075	FLI06	Notch	
T2842	Tangeretin	Notch-1	Preclinical
T2639	LY2811376	BACE1; $A\beta$	Phase 1
T2625	MK0752	$A\beta$	Phase 1
T2262	CHF5074	Beta Amyloid; γ secretase	Phase 2
T15184	E 2012	γ secretase	
T12246	CB-103	notch	Phase 2

GluR

ID	Product Name	Target	Condition
TQ0094	JNJ-40411813	mGluR2	Phase 2
T8862	ML 254	mGluR5	
T8779	HBT1	AMPA	
T8626	4-oxo-1,4-dihydroquinoline-2-carboxylic acid	GluR; NMDA receptor	
T8457	NPS2390	mGluR	
T8435	YM90K hydrochloride	AMPA	

ID	Product Name	Target	Condition
T8434	SIB-1757	mGluR5	
T7823	IDRA-21	AMPA	
T7706	LY404187	AMPA	
T7579	1-BCP	AMPA	
T7515	MTEP hydrochloride	mGluR	
T7494	TCN 238	mGluR	
T7304	DNQX	AMPA	
T7292	FITM	mGluR1	
T7178	CNQX	AMPA	
T6871	L-Glutamic acid monosodium salt	mGluR1	FDA Approved
T6727	VU 0364770	mGluR4	
T6726	VU 0361737	mGluR4 (Human); mGluR4 (Rat)	
T6725	VU 0357121	mGluR5	
T6598	MPEP	mGluR5	Preclinical
T6468	D-glutamine	GluR	
T6457	CTEP	mGluR5	
T6160	VU 0364439	mGluR4	
T6022	LY404039	Recombinant human mGlu2; Recombinant human mGlu3; Rat neurons expressing native mGlu2/3	
T5884	Chelidamic acid	Glutamate Transporters	
T5509	FPTQ	mGluR1	
T5083	L-Cysteic acid monohydrate	mGluR	
T4573	Cyclothiazide	AMPA	FDA Approved
T4500	ADX88178	human mGluR4	Preclinical
T4113	NBQX disodium salt	AMPA	Preclinical
T3957	Farampator	AMPA	Phase 2
T3565	UV0155041	mGluR4	
T3539	Lu AF21934	mGluR4	
T3486	3-MATIDA	mGluR1; NMDA	
T3484	(±)-trans-ACPD	mGluR5	
T3483	FTIDC	mGluR1	
T3482	CFMTI	mGluR	
T3479	(RS)-MCPG	mGluR	
T3478	Ro 67-7476	mGluR1	
T3477	E4CPG	mGluR	
T3473	ATPO	AMPA	
T3464	PHCCC	mGluR1	
T3451	JNJ42153605	mGluR2 PAM	
T3379	Decanoic Acid	AMPA	
T3010	Xanthurenic Acid	GluR	

ID	Product Name	Target	Condition
T2811	Harmine hydrochloride	GluR1; DYRK1A; DYRK1B; DYRK2	
T2497	MPEP hydrochloride	mGluR	Preclinical
T23515	VU 29	mGluR	
T22641	CDPPB	mGluR5	
T2194	Chicago Sky Blue 6B	Glutamate Transporters	
T2053	ADX 47273	mGluR5	Preclinical
T1884	Ampalex	AMPA	Phase 2
T1443	Memantine hydrochloride	AMPA; NMDA receptor; Kainate receptor; CYP2B6; CYP2D6	FDA Approved
T12717	Basimglurant	mGlu5	Phase 1
T10432L	AZD-8529 mesylate	mGluR2	
T0675	Topiramate	Carbonic anhydrase; GABAR; mGluR5	FDA Approved
T0426	Piracetam	AMPA	Approved
T0333	Aniracetam	5-HT; Dopamine; AMPA; GluR	Approved
T0326L	L-Glutamine	mGluR	FDA Approved
T0313	Evans blue	vesicular glutamate uptake	FDA Approved
T0256	Lithium citrate tribasic tetrahydrate	IMPDH; mGluR3; GSK-3 β	FDA Approved
T0051	Urethane	α 4 β 2 nAChR; glycine receptors; GABAR; AMPA; NMDA receptor	Approved
T0024	Primidone	nAChR; GABAR; GluR2; Sodium Channel	FDA Approved

GlyT

ID	Product Name	Target	Condition
T6975	Sarcosine	GlyT1; N-methyl-D-aspartate receptor	Phase 2
T6788	Bitopertin	GlyT1	Approved
T1568	Amoxapine	GlyT1b; GlyT2a	FDA Approved

Histamine Receptor

ID	Product Name	Target	Condition
TN1154	6-Methoxyloleolin	Calcium Channel; Histamine Receptor	
TN1008	Psoralenoside	H1 receptor	
T8822	JNJ-5207852 dihydrochloride	H3 receptor	
T8599	Betazole hydrochloride	H2 receptor	FDA Approved
T8548	Metoprine	histamine N-methyltransferase; antifolate	
T8514	LML-134	H3 receptor	Phase 2
T8439	Clobenpropit dihydrobromide	H3 receptor	
T7564	Chlorphenoxamine	Histamine Receptor	

ID	Product Name	Target	Condition
T7524	Metiamide	H2 receptor	
T7413	JNJ-5207852	H3 receptor	
T7176	Pitolisant hydrochloride	H3 receptor	FDA Approved
T7085	Mebhydroline	H1 receptor	Approved
T6535	Histamine Phosphate	Histamine H1 receptor , Histamine H2 receptor	FDA Approved
T6534	Histamine 2HCl	H1 receptor; H2 receptor	Approved
T6405	Bepotastine Besilate	H1 receptor	FDA Approved
T6242	Rupatadine Fumarate	H1 receptor; PAFR	Approved
T6164	Ciproxifan	H3 receptor	Preclinical
T5829	H4 Receptor antagonist 1	H4 receptor	
T5495	Decloxizine dihydrochloride	H1 receptor	Approved
T4566	Lodoxamide	Histamine Receptor	FDA Approved
T4563	Thonzylamine	H1 receptor	Approved
T4551	Acrivastine	H1 receptor	FDA Approved
T4507	Chlorphenesin	Histamine release	FDA Approved
T4499	Mequitazine	H1 receptor	Approved
T4250	Bilastine	H1 receptor; H1 receptor(in guinea-pig cerebellum)	Approved
T4195	Betahistine	H1 receptor	Approved
T4099	S38093	Human H3 receptor; Mouse H3 receptor; Rat H3 receptor	Phase 2
T3979	Emedastine	H1 receptor	FDA Approved
T3963	VUF10460	H4 receptor	
T3723	Dioxopromethazine hydrochloride	H1 receptor	
T3610	Ranitidin	H2 receptor	FDA Approved
T3429	Protopine	H1 receptor; platelet aggregation	
T2848	Osthole	H1 receptor	Preclinical
T2533	Alcaftadine	H1 receptor; H2 receptor; H4 receptor	FDA Approved
T2520	Desloratadine	H1 receptor	FDA Approved
T2335	Ebastine	H1 receptor	Approved
T22713	Decloxizine	H1 receptor	Approved
T2232	JNJ777120	H4 receptor	Preclinical
T2222	Carbinoxamine Maleate Salt	H1 receptor	FDA Approved
T2200	Hydroxyzine dihydrochloride	H1 receptor	FDA Approved
T20884	Hydroxyzine free base	H1 receptor	Approved
T20712	Conessine	H3 receptor	
T2004	Ciproxifan maleate	H3 receptor	Preclinical
T1822L	Clemizole hydrochloride	NS4BH1 histamine receptor	Approved
T1822	Clemizole	NS4BH1 histamine receptor	Phase 2
T1627	Famotidine	H2 receptor	FDA Approved

ID	Product Name	Target	Condition
T1619	Trazodone hydrochloride	5-HT; Sert (Sodium-dependent); Adrenergic Receptor; H1 receptor	FDA Approved
T1575	Nizatidine	AChE; H2 receptor	FDA Approved
T1553	Chlorpheniramine maleate	H1 receptor	FDA Approved
T1470L	Fexofenadine hydrochloride	H1 receptor	FDA Approved
T1470	Fexofenadine hydrochloride	Histamine H1 receptor	FDA Approved
T1469	Levocetirizine	H1 receptor	FDA Approved
T1425	Pemrolast potassium	H1 receptor	FDA Approved
T1393	Sodium butanoate	H1 receptor	Phase 3
T1327	Nortriptyline hydrochloride	5-HT; Sert (Sodium-dependent); mAChR; Adrenergic Receptor; Dopamine; H1 receptor; Noradrenaline transporter (Sodium-dependent)	FDA Approved
T1308	Orphenadrine hydrochloride	H1 receptor; NMDA receptor; Noradrenaline transporter (Sodium-dependent); Sodium Channel	FDA Approved
T1278	Astemizole	H1 receptor; Potassium Channel	
T1269	Tripelennamine hydrochloride	H1 receptor	FDA Approved
T1232	Pyrilamine maleate	H1 receptor	FDA Approved
T1182	Propionyl-L-carnitine hydrochloride	H1 receptor	Approved
T1115	Doxylamine succinate	H1 receptor	FDA Approved
T1110	Meclizine dihydrochloride	H1 receptor	FDA Approved
T1097	Loratadine	B(0)AT2	FDA Approved
T1090	Perphenazine	CAM; Dopamine; 5-HT2A receptor; Histamine H1 receptor; Alpha-1A adrenergic receptor	FDA Approved
T1045	Trimipramine maleate	5-HT; Sert (Sodium-dependent); Adrenergic Receptor; DA transporter; Dopamine; H1 receptor; Noradrenaline transporter (Sodium-dependent)	FDA Approved
T1030	Tripolidine hydrochloride	H1 receptor	FDA Approved
T0994	Ketotifen fumarate	H1 receptor; PDE	FDA Approved
T0942	Quinacrine dihydrochloride	DNA; Histamine N-methyltransferase; PLA2; PLCLP	Phase 2
T0903	Stugeron	Calcium Channel; H1 receptor	Approved
T0865	Ranitidine Hydrochloride	H2 receptor	FDA Approved
T0797	Cimetidine	H2 receptor	FDA Approved
T0785	Dexchlorpheniramine Maleate	Sert (Sodium-dependent); DA transporter; H1 receptor; Noradrenaline transporter (Sodium-dependent)	FDA Approved
T0468	Xylocaine	H1 receptor	FDA Approved
T0445L	Promethazine hydrochloride	α -adrenergic receptor; H1 receptor	FDA Approved
T0445	Promethazine	5-HT; mAChR; Adrenergic Receptor; CAM; D2; H1 receptor	FDA Approved
T0381	Amodiaquine hydrochloride	histamine N-methyl transferase	FDA Approved
T0330	Diphenhydramine hydrochloride	H1 receptor	FDA Approved

ID	Product Name	Target	Condition
T0298	Dimenhydrinate	H1 receptor	FDA Approved
T0263	Chloropyramine hydrochloride	FAK-VEGFR-3; H1 receptor	Approved
T0246L	Betahistine mesylate	H1 receptor; H3 receptor	Approved
T0246	Betahistine dihydrochloride	H3 receptor	Approved
T0211L	Azelastine hydrochloride	H1 receptor	FDA Approved
T0172	Maprotiline hydrochloride	5-HT; mAChR; Adrenergic Receptor; H1 receptor; Noradrenaline transporter (Sodium-dependent)	FDA Approved
T0157	Roxatidine Acetate hydrochloride	H2 receptor	Approved
T0147	Clemastine fumarate	H1 receptor	FDA Approved
T0118	Mizolastine	H1 receptor	Approved
T0092	Antazoline hydrochloride	H1 receptor	FDA Approved
T0089	Cetirizine dihydrochloride	H1 receptor	FDA Approved
T0076	Paliperidone	5-HT; β -adrenergic receptor; Dopamine; H1 receptor	FDA Approved
T0074L	Chlorprothixene hydrochloride	5-HT; mAChR; Dopamine; H1 receptor	FDA Approved
T0074	Chlorprothixene	5-HT ₆ ; 5-HT ₇ ; D ₂ ; D ₃ ; H1 receptor	FDA Approved
T0059	Diphenylpyraline hydrochloride	H1 receptor	FDA Approved
T0053	Hydroxyzine Pamoate	H1 receptor	FDA Approved
T0031L2	Ziprasidone	5-HT transporter; 5-HT _{1A} ; 5-HT _{1B} ; 5-HT _{1D} ; 5-HT _{2A} ; 5-HT _{2C} ; 5-HT ₆ ; 5-HT ₇ ; α 1A-adrenergic receptor; α 2A-adrenergic receptor; D ₁ ; D ₂ ; D ₃ ; H1 receptor; norepinephrine transporter (NET)	FDA Approved
T0031L	Ziprasidone hydrochloride	5-HT transporter; 5-HT _{1A} ; 5-HT _{1B} ; 5-HT _{1D} ; 5-HT _{2A} ; 5-HT _{2C} ; 5-HT ₆ ; 5-HT ₇ ; α 1A-adrenergic receptor; α 2A-adrenergic receptor; D ₁ ; D ₂ ; D ₃ ; H1 receptor; norepinephrine transporter (NET)	FDA Approved
T0031	Ziprasidone hydrochloride monohydrate	5-HT transporter; 5-HT _{1A} ; 5-HT _{1B} ; 5-HT _{1D} ; 5-HT _{2A} ; 5-HT _{2C} ; 5-HT ₆ ; 5-HT ₇ ; α 1A-adrenergic receptor; α 2A-adrenergic receptor; D ₁ ; D ₂ ; D ₃ ; H1 receptor; norepinephrine transporter (NET)	FDA Approved

iGluR

ID	Product Name	Target	Condition
T8458	CNQX disodium	AMPA	
T7599	Sunifiram	iGluR	
T7580	CX546	AMPA	
T202728	glycine	Endogenous Metabolite; iGluR; MT2 receptor; MT1 receptor	FDA Approved

MAO

ID	Product Name	Target	Condition
TN1120	Osthenol	hMAO-A	
TMS1743	Salvigenin	hMAO-A	
T8907	Minaprine dihydrochloride	MAO-A	Approved
T8849	PF-9601N	hMAO-B	
T8589	Amiflamine	MAO-A	
T7942	Tranlycypromine (hemisulfate)	MAO; LSD1	FDA Approved
T7048	1,4-Naphthoquinone	MAO; DNA topoisomerase; acetyltransferase	
T6962	Rasagiline Mesylate	MAO-A; MAO-B	FDA Approved
T6862	Isatin	MAO	
T6651	Safinamide mesylate	MAO	FDA Approved
T5887	3,4-Dihydro-7-hydroxy-2(1H)-quinolinone	MAO-A	
T5678	N-(2-Aminoethyl)-5-chlor-2-pyridincarbox	MAO-B	
T5676	(Z)-SU4312	MAO-B; NOS	
T5648	Purpurin	MAO-A	
T5323	MD 69276	MAO-A	Approved
T5053	Eprobemide	MAO-A	
T5050	Selegiline hydrochloride	MAO-B	FDA Approved
T3933	Jatrorrhizine	MAO-A; MAO-B	
T3596	TB5	hMAO-B	
T3095	Tyramine	MAOs	
T2900	Paeonol	MAO-A; MAO-B	Approved
T2765	Rosmarinic acid	MAO-A; MAO-B; COMT; IKK β	Phase 4
T2741	Glycyrrhizin	Dehydrogenase; MAO	Approved
T1747	Torezolid	MAO-A; MAO-B	FDA Approved
T1711	Harmine	MAO	
T1613	Hydralazine hydrochloride	MAO	FDA Approved
T1578	Pargyline hydrochloride	MAO	FDA Approved
T1549	Raloxifene hydrochloride	ER; AO; SERM	FDA Approved
T1455	Nialamide	AOA; AOB; COMT	
T1119	Rasagiline	Bcl-2; MAO-A; MAO-B	FDA Approved
T1025	Tranlycypromine (2-PCPA) hydrochloride	MAO; LSD1	FDA Approved
T0966	Sennoside A	MAO	Approved
T0821	Iproniazid Phosphate	MAO	
T0751	Furazolidone	MAO	FDA Approved
T0418	Allylthiourea	MAO	
T0391	Linezolid	AOA; AOB	FDA Approved

ID	Product Name	Target	Condition
T0369	Ethaverine hydrochloride	MAO	Approved
T0300	Pargyline	MAO	FDA Approved
T0235	Modaline sulfate	MAO	Approved
T0084	Moclobemide	MAO-A (5-HT)	Approved

Melanocortin Receptor

ID	Product Name	Target	Condition
TP1898	HS 024	melanocortin-4 receptor (MC4R)	
TP1889	MCL 0020	melanocortin-4 receptor (MC4R)	
TP1324	Melanotan (MT)-II	melanocortin receptors	
TP1101	Nonapeptide-1 acetate salt	α -MSH	
T8485	THIQ	melanocortin-4 receptor (MC4R)	
T7608	Bremelanotide Acetate	Melanocortin Receptor	FDA Approved
T5464	JNJ-10229570	MC1R; MC5R	

Monoamine Oxidase

ID	Product Name	Target	Condition
T7185	(2-Chloropyridin-4-yl)methanamine hydrochloride	LOXL2	
T4559	Isocarboxazid	monoamine oxidase	FDA Approved
T12441	Phenelzine sulfate	monoamine oxidase	FDA Approved

MT receptor

ID	Product Name	Target	Condition
T3495	Tasimelteon	Melatonin Receptor; MT2 receptor; MT1 receptor	FDA Approved
T202728	glycine	Endogenous Metabolite; iGluR; MT2 receptor; MT1 receptor	FDA Approved
T1463	Ramelteon	MT receptor (chicken); MT1 receptor; MT2 receptor	FDA Approved

Neurokinin Receptor

ID	Product Name	Target	Condition
TP1883	[Lys5,MeLeu9,Nle10]-NKA(4-10)	NK2	
TP1572	GR-73632	NK-1	
TP1385	Neurokinin A(4-10) TFA(97559-35-8 free base)	NK2	
TP1087	Substance P	Human Endogenous Metabolite; NK1	

ID	Product Name	Target	Condition
TP1008	Neurokinin A	NK2	
T8789	N-Acetyl-L-tryptophan	Human Endogenous Metabolite; NK1	
T8235	L-732138	NK-1	
T7828	Bhsar-sp	NK-1	
T7633	Senktide	NK3	
T7549	Talnetant	NK3	Phase 2
T7209	Maropitant	NK1	
T6905	Netupitant	NK1	FDA Approved
T3724	Rolapitant hydrochloride	NK1	FDA Approved
T1790	Fosaprepitant dimeglumine	NK1	FDA Approved
T1743	Aprepitant	NK1	FDA Approved

Neuropeptide Y Receptor

ID	Product Name	Target	Condition
TQ0286	MK-0557	neuropeptide Y (NPY) Y5 receptor	Phase 2
T8559	GALNON TFA(475115-35-6(free base))	galanin receptor	
T5587	CGP71683 hydrochloride	Y5 receptor	
T17222	Velneperit	neuropeptide Y (NPY) Y5 receptor	Phase 2

NMDAR

ID	Product Name	Target	Condition
TQ0027	Transrocetinate disodium	NMDA receptor	
T8626	4-oxo-1,4-dihydroquinoline-2-carboxylic acid	GluR; NMDA receptor	
T8450	TCN213	NMDA receptor	
T8394	(R)-Serine	NMDA receptor	Approved
T8351	UBP551	NMDA receptor	
T7870	TCN-201	NMDA receptor	
T7867	Flutriafol	NMDA receptor	
T7778	Glypromate	NMDA receptor	
T6975	Sarcosine	GlyT1; N-methyl-D-aspartate receptor	Phase 2
T6608	NMDA	NMDA receptor	
T6504	Flupirtine maleate	NMDA receptor; Potassium Channel	Approved
T6352	(-)-MK 801 Maleate	NMDA Receptor	Preclinical
T6259	Dizocilpine	NMDA receptor	Preclinical
T5819	Rapastinel Trifluoroacetate	NMDA receptor	Phase 3
T5385	Radiprodil	NR2B-NMDA	Phase 2

ID	Product Name	Target	Condition
T5080	Spermidine hydrochloride	NMDA receptor; Autophagy	
T4979	Procyclidine hydrochloride	NMDA receptor	FDA Approved
T4885	D-Aspartic acid	NMDA receptor	
T4752	1-Aminocyclopropanecarboxylic acid	NMDA receptor	Phase 2
T4225	Dextrorphan tartrate	NMDA receptor	Phase 2
T4171	PEAQX	hNMDA 1A/2A receptors	
T4096	Quinolinic acid	NMDA receptor	
T3486	3-MATIDA	mGluR1; NMDA	
T3320	Dizocilpine Maleate	NMDA receptor	Preclinical
T2362	QNZ46	NR2A; NR2C; NR2D	
T22733	DL-AP5	NMDA	
T1946	Felbamate	NMDA receptor	FDA Approved
T1909	L701324	NMDA receptor	Preclinical
T1897	MDL 29951	NMDA receptor	
T1751	Eliprodil	NR2B-NMDA	Phase 3
T1443	Memantine hydrochloride	AMPA; NMDA receptor; Kainate receptor; CYP2B6; CYP2D6	FDA Approved
T1324	Phosphoserine	Amino Acids and Derivatives; NMDA receptor	
T1308	Orphenadrine hydrochloride	H1 receptor; NMDA receptor; Noradrenaline transporter (Sodium-dependent); Sodium Channel	FDA Approved
T1186	Ifenprodil Tartrate	NMDA receptor	Approved
T0954	Anestan	Glycine receptor; GABAR; NMDA receptor; Potassium Channel	FDA Approved
T0802	Procaine hydrochloride	5-HT3; nAChR; NMDA receptor; Sodium channel	FDA Approved
T0556	6-Methoxy-2-naphthoic acid	NMDA receptor	
T0349	Riluzole	NMDA receptor; Sodium Channel; GABA	FDA Approved
T0051	Urethane	α 4 β 2 nAChR; glycine receptors; GABAR; AMPA; NMDA receptor	Approved
T0015	Mephenesin	NMDAR	Approved

NMU2R

ID	Product Name	Target	Condition
T8035	3'-Methoxyflavonol	NMU2R	

Norepinephrine

ID	Product Name	Target	Condition
T7583	solriamfetol	norepinephrine transporter (NET); dopamine transporter	FDA Approved
T6963	Reboxetine mesylate	norepinephrine reuptake	Approved

ID	Product Name	Target	Condition
T6188	Desvenlafaxine succinate hydrate	5-HT; Norepinephrine (NE)	FDA Approved
T5380	Ansofaxine hydrochloride	serotonin reuptake; dopamine reuptake; norepinephrine reuptake	
T3526	Dasotraline hydrochloride	5-HT; Dopamine; Norepinephrine (NE)	Phase 3
T2594	Levomilnacipran	5-HR-norepinephrine reuptake	FDA Approved
T2575	Guanethidine Monosulfate	Norepinephrine (NE)	FDA Approved
T2092	Amitifadine hydrochloride	5-HT; Dopamine; Norepinephrine (NE)	Phase 2/3
T1735	Lurasidone hydrochloride	5-HT1A; 5-HT2A; 5-HT7; D2; Norepinephrine α 2C	FDA Approved
T1580	Desvenlafaxine	5-HT; Norepinephrine (NE)	FDA Approved
T1540	Doxepin hydrochloride	5-HT; HT; Sert (Sodium-dependent); mAChR; Adrenergic Receptor; Dopamine; Noradrenaline transporter (Sodium-dependent)	FDA Approved
T1471	Duloxetine hydrochloride	Sert (Sodium-dependent); DA transporter; Noradrenaline transporter (Sodium-dependent)	FDA Approved
T1327	Nortriptyline hydrochloride	5-HT; Sert (Sodium-dependent); mAChR; Adrenergic Receptor; Dopamine; H1 receptor; Noradrenaline transporter (Sodium-dependent)	FDA Approved
T1308	Orphenadrine hydrochloride	H1 receptor; NMDA receptor; Noradrenaline transporter (Sodium-dependent); Sodium Channel	FDA Approved
T1189	Milnacipran hydrochloride	norepinephrine transporter (NET); norepinephrine transporter (SERT)	FDA Approved
T1045	Trimipramine maleate	5-HT; Sert (Sodium-dependent); Adrenergic Receptor; DA transporter; Dopamine; H1 receptor; Noradrenaline transporter (Sodium-dependent)	FDA Approved
T0878	Diosmin	Norepinephrine (NE)	Approved
T0869	Atomoxetine hydrochloride	5-HT; DA transporter; Norepinephrine (NE) transporter	FDA Approved
T0785	Dexchlorpheniramine Maleate	Sert (Sodium-dependent); DA transporter; H1 receptor; Noradrenaline transporter (Sodium-dependent)	FDA Approved
T0783	Mianserin hydrochloride	5-HT; HT; Sert (Sodium-dependent); Adrenergic Receptor; DA transporter; Dopamine; Noradrenaline transporter (Sodium-dependent); κ -opioid receptor	Approved
T0678	Amitriptyline hydrochloride	5-HT; 5-HT2; 5-HT4; Norepinephrine receptor; σ 1	FDA Approved
T0255	Clomipramine hydrochloride	5-HT; Sert (Sodium-dependent); GSTP; Noradrenaline transporter (Sodium-dependent); dopamine transporter (DAT)	FDA Approved
T0172	Maprotiline hydrochloride	5-HT; mAChR; Adrenergic Receptor; H1 receptor; Noradrenaline transporter (Sodium-dependent)	FDA Approved
T0031L2	Ziprasidone	5-HT transporter; 5-HT1A; 5-HT1B; 5-HT1D; 5-HT2A; 5-HT2C; 5-HT6; 5-HT7; α 1A-adrenergic receptor; α 2A-adrenergic receptor; D1; D2; D3; H1 receptor; norepinephrine transporter (NET)	FDA Approved
T0031L	Ziprasidone hydrochloride	5-HT transporter; 5-HT1A; 5-HT1B; 5-HT1D; 5-HT2A; 5-HT2C; 5-HT6; 5-HT7; α 1A-adrenergic receptor; α 2A-adrenergic receptor; D1; D2; D3; H1 receptor; norepinephrine transporter (NET)	FDA Approved
T0031	Ziprasidone hydrochloride monohydrate	5-HT transporter; 5-HT1A; 5-HT1B; 5-HT1D; 5-HT2A; 5-HT2C; 5-HT6; 5-HT7; α 1A-adrenergic receptor; α 2A-adrenergic receptor; D1; D2; D3; H1 receptor; norepinephrine transporter (NET)	FDA Approved

Opioid Receptor

ID	Product Name	Target	Condition
TWS0414	Cannabidiol	GPR55 antagonist; CB1 antagonist; CB2 inverse agonist; VR1	FDA Approved
TQ0267	Endomorphin-1	μ -opioid receptor	
TP2050L	CTAP(TFA)	δ -opioid receptor	
TP2036L	DPDPE TFA	δ -opioid receptor	
TP1905	DADLE	δ -opioid receptor	
TP1832	Gluten Exorphin C	δ -opioid receptor; μ -opioid receptor	
TP1813L	Dynorphin A 1-10 acetate(79994-24-4 free base)	κ -opioid receptor	
TP1793L	Nociceptin (1-13) amide TFA	Opioid receptor-like1 (ORL1)	
TP1367	[D-Ala2]leucine-enkephalin	Opioid Receptor	
TP1254	[Met5]-Enkephalin, amide TFA	δ and ζ opioid receptor	
TP1179L	Porcine dynorphin A(1-13) acetate(72957-38-1 free base)	κ -opioid receptor	
TP1071	Nociceptin	Opioid Receptor	
T8571	ML-184	GPR55	
T8557	N-terminally acetylated Leu-enkephalin	Opioid Receptor	
T8455	Spinorphin	enkephalin degrading enzymes	
T7665	[Leu5]-Enkephalin TFA(58822-25-6(free bas))	δ -opioid receptor; Human Endogenous Metabolite	
T7639	Deltorphin 2(TFA)	δ -opioid receptor	
T7637	Deltorphin I(TFA)	δ -opioid receptor	
T7613	β -Casomorphin, human(TFA)	Opioid Receptor	
T7576L	β -Casomorphin, bovine TFA(72122-62-4(free base))	Opioid Receptor	
T7567L	Adrenorphin 3TFA(88377-68-8(free base))	μ -opioid receptor	
T7218	Endomorphin 2	μ -opioid receptor	
T7211	Tyr-Gly-Gly-Phe-Met-OH	Opioid Receptor	
T6553	JTC801	Opioid receptor-like1 (ORL1)	Phase 2
T6221	Nalmefene hydrochloride	Opioid Receptor	FDA Approved
T6175	ADL5859 HCl	δ -opioid receptor; κ -opioid receptor; μ -opioid receptor	Phase 2
T5167	Cebranopadol	Opioid Receptor; NOP	Phase 2
T5158	N-Desmethylclozapine	5-HT2C; D4; δ -opioid receptor	Phase 2
T4691	Asimadoline hydrochloride	κ -opioid receptor	Phase 2
T4478	CID 16020046	GPR55	
T4411	DAMGO TFA (78123-71-4(Free base))	μ -opioid receptor	

ID	Product Name	Target	Condition
T4407	SR17018	μ -opioid receptor	
T4386	PZM21	μ opioid receptor	
T4351	DAMGO	μ -opioid receptor	
T4236	AR-M 1000390 hydrochloride	δ -opioid receptor	Preclinical
T3417	Amentoflavone	COX; COX-2; κ -opioid receptor; CYP2C9; CYP3A4; PLA2	
T2870	(+)-Matrine	κ -opioid receptor	
T2388	Nalfurafine hydrochloride	κ -opioid receptor	Approved
T21422	Methylnaltrexone bromide	μ -opioid receptor	FDA Approved
T2071	MCOPPB trihydrochloride	Opioid Receptor	
T20435L	Leuphasyl TFA	δ -opioid receptor	
T1407	L-Menthol	Opioid Receptor; κ -opioid receptor	FDA Approved
T13414	ZT 52656A hydrochloride	kappa opioid receptor	
T1242	Alvimopan	μ -opioid receptor	FDA Approved
T0981	Noscapine hydrochloride	Opioid alkaloid	Approved
T0963	Naltrexone hydrochloride	Opioid Receptor	FDA Approved
T0929	Docusate sodium	Opioid Receptor	Approved
T0918	Trimebutine	Opioid Receptor	Approved
T0783	Mianserin hydrochloride	5-HT; HT; Sert (Sodium-dependent); Adrenergic Receptor; DA transporter; Dopamine; Noradrenaline transporter (Sodium-dependent) κ -opioid receptor	Approved
T0478	Progesterone	ER; κ -opioid receptor	FDA Approved
T0209	Loperamide hydrochloride	δ -opioid receptor; κ -opioid receptor; κ -opioid receptor; μ -opioid receptor	FDA Approved
T0201	Meptazinol hydrochloride	Opioid Receptor	Approved
T0137	Mirtazapine	5-HT; HT; Sert (Sodium-dependent); Adrenergic Receptor; DA transporter; Dopamine; κ -opioid receptor	FDA Approved
T0102	Naloxone hydrochloride	Opioid Receptor	FDA Approved

OX Receptor

ID	Product Name	Target	Condition
T6140	SB334867	OX1	Preclinical
T5500	DORA-22	OX Receptor	
T4965	TCS-OX2-29	OX2	
T3722	MK1064	OX2	
T3347	PF3274167	OXTR	Phase 1
T3177	Orexin 2 Receptor Agonist	O2XR	
T2710	TCS 1102	OX1; OX2	
T2613	Almorexant	OX1; OX2	Phase 3
T1913	MK3697	OX2	Phase 2
T11186	EMPA	OX2 Receptor	

P2 Receptor

ID	Product Name	Target	Condition
T8582	Piperazine, 1-[(5-methyl-3-isoxazolyl)methyl]- (9Cl)	P2Y12	
T7805	GW791343 (HCl)	P2X7	
T7423	Diquafosol tetrasodium	P2Y2 receptor	Approved
T6952	Prasugrel Hydrochloride	P2Y12	FDA Approved
T6172	MRS 2578	P2Y6	
T5513	RO3	P2X3	
T5099	Gefapixant	P2X3	Phase 3
T4706	UDP disodium salt	P2Y6; P2Y14	
T4699	Hexamethylene amiloride	NHE exchangers; TRPA1; ASIC3; P2X7	
T4132	BPTU	P2Y1	
T3690	A 740003	P2X7 (Human); rat P2X7 receptor	Preclinical
T3639	A804598	P2X7	
T3536	AZD1283	P2Y12	Preclinical
T2673	A-438079 hydrochloride	P2X7	
T2087	AF 353	P2X3	
T14844	BX430	human P2X4 receptor channels	
T12568	PSB-12062	P2X4	
T1131	Ivermectin	GluCl channels; P2 receptor	FDA Approved
T10466	BAY-1797	human P2X4; human P2X1; human P2X23; human P2X3; human P2X7	
T0362	Ticlopidine hydrochloride	P2 receptor	FDA Approved
T0230	Prasugrel	P2Y; P2Y12	FDA Approved
T0182L2	(±) Clopidogrel hydrogen sulfate	P2Y12	FDA Approved
T0182L	(S)-(+)-Clopidogrel hydrogen sulfate	P2Y	FDA Approved
T0179	Ticagrelor	Midazolam 4-hydroxylation; P2Y12; CYP2C9	FDA Approved

P-gp


ID	Product Name	Target	Condition
T8426	Encequidar	P-gp (P-glycoprotein)	Phase 1
T6287	Tariquidar	P-gp (P-glycoprotein)	Phase 2
T6018	Zosuquidar 3HCl	P-gp (P-glycoprotein)	Approved
T4A2399	Cinobufotalin	Akt; IL Receptor; MRP1; P-gp	Phase 1
T3868	Agnuside	COX-2; P-gp (P-glycoprotein)	
T3392	Sinapine thiocyanate	P-gp (P-glycoprotein)	
T3002	Piperine	P-gp (P-glycoprotein); CYP3A4	Approved
T2S2018	7-beta-Hydroxylathyrol	P-gp (P-glycoprotein)	

ID	Product Name	Target	Condition
T2S0410	Euphorbia factor L1	ABCB1	
T2893	Muscone	MMP-9; P-gp (P-glycoprotein)	
T2657	Elacridar	P-gp (P-glycoprotein)	Phase 1
T16339	Norverapamil hydrochloride	Calcium channel blocker; P-gp (P-glycoprotein)	
T0012	Cinchonine	P-gp (P-glycoprotein)	Phase 1

Serotonin Transporter

ID	Product Name	Target	Condition
T8708	Paroxetine	serotonin	FDA Approved
T7941	Imipramine (hydrochloride)	serotonin	FDA Approved
T7940	Milnacipran ((1S-cis) hydrochloride)	serotonin	FDA Approved
T6493	Escitalopram Oxalate	SSRI; 5-HT	FDA Approved
T22453	Venlafaxine	serotonin-norepinephrine reuptake	Approved

NF-κB



NF-κB

IRAK

ID	Product Name	Target	Condition
T2822	Ginsenoside Rb1	Autophagy; IRAK; Mitophagy; (Na,K)-ATPase; NF-κB	

IκB/IKK

ID	Product Name	Target	Condition
TQ0306	MLN120B	IKKβ	
T8705	BOT-64	IKK2	
T8542	BMS-345541 hydrochloride	IKK1; IKK2	
T7951	TBK1/IKKε-IN-5	TBK1; IKK ε	
T7081	CCCP	TBK1; IFN-β	
T6771	AZD3264	IKK2	

ID	Product Name	Target	Condition
T6326	BMS345541	IKK1; IKK2	Approved
T6186	TRAM34	IKCa1 (KCa3.1)	
T6176	IKK16	IKK2; IKK; LRRK2; IKK1	
T6165	Bardoxolone Methyl	IKK	Approved
T6141	IMD 0354	IKKβ	Phase 1
T5540	GSK8612	TBK1	
T5209	INH14	IKKα; IKKβ	
T5162	MRT67307 HCl (1190378-57-4 (free base))	IKK ε; TBK1; ULK1; ULK2; NUAK1	
T3736	Olivetol	IκB; CYP1A1; CYP2C19	
T3094	PS1145	IKK	Preclinical
T3049	TPCA1	IKK2	
T2833	Dehydrocostus Lactone	IKKβ	
T2765	Rosmarinic acid	MAO-A; MAO-B; COMT; IKK β	Phase 4
T2118	SC514	Aurora B; CDK2/CyclinA; IKK2; p38α; PRAK	
T2106	WS6	ErbB3-Binding Protein-1 (EBP2); IκB kinase	
T2081	LY2409881 trihydrochloride	IKK2	
T2055	WS3	ErbB3-Binding Protein-1 (EBP1); IκB kinase	
T1934	Bay 11-7085	IκBα phosphorylation	
T1902	BAY 11-7082	E2-conjugating enzymes; IκBα phosphorylation	
T1639	Amllexanox	FGFR1; IL-3; Protein S100-P; IKKε; TBK1	FDA Approved
T1558	Resveratrol	COX-1; COX-2; DNA polymerase α; IKKβ; LOX; Quinone reductase 2; SIRT1; SIRT2	Approved
T15559	TBK1/IKKε-IN-2	TBK1; IKKε	
T10477	BAY-985	TBK1; TBK1; IKKε	

NF-κB

ID	Product Name	Target	Condition
TQ0185	14-Deoxy-11,12-didehydroandrographolide	NF-κB	
TN5284	Sodium Houltuyfonate	NF-κB	
TN2165	Rubrofusarin-6-O-beta-D-gentiobioside	TGFβ; NF-κB; ERK	
TN2008	Okanin	TLR4; NF-κB	
TN1126	Sakuranetin	PPAR; NF-κB; VEGFR	
TN1079	Deoxyelephantopin	NF-κB	
TN1051	1-Caffeoylquinic acid	NF-κB	
TN1035	Irisolidone	VRAC; IL Receptor; NF-Kb	
T7889	C25-140	NF-κB; TRAF6-Ubc13	
T7511	Cyclo(his-pro)	Human Endogenous Metabolite ; NF-κB	
T7283	sodium lauroyl-α-hydroxyethyl sulfonate	MAPKs; NF-κB	

ID	Product Name	Target	Condition
T6S1141	Ganoderic acid A	NF-κB	
T6718	Vanillylacetone	NF-κB	
T6661	SC75741	NF-κB	Preclinical
T6429	Caffeic Acid Phenethyl Ester	NF-κB	Preclinical
T6204	QNZ	NF-κB; TNF-α	
T5S2228	6'''-Feruloylspinosin	NF-κB	
T5S1632	8-O-Acetylshanzhiside methyl ester	TNF-α; NF-Kb; VEGFR; Akt; Caspase	
T5S1607	Morusin	STAT3; NF-Kb	
T5S1097	Neferine	Autophagy; NF-κB	
T5814	Aurantiamide	NF-κB; p38	
T5798	euphorbiafactor L2	NF-κB	
T5773	5-hydroxy-7,8-dimethoxyflavone	NF-κB	
T5769	Stachydrine	p65	
T5764	Alliin	PPARγ; NF-κB	
T5727	CAFESTOL	ERK; COX-2; NF-κB	
T5687	WITHA FERIN A	NF-κB	
T5660	Menthone	TNF-α; NF-κB; IL receptor	
T5558	Chelidonic acid	Caspase-1; NF-κB	
T4S2063	Tetrahydrocoptisine	NF-κB; ERK; p38 MAPK	
T4S1962	beta-Asarone	NF-κB; JNK	
T4S1615	Sanggenone C	NF-κB	
T4S1540	Myrislignan	NF-κB; Apoptosis	
T4S1050	Pristimerin	NF-κB	
T4S0878	Prunetin	NF-κB; ERK	
T4518	Licochalcone D	ERK phosphorylation	
T4361	CBL0137 hydrochloride	FACT; p53; NF-κB	Phase 1
T4126	CBL0137	p53; NF-κB	Phase 1
T3S0738	yangonin	NF-κB; CB1	
T3S0737	Flavokawain A	p38	
T3S0335	Soyasaponin Bb	Caspase-3; NF-Kb	
T3954	Adelmidrol	COX; NF-κB; PPAR	Phase 2
T3918	Ginsenoside Rb3	NF-κB	
T3913	Saikosaponin D	NF-κB; STAT3	
T3893	Forsythoside B	NF-κB	
T3892	Isoacteoside	NF-κB	
T3877	Esculentoside A	NF-κB	
T3862	Irigenin	NF-κB	
T3860	Isoliquiritin apioside	NF-κB	
T3826	Polygalasaponin F	NF-κB	
T3816	Velutin	NF-κB	

ID	Product Name	Target	Condition
T3729	Ethyl gallate	Akt; MMP-2; MMP-9; NF-κB	
T3668	Galangin	ERK; NF-κB	
T3662	Eleutheroside E	NF-κB	
T3627	IQ-1S	JNK1; JNK2; JNK3; NF-κB	
T3427	Polydatin	NF-κB	Phase 2
T3416	Aucubin	IL-1β; NF-κB	
T3406	Kuromanin chloride	NF-κB	
T3384	Wedelolactone	NF-κB	
T3332	Isosteviol	COX-2; IL-6; NF-κB; Potassium Channel; TNF-α	Phase 2
T3251	Stachydrine Hydrochloride	NF-κB	
T3147	Pyrrolidinedithiocarbamate ammonium	NF-κB	
T3012	Mangiferin	Nrf2; p50; p65	
T3000	Magnolol	NF-κB; p53; PPARγ; RXRα	Approved
T2992	Pinocembrin	NF-κB	Phase 2
T2947	Indole-3-carbinol	NF-κB; p53	Preclinical
T2921	Sinomenine hydrochloride	NF-κB	Approved
T2913	Schisantherin A	NF-κB	
T2898	Andrographolide	NF-κB	Approved
T2878	Ginsenoside Rd	Calcium Channel; COX; P450; NF-κB	
T2872	Ginsenoside Re	Amyloid-β; JNK; NF-κB	Phase 1
T2822	Ginsenoside Rb1	Autophagy; IRAK; Mitophagy; (Na,K)-ATPase; NF-κB	
T2794	Astilbin	Keap1-Nrf2; NF-κB; TNF-α	
T2777	Ginsenoside Rg1	Amyloid-β; NF-κB	
T2768	Saikosaponin A	NF-κB	Approved
T2759	Loganin	NF-κB; AChE; BChE; BACE1	Approved
T2140	Parthenolide	NF-κB	Phase 2
T1930	JSH23	NF-κB	
T16974	TAK-243	UBA1; NF-κB; Apoptosis	Phase 1
T16706	Quinoclamine	NF-κB	
T16290	NIK SMI1	NIK	
T13265	Urolithin B	NF-κB; JNK; ERK; Akt; AMPK; Human Endogenous Metabolite	
T1301	Guaiacol	COX; NF-κB	Approved
T1296	Aminopar	COX-2; ALOX5; MPO; NF-κB	FDA Approved
T10383	Asatone	NF-κB	
T0907	Sulfasalazine	COX-1; COX-2; NF-κB	FDA Approved
T0694	Pranlukast	IL-5; CysLTR; NF-κB; Eosinophil cationic protein; Mucin-2; TNF-α	Approved
T0646	Mesalamine	COX; ALOX5; MPO; NF-κB; PPARγ	FDA Approved
T0607	Dihydroartemisinin	Autophagy; NF-κB	Approved
T0429	Glucosamine	Chitosanase; MMP-9; NF-κB; IFγ; TNF-α	Approved

ID	Product Name	Target	Condition
T0335	Sodium salicylate	COX-1; COX-3; NF-κB	Approved
T0307	Tyloxapol	NF-κB; LPL	FDA Approved
T0167	Vinpocetine	NF-κB; PDE; Sodium Channel	Approved
T0122	Bengenin	IL-1β; IL-6; NF-κB; NOD; TNF-α	Approved
T0020	Sodium 4-aminosalicylate dihydrate	Free radical scavengers; NF-κB	FDA Approved

NOD

ID	Product Name	Target	Condition
TQ0165	Arglabin	NLRP3	
TN1273	4',7-Dihydroxyflavone	COX; NOD1	
T7682	Asymmetric dimethylarginine	NO synthesis; Human Endogenous Metabolite	
T7597	6-Biopterin	NO synthesis	
T6S1367	Procyanidin B2	NLRP3	
T6887	MCC950 sodium	NLRP3	
T6591	ML130	NOD1; NOD2; TNF-α	
T5838	L-Canavanine sulfate	NO synthesis	
T4217	INF39	NLRP3	
T4164	CY09	NLRP3	
T3587	NOD-IN-1	NOD1; NOD2	
T3230	NLRP3 Inflammasome Inhibitor I	NLRP3	
T3092	Nigericin sodium salt	NLRP3	
T2845	Imperatorin	BChE; NO synthesis; TRPV1	Approved
T15052	Dapansutrile	NLRP3	Phase 2
T0122	Bengenin	IL-1β; IL-6; NF-κB; NOD; TNF-α	Approved
T0109	Molsidomine	NOD	Approved


Reactive Oxygen Species

ID	Product Name	Target	Condition
T8320	J-14	sulfiredoxin	
T7098	BAPTA	Ca ²⁺ chelator	

RIP kinase

ID	Product Name	Target	Condition
T7504	Necrostatin 2 racemate	RIPK1	
T5401	GSK2983559	RIP2	Phase 1

PI3K/Akt/mTOR signaling



PI3K/Akt/mTOR signaling

Akt

ID	Product Name	Target	Condition
TN1034	Sennidin B	Akt; GLUT; PI3K	
TN1033	Sennidin A	Akt; GLUT; PI3K	

ID	Product Name	Target	Condition
T7885	Afuresertib hydrochloride	Akt	Phase 1
T7315	BAY1125976	Akt	Phase 1
T6S0619	Pachymic acid	Akt; ERK	
T6S0525	Farrerol	Akt; p38; ERK	
T6849	Uprosertib	Akt1; Akt2; Akt3	Phase 2
T6817	Deguelin	PI3K; Akt	
T6304	AT7867	Akt1; Akt2; Akt3; PKA; p70 S6K	Preclinical
T6285	GSK690693	Akt1; Akt3; PKC η ; PKC θ ; PrkX	Phase 1
T6252	Ipatasertib	Akt1; Akt2; Akt3	Phase 3
T6251	PF04691502	P-Akt (S473); PI3K α ; PI3K β ; PI3K γ ; PI3K δ	Phase 2
T6139L	A-674563 2HCl(552325-73-2(fb-2hcl))	Akt1; CDK2; PKA; ERK2; PKC δ	
T6065	Triciribine	Akt; HIV-1	Phase 1/2
T5S1632	8-O-Acetylshanzhiside methyl ester	TNF- α ; NF-Kb; VEGFR; Akt; Caspase	
T5S0168	Atractylenolide II	STAT3 inhibitor; p38 activator; ERK inhibitor; Akt inhibitor	
T5736	CYNARIN	Akt; PI3K	
T5574	Guggulsterone E&Z	JNK; Akt; Caspase	
T5508	PF-AKT400	Akt	
T4S1419	Praeruptorin A	p38; Akt	
T4A2399	Cinobufotalin	Akt; IL Receptor; MRP1; P-gp	Phase 1
T4489	AZD26	allosteric Akt	
T4046	BX517	PKD1; cAKT2	Preclinical
T3881	Vaccarin	P-Akt; PERK; CD31	
T3729	Ethyl gallate	Akt; MMP-2; MMP-9; NF- κ B	
T3560	Desmethylanethol trithione	Akt; VEGFR	
T3467	Miransertib	Akt	Phase 1/2
T3399	Psoralidin	Akt; Phosphatidylinositol 3-kinase; ER α ; ER β	
T3346	AKT inhibitor VIII	Akt1; Akt2; Akt3	
T3132	SC66	Akt	
T3001	Honokiol	P-Akt; MEK	Phase 2
T2895	Lupeol	P-Akt	
T2790	Oridonin	Akt1,Akt2; AKT2	
T2789	Scutellarin	Akt; STAT	
T2492	Perifosine	Akt	Phase 2
T2482	AT13148	Akt1; Akt2; Akt3; PKA; ROCK1; ROCK2; p70 S6K; RSK1; SGK3	Phase 1
T2420	PHT427	Akt; PDK1	Preclinical
T2274	SC 79	Akt	
T2176	2,3-Butanedione 2-Monoxime	Akt	
T1961	Vistusertib	P-Akt (S473); mTOR; PI3K α ; pS6 (S235/236)	Phase 1/2

ID	Product Name	Target	Condition
T1952	MK-2206 dihydrochloride	Akt1; Akt2; Akt3	Phase 2
T1920	Capivasertib	Akt1; Akt2; Akt3; PKA; mTOR (p70S6K)	Phase 2
T1911	Afuresertib	Akt1; Akt2; Akt3	Phase 2
T16104	ML-9	AKT	
T13265	Urolithin B	NF-κB; JNK; ERK; Akt; AMPK; Human Endogenous Metabolite	
T0228	Methyl hesperidin	Akt; PKC	Approved
T0033	Miltefosine	PKC; Akt	FDA Approved

AMPK

ID	Product Name	Target	Condition
TQ0028	EX229	AMPK	
TN1100	Nepodin	COX; AMPK; GLUT	
T8526	Metformin	AMPK; Autophagy	FDA Approved
T8476	RSVA 405	STAT3; AMPK	
T8432	ASP4132	AMPK	
T7362	O-304	AMPK	
T7327	7-Methoxyisoflavone	AMPK	
T6854	GSK621	AMPK	
T6291	WZ4003	NUAK1; NUAK2	
T6146	Dorsomorphin dihydrochloride	AMPK	
T5993	ARN-3236	SIK2	
T5576	YKL-06-061	SIK1; SIK2; SIK3	
T5497	AMAROGENTIN	AMPK	
T5187	MK3903	AMPK	
T5162	MRT67307 HCl (1190378-57-4(free base))	IKK ε; TBK1; ULK1; ULK2; NUAK1	
T4599	HG-9-91-01	SIK1; SIK2; SIK3	
T4427	PF06409577	AMPK	Phase 1
T3S0195	Nootkatone	AMPK	
T3904	Gomisin J	AMPK; Calcium Channel	
T3863	Chikusetsusaponin IVa	AMPK	
T3676	Sesamol	AMPK	
T3405	6-Gingerol	AMPK; Apoptosis	
T2S0820	Karanjin	AMPK	
T2978	Mogroside V	AMPK	
T2854	Forsythin	AMPK	Approved
T2750	Ginkgolide C	AMPK; MMP; Sirtuin	
T2746	Sophocarpine	AMPK	
T2468	A 769662	AMPK; FAS	

ID	Product Name	Target	Condition
T2374	HTH-01-015	NUAK1; NUAK2	
T2133	Adenosine 5'-monophosphate	5'-AMP-activated protein kinase	Phase 1
T1977	Dorsomorphin	AMPK	
T16156	MT 63-78	AMPK; mTORC1	
T16099	MK8722	AMPK	
T1477	AICAR (Acadesine)	AMPK	Approved
T1453	Phenformin hydrochloride	AMPK; Potassium Channel	
T13265	Urolithin B	NF-κB; JNK; ERK; Akt; AMPK; Human Endogenous Metabolite	
T0853L	Adenosine 5'-monophosphate monohydrate	AMPK	Phase 1
T0800	Antrapurol	AMPK	Approved
T0740	Metformin hydrochloride	AMPK	FDA Approved

ATM/ATR

ID	Product Name	Target	Condition
T8660	AZ-32	ATM	
T7318	BAY-1895344	ATR	
T6770	AZD0156	ATM	Phase 1
T6283	Wortmannin	PI3K , DNA-PK , ATM , MLCK , ATR	Preclinical
T6261	CP466722	ATM	Preclinical
T6100	Torin 2	ATM; ATR; DNA-PK; mTOR	
T5175	azd1390	ATM	Phase 1
T4443	AZ32	ATM; ATM (in cell)	Preclinical
T4251	GJ103 sodium salt	ATM	
T3338	AZD6738	ATR	Phase 2
T3134	Mirin	MRN	
T3032	VE821	ATR	Preclinical
T2925	Schizandrin B	ATR	
T2685	KU55933	ATM; ATR; DNA-PK; mTOR; PI3K	Preclinical
T2669	Berzosertib	ATM; ATR	Phase 2
T2616	PIK93	ATM; C2β; DNA-PK; hsVps34; mTORC1; p110α; p110β; p110γ; p110δ; PI3KIIβ	
T2474	KU60019	ATM	
T2433	NU7026	ATM; ATR; DNA-PK; PI3K	
T2235	Dactolisib	ATR; mTOR (p70S6K); p110α; p110γ; p110δ	Phase 2
T2084	ETP46464	ATM; ATR; DNA-PK; mTOR; PI3Kα	
T1958	AZ20	ATR; mTOR	
T1821	CGK 733	ATM; ATR	

DNA-PK

ID	Product Name	Target	Condition
TQ0031	Nedisertib	DNA-PK	Phase 1/2
T7122	AZD-7648	DNA-PK	Phase 2
T7014	Voxtalisib	DNA-PK; PI3K α ; PI3K β ; PI3K γ ; PI3K δ	Phase 1/2
T6883	LY3023414	DNA-PK; mTOR kinase; class I PI3K isoforms	Phase 2
T6319	OSI027	DNA-PK; mTOR; mTORC1; mTORC2; PI3K γ	Phase 1
T6283	Wortmannin	PI3K , DNA-PK , ATM , MLCK , ATR	Preclinical
T6276	NU7441	DNA-PK	
T6143	PI103	DNA-PK; p110 α ; p110 β ; p110 γ ; p110 δ ; mTOR	Preclinical
T6100	Torin 2	ATM; ATR; DNA-PK; mTOR	
T6087	AZD6482	DNA-PK; PI3K α ; PI3K β ; PI3K γ ; PI3K δ	Phase 1
T6045	Torin 1	DNA-PK; mTOR; mTORC1; mTORC2; p110 γ	
T5166	Leniolisib	PI3K δ ; DNA-PK	Phase 2/3
T4339	YU238259	HDR	
T3986	SF2523	DNA-PK; BRD4; mTOR; PI3K α ; PI3K γ	Preclinical
T3586	Compound 401	DNA-PK	
T3541	CC115	DNA-PK; mTOR; PI3K α	Phase 1
T3351	CC223	c-Fms; DNA-PK; FLT4; mTOR; PI3K- α	Phase 2
T2685	KU55933	ATM; ATR; DNA-PK; mTOR; PI3K	Preclinical
T2667	PIK75	DNA-PK; p110 α ; p110 β ; p110 γ ; p110 δ	
T2616	PIK93	ATM; C2 β ; DNA-PK; hsVps34; mTORC1; p110 α ; p110 β ; p110 γ ; p110 δ ; PI3KIII β	
T2461	PIK90	PI3K α ; PI3K β ; PI3K γ ; PI3K δ ; DNA-PK	
T2433	NU7026	ATM; ATR; DNA-PK; PI3K	
T2377	XL147 analogue	DNA-PK; PI3K α ; PI3K β ; PI3K γ ; PI3K δ	Phase 1/2
T2287	PIK-75 hydrochloride	DNA-PK; p110 α ; p110 β ; p110 γ ; p110 δ	
T2084	ETP46464	ATM; ATR; DNA-PK; mTOR; PI3K α	
T2083	PI3065	DNA-PK; mTOR; p110 α ; p110 β ; p110 δ	
T2008	LY294002	p110 α ; p110 β ; p110 δ ; DNA-PK	Preclinical
T1826	Voxtalisib Analogue	DNA-PK; PI3K α ; PI3K β ; PI3K γ ; PI3K δ	Phase 1/2
T15789	LTURM34	DNA-PK; PI3K β ; PI4K δ	

GSK-3

ID	Product Name	Target	Condition
T8908	4-Chloro-2'-bromoacetophenone	GSK-3 β	
T8605	GS87	GSK-3	
T7473	5-Bromoindole	GSK-3	
T6940	PHA767491 HCl	Cdk1; Cdk2; Cdk9; Cdc7; GSK-3 β	Phase 1

ID	Product Name	Target	Condition
T6787	BIO-acetoxime	GSK-3 α ; GSK-3 β	
T6659	SB415286	GSK-3 α , GSK-3 β	
T6350	CHIR124	Chk1; FLT3; GSK-3; PDGFR; Fyn	Preclinical
T6205	AT7519	CDK2/CyclinA; CDK4/CyclinD1; CDK5/p35; CDK9/CyclinT; GSK-3 β	Phase 2
T6187	TDZD8	GSK-3 β	Preclinical
T6169	Indirubin	GSK-3 β , CDK2/CyclinA , CDK5/p35 , CDK1/CyclinB , C-Raf	Approved
T6049	SNS032	CDK2/CyclinA; CDK2/CyclinE; CDK7/CyclinH; CDK9/CyclinT; GSK-3 α	Phase 2
T5956	VP3.15 dihydrobromide	GSK-3; PDE7	
T5200	Indirubin-3'-monoxime	GSK-3 β ; CDK1/CyclinB; CDK2/CyclinE; CDK5/p25	
T3684	CP21R7	GSK-3 β ; PKC α	
T3385	Gypenoside XVII	GSK-3 β	
T3166	VX-11e	Aurora A; CDK2; ERK2; FLT3; GSK-3	
T3077	SB216763	GSK-3 α ; GSK-3 β	
T3067	Tideglusib	GSK-3 β	Approved
T2873	Ginsenoside Rg2	GSK-3 β	
T2695	TBB	CK2; CDK2; GSK-3 β	
T2608	CHIR98014	bFGFR; GSK-3 α ; GSK-3 β ; p70 S6K; c-Src	
T2310	CHIR99021	GSK-3 α ; GSK-3 β	Preclinical
T2261	IM12	GSK-3 β	
T2247	KenPaullone	CDK1/CyclinB; CDK2/CyclinA; CDK2/CyclinE; CDK5/p35; GSK-3 β	Preclinical
T2166	TWS119	GSK-3 β	
T1965	Bikinin	GSK-3; Shaggy-like kinase	
T1957	AZD2858	GSK-3	Preclinical
T1917	6-BIO	CDK1/CyclinB; CDK2/CyclinA; CDK5/p35; GSK-3; Tyk2	
T1881	AR-A014418	GSK-3 β ; GSK-3 β	Preclinical
T1778	AT 7519 hydrochloride salt	CDK2/CyclinA; CDK4/CyclinD1; CDK5/p35; CDK9/CyclinT; GSK-3 β	Phase 2
T1755	LY2090314	GSK-3 α ; GSK-3 β	Phase 2
T1741	AZD1080	GSK-3 α ; GSK-3 β	Phase 1
T17019	TCS 21311	JAK3; JAK2; JAK1; PKC α ; PKC θ ; GSK-3 β	
T14066	9-ING-41	GSK-3 β	Phase 2
T11467	GSK-3 β inhibitor 1	GSK-3 β	
T0704	Cyanoacetohydrazide	GSK-3	Approved
T0256	Lithium citrate tribasic tetrahydrate	IMPDH; mGluR3; GSK-3 β	FDA Approved

MELK

ID	Product Name	Target	Condition
T21559	OTSSP167 hydrochloride	MELK	
T1759	OTSSP167	MELK	Phase 1/2

mTOR

ID	Product Name	Target	Condition
T8649	TMBIM6 antagonist-1	TMBIM6	
T8569	DMH-25	mTOR	
T7343	PF-04979064	PI3K; mTOR	
T7166	GNE-493	mTOR; PI3K	
T6883	LY3023414	DNA-PK; mTOR kinase; class I PI3K isoforms	Phase 2
T6731	WYE354	mTOR; PI3K α ; PI3K γ	
T6334	Ridaforolimus	mTOR	Phase 3
T6319	OSI027	DNA-PK; mTOR; mTORC1; mTORC2; PI3K γ	Phase 1
T6159	LY-2584702 free base	mTOR (p70S6K)	Phase 1
T6143	PI103	DNA-PK; p110 α ; p110 β ; p110 γ ; p110 δ ; mTOR	Preclinical
T6103	VS5584	mTOR; PI3K α ; PI3K β ; PI3K γ ; PI3K δ	Phase 1
T6100	Torin 2	ATM; ATR; DNA-PK; mTOR	
T6045	Torin 1	DNA-PK; mTOR; mTORC1; mTORC2; p110 γ	
T6033	Zotatarolimus	FKBP-12	
T6030	XL388	mTOR; mTORC1; mTORC2; CYP2C9; PI3K α	Preclinical
T5338	mTOR inhibitor-1	mTOR	
T4639	MSDC 0602	mTOR	Phase 2
T4488	GSK25	RSK1; mTOR (p70S6K)	
T4423	LY303511 hydrochloride	mTOR inhibitor	
T4199	Desmethyl-VS-5584	mTOR; PI3K	
T302749	L-Leucine	mTOR	FDA Approved
T3986	SF2523	DNA-PK; BRD4; mTOR; PI3K α ; PI3K γ	Preclinical
T3705	GDC0084	mTOR; PI3K α ; PI3K β ; PI3K γ ; PI3K δ	Phase 2
T3692	GNE 477	mTOR; PI3K α	
T3541	CC115	DNA-PK; mTOR; PI3K α	Phase 1
T3514	CZ415	mTOR	
T3395	Timosaponin AIII	mTORC1	
T3351	CC223	c-Fms; DNA-PK; FLT4; mTOR; PI3K- α	Phase 2
T3153	Serabelisib	mTOR; p110 α ; p110 β ; p110 γ ; p110 δ	Phase 2
T2998	Dihydropyridinone	GABAR; mTOR	Phase 2
T2717	Salidroside	mTOR	
T2706	Palomid 529	mTORC1; mTORC2	Phase 1
T2685	KU55933	ATM; ATR; DNA-PK; mTOR; PI3K	Preclinical

ID	Product Name	Target	Condition
T2619	CH5132799	mTOR; PI3K α ; PI3K β ; PI3K γ ; PI3K δ	Phase 1
T2616	PIK93	ATM; C2 β ; DNA-PK; hsVps34; mTORC1; p110 α ; p110 β ; p110 γ ; p110 δ ; PI3KIII β	
T2475	KU0063794	mTORC1; mTORC2	Preclinical
T2415	PP121	Hck; mTOR; PDGFR; Src; VEGFR; Abl	
T2414	Torkinib	mTOR; mTORC1; mTORC2; p110 δ	
T2357	GSK1059615	mTOR; PI3K α ; PI3K β ; PI3K γ ; PI3K δ	Phase 1
T2265	PI3K-IN-2	pPKB; pS6; PI3K α ; PI3K β ; mTOR; PI3K γ ; PI3K δ	Phase 2
T2235	Dactolisib	ATR; mTOR (p70S6K); p110 α ; p110 γ ; p110 δ	Phase 2
T2145	Temsirolimus	mTOR	FDA Approved
T2144	Tacrolimus	FKBP-12	FDA Approved
T2084	ETP46464	ATM; ATR; DNA-PK; mTOR; PI3K α	
T2083	PI3065	DNA-PK; mTOR; p110 α ; p110 β ; p110 δ	
T1970	Gedatolisib	mTOR; PI3K α ; PI3K γ	Phase 3
T1961	Vistusertib	P-Akt (S473); mTOR; PI3K α ; pS6 (S235/236)	Phase 1/2
T1958	AZ20	ATR; mTOR	
T1920	Capivasertib	Akt1; Akt2; Akt3; PKA; mTOR (p70S6K)	Phase 2
T1916	Apitolisib	mTOR; p110 α ; p110 β ; p110 γ ; p110 δ	Phase 2
T1908	MHY1485	mTOR	
T1861	Ompalisib	mTORC1; p110 α ; p110 β ; p110 γ ; p110 δ	Phase 1
T1859	AZD8055	mTOR	Phase 1
T1838	INK 128	mTOR; mTOR; PI3K α ; PI3K γ ; PI3K δ	Phase 2
T1784	Everolimus	mTOR (FKBP12)	FDA Approved
T16567	PQR-530	PI3K; mTORC1; mTORC2	
T16156	MT 63-78	AMPK; mTORC1	
T1537	Rapamycin	mTOR; Autophagy	FDA Approved
T11728	JR-AB2-011	mTORC2	

PDK

ID	Product Name	Target	Condition
T6084	Rabusertib	Chk1; PDK1	Phase 1
T4046	BX517	PDK1; cAKT2	Preclinical
T3604	Sodium Dichloroacetate	PDK	Phase 1
T2466	Osu03012	PDK1	Preclinical
T2420	PHT427	Akt; PDK1	Preclinical
T22350	JX06	PDK	
T1837	BX912	CDK2/CyclinE; Chk1; PDK1; PKA; VEGFR2 (KDR)	Preclinical
T1830	BX795	CDK2/CyclinE; Chk1; c-Kit; PDK1	Preclinical
T17224	VER-246608	PDK1; PDK2; PDK3; PDK4	
T0809	Dicumarol	NQO1; PDK1	FDA Approved

PI3K

ID	Product Name	Target	Condition
TQ0044	Seletalisib	PI3Kδ	Phase 3
TQ0009	UCB9608	PI4KIIIβ	
TQ0003L	740 Y-P(TFA)	PI3K	
TN1034	Sennidin B	Akt; GLUT; PI3K	
TN1033	Sennidin A	Akt; GLUT; PI3K	
T8651	CAL-101	p110δ	FDA Approved
T8461	SKI V	SphK; PI3K	
T7944	VPS34 inhibitor 1 (Compound 19, PIK-III analogue)	Vps34	
T7879	TASP0415914	PI3Kγ	
T7343	PF-04979064	PI3K; mTOR	
T7166	GNE-493	mTOR; PI3K	
T7015	VPS34-IN1	Vps34	
T7014	Voxtalisib	DNA-PK; PI3Kα; PI3Kβ; PI3Kγ; PI3Kδ	Phase 1/2
T6945	PIK-III	PI3Kα; PI3Kβ; PI3Kγ; PI3Kδ; Vps34	
T6938	PF4989216	p110δ; p110α; p110γ; Vps34; p110β	
T6883	LY3023414	DNA-PK; mTOR kinase; class I PI3K isoforms	Phase 2
T6845	GNE317	PI3K/mTOR	
T6817	Deguelin	PI3K; Akt	
T6799	IITZ-01	PI3Kγ; Autophagy	
T6774	AZD8835	PI3Kα; PI3Kβ; PI3Kγ; PI3Kδ	Phase 1
T6773	AZD8186	PI3Kα; PI3Kβ; PI3Kγ; PI3Kδ	Phase 2
T6757	AMG319	PI3Kα; PI3Kβ; PI3Kγ; PI3Kδ	Phase 2
T6731	WYE354	mTOR; PI3Kα; PI3Kγ	
T6433	CAY10505	PI3Kγ	
T6394	AS604850	PI3Kα; PI3Kβ; PI3Kγ; PI3Kδ	
T6330	PI3Kδ-IN-2	PI3Kδ	
T6322	Copanlisib	PI3Kα; PI3Kβ; PI3Kγ; PI3Kδ	FDA Approved
T6319	OSI027	DNA-PK; mTOR; mTORC1; mTORC2; PI3Kγ	Phase 1
T6283	Wortmannin	PI3K , DNA-PK , ATM , MLCK , ATR	Preclinical
T6251	PF04691502	P-Akt (S473); PI3Kα; PI3Kβ; PI3Kγ; PI3Kδ	Phase 2
T6208	AS252424	Casein Kinase 2 , PI3Kγ , PI3Kα	
T6168	ZSTK474	PI3K; PI3Kα; PI3Kβ; PI3Kγ; PI3Kδ	Phase 1
T6143	PI103	DNA-PK; p110α; p110β; p110γ; p110δ; mTOR	Preclinical
T6110	YM201636	p110α; PIKfyve	
T6103	VS5584	mTOR; PI3Kα; PI3Kβ; PI3Kγ; PI3Kδ	Phase 1
T6087	AZD6482	DNA-PK; PI3Kα; PI3Kβ; PI3Kγ; PI3Kδ	Phase 1
T6072	BGT226	PI3Kα; PI3Kβ; PI3Kγ	Phase 1/2
T6045	Torin 1	DNA-PK; mTOR; mTORC1; mTORC2; p110γ	

ID	Product Name	Target	Condition
T6030	XL388	mTOR; mTORC1; mTORC2; CYP2C9; PI3K α	Preclinical
T550896	Loureirin A	PI3K	
T5831	Selective PI3K δ Inhibitor 1	PI3K δ	
T5736	CYNARIN	Akt; PI3K	
T5432	IPI-549	PI3K α /PI3K β /PI3K γ	Phase 2
T5166	Leniolisib	PI3K δ ; DNA-PK	Phase 2/3
T4976	TGR1202	PI3K δ	Phase 3
T4958	Alkannin	PI3K α	
T4398	LX2343	BACE1; PI3K	
T4296	MTX211	EGFR; PI3K	Preclinical
T4220	BQR695	PI3KIII β	
T4219	Autophinib	rapamycin-induced autophagy; starvation-induced autophagy; VPS34	
T4199	Desmethyl-VS-5584	mTOR; PI3K	
T4079	LY-294002 hydrochloride	p110 α ; p110 β ; p110 δ	Preclinical
T3986	SF2523	DNA-PK; BRD4; mTOR; PI3K α ; PI3K γ	Preclinical
T3985	GDC0326	PI3K α	
T3705	GDC0084	mTOR; PI3K α ; PI3K β ; PI3K γ ; PI3K δ	Phase 2
T3692	GNE 477	mTOR; PI3K α	
T3556	NIH12848	PI5P4K γ	
T3541	CC115	DNA-PK; mTOR; PI3K α	Phase 1
T3410	Momordin Ic	MAPK; PI3K	
T3351	CC223	c-Fms; DNA-PK; FLT4; mTOR; PI3K- α	Phase 2
T3348	PIK293	p110 α ; p110 β ; p110 γ ; p110 δ	
T3190	PIK-inhibitors	PI3K	
T3153	Serabelisib	mTOR; p110 α ; p110 β ; p110 γ ; p110 δ	Phase 2
T2P2919	(4S)-4-Hydroxy-L-isoleucine	PI3K	
T2836	Isorhamnetin	MEK; PI3K	
T2685	KU55933	ATM; ATR; DNA-PK; mTOR; PI3K	Preclinical
T2682	Acalisib	PI3K δ	Phase 2
T2672	TG100-115	PI3K α ; PI3K β ; PI3K γ ; PI3K δ	Phase 2
T2667	PIK75	DNA-PK; p110 α ; p110 β ; p110 γ ; p110 δ	
T2661	TGX221	p110 α ; p110 β ; p110 γ ; p110 δ	Preclinical
T2660	IC87114	PI3K β ; PI3K γ ; PI3K δ	
T2619	CH5132799	mTOR; PI3K α ; PI3K β ; PI3K γ ; PI3K δ	Phase 1
T2616	PIK93	ATM; C2 β ; DNA-PK; hsvps34; mTORC1; p110 α ; p110 β ; p110 γ ; p110 δ ; PI3KIII β	
T2461	PIK90	PI3K α ; PI3K β ; PI3K γ ; PI3K δ ; DNA-PK	
T2433	NU7026	ATM; ATR; DNA-PK; PI3K	
T2418	A66	p110 α ; p110 γ ; p110 δ ; PI3K β	
T2414	Torkinib	mTOR; mTORC1; mTORC2; p110 δ	

ID	Product Name	Target	Condition
T2377	XL147 analogue	DNA-PK; PI3K α ; PI3K β ; PI3K γ ; PI3K δ	Phase 1/2
T2365	Pilaralisib	PI3K α ; PI3K β ; PI3K γ ; PI3K δ	Phase 1/2
T2357	GSK1059615	mTOR; PI3K α ; PI3K β ; PI3K γ ; PI3K δ	Phase 1
T2308	HS173	PI3K α	
T2297	PIK294	p110 α ; p110 α ; p110 β ; p110 γ ; p110 δ	
T2287	PIK-75 hydrochloride	DNA-PK; p110 α ; p110 β ; p110 γ ; p110 δ	
T2265	PI3K-IN-2	pPKB; pS6; PI3K α ; PI3K β ; mTOR; PI3K γ ; PI3K δ	Phase 2
T2256	CNX1351	PI3K α	Preclinical
T2248	AS605240	PI3K α ; PI3K β ; PI3K γ ; PI3K δ	
T2235	Dactolisib	ATR; mTOR (p70S6K); p110 α ; p110 γ ; p110 δ	Phase 2
T21992	Vacuolin-1	PIKfyve	
T2174	Quercetin	PI3K γ ; PI3K δ	Phase 2/3
T2084	ETP46464	ATM; ATR; DNA-PK; mTOR; PI3K α	
T2083	PI3065	DNA-PK; mTOR; p110 α ; p110 β ; p110 δ	
T2078	PI3K/HDAC Inhibitor	HDAC1; HDAC10; HDAC11; HDAC2; HDAC3	Phase 2
T2073	GSK2636771	PI3K β	Phase 2
T2061	APY0201	PIKfyve	
T2018	Apilimod	IL-12; IL-23; PIKfyve	Phase 1
T2008	LY294002	p110 α ; p110 β ; p110 δ ; DNA-PK	Preclinical
T1999	Taselisib	PI3K α ; PI3K β ; PI3K γ ; PI3K δ ; C2 β	Phase 1
T1994	Pictilisib	p110 α ; p110 β ; p110 γ ; p110 δ	Phase 2
T1988	Duvelisib	PI3K α ; PI3K β ; PI3K γ ; PI3K δ	FDA Approved
T1970	Gedatolisib	mTOR; PI3K α ; PI3K γ	Phase 3
T1961	Vistusertib	P-Akt (S473); mTOR; PI3K α ; pS6 (S235/236)	Phase 1/2
T1949	CZC24832	PI3K β ; PI3K γ ; PI3K δ	
T1921	Alpelisib	PI3K α	FDA Approved
T1916	Apitolisib	mTOR; p110 α ; p110 β ; p110 γ ; p110 δ	Phase 2
T1894	Idelalisib	p110 γ ; p110 δ	FDA Approved
T1879	3-Methyladenine	PI3K γ ; Vps34	
T1861	Ompalisib	mTORC1; p110 α ; p110 β ; p110 γ ; p110 δ	Phase 1
T1838	INK 128	mTOR; mTOR; PI3K α ; PI3K γ ; PI3K δ	Phase 2
T1827	Buparlisib	p110 α ; p110 β ; p110 γ ; p110 δ ; Vps34	Phase 2
T1826	Voxtalibis Analogue	DNA-PK; PI3K α ; PI3K β ; PI3K γ ; PI3K δ	Phase 1/2
T16567	PQR-530	PI3K; mTORC1; mTORC2	
T15789	LTURM34	DNA-PK; PI3K β ; PI4K δ	
T14998	Copanlisib dihydrochloride	PI3K α ; PI3K δ ; PI3K β ; PI3K γ ; mTOR	FDA Approved
T14511	BAY1082439	PI3K α ; PI3K β ; PI3K δ	Phase 1
T12831L	SAR405	Vps34; Vps34; Autophagy	
T12469	PI4KIII β -IN-9	PI4KIII β ; PI4KIII α ; PI3K δ ; PI3K γ ; PI3K α ; PI3K2 γ	
T12468	PI4KIII β -IN-10	PI4KIII β ; PI4KIII α ; PI3K δ ; PI3K2 γ ; PI3K α ; PI3K γ	

ID	Product Name	Target	Condition
T1056	Isoprenaline hydrochloride	Adrenergic Receptor; cAMP PDE; PI3K	FDA Approved
T0579	Myricetin	PI3Kγ	

PI4K

ID	Product Name	Target	Condition
T5421	KDU691	PI4K	
T15789	LTURM34	DNA-PK; PI3Kβ; PI4Kδ	


PTEN

ID	Product Name	Target	Condition
T3404	Cucurbitacin B	HIF-1; PTEN; STAT3	

SIK

ID	Product Name	Target	Condition
T5993	ARN-3236	SIK2	
T5576	YKL-06-061	SIK1; SIK2; SIK3	

Proteases/Proteasome



Acetyl-CoA Carboxylase

ID	Product Name	Target	Condition
TQ0243	ND-646	ACC	
T7184	ND-630	ACC	Phase 2
T7163	PF 05175157	ACC	Phase 2
T3988	TOFA	ACC1	
T3622	CP-640186 hydrochloride	ACC1; ACC2	
T3510	Olumacostat Glasaretil	ACC	Phase 3
T1889	CP 640186	ACC	

Acyltransferase

ID	Product Name	Target	Condition
T2753	Avasimibe	ACAT; CYP1A2; CYP2C19; CYP2C9	Phase 3
T1519L	Rimonabant	ACAT; hCB1; hCB2	Approved

ID	Product Name	Target	Condition
T12225L	Nevanimibe hydrochloride	ACAT-1	Phase 2
T11733	K-604 dihydrochloride	ACAT-1; ACAT-2	
T10035	10,12-Tricosadiynoic acid	acyl-CoA oxidase-1	

ATP Citrate Lyase

ID	Product Name	Target	Condition
T7424	NDI-091143	ACLY	
T3625	ETC1002	ACL	FDA Approved
T11589	Hydroxycitric acid tripotassium hydrate	ATP citrate lyase; HIF	

Caspase

ID	Product Name	Target	Condition
TP1466	Z-YVAD-FMK	caspase-1	
T9113	Myristicin	Antifection; Bcl-2; Caspase; CYP17; GABA Receptor; IL Receptor; NO; PARP	
T8652	CASP3 Activator 1541	caspase-3	
T8296	4',5,7-Trimethoxyflavone	Caspase-3; PARP	
T8092	Taurohydoxychocholic acid sodium salt hydrate	Caspase	
T7374	2-HBA	NQO1; Caspase	
T7020	Z-VAD(OH)-FMK	Caspase-8	
T7019	Z-IETD-FMK	Caspase-8	
T7016	VR23	Caspase-like proteasomes; Chymotrypsin-like proteasomes; Trypsin-like proteasomes	
T6993	Sodium Tauroursodeoxycholate (TUDC)	Caspase; ERK	
T6826	Emricasan	Caspase	Phase 2
T6191	Tasisulam	Caspase	Preclinical
T6090	Belnacasan	Caspase-1; Caspase-4	Phase 2
T6013	Z-VAD(OMe)-FMK	Pan-caspase	Preclinical
T6005	Z-DEVD-FMK	Caspase-3	
T5S2283	Sesamol	p38 MAPK; Caspase-3	
T5S2083	Puerarin 6''-O-Xyloside	Caspase	
T5S1632	8-O-Acetylshanzhiside methyl ester	TNF- α ; NF-Kb; VEGFR; Akt; Caspase	
T5574	Guggulsterone E&Z	JNK; Akt; Caspase	
T5558	Chelidonic acid	Caspase-1; NF- κ B	
T4S2012	Dihydro Sanguinarine	Caspase	
T4S1335	Daphnoretin	Caspase-3	

ID	Product Name	Target	Condition
T3S1227	Aristololactam I	Caspase-3	
T3S0335	Soyasaponin Bb	Caspase-3; NF-Kb	
T3914	Saikosaponin C	Caspase-3	
T3907	Senegenin	Caspase-3	
T3600	Licochalcone A	Caspase-3; UGT1A1	Phase 1
T3519	Polyphyllin B	Caspase-2	
T2A2481	Taurochenodeoxycholic Acid	Caspase; TNF- α	Approved
T2503	PAC1	Procaspase-3	Phase 1
T2122	Ixazomib	20S proteasome; 20S proteasome; caspase-like (β 1)	FDA Approved
T1772	Apoptosis Activator 2	Caspase-3	
T10990	Dehydrocorydaline chloride	p38 MAPK; Bax; Bcl-2; caspase-7; caspase-8; PARP	
T10580	BOC-D-FMK	Caspase	
T0282	Q-VD-OPH	Caspase-1; Caspase-3; Caspase-8; Caspase-9	

Cysteine Protease

ID	Product Name	Target	Condition
TQ0116	LY 3000328	Cathepsin S	Phase 1
T7451	2-cyano-Pyrimidine	Cathepsin K	
T6738	Z-FA-FMK	Cysteine protease	
T6583	MG101	Cysteine protease	
T6573	Loxistatin Acid	Cysteine protease	
T6564	Leupeptin Hemisulfate	Cysteine protease; Serine Protease	
T6432	Calpeptin	Calpain 1 (human platelets); Calpain 1 (porcine erythrocytes); Calpain 2 (porcine kidney); Papainb	Preclinical
T6040	Aloxistatin	Cysteine protease	Preclinical
T6037	E64	Cysteine protease	Preclinical
T6035	Odanacatib	Cathepsin K (human); Cathepsin K (rabbit)	Approved
T5211	NSC185058	ATG4B; Autophagy	
T3420	CA-074 methyl ester	Cathepsin B	Preclinical
T3088	N-Ethylmaleimide	Cysteine protease	
T2493	PD 151746	m-calpain; μ -Calpain	
T2470	Calpain Inhibitor III	Calpain	
T21616	L 006235	cathepsin K	
T2154	MG132	20S proteasome, calpain	Preclinical
T1850	Balicatib	Cathepsin K	Phase 2
T17026	Tecovirimat	Cysteine protease	FDA Approved
T1080	2-Aminoethanethiol	Cystine; NPYR2; Somatostatin Receptor	FDA Approved
T0789	PMSF	Cysteine protease; Serine Protease	
T0448	Dexibuprofen	Bcl-2; COX; Cystic fibrosis transmembrane conductance regulator; PPAR γ ; thrombomodulin	Approved

DPP-4

ID	Product Name	Target	Condition
T7369	Gemigliptin	DPP-4	Approved
T7133	Anagliptin	DPP-4; DPP-8; DPP-9;	Approved
T6999	Teneligliptin hydrobromide	Dipeptidyl peptidase-4 ; DPP-9; DPP-8; FAP	Approved
T6237	Trelagliptin	DPP-4	Approved
T6203	Saxagliptin	DPP-4	FDA Approved
T6192	Alogliptin	DPP-4	FDA Approved
T4042	Talabostat mesylate	DPP-4	Phase 1/2
T2401	Alogliptin Benzoate	DPP-4	FDA Approved
T2316	Omarigliptin	DPP-4	Approved
T2296	Trelagliptin succinate	DPP-4	Approved
T1581	Picolamine	DPP-4	
T1502	Vildagliptin	DPP-4	Approved
T1366	3-Pyridylacetic acid hydrochloride	DPP-4	
T0242	Sitagliptin	DPP-4	FDA Approved
T0191	Linagliptin	DPP-4	FDA Approved
T0178	Saxagliptin hydrate	DPP-4	FDA Approved

Gamma-secretase

ID	Product Name	Target	Condition
TP1540	Jagged-1 188-204	Notch	
T6870	L-685,458	γ secretase	
T6861	IMR1	Notch	
T6274	RO4929097	A β 40; γ secretase; Notch	Phase 2
T6249	Avagacestat	γ secretase(A β 42) , γ secretase(A β 40)	Phase 1
T6202	DAPT	γ secretase(A β); A β	Preclinical
T6135	Dibenzazepine	γ secretase (APPL); γ secretase(Notch)	
T6125	Semagacestat	Notch; γ secretase(A β 38); γ secretase(A β 40); γ secretase(A β 42)	Phase 3
T6063	LY411575	Notch S3 cleavage; γ secretase (cell-based); γ secretase (membrane-based)	
T4364	Aftin4	γ secretase(A β 42)	
T4077	PE859	A β ; tau; A β	
T3633	Crenigacestat	Notch-1	Phase 1/2
T3540	IMR-1A	Notch	
T3075	FLI06	Notch	
T2842	Tangeretin	Notch-1	Preclinical
T2639	LY2811376	BACE1; A β	Phase 1
T2625	MK0752	A β	Phase 1

ID	Product Name	Target	Condition
T2262	CHF5074	Beta Amyloid; γ secretase	Phase 2
T15184	E 2012	γ secretase	
T12246	CB-103	notch	Phase 2

Glutaminase

ID	Product Name	Target	Condition
T3968	GK921	TGase	

HCV Protease

ID	Product Name	Target	Condition
T7215	NM107	HCV	
T7158	Ombitasvir	HCV NS5A	FDA Approved
T6729	Lomibuvir	HCV NS5B 1a; HCV NS5B 1b	Phase 2
T6676	Sofosbuvir	HCV	FDA Approved
T6229	Daclatasvir	HCV NS5A	FDA Approved
T6190	Telaprevir	HCV NS3-4A serine protease	FDA Approved
T6025	Danoprevir	HCV NS3/4A protease	Approved
T5938	4-Phenoxybenzylamine	HCV NS3/4A	
T5396	Letermovir	HCMV	FDA Approved
T5127	ABT530	HCV NS5A	FDA Approved
T5126	Glecaprevir	HCV NS3/4A protease	FDA Approved
T4988	Boceprevir	HCV NS3 protease	FDA Approved
T4686	Simeprevir	HCV NS3/4A protease; HCV	FDA Approved
T4547	Grazoprevir	NS3/4a protease; gt1a; gt1b	FDA Approved
T4544	Elbasvir	HCV NS5A	FDA Approved
T4474	Asunaprevir	HCV NS3/4A protease	Approved
T4203	Ledipasvir acetone	HCV	FDA Approved
T4197	HZ1157	HCV NS3/4A protease	Preclinical
T3489	Dasabuvir	NS5B polymerase	FDA Approved
T3334	Velpatasvir	HCV NS5A	FDA Approved
T3226	Paritaprevir	HCV NS3/4A	FDA Approved
T2774	Lycorine chloride	HCV	
T2162	Maribavir	HCMV	Phase 3
T2117	PSI6206	HCV replicon	Preclinical
T19862	Voxilaprevir	HCV	FDA Approved
T1786	Daclatasvir dihydrochloride	HCV NS5A	FDA Approved
T17029	Tegobuvir	HCV NS5B polymerase	Phase 2
T1643	Penciclovir	EBV; HCMV; HSV-1; HSV-2; VZV	FDA Approved

ID	Product Name	Target	Condition
T16088	MK-0608	HCV replicon	
T15573	Inarigivir soproxil	HCV	Phase 2
T14667	BLT-1	HCV; SR-BI	
T0392	Artemisinin	HCV; Parasite	Approved
T0013	Mecarbinat	HCV	Approved

HIV Protease

ID	Product Name	Target	Condition
TQ0297	Cenicriviroc	CCR2; CCR5; HIV-1; HIV-2	Phase 3
TP1809	TAT	HIV-1	
TP1348	FC131 TFA	CXCR4; HIV	
TN1727	Helichrysetin	HIV	
TN1103	Diphyllin	HIV-1; Vesicular stomatitis virus (VSV); Vacuolar type H ⁺ -ATPase	
TL0006	Chicoric Acid	HIV-I integrase	
T8689	CHLOROQUINE	HIV-1; autophagy; TLR; SARS-COV-2	FDA Approved
T8311	ABX-464	HIV	Phase 2
T7903	Saquinavir	HIV Protease	FDA Approved
T7789	DRB	HIV	
T7779	Nelfinavir	HIV-1	FDA Approved
T7700	Lersivirine(UK 453061)	HIV	Phase 2
T7455	4-Chloro-2-(trifluoroacetyl) aniline hydrochloride	HIV-1 RT	
T7382	NBD-557	HIV	
T7282	Tenofovir alafenamide fumarate	HIV-1	FDA Approved
T7212	Delavirdine (mesylate)	HIV-1	FDA Approved
T7111	Tenofovir Disoproxil	HIV	FDA Approved
T6653	Salmeterol Xinafoate	β ₂ -adrenergic receptor; WT β ₂ AR	FDA Approved
T6420	BMS707035	HIV-I integrase	Preclinical
T6388	Amprenavir	HIV protease	FDA Approved
T6367	Abacavir sulfate	HIV-1 reverse-transcriptase	FDA Approved
T6256	YYA021	Gp120; HIV	
T6198	Dolutegravir	HIV integrase	FDA Approved
T6098	Cabotegravir	HIV integrase	Phase 3
T6065	Triciribine	Akt; HIV-1	Phase 1/2
T6001	Nelfinavir Mesylate	HIV protease	FDA Approved
T5965	Ditiocarb sodium	HIV	
T5863	Indinavir sulfate	HIV Protease	FDA Approved
T5782	Bevirimat	HIV-1	Phase 2

ID	Product Name	Target	Condition
T4S1999	Valepotriate	HIV	
T4S1718	Punicalin	HIV-1	
T4S1383	Escin IA; Aescin IA	HIV-1 protease	
T4S0295	Apigenin 7-glucoside	HIV	
T4962	Ginsenoside Z-R1	HIV	
T4665	BMS626529	HIV	
T4537	SodiumCholate	HIV	
T4493	Bictegravir	HIV-I integrase	FDA Approved
T4182	lavendustin B	Tyrosine Kinase inhibitor; HIV-1 integrase	
T3732	Sebacic acid	HIV	
T3683	lithospermic acid	HIV	
T3632	Doravirine	HIV-1	FDA Approved
T3335	Darunavir Ethanolate	WT HIV-1 protease	FDA Approved
T3321	Oleanonic Acid	HIV	
T3172	Trovirdine	HIV RT	
T2S0223	Isosinensetin	Antioxidant; HIV-1	
T2830	Betulinic acid	Aminopeptidase N; HIV-1; Eukaryotic topoisomerase I	Phase 1
T2728	Limonin	HIV Protease	Approved
T2409L	Tenofovir Disoproxil Fumarate	HIV reverse transcriptase	FDA Approved
T2393	Efavirenz	HIV-1 RT	FDA Approved
T2332	Elvitegravir	HIV-1 IIIB; HIV-2 EHO; HIV-2 ROD	FDA Approved
T2329	Dolutegravir sodium	HIV integrase	FDA Approved
T2324	Darunavir	HIV Protease	FDA Approved
T2239	Raltegravir potassium	HIV; Integrase (IN)	FDA Approved
T1883	Des(benzylpyridyl) Atazanavi	HIV-1 protease	
T1815	Dapivirine	HIV reverse transcriptase	Phase 3
T16764	RN-18	HIV-1	
T1623	Lopinavir	HIV protease	FDA Approved
T1595	Nevirapine	HIV-1 reverse transcriptase	FDA Approved
T15436	GSK2838232	HIV	
T1525	Ritonavir	HIV Protease	FDA Approved
T13647	Dextran sulfate sodium salt (MW 16000-24000)	HIV; Apoptosis	FDA Approved
T1267	Abacavir	HIV-1 reverse-transcriptase	FDA Approved
T11451	GPI-1046	HIV	
T10570	Fostemsavir Tris	HIV-1	FDA Approved
T10111	3-Deazaadenosine hydrochloride	HIV-1, A012 isolate; HIV-1, A018 isolate; S-adenosylhomocysteine hydrolase	
T0110	Zalcitabine	HIV	FDA Approved

ID	Product Name	Target	Condition
T0100L	Atazanavir	HIV Protease	FDA Approved
T0100	Atazanavir sulfate	HIV protease	FDA Approved

MMP

ID	Product Name	Target	Condition
TP1446	Histatin 5 (TFA)(115966-68-2,free)	MMP-2; MMP-2	
TN3016	4',6,7-Trimethoxyisoflavone	MMP	
TN1928	Methyl rosmarinat	Tyrosinase; Antifection; MMP	
T8310	MMP-9-IN-1	MMP-9	
T7522	GI 254023X	MMP-9; ADAM10	
T7449	1, 10-Phenanthroline monohydrate	MMP	
T7044	Norepinephrine	MMP-2; MMP-9; α2A adrenoceptor; α1 adrenoceptor; β1 adrenoceptor	FDA Approved
T6S0444	Salvianolic acid A	MMP-9	Phase 1
T6011	Batimastat	MMP-1; MMP-2; MMP-3; MMP-7; MMP-9	Preclinical
T5S1026	Apigenin-7-glucuronide	MMP-3; MMP-8; MMP-13; MMP-9	
T5680	ALOIN	MMP; IL Receptor	
T5416	T-5224	c-Fos/AP-1	
T5361	T-26c	MMP-13	
T4S0181	Hinokiflavone	MMP; bax; bcl-2	
T4783	JNJ0966	MMP-9	
T3850	Luteolin-7-glucuronide	MMP-13; MMP-3; MMP-8; MMP-9; MMP-1	
T3813	Ginsenoside Rh2	MMP	
T3729	Ethyl gallate	Akt; MMP-2; MMP-9; NF-κB	
T3472	CGS 27023A	MMP	Preclinical
T3414	Morrisonide	MMP-2; MMP-9	
T3388	Calycosin-7-O-beta-D-glucoside	MMP-2; MMP-9	
T3090	Abietic Acid	MMP-1; PPARα; PPARγ; 5-lipoxygenase	
T2987	Epigallocatechin	MMP	
T2967	Stigmasterol	MMP	
T2957	Arctigenin	Autophagy; MMP	Approved
T2893	Muscone	MMP-9; P-gp (P-glycoprotein)	
T2834	Nobiletin	MMP	
T2792	Glucosamine sulfate	MMP-3	Approved
T2787	Picroside I	MMP	Preclinical
T2750	Ginkgolide C	AMPK; MMP; Sirtuin	
T2743	Ilomastat	MMP-1; MMP-12; MMP-2; MMP-26; MMP-7; MMP-8; MMP-9	Preclinical

ID	Product Name	Target	Condition
T2009	SB-3CT	MMP-2; MMP-9	
T1891	NSC 405020	MT1-MMP	
T1592	Acetohydroxamic acid	MMP	FDA Approved
T1402	Fenofibric acid	MMP; PPAR α ; COX-2	FDA Approved
T0429	Glucosamine	Chitosanase; MMP-9; NF- κ B; IF γ ; TNF- α	Approved

Neprilysin

ID	Product Name	Target	Condition
TQ0106	Sacubitrilat	Neprilysin	
T19626	LHW090-A7	neutral endopeptidase (NEP)	

phosphatase

ID	Product Name	Target	Condition
TCS1372	Atracic acid	Androgen Receptor; PTP1B	
T8519	Raphin1 acetate	phosphatase PPP1R15B (R15B)	
T8478	SC-43	SHP-1; STAT3; apoptosis	
T6459	Cyclosporine	calcineurin phosphatase	FDA Approved
T4671	CDC25 Phosphatase Inhibitor I	CDC25A; CDC25B2; CDC25B3; CDC25C; CDC25C-cat	
T4308	F1063-0967	DUSP26	
T4256	PTP1B-IN-2	PTP1B	
T20879	Tacrolimus hydrate	FKBP; Phosphatase; Autophagy; Bacterial; Antibiotic	FDA Approved
T16350	NSC-87877	SHP-2; SHP-1; DUSP26	
T13176	TN0155	SHP-2	Phase 1/2
T10486	BCI	phosphatase	

Proteasome

ID	Product Name	Target	Condition
T8397	Ixazomib citrate	Proteasome	FDA Approved
T7854	Bortezomib-pinanediol	Proteasome	
T7814	Alloxan Monohydrate	Proteasome	
T7016	VR23	Caspase-like proteasomes; Chymotrypsin-like proteasomes; Trypsin-like proteasomes	
T6999	Teneligliptin hydrobromide	Dipeptidyl peptidase-4; DPP-9; DPP-8; FAP	Approved
T6941	PI1840	Chymotrypsin-like proteasome	
T6830	Epoxomicin	20S proteasome	
T6041	Oprozomib	20S proteasome; 20S proteasome	Phase 1/2

ID	Product Name	Target	Condition
T6029	ONX0914	immunoproteasome	Preclinical
T6027	Delanzomib	Chymotrypsin-like proteasome	Phase 1
T4467	UAMC 00039 dihydrochloride	Dipeptidyl peptidase II	
T3359	Aprotinin	Chymotrypsin-like proteasome; kallikrein; Trypsin; trypsinogen	FDA Approved
T3028	Celastrol	20S proteasome	
T2583	Cilastatin	Dipeptidase 1	FDA Approved
T2399	Bortezomib	20S proteasome	FDA Approved
T2370	AOB2796	Protease-Activated Receptor 2	
T2154	MG132	20S proteasome, calpain	Preclinical
T2122	Ixazomib	20S proteasome; 20S proteasome; caspase-like (β 1)	FDA Approved
T2016	MLN9708	20S proteasome; 20S proteasome	FDA Approved
T1795	Carfilzomib	Proteasome	FDA Approved
T17011	TCH-165	Proteasome	
T16684	Puromycin aminonucleoside	apoptosis; dipeptidyl peptidase II; antibiotic	
T13858	RA190	Proteasome	
T12628	(R)-MG-132	Proteasome	
T12579	PTP1B-IN-9	Proteasome	
T1176	Racecadotril	Endopeptidase	Approved

Serine Protease

ID	Product Name	Target	Condition
T8362	Benzamidine HCl	Serine Protease	
T6986	Sivelestat	neutrophil elastase	Approved
T6564	Leupeptin Hemisulfate	Cysteine protease; Serine Protease	
T6370	AESBF hydrochloride	Serine Protease	
T6285	GSK690693	Akt1; Akt3; PKC η ; PKC θ ; PrkX	Phase 1
T5S0689	Demethylwedelolactone	trypsin	
T5597	ZT-12-037-01	STK19	
T3990	AA26-9	serine hydrolase	
T3442	UK371804	uPA	Preclinical
T3423	ML281	STK33	
T3359	Aprotinin	Chymotrypsin-like proteasome; kallikrein; Trypsin; trypsinogen	FDA Approved
T3107	Alvelestat	neutrophil elastase; neutrophil elastase	Phase 2
T2392	Nafamostat mesylate	Serine Protease	Approved
T2118	SC514	Aurora B; CDK2/CyclinA; IKK2; p38 α ; PRAK	
T1791	LDK378	ALK; IGF-1R; Insulin Receptor; STK22D	FDA Approved

ID	Product Name	Target	Condition
T1145	Diminazene Aceturate	Peroxiredoxin-5; QacR; Trypsin-1	Approved
T0789	PMSF	Cysteine protease; Serine Protease	
T0372	Gabexate mesylate	Serine Protease	Approved
T0175	Amiloride hydrochloride	uPA	FDA Approved

Thrombin


ID	Product Name	Target	Condition
T7053	p-Hydroxy-cinnamic acid	Thromboxane A2 synthetase; PGE2	
T6825	Eltrombopag Olamine	Thrombopoietin receptor	FDA Approved
T6625	Ozagrel hydrochloride	Thromboxane A2 synthetase	Approved
T6531	Heparin sodium	Thrombin III	FDA Approved
T6236	Ozagrel	Thromboxane A2 synthetase	Approved
T5519	Bivalirudin	Thrombin	FDA Approved
T5133	Dabigatran Etxilate Mesylate	Thrombin	FDA Approved
T2562	Eltrombopag	Thrombopoietin receptor	FDA Approved
T2368L	Edoxaban	Factor Xa; Thrombin	FDA Approved
T2368	Edoxaban Tosylate Monohydrate	Factor Xa; Factor Xa; Thrombin	FDA Approved
T22246	Argatroban Monohydrate	Thrombin	FDA Approved
T1184	Rivaroxaban	Factor Xa; Thrombin	FDA Approved
T10951	Dabigatran ethyl ester hydrochloride	thrombin; NQO2	
T0449	Menadione	Thrombin; VK	FDA Approved
T0448	Dexibuprofen	Bcl-2; COX; Cystic fibrosis transmembrane conductance regulator; PPARγ; thrombomodulin	Approved
T0438	Proflavine Hemisulfate	DNA mutation; LfrR; QacR; Thrombin	Approved
T0389	Dabigatran etexilate	Thrombin	FDA Approved
T0155	Argatroban	Thrombin	FDA Approved

Tyrosinase

ID	Product Name	Target	Condition
TN2246	Swertiajaponin	tyrosinase	
TN1928	Methyl rosmarinate	Tyrosinase; Antifection; MMP	
TN1772	Isoastilbin	Antifection; Tyrosinase	
TN1545	D-Tyrosine	Tyrosinase	FDA Approved
TCS2170	2-5-dihydroxyacetophenone	Tyrosinase	
T8087	Tropolone	Tyrosinase	
T7438	3,5-Dimethoxyphenol	Tyrosinase	

ID	Product Name	Target	Condition
T7125	4-Butylresorcinol	Tyrosinase	
T7052	Gnetol	BChE; Tyrosinase	
T6S1597	Mulberroside A	monophenolase	
T6463	Deoxyarbutin	Tyrosinase	
T5985	Glycolic acid	Tyrosinase	Phase 1
T5755	Aloesin	Tyrosinase	
T5552	Methyl cinnamate	Tyrosinase	
T4S1658	Benzoyloxypeoniflorin	Tyrosinase	
T4291	(+)-Isocorydine hydrochloride	eukaryote protein kinases; tyrosine kinase	
T4185	lavendustin C	tyrosine kinase	
T4182	lavendustin B	Tyrosine Kinase inhibitor; HIV-1 integrase	
T3S1612	kuwanon G	α -glucosidase; PTP1B; AChE; BChE	
T3S1068	Oxyresveratrol	Tyrosinase	
T3923	Calycosin	Tyrosinase	
T3737	Hydroumbellic acid	Tyrosinase	
T3403	Glabridin	T1 tyrosinase; T3 tyrosinase; α 1 β 2 γ 2 (GABAA receptor); α 1 β 3 γ 2 (GABAA receptor); α 1 β 2 (GABAA receptor); α 1 β 1 γ 2 (GABAA receptor)	
T3382	Wilforlide A	Tyrosinase	
T2P2923	Stearic acid	Tyrosine Phosphatase 1B	
T2A2524	4-Methoxysalicylaldehyde	Tyrosinase	
T1738	Taxifolin	β -adrenergic receptor; TNF- α ; Collagenase Tyrosinase; Beta-nerve growth factor; VEGFR2	
T1210	Sodium etidronate	protein tyrosine phosphatase	FDA Approved
T1188	Mizoribine	monophosphate synthetase	Approved
T0759	Monobenzene	Tyrosinase	FDA Approved
T0666	4-Chlorosalicylic acid	Antibiotic; diphenolase; monophenolase	
T0473	Arbutin	Tyrosinase	Approved
T0314	Hexylresorcinol	diphenolase; monophenolase	Approved

Stem Cells



Casein Kinase

ID	Product Name	Target	Condition
T7390	DMAT	CK2	
T6735	XL413 hydrochloride	CK2; Cdc7; Pim1; Cdc7	Phase 1/2
T6315	MLN8054	Aurora A; Aurora B; CK2; PKA; Lck	
T6208	AS252424	Casein Kinase 2, PI3Ky, PI3Kα	
T5393	CK1-IN-1	CK1; p38σ MAPK	
T5358	Longdaysin	CK1α; CK1δ; CDK7; ERK2	
T5056	PF4800567	CK1ε	
T4645	TA01	CK1 ε ; CK1δ; p38 MAPK	
T3972	SR3029	CK1δ	
T3073	PF670462	CK1ε	
T2869	Emodin	CK2	Preclinical
T2695	TBB	CK2; CDK2; GSK-3β	
T2449	D 4476	ALK5; CK1; CK1δ	
T2440	IC261	CK1; CDK5	
T2259	Silmitasertib	CK2	Phase 1/2
T2048	LY364947	CK1δ; MLK-7K; TGFβRI; TGFβRII; RIPK2	
T1828	TTP 22	CK2	

ID	Product Name	Target	Condition
T15024	Silmitasertib sodium salt	CK2; Autophagy	Phase 1/2
T14069	A-3 hydrochloride	CK1; CK2; PKC; PKA	
T0465	Ellagic acid	Carbonic anhydrase; CK2; Smoothened; PKA; PKC; Syk; ATP-competitive CK2	Phase 2

Gamma-secretase

ID	Product Name	Target	Condition
TP1540	Jagged-1 188-204	Notch	
T6870	L-685,458	γ secretase	
T6861	IMR1	Notch	
T6274	RO4929097	A β 40; γ secretase; Notch	Phase 2
T6249	Avagacestat	γ secretase(A β 42) , γ secretase(A β 40)	Phase 1
T6202	DAPT	γ secretase(A β); A β	Preclinical
T6135	Dibenzazepine	γ secretase (APPL); γ secretase(Notch)	
T6125	Semagacestat	Notch; γ secretase(A β 38); γ secretase(A β 40); γ secretase(A β 42)	Phase 3
T6063	LY411575	Notch S3 cleavage; γ secretase (cell-based); γ secretase (membrane-based)	
T4364	Aftin4	γ secretase(A β 42)	
T4077	PE859	A β ; tau; A β	
T3633	Crenigacestat	Notch-1	Phase 1/2
T3540	IMR-1A	Notch	
T3075	FLI06	Notch	
T2842	Tangeretin	Notch-1	Preclinical
T2639	LY2811376	BACE1; A β	Phase 1
T2625	MK0752	A β	Phase 1
T2262	CHF5074	Beta Amyloid; γ secretase	Phase 2
T15184	E 2012	γ secretase	
T12246	CB-103	notch	Phase 2

GSK-3

ID	Product Name	Target	Condition
T8908	4-Chloro-2'-bromoacetophenone	GSK-3 β	
T8605	GS87	GSK-3	
T7473	5-Bromoindole	GSK-3	
T6940	PHA767491 HCl	Cdk1; Cdk2; Cdk9; Cdc7; GSK-3 β	Phase 1
T6787	BIO-acetoxime	GSK-3 α ; GSK-3 β	
T6659	SB415286	GSK-3 α , GSK-3 β	
T6350	CHIR124	Chk1; FLT3; GSK-3; PDGFR; Fyn	Preclinical

ID	Product Name	Target	Condition
T6205	AT7519	CDK2/CyclinA; CDK4/CyclinD1; CDK5/p35; CDK9/CyclinT; GSK-3β	Phase 2
T6187	TDZD8	GSK-3β	Preclinical
T6169	Indirubin	GSK-3β, CDK2/CyclinA, CDK5/p35, CDK1/CyclinB, C-Raf	Approved
T6049	SNS032	CDK2/CyclinA; CDK2/CyclinE; CDK7/CyclinH; CDK9/CyclinT; GSK-3α	Phase 2
T5956	VP3.15 dihydrobromide	GSK-3; PDE7	
T5200	Indirubin-3'-monoxime	GSK-3β; CDK1/CyclinB; CDK2/CyclinE; CDK5/p25	
T3684	CP21R7	GSK-3β; PKCα	
T3385	Gypenoside XVII	GSK-3β	
T3166	VX-11e	Aurora A; CDK2; ERK2; FLT3; GSK-3	
T3077	SB216763	GSK-3α; GSK-3β	
T3067	Tideglusib	GSK-3β	Approved
T2873	Ginsenoside Rg2	GSK-3β	
T2695	TBB	CK2; CDK2; GSK-3β	
T2608	CHIR98014	bFGFR; GSK-3α; GSK-3β; p70 S6K; c-Src	
T2310	CHIR99021	GSK-3α; GSK-3β	Preclinical
T2261	IM12	GSK-3β	
T2247	KenPaullone	CDK1/CyclinB; CDK2/CyclinA; CDK2/CyclinE; CDK5/p35; GSK-3β	Preclinical
T2166	TWS119	GSK-3β	
T1965	Bikinin	GSK-3; Shaggy-like kinase	
T1957	AZD2858	GSK-3	Preclinical
T1917	6-BIO	CDK1/CyclinB; CDK2/CyclinA; CDK5/p35; GSK-3; Tyk2	
T1881	AR-A014418	GSK-3β; GSK-3β	Preclinical
T1778	AT 7519 hydrochloride salt	CDK2/CyclinA; CDK4/CyclinD1; CDK5/p35; CDK9/CyclinT; GSK-3β	Phase 2
T1755	LY2090314	GSK-3α; GSK-3β	Phase 2
T1741	AZD1080	GSK-3α; GSK-3β	Phase 1
T17019	TCS 21311	JAK3; JAK2; JAK1; PKCα; PKCβ; GSK-3β	
T14066	9-ING-41	GSK-3β	Phase 2
T11467	GSK-3β inhibitor 1	GSK-3β	
T0704	Cyanoacetohydrazide	GSK-3	Approved
T0256	Lithium citrate tribasic tetrahydrate	IMPDH; mGluR3; GSK-3β	FDA Approved

Hedgehog/Smoothened

ID	Product Name	Target	Condition
T6891	MK4101	Smoothened	Phase 1
T6514	Glasdegib	Smoothened	FDA Approved
T4211	SAG hydrochloride (912545-86-9(free base))	Hedgehog/Smoothened	

ID	Product Name	Target	Condition
T3588	JK184	Hedgehog	
T3460	HhAntag	Gli	Preclinical
T3363	Jervine	Hedgehog; Smoothened	
T3156	Ciliobrevin A	Hedgehog	
T3070	GANT61	GLI1	
T2825	Cyclopamine	Smoothened	Preclinical
T2666	Taladegib	Smoothened	Phase 1/2
T2590	Vismodegib	Hedgehog; ABCG2	FDA Approved
T2450	SANT1	Smoothened	
T2299	BMS833923	Smoothened	Phase 2
T1926	NVP-LDE225	Smoothened; Smoothened	FDA Approved
T1810	Purmorphamine	Smoothened	
T1543	Naftifine hydrochloride	Smoothened	FDA Approved
T14188	ALLO-2	Smoothened	
T1094	Tolnaftate	Smoothened	Approved
T0465	Ellagic acid	Carbonic anhydrase; CK2; Smoothened; PKA; PKC; Syk; ATP-competitive CK2	Phase 2

Hippo pathway

ID	Product Name	Target	Condition
T8851	I3MT-3	MST3	
T5093	Pim1/AKK1-IN-1	Pim1; MST2	
T4212	XMU-MP-1	MST1; MST2	

JAK

ID	Product Name	Target	Condition
TQ0037	Abrocitinib	JAK1; JAK2	Phase 3
T8742	JAK2 inhibitor G5-7	JAK2	
T8719	SC99	STAT3; JAK2	
T8546	BD750	JAK3; STAT5	
T7503	Upadacitinib	JAK1; JAK2	FDA Approved
T6933	Peficitinib	JAK3; JAK1; Tyk2; JAK2	Approved
T6920	ON123300	CDK; Ark5; RET; Fyn; PDGFRβ; FGFR1	Preclinical
T6916	OICR9429	WDR5	
T6914	Oclacitinib maleate	JAK1; JAK2; TYK2; JAK3; JAK1-dependent	
T6838	FLLL32	JAK2	
T6790	BMS911543	JAK2 ; SET-2; TYK2; JAK3; JAK1	Phase 1/2
T6321	Tofacitinib	JAK1; JAK2; JAK3; ROCK2; Lck	FDA Approved
T6309	AZ 960	JAK2; JAK2	Preclinical

ID	Product Name	Target	Condition
T6266	PP2	EGFR; JAK2; Fyn; Lck; ZAP70	
T6156	S-Ruxolitinib	JAK2; JAK1; Tyk2	FDA Approved
T6145	ZM 39923 HCl	TGM2 , JAK3 , EGFR , JAK1	
T6124	Mubritinib	EGFR; HER2/ErbB2; FGFR; JAK1; PDGFR	Phase 1
T6122	CEP33779	JAK2	
T6020	Pacritinib	FLT3; FLT3 (D835Y); JAK2; JAK2 (V617F); Tyk2; JAK3	Approved
T5492	JAK3-IN-6	JAK3	
T5382	PF-06651600	JAK3	Phase 2/3
T5140	WDR5-0103 hydrochloride[890190-22-4(free base)]	WDR5	
T5091	FM381	JAK3	
T4672	Brevilin A	Antifection; JAK; STAT	
T4657L	WHI-P97 HCl 211555-05-4(free base)	JAK3	
T4657	WHI-P97	JAK3	Preclinical
T4227	SB1317 hydrochloride (1204918-72-8(free base))	CDK2; FLT3; JAK2	Phase 1/2
T4210	SAR20347	JAK1; JAK2; JAK3; TYK2	Preclinical
T4209	TAK-659 hydrochloride	FLT3; JAK3; Syk; ZAP70; VEGFR2	Phase 2
T3998	Itacitinib	JAK1	Phase 3
T3673	Mollugin	HER2; JAK2	
T3620	Solcitinib	JAK1	Phase 1
T3398	Icaritin	JAK2; STAT3	Phase 3
T3201	WDR5-0103	WDR5	
T3080	Pyridone 6	JAK1; JAK2; JAK3; Tyk2	
T3076	GLPG0634 analogue	JAK1; JAK2; JAK3; TYK2	
T3072	XL019	FLT3; JAK1; JAK2; JAK3; PDGFRβ	Phase 1
T3069	AZD1480	JAK2	Phase 1
T3068	AT9283	Aurora A; Aurora B; Abl1 (T315I); JAK2; JAK3	Phase 1
T3065	TG101209	RET; FLT3; JAK2; JAK3	Preclinical
T3043	Ruxolitinib (INCB-18424) phosphate	JAK1; JAK2	FDA Approved
T3042	JAK2 Inhibitor V	JAK2; JAK2 (V617F)	
T3024	Avitinib	EGFR; JAK3; BTK	Phase 2
T2853	Curcumol	JAK	Phase 3
T2709	TAK901	CLK2; JAK3; c-Src; FGR; Yes1	Phase 1
T2638	Gandotinib	FLT3; JAK1; JAK2; JAK2; JAK2 (V617F)	Phase 2
T2636	Decernotinib	JAK1; JAK2; JAK3; Tyk2	Phase 3
T2487	Cerdulatinib	JAK1; JAK3; Syk; Tyk2	Phase 2
T2485	Baricitinib	Chk2; JAK1; JAK2; JAK3; Tyk2	FDA Approved
T2398	Tofacitinib Citrate	JAK1; JAK2; JAK3	FDA Approved
T2360	Baricitinib Phosphate	JAK1; JAK2; JAK3; Tyk2	FDA Approved

ID	Product Name	Target	Condition
T2341	KW2449	Aurora A; Abl; Abl (T315I); Kit; FGFR1; FLT3; FLT3 (D835Y); JAK2; Src	Phase 1/2
T2156	WP1066	JAK2; STAT3	Phase 1/2
T2045	WHI-P131	JAK3; JAK3	Preclinical
T2035	WHI-P258	EGFR; JAK3	
T2012	Oclacitinib	JAKs	
T1995	Fedratinib	JAK2; JAK2 (V617F); RET; FLT3	FDA Approved
T1985	WHI-P154	EGFR; JAK3; Src; VEGFR	Preclinical
T1929	Filgotinib	JAK1; JAK2; JAK3; Tyk2	Approved
T1849	Momelotinib	JAK1; JAK2; JAK3	Phase 3
T1829	Ruxolitinib	JAK1; JAK2; Tyk2	FDA Approved
T17019	TCS 21311	JAK3; JAK2; JAK1; PKC α ; PKC θ ; GSK-3 β	
T14687	BMS-986165	Tyk2 JH2; JAK1 JH2	Phase 3
T14331	Gusacitinib	SYK; JAK	Phase 2
T12427	PF-06700841 (P-Tosylate)	JAK1; JAK2; JAK3	Phase 2

Porcupine

ID	Product Name	Target	Condition
T5342	IWP-O1	Porcn	
T4438	Porcupine-IN-1	Porcupine	
T2683	IWP-L6	Porcn	
T2618	LGK974	Porcn	Phase 1/2
T2242	Wnt-C59	Porcn	

ROCK

ID	Product Name	Target	Condition
TQ0319	Ripasudil hydrochloride dihydrate	ROCK1; ROCK2	Approved
T7301	BDP5290	ROCK	
T6867	KD025	ROCK2; ROCK2	Phase 2
T6321	Tofacitinib	JAK1; JAK2; JAK3; ROCK2; Lck	FDA Approved
T4276	Hydroxyfasudil Hydrochloride	ROCK	
T4095	ZINC00881524	ROCK	
T3518	GSK269962A	MSK1; ROCK1; ROCK2; RSK1	
T3513	GSK180736A	GRK1; GRK2; GRK5; PKA; ROCK	
T3060	Fasudil hydrochloride	PKA; PKG; PKC; ROCK2; MLCK	Approved
T2633	GSK429286A	ROCK1; ROCK2	
T2482	AT13148	Akt1; Akt2; Akt3; PKA; ROCK1; ROCK2; p70 S6K; RSK1; SGK3	Phase 1
T2155	Thiazovivin	ROCK	

ID	Product Name	Target	Condition
T2011	RK11313	ROCK1; ROCK2	
T1898	RK11447	ROCK1; ROCK2	
T1725	Y-27632 dihydrochloride	ROCK1 (p160ROCK); ROCK2	Preclinical

Smo

ID	Product Name	Target	Condition
T5465	PF-5274857 freebase	smo	
T15727	Erismodegib diphosphate	mSmo; hSmo	Approved

STAT

ID	Product Name	Target	Condition
TP1856	Colivelin	STAT3; Amyloid- β	
TP1433	CMD178 TFA	STAT5	
TN2346	Mogrol	ERK1; ERK2; STAT3	
TN2269	Tetramethylcurcumin	STAT3; Apoptosis	
T8719	SC99	STAT3; JAK2	
T8597	ML116	STAT3	
T8546	BD750	JAK3; STAT5	
T8478	SC-43	SHP-1; STAT3; apoptosis	
T8476	RSVA 405	STAT3; AMPK	
T8378	AS2863619	STAT5; CDK8; CDK19	
T8213	Isolinderalactone	STAT3; INOS	
T6S1373	Vitexicarpin	STAT3	
T6S0141	Corylin	STAT3	
T6669	SH-4-54	STAT3; STAT5	
T6537	HO3867	STAT3	
T6308	Stattic	STAT3	
T5S1607	Morusin	STAT3; NF-Kb	
T5S0168	Atractylenolide II	STAT3 inhibitor; p38 activator; ERK inhibitor; Akt inhibitor	
T5668	Acetyl-trans-resveratrol	STAT3; Mcl-1	
T4S2126	Ginkgetin	STAT3; COX-2	
T4S0145	Corylifol A	UGT1A1; hCE2; STAT3	
T4672	Brevilin A	Antifection; JAK; STAT	
T4650	C188-9	STAT3	Phase 1
T4615	Balsalazide disodium salt dihydrate	STAT	FDA Approved
T4476	AS1517499	STAT6	Preclinical
T4234	HJC0152 hydrochloride	STAT3	

ID	Product Name	Target	Condition
T4216	STAT5 Inhibitor	STAT5β	
T4034	Solamargine	p38 MAPK; STAT3	
T3S1775	Tectochrysin	STAT3	
T3971	CASIN	STAT3; GTPase Cdc42	
T3913	Saikosaponin D	NF-κB; STAT3	
T3708	BP-1-102	STAT3	
T3404	Cucurbitacin B	HIF-1; PTEN; STAT3	
T3398	Icaritin	JAK2; STAT3	Phase 3
T3380	Homoharringtonine	STAT3	FDA Approved
T3218	Napabucasin	STAT3	Phase 3
T2896	Helenine	STAT	
T2867	Diosgenin	STAT3	
T2814	Cryptotanshinone	STAT3	
T2789	Scutellarin	Akt; STAT	
T2505	S31201	STAT3	
T2168	2-NP	STAT1	
T2156	WP1066	JAK2; STAT3	Phase 1/2
T21267	HODHBt	STAT5	
T1563	Nifuroxazide	STAT1; STAT3; STAT5	Approved
T13009	STAT3-IN-1	STAT3	
T1038	Fludarabine	STAT1; DNA synthesis	FDA Approved
T0711	Niclosamide	STAT3	FDA Approved
T0433	Artesunate	STAT	Approved

Stemness kinase

ID	Product Name	Target	Condition
T3995	Amcasertib	Stemness kinase	Phase 2

TACC

ID	Product Name	Target	Condition
T5170	KHS101 hydrochloride	TACC3	

TGF-beta/Smad

ID	Product Name	Target	Condition
TQ0184	Chebulinic acid	bacterial DNA gyrase; Smad3; H+/K+-ATPase	
TN2165	Rubrofusarin-6-O-beta-D-gentiobioside	TGFβ; NF-κB; ERK	
TN1040	Skullcapflavone II	TGFβ; COX	

ID	Product Name	Target	Condition
T8785	HALOFUGINONE LACTATE	prolyl-tRNA synthetase; TGF-β	Phase 2
T8730	BMS986260	TGFβR1	
T8330	BIO-013077-01	TGFβ	
T7799	SB 4	bone morphogenetic protein (BMP)	
T7676	LSKL, Inhibitor of Thrombospondin TSP-1	TGFβ	
T6337	RepSox	ALK5; TGFβR1	
T6324	BIX02188	ERK5; MEK1; MEK2; MEK5; TGFβR1	
T5197	BIBF0775	TGFβR1(ALK5); Alk5	
T5125	LY3200882	TGF-βRI (ALK5)	Phase 2
T4662	SJ000291942	TGFβ	
T3924	Astragaloside II	Smad1; Smad5; Smad8	
T3674	Hydroxysafflor yellow A	TGFβ	
T3636	SIS3	Smad3	
T3025	Asiaticoside	p38 MAPK; TGFβ1	
T2803	Monocrotaline	TGFβ	
T2565	Hesperetin	HT; TGFβ	Approved
T2510	Galunisertib	TβRI	Phase 2/3
T2416	BIX02189	ERK5; MEK1; MEK2; MEK5; TGFβR1	
T2386	Pirfenidone	TGFβ2	FDA Approved
T2273	ITD1	TGFβ	Preclinical
T2123	LY2109761	TβRI; TβRII	
T2109	SD208	TGF-βRI (ALK5)	Preclinical
T2048	LY364947	CK1δ; MLK-7K; TGFβRI; TGFβRII; RIPK2	
T1763	SB525334	TβRI; ALK5; ALK4	
T1748	Kartogenin	Smad4; Smad5	

Wnt/beta-catenin


ID	Product Name	Target	Condition
TQ0215	Salinomycin sodium salt	Wnt/β-catenin	
TP1263	Fz7-21	human FZD7 CRD; mouse FZD7 CRD	
TL0008	Gigantol	β-catenin; α-glucosidase	
TL0007	Bisdemethoxycurcumin	p300; Wnt/β-catenin	
T8820	BML-284 HCL	Wnt	
T8710	MSAB	Wnt/β-catenin	
T8400	Pamidronic acid	β-catenin; Wnt	Phase 4
T8005	Cardiogenol C hydrochloride	Wnt	
T7830	Windorphen	Wnt	
T7399	LF3	Wnt/β-catenin	
T7333	Pyrvinium pamoate	Wnt	FDA Approved

ID	Product Name	Target	Condition
T7204	PNU 74654	Wnt/ β -catenin	
T6989	SKL2001	Wnt/ β -catenin	
T6868	KYA1797K	Wnt/ β -catenin	
T6842	G007-LK	TNKS1; TNKS2	
T6768	AZ6102	TNKS1; TNKS2	
T5S0754	Isoquercitrin	Wnt/ β -catenin	
T5729	L-quebrachitol	Wnt	
T5642	BC2059	Wnt/ β -catenin	Phase 1
T5636	Adavivint (SM04690)	Wnt	Phase 3
T4S1943	Kirenol	Wnt/ β -catenin	
T4486	iCRT 14	Wnt	
T4468	WAY 316606	sFRP-1	
T4302	iCRT3	Wnt,Wnt/ β -catenin	
T4245	IWP 4	Wnt	
T4043	ETC159	β -catenin	Phase 1
T4011	NCB0846	TNKS1	Preclinical
T3S0153	Xanthatin	Wnt/ β -catenin	
T3635	IQ1	Wnt	
T3168	MN64	Tankyrase; TNKS1; TNKS2	
T3144	Wnt agonist 1	Wnt	
T3062	WIK14	TNKS2	
T2818	Methyl Vanillate	Wnt	
T2702	IWP2	Wnt	
T2651	IWR-1-endo	Wnt	
T2413	FH535	PPAR γ ; PPAR δ ; Wnt/ β -catenin	
T22775	exo-IWR-1	wnt	
T2237	ICG001	Wnt/ β -catenin; CBP	Phase 1
T2052	KY02111	Wnt	
T2003	Isx 9	Wnt/ β -catenin	
T1971	WAY262611	Wnt/ β -catenin	
T1878	XAV939	TNKS1; TNKS2	
T1807	JW55	TNKS1; TNKS2; auto-PARsylation of TNKS2; auto-PARsylation of TNKS1	
T17142	Toxoflavin	TCF4/ β -catenin	
T14907	CCT251545	Wnt	
T0738	Urea	Arginase-1; Carbonic anhydrase II; DHFR; Sulfoxide reductase catalytic subunit YedY; Wnt/ β -catenin	FDA Approved

YAP

ID	Product Name	Target	Condition
T8421	TED-347	TEAD4-Yap1	

Tyrosine Kinase/Adaptors



ACK

ID	Product Name	Target	Condition
T5092	AIM100	ACK1	
T2641	KRCA0008	ACK; ALK	
T2382	Vemurafenib	ACK1; MAP4K5 (KHS1); B-Raf; B-Raf (V600E); C-Raf; SRMS; FGR	FDA Approved

ALK

ID	Product Name	Target	Condition
T8399	Crizotinib hydrochloride	ALK; c-Met	FDA Approved
T8387	Alectinib hydrochloride	ALK	FDA Approved
T8152	6-Demethoxytangeretin	ALK; MAPK	
T8108	Blu-782	ALK2	Phase 1
T6496	Vactosertib	ALK1; ALK2; ALK3; ALK4; ALK5	Phase 1/2
T6337	RepSox	ALK5; TGFβR1	
T6158	LDN-193189 HCl	ALK2; ALK3	
T5197	BIBF0775	TGFβR1(ALK5); Alk5	
T4975	SM 16	ALK4; ALK5	Preclinical
T4257	Belizatinib	ALK	Phase 1/2
T4071	TPX0005	ALK; Src	Phase 1/2
T4015	HG-14-10-04	ALK	
T3678	Entrectinib	ALK; ROS1; TrkA; TrkB; TrkC	FDA Approved
T3621	Brigatinib	ALK; EGFR (C797S/del19); FLT3; IGF-1R; ROS1	FDA Approved
T3550	Ensartinib	ALK; MET	Phase 3
T3079	GSK1838705A	ALK; IGF-1R; Insulin Receptor; JNK3; RSK1	Preclinical
T3061	Lorlatinib	ALK; ALK (L1196M); ROS1; ROS1; LTK (TYK1)	FDA Approved
T3059	AP26113	ALK; EGFR (C797S/del19); EGFR (del19); IGF-1R	
T3041	ALK inhibitor 2	ALK	
T3031	ALK5 Inhibitor IV	ALK4; ALK5; ALK7	
T2655	CEP37440	ALK; FAK	Phase 1
T2641	KRCA0008	ACK; ALK	
T2612	CEP28122	ALK	Preclinical
T2462	SB505124	ALK4; ALK5	Preclinical
T2449	D 4476	ALK5; CK1; CK1δ	
T2251	TAE684	ALK	Preclinical
T2098	A77-01	ALK5	
T1962	ASP 3026	ALK	Phase 1
T1944	LDN214117	ALK2	
T1943	ML347	ALK1; ALK2; ALK3; ALK6	
T1942	DMH1	ALK2	
T1936	Alectinib	ALK; ALK (F1174L); ALK (R1275Q); INSR; VEGFR2 (KDR)	FDA Approved
T1935	LDN193189	ALK2; ALK3	
T1914	K 02288	ALK1; ALK2; ALK3; ALK4; ALK6	
T1900	LDN212854	ALK1; ALK2; ALK3; ALK4; ALK5	
T1800	GW 788388	ALK5	
T1791L	LDK378 dihydrochloride	ALK	FDA Approved
T1791	LDK378	ALK; IGF-1R; Insulin Receptor; STK22D	FDA Approved

ID	Product Name	Target	Condition
T1763	SB525334	TβR1; ALK5; ALK4	
T1726	SB 431542	ALK5; ALK4; ALK7	Preclinical
T16708	R-268712	ALK5	
T1661	Crizotinib	ALK; c-Met	FDA Approved

Bcr-Abl

ID	Product Name	Target	Condition
T8488	GMB-475	Bcr-Abl1	
T7861	Flumatinib mesylate	PDGFRβ ; c-Kit ; c-Abl	Phase 3
T7186	CZC-8004	Abl	
T6348	NVP-BHG712	EphB4; c-Raf; c-Src; c-Abl	
T6311	Bafetinib	Abl; Lyn	Phase 1
T6300	Degrasyn	Bcr-Abl	Preclinical
T6230	Imatinib	v-Abl; c-Kit; PDGFR	FDA Approved
T6196	PP1	Bcr-Abl; Kit; EGFR; Fyn; Lck	
T6128	PHA665752	c-Abl; c-Met; RON; FGFR1; Flk1	Preclinical
T6057	URMC099	Aurora A; Aurora B; Aurora C; Abl1; CDK1; CDK2; c-Met; DLK; IGF-1R; Insulin Receptor; LRRK2; MEKK2; MLK1; MLK2; MLK3; ROCK1; ROCK2; SGK; SGK1; Lck; Syk; TrkA; TrkB; VEGFR1/FLT1	
T5177	Asciminib	Abl1	Phase 3
T4618	K 0859	c-ABL-T334; Abl; Abl (T315I)	
T4320	Flumatinib	c-Abl; PDGFRβ; c-Kit;	Phase 3
T3641	BAW2881	c-Abl; B-Raf (V599E); C-Raf-1; hVEGFR2	
T3196	GNF7	M351T; c-Abl; E255V; G250E; T315I	
T3071	GZD 824	Abl (E254K)	Phase 2
T3068	AT9283	Aurora A; Aurora B; Abl1 (T315I); JAK2; JAK3	Phase 1
T3063	PD173955	Bcr-Abl; Src	Preclinical
T2920	Berbamine dihydrochloride	Abl	Approved
T2802	Nocodazole	Abl; Abl (E255K); Abl (T315I); microtubule	
T2640	DCC2036	Abl1; p-Abl1 (native); p-Abl1 (T315I); u-Abl1 (native); FLT3	Phase 1/2
T2609	Masitinib	Abl1; c-Fms; Kit; Hck; PDGFRα; PDGFRβ; Lyn B; Src	Approved
T2429	GZD824 Dimesylate	Abl; Abl (E255K); Abl (H396P); Abl (M351T); Abl (Q252H)	Phase 2
T2415	PP121	Hck; mTOR; PDGFR; Src; VEGFR; Abl	
T2372	Ponatinib	Abl; c-Kit; FGFR1; PDGFRα; c-Src; VEGFR2	FDA Approved
T2341	KW2449	Aurora A; Abl; Abl (T315I); Kit; FGFR1; FLT3; FLT3 (D835Y); JAK2; Src	Phase 1/2
T2328	Radotinib	Bcr-Abl1	Approved
T2293	SGX523	Abl; c-Met; p38α; B-Raf (V599E); C-Raf	Phase 1

ID	Product Name	Target	Condition
T2147	Nilotinib (monohydrochloride monohydrate)	Bcr-Abl	FDA Approved
T2116	AEE788	c-Abl; c-Fms; EGFR; HER2/ErbB2; FLT1	Phase 1/2
T2094	Danuseritib	Aurora A; Aurora B; Aurora C; Abl; RET; FGFR1; TrkA	Phase 2
T2070	CEP32496	Abl1; c-Kit; RET; PDGFR β ; Lck	Phase 1
T1817	GNF2	Bcr-Abl (K562 cell line); Bcr-Abl (SUP-B15 cell line)	
T1803	GNF5	Bcr-Abl	
T1754	ZM 306416	Abl; Src; VEGFR1	
T1621	Imatinib Mesylate	v-Abl; c-Kit; PDGFR	FDA Approved
T1524	Nilotinib	Bcr-Abl	FDA Approved
T1448L	Dasatinib monohydrate	Abl; c-Kit (D816V); c-Kit (wt); EphA2; Src	FDA Approved
T1448	Dasatinib	Abl; c-Kit (D816V); c-Kit (wt); Src	FDA Approved
T0152	Bosutinib	Abl; c-Src	FDA Approved

BTK

ID	Product Name	Target	Condition
TQ0230	BTK IN-1	BTK	
T8636	Ibrutinib deacryloylpiperidine	Btk	
T7584	zanubrutinib	BTK	FDA Approved
T6921	ONO-4059 analogue	BTK	
T6918	Olmutinib	EGFR (cell: H1975); EGFR (cell: HCC827); BTK	Approved
T6217	LFM-A13	BTK	Preclinical
T6078	Saracatinib	c-Src; Lck; BLK; EGFR (L858R); EGFR (L861Q); c-Yes; FGR; Fyn; Lyn	Phase 2
T5407	BMS986195	BTK	Phase 1
T5138	BMS986142	BTK	Phase 2
T4391	Syk Inhibitor II (hydrochloride)	Syk; PKC ϵ ; PKC β II; ZAP-70; Btk; Itk; ZAP70; Btk	
T4387	evobrutinib	BTK	Phase 2
T4337	PCI29732	BTK; Itk	
T4268	CHMFL-BMX-078	Bmx	
T3626	Acalabrutinib	BTK	FDA Approved
T3024	Avitinib	EGFR; JAK3; BTK	Phase 2
T2603	Spebrutinib	BRK; BTK; c-Src; Lyn; Yes	Phase 2
T2472	CGI1746	BTK	
T2302	CNX774	BTK	
T1976	RN486	BTK	
T1835	Ibrutinib	BLK; Bmx; BTK; FGR; CSK	FDA Approved
T14323	ARQ 531	WT-BTK; C481S-BTK	Phase 2

ID	Product Name	Target	Condition
T12542	PRN1008	BTK; BMX; ITK; TEC; RLK; BLK; EGFR; ERBB2; ERBB4	Phase 3
T12317	Orelabrutinib	BTK	
T10629	Btk inhibitor 2	BTK	
T10625	IBT6A	BTK	

c-Fms

ID	Product Name	Target	Condition
T6930	Pazopanib HCl	FGFR; PDGFR; VEGFR1; VEGFR2; VEGFR3; c-Kit; c-Fms	FDA Approved
T6028	PF477736	c-Fms; Chk1; Chk2; Yes; VEGFR2	Phase 1
T5586	cFMS Receptor Inhibitor II	CSF1R	
T5172	AZ304	B-Raf (V600E); B-Raf (WT); p38; CSF1R	Preclinical
T4376	Nampt-IN-1	NAMPT; CSF-1R	
T4315	KI20227	CSF-1R; VEGFR2; VEGFR2	Preclinical
T3351	CC223	c-Fms; DNA-PK; FLT4; mTOR; PI3K-α	Phase 2
T2659	GW 2580	c-Fms	
T2609	Masitinib	Abl1; c-Fms; Kit; Hck; PDGFRα; PDGFRβ; Lyn B; Src	Approved
T2116	AEE788	c-Abl; c-Fms; EGFR; HER2/ErbB2; FLT1	Phase 1/2
T1925	PLX647	c-Fms; c-Kit	Preclinical

c-Kit

ID	Product Name	Target	Condition
T8544	Masitinib mesylate	Kit; PDGFRα; PDGFRβ; Lyn; Lck; FGFR3; FAK	Approved
T8541	Lenvatinib mesylate	VEGFR; VEGFR3; VEGFR1; FGFR1; PDGFRα; PDGFRβ; c-Kit	FDA Approved
T8482	Ripretinib	Kit; PDGFR	FDA Approved
T7945	SU14813	VEGFR; Kit	
T7861	Flumatinib mesylate	PDGFRβ; c-Kit; c-Abl	Phase 3
T6930	Pazopanib HCl	FGFR; PDGFR; VEGFR1; VEGFR2; VEGFR3; c-Kit; c-Fms	FDA Approved
T6711	Tyrphostin AG 1296	PDGFR; c-Kit (Swiss 3T3); FGFR (Swiss 3T3)	Preclinical
T6479	Dovitinib Lactate	c-Kit; FGFR1; FGFR3; FLT3; VEGFR3/FLT4	
T6289	Dovitinib	c-Kit; FGFR1; FGFR3; FLT3; VEGFR3/FLT4	Phase 2
T6230	Imatinib	v-Abl; c-Kit; PDGFR	FDA Approved
T6196	PP1	Bcr-Abl; Kit; EGFR; Fyn; Lck	
T6166	Telatinib	c-Kit; PDGFRα; VEGFR2; VEGFR3	Phase 2
T6097	GNF5837	Kit; PDGFRβ; TrkA; TrkB; TrkC	
T6091	CP673451	c-Kit; PDGFRα; PDGFRβ; VEGFR1; VEGFR2	Preclinical
T6078	Saracatinib	c-Src; Lck; BLK; EGFR (L858R); EGFR (L861Q); c-Yes; FGR; Fyn; Lyn	Phase 2

ID	Product Name	Target	Condition
T5409	AZD3229	Kit	
T5164	Cabozantinib hydrochloride (849217-68-1(free base))	c-Kit; c-Met; VEGFR2/KDR; FLT4; Axl; RORy; RORα	FDA Approved
T5109	Avapritinib	PDGFRα, c-Kit (D816V)	FDA Approved
T4409	Gilteritinib	FLT3; AXL; c-KIT	FDA Approved
T4332	c-Kit-IN-1	c-Kit; c-Met	Phase 3
T4320	Flumatinib	c-Abl; PDGFRβ; c-Kit;	Phase 3
T4053	AST 487	c-Kit; RET; FLT4; KDR	Preclinical
T3452	ISCK03	c-Kit	
T2668	JNK-IN-8	Kit (V559D); Kit (V559D,T670I); JNK1; JNK2; JNK3	
T2609	Masitinib	Abl1; c-Fms; Kit; Hck; PDGFRα; PDGFRβ; Lyn B; Src	Approved
T2586	Cabozantinib	c-Kit; c-Met; VEGFR2/KDR; FLT4; Axl; RET; FLT3	FDA Approved
T2516	Amuvatinib	c-Kit (D816H); FLT3 (D835Y); PDGFRα (V561D)	Phase 2
T2514	Linifanib	Kit; CSF-1R; FLT3; VEGFR1/FLT1; VEGFR2/KDR; PDGFRβ	Phase 1
T2500	Cediranib	c-Kit; PDGFRβ; VEGFR1/FLT1; VEGFR2/KDR; VEGFR3/FLT4; Flt1	Approved
T2446	KI8751	c-Kit; EGFR; FGFR2; PDGFRα; VEGFR2	
T2372	Ponatinib	Abl; c-Kit; FGFR1; PDGFRα; c-Src; VEGFR2	FDA Approved
T2341	KW2449	Aurora A; Abl; Abl (T315I); Kit; FGFR1; FLT3; FLT3 (D835Y); JAK2; Src	Phase 1/2
T2288	Motesanib	VEGFR1; VEGFR2; VEGFR3; c-Kit	Phase 3
T2115	Pexidartinib	Kit; CSF-1R; FLT3	FDA Approved
T2070	CEP32496	Abl1; c-Kit; RET; PDGFRβ; Lck	Phase 1
T1925	PLX647	c-Fms; c-Kit	Preclinical
T1836	AZD2932	c-Kit; FLT3; PDGFRβ; VEGFR2	
T1830	BX795	CDK2/CyclinE; Chk1; c-Kit; PDK1	Preclinical
T1797	Cabozantinib Malate	Kit; c-Met; AXL; VEGFR2/KDR; VEGFR3/FLT4	FDA Approved
T1792L	Regorafenib monohydrate	murine VEGFR2; murine VEGFR3; PDGFRβ; Kit; RET; RAF-1; B-RAF; B-Raf (V600E)	FDA Approved
T1792	Regorafenib	Kit; RET; Raf-1; VEGFR1; VEGFR2	FDA Approved
T1667	Tandutinib	c-Kit; CSF-1R; FLT3; PDGFRβ; Src	Phase 2
T1621	Imatinib Mesylate	v-Abl; c-Kit; PDGFR	FDA Approved
T15199	Edicotinib	FLT3; CSF-1R; kit	Phase 2
T1452	Axitinib	PDGFRβ; VEGFR1; VEGFR2; VEGFR3; c-kit	FDA Approved
T1448L	Dasatinib monohydrate	Abl; c-Kit (D816V); c-Kit (wt); EphA2; Src	FDA Approved
T1448	Dasatinib	Abl; c-Kit (D816V); c-Kit (wt); Src	FDA Approved
T10157	Regorafenib N-oxye (M2)	VEGFR1; VEGFR2; VEGFR3; PDGFRβ; RET; Kit; Raf-1	
T0374L	Sunitinib	c-Kit; FLT3; PDGFRβ; VEGFR2	FDA Approved
T0374	Sunitinib Malate	Kit; FLT3; PDGFRβ; VEGFR2	FDA Approved
T0097L	Pazopanib	c-Kit; PDGFR; VEGFR1; VEGFR2; VEGFR3	FDA Approved
T0093L	Sorafenib	c-Kit; FLT3; mPDGFRβ; PDGFRβ; B-Raf; B-Raf (V599E); Raf-1; VEGFR2/Flk2	FDA Approved

ID	Product Name	Target	Condition
T0093	Sorafenib tosylate	c-Kit; FLT3; mPDGFRβ; PDGFRβ; B-Raf; B-Raf (V599E); Raf-1; VEGFR2/Flk1	FDA Approved

c-Met/HGFR

ID	Product Name	Target	Condition
TQ0210	Savolitinib	c-Met	Phase 1
TQ0021	Ningetinib	c-Met; VEGFR2; AXL	Phase 1/2
T8825	Capmatinib hydrochloride	c-Met	FDA Approved
T8416	Capmatinib hydrochloride(free base)	c-Met	FDA Approved
T8399	Crizotinib hydrochloride	ALK; c-Met	FDA Approved
T8326	BMS-2	Met; FLT3; VEGFR2	
T7900	BAY-474	c-Met	
T7787	BMS817378	Met	
T7376	Dihexa	HGF	
T6982	SGI7079	Met; RET; FLT3; Yes; AXL; Mer	
T6907	NPS1034	Met; AXL	
T6517	Golvatinib	c-Met; VEGFR2	Phase 1/2
T6351	MGCD-265 analog	Met; RON; VEGFR1; VEGFR2; VEGFR3	Phase 1
T6260	AMG208	c-Met	Phase 1
T6154	SU11274	CDK2; Met; RON; FGFR1; Flk1	Preclinical
T6128	PHA665752	c-Abl; c-Met; RON; FGFR1; Flk1	Preclinical
T6121	Tepotinib	c-Met; AXL; TrkA	Approved
T6117	Tivantinib	c-Met	Phase 1
T6095	JNJ38877605	c-Met	Phase 1
T6094	MK2461	c-Met (M1250T); c-Met (N1100); c-Met (Y1230C); c-Met (Y1230H); c-Met (Y1235D)	Phase 1
T6057	URMC099	Aurora A; Aurora B; Aurora C; Abl1; CDK1; CDK2; c-Met; DLK; IGF-1R; Insulin Receptor; LRRK2; MEKK2; MLK1; MLK2; MLK3; ROCK1; ROCK2; SGK; SGK1; Lck; Syk; TrkA; TrkB; VEGFR1/FLT1	
T5677	SAR125884 hydrochlorid (1116743-46-4(free base))	MET RTK	
T5656	Norcantharidin	EGFR,c-Met	
T5478	SRI 31215	HGFA; matriptase; hepsin	
T5414	Glumetinib	c-Met	Phase 1
T5164	Cabozantinib hydrochloride (849217-68-1(free base))	c-Kit; c-Met; VEGFR2/KDR; FLT4; Axl; RORγ; RORα	FDA Approved
T4426	CEP40783	AXL; Mer; Tyro3; c-MET	Preclinical
T4332	c-Kit-IN-1	c-Kit; c-Met	Phase 3
T4260	Capmatinib 2HCl	c-Met	FDA Approved
T3550	Ensartinib	ALK; MET	Phase 3
T3455	Merestinib	Met	Phase 2

ID	Product Name	Target	Condition
T3274	S49076	Met; FGFR2; FGFR3; AXL; Mer	Phase 1/2
T3209	AMG337	Met; Met(H1094R); Met(M1250T); Met(V1092I); Met(V1230H)	Phase 2
T3113	Foretinib	Met; RON; Tie-2; VEGFR2 (KDR); VEGFR3/FLT4	Phase 1
T2894	Norcantharidin	c-Met; EGFR	Preclinical
T2699	BMS777607	Met; RON; AXL; Mer; Tyro3	Phase 2
T2680	NVP-BVU972	Met	
T2586	Cabozantinib	c-Kit; c-Met; VEGFR2/KDR; FLT4; Axl; RET; FLT3	FDA Approved
T2419	BMS794833	Met; VEGFR2	Preclinical
T2349	BMS754807	Met; IGF-1R; Insulin Receptor; TrkA; TrkB	Phase 1/2
T2293	SGX523	Abl; c-Met; p38α; B-Raf (V599E); C-Raf	Phase 1
T2282	RPI1	Met; RET; CTND1; DCDB2; PLCγ	
T2208	Zinc bacitracin	Met	FDA Approved
T2054	Altiratinib	c-Met; Tie-2; VEGFR; TrkA; TrkC	Phase 1
T1963	Capmatinib	c-Met	FDA Approved
T1918	TAE226	c-Met; FAK; IGF-1R; Insulin Receptor; PYK2	Preclinical
T1797	Cabozantinib Malate	Kit; c-Met; AXL; VEGFR2/KDR; VEGFR3/FLT4	FDA Approved
T1661	Crizotinib	ALK; c-Met	FDA Approved
T10655	c-Met inhibitor 1	c-Met	

c-RET

ID	Product Name	Target	Condition
TQ0277	Pralsetinib	RET	FDA Approved
TQ0059	Ilorasertib	Aurora A; Aurora B; Aurora C; PDGFRβ; RET; FLT1; VEGFR1; VEGFR2; VEGFR3	Phase 2
T8541	Lenvatinib mesylate	VEGFR; VEGFR3; VEGFR1; FGFR1; PDGFRα; PDGFRβ; c-Kit	FDA Approved
T8467	RET V804M-IN-1	RET V804M	
T8402	Regorafenib Hydrochloride	VEGFR; PDGFR; RET; Raf-1	FDA Approved
T8222	Selpercatinib	RET	FDA Approved
T7418	BBT594	RET	
T6982	SGI7079	Met; RET; FLT3; Yes; AXL; Mer	
T6920	ON123300	CDK; Ark5; RET; Fyn; PDGFRβ; FGFR1	Preclinical
T5491	GSK3179106	RET	Phase 1
T5171	Treprostinil Sodium	DP1, IP, EP2; VEGFR2; RET	FDA Approved
T4301	AD80	RET, RAF, SRC, S6K; RET V804M; RET V804L	
T4053	AST 487	c-Kit; RET; FLT4; KDR	Preclinical
T3065	TG101209	RET; FLT3; JAK2; JAK3	Preclinical
T2620	G749	Aurora B; RET; FLT3; FLT3 (D835Y); Mer	Preclinical
T2586	Cabozantinib	c-Kit; c-Met; VEGFR2/KDR; FLT4; Axl; RET; FLT3	FDA Approved
T2358	ENMD2076	Aurora A; RET; FLT3; Src; VEGFR3/FLT4; Src	Phase 2

ID	Product Name	Target	Condition
T2282	RPI1	Met; RET; CTND1; DCDB2; PLCy	
T2094	Danusertib	Aurora A; Aurora B; Aurora C; Abl; RET; FGFR1; TrkA	Phase 2
T2070	CEP32496	Abl1; c-Kit; RET; PDGFRβ; Lck	Phase 1
T1995	Fedratinib	JAK2; JAK2 (V617F); RET; FLT3	FDA Approved
T1792L	Regorafenib monohydrate	murine VEGFR2; murine VEGFR3; PDGFRβ; Kit; RET; RAF-1; B-RAF; B-Raf (V600E)	FDA Approved
T1792	Regorafenib	Kit; RET; Raf-1; VEGFR1; VEGFR2	FDA Approved
T10157	Regorafenib N-oxide (M2)	VEGFR1; VEGFR2; VEGFR3; PDGFRβ; RET; Kit; Raf-1	

CSF-1R

ID	Product Name	Target	Condition
TQ0015	PRN1371	FGFR1; FGFR2; FGFR3; FGFR4; CSF-1R	Phase 1
T7100	PLX-5622	CSF-1R	
T6119	BLZ945	CSF-1R	Phase 1/2
T4376	Nampt-IN-1	NAMPT; CSF-1R	
T4315	Ki20227	CSF-1R; VEGFR2; VEGFR2	Preclinical
T2624	OSI 930	CSF-1R; FLT1; C-Raf; Lck; VEGFR2 (KDR)	Phase 1
T2514	Linifanib	Kit; CSF-1R; FLT3; VEGFR1/FLT1; VEGFR2/KDR; PDGFRβ	Phase 1
T2115	Pexidartinib	Kit; CSF-1R; FLT3	FDA Approved
T1667	Tandutinib	c-Kit; CSF-1R; FLT3; PDGFRβ; Src	Phase 2
T15199	Edicotinib	FLT3; CSF-1R; kit	Phase 2

Discoidin Domain Receptor (DDR)

ID	Product Name	Target	Condition
T7862	VU6015929	DDR1/2	
T5402	DDR1-IN-2	DDR1	
T4349	Sitravatinib	DDR2; EPHA3; Axl; Mer; VEGFR3 (FLT4); Mer; VEGFR3 (FLT4)	Phase 2
T3337	Ddr1-In-1	DDR1; DDR2	
T17258	WRG-28	DDR2	

DYRK

ID	Product Name	Target	Condition
TQ0111	LDN-192960	DYRK2; Haspin	
T6257	AZ191	DYRK1A; DYRK1B; DYRK2	
T2811	Harmine hydrochloride	GluR1; DYRK1A; DYRK1B; DYRK2	
T2431	ID8	DYRK	
T11447	GNF4877	GSK3β; DYRK1A	

EGFR

ID	Product Name	Target	Condition
T9905	Cetuximab (anti-EGFR)	EGFR	Approved
T8872	(Rac)-JBJ-04-125-02	EGFR (L858R/T790M)	
T8758	Poziotinib hydrochloride	EGFR	
T8751	AZD8931 diFuMaric acid	EGFR; ErbB2; ErbB3	
T8679	Epidermal Growth Factor	EGFR	
T8460	Olmotinib	EGFR	
T8431	JCN037	EGFR	
T8189	Dihydroberberine	hERG; HSP90	
T8151	Mobocertinib	EGFR	
T7649	Tyrphostin A1	EGFR	
T7322	Theliatinib	EGFR	
T7198	E-4031	hERG Potassium Channel	
T7175	AST2818 mesylate	EGFR	Phase 3
T6932	PD168393	EGFR; FGFR; Insulin Receptor; PDGFR; PKC	Preclinical
T6918	Olmotinib	EGFR (cell: H1975); EGFR (cell: HCC827); BTK	Approved
T6824	EAI045	EGFR mutants	
T6734	WZ8040	EGFR (T790M)	
T6733	WZ3146	EGFR (E746_A750); EGFR (E746_A750/T790M); EGFR (L858R); EGFR (L858R/T790M)	
T6712	Tyrphostin AG 879	EGFR; HER2-Neu; PDGFR; Trk	
T6427	Butein	EGFR; p60c-src	
T6331	AST-1306 TsOH	EGFR; EGFR (T790M/L858R); HER2/ErbB2; HER2/ErbB2; FLT1	Phase 1
T6328	Desmethyl Erlotinib	EGFR	
T6266	PP2	EGFR; JAK2; Fyn; Lck; ZAP70	
T6238	WZ4002	EGFR (L858R); EGFR (L858R/T790M)	
T6235	Lapatinib Ditosylate	EGFR; HER2/ErbB2	FDA Approved
T6227	Benidipine hydrochloride	EGFR (L861Q); c-Src; c-Yes; Lck; Lyn	Approved
T6196	PP1	Bcr-Abl; Kit; EGFR; Fyn; Lck	
T6153	Icotinib	EGFR	Approved
T6136	Canertinib	EGFR; HER2/ErbB2	Phase 2
T6124	Mubritinib	EGFR; HER2/ErbB2; FGFR; JAK1; PDGFR	Phase 1
T6092	Sapitinib	EGFR; HER2/ErbB2; HER2/ErbB2	Phase 1/2
T6078	Saracatinib	c-Src; Lck; BLK; EGFR (L858R); EGFR (L861Q); c-Yes; FGR; Fyn; Lyn	Phase 2
T6008	CNX2006	EGFR (mutant)	
T5675	HS-10296 hydrochloride	EGFR	Phase 3
T5437	Gefitinib-based PROTAC 3	EGFR	
T5410	PD158780	EGFR; ErbB2; ErbB3; ErbB4	
T5168	EGFR Inhibitor	EGFR; EGFR (L858R); EGFR (L861Q)	

ID	Product Name	Target	Condition
T5155	AG 99	EGFR	
T4694	AG-1557 hydrochloride (189290-58-2(free base))	hERG; EGFR	
T4612	NS309	Potassium Channel; hERG	Preclinical
T4528	Tyrphostin AG 528	EGFR; ErbB2	
T4326	AG 555	EGFR	
T4296	MTX211	EGFR; PI3K	Preclinical
T4249	AZD3759 hydrochloride	EGFR (exon 19De); EGFR (L858R); EGFR (wt)	Phase 2/3
T4205	AG 494	EGFR	
T4014	CP724714	HER2/ErbB2	
T3870	Cyasterone	EGFR	
T3721	Avitinib maleate	EGFR	Phase 2
T3659	AZD3759	EGFR (exon 19Del); EGFR (L858R); EGFR (WT)	Phase 2/3
T3634	Osimertinib mesylate	EGFR (L858R); EGFR (L858R/T790M)	FDA Approved
T3621	Brigatinib	ALK; EGFR (C797S/del19); FLT3; IGF-1R; ROS1	FDA Approved
T3558	EBE-A22	EGFR/ErbB1	
T3554	RG 14620	HER14 colony formation; HER14 DNA synthesis; EGFR	
T3545	RG 13022	EGFR	Preclinical
T3506	Nazartinib	EGFR (mutant)	Phase 3
T3402	Ginsenoside Rg3	EGFR	Approved
T3192	NS1643	hERG	
T3108	CUDC101	EGFR; HDAC; HDAC1; HDAC10; HDAC2; HDAC3; HDAC4; HDAC5; HDAC6; HDAC7; HDAC8; HDAC9; HER2	Phase 1
T3059	AP26113	ALK; EGFR (C797S/del19); EGFR (del19); EGFR (del19); IGF-1R	
T3024	Avitinib	EGFR; JAK3; BTK	Phase 2
T2S0961	Chalcone	EGFR	
T2995	Chrysophanic Acid	EGFR	Approved
T2959	Ginsenoside Rh2	EGFR	
T2894	Norcantharidin	c-Met; EGFR	Preclinical
T2859	Biochanin A	EGFR; FAAH (human); FAAH (mouse); FAAH (rat)	
T2851	Daphnetin	EGFR; PKA; PKC	Approved
T2705	Mutant EGFR inhibitor	EGFR (mutant)	
T2642	PD173074	EGFR; FGFR1; Insulin Receptor; c-Src; VEGFR2	Preclinical
T2501	Canertinib dihydrochloride	EGFR; HER2/ErbB2	Phase 2
T2491	AZ5104	EGFR (L858R); EGFR (L858R/T790M); EGFR (L861Q); EGFR (wildtype); HER2/ErbB2	
T2490	Osimertinib	EGFR (Exon 19 deletion); EGFR (L858R/T790M)	FDA Approved
T2483	Dacomitinib	EGFR; HER2/ErbB2; HER2/ErbB2	FDA Approved
T2479	Tyrphostin 9	EGFR; PDGFR	Preclinical
T2446	KI8751	c-Kit; EGFR; FGFR2; PDGFR α ; VEGFR2	
T2369	Rociletinib	EGFR (L858R/T790M); EGFR (wt)	Approved

ID	Product Name	Target	Condition
T2364	Irbinitinib	EGFR; HER2/ErbB2; p95 HER2	FDA Approved
T2327	Pelitinib	EGFR; HER2/ErbB2; MEK; Raf; Src	Phase 2
T2325	Neratinib	EGFR; HER2	FDA Approved
T2303	Afatinib	EGFR (L858R); EGFR (L858R/T790M); EGFR (wt); HER2; HER4	FDA Approved
T2280	Endoxifen Z-isomer	hERG Potassium Channel; ER; ERR; hERG	Phase 3
T2245	CL387785	EGFR	Preclinical
T21312	Afatinib free base	EGFR	FDA Approved
T2116	AEE788	c-AbI; c-Fms; EGFR; HER2/ErbB2; FLT1	Phase 1/2
T2106	WS6	ErbB3-Binding Protein-1 (EBP2); IκB kinase	
T2063	AG18	EGFR	Preclinical
T2055	WS3	ErbB3-Binding Protein-1 (EBP1); IκB kinase	
T2047	AG1478	EGFR; HER2; PDGFR	Preclinical
T2041	PD153035	EGFR	Phase 1
T2035	WHI-P258	EGFR; JAK3	
T2034	AG1557	hERG; EGFR	
T2032	WHI-P180	CDK2; EGFR	Preclinical
T1985	WHI-P154	EGFR; JAK3; Src; VEGFR	Preclinical
T19814	CP-380736	EGFR	
T1773	Afatinib Dimaleate	EGFR (L858R); EGFR (L858R/T790M); EGFR (wt); HER2	FDA Approved
T1761	PD153035 hydrochloride	EGFR; EGFR	Preclinical
T1737	Genistein	EGFR	Approved
T1656	Vandetanib	EGFR; VEGFR2; VEGFR3	FDA Approved
T16369	O-Desmethyl gefitinib	EGFR	
T1291	Cisapride	5-HT; Potassium Channel; hERG channel	FDA Approved
T1266	Terfenadine	HT; mAChR; Potassium Channel; hERG	Approved
T1181	Gefitinib	Tyr1173 (NR6W cells); Tyr1173 (NR6wEGFR cells); Tyr992 (NR6W cells); Tyr992 (NR6wEGFR cells); Tyr992	FDA Approved
T1144L	Lidocaine Hydrochloride hydrate	EGFR; Sodium Channel	FDA Approved
T11213	Epertinib hydrochloride	EGFR; HER4; HER2	
T11161	EGFR-IN-7	EGFR	
T10419	AV-412	EGFR; EGFR(L858R); EGFR(T790M); EGFR(L858R/T790M); ErbB2	Phase 1
T0801	Tannic acid	CXCR; hERG channel	FDA Approved
T0373L	Erlotinib hydrochloride	EGFR	FDA Approved
T0373	Erlotinib	EGFR	FDA Approved
T0129	Sanguinarine chloride	Egr-1; VEGFR	Approved
T0078L	Lapatinib ditosylate monohydrate	EGFR; HER2/ErbB2	FDA Approved
T0078	Lapatinib	EGFR; HER2/ErbB2	FDA Approved

Ephrin Receptor

ID	Product Name	Target	Condition
T6348	NVP-BHG712	EphB4; c-Raf; c-Src; c-Abl	
T5452	Ehp-inhibitor-2	Ephrin Receptor	
T5451	Ehp-inhibitor-1	Ephrin Receptor	
T4344	ALW-II-41-27	Ephrin Receptor	
T3476	J1101	Ephrin Receptor; PDGFR; VEGFR	Phase 1/2
T2456	Tivozanib	EphB2; PDGFR α ; VEGFR1; VEGFR2; VEGFR3	Approved
T1448L	Dasatinib monohydrate	Abl; c-Kit (D816V); c-Kit (wt); EphA2; Src	FDA Approved

FAK

ID	Product Name	Target	Condition
T8544	Masitinib mesylate	Kit; PDGFR α ; PDGFR β ; Lyn; LCK; FGFR3; FAK	Approved
T7119	Y15	FAK	
T6419	BMS536924	FAK; IGF-1R; Insulin Receptor; MEK; Lck	Preclinical
T6177	PF-562271 besylate	CDK1/CyclinB; CDK2/CyclinE; CDK3/CyclinE; FAK; PYK2	Phase 1
T5480	BI-4464	PTK2/FAK	
T3391	Corosolic acid	FAK	
T3122	(+)-Fangchinoline	FAK	
T2809	(+)-Thalrugosine	FAK	
T2655	CEP37440	ALK; FAK	Phase 1
T2465	PF562271	CDK1/CyclinB; CDK2/CyclinE; CDK3/CyclinE; FAK; PYK2	Phase 1
T2314	PF 431396	FAK; PYK2	
T2281	GSK2256098	FAK	Phase 2
T21768	PF-562271 HCl	FAK; PYK2; CDK2/CDK3/CDK1/CDK7	Phase 1
T2001	PF 573228	FAK	Preclinical
T1996	Defactinib	FAK	Phase 2
T1950	PND1186	FAK	Phase 1
T1918	TAE226	c-Met; FAK; IGF-1R; Insulin Receptor; PYK2	Preclinical
T0263	Chloropyramine hydrochloride	FAK-VEGFR-3; H1 receptor	Approved

FGFR

ID	Product Name	Target	Condition
TQ0228	Derazantinib	FGFR1; FGFR2; FGFR3	Phase 2
TQ0015	PRN1371	FGFR1; FGFR2; FGFR3; FGFR4; CSF-1R	Phase 1
T8544	Masitinib mesylate	Kit; PDGFR α ; PDGFR β ; Lyn; LCK; FGFR3; FAK	Approved
T8541	Lenvatinib mesylate	VEGFR; VEGFR3; VEGFR1; FGFR1; PDGFR α ; PDGFR β ; c-Kit	FDA Approved

ID	Product Name	Target	Condition
T8492	BO-264	FGFR; Apoptosis	
T7738	H3B-6527	FGFR	
T7611	ODM-203	FGFR; VEGFR	Phase 2
T7104	Dovitinib lactate	FGFR3	Phase 2
T6996	SU5402	FGFR1; PDGFR β ; VEGFR2	Preclinical
T6932	PD168393	EGFR; FGFR; Insulin Receptor; PDGFR; PKC	Preclinical
T6930	Pazopanib HCl	FGFR; PDGFR; VEGFR1; VEGFR2; VEGFR3; c-Kit; c-Fms	FDA Approved
T6920	ON123300	CDK; Ark5; RET; Fyn; PDGFR β ; FGFR1	Preclinical
T6836	FIIN2	FGFR1; FGFR2; FGFR3; FGFR4	
T6711	Tyrphostin AG 1296	PDGFR; c-Kit (Swiss 3T3); FGFR (Swiss 3T3)	Preclinical
T6479	Dovitinib Lactate	c-Kit; FGFR1; FGFR3; FLT3; VEGFR3/FLT4	
T6338	PHA680632	Aurora A; Aurora B; Aurora C; FGFR1; PLK1	Preclinical
T6289	Dovitinib	c-Kit; FGFR1; FGFR3; FLT3; VEGFR3/FLT4	Phase 2
T6184	Orantinib	FGFR1; PDGFR β ; Flk1	Phase 1
T6154	SU11274	CDK2; Met; RON; FGFR1; Flk1	Preclinical
T6128	PHA665752	c-Abl; c-Met; RON; FGFR1; Flk1	Preclinical
T6124	Mubritinib	EGFR; HER2/ErbB2; FGFR; JAK1; PDGFR	Phase 1
T6082	SSR128129E	FGFR1	
T6024	CH5183284	FGFR1; FGFR2; FGFR3; FGFR4	Phase 2
T5473	ASP-5878	FGFR1/2/3/4	Phase 1
T5122	Alofanib	FGFR2	Preclinical
T5044	TAS120	FGFR	Phase 1/2
T5001	Nintedanib Ethanesulfonate Salt	VEGFR1/2/3; FGFR1/2/3; PDGFR α / β	FDA Approved
T4318	ACTB1003	FGFR1,VEGFR2,Tie-2	Phase 1
T4235	Roblitinib	FGFR4	Phase 1/2
T4075	Sulfatinib	FGFR1; hERG; KDR	Phase 3
T3726	Erdafitinib	FGFR1; FGFR2; FGFR3; FGFR4	FDA Approved
T3714	SUN 11602	ERK1; ERK2; FGFR	
T3492	PD166866	FGFR1	
T3466	FIIN3	FGFR1; FGFR2; FGFR3; FGFR4	
T3456	BLU554	FGFR1; FGFR2; FGFR3; FGFR4	Phase 1
T3274	S49076	Met; FGFR2; FGFR3; AXL; Mer	Phase 1/2
T2642	PD173074	EGFR; FGFR1; Insulin Receptor; c-Src; VEGFR2	Preclinical
T2608	CHIR98014	bFGFR; GSK-3 α ; GSK-3 β ; p70 S6K; c-Src	
T2576	Brivanim Alaninate	FGFR1; Flk1; VEGFR1; VEGFR2	Phase 3
T2446	KI8751	c-Kit; EGFR; FGFR2; PDGFR α ; VEGFR2	
T2372	Ponatinib	Abl; c-Kit; FGFR1; PDGFR α ; c-Src; VEGFR2	FDA Approved
T2361	LY2874455	FGFR1; FGFR2; FGFR3; FGFR4; VEGFR2	Phase 2
T2347	BLU9931	FGFR1; FGFR2; FGFR3; FGFR4	Preclinical
T2341	KW2449	Aurora A; Abl; Abl (T315I); Kit; FGFR1; FLT3; FLT3 (D835Y); JAK2; Src	Phase 1/2

ID	Product Name	Target	Condition
T22306	DGY-06-116	Src; FGFR1	
T2215	Ferulic Acid	FGFR1	Approved
T2094	Danusertib	Aurora A; Aurora B; Aurora C; Abl; RET; FGFR1; TrkA	Phase 2
T1975	Infigratinib	FGFR1; FGFR2; FGFR3; FGFR3 (K650E); FGFR4	Phase 3
T1948	AZD4547	FGFR1; FGFR2; FGFR3; FGFR4; KDR	Phase 2/3
T1895	SKLB 610	FGFR; PDGFR; VEGFR	
T1886	TAK632	Aurora B; FGFR3; PDGFR β ; B-Raf; C-Raf	Preclinical
T1777	Nintedanib	FLT3; Lck; VEGFR1; VEGFR2; VEGFR3; FGPR1; FGFR2; FGFR3; PDGFR α ; PDGFR β	FDA Approved
T1639	Amlexanox	FGFR1; IL-3; Protein S100-P; IKK ϵ ; TBK1	FDA Approved
T1338	Sucralfate	FGF2; Fibrinogen chain; Pepsin; PGF	FDA Approved
T12401	Pemigatinib	FGFR1; FGFR2; FGFR3; FGFR4	FDA Approved
T0724	Formononetin	FGFR	
T0520	Lenvatinib	FGFR1; PDGFR β ; VEGFR1/FLT1; VEGFR2/KDR; VEGFR3/FLT4	FDA Approved

FLT

ID	Product Name	Target	Condition
TQ0059	Ilorasertib	Aurora A; Aurora B; Aurora C; PDGFR β ; RET; FLT1; VEGFR1; VEGFR2; VEGFR3	Phase 2
T8326	BMS-2	Met; FLT3; VEGFR2	
T8317	5'-Fluorouridurubinoxime	FLT3	
T7673	ATH 686	FLT3	
T7007	UNC2025	FLT3; AXL; Mer; Tyro3	Preclinical
T6982	SGI7079	Met; RET; FLT3; Yes; AXL; Mer	
T6756	AMG 925	FLT3; CDK4; CDK1	Phase 1
T6479	Dovitinib Lactate	c-Kit; FGFR1; FGFR3; FLT3; VEGFR3/FLT4	
T6458	CYC116	Aurora A; Aurora B; CDK2/CyclinE; CDK9/CyclinT; FLT3; p70 S6K; VEGFR2	Phase 1
T6350	CHIR124	Chk1; FLT3; GSK-3; PDGFR; Fyn	Preclinical
T6331	AST-1306 TsOH	EGFR; EGFR (T790M/L858R); HER2/ErbB2; HER2/ErbB2; FLT1	Phase 1
T6289	Dovitinib	c-Kit; FGFR1; FGFR3; FLT3; VEGFR3/FLT4	Phase 2
T6138	TCS 359	FLT3	
T6080	NVP-AEW541	FLT1; FLT3; IGF-1R; Insulin Receptor; Tek	Phase 1
T6020	Pacritinib	FLT3; FLT3 (D835Y); JAK2; JAK2 (V617F); Tyk2; JAK3	Approved
T4428	CCT241736	FLT3; Aurora Kinase	
T4419	UNC2025 2HCl (1429881-91-3(free base))	Mer; Flt3	
T4409	Gilteritinib	FLT3; AXL; c-KIT	FDA Approved
T4261	BPR1J-097 hydrochloride (1327167-19-0(free base))	FLT3	

ID	Product Name	Target	Condition
T4227	SB1317 hydrochloride (1204918-72-8(free base))	CDK2; FLT3; JAK2	Phase 1/2
T4213	NCT503	PHGDH(Cell-free); FLT3; AXL	
T4209	TAK-659 hydrochloride	FLT3; JAK3; Syk; ZAP70; VEGFR2	Phase 2
T4053	AST 487	c-Kit; RET; FLT4; KDR	Preclinical
T3621	Brigatinib	ALK; EGFR (C797S/del19); FLT3; IGF-1R; ROS1	FDA Approved
T3351	CC223	c-Fms; DNA-PK; FLT4; mTOR; PI3K-α	Phase 2
T3166	VX-11e	Aurora A; CDK2; ERK2; FLT3; GSK-3	
T3078	SGI-1776 free base	FLT3; Pim1; Pim2; Pim3	Phase 1
T3072	XL019	FLT3; JAK1; JAK2; JAK3; PDGFRβ	Phase 1
T3065	TG101209	RET; FLT3; JAK2; JAK3	Preclinical
T2677	Crenolanib	PDGFRα; PDGFRβ; FLT3	Approved
T2640	DCC2036	Abl1; p-Abl1 (native); p-Abl1 (T315I); u-Abl1 (native); FLT3	Phase 1/2
T2638	Gandotinib	FLT3; JAK1; JAK2; JAK2; JAK2 (V617F)	Phase 2
T2624	OSI 930	CSF-1R; FLT1; C-Raf; Lck; VEGFR2 (KDR)	Phase 1
T2620	G749	Aurora B; RET; FLT3; FLT3 (D835Y); Mer	Preclinical
T2586	Cabozantinib	c-Kit; c-Met; VEGFR2/KDR; FLT4; Axl; RET; FLT3	FDA Approved
T2516	Amuvatinib	c-Kit (D816H); FLT3 (D835Y); PDGFRα (V561D)	Phase 2
T2514	Linifanib	Kit; CSF-1R; FLT3; VEGFR1/FLT1; VEGFR2/KDR; PDGFRβ	Phase 1
T2500	Cediranib	c-Kit; PDGFRβ; VEGFR1/FLT1; VEGFR2/KDR; VEGFR3/FLT4; FLT4; FLT1	Approved
T2358	ENMD2076	Aurora A; RET; FLT3; Src; VEGFR3/FLT4; Src	Phase 2
T2341	KW2449	Aurora A; Abl; Abl (T315I); Kit; FGFR1; FLT3; FLT3 (D835Y); JAK2; Src	Phase 1/2
T2272	BPR1J097	FLT3	
T2116	AEE788	c-Abl; c-Fms; EGFR; HER2/ErbB2; FLT1	Phase 1/2
T2115	Pexidartinib	Kit; CSF-1R; FLT3	FDA Approved
T2066	Quizartinib	FLT3 (ITD); FLT3 (WT)	Approved
T2051	FLT3-IN-1	FLT3	
T1995	Fedratinib	JAK2; JAK2 (V617F); RET; FLT3	FDA Approved
T1938	FLT3-IN-2	FLT3	
T1836	AZD2932	c-Kit; FLT3; PDGFRβ; VEGFR2	
T1777	Nintedanib	FLT3; Lck; VEGFR1; VEGFR2; VEGFR3; FGPR1; FGFR2; FGFR3; PDGFRα; PDGFRβ	FDA Approved
T1667	Tandutinib	c-Kit; CSF-1R; FLT3; PDGFRβ; Src	Phase 2
T16144	MRX-2843	FLT3; MERTK	Phase 1
T15199	Edicotinib	FLT3; CSF-1R; kit	Phase 2
T0374L	Sunitinib	c-Kit; FLT3; PDGFRβ; VEGFR2	FDA Approved
T0374	Sunitinib Malate	Kit; FLT3; PDGFRβ; VEGFR2	FDA Approved
T0093L	Sorafenib	c-Kit; FLT3; mPDGFRβ; PDGFRβ; B-Raf; B-Raf (V599E); Raf-1; VEGFR2/Flk2	FDA Approved
T0093	Sorafenib tosylate	c-Kit; FLT3; mPDGFRβ; PDGFRβ; B-Raf; B-Raf (V599E); Raf-1; VEGFR2/Flk1	FDA Approved

Hck

ID	Product Name	Target	Condition
T2609	Masitinib	Abl1; c-Fms; Kit; Hck; PDGFR α ; PDGFR β ; Lyn B; Src	Approved
T2415	PP121	Hck; mTOR; PDGFR; Src; VEGFR; Abl	
T11538	Hck-IN-1	Hck	

HER

ID	Product Name	Target	Condition
T7819	TAS0728	HER2	Phase 1/2
T6712	Tyrphostin AG 879	EGFR; HER2-Neu; PDGFR; Trk	
T6341	PF04929113	HER2; HSP90	Phase 2
T5398	BMS 599626 2HCl (873837-23-1(HCl))	HER1; HER2; HER4	Phase 1
T4S0544	Furanodienone	HER2	
T4612	NS309	Potassium Channel; hERG	Preclinical
T4342	PF-04929113 Mesylate	HSP90; HER2	Phase 2
T4075	Sulfatinib	FGFR1; hERG; KDR	Phase 3
T3673	Mollugin	HER2; JAK2	
T3554	RG 14620	HER14 colony formation; HER14 DNA synthesis; EGFR	
T3192	NS1643	hERG	
T3108	CUDC101	EGFR; HDAC; HDAC1; HDAC10; HDAC2; HDAC3; HDAC4; HDAC5; HDAC6; HDAC7; HDAC8; HDAC9; HER2	Phase 1
T2630	Pozotinib	HER1; HER2; HER4	Phase 2
T2364	Irbinitinib	EGFR; HER2/ErbB2; p95 HER2	FDA Approved
T2325	Neratinib	EGFR; HER2	FDA Approved
T2303	Afatinib	EGFR (L858R); EGFR (L858R/T790M); EGFR (wt); HER2; HER4	FDA Approved
T2280	Endoxifen Z-isomer	hERG Potassium Channel; ER; ERR; hERG	Phase 3
T22431	SU5204	VEGFR2; HER2	
T2047	AG1478	EGFR; HER2; PDGFR	Preclinical
T1773	Afatinib Dimaleate	EGFR (L858R); EGFR (L858R/T790M); EGFR (wt); HER2	FDA Approved
T1266	Terfenadine	HT; mAChR; Potassium Channel; hERG	Approved
T11213	Epertinib hydrochloride	EGFR; HER4; HER2	
T0801	Tannic acid	CXCR; hERG channel	FDA Approved

IGF-1R

ID	Product Name	Target	Condition
TP1125	Insulin(cattle)	Insulin Receptor	
T8221	INSULIN	Insulin Receptor	FDA Approved
T6S1487	Ginsenoside Rg5	IGF-1R	

ID	Product Name	Target	Condition
T6943	Picropodophyllin	IGF-1R	Phase 2
T6932	PD168393	EGFR; FGFR; Insulin Receptor; PDGFR; PKC	Preclinical
T6419	BMS536924	FAK; IGF-1R; Insulin Receptor; MEK; Lck	Preclinical
T6080	NVP-AEW541	FLT1; FLT3; IGF-1R; Insulin Receptor; Tek	Phase 1
T6079	NVP-ADW742	IGF-1R	
T6057	URMC099	Aurora A; Aurora B; Aurora C; Abl1; CDK1; CDK2; c-Met; DLK; IGF-1R; Insulin Receptor; LRRK2; MEKK2; MLK1; MLK2; MLK3; ROCK1; ROCK2; SGK1; Lck; Syk; TrkA; TrkB; VEGFR1/FLT1	
T6017	Linsitinib	IGF-1R; Insulin Receptor; IRR	Phase 1/2
T4324	PQ401 hydrochloride (196868-63-0(free base))	IGF-1R	Preclinical
T3S0027	Picropodophyllotoxin	IGF-1R	Phase 2
T3621	Brigatinib	ALK; EGFR (C797S/del19); FLT3; IGF-1R; ROS1	FDA Approved
T3079	GSK1838705A	ALK; IGF-1R; Insulin Receptor; JNK3; RSK1	Preclinical
T3059	AP26113	ALK; EGFR (C797S/del19); EGFR (del19); EGFR (del19); IGF-1R	
T2693	AG1024	IGF-1R; Insulin Receptor	
T2642	PD173074	EGFR; FGFR1; Insulin Receptor; c-Src; VEGFR2	Preclinical
T2349	BMS754807	Met; IGF-1R; Insulin Receptor; TrkA; TrkB	Phase 1/2
T1918	TAE226	c-Met; FAK; IGF-1R; Insulin Receptor; PYK2	Preclinical
T1791	LDK378	ALK; IGF-1R; Insulin Receptor; STK22D	FDA Approved

PDGFR

ID	Product Name	Target	Condition
TQ0059	lloerasitib	Aurora A; Aurora B; Aurora C; PDGFR β ; RET; FLT1; VEGFR1; VEGFR2; VEGFR3	Phase 2
TN1969	N-(p-Coumaroyl) serotonin	PDGFR	
T8544	Masitinib mesylate	Kit; PDGFR α ; PDGFR β ; Lyn; LCK; FGFR3; FAK	Approved
T8541	Lenvatinib mesylate	VEGFR; VEGFR3; VEGFR1; FGFR1; PDGFR α ; PDGFR β ; c-Kit	FDA Approved
T8491	Vorolanib	VEGFR; PDGFR	Phase 2/3
T8482	Ripretinib	Kit; PDGFR	FDA Approved
T8402	Regorafenib Hydrochloride	VEGFR; PDGFR; RET; Raf-1	FDA Approved
T7861	Flumatinib mesylate	PDGFR β ; c-Kit; c-Abl	Phase 3
T6996	SU5402	FGFR1; PDGFR β ; VEGFR2	Preclinical
T6932	PD168393	EGFR; FGFR; Insulin Receptor; PDGFR; PKC	Preclinical
T6930	Pazopanib HCl	FGFR; PDGFR; VEGFR1; VEGFR2; VEGFR3; c-Kit; c-Fms	FDA Approved
T6920	ON123300	CDK; Ark5; RET; Fyn; PDGFR β ; FGFR1	Preclinical
T6720	Vatalanib 2HCl	PDGFR β ; VEGFR1/FLT1; VEGFR2/Flk1; VEGFR2/KDR; VEGFR3/FLT4	Phase 1
T6712	Tyrphostin AG 879	EGFR; HER2-Neu; PDGFR; Trk	
T6711	Tyrphostin AG 1296	PDGFR; c-Kit (Swiss 3T3); FGFR (Swiss 3T3)	Preclinical

ID	Product Name	Target	Condition
T6513	Bisindolylmaleimide I	PDGFR; PKC α ; PKC β 1; PKC β 2; PKC γ	
T6350	CHIR124	Chk1; FLT3; GSK-3; PDGFR; Fyn	Preclinical
T6230	Imatinib	v-Abl; c-Kit; PDGFR	FDA Approved
T6184	Orantinib	FGFR1; PDGFR β ; Flk1	Phase 1
T6166	Telatinib	c-Kit; PDGFR α ; VEGFR2; VEGFR3	Phase 2
T6124	Mubritinib	EGFR; HER2/ErbB2; FGFR; JAK1; PDGFR	Phase 1
T6097	GNF5837	Kit; PDGFR β ; TrkA; TrkB; TrkC	
T6091	CP673451	c-Kit; PDGFR α ; PDGFR β ; VEGFR1; VEGFR2	Preclinical
T5466	Tyrosine kinase-IN-1	KDR; Flt-1; FGFR1; PDGFR α ; PDGFR β	
T5109	Avapritinib	PDGFR α , c-Kit (D816V)	FDA Approved
T5001	Nintedanib Ethanesulfonate Salt	VEGFR1/2/3; FGFR1/2/3; PDGFR α / β	FDA Approved
T4320	Flumatinib	c-Abl; PDGFR β ; c-Kit;	Phase 3
T3570	NSC 86429	PDGFR; VEGFR	
T3476	J1101	Ephrin Receptor; PDGFR; VEGFR	Phase 1/2
T3463	NVP-ACC789	VEGFR; PDGFR- β	
T3072	XL019	FLT3; JAK1; JAK2; JAK3; PDGFR β	Phase 1
T2734	Senoside B	PDGFR	
T2677	Crenolanib	PDGFR α ; PDGFR β ; FLT3	Approved
T2609	Masitinib	Abl1; c-Fms; Kit; Hck; PDGFR α ; PDGFR β ; Lyn B; Src	Approved
T2516	Amuvatinib	c-Kit (D816H); FLT3 (D835Y); PDGFR α (V561D)	Phase 2
T2514	Linifanib	Kit; CSF-1R; FLT3; VEGFR1/FLT1; VEGFR2/KDR; PDGFR β	Phase 1
T2500	Cediranib	c-Kit; PDGFR β ; VEGFR1/FLT1; VEGFR2/KDR; VEGFR3/FLT4; Flt4; Flt1	Approved
T2479	Tyrphostin 9	EGFR; PDGFR	Preclinical
T2456	Tivozanib	EphB2; PDGFR α ; VEGFR1; VEGFR2; VEGFR3	Approved
T2446	KI8751	c-Kit; EGFR; FGFR2; PDGFR α ; VEGFR2	
T2415	PP121	Hck; mTOR; PDGFR; Src; VEGFR; Abl	
T2372	Ponatinib	Abl; c-Kit; FGFR1; PDGFR α ; c-Src; VEGFR2	FDA Approved
T2070	CEP32496	Abl1; c-Kit; RET; PDGFR β ; Lck	Phase 1
T2047	AG1478	EGFR; HER2; PDGFR	Preclinical
T1895	SKLB 610	FGFR; PDGFR; VEGFR	
T1886	TAK632	Aurora B; FGFR3; PDGFR β ; B-Raf; C-Raf	Preclinical
T1836	AZD2932	c-Kit; FLT3; PDGFR β ; VEGFR2	
T1792L	Regorafenib monohydrate	murine VEGFR2; murine VEGFR3; PDGFR β ; Kit; RET; RAF-1; B-RAF; B-Raf (V600E)	FDA Approved
T1777	Nintedanib	FLT3; Lck; VEGFR1; VEGFR2; VEGFR3; FGPR1; FGFR2; FGFR3; PDGFR α ; PDGFR β	FDA Approved
T1667	Tandutinib	c-Kit; CSF-1R; FLT3; PDGFR β ; Src	Phase 2
T1621	Imatinib Mesylate	v-Abl; c-Kit; PDGFR	FDA Approved
T15616	JNJ-10198409	PDGFR β ; PDGFR α	
T1452	Axitinib	PDGFR β ; VEGFR1; VEGFR2; VEGFR3; c-kit	FDA Approved

ID	Product Name	Target	Condition
T10157	Regorafenib N-oxide (M2)	VEGFR1; VEGFR2; VEGFR3; PDGFRβ; RET; Kit; Raf-1	
T0520	Lenvatinib	FGFR1; PDGFRβ; VEGFR1/FLT1; VEGFR2/KDR; VEGFR3/FLT4	FDA Approved
T0374L	Sunitinib	c-Kit; FLT3; PDGFRβ; VEGFR2	FDA Approved
T0374	Sunitinib Malate	Kit; FLT3; PDGFRβ; VEGFR2	FDA Approved
T0097L	Pazopanib	c-Kit; PDGFR; VEGFR1; VEGFR2; VEGFR3	FDA Approved
T0093L	Sorafenib	c-Kit; FLT3; mPDGFRβ; PDGFRβ; B-Raf; B-Raf (V599E); Raf-1; VEGFR2/Flk2	FDA Approved
T0093	Sorafenib tosylate	c-Kit; FLT3; mPDGFRβ; PDGFRβ; B-Raf; B-Raf (V599E); Raf-1; VEGFR2/Flk1	FDA Approved
T0080	Trapidil	PDE; PDGFR	Approved

PKA

ID	Product Name	Target	Condition
TP1523	PKG inhibitor peptide TFA	PKG	
T8681	HA-1004 dihydrochloride	PKA; PKC; calcium channel	
T7648	HA-100	PKA	
T6747	8-Bromo-cAMP(sodium salt)	PKA	
T6605	NH125	CaMKII; eEF-2 kinase; PKA; PKC	
T6315	MLN8054	Aurora A; Aurora B; CK2; PKA; Lck	
T6304	AT7867	Akt1; Akt2; Akt3; PKA; p70 S6K	Preclinical
T6250	H 89 2HCl	PKA; S6K1	
T6139L	A-674563 2HCl(552325-73-2(fb-2hcl))	Akt1; CDK2; PKA; ERK2; PKCδ	
T5065	GUANOSINE 3':5'-CYCLIC MONOPHOSPHATE SOD	PKG	
T3513	GSK180736A	GRK1; GRK2; GRK5; PKA; ROCK	
T3498	CCG215022	GRK1; GRK2; GRK5; PKA	
T3060	Fasudil hydrochloride	PKA; PKG; PKC; ROCK2; MLCK	Approved
T3050	ML-7 hydrochloride	PKA; PKC; MLCK	
T2851	Daphnetin	EGFR; PKA; PKC	Approved
T2482	AT13148	Akt1; Akt2; Akt3; PKA; ROCK1; ROCK2; p70 S6K; RSK1; SGK3	Phase 1
T2356	Ro 3306	CDK1; ERK; PKA; PKCδ; SGK	
T2205	Theophylline-7-acetic acid	A1; A2; A3; HDAC2; PDE4; PKA; TNF-α	Approved
T1920	Capivasertib	Akt1; Akt2; Akt3; PKA; mTOR (p70S6K)	Phase 2
T1837	BX912	CDK2/CyclinE; Chk1; PDK1; PKA; VEGFR2 (KDR)	Preclinical
T1418	Bucladesine sodium salt	PKA	Approved
T14069	A-3 hydrochloride	CK1; CK2; PKC; PKA	
T0610	Piceatannol	cAK; PKC; MLCK	Approved
T0465	Ellagic acid	Carbonic anhydrase; CK2; Smoothened; PKA; PKC; Syk; ATP-competitive CK2	Phase 2

PYK2

ID	Product Name	Target	Condition
T6177	PF-562271 besylate	CDK1/CyclinB; CDK2/CyclinE; CDK3/CyclinE; FAK; PYK2	Phase 1
T2465	PF562271	CDK1/CyclinB; CDK2/CyclinE; CDK3/CyclinE; FAK; PYK2	Phase 1
T2314	PF 431396	FAK; PYK2	
T1918	TAE226	c-Met; FAK; IGF-1R; Insulin Receptor; PYK2	Preclinical

Src

ID	Product Name	Target	Condition
T8544	Masitinib mesylate	Kit; PDGFR α ; PDGFR β ; Lyn; LCK; FGFR3; FAK	Approved
T8499	eCF506	Src	
T7371	1-Naphthyl PP1 hydrochloride	Src	
T7345	7-Hydroxy-4-chromone	Src	
T7123	AMG-47a	Lck	
T6997	SU6656	Fyn; Lyn; Src; Yes	
T6982	SGI7079	Met; RET; FLT3; Yes; AXL; Mer	
T6920	ON123300	CDK; Ark5; RET; Fyn; PDGFR β ; FGFR1	Preclinical
T6896	Tolimidone	Lyn kinase	Phase 2
T6886	MCB613	Src	
T6680	Staurosporine	PKC; PKC α ; PKC γ ; PKC η ; c-Fgr	
T6427	Butein	EGFR; p60c-src	
T6419	BMS536924	FAK; IGF-1R; Insulin Receptor; MEK; Lck	Preclinical
T6350	CHIR124	Chk1; FLT3; GSK-3; PDGFR; Fyn	Preclinical
T6348	NVP-BHG712	EphB4; c-Raf; c-Src; c-Abl	
T6345	KX2-391	Src (Hep 3B); Src (Hep G2); Src (HuH7); Src (PLC/PRF/5)	Phase 3
T6321	Tofacitinib	JAK1; JAK2; JAK3; ROCK2; Lck	FDA Approved
T6315	MLN8054	Aurora A; Aurora B; CK2; PKA; Lck	
T6311	Bafetinib	Abl; Lyn	Phase 1
T6266	PP2	EGFR; JAK2; Fyn; Lck; ZAP70	
T6227	Benidipine hydrochloride	EGFR (L861Q); c-Src; c-Yes; Lck; Lyn	Approved
T6196	PP1	Bcr-Abl; Kit; EGFR; Fyn; Lck	
T6078	Saracatinib	c-Src; Lck; BLK; EGFR (L858R); EGFR (L861Q); c-Yes; FGR; Fyn; Lyn	Phase 2
T6077	ZM 447439	Aurora A; Aurora B; MEK1; Lck; Src	Preclinical
T6028	PF477736	c-Fms; Chk1; Chk2; Yes; VEGFR2	Phase 1
T4618	K 0859	c-ABL-T334I; Abl; Abl (T315I)	
T4597	UM164	c-Src; p38 α ; p38 β	
T4301	AD80	RET, RAF, SRC, S6K; RET V804M; RET V804L	
T4133	CCT196969	C-RAF; Src	
T4071	TPX0005	ALK; Src	Phase 1/2

ID	Product Name	Target	Condition
T3935	1-Naphthyl PP1	Src	
T3593	Src Inhibitor 1	Lck; Src	
T3319	Scutellarein	Src	
T3063	PD173955	Bcr-Abl; Src	Preclinical
T2709	TAK901	CLK2; JAK3; c-Src; FGR; Yes1	Phase 1
T2696	PRT062607 hydrochloride	MLK1; FGR; Syk	Phase 1
T2642	PD173074	EGFR; FGFR1; Insulin Receptor; c-Src; VEGFR2	Preclinical
T2624	OSI 930	CSF-1R; FLT1; C-Raf; Lck; VEGFR2 (KDR)	Phase 1
T2609	Masitinib	Abl1; c-Fms; Kit; Hck; PDGFR α ; PDGFR β ; Lyn B; Src	Approved
T2608	CHIR98014	bFGFR; GSK-3 α ; GSK-3 β ; p70 S6K; c-Src	
T2603	Spebrutinib	BRK; BTK; c-Src; Lyn; Yes	Phase 2
T2415	PP121	Hck; mTOR; PDGFR; Src; VEGFR; Abl	
T2372	Ponatinib	Abl; c-Kit; FGFR1; PDGFR α ; c-Src; VEGFR2	FDA Approved
T2358	ENMD2076	Aurora A; RET; FLT3; Src; VEGFR3/FLT4; Src	Phase 2
T2341	KW2449	Aurora A; Abl; Abl (T315I); Kit; FGFR1; FLT3; FLT3 (D835Y); JAK2; Src	Phase 1/2
T2327	Pelitinib	EGFR; HER2/ErbB2; MEK; Raf; Src	Phase 2
T22306	DGY-06-116	Src; FGFR1	
T2070	CEP32496	Abl1; c-Kit; RET; PDGFR β ; Lck	Phase 1
T1985	WHI-P154	EGFR; JAK3; Src; VEGFR	Preclinical
T1835	Ibrutinib	BLK; Bmx; BTK; FGR; CSK	FDA Approved
T1812	KX1004	Src-PTK	
T1811	WH-4-023	Lck; Src	
T1777	Nintedanib	FLT3; Lck; VEGFR1; VEGFR2; VEGFR3; FGPR1; FGFR2; FGFR3; PDGFR α ; PDGFR β	FDA Approved
T1754	ZM 306416	Abl; Src; VEGFR1	
T16760	RK-24466	Lck	
T1667	Tandutinib	c-Kit; CSF-1R; FLT3; PDGFR β ; Src	Phase 2
T1448L	Dasatinib monohydrate	Abl; c-Kit (D816V); c-Kit (wt); EphA2; Src	FDA Approved
T1448	Dasatinib	Abl; c-Kit (D816V); c-Kit (wt); Src	FDA Approved
T0152	Bosutinib	Abl; c-Src	FDA Approved

Syk

ID	Product Name	Target	Condition
T7035	ANTHRAQUINONE-2-CARBOXYLIC ACID	IRAK-1; Syk	
T6174	R406	Syk	
T6115	Fostamatinib	Adenosine transporter; A3; Monoamine transporter; Syk	FDA Approved
T6101	Entospletinib	Syk	Approved
T4391	Syk Inhibitor II (hydrochloride)	Syk; PKC ϵ ; PKC β II; ZAP-70; Btk; Itk; ZAP70; Btk	

ID	Product Name	Target	Condition
T4263	BAY 61-3606	Syk	
T4209	TAK-659 hydrochloride	FLT3; JAK3; Syk; ZAP70; VEGFR2	Phase 2
T3185	(E)-Elafibranor	Syk	Phase 2
T2696	PRT062607 hydrochloride	MLK1; FGR; Syk	Phase 1
T2605	R788 Disodium	Syk	FDA Approved
T2487	Cerdulatinib	JAK1; JAKs; Syk; Tyk2	Phase 2
T2467	R406 free base	Syk	
T11824LL	Lanraplenib	SYK	phase 2
T0465	Ellagic acid	Carbonic anhydrase; CK2; Smoothened; PKA; PKC; Syk; ATP-competitive CK2	Phase 2

TAM Receptor

ID	Product Name	Target	Condition
TQ0021	Ningetinib	c-Met; VEGFR2; AXL	Phase 1/2
T8327	ONO-7475	Mer	
T7425	RU-301	pan-TAM receptor	
T7379	2-D08	sumoylation; AXL	
T7007	UNC2025	FLT3; AXL; Mer; Tyro3	Preclinical
T6982	SGI7079	Met; RET; FLT3; Yes; AXL; Mer	
T6907	NPS1034	Met; AXL	
T6269	Bemcentinib	AXL	Phase 2
T6121	Tepotinib	c-Met; AXL; TrkA	Approved
T6120	Pralatrexate	DHFR; Axl(KPL-4 cells); Axl(SUM149 cells)	FDA Approved
T5164	Cabozantinib hydrochloride (849217-68-1(free base))	c-Kit; c-Met; VEGFR2/KDR; FLT4; AxL; RORγ; RORα	FDA Approved
T4426	CEP40783	AXL; Mer; Tyro3; c-MET	Preclinical
T4419	UNC2025 2HCl (1429881-91-3(free base))	Mer; Flt3	
T4409	Gilteritinib	FLT3; AXL; c-KIT	FDA Approved
T4349	Sitravatinib	DDR2; EPHA3; AxL; Mer; VEGFR3 (FLT4); Mer; VEGFR3 (FLT4)	Phase 2
T4213	NCT503	PHGDH(Cell-free); FLT3; AXL	
T3274	S49076	Met; FGFR2; FGFR3; AXL; Mer	Phase 1/2
T2699	BMS777607	Met; RON; AXL; Mer; Tyro3	Phase 2
T2629	UNC2881	AXL; Mer; Tyro3	
T2620	G749	Aurora B; RET; FLT3; FLT3 (D835Y); Mer	Preclinical
T2586	Cabozantinib	c-Kit; c-Met; VEGFR2/KDR; FLT4; AxL; RET; FLT3	FDA Approved
T2311	LDC1267	AXL; Mer; Tyro3	
T2005	TP0903	AXL	Phase 1/2
T1797	Cabozantinib Malate	Kit; c-Met; AXL; VEGFR2/KDR; VEGFR3/FLT4	FDA Approved

Tie-2

ID	Product Name	Target	Condition
T6934	Pexmetinib	p38 MAPK; Tie-2	Phase 1
T6335	Tie2 kinase inhibitor	Tie-2	
T4318	ACTB1003	FGFR1,VEGFR2,Tie-2	Phase 1
T3113	Foretinib	Met; RON; Tie-2; VEGFR2 (KDR); VEGFR3/FLT4	Phase 1
T2054	Altiratinib	c-Met; Tie-2; VEGFR; TrkA; TrkC	Phase 1

Trk receptor

ID	Product Name	Target	Condition
T7568	LM22A-4	Trk	
T7435	Selitrectinib	Trk	
T6880	Larotrectinib sulfate	Trk	FDA Approved
T6712	Tyrphostin AG 879	EGFR; HER2-Neu; PDGFR; Trk	
T6121	Tepotinib	c-Met; AXL; TrkA	Approved
T6097	GNF5837	Kit; PDGFR β ; TrkA; TrkB; TrkC	
T6081	Milciclib	CDK2/CyclinA; CDK4/CyclinD1; CDK5/p35; CDK7/CyclinH; TrkA	Phase 2
T6052	GW 441756	CDK2; C-Raf-1; TrkA	
T5995	Larotrectinib	Trk	FDA Approved
T5635	CH7057288	Trk	
T4496	LM22B10	TrkB; TrkC	
T3678	Entrectinib	ALK; ROS1; TrkA; TrkB; TrkC	FDA Approved
T3109	Pyrazolanthrone	Aurora A; JNK1; JNK2; JNK3; TrkA	Preclinical
T2816	7,8-Dihydroxyflavone	TrkB	
T2359	ANA12	TrkB	
T2349	BMS754807	Met; IGF-1R; Insulin Receptor; TrkA; TrkB	Phase 1/2
T22318	DS-6051b	ROS1; TrkA; TrkB; TrkC	
T2094	Danusertib	Aurora A; Aurora B; Aurora C; Abl; RET; FGFR1; TrkA	Phase 2
T2054	Altiratinib	c-Met; Tie-2; VEGFR; TrkA; TrkC	Phase 1
T1704	Diosmetin	CYP1A1; TrkB	
T1354	N-Acetyl-5-hydroxytryptamine	TrkB	

Tyrosine Kinases

ID	Product Name	Target	Condition
T8697	ZAP-180013	ZAP70	
T7101	Tyrphostin AG30(AG30)	PTK	
T6S0923	Hypericin	antibacterial; antiviral; tyrosine kinases	Phase 3
T6933	Peficitinib	JAK3; JAK1; Tyk2; JAK2	Approved

ID	Product Name	Target	Condition
T6914	Oclacitinib maleate	JAK1; JAK2; TYK2; JAK3; JAK1-dependent	
T6790	BMS911543	JAK2 ; SET-2; TYK2; JAK3; JAK1	Phase 1/2
T6380	AMG900	Aurora A; Aurora B; Aurora C; p38 α ; Tyk2	Phase 1
T6343	Geldanamycin	HSP90; HSP90; p185	Preclinical
T6266	PP2	EGFR; JAK2; Fyn; Lck; ZAP70	
T6156	S-Ruxolitinib	JAK2; JAK1; Tyk2	FDA Approved
T6080	NVP-AEW541	FLT1; FLT3; IGF-1R; Insulin Receptor; Tek	Phase 1
T6020	Pacritinib	FLT3; FLT3 (D835Y); JAK2; JAK2 (V617F); Tyk2; JAK3	Approved
T4511	ST 271	PTK	
T4391	Syk Inhibitor II (hydrochloride)	Syk; PKC ϵ ; PKC β II; ZAP-70; Btk; Itk; ZAP70; Btk	
T4349	Sitravatinib	DDR2; EPHA3; Axl; Mer; VEGFR3 (FLT4); Mer; VEGFR3 (FLT4)	Phase 2
T4210	SAR20347	JAK1; JAK2; JAK3; TYK2	Preclinical
T4209	TAK-659 hydrochloride	FLT3; JAK3; Syk; ZAP70; VEGFR2	Phase 2
T3080	Pyridone 6	JAK1; JAK2; JAK3; Tyk2	
T3076	GLPG0634 analogue	JAK1; JAK2; JAK3; TYK2	
T3061	Lorlatinib	ALK; ALK (L1196M); ROS1; ROS1; LTK (TYK1)	FDA Approved
T2636	Decernotinib	JAK1; JAK2; JAK3; Tyk2	Phase 3
T2487	Cerdulatinib	JAK1; JAK3; Syk; Tyk2	Phase 2
T2485	Baricitinib	Chk2; JAK1; JAK2; JAK3; Tyk2	FDA Approved
T2382	Vemurafenib	ACK1; MAP4K5 (KHS1); B-Raf; B-Raf (V600E); C-Raf; SRMS; FGR	FDA Approved
T2360	Baricitinib Phosphate	JAK1; JAK2; JAK3; Tyk2	FDA Approved
T22416	RO495	TYK2	
T1936	Alectinib	ALK; ALK (F1174L); ALK (R1275Q); INSR; VEGFR2 (KDR)	FDA Approved
T1929	Filgotinib	JAK1; JAK2; JAK3; Tyk2	Approved
T1917	6-BIO	CDK1/CyclinB; CDK2/CyclinA; CDK5/p35; GSK-3; Tyk2	
T1835	Ibrutinib	BLK; Bmx; BTK; FGR; CSK	FDA Approved
T1829	Ruxolitinib	JAK1; JAK2; Tyk2	FDA Approved
T1506	Vidarabine	DNA polymerase; DNA polymerase; Tyrosine Kinases	FDA Approved
T14687	BMS-986165	Tyk2 JH2; JAK1 JH2	Phase 3
T1181	Gefitinib	Tyr1173 (NR6W cells); Tyr1173 (NR6wtEGFR cells); Tyr992 (NR6W cells); Tyr992 (NR6wtEGFR cells); Tyr992	FDA Approved

VEGFR


ID	Product Name	Target	Condition
TQ0059	Ilorasertib	Aurora A; Aurora B; Aurora C; PDGFR β ; RET; FLT1; VEGFR1; VEGFR2; VEGFR3	Phase 2
TQ0021	Ningetinib	c-Met; VEGFR2; AXL	Phase 1/2
TN1126	Sakuranetin	PPAR; NF- κ B; VEGFR	
TJS0339	Coumarin-3-carboxylic acid	VEGFR	

ID	Product Name	Target	Condition
T8541	Lenvatinib mesylate	VEGFR; VEGFR3; VEGFR1; FGFR1; PDGFRα; PDGFRβ; c-Kit	FDA Approved
T8496	MAZ51	VEGFR3	
T8491	Vorolanib	VEGFR; PDGFR	Phase 2/3
T8402	Regorafenib Hydrochloride	VEGFR; PDGFR; RET; Raf-1	FDA Approved
T8326	BMS-2	Met; FLT3; VEGFR2	
T7945	SU14813	VEGFR; Kit	
T7611	ODM-203	FGFR; VEGFR	Phase 2
T7493	AG-13958	VEGFR	
T7203	Oglufanide	VEGFR	Phase 2
T6996	SU5402	FGFR1; PDGFRβ; VEGFR2	Preclinical
T6930	Pazopanib HCl	FGFR; PDGFR; VEGFR1; VEGFR2; VEGFR3; c-Kit; c-Fms	FDA Approved
T6720	Vatalanib 2HCl	PDGFRβ; VEGFR1/FLT1; VEGFR2/Flk1; VEGFR2/KDR; VEGFR3/FLT4	Phase 1
T6517	Golvatinib	c-Met; VEGFR2	Phase 1/2
T6479	Dovitinib Lactate	c-Kit; FGFR1; FGFR3; FLT3; VEGFR3/FLT4	
T6458	CYC116	Aurora A; Aurora B; CDK2/CyclinE; CDK9/CyclinT; FLT3; p70 S6K; VEGFR2	Phase 1
T6351	MGCD-265 analog	Met; RON; VEGFR1; VEGFR2; VEGFR3	Phase 1
T6289	Dovitinib	c-Kit; FGFR1; FGFR3; FLT3; VEGFR3/FLT4	Phase 2
T6199	Ribociclib	CDK4; VEGFR4; VEGFR6	FDA Approved
T6184	Orantinib	FGFR1; PDGFRβ; Flk1	Phase 1
T6166	Telatinib	c-Kit; PDGFRα; VEGFR2; VEGFR3	Phase 2
T6154	SU11274	CDK2; Met; RON; FGFR1; Flk1	Preclinical
T6137	KRN633	VEGFR1; VEGFR2; VEGFR3	Phase 1
T6128	PHA665752	c-Abl; c-Met; RON; FGFR1; Flk1	Preclinical
T6091	CP673451	c-Kit; PDGFRα; PDGFRβ; VEGFR1; VEGFR2	Preclinical
T6028	PF477736	c-Fms; Chk1; Chk2; Yes; VEGFR2	Phase 1
T5S1632	8-O-Acetylshanzhiside methyl ester	TNF-α; NF-Kb; VEGFR; Akt; Caspase	
T5466	Tyrosine kinase-IN-1	KDR; Flt-1; FGFR1; PDGFRα; PDGFRα	
T5349	SCR-1481B1	VEGFR1	
T5171	Treprostinil Sodium	DP1, IP, EP2; VEGFR2; RET	FDA Approved
T5164	Cabozantinib hydrochloride (849217-68-1 (free base))	c-Kit; c-Met; VEGFR2/KDR; FLT4; Axl; RORy; RORα	FDA Approved
T5001	Nintedanib Ethanesulfonate Salt	VEGFR1/2/3; FGFR1/2/3; PDGFRα/β	FDA Approved
T4554	AG 1406	VEGFR2	
T4425	JK-P3	VEGFR2	
T4349	Sitravatinib	DDR2; EPHA3; Axl; Mer; VEGFR3 (FLT4); Mer; VEGFR3 (FLT4)	Phase 2
T4318	ACTB1003	FGFR1, VEGFR2, Tie-2	Phase 1
T4315	Ki20227	CSF-1R, VEGFR2; VEGFR2	Preclinical

ID	Product Name	Target	Condition
T4288	hVEGF-IN-1	VEGF-A	
T4209	TAK-659 hydrochloride	FLT3; JAK3; Syk; ZAP70; VEGFR2	Phase 2
T4075	Sulfatinib	FGFR1; hERG; KDR	Phase 3
T4053	AST 487	c-Kit; RET; FLT4; KDR	Preclinical
T4026	VEGFR2 Kinase Inhibitor I	VEGFR2	
T3980	Su1498	VEGFR2	
T3691	SAR131675	VEGFR3	Preclinical
T3641	BAW2881	c-Abl; B-Raf (V599E); C-Raf-1; hVEGFR2	
T3599	BFH772	VEGFR2	Phase 2
T3570	NSC 86429	PDGFR; VEGFR	
T3566	SU 5205	VEGFR2	
T3560	Desmethylanethol trithione	Akt; VEGFR	
T3476	JI101	Ephrin Receptor; PDGFR; VEGFR	Phase 1/2
T3463	NVP-ACC789	VEGFR; PDGFR-β	
T3113	Foretinib	Met; RON; Tie-2; VEGFR2 (KDR); VEGFR3/FLT4	Phase 1
T2906	Tanshinone IIA	VEGFR2	Phase 4
T2656	Fruquintinib	VEGFR	Approved
T2642	PD173074	EGFR; FGFR1; Insulin Receptor; c-Src; VEGFR2	Preclinical
T2624	OSI 930	CSF-1R; FLT1; C-Raf; Lck; VEGFR2 (KDR)	Phase 1
T2586	Cabozantinib	c-Kit; c-Met; VEGFR2/KDR; FLT4; Axl; RET; FLT3	FDA Approved
T2576	Brivanib Alaninate	FGFR1; Flk1; VEGFR1; VEGFR2	Phase 3
T2514	Linifanib	Kit; CSF-1R; FLT3; VEGFR1/FLT1; VEGFR2/KDR; PDGFRβ	Phase 1
T2500	Cediranib	c-Kit; PDGFRβ; VEGFR1/FLT1; VEGFR2/KDR; VEGFR3/FLT4; Flt4; Kit1	Approved
T2496	(Z)-Semaxinib	VEGFR2/Flk1	Phase 1
T2456	Tivozanib	EphB2; PDGFRα; VEGFR1; VEGFR2; VEGFR3	Approved
T2446	KI8751	c-Kit; EGFR; FGFR2; PDGFRα; VEGFR2	
T2421	SKLB1002	VEGFR2	
T2419	BMS794833	Met; VEGFR2	Preclinical
T2415	PP121	Hck; mTOR; PDGFR; Src; VEGFR; Abl	
T2372	Ponatinib	Abl; c-Kit; FGFR1; PDGFRα; c-Src; VEGFR2	FDA Approved
T2361	LY2874455	FGFR1; FGFR2; FGFR3; FGFR4; VEGFR2	Phase 2
T2358	ENMD2076	Aurora A; RET; FLT3; Src; VEGFR3/FLT4; Src	Phase 2
T2288	Motesanib	VEGFR1; VEGFR2; VEGFR3; c-Kit	Phase 3
T22432	SU5208	VEGFR2	
T22431	SU5204	VEGFR2; HER2	
T2064	Semaxinib	Flk1	Phase 1
T2056L	UNC0064-12 hydrochloride (1430089-64-7 (free base))	VEGFR2	
T2054	Altiratinib	c-Met; Tie-2; VEGFR; TrkA; TrkC	Phase 1
T1985	WHI-P154	EGFR; JAK3; Src; VEGFR	Preclinical

ID	Product Name	Target	Condition
T1948	AZD4547	FGFR1; FGFR2; FGFR3; FGFR4; KDR	Phase 2/3
T1936	Alectinib	ALK; ALK (F1174L); ALK (R1275Q); INSR; VEGFR2 (KDR)	FDA Approved
T1895	SKLB 610	FGFR; PDGFR; VEGFR	
T1837	BX912	CDK2/CyclinE; Chk1; PDK1; PKA; VEGFR2 (KDR)	Preclinical
T1836	AZD2932	c-Kit; FLT3; PDGFR β ; VEGFR2	
T1797	Cabozantinib Malate	Kit; c-Met; AXL; VEGFR2/KDR; VEGFR3/FLT4	FDA Approved
T1792L	Regorafenib monohydrate	murine VEGFR2; murine VEGFR3; PDGFR β ; Kit; RET; RAF-1; B-RAF; B-Raf (V600E)	FDA Approved
T1792	Regorafenib	Kit; RET; Raf-1; VEGFR1; VEGFR2	FDA Approved
T1777	Nintedanib	FLT3; Lck; VEGFR1; VEGFR2; VEGFR3; FGPR1; FGFR2; FGFR3; PDGFR α ; PDGFR β	FDA Approved
T1754	ZM 306416	Abl; Src; VEGFR1	
T1738	Taxifolin	β -adrenergic receptor; TNF- α ; Collagenase Tyrosinase; Beta-nerve growth factor; VEGFR2	
T17219	Vatalanib free base	VEGFR2	
T1656	Vandetanib	EGFR; VEGFR2; VEGFR3	FDA Approved
T1452	Axitinib	PDGFR β ; VEGFR1; VEGFR2; VEGFR3; c-kit	FDA Approved
T11520	GW806742X	MLKL; VEGFR2	
T0520	Lenvatinib	FGFR1; PDGFR β ; VEGFR1/FLT1; VEGFR2/KDR; VEGFR3/FLT4	FDA Approved
T0447	Carvedilol	Adrenergic Receptor; HIF; E-selectin; NADPH; Vcam; Potassium Channel; VEGFR; LDL oxidation	FDA Approved
T0374L	Sunitinib	c-Kit; FLT3; PDGFR β ; VEGFR2	FDA Approved
T0374	Sunitinib Malate	Kit; FLT3; PDGFR β ; VEGFR2	FDA Approved
T0342	Carvedilol phosphate	Adrenergic Receptor; Gap Junction Protein; E-selectin; NADPH dehydrogenase; Natriuretic peptides B; VCAM1; Potassium Channel; VEGFR; LDL oxidation	FDA Approved
T0129	Sanguinarine chloride	Egr-1; VEGFR	Approved
T0097L	Pazopanib	c-Kit; PDGFR; VEGFR1; VEGFR2; VEGFR3	FDA Approved
T0093L	Sorafenib	c-Kit; FLT3; mPDGFR β ; PDGFR β ; B-Raf; B-Raf (V599E); Raf-1; VEGFR2/Flk2	FDA Approved
T0093	Sorafenib tosylate	c-Kit; FLT3; mPDGFR β ; PDGFR β ; B-Raf; B-Raf (V599E); Raf-1; VEGFR2/Flk1	FDA Approved

Ubiquitination



DUB

ID	Product Name	Target	Condition
T7678	SJB2-043	USP1-UAF1	
T6925	P005091	USP7	Preclinical
T6697	TCID	UCH-L1; UCH-L3	
T6107	IU1	USP14	
T5461	GNE-6640	USP7	
T4634	GEN6776	USP7	
T4338	USP7/USP47 inhibitor	USP7; USP47	
T4067	VLX1570	DUB	Phase 1/2
T3951	NSC632839	SEN2; USP2; USP7	
T3555	ML364	USP2	
T3089	Thioguanine	DNMT1; USP2	FDA Approved
T2424	P22077	USP2; USP4; USP47; USP5; USP7	

ID	Product Name	Target	Condition
T1937	Spautin-1	USP10; USP13	
T1932	B-AP15	UCH-L5	
T1924	LDN57444	UCH-L1; UCH-L1; UCH-L3	
T1862	PR619	JOSD2; SENP6 core; UCH-L3; USP4; USP8	
T1757	ML323	USP1-UAF1	

E1/E2/E3 Enzyme

ID	Product Name	Target	Condition
T8816	NAE-IN-M22	NAE	
T7415	DKM 2-93	UBA5	
T7379	2-D08	sumoylation; AXL	
T6629	PYR41	Ubiquitin-activating Enzyme E1	
T6332	Pevonedistat	NAE	Phase 3
T5199	COH000	Ubiquitin-activating Enzyme E1	
T4253	Skp2 Inhibitor C1	Skp2	
T16974	TAK-243	UBA1; NF-κB; Apoptosis	Phase 1
T13349	WS-383	DCN1-UBC12	

p97

ID	Product Name	Target	Condition
T6796	CB5083	p97	Phase 1
T4684	ML241 hydrochloride	p97	
T3535	ML240	P97	
T1969	DBEQ	p97	
T1853	NMS 873	p97	

Proteasome

ID	Product Name	Target	Condition
T8397	Ixazomib citrate	Proteasome	FDA Approved
T7854	Bortezomib-pinanediol	Proteasome	
T7814	Alloxan Monohydrate	Proteasome	
T7016	VR23	Caspase-like proteasomes; Chymotrypsin-like proteasomes; Trypsin-like proteasomes	
T6999	Teneligliptin hydrobromide	Dipeptidyl peptidase-4 ; DPP-9; DPP-8; FAP	Approved
T6941	PI1840	Chymotrypsin-like proteasome	
T6830	Epoxomicin	20S proteasome	
T6041	Oprozomib	20S proteasome; 20S proteasome	Phase 1/2

ID	Product Name	Target	Condition
T6029	ONX0914	immunoproteasome	Preclinical
T6027	Delanzomib	Chymotrypsin-like proteasome	Phase 1
T4467	UAMC 00039 dihydrochloride	Dipeptidyl peptidase II	
T3359	Aprotinin	Chymotrypsin-like proteasome; kallikrein; Trypsin; trypsinogen	FDA Approved
T3028	Celastrol	20S proteasome	
T2583	Cilastatin	Dipeptidase 1	FDA Approved
T2399	Bortezomib	20S proteasome	FDA Approved
T2370	AOB2796	Protease-Activated Receptor 2	
T2154	MG132	20S proteasome, calpain	Preclinical
T2122	Ixazomib	20S proteasome; 20S proteasome; caspase-like (β 1)	FDA Approved
T2016	MLN9708	20S proteasome; 20S proteasome	FDA Approved
T1795	Carfilzomib	Proteasome	FDA Approved
T17011	TCH-165	Proteasome	
T16684	Puromycin aminonucleoside	apoptosis; dipeptidyl peptidase II; antibiotic	
T13858	RA190	Proteasome	
T12628	(R)-MG-132	Proteasome	
T12579	PTP1B-IN-9	Proteasome	
T1176	Racecadotril	Endopeptidase	Approved

Reagent Kits

A Reliable kit is an important factor to ensure the success of your experiment. Targetmol can provide cocktails and CCK8 for molecular biology experiments, which have many advantages, such as high sensitivity, good stability, strong anti-interference ability, and these properties can ensure the smooth progress of your experiments.

Protease Inhibitor Cocktail



ID	Product Name	Form	Components
C0001	Protease Inhibitor Cocktail	Solution(100×in DMSO)	AEBSF, Aprotinin, Bestatin, E-64, Leupeptin, Pepstatin A

Phosphatase Inhibitor Cocktail



ID	Product Name	Form	Components
C0002	Phosphatase Inhibitor Cocktail I (100× ddH2O)	Solution(100×in ddH2O)	Sodium Fluoride; Sodium Orthovanadate; Sodium Molybdate; Sodium Tartrate; Imidazole
C0003	Phosphatase Inhibitor Cocktail II (100× DMSO)	Solution(100×in DMSO)	(-)-p-Bromotetramisole oxalate; Cantharidin; Microcystin LR
C0004	Phosphatase Inhibitor Cocktail III (2 Tubes, 100x)	2 Tube Solution (100×)	C0002+C0003

Cell Counting Kit-8



ID	Product Name	Form	Components
C0005	Cell Counting Kit-8 (CCK-8)	Solution	WST-8 etc.

SYBR Green qPCR Master Mix



ID	Product Name	Form	Components
C0006	SYBR Green qPCR Master Mix (No ROX)	Solution	Taq DNA polymerase, dNTPs, Mg ²⁺ , SYBR Green I dye
C0007	SYBR Green qPCR Master Mix (High ROX)	Solution	Taq DNA polymerase, dNTPs, Mg ²⁺ , SYBR Green I dye, High ROX
C0008	SYBR Green qPCR Master Mix (Low ROX)	Solution	Taq DNA polymerase, dNTPs, Mg ²⁺ , SYBR Green I dye, Low ROX

Order & Inquiry

United States

Tel 781-999-5354

Fax 781-281-9145

E-Mail sales@targetmol.com

Add 36 Washington Street, Wellesley Hills, MA 02481

Technical Support

tech@targetmol.com

International

Tel 781-999-4286

Fax 781-281-9145

E-mail info@targetmol.com

China

Tel 86-400-821-2233

Fax 86-21-34692979

E-mail info@tsbiochem.com

TargetMol[®]
A DRUG SCREENING EXPERT

Target Molecule Corp.

—Drug Screening Expert(Inhibitors, Libraries, Natural Compounds)

www.targetmol.com
